Genomic_location,ProteinID,MUTATION,MUTPRED Score,Hypothesis
17:44039704:A:C,P10636,M1L,0.996,Gain of stability (P = 0.0205); Loss of disorder (P = 0.3253); Loss of glycosylation at P4 (P = 0.3592); Loss of solvent accessibility (P = 0.5485); Gain of catalytic residue at M1 (P = 0.5579)
17:44039704:A:G,P10636,M1V,0.997,Loss of glycosylation at P4 (P = 0.2544); Loss of disorder (P = 0.293); Loss of solvent accessibility (P = 0.3103); Gain of catalytic residue at M1 (P = 0.3235); Loss of sheet (P = 0.6423)
17:44039704:A:T,P10636,M1L,0.996,Gain of stability (P = 0.0205); Loss of disorder (P = 0.3253); Loss of glycosylation at P4 (P = 0.3592); Loss of solvent accessibility (P = 0.5485); Gain of catalytic residue at M1 (P = 0.5579)
17:44039705:T:A,P10636,M1K,0.992,Gain of ubiquitination at M1 (P = 0.0109); Loss of stability (P = 0.1035); Gain of glycosylation at P4 (P = 0.1906); Gain of solvent accessibility (P = 0.3819); Gain of methylation at M1 (P = 0.5895)
17:44039705:T:C,P10636,M1T,0.997,Gain of glycosylation at M1 (P = 0.0039); Gain of phosphorylation at M1 (P = 0.0186); Gain of catalytic residue at M1 (P = 0.0211); Loss of stability (P = 0.2281); Loss of solvent accessibility (P = 0.3103)
17:44039705:T:G,P10636,M1R,0.994,Gain of methylation at M1 (P = 0.0379); Gain of solvent accessibility (P = 0.11); Gain of glycosylation at P4 (P = 0.4074); Loss of stability (P = 0.5901); Gain of disorder (P = 0.6109)
17:44039706:G:A,P10636,M1I,0.999,Gain of catalytic residue at M1 (P = 0.0337); Loss of disorder (P = 0.0817); Loss of glycosylation at P4 (P = 0.2331); Gain of stability (P = 0.5424); Loss of solvent accessibility (P = 0.6392)
17:44039706:G:C,P10636,M1I,0.999,Gain of catalytic residue at M1 (P = 0.0337); Loss of disorder (P = 0.0817); Loss of glycosylation at P4 (P = 0.2331); Gain of stability (P = 0.5424); Loss of solvent accessibility (P = 0.6392)
17:44039706:G:T,P10636,M1I,0.999,Gain of catalytic residue at M1 (P = 0.0337); Loss of disorder (P = 0.0817); Loss of glycosylation at P4 (P = 0.2331); Gain of stability (P = 0.5424); Loss of solvent accessibility (P = 0.6392)
17:44039707:G:A,P10636,A2T,0.162,Gain of phosphorylation at A2 (P = 0.0331); Gain of glycosylation at A2 (P = 0.0332); Gain of solvent accessibility (P = 0.2291); Gain of disorder (P = 0.6065); Loss of sheet (P = 0.6423)
17:44039707:G:C,P10636,A2P,0.204,Gain of glycosylation at A2 (P = 0.0279); Gain of catalytic residue at A2 (P = 0.0327); Loss of relative solvent accessibility (P = 0.5582); Gain of disorder (P = 0.5619); Gain of solvent accessibility (P = 0.5843)
17:44039707:G:T,P10636,A2S,0.17,Gain of phosphorylation at A2 (P = 0.0087); Gain of glycosylation at P4 (P = 0.1338); Gain of solvent accessibility (P = 0.3089); Loss of catalytic residue at A2 (P = 0.4591); Gain of disorder (P = 0.6009)
17:44039708:C:A,P10636,A2D,0.207,Gain of solvent accessibility (P = 0.1154); Loss of glycosylation at P4 (P = 0.251); Loss of catalytic residue at A2 (P = 0.4906); Gain of disorder (P = 0.5683); Loss of sheet (P = 0.6423)
17:44039708:C:G,P10636,A2G,0.144,Gain of glycosylation at P4 (P = 0.3672); Loss of solvent accessibility (P = 0.3744); Gain of catalytic residue at E7 (P = 0.4894); Loss of relative solvent accessibility (P = 0.5582); Gain of disorder (P = 0.5846)
17:44039708:C:T,P10636,A2V,0.255,Gain of stability (P = 0.0364); Gain of solvent accessibility (P = 0.2291); Loss of glycosylation at P4 (P = 0.2467); Gain of catalytic residue at A2 (P = 0.4674); Loss of disorder (P = 0.5046)
17:44039710:G:A,P10636,E3K,0.21,Gain of ubiquitination at E3 (P = 0.0082); Gain of methylation at E3 (P = 0.0404); Gain of glycosylation at E3 (P = 0.1454); Loss of stability (P = 0.2335); Gain of catalytic residue at E3 (P = 0.4192)
17:44039710:G:C,P10636,E3Q,0.13,Loss of glycosylation at P4 (P = 0.3453); Gain of solvent accessibility (P = 0.5843); Loss of stability (P = 0.5934); Loss of disorder (P = 0.6175); Loss of sheet (P = 0.6423)
17:44039711:A:C,P10636,E3A,0.134,Loss of disorder (P = 0.3194); Loss of solvent accessibility (P = 0.3543); Gain of glycosylation at P4 (P = 0.3921); Gain of catalytic residue at A2 (P = 0.6084); Loss of stability (P = 0.6373)
17:44039711:A:G,P10636,E3G,0.163,Loss of stability (P = 0.0711); Gain of catalytic residue at A2 (P = 0.1299); Loss of solvent accessibility (P = 0.2732); Loss of glycosylation at P4 (P = 0.408); Loss of disorder (P = 0.5465)
17:44039711:A:T,P10636,E3V,0.203,Loss of disorder (P = 0.0635); Loss of glycosylation at P4 (P = 0.2542); Loss of solvent accessibility (P = 0.3368); Gain of catalytic residue at F8 (P = 0.3893); Gain of sheet (P = 0.6509)
17:44039712:G:C,P10636,E3D,0.108,Loss of glycosylation at P4 (P = 0.2878); Loss of stability (P = 0.5347); Loss of disorder (P = 0.6196); Loss of sheet (P = 0.6423); Gain of methylation at R5 (P = 0.6561)
17:44039712:G:T,P10636,E3D,0.108,Loss of glycosylation at P4 (P = 0.2878); Loss of stability (P = 0.5347); Loss of disorder (P = 0.6196); Loss of sheet (P = 0.6423); Gain of methylation at R5 (P = 0.6561)
17:44039713:C:A,P10636,P4T,0.27,Gain of phosphorylation at P4 (P = 0.0889); Loss of catalytic residue at P4 (P = 0.2972); Loss of glycosylation at P4 (P = 0.3215); Loss of stability (P = 0.414); Gain of solvent accessibility (P = 0.5843)
17:44039713:C:G,P10636,P4A,0.234,Loss of glycosylation at P4 (P = 0.107); Loss of stability (P = 0.2104); Loss of catalytic residue at P4 (P = 0.353); Loss of disorder (P = 0.562); Gain of methylation at R5 (P = 0.6197)
17:44039713:C:T,P10636,P4S,0.281,Gain of phosphorylation at P4 (P = 0.0148); Loss of glycosylation at P4 (P = 0.2344); Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at P4 (P = 0.2471); Gain of solvent accessibility (P = 0.3956)
17:44039714:C:A,P10636,P4H,0.244,Loss of glycosylation at P4 (P = 0.107); Loss of catalytic residue at P4 (P = 0.2765); Gain of solvent accessibility (P = 0.3819); Loss of stability (P = 0.4444); Gain of disorder (P = 0.6268)
17:44039714:C:G,P10636,P4R,0.275,Gain of solvent accessibility (P = 0.0789); Loss of glycosylation at P4 (P = 0.107); Gain of relative solvent accessibility (P = 0.2363); Gain of disorder (P = 0.5878); Loss of catalytic residue at P4 (P = 0.6301)
17:44039714:C:T,P10636,P4L,0.27,Loss of glycosylation at P4 (P = 0.107); Loss of disorder (P = 0.2204); Loss of catalytic residue at P4 (P = 0.2679); Loss of relative solvent accessibility (P = 0.5582); Loss of solvent accessibility (P = 0.5743)
17:44039716:C:A,P10636,R5S,0.17,Gain of phosphorylation at E5 (P = 0.0276); Gain of glycosylation at R5 (P = 0.0367); Gain of relative solvent accessibility (P = 0.2363); Gain of catalytic residue at E9 (P = 0.2894); Loss of solvent accessibility (P = 0.5904)
17:44039716:C:G,P10636,R5G,0.187,Loss of solvent accessibility (P = 0.239); Gain of catalytic residue at E9 (P = 0.2508); Loss of glycosylation at P4 (P = 0.2626); Loss of stability (P = 0.4964); Gain of disorder (P = 0.6187)
17:44039716:C:T,P10636,R5C,0.241,Gain of catalytic residue at E7 (P = 0.0864); Loss of disorder (P = 0.1946); Loss of glycosylation at P4 (P = 0.2166); Loss of solvent accessibility (P = 0.3854); Gain of sheet (P = 0.6509)
17:44039717:G:C,P10636,R5P,0.176,Gain of catalytic residue at P4 (P = 0.1462); Gain of relative solvent accessibility (P = 0.2363); Gain of glycosylation at P4 (P = 0.2896); Gain of disorder (P = 0.5929); Loss of solvent accessibility (P = 0.6392)
17:44039717:G:T,P10636,R5L,0.288,Gain of stability (P = 0.0485); Loss of disorder (P = 0.1465); Loss of solvent accessibility (P = 0.1922); Loss of glycosylation at P4 (P = 0.2241); Gain of catalytic residue at E9 (P = 0.2984)
17:44039719:C:A,P10636,Q6K,0.194,Gain of ubiquitination at Q6 (P = 0.0054); Gain of methylation at Q6 (P = 0.0335); Gain of glycosylation at Q6 (P = 0.0493); Loss of stability (P = 0.3031); Gain of solvent accessibility (P = 0.571)
17:44039719:C:G,P10636,Q6E,0.136,Gain of glycosylation at P4 (P = 0.4086); Gain of disorder (P = 0.5745); Gain of methylation at R5 (P = 0.6262); Loss of stability (P = 0.6728); Loss of sheet (P = 0.7751)
17:44039720:A:C,P10636,Q6P,0.165,Gain of glycosylation at Q6 (P = 0.0657); Gain of catalytic residue at Q6 (P = 0.131); Loss of stability (P = 0.2065); Loss of solvent accessibility (P = 0.4995); Gain of methylation at R5 (P = 0.541)
17:44039720:A:G,P10636,Q6R,0.143,Gain of solvent accessibility (P = 0.3194); Gain of glycosylation at P4 (P = 0.4098); Loss of stability (P = 0.5602); Gain of disorder (P = 0.5976); Gain of methylation at Q6 (P = 0.645)
17:44039720:A:T,P10636,Q6L,0.219,Loss of disorder (P = 0.1309); Loss of solvent accessibility (P = 0.3854); Loss of glycosylation at P4 (P = 0.394); Gain of methylation at R5 (P = 0.5518); Gain of catalytic residue at Q6 (P = 0.5642)
17:44039721:G:C,P10636,Q6H,0.158,Loss of stability (P = 0.2962); Gain of catalytic residue at E7 (P = 0.31); Loss of glycosylation at P4 (P = 0.3527); Loss of solvent accessibility (P = 0.4653); Loss of disorder (P = 0.5906)
17:44039721:G:T,P10636,Q6H,0.158,Loss of stability (P = 0.2962); Gain of catalytic residue at E7 (P = 0.31); Loss of glycosylation at P4 (P = 0.3527); Loss of solvent accessibility (P = 0.4653); Loss of disorder (P = 0.5906)
17:44039722:G:A,P10636,E7K,0.31,Gain of methylation at E7 (P = 0.0051); Gain of ubiquitination at E7 (P = 0.006); Gain of glycosylation at E7 (P = 0.0648); Loss of stability (P = 0.3716); Gain of solvent accessibility (P = 0.4821)
17:44039722:G:C,P10636,E7Q,0.173,Loss of solvent accessibility (P = 0.1868); Gain of glycosylation at P4 (P = 0.195); Loss of relative solvent accessibility (P = 0.3219); Loss of disorder (P = 0.6031); Loss of methylation at R5 (P = 0.6603)
17:44039723:A:C,P10636,E7A,0.236,Loss of solvent accessibility (P = 0.0224); Loss of relative solvent accessibility (P = 0.1807); Loss of disorder (P = 0.2463); Gain of glycosylation at P4 (P = 0.4241); Loss of stability (P = 0.5483)
17:44039723:A:G,P10636,E7G,0.221,Loss of solvent accessibility (P = 0.0299); Loss of stability (P = 0.1595); Loss of glycosylation at P4 (P = 0.2598); Loss of relative solvent accessibility (P = 0.3219); Loss of disorder (P = 0.5164)
17:44039723:A:T,P10636,E7V,0.366,Loss of solvent accessibility (P = 0.0199); Loss of disorder (P = 0.0364); Gain of catalytic residue at E7 (P = 0.0448); Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at P4 (P = 0.2769)
17:44039724:G:C,P10636,E7D,0.172,Loss of glycosylation at P4 (P = 0.3148); Loss of solvent accessibility (P = 0.5485); Loss of disorder (P = 0.6097); Gain of methylation at R5 (P = 0.656); Loss of stability (P = 0.7121)
17:44039724:G:T,P10636,E7D,0.172,Loss of glycosylation at P4 (P = 0.3148); Loss of solvent accessibility (P = 0.5485); Loss of disorder (P = 0.6097); Gain of methylation at R5 (P = 0.656); Loss of stability (P = 0.7121)
17:44039725:T:A,P10636,F8I,0.101,Loss of glycosylation at P4 (P = 0.4106); Loss of disorder (P = 0.5398); Loss of stability (P = 0.578); Loss of sheet (P = 0.6423); Loss of methylation at R5 (P = 0.6602)
17:44039725:T:C,P10636,F8L,0.135,Loss of glycosylation at P4 (P = 0.4371); Gain of disorder (P = 0.5114); Loss of stability (P = 0.6196); Loss of sheet (P = 0.6423); Gain of methylation at R5 (P = 0.6555)
17:44039725:T:G,P10636,F8V,0.1,Loss of stability (P = 0.331); Loss of glycosylation at P4 (P = 0.3572); Gain of disorder (P = 0.5234); Loss of sheet (P = 0.6423); Gain of methylation at R5 (P = 0.6502)
17:44039726:T:A,P10636,F8Y,0.127,Gain of phosphorylation at F8 (P = 0.0056); Loss of stability (P = 0.2032); Gain of glycosylation at P4 (P = 0.2746); Gain of disorder (P = 0.5331); Gain of solvent accessibility (P = 0.571)
17:44039726:T:C,P10636,F8S,0.188,Gain of phosphorylation at F8 (P = 0.0085); Gain of glycosylation at F8 (P = 0.0239); Loss of stability (P = 0.0578); Gain of relative solvent accessibility (P = 0.2751); Gain of disorder (P = 0.4156)
17:44039726:T:G,P10636,F8C,0.15,Gain of catalytic residue at V10 (P = 0.0891); Loss of stability (P = 0.2264); Loss of glycosylation at P4 (P = 0.4106); Gain of disorder (P = 0.5019); Gain of methylation at R5 (P = 0.6498)
17:44039727:C:A,P10636,F8L,0.135,Loss of glycosylation at P4 (P = 0.4371); Gain of disorder (P = 0.5114); Loss of stability (P = 0.6196); Loss of sheet (P = 0.6423); Gain of methylation at R5 (P = 0.6555)
17:44039727:C:G,P10636,F8L,0.135,Loss of glycosylation at P4 (P = 0.4371); Gain of disorder (P = 0.5114); Loss of stability (P = 0.6196); Loss of sheet (P = 0.6423); Gain of methylation at R5 (P = 0.6555)
17:44039728:G:C,P10636,E9Q,0.118,Gain of glycosylation at P4 (P = 0.1897); Loss of stability (P = 0.4587); Loss of catalytic residue at H14 (P = 0.5457); Loss of disorder (P = 0.5602); Gain of solvent accessibility (P = 0.5843)
17:44039729:A:C,P10636,E9A,0.164,Gain of glycosylation at P4 (P = 0.126); Loss of disorder (P = 0.1959); Loss of solvent accessibility (P = 0.2106); Loss of stability (P = 0.2654); Gain of catalytic residue at E7 (P = 0.3143)
17:44039729:A:G,P10636,E9G,0.141,Gain of catalytic residue at V10 (P = 0.0444); Loss of stability (P = 0.124); Loss of solvent accessibility (P = 0.2732); Gain of glycosylation at P4 (P = 0.3494); Loss of disorder (P = 0.4729)
17:44039729:A:T,P10636,E9V,0.225,Loss of disorder (P = 0.0307); Gain of catalytic residue at E12 (P = 0.1081); Gain of glycosylation at P4 (P = 0.2145); Loss of solvent accessibility (P = 0.3368); Loss of stability (P = 0.5857)
17:44039730:A:C,P10636,E9D,0.101,Loss of glycosylation at P4 (P = 0.3591); Loss of stability (P = 0.3959); Loss of disorder (P = 0.5722); Gain of sheet (P = 0.6509); Gain of methylation at R5 (P = 0.6546)
17:44039730:A:T,P10636,E9D,0.101,Loss of glycosylation at P4 (P = 0.3591); Loss of stability (P = 0.3959); Loss of disorder (P = 0.5722); Gain of sheet (P = 0.6509); Gain of methylation at R5 (P = 0.6546)
17:44039731:G:A,P10636,V10M,0.19,Loss of stability (P = 0.1427); Loss of catalytic residue at D13 (P = 0.2569); Gain of disorder (P = 0.39); Gain of solvent accessibility (P = 0.5334); Gain of methylation at R5 (P = 0.6409)
17:44039731:G:C,P10636,V10L,0.136,Loss of catalytic residue at D13 (P = 0.3749); Loss of stability (P = 0.4933); Gain of disorder (P = 0.5083); Gain of solvent accessibility (P = 0.5843); Loss of sheet (P = 0.6423)
17:44039731:G:T,P10636,V10L,0.136,Loss of catalytic residue at D13 (P = 0.3749); Loss of stability (P = 0.4933); Gain of disorder (P = 0.5083); Gain of solvent accessibility (P = 0.5843); Loss of sheet (P = 0.6423)
17:44039732:T:A,P10636,V10E,0.187,Loss of catalytic residue at D13 (P = 0.0381); Loss of stability (P = 0.0756); Gain of solvent accessibility (P = 0.0789); Gain of relative solvent accessibility (P = 0.09); Gain of disorder (P = 0.337)
17:44039732:T:C,P10636,V10A,0.188,Loss of stability (P = 0.0578); Loss of catalytic residue at D13 (P = 0.2989); Gain of disorder (P = 0.4378); Gain of methylation at R5 (P = 0.6361); Loss of sheet (P = 0.6423)
17:44039732:T:G,P10636,V10G,0.256,Loss of stability (P = 9e-04); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at D13 (P = 0.2814); Gain of disorder (P = 0.3833); Gain of solvent accessibility (P = 0.4821)
17:44039734:A:C,P10636,M11L,0.305,Loss of disorder (P = 0.1636); Loss of catalytic residue at H14 (P = 0.6882); Loss of MoRF binding (P = 0.7541); Loss of sheet (P = 0.7751); Loss of stability (P = 0.8122)
17:44039734:A:G,P10636,M11V,0.284,Loss of disorder (P = 0.1217); Loss of stability (P = 0.4952); Loss of MoRF binding (P = 0.7571); Loss of sheet (P = 0.7751); Gain of catalytic residue at H14 (P = 0.8329)
17:44039734:A:T,P10636,M11L,0.305,Loss of disorder (P = 0.1636); Loss of catalytic residue at H14 (P = 0.6882); Loss of MoRF binding (P = 0.7541); Loss of sheet (P = 0.7751); Loss of stability (P = 0.8122)
17:44039735:T:A,P10636,M11K,0.292,Gain of ubiquitination at M11 (P = 0.0039); Gain of glycosylation at M11 (P = 0.0363); Gain of solvent accessibility (P = 0.0789); Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.1318)
17:44039735:T:C,P10636,M11T,0.233,Gain of phosphorylation at M11 (P = 0.014); Gain of glycosylation at M11 (P = 0.0279); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.2285); Gain of solvent accessibility (P = 0.3304)
17:44039735:T:G,P10636,M11R,0.255,Gain of solvent accessibility (P = 0.1133); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.2896); Gain of methylation at M11 (P = 0.5137); Gain of disorder (P = 0.5234)
17:44039736:G:A,P10636,M11I,0.324,Loss of disorder (P = 0.0287); Loss of stability (P = 0.6754); Loss of MoRF binding (P = 0.7553); Loss of sheet (P = 0.7751); Loss of catalytic residue at H14 (P = 0.8451)
17:44039736:G:C,P10636,M11I,0.324,Loss of disorder (P = 0.0287); Loss of stability (P = 0.6754); Loss of MoRF binding (P = 0.7553); Loss of sheet (P = 0.7751); Loss of catalytic residue at H14 (P = 0.8451)
17:44039736:G:T,P10636,M11I,0.324,Loss of disorder (P = 0.0287); Loss of stability (P = 0.6754); Loss of MoRF binding (P = 0.7553); Loss of sheet (P = 0.7751); Loss of catalytic residue at H14 (P = 0.8451)
17:44039737:G:A,P10636,E12K,0.295,Gain of ubiquitination at E12 (P = 0.0042); Gain of glycosylation at E12 (P = 0.0311); Gain of catalytic residue at E12 (P = 0.1211); Gain of relative solvent accessibility (P = 0.1894); Gain of solvent accessibility (P = 0.2192)
17:44039737:G:C,P10636,E12Q,0.184,Loss of phosphorylation at T17 (P = 0.2943); Loss of glycosylation at T17 (P = 0.3178); Loss of stability (P = 0.4479); Loss of disorder (P = 0.5369); Gain of MoRF binding (P = 0.5681)
17:44039738:A:C,P10636,E12A,0.264,Loss of disorder (P = 0.1404); Loss of solvent accessibility (P = 0.3543); Loss of stability (P = 0.3617); Gain of phosphorylation at T17 (P = 0.3663); Loss of glycosylation at T17 (P = 0.3803)
17:44039738:A:G,P10636,E12G,0.195,Loss of stability (P = 0.0686); Loss of solvent accessibility (P = 0.1868); Gain of catalytic residue at F8 (P = 0.235); Gain of phosphorylation at T17 (P = 0.3242); Loss of glycosylation at T17 (P = 0.3783)
17:44039738:A:T,P10636,E12V,0.316,Loss of disorder (P = 0.0161); Loss of phosphorylation at T17 (P = 0.2371); Loss of solvent accessibility (P = 0.3368); Loss of glycosylation at T17 (P = 0.357); Gain of catalytic residue at E9 (P = 0.398)
17:44039739:A:C,P10636,E12D,0.172,Loss of stability (P = 0.2544); Gain of phosphorylation at T17 (P = 0.308); Loss of glycosylation at T17 (P = 0.3681); Loss of disorder (P = 0.5633); Loss of solvent accessibility (P = 0.7091)
17:44039739:A:T,P10636,E12D,0.172,Loss of stability (P = 0.2544); Gain of phosphorylation at T17 (P = 0.308); Loss of glycosylation at T17 (P = 0.3681); Loss of disorder (P = 0.5633); Loss of solvent accessibility (P = 0.7091)
17:44039740:G:A,P10636,D13N,0.224,Loss of phosphorylation at T17 (P = 0.1333); Loss of stability (P = 0.2348); Gain of relative solvent accessibility (P = 0.2363); Loss of disorder (P = 0.2447); Gain of glycosylation at T17 (P = 0.3274)
17:44039740:G:C,P10636,D13H,0.195,Loss of catalytic residue at D13 (P = 0.0302); Loss of stability (P = 0.1171); Loss of phosphorylation at T17 (P = 0.2371); Gain of glycosylation at T17 (P = 0.3367); Loss of disorder (P = 0.4039)
17:44039740:G:T,P10636,D13Y,0.332,Loss of disorder (P = 0.0292); Loss of catalytic residue at D13 (P = 0.0295); Gain of phosphorylation at D13 (P = 0.0323); Loss of stability (P = 0.3001); Loss of glycosylation at T17 (P = 0.3416)
17:44039741:A:C,P10636,D13A,0.24,Loss of catalytic residue at D13 (P = 0.0297); Loss of stability (P = 0.1573); Gain of glycosylation at T17 (P = 0.2389); Loss of phosphorylation at T17 (P = 0.2654); Loss of disorder (P = 0.2773)
17:44039741:A:G,P10636,D13G,0.183,Loss of stability (P = 0.0273); Loss of catalytic residue at D13 (P = 0.1112); Gain of glycosylation at T17 (P = 0.2606); Loss of phosphorylation at T17 (P = 0.3684); Gain of MoRF binding (P = 0.5147)
17:44039741:A:T,P10636,D13V,0.294,Loss of disorder (P = 0.0347); Loss of phosphorylation at T17 (P = 0.1531); Gain of glycosylation at T17 (P = 0.2892); Gain of catalytic residue at E12 (P = 0.3708); Loss of solvent accessibility (P = 0.4218)
17:44039742:T:A,P10636,D13E,0.134,Loss of catalytic residue at D13 (P = 0.0954); Gain of glycosylation at T17 (P = 0.3123); Loss of stability (P = 0.3476); Gain of phosphorylation at T17 (P = 0.3709); Gain of solvent accessibility (P = 0.4496)
17:44039742:T:G,P10636,D13E,0.134,Loss of catalytic residue at D13 (P = 0.0954); Gain of glycosylation at T17 (P = 0.3123); Loss of stability (P = 0.3476); Gain of phosphorylation at T17 (P = 0.3709); Gain of solvent accessibility (P = 0.4496)
17:44039743:C:A,P10636,H14N,0.091,Loss of catalytic residue at D13 (P = 0.0883); Gain of glycosylation at T17 (P = 0.3148); Gain of phosphorylation at T17 (P = 0.3515); Gain of disorder (P = 0.5707); Loss of sheet (P = 0.6423)
17:44039743:C:G,P10636,H14D,0.133,Loss of catalytic residue at D13 (P = 0.0371); Gain of relative solvent accessibility (P = 0.1571); Gain of phosphorylation at T17 (P = 0.2278); Gain of solvent accessibility (P = 0.28); Loss of glycosylation at T17 (P = 0.4032)
17:44039743:C:T,P10636,H14Y,0.191,Gain of phosphorylation at H14 (P = 0.0059); Loss of catalytic residue at D13 (P = 0.1282); Loss of disorder (P = 0.2155); Loss of glycosylation at T17 (P = 0.3742); Gain of solvent accessibility (P = 0.5485)
17:44039744:A:C,P10636,H14P,0.143,Loss of catalytic residue at D13 (P = 0.0408); Gain of glycosylation at T17 (P = 0.0992); Gain of phosphorylation at T17 (P = 0.2345); Gain of disorder (P = 0.4748); Loss of stability (P = 0.5351)
17:44039744:A:G,P10636,H14R,0.121,Gain of solvent accessibility (P = 0.1133); Loss of catalytic residue at D13 (P = 0.1431); Gain of relative solvent accessibility (P = 0.1571); Gain of phosphorylation at T17 (P = 0.187); Loss of glycosylation at T17 (P = 0.2819)
17:44039744:A:T,P10636,H14L,0.184,Loss of catalytic residue at H14 (P = 0.0446); Loss of phosphorylation at T17 (P = 0.1333); Gain of stability (P = 0.3061); Loss of disorder (P = 0.3315); Loss of glycosylation at T17 (P = 0.3625)
17:44039745:C:A,P10636,H14Q,0.1,Loss of catalytic residue at D13 (P = 0.0641); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.194); Gain of phosphorylation at T17 (P = 0.3386); Loss of glycosylation at T17 (P = 0.3798)
17:44039745:C:G,P10636,H14Q,0.1,Loss of catalytic residue at D13 (P = 0.0641); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.194); Gain of phosphorylation at T17 (P = 0.3386); Loss of glycosylation at T17 (P = 0.3798)
17:44039746:G:C,P10636,A15P,0.1,Gain of glycosylation at T17 (P = 0.1447); Loss of stability (P = 0.15); Gain of phosphorylation at T17 (P = 0.2154); Loss of catalytic residue at D13 (P = 0.2395); Gain of solvent accessibility (P = 0.4067)
17:44039746:G:T,P10636,A15S,0.056,Gain of glycosylation at A15 (P = 0.0171); Gain of phosphorylation at A15 (P = 0.048); Loss of catalytic residue at A15 (P = 0.3188); Loss of stability (P = 0.4222); Gain of solvent accessibility (P = 0.4496)
17:44039747:C:A,P10636,A15D,0.099,Gain of phosphorylation at T17 (P = 0.2387); Gain of solvent accessibility (P = 0.2902); Loss of catalytic residue at D13 (P = 0.3002); Loss of glycosylation at T17 (P = 0.3713); Gain of disorder (P = 0.4636)
17:44039747:C:G,P10636,A15G,0.055,Loss of stability (P = 0.1047); Gain of glycosylation at T17 (P = 0.1682); Gain of catalytic residue at G16 (P = 0.2288); Gain of phosphorylation at T17 (P = 0.3286); Gain of disorder (P = 0.4925)
17:44039747:C:T,P10636,A15V,0.064,Loss of catalytic residue at A15 (P = 0.1898); Loss of phosphorylation at T17 (P = 0.2896); Loss of disorder (P = 0.3208); Loss of glycosylation at T17 (P = 0.3721); Gain of solvent accessibility (P = 0.3819)
17:44039749:G:A,P10636,G16R,0.215,Gain of solvent accessibility (P = 0.0023); Loss of catalytic residue at A15 (P = 0.0367); Gain of relative solvent accessibility (P = 0.0479); Gain of MoRF binding (P = 0.085); Loss of glycosylation at T17 (P = 0.1653)
17:44039749:G:C,P10636,G16R,0.215,Gain of solvent accessibility (P = 0.0023); Loss of catalytic residue at A15 (P = 0.0367); Gain of relative solvent accessibility (P = 0.0479); Gain of MoRF binding (P = 0.085); Loss of glycosylation at T17 (P = 0.1653)
17:44039749:G:T,P10636,G16W,0.337,Loss of disorder (P = 9e-04); Loss of phosphorylation at T17 (P = 0.0927); Loss of glycosylation at T17 (P = 0.186); Gain of MoRF binding (P = 0.4518); Gain of catalytic residue at G16 (P = 0.4823)
17:44039750:G:A,P10636,G16E,0.17,Gain of solvent accessibility (P = 0.012); Loss of catalytic residue at A15 (P = 0.0291); Gain of relative solvent accessibility (P = 0.0479); Loss of glycosylation at T17 (P = 0.2041); Gain of phosphorylation at T17 (P = 0.3112)
17:44039750:G:C,P10636,G16A,0.123,Gain of relative solvent accessibility (P = 0.0166); Loss of catalytic residue at A15 (P = 0.061); Gain of solvent accessibility (P = 0.0648); Gain of glycosylation at T17 (P = 0.2089); Loss of phosphorylation at T17 (P = 0.3109)
17:44039750:G:T,P10636,G16V,0.238,Loss of catalytic residue at A15 (P = 0.0601); Loss of disorder (P = 0.0672); Loss of phosphorylation at T17 (P = 0.2248); Loss of glycosylation at T17 (P = 0.3836); Loss of relative solvent accessibility (P = 0.5582)
17:44039752:A:C,P10636,T17P,0.15,Loss of phosphorylation at T17 (P = 0.0248); Gain of catalytic residue at T17 (P = 0.1268); Loss of glycosylation at T17 (P = 0.1402); Loss of stability (P = 0.2645); Gain of disorder (P = 0.4902)
17:44039752:A:G,P10636,T17A,0.144,Loss of phosphorylation at T17 (P = 0.0248); Loss of glycosylation at T17 (P = 0.0916); Gain of catalytic residue at T17 (P = 0.155); Gain of disorder (P = 0.5693); Gain of MoRF binding (P = 0.6014)
17:44039752:A:T,P10636,T17S,0.095,Loss of glycosylation at T17 (P = 0.1704); Loss of phosphorylation at T17 (P = 0.1742); Gain of disorder (P = 0.529); Gain of MoRF binding (P = 0.6153); Loss of stability (P = 0.629)
17:44039753:C:A,P10636,T17K,0.25,Gain of ubiquitination at T17 (P = 0.0025); Loss of phosphorylation at T17 (P = 0.0248); Gain of methylation at T17 (P = 0.0352); Gain of glycosylation at T17 (P = 0.0645); Gain of solvent accessibility (P = 0.154)
17:44039753:C:G,P10636,T17R,0.192,Loss of phosphorylation at T17 (P = 0.0248); Gain of solvent accessibility (P = 0.0808); Loss of glycosylation at T17 (P = 0.0916); Loss of catalytic residue at D13 (P = 0.2051); Gain of relative solvent accessibility (P = 0.2363)
17:44039755:T:A,P10636,Y18N,0.241,Loss of phosphorylation at Y18 (P = 0.0109); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.1422); Gain of catalytic residue at T17 (P = 0.2228); Loss of glycosylation at T17 (P = 0.3743)
17:44039755:T:C,P10636,Y18H,0.228,Loss of phosphorylation at Y18 (P = 0.0109); Gain of catalytic residue at L20 (P = 0.1928); Gain of glycosylation at T17 (P = 0.2014); Gain of disorder (P = 0.4235); Gain of MoRF binding (P = 0.6111)
17:44039755:T:G,P10636,Y18D,0.251,Loss of phosphorylation at Y18 (P = 0.0109); Gain of relative solvent accessibility (P = 0.0479); Loss of catalytic residue at Y18 (P = 0.0895); Gain of solvent accessibility (P = 0.1154); Loss of glycosylation at T17 (P = 0.2981)
17:44039756:A:C,P10636,Y18S,0.254,Gain of glycosylation at Y18 (P = 0.0039); Gain of relative solvent accessibility (P = 0.0166); Loss of phosphorylation at Y18 (P = 0.0687); Gain of solvent accessibility (P = 0.1154); Gain of catalytic residue at G16 (P = 0.1636)
17:44039756:A:G,P10636,Y18C,0.247,Loss of phosphorylation at Y18 (P = 0.0109); Gain of glycosylation at T17 (P = 0.222); Loss of catalytic residue at Y18 (P = 0.3699); Loss of solvent accessibility (P = 0.4995); Gain of disorder (P = 0.5096)
17:44039756:A:T,P10636,Y18F,0.241,Loss of phosphorylation at Y18 (P = 0.0109); Loss of glycosylation at T17 (P = 0.4011); Loss of catalytic residue at Y18 (P = 0.4654); Gain of disorder (P = 0.5285); Loss of MoRF binding (P = 0.6213)
17:44039758:G:A,P10636,G19R,0.206,Gain of solvent accessibility (P = 0.0456); Gain of MoRF binding (P = 0.0644); Loss of glycosylation at K24 (P = 0.0926); Loss of catalytic residue at L20 (P = 0.1423); Loss of methylation at K24 (P = 0.1742)
17:44039758:G:C,P10636,G19R,0.206,Gain of solvent accessibility (P = 0.0456); Gain of MoRF binding (P = 0.0644); Loss of glycosylation at K24 (P = 0.0926); Loss of catalytic residue at L20 (P = 0.1423); Loss of methylation at K24 (P = 0.1742)
17:44039758:G:T,P10636,G19W,0.352,Loss of disorder (P = 0.0024); Loss of phosphorylation at T17 (P = 0.0956); Loss of catalytic residue at L20 (P = 0.1691); Loss of glycosylation at K24 (P = 0.1893); Gain of solvent accessibility (P = 0.3304)
17:44039759:G:A,P10636,G19E,0.159,Gain of solvent accessibility (P = 0.1045); Loss of catalytic residue at L20 (P = 0.166); Loss of glycosylation at K24 (P = 0.2072); Gain of relative solvent accessibility (P = 0.2363); Gain of phosphorylation at T17 (P = 0.2799)
17:44039759:G:C,P10636,G19A,0.124,Loss of catalytic residue at L20 (P = 0.1597); Loss of glycosylation at K24 (P = 0.2528); Loss of phosphorylation at T17 (P = 0.3162); Loss of methylation at K24 (P = 0.3906); Loss of ubiquitination at K24 (P = 0.3955)
17:44039759:G:T,P10636,G19V,0.257,Loss of disorder (P = 0.0792); Gain of catalytic residue at G19 (P = 0.1579); Loss of glycosylation at K24 (P = 0.1759); Loss of phosphorylation at T17 (P = 0.2371); Loss of ubiquitination at K24 (P = 0.3851)
17:44039761:T:A,P10636,L20M,0.114,Gain of glycosylation at K24 (P = 0.1874); Gain of catalytic residue at L20 (P = 0.2378); Gain of phosphorylation at T17 (P = 0.3457); Loss of stability (P = 0.3681); Loss of ubiquitination at K24 (P = 0.3851)
17:44039761:T:G,P10636,L20V,0.067,Loss of glycosylation at K24 (P = 0.2116); Gain of catalytic residue at L20 (P = 0.2378); Loss of stability (P = 0.2784); Gain of phosphorylation at T17 (P = 0.333); Gain of methylation at K24 (P = 0.3865)
17:44039762:T:C,P10636,L20S,0.111,Gain of glycosylation at L20 (P = 0.007); Gain of phosphorylation at L20 (P = 0.0275); Loss of stability (P = 0.1096); Gain of methylation at K24 (P = 0.3884); Loss of ubiquitination at K24 (P = 0.3911)
17:44039762:T:G,P10636,L20W,0.124,Loss of stability (P = 0.126); Loss of phosphorylation at T17 (P = 0.1782); Loss of disorder (P = 0.2297); Gain of glycosylation at K24 (P = 0.2681); Gain of MoRF binding (P = 0.3402)
17:44039763:G:C,P10636,L20F,0.064,Gain of catalytic residue at L20 (P = 0.2283); Loss of glycosylation at K24 (P = 0.2595); Loss of stability (P = 0.2598); Gain of phosphorylation at T17 (P = 0.3354); Gain of methylation at K24 (P = 0.3886)
17:44039763:G:T,P10636,L20F,0.064,Gain of catalytic residue at L20 (P = 0.2283); Loss of glycosylation at K24 (P = 0.2595); Loss of stability (P = 0.2598); Gain of phosphorylation at T17 (P = 0.3354); Gain of methylation at K24 (P = 0.3886)
17:44039764:G:A,P10636,G21R,0.103,Loss of glycosylation at K24 (P = 0.0761); Gain of solvent accessibility (P = 0.1319); Gain of MoRF binding (P = 0.169); Loss of methylation at K24 (P = 0.2202); Gain of catalytic residue at G21 (P = 0.2706)
17:44039764:G:C,P10636,G21R,0.103,Loss of glycosylation at K24 (P = 0.0761); Gain of solvent accessibility (P = 0.1319); Gain of MoRF binding (P = 0.169); Loss of methylation at K24 (P = 0.2202); Gain of catalytic residue at G21 (P = 0.2706)
17:44039764:G:T,P10636,G21W,0.298,Loss of disorder (P = 0.0049); Loss of phosphorylation at T17 (P = 0.1294); Gain of solvent accessibility (P = 0.1583); Loss of glycosylation at K24 (P = 0.1715); Loss of catalytic residue at K24 (P = 0.3035)
17:44039765:G:A,P10636,G21E,0.188,Gain of solvent accessibility (P = 0.0026); Gain of relative solvent accessibility (P = 0.0166); Loss of glycosylation at K24 (P = 0.1695); Loss of methylation at K24 (P = 0.2249); Loss of catalytic residue at R23 (P = 0.3549)
17:44039765:G:C,P10636,G21A,0.077,Gain of catalytic residue at G21 (P = 0.0718); Loss of glycosylation at K24 (P = 0.2409); Loss of phosphorylation at T17 (P = 0.3294); Loss of ubiquitination at K24 (P = 0.3955); Loss of methylation at K24 (P = 0.4073)
17:44039765:G:T,P10636,G21V,0.169,Loss of disorder (P = 0.0978); Loss of glycosylation at K24 (P = 0.1772); Loss of phosphorylation at T17 (P = 0.1993); Gain of catalytic residue at G21 (P = 0.3438); Gain of solvent accessibility (P = 0.3602)
17:44039767:G:A,P10636,D22N,0.107,Loss of solvent accessibility (P = 0.1202); Loss of glycosylation at K24 (P = 0.1604); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.1996); Loss of phosphorylation at T17 (P = 0.2205)
17:44039767:G:C,P10636,D22H,0.097,Loss of solvent accessibility (P = 0.1473); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.1981); Gain of catalytic residue at D22 (P = 0.241); Gain of glycosylation at K24 (P = 0.2499)
17:44039767:G:T,P10636,D22Y,0.152,Loss of disorder (P = 0.0667); Gain of phosphorylation at D22 (P = 0.112); Loss of glycosylation at K24 (P = 0.1141); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2073)
17:44039768:A:C,P10636,D22A,0.099,Loss of solvent accessibility (P = 0.0595); Loss of stability (P = 0.1361); Loss of glycosylation at K24 (P = 0.1599); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at D22 (P = 0.2107)
17:44039768:A:G,P10636,D22G,0.126,Loss of solvent accessibility (P = 0.0477); Loss of stability (P = 0.0651); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at G19 (P = 0.2303); Gain of glycosylation at K24 (P = 0.2364)
17:44039768:A:T,P10636,D22V,0.155,Loss of solvent accessibility (P = 0.0371); Gain of catalytic residue at D22 (P = 0.0568); Loss of disorder (P = 0.0665); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K24 (P = 0.0959)
17:44039769:C:A,P10636,D22E,0.084,Loss of solvent accessibility (P = 0.1651); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at K24 (P = 0.2137); Gain of catalytic residue at D22 (P = 0.354); Gain of phosphorylation at T17 (P = 0.3709)
17:44039769:C:G,P10636,D22E,0.084,Loss of solvent accessibility (P = 0.1651); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at K24 (P = 0.2137); Gain of catalytic residue at D22 (P = 0.354); Gain of phosphorylation at T17 (P = 0.3709)
17:44039770:A:G,P10636,R23G,0.117,Loss of stability (P = 0.1636); Loss of solvent accessibility (P = 0.239); Loss of catalytic residue at R23 (P = 0.244); Loss of methylation at K24 (P = 0.2462); Gain of glycosylation at K24 (P = 0.2561)
17:44039770:A:T,P10636,R23W,0.232,Loss of disorder (P = 0.011); Loss of glycosylation at K24 (P = 0.126); Loss of catalytic residue at R23 (P = 0.2597); Loss of solvent accessibility (P = 0.2668); Loss of ubiquitination at K24 (P = 0.3339)
17:44039771:G:A,P10636,R23K,0.221,Gain of ubiquitination at R23 (P = 0.0114); Gain of methylation at R23 (P = 0.0121); Gain of glycosylation at R23 (P = 0.0137); Loss of stability (P = 0.1152); Gain of disorder (P = 0.5937)
17:44039771:G:C,P10636,R23T,0.13,Gain of phosphorylation at R23 (P = 0.0331); Loss of ubiquitination at K24 (P = 0.0598); Gain of glycosylation at R23 (P = 0.1441); Loss of stability (P = 0.2672); Loss of solvent accessibility (P = 0.2732)
17:44039771:G:T,P10636,R23M,0.134,Loss of methylation at K24 (P = 0.0235); Loss of glycosylation at K24 (P = 0.1987); Loss of solvent accessibility (P = 0.2034); Gain of catalytic residue at R23 (P = 0.3636); Loss of ubiquitination at K24 (P = 0.3787)
17:44039772:G:C,P10636,R23S,0.117,Loss of ubiquitination at K24 (P = 0.0598); Gain of phosphorylation at R23 (P = 0.1168); Loss of glycosylation at K24 (P = 0.1565); Loss of methylation at K24 (P = 0.2162); Loss of stability (P = 0.3581)
17:44039772:G:T,P10636,R23S,0.117,Loss of ubiquitination at K24 (P = 0.0598); Gain of phosphorylation at R23 (P = 0.1168); Loss of glycosylation at K24 (P = 0.1565); Loss of methylation at K24 (P = 0.2162); Loss of stability (P = 0.3581)
17:44039773:A:C,P10636,K24Q,0.264,Loss of ubiquitination at K24 (P = 0.0011); Loss of methylation at K24 (P = 0.004); Loss of catalytic residue at K24 (P = 0.0177); Loss of glycosylation at K24 (P = 0.0219); Loss of stability (P = 0.2016)
17:44039773:A:G,P10636,K24E,0.243,Loss of ubiquitination at K24 (P = 0.0011); Loss of methylation at K24 (P = 0.004); Loss of glycosylation at K24 (P = 0.0219); Loss of catalytic residue at K24 (P = 0.0488); Gain of phosphorylation at Y29 (P = 0.3512)
17:44039774:A:C,P10636,K24T,0.29,Loss of ubiquitination at K24 (P = 0.0011); Loss of methylation at K24 (P = 0.004); Loss of glycosylation at K24 (P = 0.0242); Loss of solvent accessibility (P = 0.0249); Gain of phosphorylation at K24 (P = 0.041)
17:44039774:A:G,P10636,K24R,0.234,Loss of ubiquitination at K24 (P = 0.0011); Loss of methylation at K24 (P = 0.0057); Loss of glycosylation at K24 (P = 0.0219); Loss of solvent accessibility (P = 0.1115); Loss of catalytic residue at K24 (P = 0.1258)
17:44039774:A:T,P10636,K24I,0.311,Loss of ubiquitination at K24 (P = 0.0011); Loss of methylation at K24 (P = 0.004); Loss of glycosylation at K24 (P = 0.0219); Loss of solvent accessibility (P = 0.0431); Loss of disorder (P = 0.0734)
17:44039775:A:C,P10636,K24N,0.256,Loss of ubiquitination at K24 (P = 0.0011); Loss of methylation at K24 (P = 0.004); Loss of glycosylation at K24 (P = 0.0219); Loss of catalytic residue at K24 (P = 0.095); Loss of solvent accessibility (P = 0.1579)
17:44039775:A:T,P10636,K24N,0.256,Loss of ubiquitination at K24 (P = 0.0011); Loss of methylation at K24 (P = 0.004); Loss of glycosylation at K24 (P = 0.0219); Loss of catalytic residue at K24 (P = 0.095); Loss of solvent accessibility (P = 0.1579)
17:44039776:G:A,P10636,D25N,0.092,Loss of solvent accessibility (P = 0.0595); Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at K24 (P = 0.2023); Loss of phosphorylation at Y29 (P = 0.3374); Gain of MoRF binding (P = 0.3607)
17:44039776:G:C,P10636,D25H,0.091,Loss of solvent accessibility (P = 0.0442); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at K24 (P = 0.1818); Gain of catalytic residue at Y29 (P = 0.2824); Loss of phosphorylation at Y29 (P = 0.3645)
17:44039776:G:T,P10636,D25Y,0.151,Gain of phosphorylation at D25 (P = 0.033); Loss of solvent accessibility (P = 0.0509); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K24 (P = 0.167); Loss of disorder (P = 0.1688)
17:44039777:A:C,P10636,D25A,0.118,Loss of solvent accessibility (P = 0.0249); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K24 (P = 0.2554); Gain of MoRF binding (P = 0.2643); Loss of stability (P = 0.2658)
17:44039777:A:G,P10636,D25G,0.113,Loss of solvent accessibility (P = 0.0231); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at K24 (P = 0.1203); Loss of stability (P = 0.2243); Gain of MoRF binding (P = 0.3255)
17:44039777:A:T,P10636,D25V,0.148,Loss of solvent accessibility (P = 0.0371); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K24 (P = 0.1394); Loss of disorder (P = 0.156); Gain of MoRF binding (P = 0.2197)
17:44039778:T:A,P10636,D25E,0.065,Gain of glycosylation at K24 (P = 0.175); Loss of catalytic residue at K24 (P = 0.2555); Gain of phosphorylation at Y29 (P = 0.2874); Gain of solvent accessibility (P = 0.3089); Gain of methylation at K24 (P = 0.3901)
17:44039778:T:G,P10636,D25E,0.065,Gain of glycosylation at K24 (P = 0.175); Loss of catalytic residue at K24 (P = 0.2555); Gain of phosphorylation at Y29 (P = 0.2874); Gain of solvent accessibility (P = 0.3089); Gain of methylation at K24 (P = 0.3901)
17:44039779:C:A,P10636,Q26K,0.199,Gain of ubiquitination at Q26 (P = 0.0018); Gain of methylation at Q26 (P = 0.016); Gain of glycosylation at Q26 (P = 0.0242); Gain of solvent accessibility (P = 0.0328); Gain of relative solvent accessibility (P = 0.0479)
17:44039779:C:G,P10636,Q26E,0.08,Gain of glycosylation at T30 (P = 0.1336); Gain of relative solvent accessibility (P = 0.2363); Gain of phosphorylation at Y29 (P = 0.2571); Gain of solvent accessibility (P = 0.3089); Loss of methylation at K24 (P = 0.3252)
17:44039780:A:C,P10636,Q26P,0.085,Loss of ubiquitination at K24 (P = 0.0715); Gain of glycosylation at T30 (P = 0.126); Loss of stability (P = 0.3072); Gain of phosphorylation at Y29 (P = 0.3165); Gain of catalytic residue at Y29 (P = 0.3727)
17:44039780:A:G,P10636,Q26R,0.066,Loss of glycosylation at K24 (P = 0.1501); Loss of methylation at K24 (P = 0.182); Gain of MoRF binding (P = 0.2262); Loss of phosphorylation at Y29 (P = 0.2423); Gain of solvent accessibility (P = 0.3819)
17:44039780:A:T,P10636,Q26L,0.144,Loss of ubiquitination at K24 (P = 0.0385); Loss of methylation at K24 (P = 0.1464); Loss of phosphorylation at Y29 (P = 0.1659); Loss of glycosylation at K24 (P = 0.1912); Gain of catalytic residue at Q26 (P = 0.2226)
17:44039781:G:C,P10636,Q26H,0.06,Gain of catalytic residue at D25 (P = 0.0796); Gain of glycosylation at K24 (P = 0.1989); Loss of stability (P = 0.3468); Loss of methylation at K24 (P = 0.3577); Gain of phosphorylation at Y29 (P = 0.3794)
17:44039781:G:T,P10636,Q26H,0.06,Gain of catalytic residue at D25 (P = 0.0796); Gain of glycosylation at K24 (P = 0.1989); Loss of stability (P = 0.3468); Loss of methylation at K24 (P = 0.3577); Gain of phosphorylation at Y29 (P = 0.3794)
17:44039782:G:A,P10636,G27R,0.086,Gain of solvent accessibility (P = 0.1319); Gain of phosphorylation at T30 (P = 0.1548); Gain of MoRF binding (P = 0.1718); Gain of glycosylation at K24 (P = 0.2384); Loss of methylation at K24 (P = 0.3352)
17:44039782:G:C,P10636,G27R,0.086,Gain of solvent accessibility (P = 0.1319); Gain of phosphorylation at T30 (P = 0.1548); Gain of MoRF binding (P = 0.1718); Gain of glycosylation at K24 (P = 0.2384); Loss of methylation at K24 (P = 0.3352)
17:44039782:G:T,P10636,G27W,0.193,Loss of disorder (P = 0.0646); Gain of catalytic residue at G27 (P = 0.0992); Loss of phosphorylation at Y29 (P = 0.1314); Loss of glycosylation at K24 (P = 0.1404); Gain of solvent accessibility (P = 0.1583)
17:44039783:G:A,P10636,G27E,0.079,Gain of solvent accessibility (P = 0.012); Gain of relative solvent accessibility (P = 0.0479); Gain of glycosylation at T30 (P = 0.1208); Gain of phosphorylation at Y29 (P = 0.3154); Loss of catalytic residue at K24 (P = 0.3671)
17:44039783:G:C,P10636,G27A,0.069,Gain of catalytic residue at G27 (P = 0.0995); Gain of glycosylation at T30 (P = 0.1366); Gain of relative solvent accessibility (P = 0.2363); Gain of solvent accessibility (P = 0.3418); Loss of methylation at K24 (P = 0.3619)
17:44039783:G:T,P10636,G27V,0.116,Gain of catalytic residue at G27 (P = 0.0426); Gain of glycosylation at T30 (P = 0.1156); Gain of solvent accessibility (P = 0.3602); Gain of phosphorylation at Y29 (P = 0.3878); Loss of ubiquitination at K24 (P = 0.3955)
17:44039785:G:C,P10636,G28R,0.15,Loss of glycosylation at K24 (P = 0.0888); Gain of solvent accessibility (P = 0.0971); Loss of phosphorylation at Y29 (P = 0.1233); Gain of relative solvent accessibility (P = 0.2629); Gain of MoRF binding (P = 0.2885)
17:44039785:G:T,P10636,G28C,0.154,Loss of phosphorylation at Y29 (P = 0.1178); Loss of glycosylation at T30 (P = 0.1477); Gain of catalytic residue at T30 (P = 0.2096); Loss of ubiquitination at K24 (P = 0.3911); Gain of methylation at K24 (P = 0.4084)
17:44039786:G:A,P10636,G28D,0.12,Gain of solvent accessibility (P = 0.0216); Gain of relative solvent accessibility (P = 0.0249); Loss of glycosylation at K24 (P = 0.15); Gain of phosphorylation at Y29 (P = 0.2659); Loss of ubiquitination at K24 (P = 0.3715)
17:44039786:G:C,P10636,G28A,0.112,Gain of catalytic residue at G28 (P = 0.1631); Loss of glycosylation at T30 (P = 0.2244); Loss of methylation at K24 (P = 0.3619); Gain of phosphorylation at Y29 (P = 0.3708); Loss of ubiquitination at K24 (P = 0.3955)
17:44039786:G:T,P10636,G28V,0.156,Gain of catalytic residue at G28 (P = 0.0482); Loss of glycosylation at K24 (P = 0.1828); Gain of phosphorylation at Y29 (P = 0.3136); Loss of ubiquitination at K24 (P = 0.3911); Gain of methylation at K24 (P = 0.4072)
17:44039788:T:A,P10636,Y29N,0.164,Loss of phosphorylation at Y29 (P = 0.0241); Gain of glycosylation at T30 (P = 0.1651); Loss of methylation at K24 (P = 0.2507); Loss of solvent accessibility (P = 0.3744); Loss of ubiquitination at K24 (P = 0.4067)
17:44039788:T:C,P10636,Y29H,0.195,Loss of phosphorylation at Y29 (P = 0.0241); Gain of catalytic residue at Y29 (P = 0.1242); Gain of glycosylation at K24 (P = 0.1344); Loss of methylation at K24 (P = 0.2603); Loss of ubiquitination at K24 (P = 0.4001)
17:44039788:T:G,P10636,Y29D,0.173,Loss of phosphorylation at Y29 (P = 0.0241); Gain of glycosylation at K24 (P = 0.1482); Loss of methylation at K24 (P = 0.274); Gain of ubiquitination at K24 (P = 0.4079); Loss of catalytic residue at H32 (P = 0.4477)
17:44039789:A:C,P10636,Y29S,0.208,Gain of glycosylation at Y29 (P = 0.0154); Loss of phosphorylation at Y29 (P = 0.1764); Loss of stability (P = 0.3114); Loss of solvent accessibility (P = 0.322); Gain of catalytic residue at G27 (P = 0.3266)
17:44039789:A:G,P10636,Y29C,0.19,Loss of phosphorylation at Y29 (P = 0.0241); Gain of catalytic residue at Y29 (P = 0.1544); Gain of glycosylation at T30 (P = 0.1929); Loss of methylation at K24 (P = 0.2911); Loss of solvent accessibility (P = 0.3368)
17:44039789:A:T,P10636,Y29F,0.197,Loss of phosphorylation at Y29 (P = 0.0241); Gain of catalytic residue at Y29 (P = 0.0775); Loss of methylation at K24 (P = 0.2052); Gain of glycosylation at T30 (P = 0.2071); Loss of ubiquitination at K24 (P = 0.4035)
17:44039791:A:C,P10636,T30P,0.105,Loss of phosphorylation at Y29 (P = 0.0972); Loss of glycosylation at T30 (P = 0.1128); Gain of relative solvent accessibility (P = 0.2363); Gain of solvent accessibility (P = 0.3819); Loss of catalytic residue at H32 (P = 0.579)
17:44039791:A:G,P10636,T30A,0.159,Gain of catalytic residue at T30 (P = 0.0361); Loss of glycosylation at T30 (P = 0.0649); Gain of phosphorylation at Y29 (P = 0.3204); Gain of MoRF binding (P = 0.6346); Loss of sheet (P = 0.6423)
17:44039791:A:T,P10636,T30S,0.135,Gain of phosphorylation at T30 (P = 0.0721); Loss of glycosylation at T30 (P = 0.0809); Gain of relative solvent accessibility (P = 0.2363); Gain of catalytic residue at T30 (P = 0.3693); Gain of solvent accessibility (P = 0.4137)
17:44039792:C:A,P10636,T30N,0.13,Loss of glycosylation at T30 (P = 0.0649); Gain of relative solvent accessibility (P = 0.2363); Gain of solvent accessibility (P = 0.2987); Loss of phosphorylation at T30 (P = 0.3631); Loss of catalytic residue at H32 (P = 0.5954)
17:44039792:C:G,P10636,T30S,0.135,Gain of phosphorylation at T30 (P = 0.0721); Loss of glycosylation at T30 (P = 0.0809); Gain of relative solvent accessibility (P = 0.2363); Gain of catalytic residue at T30 (P = 0.3693); Gain of solvent accessibility (P = 0.4137)
17:44039794:A:C,P10636,M31L,0.11,Loss of glycosylation at T30 (P = 0.1831); Loss of phosphorylation at Y29 (P = 0.1926); Loss of catalytic residue at M31 (P = 0.2404); Gain of relative solvent accessibility (P = 0.2751); Gain of solvent accessibility (P = 0.4496)
17:44039794:A:G,P10636,M31V,0.105,Loss of catalytic residue at M31 (P = 0.0658); Gain of glycosylation at T30 (P = 0.2781); Loss of stability (P = 0.3317); Loss of phosphorylation at Y29 (P = 0.3347); Loss of sheet (P = 0.6423)
17:44039794:A:T,P10636,M31L,0.11,Loss of glycosylation at T30 (P = 0.1831); Loss of phosphorylation at Y29 (P = 0.1926); Loss of catalytic residue at M31 (P = 0.2404); Gain of relative solvent accessibility (P = 0.2751); Gain of solvent accessibility (P = 0.4496)
17:44039795:T:A,P10636,M31K,0.244,Gain of solvent accessibility (P = 0.0016); Gain of relative solvent accessibility (P = 0.005); Gain of ubiquitination at M31 (P = 0.0051); Loss of stability (P = 0.019); Gain of glycosylation at M31 (P = 0.027)
17:44039795:T:C,P10636,M31T,0.137,Loss of catalytic residue at M31 (P = 0.0172); Loss of stability (P = 0.0202); Gain of phosphorylation at M31 (P = 0.0293); Gain of glycosylation at T30 (P = 0.0986); Gain of relative solvent accessibility (P = 0.2751)
17:44039795:T:G,P10636,M31R,0.15,Loss of catalytic residue at M31 (P = 0.012); Loss of stability (P = 0.0663); Gain of solvent accessibility (P = 0.1133); Gain of phosphorylation at T30 (P = 0.139); Gain of relative solvent accessibility (P = 0.1571)
17:44039796:G:A,P10636,M31I,0.116,Loss of catalytic residue at M31 (P = 0.0359); Loss of phosphorylation at Y29 (P = 0.2076); Gain of glycosylation at T30 (P = 0.296); Loss of stability (P = 0.4479); Loss of disorder (P = 0.5005)
17:44039796:G:C,P10636,M31I,0.116,Loss of catalytic residue at M31 (P = 0.0359); Loss of phosphorylation at Y29 (P = 0.2076); Gain of glycosylation at T30 (P = 0.296); Loss of stability (P = 0.4479); Loss of disorder (P = 0.5005)
17:44039796:G:T,P10636,M31I,0.116,Loss of catalytic residue at M31 (P = 0.0359); Loss of phosphorylation at Y29 (P = 0.2076); Gain of glycosylation at T30 (P = 0.296); Loss of stability (P = 0.4479); Loss of disorder (P = 0.5005)
17:44039797:C:A,P10636,H32N,0.091,Loss of catalytic residue at H32 (P = 0.0926); Gain of relative solvent accessibility (P = 0.2629); Loss of glycosylation at T30 (P = 0.2986); Loss of phosphorylation at Y29 (P = 0.3673); Gain of solvent accessibility (P = 0.4304)
17:44039797:C:G,P10636,H32D,0.096,Loss of catalytic residue at H32 (P = 0.0944); Loss of phosphorylation at Y29 (P = 0.0972); Loss of glycosylation at T30 (P = 0.2012); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.4137)
17:44039797:C:T,P10636,H32Y,0.109,Gain of phosphorylation at H32 (P = 0.0113); Loss of catalytic residue at H32 (P = 0.1362); Loss of glycosylation at T30 (P = 0.2284); Gain of solvent accessibility (P = 0.4821); Gain of sheet (P = 0.6509)
17:44039798:A:C,P10636,H32P,0.084,Loss of catalytic residue at H32 (P = 0.1152); Gain of phosphorylation at T30 (P = 0.2506); Gain of relative solvent accessibility (P = 0.2629); Loss of glycosylation at T30 (P = 0.3231); Gain of solvent accessibility (P = 0.5485)
17:44039798:A:G,P10636,H32R,0.127,Gain of phosphorylation at T30 (P = 0.1193); Loss of catalytic residue at H32 (P = 0.1204); Loss of glycosylation at T30 (P = 0.1463); Gain of solvent accessibility (P = 0.1903); Gain of relative solvent accessibility (P = 0.2629)
17:44039798:A:T,P10636,H32L,0.155,Gain of stability (P = 0.0417); Loss of glycosylation at T30 (P = 0.1616); Loss of phosphorylation at Y29 (P = 0.2334); Loss of catalytic residue at D34 (P = 0.3015); Gain of MoRF binding (P = 0.6659)
17:44039799:C:A,P10636,H32Q,0.1,Loss of catalytic residue at H32 (P = 0.0986); Loss of glycosylation at T30 (P = 0.1399); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2987); Loss of phosphorylation at Y29 (P = 0.3829)
17:44039799:C:G,P10636,H32Q,0.1,Loss of catalytic residue at H32 (P = 0.0986); Loss of glycosylation at T30 (P = 0.1399); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2987); Loss of phosphorylation at Y29 (P = 0.3829)
17:44039800:C:A,P10636,Q33K,0.131,Gain of ubiquitination at Q33 (P = 0.0022); Gain of methylation at Q33 (P = 0.0061); Gain of glycosylation at Q33 (P = 0.022); Gain of solvent accessibility (P = 0.0328); Gain of relative solvent accessibility (P = 0.0479)
17:44039800:C:G,P10636,Q33E,0.06,Gain of relative solvent accessibility (P = 0.2363); Loss of glycosylation at T30 (P = 0.2503); Gain of solvent accessibility (P = 0.3089); Gain of phosphorylation at Y29 (P = 0.3239); Loss of catalytic residue at E36 (P = 0.356)
17:44039801:A:C,P10636,Q33P,0.119,Gain of catalytic residue at Q33 (P = 0.0191); Gain of glycosylation at T30 (P = 0.0421); Loss of stability (P = 0.2509); Gain of phosphorylation at Y29 (P = 0.2804); Loss of solvent accessibility (P = 0.6134)
17:44039801:A:G,P10636,Q33R,0.06,Loss of glycosylation at T30 (P = 0.1578); Gain of phosphorylation at T30 (P = 0.1941); Loss of catalytic residue at E36 (P = 0.331); Gain of MoRF binding (P = 0.4163); Gain of methylation at Q33 (P = 0.6426)
17:44039801:A:T,P10636,Q33L,0.131,Gain of catalytic residue at Q33 (P = 0.0168); Loss of phosphorylation at Y29 (P = 0.2844); Loss of glycosylation at T30 (P = 0.3105); Loss of solvent accessibility (P = 0.4838); Gain of sheet (P = 0.6509)
17:44039802:A:C,P10636,Q33H,0.074,Gain of catalytic residue at Q33 (P = 0.0772); Gain of glycosylation at T30 (P = 0.1642); Loss of stability (P = 0.3706); Gain of phosphorylation at T30 (P = 0.375); Loss of MoRF binding (P = 0.6979)
17:44039802:A:T,P10636,Q33H,0.074,Gain of catalytic residue at Q33 (P = 0.0772); Gain of glycosylation at T30 (P = 0.1642); Loss of stability (P = 0.3706); Gain of phosphorylation at T30 (P = 0.375); Loss of MoRF binding (P = 0.6979)
17:44039803:G:A,P10636,D34N,0.107,Gain of glycosylation at T30 (P = 0.2181); Loss of phosphorylation at Y29 (P = 0.2869); Loss of catalytic residue at D34 (P = 0.3287); Gain of MoRF binding (P = 0.5785); Loss of solvent accessibility (P = 0.6392)
17:44039803:G:C,P10636,D34H,0.112,Gain of catalytic residue at E36 (P = 0.3063); Loss of phosphorylation at Y29 (P = 0.3139); Gain of glycosylation at T30 (P = 0.3153); Gain of solvent accessibility (P = 0.4946); Loss of stability (P = 0.5286)
17:44039803:G:T,P10636,D34Y,0.136,Gain of phosphorylation at D34 (P = 0.009); Loss of glycosylation at T30 (P = 0.2356); Loss of catalytic residue at D34 (P = 0.3505); Loss of solvent accessibility (P = 0.5485); Loss of relative solvent accessibility (P = 0.5582)
17:44039804:A:C,P10636,D34A,0.12,Loss of glycosylation at T30 (P = 0.3013); Loss of phosphorylation at Y29 (P = 0.3347); Loss of solvent accessibility (P = 0.3646); Loss of stability (P = 0.4811); Gain of MoRF binding (P = 0.4964)
17:44039804:A:G,P10636,D34G,0.123,Loss of glycosylation at T30 (P = 0.2905); Loss of phosphorylation at Y29 (P = 0.2965); Loss of stability (P = 0.3236); Gain of catalytic residue at D34 (P = 0.4169); Gain of MoRF binding (P = 0.5261)
17:44039804:A:T,P10636,D34V,0.127,Loss of glycosylation at T30 (P = 0.24); Loss of phosphorylation at Y29 (P = 0.3006); Loss of solvent accessibility (P = 0.4218); Gain of MoRF binding (P = 0.4704); Gain of catalytic residue at T39 (P = 0.554)
17:44039805:C:A,P10636,D34E,0.095,Gain of glycosylation at T30 (P = 0.2337); Gain of catalytic residue at D34 (P = 0.279); Gain of phosphorylation at Y29 (P = 0.3674); Gain of solvent accessibility (P = 0.4496); Loss of sheet (P = 0.6423)
17:44039805:C:G,P10636,D34E,0.095,Gain of glycosylation at T30 (P = 0.2337); Gain of catalytic residue at D34 (P = 0.279); Gain of phosphorylation at Y29 (P = 0.3674); Gain of solvent accessibility (P = 0.4496); Loss of sheet (P = 0.6423)
17:44039806:C:A,P10636,Q35K,0.149,Gain of ubiquitination at Q35 (P = 6e-04); Gain of methylation at Q35 (P = 0.0053); Gain of glycosylation at Q35 (P = 0.0313); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.3089)
17:44039806:C:G,P10636,Q35E,0.075,Gain of glycosylation at T30 (P = 0.1525); Gain of catalytic residue at Q35 (P = 0.1965); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.3418); Gain of phosphorylation at T30 (P = 0.4886)
17:44039807:A:C,P10636,Q35P,0.092,Gain of glycosylation at T30 (P = 0.1155); Loss of stability (P = 0.2049); Gain of phosphorylation at T30 (P = 0.3063); Loss of solvent accessibility (P = 0.5288); Loss of catalytic residue at D34 (P = 0.717)
17:44039807:A:G,P10636,Q35R,0.068,Loss of glycosylation at T30 (P = 0.3166); Gain of phosphorylation at T30 (P = 0.4356); Gain of solvent accessibility (P = 0.4496); Loss of catalytic residue at E36 (P = 0.4644); Gain of MoRF binding (P = 0.5793)
17:44039807:A:T,P10636,Q35L,0.097,Gain of glycosylation at T30 (P = 0.3162); Loss of phosphorylation at T39 (P = 0.4923); Loss of solvent accessibility (P = 0.5904); Gain of sheet (P = 0.6509); Loss of catalytic residue at H32 (P = 0.6572)
17:44039808:A:C,P10636,Q35H,0.068,Gain of catalytic residue at D34 (P = 0.1329); Gain of glycosylation at T30 (P = 0.2238); Loss of stability (P = 0.3415); Loss of phosphorylation at T30 (P = 0.5183); Loss of solvent accessibility (P = 0.6392)
17:44039808:A:T,P10636,Q35H,0.068,Gain of catalytic residue at D34 (P = 0.1329); Gain of glycosylation at T30 (P = 0.2238); Loss of stability (P = 0.3415); Loss of phosphorylation at T30 (P = 0.5183); Loss of solvent accessibility (P = 0.6392)
17:44039809:G:A,P10636,E36K,0.172,Gain of ubiquitination at E36 (P = 9e-04); Gain of methylation at E36 (P = 0.0117); Gain of glycosylation at E36 (P = 0.0127); Gain of solvent accessibility (P = 0.0314); Gain of relative solvent accessibility (P = 0.0479)
17:44039809:G:C,P10636,E36Q,0.113,Gain of relative solvent accessibility (P = 0.2363); Gain of solvent accessibility (P = 0.2863); Gain of catalytic residue at E36 (P = 0.4308); Loss of glycosylation at T39 (P = 0.4917); Loss of stability (P = 0.5116)
17:44039810:A:C,P10636,E36A,0.132,Gain of catalytic residue at E36 (P = 0.1422); Loss of stability (P = 0.2009); Gain of glycosylation at T39 (P = 0.2955); Loss of solvent accessibility (P = 0.4838); Loss of phosphorylation at T39 (P = 0.5566)
17:44039810:A:G,P10636,E36G,0.105,Loss of stability (P = 0.1784); Gain of relative solvent accessibility (P = 0.2363); Gain of catalytic residue at G37 (P = 0.2758); Loss of glycosylation at T39 (P = 0.3942); Loss of solvent accessibility (P = 0.5288)
17:44039810:A:T,P10636,E36V,0.138,Gain of glycosylation at T39 (P = 0.1504); Gain of catalytic residue at E36 (P = 0.3737); Loss of phosphorylation at T39 (P = 0.4048); Loss of solvent accessibility (P = 0.6498); Gain of sheet (P = 0.6509)
17:44039811:G:C,P10636,E36D,0.097,Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at E36 (P = 0.4216); Gain of solvent accessibility (P = 0.4496); Gain of glycosylation at T39 (P = 0.458); Loss of stability (P = 0.4664)
17:44039811:G:T,P10636,E36D,0.097,Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at E36 (P = 0.4216); Gain of solvent accessibility (P = 0.4496); Gain of glycosylation at T39 (P = 0.458); Loss of stability (P = 0.4664)
17:44039812:G:C,P10636,G37R,0.263,Gain of solvent accessibility (P = 0.0789); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at E36 (P = 0.2781); Loss of glycosylation at T39 (P = 0.401); Loss of stability (P = 0.466)
17:44039812:G:T,P10636,G37C,0.276,Gain of catalytic residue at T39 (P = 0.1064); Loss of glycosylation at T39 (P = 0.4017); Loss of phosphorylation at T39 (P = 0.4628); Gain of solvent accessibility (P = 0.5093); Loss of stability (P = 0.5435)
17:44039813:G:A,P10636,G37D,0.266,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0971); Loss of catalytic residue at E36 (P = 0.2929); Loss of glycosylation at T39 (P = 0.3616); Loss of stability (P = 0.4742)
17:44039813:G:C,P10636,G37A,0.269,Loss of catalytic residue at E36 (P = 0.3625); Loss of stability (P = 0.3797); Loss of glycosylation at T39 (P = 0.4832); Loss of phosphorylation at T39 (P = 0.5477); Gain of solvent accessibility (P = 0.5843)
17:44039813:G:T,P10636,G37V,0.302,Gain of glycosylation at T39 (P = 0.3309); Gain of catalytic residue at G37 (P = 0.3878); Loss of phosphorylation at T39 (P = 0.4658); Gain of solvent accessibility (P = 0.4946); Gain of sheet (P = 0.6509)
17:44039815:G:A,P10636,D38N,0.096,Gain of glycosylation at T39 (P = 0.1938); Loss of phosphorylation at T39 (P = 0.3381); Gain of catalytic residue at D38 (P = 0.4936); Loss of sheet (P = 0.6423); Loss of stability (P = 0.6598)
17:44039815:G:C,P10636,D38H,0.077,Gain of catalytic residue at D38 (P = 0.2567); Loss of phosphorylation at T39 (P = 0.308); Gain of glycosylation at T39 (P = 0.4312); Loss of stability (P = 0.4414); Gain of sheet (P = 0.6509)
17:44039815:G:T,P10636,D38Y,0.145,Gain of phosphorylation at D38 (P = 0.0055); Gain of catalytic residue at D38 (P = 0.3058); Gain of glycosylation at T39 (P = 0.4156); Loss of solvent accessibility (P = 0.5485); Loss of relative solvent accessibility (P = 0.5582)
17:44039816:A:C,P10636,D38A,0.109,Gain of glycosylation at T39 (P = 0.0788); Loss of phosphorylation at T39 (P = 0.3875); Loss of stability (P = 0.3938); Loss of catalytic residue at E36 (P = 0.4597); Loss of solvent accessibility (P = 0.6392)
17:44039816:A:G,P10636,D38G,0.086,Gain of glycosylation at T39 (P = 0.1868); Gain of catalytic residue at L43 (P = 0.2564); Loss of stability (P = 0.4032); Loss of phosphorylation at T39 (P = 0.4233); Loss of solvent accessibility (P = 0.5288)
17:44039816:A:T,P10636,D38V,0.132,Gain of catalytic residue at D38 (P = 0.0865); Gain of glycosylation at T39 (P = 0.1446); Loss of phosphorylation at T39 (P = 0.2839); Loss of solvent accessibility (P = 0.4218); Loss of relative solvent accessibility (P = 0.5582)
17:44039817:C:A,P10636,D38E,0.065,Loss of catalytic residue at E36 (P = 0.4173); Gain of solvent accessibility (P = 0.4496); Loss of glycosylation at T39 (P = 0.4585); Loss of phosphorylation at T39 (P = 0.49); Loss of sheet (P = 0.6423)
17:44039817:C:G,P10636,D38E,0.065,Loss of catalytic residue at E36 (P = 0.4173); Gain of solvent accessibility (P = 0.4496); Loss of glycosylation at T39 (P = 0.4585); Loss of phosphorylation at T39 (P = 0.49); Loss of sheet (P = 0.6423)
17:44039818:A:C,P10636,T39P,0.067,Loss of phosphorylation at T39 (P = 0.0141); Gain of glycosylation at K44 (P = 0.2395); Loss of stability (P = 0.2471); Gain of relative solvent accessibility (P = 0.2751); Loss of methylation at K44 (P = 0.382)
17:44039818:A:G,P10636,T39A,0.073,Loss of phosphorylation at T39 (P = 0.0141); Loss of glycosylation at T39 (P = 0.1546); Gain of relative solvent accessibility (P = 0.1571); Loss of methylation at K44 (P = 0.1621); Gain of solvent accessibility (P = 0.3956)
17:44039818:A:T,P10636,T39S,0.051,Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at T39 (P = 0.2275); Gain of solvent accessibility (P = 0.3089); Loss of methylation at K44 (P = 0.3167); Loss of ubiquitination at K44 (P = 0.4035)
17:44039819:C:A,P10636,T39K,0.149,Gain of ubiquitination at T39 (P = 0.0018); Gain of solvent accessibility (P = 0.006); Loss of phosphorylation at T39 (P = 0.0141); Gain of relative solvent accessibility (P = 0.0166); Gain of glycosylation at T39 (P = 0.0451)
17:44039819:C:G,P10636,T39R,0.089,Loss of phosphorylation at T39 (P = 0.0141); Gain of solvent accessibility (P = 0.1014); Gain of glycosylation at K44 (P = 0.1416); Gain of relative solvent accessibility (P = 0.1571); Loss of methylation at K44 (P = 0.3061)
17:44039819:C:T,P10636,T39M,0.069,Loss of phosphorylation at T39 (P = 0.0141); Loss of glycosylation at T39 (P = 0.1546); Loss of methylation at K44 (P = 0.2417); Gain of ubiquitination at K44 (P = 0.4079); Gain of solvent accessibility (P = 0.5334)
17:44039821:G:A,P10636,D40N,0.079,Gain of glycosylation at T39 (P = 0.1541); Loss of phosphorylation at T39 (P = 0.1544); Gain of methylation at K44 (P = 0.3706); Gain of ubiquitination at K44 (P = 0.4079); Gain of catalytic residue at D40 (P = 0.464)
17:44039821:G:C,P10636,D40H,0.079,Gain of glycosylation at T39 (P = 0.0871); Loss of phosphorylation at T39 (P = 0.311); Gain of methylation at K44 (P = 0.3618); Gain of catalytic residue at D38 (P = 0.4011); Gain of ubiquitination at K44 (P = 0.4066)
17:44039821:G:T,P10636,D40Y,0.202,Gain of phosphorylation at D40 (P = 0.0016); Gain of catalytic residue at D40 (P = 0.0226); Gain of glycosylation at K44 (P = 0.2154); Gain of methylation at K44 (P = 0.3176); Gain of ubiquitination at K44 (P = 0.4069)
17:44039822:A:C,P10636,D40A,0.106,Gain of glycosylation at K44 (P = 0.1412); Loss of methylation at K44 (P = 0.3462); Loss of solvent accessibility (P = 0.3646); Loss of phosphorylation at T39 (P = 0.4018); Gain of ubiquitination at K44 (P = 0.4066)
17:44039822:A:G,P10636,D40G,0.113,Gain of glycosylation at K44 (P = 0.1311); Loss of stability (P = 0.2848); Gain of catalytic residue at A41 (P = 0.2853); Loss of solvent accessibility (P = 0.3473); Loss of methylation at K44 (P = 0.3814)
17:44039822:A:T,P10636,D40V,0.101,Gain of catalytic residue at D40 (P = 0.1711); Gain of glycosylation at K44 (P = 0.1819); Loss of phosphorylation at T39 (P = 0.308); Gain of methylation at K44 (P = 0.3658); Gain of ubiquitination at K44 (P = 0.4064)
17:44039823:C:A,P10636,D40E,0.061,Gain of glycosylation at K44 (P = 0.2181); Gain of methylation at K44 (P = 0.372); Loss of ubiquitination at K44 (P = 0.4001); Loss of catalytic residue at A41 (P = 0.443); Gain of solvent accessibility (P = 0.4496)
17:44039823:C:G,P10636,D40E,0.061,Gain of glycosylation at K44 (P = 0.2181); Gain of methylation at K44 (P = 0.372); Loss of ubiquitination at K44 (P = 0.4001); Loss of catalytic residue at A41 (P = 0.443); Gain of solvent accessibility (P = 0.4496)
17:44039824:G:C,P10636,A41P,0.125,Loss of catalytic residue at A41 (P = 0.1699); Gain of glycosylation at A41 (P = 0.1821); Gain of methylation at K44 (P = 0.3414); Loss of ubiquitination at K44 (P = 0.4067); Gain of phosphorylation at S46 (P = 0.4389)
17:44039824:G:T,P10636,A41S,0.094,Gain of phosphorylation at A41 (P = 0.018); Gain of glycosylation at A41 (P = 0.0215); Loss of catalytic residue at A41 (P = 0.1581); Loss of methylation at K44 (P = 0.3767); Gain of ubiquitination at K44 (P = 0.4069)
17:44039825:C:A,P10636,A41D,0.085,Loss of catalytic residue at A41 (P = 0.135); Gain of glycosylation at K44 (P = 0.1399); Loss of methylation at K44 (P = 0.2386); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2689)
17:44039825:C:G,P10636,A41G,0.083,Loss of glycosylation at S46 (P = 0.1626); Loss of catalytic residue at A41 (P = 0.1803); Gain of methylation at K44 (P = 0.3785); Loss of ubiquitination at K44 (P = 0.4067); Gain of phosphorylation at S46 (P = 0.4536)
17:44039825:C:T,P10636,A41V,0.099,Loss of glycosylation at K44 (P = 0.1834); Gain of methylation at K44 (P = 0.3592); Loss of ubiquitination at K44 (P = 0.4001); Loss of phosphorylation at S46 (P = 0.4438); Gain of catalytic residue at L43 (P = 0.5005)
17:44039827:G:A,P10636,G42S,0.197,Gain of phosphorylation at G42 (P = 0.0216); Gain of glycosylation at G42 (P = 0.0688); Loss of catalytic residue at A41 (P = 0.1652); Loss of methylation at K44 (P = 0.226); Loss of stability (P = 0.2353)
17:44039827:G:C,P10636,G42R,0.214,Gain of solvent accessibility (P = 0.0674); Loss of glycosylation at K44 (P = 0.0808); Loss of methylation at K44 (P = 0.093); Loss of catalytic residue at A41 (P = 0.144); Loss of stability (P = 0.3952)
17:44039827:G:T,P10636,G42C,0.227,Gain of catalytic residue at L43 (P = 0.1554); Loss of glycosylation at K44 (P = 0.1604); Loss of phosphorylation at S46 (P = 0.2923); Gain of solvent accessibility (P = 0.3194); Loss of stability (P = 0.3474)
17:44039828:G:A,P10636,G42D,0.218,Loss of methylation at K44 (P = 0.052); Gain of solvent accessibility (P = 0.1045); Gain of glycosylation at S46 (P = 0.1116); Loss of catalytic residue at A41 (P = 0.158); Gain of relative solvent accessibility (P = 0.1894)
17:44039828:G:C,P10636,G42A,0.194,Gain of glycosylation at S46 (P = 0.1183); Loss of catalytic residue at A41 (P = 0.1583); Loss of stability (P = 0.1782); Loss of methylation at K44 (P = 0.3767); Gain of ubiquitination at K44 (P = 0.4073)
17:44039828:G:T,P10636,G42V,0.207,Loss of catalytic residue at A41 (P = 0.1552); Loss of glycosylation at K44 (P = 0.1604); Gain of solvent accessibility (P = 0.2902); Gain of methylation at K44 (P = 0.3369); Loss of phosphorylation at S46 (P = 0.3779)
17:44039830:C:A,P10636,L43M,0.155,Loss of methylation at K44 (P = 0.04); Gain of glycosylation at K44 (P = 0.2024); Loss of catalytic residue at L43 (P = 0.2788); Loss of stability (P = 0.362); Loss of ubiquitination at K44 (P = 0.3955)
17:44039830:C:G,P10636,L43V,0.1,Gain of glycosylation at S46 (P = 0.1562); Gain of methylation at K44 (P = 0.2927); Gain of catalytic residue at L43 (P = 0.3185); Loss of phosphorylation at S46 (P = 0.3888); Loss of stability (P = 0.3941)
17:44039831:T:A,P10636,L43Q,0.139,Loss of stability (P = 0.0769); Gain of glycosylation at K44 (P = 0.168); Loss of catalytic residue at L43 (P = 0.2432); Gain of methylation at K44 (P = 0.3482); Gain of ubiquitination at K44 (P = 0.4073)
17:44039831:T:C,P10636,L43P,0.177,Loss of stability (P = 0.0346); Gain of glycosylation at K44 (P = 0.0882); Loss of catalytic residue at L43 (P = 0.2361); Gain of methylation at K44 (P = 0.3349); Gain of ubiquitination at K44 (P = 0.4073)
17:44039831:T:G,P10636,L43R,0.178,Loss of stability (P = 0.0717); Gain of solvent accessibility (P = 0.1071); Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at S46 (P = 0.1599); Gain of phosphorylation at S46 (P = 0.3555)
17:44039833:A:C,P10636,K44Q,0.204,Loss of ubiquitination at K44 (P = 0.0011); Loss of methylation at K44 (P = 0.0051); Loss of glycosylation at K44 (P = 0.04); Loss of solvent accessibility (P = 0.1922); Loss of relative solvent accessibility (P = 0.3589)
17:44039833:A:G,P10636,K44E,0.222,Loss of ubiquitination at K44 (P = 0.0011); Loss of methylation at K44 (P = 0.0051); Loss of glycosylation at K44 (P = 0.04); Loss of solvent accessibility (P = 0.1868); Gain of stability (P = 0.2061)
17:44039834:A:C,P10636,K44T,0.205,Loss of ubiquitination at K44 (P = 0.0011); Loss of methylation at K44 (P = 0.0051); Gain of phosphorylation at K44 (P = 0.0292); Gain of glycosylation at K44 (P = 0.0448); Loss of solvent accessibility (P = 0.1144)
17:44039834:A:G,P10636,K44R,0.204,Loss of ubiquitination at K44 (P = 0.0011); Loss of methylation at K44 (P = 0.0079); Loss of glycosylation at K44 (P = 0.04); Loss of solvent accessibility (P = 0.322); Loss of relative solvent accessibility (P = 0.3589)
17:44039834:A:T,P10636,K44I,0.293,Loss of ubiquitination at K44 (P = 0.0011); Loss of methylation at K44 (P = 0.0051); Gain of stability (P = 0.0068); Loss of glycosylation at K44 (P = 0.04); Loss of solvent accessibility (P = 0.045)
17:44039835:A:C,P10636,K44N,0.2,Loss of ubiquitination at K44 (P = 0.0011); Loss of methylation at K44 (P = 0.0051); Loss of glycosylation at K44 (P = 0.04); Loss of solvent accessibility (P = 0.1301); Loss of phosphorylation at S46 (P = 0.1813)
17:44039835:A:T,P10636,K44N,0.2,Loss of ubiquitination at K44 (P = 0.0011); Loss of methylation at K44 (P = 0.0051); Loss of glycosylation at K44 (P = 0.04); Loss of solvent accessibility (P = 0.1301); Loss of phosphorylation at S46 (P = 0.1813)
17:44039836:G:A,P10636,E45K,0.139,Gain of ubiquitination at E45 (P = 9e-04); Gain of methylation at E45 (P = 0.0118); Gain of glycosylation at E45 (P = 0.0552); Gain of catalytic residue at K44 (P = 0.3433); Loss of phosphorylation at S46 (P = 0.4604)
17:44039836:G:C,P10636,E45Q,0.092,Gain of glycosylation at S46 (P = 0.1165); Loss of phosphorylation at S46 (P = 0.2728); Gain of methylation at K44 (P = 0.3495); Loss of ubiquitination at K44 (P = 0.4001); Gain of solvent accessibility (P = 0.5485)
17:44049225:A:C,P10636,E45A,0.096,Loss of solvent accessibility (P = 0.0053); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at S46 (P = 0.1278); Loss of phosphorylation at S46 (P = 0.3228); Gain of catalytic residue at K44 (P = 0.3633)
17:44049225:A:G,P10636,E45G,0.13,Loss of solvent accessibility (P = 0.0022); Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at S46 (P = 0.0856); Gain of catalytic residue at K44 (P = 0.2466); Loss of methylation at K44 (P = 0.3792)
17:44049225:A:T,P10636,E45V,0.144,Loss of solvent accessibility (P = 0.0052); Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at K44 (P = 0.1626); Loss of phosphorylation at S46 (P = 0.1767); Gain of stability (P = 0.2909)
17:44049226:A:C,P10636,E45D,0.065,Gain of glycosylation at S46 (P = 0.1029); Loss of solvent accessibility (P = 0.1813); Loss of methylation at K44 (P = 0.2734); Loss of ubiquitination at K44 (P = 0.4035); Gain of catalytic residue at A41 (P = 0.4088)
17:44049226:A:T,P10636,E45D,0.065,Gain of glycosylation at S46 (P = 0.1029); Loss of solvent accessibility (P = 0.1813); Loss of methylation at K44 (P = 0.2734); Loss of ubiquitination at K44 (P = 0.4035); Gain of catalytic residue at A41 (P = 0.4088)
17:44049227:T:A,P10636,S46T,0.121,Loss of glycosylation at S46 (P = 0.1187); Gain of phosphorylation at S46 (P = 0.3627); Gain of methylation at K44 (P = 0.3668); Loss of ubiquitination at K44 (P = 0.4035); Loss of stability (P = 0.5163)
17:44049227:T:C,P10636,S46P,0.167,Gain of catalytic residue at S46 (P = 0.0053); Loss of phosphorylation at S46 (P = 0.0176); Gain of glycosylation at P47 (P = 0.1281); Gain of methylation at K44 (P = 0.3652); Gain of ubiquitination at K44 (P = 0.4073)
17:44049227:T:G,P10636,S46A,0.094,Loss of phosphorylation at S46 (P = 0.0176); Loss of glycosylation at S46 (P = 0.038); Loss of methylation at K44 (P = 0.3011); Gain of ubiquitination at K44 (P = 0.4058); Loss of solvent accessibility (P = 0.4838)
17:44049228:C:A,P10636,S46Y,0.094,Loss of glycosylation at S46 (P = 0.038); Loss of phosphorylation at S46 (P = 0.1454); Loss of methylation at K44 (P = 0.2795); Gain of ubiquitination at K44 (P = 0.4058); Loss of relative solvent accessibility (P = 0.5582)
17:44049228:C:G,P10636,S46C,0.101,Loss of phosphorylation at S46 (P = 0.0176); Loss of glycosylation at S46 (P = 0.038); Gain of catalytic residue at A41 (P = 0.3639); Gain of methylation at K44 (P = 0.3696); Gain of ubiquitination at K44 (P = 0.4079)
17:44049228:C:T,P10636,S46F,0.11,Loss of phosphorylation at S46 (P = 0.0176); Loss of glycosylation at S46 (P = 0.038); Gain of catalytic residue at S46 (P = 0.3042); Loss of methylation at K44 (P = 0.3622); Gain of ubiquitination at K44 (P = 0.4066)
17:44049230:C:A,P10636,P47T,0.105,Gain of phosphorylation at P47 (P = 0.0758); Gain of glycosylation at S46 (P = 0.0952); Gain of relative solvent accessibility (P = 0.1571); Loss of methylation at K44 (P = 0.2749); Gain of solvent accessibility (P = 0.28)
17:44049230:C:G,P10636,P47A,0.116,Loss of glycosylation at T50 (P = 0.0729); Loss of methylation at K44 (P = 0.2039); Loss of catalytic residue at L48 (P = 0.2248); Loss of phosphorylation at S46 (P = 0.2284); Gain of ubiquitination at K44 (P = 0.4079)
17:44049230:C:T,P10636,P47S,0.126,Gain of phosphorylation at P47 (P = 0.023); Gain of relative solvent accessibility (P = 0.09); Loss of glycosylation at T50 (P = 0.1265); Gain of solvent accessibility (P = 0.1903); Gain of catalytic residue at L43 (P = 0.2523)
17:44049231:C:A,P10636,P47H,0.118,Loss of glycosylation at T50 (P = 0.1701); Loss of phosphorylation at S46 (P = 0.193); Loss of methylation at K44 (P = 0.2603); Loss of catalytic residue at L48 (P = 0.3914); Gain of ubiquitination at K44 (P = 0.4079)
17:44049231:C:G,P10636,P47R,0.148,Loss of glycosylation at T50 (P = 0.0519); Loss of methylation at K44 (P = 0.0919); Gain of solvent accessibility (P = 0.0971); Gain of relative solvent accessibility (P = 0.1571); Gain of catalytic residue at P47 (P = 0.2071)
17:44049231:C:T,P10636,P47L,0.16,Loss of glycosylation at T50 (P = 0.0671); Loss of methylation at K44 (P = 0.1517); Loss of catalytic residue at L48 (P = 0.2667); Loss of phosphorylation at S46 (P = 0.2676); Gain of stability (P = 0.3924)
17:44049233:C:A,P10636,L48M,0.112,Loss of catalytic residue at L48 (P = 0.1134); Gain of glycosylation at K44 (P = 0.2066); Gain of methylation at K44 (P = 0.3432); Loss of ubiquitination at K44 (P = 0.3911); Gain of phosphorylation at S46 (P = 0.4777)
17:44049233:C:G,P10636,L48V,0.08,Gain of glycosylation at S46 (P = 0.146); Loss of catalytic residue at L48 (P = 0.201); Gain of methylation at K44 (P = 0.3482); Loss of stability (P = 0.395); Loss of ubiquitination at K44 (P = 0.4035)
17:44049234:T:A,P10636,L48Q,0.12,Loss of glycosylation at T50 (P = 0.0994); Loss of catalytic residue at L48 (P = 0.1167); Loss of stability (P = 0.1592); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2689)
17:44049234:T:C,P10636,L48P,0.184,Gain of catalytic residue at P47 (P = 0.0164); Gain of relative solvent accessibility (P = 0.0249); Loss of stability (P = 0.0674); Gain of glycosylation at P47 (P = 0.0699); Gain of solvent accessibility (P = 0.0766)
17:44049234:T:G,P10636,L48R,0.13,Loss of glycosylation at T50 (P = 0.0868); Loss of stability (P = 0.1534); Gain of solvent accessibility (P = 0.1683); Gain of relative solvent accessibility (P = 0.2629); Gain of methylation at K44 (P = 0.3237)
17:44049236:C:A,P10636,Q49K,0.138,Gain of ubiquitination at Q49 (P = 0.0039); Gain of methylation at Q49 (P = 0.0157); Gain of relative solvent accessibility (P = 0.0507); Gain of solvent accessibility (P = 0.0514); Gain of glycosylation at Q49 (P = 0.0683)
17:44049236:C:G,P10636,Q49E,0.071,Gain of glycosylation at K44 (P = 0.2066); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.3418); Gain of methylation at K44 (P = 0.3811); Gain of phosphorylation at S46 (P = 0.3839)
17:44049237:A:C,P10636,Q49P,0.08,Gain of glycosylation at Q49 (P = 0.0553); Loss of stability (P = 0.3284); Gain of methylation at K44 (P = 0.3679); Gain of catalytic residue at L48 (P = 0.3743); Gain of phosphorylation at S46 (P = 0.4058)
17:44049237:A:G,P10636,Q49R,0.068,Loss of glycosylation at T50 (P = 0.1075); Gain of solvent accessibility (P = 0.204); Loss of methylation at K44 (P = 0.2553); Gain of relative solvent accessibility (P = 0.2629); Gain of phosphorylation at S46 (P = 0.3839)
17:44049237:A:T,P10636,Q49L,0.127,Gain of glycosylation at K44 (P = 0.1413); Loss of methylation at K44 (P = 0.2582); Gain of stability (P = 0.3318); Loss of phosphorylation at T52 (P = 0.3633); Gain of ubiquitination at K44 (P = 0.4069)
17:44049238:G:C,P10636,Q49H,0.056,Gain of glycosylation at S46 (P = 0.1163); Gain of catalytic residue at L48 (P = 0.3049); Loss of methylation at K44 (P = 0.3175); Loss of ubiquitination at K44 (P = 0.3955); Loss of stability (P = 0.4486)
17:44049238:G:T,P10636,Q49H,0.056,Gain of glycosylation at S46 (P = 0.1163); Gain of catalytic residue at L48 (P = 0.3049); Loss of methylation at K44 (P = 0.3175); Loss of ubiquitination at K44 (P = 0.3955); Loss of stability (P = 0.4486)
17:44049239:A:C,P10636,T50P,0.159,Loss of phosphorylation at T50 (P = 0.0024); Gain of catalytic residue at T50 (P = 0.0032); Loss of glycosylation at T50 (P = 0.054); Loss of stability (P = 0.4059); Loss of sheet (P = 0.6423)
17:44049239:A:G,P10636,T50A,0.111,Loss of phosphorylation at T50 (P = 0.0024); Loss of glycosylation at T50 (P = 0.0115); Loss of catalytic residue at L48 (P = 0.4929); Loss of sheet (P = 0.6423); Loss of stability (P = 0.8044)
17:44049239:A:T,P10636,T50S,0.168,Loss of glycosylation at T50 (P = 0.048); Gain of phosphorylation at S46 (P = 0.423); Gain of catalytic residue at P51 (P = 0.5637); Loss of sheet (P = 0.6423); Loss of stability (P = 0.6542)
17:44049240:C:A,P10636,T50N,0.134,Loss of phosphorylation at T50 (P = 0.0024); Loss of glycosylation at T50 (P = 0.0115); Gain of catalytic residue at P51 (P = 0.332); Gain of solvent accessibility (P = 0.571); Loss of sheet (P = 0.6423)
17:44049240:C:G,P10636,T50S,0.168,Loss of glycosylation at T50 (P = 0.048); Gain of phosphorylation at S46 (P = 0.423); Gain of catalytic residue at P51 (P = 0.5637); Loss of sheet (P = 0.6423); Loss of stability (P = 0.6542)
17:44049240:C:T,P10636,T50I,0.138,Loss of phosphorylation at T50 (P = 0.0024); Loss of glycosylation at T50 (P = 0.0115); Gain of catalytic residue at L48 (P = 0.4036); Gain of solvent accessibility (P = 0.5334); Loss of sheet (P = 0.6423)
17:44049242:C:A,P10636,P51T,0.199,Gain of glycosylation at P51 (P = 0.0279); Gain of phosphorylation at P51 (P = 0.0377); Loss of stability (P = 0.0428); Loss of catalytic residue at L48 (P = 0.2199); Gain of solvent accessibility (P = 0.5843)
17:44049242:C:G,P10636,P51A,0.172,Loss of glycosylation at P51 (P = 0.0506); Loss of stability (P = 0.0632); Loss of catalytic residue at L48 (P = 0.1564); Loss of phosphorylation at T52 (P = 0.3041); Loss of sheet (P = 0.6423)
17:44049242:C:T,P10636,P51S,0.177,Gain of phosphorylation at P51 (P = 0.0103); Gain of glycosylation at P51 (P = 0.0674); Loss of stability (P = 0.084); Loss of catalytic residue at P51 (P = 0.1168); Loss of sheet (P = 0.6423)
17:44049243:C:A,P10636,P51H,0.185,Loss of glycosylation at P51 (P = 0.0506); Loss of stability (P = 0.1178); Gain of catalytic residue at E53 (P = 0.1642); Loss of phosphorylation at T52 (P = 0.2212); Gain of solvent accessibility (P = 0.3819)
17:44049243:C:G,P10636,P51R,0.193,Loss of glycosylation at T52 (P = 0.0374); Gain of solvent accessibility (P = 0.0789); Loss of catalytic residue at L48 (P = 0.1893); Gain of relative solvent accessibility (P = 0.2363); Loss of stability (P = 0.2612)
17:44049243:C:T,P10636,P51L,0.174,Loss of glycosylation at P51 (P = 0.0506); Loss of catalytic residue at L48 (P = 0.1738); Loss of phosphorylation at T52 (P = 0.2168); Loss of sheet (P = 0.6423); Loss of solvent accessibility (P = 0.8212)
17:44049245:A:C,P10636,T52P,0.141,Gain of relative solvent accessibility (P = 0.005); Loss of phosphorylation at T52 (P = 0.013); Gain of solvent accessibility (P = 0.0156); Loss of glycosylation at T52 (P = 0.0424); Gain of catalytic residue at P51 (P = 0.1284)
17:44049245:A:G,P10636,T52A,0.087,Loss of glycosylation at T52 (P = 0.0074); Loss of phosphorylation at T52 (P = 0.013); Loss of catalytic residue at L48 (P = 0.4931); Loss of stability (P = 0.6309); Loss of sheet (P = 0.6423)
17:44049245:A:T,P10636,T52S,0.197,Gain of relative solvent accessibility (P = 0.005); Gain of solvent accessibility (P = 0.0221); Loss of glycosylation at T52 (P = 0.0391); Loss of loop (P = 0.2897); Gain of catalytic residue at L48 (P = 0.348)
17:44049246:C:A,P10636,T52N,0.089,Loss of glycosylation at T52 (P = 0.0074); Loss of phosphorylation at T52 (P = 0.013); Gain of relative solvent accessibility (P = 0.2751); Gain of solvent accessibility (P = 0.3956); Gain of catalytic residue at P51 (P = 0.5637)
17:44049246:C:G,P10636,T52S,0.197,Gain of relative solvent accessibility (P = 0.005); Gain of solvent accessibility (P = 0.0221); Loss of glycosylation at T52 (P = 0.0391); Loss of loop (P = 0.2897); Gain of catalytic residue at L48 (P = 0.348)
17:44049246:C:T,P10636,T52I,0.111,Loss of glycosylation at T52 (P = 0.0074); Loss of phosphorylation at T52 (P = 0.013); Gain of catalytic residue at L48 (P = 0.4335); Gain of solvent accessibility (P = 0.571); Loss of sheet (P = 0.6423)
17:44049248:G:A,P10636,E53K,0.166,Gain of methylation at E53 (P = 0.0052); Gain of ubiquitination at E53 (P = 0.0069); Loss of stability (P = 0.0789); Loss of glycosylation at S56 (P = 0.08); Gain of relative solvent accessibility (P = 0.0999)
17:44049248:G:C,P10636,E53Q,0.101,Gain of glycosylation at P51 (P = 0.2071); Loss of stability (P = 0.2183); Loss of phosphorylation at T52 (P = 0.4127); Gain of solvent accessibility (P = 0.5946); Gain of sheet (P = 0.6509)
17:44049249:A:C,P10636,E53A,0.097,Loss of stability (P = 0.1344); Gain of glycosylation at T50 (P = 0.1688); Loss of phosphorylation at T52 (P = 0.4127); Loss of solvent accessibility (P = 0.4838); Loss of catalytic residue at L48 (P = 0.5581)
17:44049249:A:G,P10636,E53G,0.133,Loss of stability (P = 0.0211); Loss of glycosylation at P51 (P = 0.1849); Loss of solvent accessibility (P = 0.3103); Loss of phosphorylation at T52 (P = 0.4609); Gain of catalytic residue at L48 (P = 0.5819)
17:44049249:A:T,P10636,E53V,0.101,Loss of glycosylation at P51 (P = 0.1066); Loss of phosphorylation at T52 (P = 0.28); Gain of catalytic residue at E53 (P = 0.4093); Loss of solvent accessibility (P = 0.4274); Loss of stability (P = 0.5096)
17:44049250:G:C,P10636,E53D,0.107,Loss of stability (P = 0.1838); Loss of glycosylation at P51 (P = 0.1864); Gain of catalytic residue at G55 (P = 0.2936); Gain of phosphorylation at T52 (P = 0.568); Gain of sheet (P = 0.6509)
17:44049250:G:T,P10636,E53D,0.107,Loss of stability (P = 0.1838); Loss of glycosylation at P51 (P = 0.1864); Gain of catalytic residue at G55 (P = 0.2936); Gain of phosphorylation at T52 (P = 0.568); Gain of sheet (P = 0.6509)
17:44049251:G:A,P10636,D54N,0.138,Gain of glycosylation at P51 (P = 0.1706); Loss of phosphorylation at T52 (P = 0.2122); Loss of stability (P = 0.6234); Gain of sheet (P = 0.6509); Loss of catalytic residue at P51 (P = 0.7569)
17:44049251:G:C,P10636,D54H,0.124,Loss of solvent accessibility (P = 0.0703); Loss of relative solvent accessibility (P = 0.0981); Loss of phosphorylation at T52 (P = 0.1957); Gain of glycosylation at P59 (P = 0.2568); Loss of stability (P = 0.4709)
17:44049251:G:T,P10636,D54Y,0.186,Gain of phosphorylation at D54 (P = 0.0039); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T50 (P = 0.1845); Loss of solvent accessibility (P = 0.2073); Gain of sheet (P = 0.6509)
17:44049252:A:C,P10636,D54A,0.128,Loss of solvent accessibility (P = 0.0595); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T50 (P = 0.1966); Loss of phosphorylation at T52 (P = 0.251); Gain of catalytic residue at D54 (P = 0.536)
17:44049252:A:G,P10636,D54G,0.126,Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at T50 (P = 0.1571); Loss of stability (P = 0.2915); Loss of phosphorylation at T52 (P = 0.2934); Loss of solvent accessibility (P = 0.3103)
17:44049252:A:T,P10636,D54V,0.148,Loss of solvent accessibility (P = 0.0907); Loss of glycosylation at P51 (P = 0.1238); Loss of phosphorylation at T52 (P = 0.1608); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at E57 (P = 0.3116)
17:44049253:C:A,P10636,D54E,0.134,Gain of helix (P = 0.0893); Gain of glycosylation at P51 (P = 0.1014); Gain of solvent accessibility (P = 0.1014); Gain of relative solvent accessibility (P = 0.1571); Loss of loop (P = 0.2897)
17:44049253:C:G,P10636,D54E,0.134,Gain of helix (P = 0.0893); Gain of glycosylation at P51 (P = 0.1014); Gain of solvent accessibility (P = 0.1014); Gain of relative solvent accessibility (P = 0.1571); Loss of loop (P = 0.2897)
17:44049254:G:A,P10636,G55R,0.142,Loss of glycosylation at S56 (P = 0.0553); Gain of solvent accessibility (P = 0.1319); Loss of catalytic residue at P51 (P = 0.1789); Gain of phosphorylation at T52 (P = 0.526); Gain of methylation at G55 (P = 0.6147)
17:44049254:G:C,P10636,G55R,0.142,Loss of glycosylation at S56 (P = 0.0553); Gain of solvent accessibility (P = 0.1319); Loss of catalytic residue at P51 (P = 0.1789); Gain of phosphorylation at T52 (P = 0.526); Gain of methylation at G55 (P = 0.6147)
17:44049255:G:A,P10636,G55E,0.107,Loss of glycosylation at S56 (P = 0.1224); Loss of catalytic residue at P51 (P = 0.1789); Gain of solvent accessibility (P = 0.2192); Gain of phosphorylation at T52 (P = 0.5474); Loss of sheet (P = 0.6423)
17:44049255:G:C,P10636,G55A,0.092,Loss of catalytic residue at P51 (P = 0.1789); Loss of glycosylation at S56 (P = 0.2345); Loss of phosphorylation at T52 (P = 0.5576); Loss of sheet (P = 0.6423); Loss of stability (P = 0.6788)
17:44049255:G:T,P10636,G55V,0.11,Loss of glycosylation at S56 (P = 0.1565); Loss of catalytic residue at P51 (P = 0.1789); Loss of phosphorylation at T52 (P = 0.4719); Loss of relative solvent accessibility (P = 0.5582); Loss of sheet (P = 0.6423)
17:44049257:T:A,P10636,S56T,0.151,Loss of glycosylation at P59 (P = 0.2702); Gain of phosphorylation at T52 (P = 0.5223); Gain of sheet (P = 0.6509); Loss of stability (P = 0.7266); Loss of solvent accessibility (P = 0.7428)
17:44049257:T:C,P10636,S56P,0.172,Loss of phosphorylation at S56 (P = 0.0034); Gain of catalytic residue at S56 (P = 0.0107); Loss of glycosylation at S56 (P = 0.0371); Loss of stability (P = 0.5047); Loss of solvent accessibility (P = 0.7225)
17:44049257:T:G,P10636,S56A,0.097,Loss of phosphorylation at S56 (P = 0.0034); Loss of glycosylation at S56 (P = 0.0111); Loss of catalytic residue at P51 (P = 0.7569); Loss of stability (P = 0.7759); Loss of solvent accessibility (P = 0.8212)
17:44049258:C:A,P10636,S56Y,0.228,Loss of glycosylation at S56 (P = 0.0111); Gain of catalytic residue at S56 (P = 0.3256); Gain of solvent accessibility (P = 0.5334); Gain of phosphorylation at T52 (P = 0.5735); Gain of sheet (P = 0.6509)
17:44049258:C:G,P10636,S56C,0.125,Loss of phosphorylation at S56 (P = 0.0034); Loss of glycosylation at S56 (P = 0.0111); Gain of catalytic residue at E53 (P = 0.3892); Loss of solvent accessibility (P = 0.7225); Loss of stability (P = 0.8381)
17:44049258:C:T,P10636,S56F,0.162,Loss of phosphorylation at S56 (P = 0.0034); Loss of glycosylation at S56 (P = 0.0111); Gain of catalytic residue at S56 (P = 0.0719); Loss of relative solvent accessibility (P = 0.5582); Loss of solvent accessibility (P = 0.6498)
17:44049260:G:A,P10636,E57K,0.163,Gain of methylation at E57 (P = 0.0053); Gain of ubiquitination at E57 (P = 0.0117); Gain of glycosylation at E57 (P = 0.0165); Loss of solvent accessibility (P = 0.4838); Loss of relative solvent accessibility (P = 0.5582)
17:44049260:G:C,P10636,E57Q,0.113,Loss of glycosylation at S56 (P = 0.1815); Loss of phosphorylation at T52 (P = 0.5294); Gain of solvent accessibility (P = 0.5485); Gain of catalytic residue at E62 (P = 0.797); Loss of stability (P = 0.9079)
17:44049261:A:C,P10636,E57A,0.165,Loss of solvent accessibility (P = 0.0053); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at P59 (P = 0.208); Gain of phosphorylation at T52 (P = 0.5667); Gain of catalytic residue at E62 (P = 0.5749)
17:44049261:A:G,P10636,E57G,0.138,Loss of solvent accessibility (P = 0.0387); Gain of glycosylation at S56 (P = 0.0957); Gain of catalytic residue at E62 (P = 0.3277); Loss of stability (P = 0.5542); Loss of phosphorylation at T52 (P = 0.5576)
17:44049261:A:T,P10636,E57V,0.227,Loss of solvent accessibility (P = 0.0022); Loss of relative solvent accessibility (P = 0.0186); Loss of glycosylation at P59 (P = 0.1376); Gain of catalytic residue at E57 (P = 0.3798); Loss of phosphorylation at T52 (P = 0.4019)
17:44049262:G:C,P10636,E57D,0.12,Loss of glycosylation at P59 (P = 0.1418); Loss of solvent accessibility (P = 0.1813); Loss of relative solvent accessibility (P = 0.5582); Gain of phosphorylation at T52 (P = 0.5638); Gain of catalytic residue at E62 (P = 0.6423)
17:44049262:G:T,P10636,E57D,0.12,Loss of glycosylation at P59 (P = 0.1418); Loss of solvent accessibility (P = 0.1813); Loss of relative solvent accessibility (P = 0.5582); Gain of phosphorylation at T52 (P = 0.5638); Gain of catalytic residue at E62 (P = 0.6423)
17:44049263:G:A,P10636,E58K,0.131,Gain of methylation at E58 (P = 0.0051); Gain of ubiquitination at E58 (P = 0.0109); Gain of solvent accessibility (P = 0.0314); Gain of glycosylation at E58 (P = 0.0436); Gain of relative solvent accessibility (P = 0.0479)
17:44049263:G:C,P10636,E58Q,0.068,Loss of glycosylation at P59 (P = 0.1685); Loss of stability (P = 0.5607); Loss of phosphorylation at T63 (P = 0.5967); Loss of solvent accessibility (P = 0.6134); Loss of sheet (P = 0.6423)
17:44049264:A:C,P10636,E58A,0.073,Loss of glycosylation at T63 (P = 0.1255); Loss of solvent accessibility (P = 0.3543); Loss of stability (P = 0.5282); Loss of sheet (P = 0.6423); Gain of phosphorylation at T63 (P = 0.6534)
17:44049264:A:G,P10636,E58G,0.135,Loss of stability (P = 0.0744); Loss of glycosylation at T63 (P = 0.1134); Loss of solvent accessibility (P = 0.3103); Gain of catalytic residue at E62 (P = 0.454); Gain of phosphorylation at T63 (P = 0.6518)
17:44049264:A:T,P10636,E58V,0.091,Loss of glycosylation at P59 (P = 0.1228); Loss of solvent accessibility (P = 0.3136); Gain of catalytic residue at E62 (P = 0.3869); Loss of relative solvent accessibility (P = 0.5582); Loss of phosphorylation at T63 (P = 0.5754)
17:44049265:A:C,P10636,E58D,0.073,Loss of glycosylation at P59 (P = 0.1988); Gain of catalytic residue at E58 (P = 0.5709); Loss of stability (P = 0.579); Loss of sheet (P = 0.6423); Gain of phosphorylation at T63 (P = 0.6487)
17:44049265:A:T,P10636,E58D,0.073,Loss of glycosylation at P59 (P = 0.1988); Gain of catalytic residue at E58 (P = 0.5709); Loss of stability (P = 0.579); Loss of sheet (P = 0.6423); Gain of phosphorylation at T63 (P = 0.6487)
17:44049266:C:A,P10636,P59T,0.17,Gain of phosphorylation at P59 (P = 0.0077); Gain of relative solvent accessibility (P = 0.1066); Loss of glycosylation at T63 (P = 0.2084); Gain of solvent accessibility (P = 0.2291); Loss of loop (P = 0.2897)
17:44049266:C:G,P10636,P59A,0.162,Loss of glycosylation at P59 (P = 0.0609); Loss of stability (P = 0.2533); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.5485); Loss of phosphorylation at T63 (P = 0.583)
17:44049266:C:T,P10636,P59S,0.202,Gain of phosphorylation at P59 (P = 0.0028); Gain of glycosylation at P59 (P = 0.0205); Gain of relative solvent accessibility (P = 0.0507); Gain of solvent accessibility (P = 0.1505); Loss of loop (P = 0.2897)
17:44049267:C:A,P10636,P59Q,0.187,Loss of glycosylation at P59 (P = 0.0609); Gain of solvent accessibility (P = 0.2291); Gain of relative solvent accessibility (P = 0.2629); Loss of phosphorylation at T63 (P = 0.542); Loss of stability (P = 0.5739)
17:44049267:C:G,P10636,P59R,0.195,Loss of glycosylation at P59 (P = 0.0609); Gain of solvent accessibility (P = 0.1422); Gain of relative solvent accessibility (P = 0.2629); Loss of stability (P = 0.5245); Loss of catalytic residue at E62 (P = 0.5275)
17:44049269:G:A,P10636,G60S,0.136,Gain of phosphorylation at G60 (P = 0.002); Gain of glycosylation at G60 (P = 0.0099); Loss of relative solvent accessibility (P = 0.107); Loss of solvent accessibility (P = 0.5743); Gain of catalytic residue at P59 (P = 0.6717)
17:44049269:G:C,P10636,G60R,0.111,Loss of relative solvent accessibility (P = 0.107); Gain of glycosylation at T63 (P = 0.1316); Gain of solvent accessibility (P = 0.2455); Gain of methylation at G60 (P = 0.5012); Loss of catalytic residue at E62 (P = 0.5693)
17:44049269:G:T,P10636,G60C,0.122,Gain of catalytic residue at P59 (P = 0.0122); Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at T63 (P = 0.0932); Loss of solvent accessibility (P = 0.2517); Loss of phosphorylation at T63 (P = 0.5507)
17:44049270:G:A,P10636,G60D,0.089,Gain of glycosylation at T63 (P = 0.0883); Gain of solvent accessibility (P = 0.1683); Loss of relative solvent accessibility (P = 0.5582); Gain of phosphorylation at T63 (P = 0.6486); Loss of catalytic residue at E62 (P = 0.7464)
17:44049270:G:C,P10636,G60A,0.114,Loss of relative solvent accessibility (P = 0.0186); Gain of glycosylation at T63 (P = 0.0977); Loss of solvent accessibility (P = 0.1459); Loss of catalytic residue at E62 (P = 0.6147); Gain of phosphorylation at T63 (P = 0.6534)
17:44049270:G:T,P10636,G60V,0.101,Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at T63 (P = 0.0848); Loss of solvent accessibility (P = 0.2668); Loss of phosphorylation at T63 (P = 0.5578); Gain of stability (P = 0.6106)
17:44049272:T:A,P10636,S61T,0.176,Gain of glycosylation at S64 (P = 0.1663); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.367); Gain of catalytic residue at S61 (P = 0.5298); Loss of phosphorylation at T63 (P = 0.6366)
17:44049272:T:C,P10636,S61P,0.101,Loss of phosphorylation at S61 (P = 0.0042); Loss of glycosylation at S61 (P = 0.0252); Loss of stability (P = 0.3613); Gain of solvent accessibility (P = 0.5946); Gain of catalytic residue at E62 (P = 0.6282)
17:44049272:T:G,P10636,S61A,0.124,Loss of phosphorylation at S61 (P = 0.0042); Loss of glycosylation at S61 (P = 0.0048); Gain of catalytic residue at S61 (P = 0.3722); Loss of stability (P = 0.6726); Loss of solvent accessibility (P = 0.8887)
17:44049273:C:A,P10636,S61Y,0.262,Loss of glycosylation at S61 (P = 0.0048); Gain of catalytic residue at S61 (P = 0.0401); Loss of phosphorylation at S64 (P = 0.5953); Gain of sheet (P = 0.6509); Loss of stability (P = 0.7378)
17:44049273:C:G,P10636,S61C,0.131,Loss of phosphorylation at S61 (P = 0.0042); Loss of glycosylation at S61 (P = 0.0048); Gain of catalytic residue at T63 (P = 0.1886); Gain of solvent accessibility (P = 0.5946); Gain of sheet (P = 0.6509)
17:44049273:C:T,P10636,S61F,0.148,Loss of phosphorylation at S61 (P = 0.0042); Loss of glycosylation at S61 (P = 0.0048); Gain of catalytic residue at P59 (P = 0.1992); Gain of sheet (P = 0.6509); Loss of stability (P = 0.9119)
17:44049275:G:A,P10636,E62K,0.184,Gain of ubiquitination at E62 (P = 0.0031); Gain of methylation at E62 (P = 0.0121); Gain of solvent accessibility (P = 0.0314); Gain of relative solvent accessibility (P = 0.0479); Gain of glycosylation at E62 (P = 0.0484)
17:44049275:G:C,P10636,E62Q,0.074,Loss of glycosylation at S64 (P = 0.1334); Gain of methylation at K67 (P = 0.3182); Loss of ubiquitination at K67 (P = 0.4006); Loss of phosphorylation at T63 (P = 0.569); Gain of solvent accessibility (P = 0.5946)
17:44049276:A:C,P10636,E62A,0.078,Gain of glycosylation at T63 (P = 0.072); Loss of methylation at K67 (P = 0.1181); Loss of ubiquitination at K67 (P = 0.3916); Loss of stability (P = 0.4545); Loss of solvent accessibility (P = 0.4838)
17:44049276:A:G,P10636,E62G,0.13,Gain of glycosylation at T63 (P = 0.093); Loss of stability (P = 0.1278); Loss of methylation at K67 (P = 0.2158); Loss of solvent accessibility (P = 0.3103); Gain of catalytic residue at K67 (P = 0.342)
17:44049276:A:T,P10636,E62V,0.094,Gain of glycosylation at T63 (P = 0.0736); Loss of methylation at K67 (P = 0.2162); Gain of ubiquitination at K67 (P = 0.4041); Loss of phosphorylation at T63 (P = 0.4576); Gain of catalytic residue at D65 (P = 0.4836)
17:44049277:A:C,P10636,E62D,0.105,Gain of glycosylation at T63 (P = 0.1126); Loss of methylation at K67 (P = 0.3109); Loss of catalytic residue at E62 (P = 0.38); Gain of ubiquitination at K67 (P = 0.4036); Gain of phosphorylation at T63 (P = 0.6501)
17:44049277:A:T,P10636,E62D,0.105,Gain of glycosylation at T63 (P = 0.1126); Loss of methylation at K67 (P = 0.3109); Loss of catalytic residue at E62 (P = 0.38); Gain of ubiquitination at K67 (P = 0.4036); Gain of phosphorylation at T63 (P = 0.6501)
17:44049278:A:C,P10636,T63P,0.064,Loss of phosphorylation at T63 (P = 0.0091); Loss of glycosylation at T63 (P = 0.0411); Loss of stability (P = 0.2761); Loss of methylation at K67 (P = 0.3268); Gain of ubiquitination at K67 (P = 0.4036)
17:44049278:A:G,P10636,T63A,0.055,Loss of phosphorylation at T63 (P = 0.0091); Loss of glycosylation at T63 (P = 0.0224); Loss of methylation at K67 (P = 0.1579); Loss of ubiquitination at K67 (P = 0.3857); Loss of stability (P = 0.4116)
17:44049278:A:T,P10636,T63S,0.14,Loss of glycosylation at T63 (P = 0.1006); Loss of methylation at K67 (P = 0.277); Loss of ubiquitination at K67 (P = 0.4039); Gain of phosphorylation at S68 (P = 0.4954); Loss of stability (P = 0.5939)
17:44049279:C:A,P10636,T63N,0.074,Loss of phosphorylation at T63 (P = 0.0091); Loss of glycosylation at T63 (P = 0.0224); Loss of methylation at K67 (P = 0.1305); Loss of ubiquitination at K67 (P = 0.4039); Gain of solvent accessibility (P = 0.5334)
17:44049279:C:G,P10636,T63S,0.14,Loss of glycosylation at T63 (P = 0.1006); Loss of methylation at K67 (P = 0.277); Loss of ubiquitination at K67 (P = 0.4039); Gain of phosphorylation at S68 (P = 0.4954); Loss of stability (P = 0.5939)
17:44049279:C:T,P10636,T63I,0.079,Loss of phosphorylation at T63 (P = 0.0091); Loss of glycosylation at T63 (P = 0.0224); Gain of catalytic residue at T63 (P = 0.2659); Gain of methylation at K67 (P = 0.3232); Loss of ubiquitination at K67 (P = 0.3792)
17:44049281:T:A,P10636,S64T,0.115,Gain of glycosylation at T63 (P = 0.093); Gain of methylation at K67 (P = 0.314); Loss of stability (P = 0.3233); Loss of phosphorylation at T63 (P = 0.3758); Loss of ubiquitination at K67 (P = 0.3963)
17:44049281:T:C,P10636,S64P,0.091,Loss of phosphorylation at S64 (P = 0.0064); Loss of glycosylation at S64 (P = 0.054); Loss of catalytic residue at K67 (P = 0.2665); Loss of stability (P = 0.2836); Gain of methylation at K67 (P = 0.2871)
17:44049281:T:G,P10636,S64A,0.088,Loss of phosphorylation at S64 (P = 0.0064); Loss of glycosylation at S64 (P = 0.0233); Loss of methylation at K67 (P = 0.2213); Loss of stability (P = 0.3048); Loss of ubiquitination at K67 (P = 0.4006)
17:44049282:C:A,P10636,S64Y,0.141,Loss of glycosylation at S64 (P = 0.0233); Loss of phosphorylation at S64 (P = 0.1422); Loss of methylation at K67 (P = 0.1572); Gain of catalytic residue at S64 (P = 0.2326); Loss of ubiquitination at K67 (P = 0.4039)
17:44049282:C:G,P10636,S64C,0.138,Loss of phosphorylation at S64 (P = 0.0064); Loss of glycosylation at S64 (P = 0.0233); Gain of methylation at K67 (P = 0.3094); Gain of catalytic residue at K67 (P = 0.3859); Loss of ubiquitination at K67 (P = 0.3916)
17:44049282:C:T,P10636,S64F,0.144,Loss of phosphorylation at S64 (P = 0.0064); Loss of glycosylation at S64 (P = 0.0233); Gain of catalytic residue at S64 (P = 0.074); Loss of methylation at K67 (P = 0.2941); Loss of ubiquitination at K67 (P = 0.4039)
17:44049284:G:A,P10636,D65N,0.063,Loss of solvent accessibility (P = 0.1202); Gain of glycosylation at S64 (P = 0.126); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S68 (P = 0.2024); Gain of methylation at K67 (P = 0.2792)
17:44049284:G:C,P10636,D65H,0.064,Gain of glycosylation at T63 (P = 0.1173); Loss of solvent accessibility (P = 0.1473); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at K67 (P = 0.2678); Gain of catalytic residue at E62 (P = 0.289)
17:44049284:G:T,P10636,D65Y,0.193,Gain of phosphorylation at D65 (P = 0.0024); Gain of catalytic residue at D65 (P = 0.0229); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1115); Gain of glycosylation at S64 (P = 0.1842)
17:44049285:A:C,P10636,D65A,0.067,Loss of solvent accessibility (P = 0.0595); Gain of glycosylation at S64 (P = 0.0828); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.2678); Gain of methylation at K67 (P = 0.2942)
17:44049285:A:G,P10636,D65G,0.066,Gain of glycosylation at S64 (P = 0.0443); Loss of solvent accessibility (P = 0.0477); Loss of stability (P = 0.1047); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at K67 (P = 0.2735)
17:44049285:A:T,P10636,D65V,0.064,Loss of solvent accessibility (P = 0.0544); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at S64 (P = 0.136); Loss of phosphorylation at S68 (P = 0.2434); Gain of methylation at K67 (P = 0.2451)
17:44049286:T:A,P10636,D65E,0.059,Loss of solvent accessibility (P = 0.1651); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T63 (P = 0.2035); Gain of methylation at K67 (P = 0.2899); Loss of ubiquitination at K67 (P = 0.4039)
17:44049286:T:G,P10636,D65E,0.059,Loss of solvent accessibility (P = 0.1651); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T63 (P = 0.2035); Gain of methylation at K67 (P = 0.2899); Loss of ubiquitination at K67 (P = 0.4039)
17:44049287:G:A,P10636,A66T,0.052,Gain of glycosylation at A66 (P = 0.0096); Gain of phosphorylation at A66 (P = 0.023); Loss of stability (P = 0.2134); Gain of methylation at K67 (P = 0.2932); Loss of ubiquitination at K67 (P = 0.4006)
17:44049287:G:C,P10636,A66P,0.047,Gain of glycosylation at A66 (P = 0.0356); Loss of stability (P = 0.1872); Gain of methylation at K67 (P = 0.2736); Gain of catalytic residue at K67 (P = 0.3561); Loss of ubiquitination at K67 (P = 0.4039)
17:44049287:G:T,P10636,A66S,0.093,Gain of glycosylation at A66 (P = 0.0044); Gain of phosphorylation at A66 (P = 0.0103); Gain of catalytic residue at K67 (P = 0.2608); Loss of stability (P = 0.3059); Gain of methylation at K67 (P = 0.3196)
17:44049288:C:A,P10636,A66D,0.093,Gain of solvent accessibility (P = 0.0109); Gain of relative solvent accessibility (P = 0.0166); Loss of glycosylation at T63 (P = 0.0753); Loss of methylation at K67 (P = 0.2408); Gain of ubiquitination at K67 (P = 0.4036)
17:44049288:C:G,P10636,A66G,0.049,Loss of stability (P = 0.1035); Loss of glycosylation at T63 (P = 0.1103); Gain of methylation at K67 (P = 0.3131); Loss of ubiquitination at K67 (P = 0.4006); Gain of catalytic residue at K67 (P = 0.4051)
17:44049288:C:T,P10636,A66V,0.038,Gain of glycosylation at S64 (P = 0.1929); Gain of methylation at K67 (P = 0.2134); Loss of ubiquitination at K67 (P = 0.3963); Loss of phosphorylation at S68 (P = 0.4115); Loss of stability (P = 0.5238)
17:44049290:A:C,P10636,K67Q,0.187,Loss of ubiquitination at K67 (P = 0.0012); Loss of methylation at K67 (P = 0.0069); Loss of solvent accessibility (P = 0.0561); Loss of glycosylation at K67 (P = 0.1378); Loss of relative solvent accessibility (P = 0.1807)
17:44049290:A:G,P10636,K67E,0.201,Loss of ubiquitination at K67 (P = 0.0012); Loss of methylation at K67 (P = 0.0069); Loss of solvent accessibility (P = 0.0544); Loss of glycosylation at K67 (P = 0.1378); Loss of relative solvent accessibility (P = 0.1807)
17:44049291:A:C,P10636,K67T,0.278,Loss of ubiquitination at K67 (P = 0.0012); Loss of methylation at K67 (P = 0.0069); Gain of phosphorylation at K67 (P = 0.0073); Gain of glycosylation at K67 (P = 0.0129); Loss of solvent accessibility (P = 0.0155)
17:44049291:A:G,P10636,K67R,0.175,Loss of ubiquitination at K67 (P = 0.0012); Loss of methylation at K67 (P = 0.0123); Loss of solvent accessibility (P = 0.1115); Loss of glycosylation at K67 (P = 0.1378); Loss of relative solvent accessibility (P = 0.1807)
17:44049291:A:T,P10636,K67M,0.228,Loss of ubiquitination at K67 (P = 0.0012); Loss of methylation at K67 (P = 0.0069); Loss of solvent accessibility (P = 0.0117); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at S64 (P = 0.1112)
17:44049292:G:C,P10636,K67N,0.201,Loss of ubiquitination at K67 (P = 0.0012); Loss of methylation at K67 (P = 0.0069); Loss of solvent accessibility (P = 0.0371); Gain of glycosylation at T63 (P = 0.1094); Loss of relative solvent accessibility (P = 0.1807)
17:44049292:G:T,P10636,K67N,0.201,Loss of ubiquitination at K67 (P = 0.0012); Loss of methylation at K67 (P = 0.0069); Loss of solvent accessibility (P = 0.0371); Gain of glycosylation at T63 (P = 0.1094); Loss of relative solvent accessibility (P = 0.1807)
17:44049293:A:C,P10636,S68R,0.11,Loss of glycosylation at S68 (P = 0.0052); Loss of phosphorylation at S68 (P = 0.0151); Gain of solvent accessibility (P = 0.204); Gain of methylation at K67 (P = 0.2494); Gain of ubiquitination at K67 (P = 0.4036)
17:44049293:A:G,P10636,S68G,0.072,Loss of glycosylation at S68 (P = 0.0052); Loss of phosphorylation at S68 (P = 0.0151); Loss of methylation at K67 (P = 0.3098); Loss of ubiquitination at K67 (P = 0.3916); Loss of stability (P = 0.563)
17:44049293:A:T,P10636,S68C,0.092,Loss of glycosylation at S68 (P = 0.0052); Loss of phosphorylation at S68 (P = 0.0151); Gain of methylation at K67 (P = 0.1378); Loss of ubiquitination at K67 (P = 0.3792); Gain of sheet (P = 0.6509)
17:44049294:G:A,P10636,S68N,0.094,Loss of glycosylation at S68 (P = 0.0052); Loss of phosphorylation at S68 (P = 0.0151); Gain of catalytic residue at S68 (P = 0.0603); Gain of methylation at K67 (P = 0.2992); Loss of ubiquitination at K67 (P = 0.3792)
17:44049294:G:C,P10636,S68T,0.099,Loss of phosphorylation at S68 (P = 0.0691); Gain of glycosylation at T69 (P = 0.2226); Gain of methylation at K67 (P = 0.3288); Loss of ubiquitination at K67 (P = 0.3963); Gain of catalytic residue at K67 (P = 0.4901)
17:44049294:G:T,P10636,S68I,0.153,Loss of glycosylation at S68 (P = 0.0052); Loss of phosphorylation at S68 (P = 0.0151); Gain of stability (P = 0.0553); Gain of catalytic residue at P70 (P = 0.0576); Gain of methylation at K67 (P = 0.2843)
17:44049295:C:A,P10636,S68R,0.11,Loss of glycosylation at S68 (P = 0.0052); Loss of phosphorylation at S68 (P = 0.0151); Gain of solvent accessibility (P = 0.204); Gain of methylation at K67 (P = 0.2494); Gain of ubiquitination at K67 (P = 0.4036)
17:44049295:C:G,P10636,S68R,0.11,Loss of glycosylation at S68 (P = 0.0052); Loss of phosphorylation at S68 (P = 0.0151); Gain of solvent accessibility (P = 0.204); Gain of methylation at K67 (P = 0.2494); Gain of ubiquitination at K67 (P = 0.4036)
17:44049296:A:C,P10636,T69P,0.153,Loss of phosphorylation at T69 (P = 0.0064); Gain of catalytic residue at T69 (P = 0.0076); Loss of glycosylation at T69 (P = 0.0487); Loss of stability (P = 0.2268); Gain of methylation at K67 (P = 0.3136)
17:44049296:A:G,P10636,T69A,0.088,Loss of phosphorylation at T69 (P = 0.0064); Loss of glycosylation at T69 (P = 0.0112); Loss of methylation at K67 (P = 0.2501); Loss of stability (P = 0.3968); Gain of ubiquitination at K67 (P = 0.4036)
17:44049296:A:T,P10636,T69S,0.122,Loss of glycosylation at S68 (P = 0.0672); Loss of methylation at K67 (P = 0.2038); Loss of stability (P = 0.2552); Loss of ubiquitination at K67 (P = 0.4006); Gain of phosphorylation at S68 (P = 0.5008)
17:44049297:C:A,P10636,T69N,0.096,Loss of phosphorylation at T69 (P = 0.0064); Loss of glycosylation at T69 (P = 0.0112); Loss of methylation at K67 (P = 0.2202); Gain of catalytic residue at K67 (P = 0.2416); Loss of ubiquitination at K67 (P = 0.3963)
17:44049297:C:G,P10636,T69S,0.122,Loss of glycosylation at S68 (P = 0.0672); Loss of methylation at K67 (P = 0.2038); Loss of stability (P = 0.2552); Loss of ubiquitination at K67 (P = 0.4006); Gain of phosphorylation at S68 (P = 0.5008)
17:44049297:C:T,P10636,T69I,0.097,Loss of phosphorylation at T69 (P = 0.0064); Loss of glycosylation at T69 (P = 0.0112); Gain of methylation at K67 (P = 0.2663); Gain of ubiquitination at K67 (P = 0.4031); Loss of catalytic residue at K67 (P = 0.5192)
17:44049299:C:A,P10636,P70T,0.096,Gain of glycosylation at P70 (P = 0.018); Gain of phosphorylation at P70 (P = 0.0374); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1235); Loss of stability (P = 0.2141)
17:44049299:C:G,P10636,P70A,0.097,Loss of glycosylation at T71 (P = 0.0926); Loss of solvent accessibility (P = 0.1322); Loss of methylation at K67 (P = 0.1393); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at T69 (P = 0.2904)
17:44049299:C:T,P10636,P70S,0.114,Gain of phosphorylation at P70 (P = 0.0175); Gain of glycosylation at P70 (P = 0.0345); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1177); Loss of methylation at K67 (P = 0.165)
17:44049300:C:A,P10636,P70Q,0.089,Loss of glycosylation at T71 (P = 0.0468); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S68 (P = 0.2533); Loss of catalytic residue at K67 (P = 0.2819); Loss of methylation at K67 (P = 0.3055)
17:44049300:C:G,P10636,P70R,0.173,Loss of glycosylation at T71 (P = 0.032); Gain of catalytic residue at P70 (P = 0.0381); Loss of methylation at K67 (P = 0.1612); Loss of relative solvent accessibility (P = 0.1807); Gain of ubiquitination at K67 (P = 0.4041)
17:44049300:C:T,P10636,P70L,0.105,Loss of glycosylation at T71 (P = 0.0567); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at K67 (P = 0.1084); Loss of phosphorylation at T69 (P = 0.1279); Loss of solvent accessibility (P = 0.1362)
17:44049302:A:C,P10636,T71P,0.081,Loss of phosphorylation at T71 (P = 0.0148); Gain of catalytic residue at P70 (P = 0.0179); Loss of glycosylation at T71 (P = 0.038); Loss of methylation at K67 (P = 0.2486); Loss of ubiquitination at K67 (P = 0.4039)
17:44049302:A:G,P10636,T71A,0.074,Loss of phosphorylation at T71 (P = 0.0148); Loss of glycosylation at T71 (P = 0.0155); Loss of methylation at K67 (P = 0.1163); Loss of ubiquitination at K67 (P = 0.4039); Loss of catalytic residue at K67 (P = 0.56)
17:44049302:A:T,P10636,T71S,0.087,Loss of glycosylation at T71 (P = 0.0652); Loss of methylation at K67 (P = 0.2364); Loss of ubiquitination at K67 (P = 0.4006); Gain of phosphorylation at S68 (P = 0.5027); Loss of catalytic residue at K67 (P = 0.6206)
17:44049303:C:A,P10636,T71K,0.207,Gain of ubiquitination at T71 (P = 0.0014); Gain of solvent accessibility (P = 0.0044); Loss of phosphorylation at T71 (P = 0.0148); Gain of methylation at T71 (P = 0.0158); Gain of relative solvent accessibility (P = 0.0166)
17:44049303:C:G,P10636,T71R,0.13,Loss of phosphorylation at T71 (P = 0.0148); Loss of glycosylation at T71 (P = 0.0155); Loss of methylation at K67 (P = 0.0519); Gain of solvent accessibility (P = 0.2291); Gain of ubiquitination at K67 (P = 0.4036)
17:44049303:C:T,P10636,T71I,0.081,Loss of phosphorylation at T71 (P = 0.0148); Loss of glycosylation at T71 (P = 0.0155); Gain of catalytic residue at D74 (P = 0.2862); Gain of methylation at K67 (P = 0.3251); Gain of ubiquitination at K67 (P = 0.4036)
17:44049305:G:A,P10636,A72T,0.141,Gain of glycosylation at A72 (P = 0.0042); Gain of phosphorylation at A72 (P = 0.0042); Gain of methylation at K67 (P = 0.2521); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.3194)
17:44049305:G:C,P10636,A72P,0.091,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0503); Gain of glycosylation at T76 (P = 0.1412); Gain of methylation at K67 (P = 0.2753); Loss of ubiquitination at K67 (P = 0.3963)
17:44049305:G:T,P10636,A72S,0.107,Gain of glycosylation at A72 (P = 0.0082); Gain of phosphorylation at A72 (P = 0.017); Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0611); Gain of methylation at K67 (P = 0.2753)
17:44049306:C:A,P10636,A72E,0.067,Loss of glycosylation at T69 (P = 0.0546); Gain of solvent accessibility (P = 0.194); Gain of relative solvent accessibility (P = 0.2629); Gain of methylation at K67 (P = 0.3089); Loss of ubiquitination at K67 (P = 0.3963)
17:44049306:C:G,P10636,A72G,0.068,Loss of glycosylation at T69 (P = 0.1051); Gain of relative solvent accessibility (P = 0.2629); Loss of stability (P = 0.2852); Gain of methylation at K67 (P = 0.304); Gain of catalytic residue at K67 (P = 0.379)
17:44049308:G:A,P10636,E73K,0.186,Gain of ubiquitination at E73 (P = 0.0016); Gain of methylation at E73 (P = 0.0042); Loss of stability (P = 0.0841); Gain of glycosylation at E73 (P = 0.0984); Gain of relative solvent accessibility (P = 0.1684)
17:44049308:G:C,P10636,E73Q,0.101,Loss of glycosylation at T71 (P = 0.1743); Loss of solvent accessibility (P = 0.239); Loss of stability (P = 0.2594); Loss of phosphorylation at T71 (P = 0.3572); Loss of relative solvent accessibility (P = 0.3589)
17:44049309:A:C,P10636,E73A,0.113,Loss of solvent accessibility (P = 0.0576); Gain of glycosylation at T76 (P = 0.1427); Loss of relative solvent accessibility (P = 0.1903); Loss of stability (P = 0.3505); Loss of phosphorylation at T71 (P = 0.3715)
17:44049309:A:G,P10636,E73G,0.15,Loss of stability (P = 0.0399); Gain of catalytic residue at A72 (P = 0.1525); Loss of glycosylation at T76 (P = 0.155); Gain of relative solvent accessibility (P = 0.1684); Loss of solvent accessibility (P = 0.2517)
17:44049309:A:T,P10636,E73V,0.138,Loss of solvent accessibility (P = 0.0509); Loss of relative solvent accessibility (P = 0.114); Gain of glycosylation at T76 (P = 0.133); Loss of phosphorylation at T71 (P = 0.2864); Gain of catalytic residue at D74 (P = 0.5142)
17:44049310:A:C,P10636,E73D,0.072,Gain of glycosylation at T76 (P = 0.1633); Gain of relative solvent accessibility (P = 0.1684); Loss of stability (P = 0.2348); Gain of solvent accessibility (P = 0.4656); Gain of phosphorylation at S68 (P = 0.5109)
17:44049310:A:T,P10636,E73D,0.072,Gain of glycosylation at T76 (P = 0.1633); Gain of relative solvent accessibility (P = 0.1684); Loss of stability (P = 0.2348); Gain of solvent accessibility (P = 0.4656); Gain of phosphorylation at S68 (P = 0.5109)
17:44049311:G:A,P10636,D74N,0.118,Loss of solvent accessibility (P = 0.1202); Gain of glycosylation at T71 (P = 0.1253); Loss of phosphorylation at T76 (P = 0.1577); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at D74 (P = 0.4306)
17:44049311:G:C,P10636,D74H,0.108,Loss of solvent accessibility (P = 0.0703); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at E73 (P = 0.0993); Gain of glycosylation at T71 (P = 0.1184); Loss of phosphorylation at T76 (P = 0.2681)
17:44049311:G:T,P10636,D74Y,0.19,Gain of phosphorylation at D74 (P = 0.0042); Loss of solvent accessibility (P = 0.0509); Loss of relative solvent accessibility (P = 0.0676); Gain of catalytic residue at E73 (P = 0.0731); Gain of glycosylation at T71 (P = 0.1071)
17:44051751:A:C,P10636,D74A,0.078,Loss of solvent accessibility (P = 0.0435); Gain of glycosylation at T71 (P = 0.0882); Loss of relative solvent accessibility (P = 0.0981); Loss of phosphorylation at T71 (P = 0.2864); Gain of catalytic residue at V75 (P = 0.3904)
17:44051751:A:G,P10636,D74G,0.086,Loss of solvent accessibility (P = 0.0477); Gain of catalytic residue at V75 (P = 0.0803); Gain of glycosylation at T76 (P = 0.1061); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.1869)
17:44051751:A:T,P10636,D74V,0.171,Loss of solvent accessibility (P = 0.0371); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at T71 (P = 0.1058); Gain of catalytic residue at E73 (P = 0.1087); Loss of phosphorylation at T71 (P = 0.2276)
17:44051752:T:A,P10636,D74E,0.052,Gain of glycosylation at T76 (P = 0.1541); Loss of relative solvent accessibility (P = 0.3219); Loss of solvent accessibility (P = 0.3646); Loss of phosphorylation at T71 (P = 0.4197); Gain of catalytic residue at D74 (P = 0.6214)
17:44051752:T:G,P10636,D74E,0.052,Gain of glycosylation at T76 (P = 0.1541); Loss of relative solvent accessibility (P = 0.3219); Loss of solvent accessibility (P = 0.3646); Loss of phosphorylation at T71 (P = 0.4197); Gain of catalytic residue at D74 (P = 0.6214)
17:44051753:G:A,P10636,V75M,0.062,Gain of glycosylation at T76 (P = 0.2494); Loss of phosphorylation at T76 (P = 0.5028); Gain of solvent accessibility (P = 0.5334); Gain of sheet (P = 0.6509); Gain of catalytic residue at V75 (P = 0.7588)
17:44051753:G:C,P10636,V75L,0.098,Loss of glycosylation at T76 (P = 0.1273); Gain of catalytic residue at V75 (P = 0.1488); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2291); Loss of phosphorylation at T76 (P = 0.4897)
17:44051753:G:T,P10636,V75L,0.098,Loss of glycosylation at T76 (P = 0.1273); Gain of catalytic residue at V75 (P = 0.1488); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2291); Loss of phosphorylation at T76 (P = 0.4897)
17:44051754:T:A,P10636,V75E,0.128,Gain of solvent accessibility (P = 0.0078); Gain of relative solvent accessibility (P = 0.0166); Loss of glycosylation at T76 (P = 0.1013); Gain of phosphorylation at T76 (P = 0.4979); Loss of sheet (P = 0.6423)
17:44051754:T:C,P10636,V75A,0.08,Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at T76 (P = 0.1803); Gain of solvent accessibility (P = 0.3956); Gain of phosphorylation at T71 (P = 0.5089); Loss of stability (P = 0.618)
17:44051754:T:G,P10636,V75G,0.098,Loss of stability (P = 0.0472); Gain of glycosylation at T76 (P = 0.2163); Gain of relative solvent accessibility (P = 0.2751); Gain of phosphorylation at T76 (P = 0.5113); Loss of sheet (P = 0.6423)
17:44051756:A:C,P10636,T76P,0.129,Loss of phosphorylation at T76 (P = 0.015); Loss of glycosylation at T76 (P = 0.0349); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.1071); Loss of stability (P = 0.4122)
17:44051756:A:G,P10636,T76A,0.108,Loss of phosphorylation at T76 (P = 0.015); Loss of glycosylation at T76 (P = 0.0255); Loss of solvent accessibility (P = 0.4274); Loss of relative solvent accessibility (P = 0.5582); Gain of catalytic residue at D74 (P = 0.5689)
17:44051756:A:T,P10636,T76S,0.13,Gain of glycosylation at T76 (P = 0.1318); Gain of relative solvent accessibility (P = 0.2363); Loss of phosphorylation at T76 (P = 0.3681); Gain of solvent accessibility (P = 0.4137); Loss of sheet (P = 0.6423)
17:44051757:C:A,P10636,T76K,0.243,Gain of ubiquitination at T76 (P = 0.0025); Gain of methylation at T76 (P = 0.0043); Loss of phosphorylation at T76 (P = 0.015); Gain of solvent accessibility (P = 0.0156); Gain of relative solvent accessibility (P = 0.0479)
17:44051757:C:G,P10636,T76R,0.173,Loss of phosphorylation at T76 (P = 0.015); Loss of glycosylation at T76 (P = 0.0255); Gain of solvent accessibility (P = 0.0808); Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at D81 (P = 0.4097)
17:44051757:C:T,P10636,T76I,0.226,Loss of phosphorylation at T76 (P = 0.015); Loss of glycosylation at T76 (P = 0.0255); Gain of catalytic residue at P78 (P = 0.0307); Loss of solvent accessibility (P = 0.5485); Loss of relative solvent accessibility (P = 0.5582)
17:44051759:G:A,P10636,A77T,0.096,Gain of glycosylation at A77 (P = 0.0056); Gain of phosphorylation at A77 (P = 0.0323); Loss of stability (P = 0.3344); Gain of sheet (P = 0.6509); Loss of catalytic residue at D81 (P = 0.6854)
17:44051759:G:C,P10636,A77P,0.149,Gain of catalytic residue at A77 (P = 0.0095); Gain of glycosylation at T76 (P = 0.1308); Loss of stability (P = 0.419); Gain of phosphorylation at T76 (P = 0.4593); Loss of sheet (P = 0.7751)
17:44051759:G:T,P10636,A77S,0.088,Gain of glycosylation at A77 (P = 0.0067); Gain of phosphorylation at A77 (P = 0.0198); Gain of solvent accessibility (P = 0.4821); Loss of stability (P = 0.5096); Loss of catalytic residue at D81 (P = 0.6176)
17:44051760:C:A,P10636,A77E,0.097,Loss of glycosylation at T76 (P = 0.0942); Gain of solvent accessibility (P = 0.2689); Gain of catalytic residue at A77 (P = 0.4201); Gain of phosphorylation at T76 (P = 0.517); Gain of sheet (P = 0.6509)
17:44051760:C:G,P10636,A77G,0.067,Gain of catalytic residue at A77 (P = 0.1304); Loss of stability (P = 0.1308); Loss of glycosylation at T76 (P = 0.1492); Gain of phosphorylation at T76 (P = 0.5361); Loss of sheet (P = 0.7751)
17:44051760:C:T,P10636,A77V,0.099,Gain of glycosylation at T76 (P = 0.1989); Loss of phosphorylation at T76 (P = 0.427); Loss of relative solvent accessibility (P = 0.5582); Gain of catalytic residue at E82 (P = 0.6421); Loss of solvent accessibility (P = 0.6935)
17:44051762:C:A,P10636,P78T,0.186,Gain of glycosylation at P78 (P = 0.0304); Gain of phosphorylation at P78 (P = 0.0545); Loss of stability (P = 0.1627); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1922)
17:44051762:C:G,P10636,P78A,0.186,Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.2186); Gain of glycosylation at T76 (P = 0.2376); Loss of phosphorylation at T76 (P = 0.4686)
17:44051762:C:T,P10636,P78S,0.193,Gain of glycosylation at P78 (P = 0.0211); Gain of phosphorylation at P78 (P = 0.035); Loss of stability (P = 0.0955); Loss of solvent accessibility (P = 0.1744); Loss of relative solvent accessibility (P = 0.1807)
17:44051763:C:A,P10636,P78H,0.231,Loss of stability (P = 0.0914); Gain of glycosylation at T76 (P = 0.1679); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at P78 (P = 0.2205); Loss of solvent accessibility (P = 0.3103)
17:44051763:C:G,P10636,P78R,0.241,Loss of glycosylation at T76 (P = 0.0909); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.2823); Loss of catalytic residue at D81 (P = 0.3173); Gain of MoRF binding (P = 0.4068)
17:44051763:C:T,P10636,P78L,0.233,Loss of glycosylation at T76 (P = 0.1531); Loss of phosphorylation at T76 (P = 0.1697); Gain of solvent accessibility (P = 0.3194); Gain of catalytic residue at E82 (P = 0.6249); Loss of sheet (P = 0.6423)
17:44051765:T:A,P10636,L79I,0.121,Loss of phosphorylation at T76 (P = 0.1508); Gain of relative solvent accessibility (P = 0.1571); Gain of catalytic residue at E82 (P = 0.1624); Gain of glycosylation at T76 (P = 0.1791); Gain of solvent accessibility (P = 0.2346)
17:44051765:T:G,P10636,L79V,0.08,Gain of glycosylation at T76 (P = 0.1431); Gain of catalytic residue at E82 (P = 0.1778); Loss of stability (P = 0.5023); Gain of phosphorylation at T76 (P = 0.5284); Loss of sheet (P = 0.6423)
17:44051766:T:C,P10636,L79S,0.102,Gain of phosphorylation at L79 (P = 0.0177); Gain of glycosylation at L79 (P = 0.0435); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.204); Loss of stability (P = 0.3087)
17:44051767:A:C,P10636,L79F,0.173,Gain of catalytic residue at L79 (P = 0.0095); Gain of glycosylation at T76 (P = 0.1604); Gain of phosphorylation at T76 (P = 0.5277); Gain of solvent accessibility (P = 0.5485); Loss of stability (P = 0.6437)
17:44051767:A:T,P10636,L79F,0.173,Gain of catalytic residue at L79 (P = 0.0095); Gain of glycosylation at T76 (P = 0.1604); Gain of phosphorylation at T76 (P = 0.5277); Gain of solvent accessibility (P = 0.5485); Loss of stability (P = 0.6437)
17:44051768:G:A,P10636,V80M,0.09,Loss of stability (P = 0.2282); Loss of glycosylation at T76 (P = 0.2315); Gain of relative solvent accessibility (P = 0.2751); Gain of catalytic residue at V80 (P = 0.2826); Gain of solvent accessibility (P = 0.3304)
17:44051768:G:C,P10636,V80L,0.071,Gain of glycosylation at T76 (P = 0.2474); Loss of stability (P = 0.4484); Gain of phosphorylation at T76 (P = 0.5312); Loss of catalytic residue at D81 (P = 0.5519); Gain of solvent accessibility (P = 0.5843)
17:44051768:G:T,P10636,V80L,0.071,Gain of glycosylation at T76 (P = 0.2474); Loss of stability (P = 0.4484); Gain of phosphorylation at T76 (P = 0.5312); Loss of catalytic residue at D81 (P = 0.5519); Gain of solvent accessibility (P = 0.5843)
17:44051769:T:A,P10636,V80E,0.153,Gain of solvent accessibility (P = 0.0078); Gain of relative solvent accessibility (P = 0.0166); Loss of stability (P = 0.0871); Loss of glycosylation at T76 (P = 0.2575); Loss of catalytic residue at D81 (P = 0.3639)
17:44051769:T:C,P10636,V80A,0.09,Loss of stability (P = 0.0387); Gain of glycosylation at T76 (P = 0.2538); Gain of relative solvent accessibility (P = 0.2751); Gain of phosphorylation at T76 (P = 0.5151); Loss of catalytic residue at D81 (P = 0.5258)
17:44051769:T:G,P10636,V80G,0.154,Loss of stability (P = 0.002); Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at T76 (P = 0.2619); Gain of solvent accessibility (P = 0.4821); Gain of phosphorylation at T76 (P = 0.5234)
17:44051771:G:A,P10636,D81N,0.08,Gain of glycosylation at T76 (P = 0.1932); Loss of solvent accessibility (P = 0.2034); Loss of relative solvent accessibility (P = 0.3219); Loss of catalytic residue at D81 (P = 0.3526); Loss of phosphorylation at T76 (P = 0.4191)
17:44051771:G:C,P10636,D81H,0.071,Loss of solvent accessibility (P = 0.1473); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at E82 (P = 0.2234); Gain of glycosylation at T76 (P = 0.2434); Loss of phosphorylation at T76 (P = 0.4026)
17:44051771:G:T,P10636,D81Y,0.185,Gain of phosphorylation at D81 (P = 0.0202); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at P85 (P = 0.1082); Loss of solvent accessibility (P = 0.1115); Loss of glycosylation at T76 (P = 0.1792)
17:44051772:A:C,P10636,D81A,0.088,Loss of solvent accessibility (P = 0.0595); Loss of catalytic residue at D81 (P = 0.1243); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T76 (P = 0.21); Gain of phosphorylation at T76 (P = 0.5157)
17:44051772:A:G,P10636,D81G,0.072,Loss of solvent accessibility (P = 0.0477); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at V80 (P = 0.1996); Loss of glycosylation at T76 (P = 0.2145); Loss of stability (P = 0.3526)
17:44051772:A:T,P10636,D81V,0.109,Loss of solvent accessibility (P = 0.0907); Gain of catalytic residue at E82 (P = 0.1289); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T76 (P = 0.2487); Loss of phosphorylation at T76 (P = 0.4455)
17:44051773:T:A,P10636,D81E,0.099,Loss of glycosylation at T76 (P = 0.2594); Gain of solvent accessibility (P = 0.3089); Loss of catalytic residue at D81 (P = 0.3107); Loss of phosphorylation at T76 (P = 0.5311); Gain of sheet (P = 0.6509)
17:44051773:T:G,P10636,D81E,0.099,Loss of glycosylation at T76 (P = 0.2594); Gain of solvent accessibility (P = 0.3089); Loss of catalytic residue at D81 (P = 0.3107); Loss of phosphorylation at T76 (P = 0.5311); Gain of sheet (P = 0.6509)
17:44051774:G:A,P10636,E82K,0.274,Gain of ubiquitination at E82 (P = 0.0018); Gain of methylation at E82 (P = 0.0093); Gain of glycosylation at E82 (P = 0.0173); Loss of stability (P = 0.1837); Loss of catalytic residue at D81 (P = 0.3096)
17:44051774:G:C,P10636,E82Q,0.145,Gain of methylation at K87 (P = 0.1464); Loss of glycosylation at K87 (P = 0.2582); Loss of ubiquitination at K87 (P = 0.3642); Loss of solvent accessibility (P = 0.4141); Gain of catalytic residue at E82 (P = 0.4958)
17:44051775:A:C,P10636,E82A,0.219,Loss of solvent accessibility (P = 0.0023); Loss of relative solvent accessibility (P = 0.0404); Loss of methylation at K87 (P = 0.0536); Loss of glycosylation at K87 (P = 0.1679); Loss of stability (P = 0.3179)
17:44051775:A:G,P10636,E82G,0.261,Loss of solvent accessibility (P = 0.0036); Gain of catalytic residue at E82 (P = 0.0232); Loss of relative solvent accessibility (P = 0.0676); Loss of methylation at K87 (P = 0.0715); Loss of stability (P = 0.0947)
17:44051775:A:T,P10636,E82V,0.262,Loss of solvent accessibility (P = 0.0022); Loss of relative solvent accessibility (P = 0.0186); Loss of methylation at K87 (P = 0.0643); Loss of glycosylation at K87 (P = 0.1064); Loss of ubiquitination at K87 (P = 0.3642)
17:44051776:G:C,P10636,E82D,0.116,Loss of methylation at K87 (P = 0.128); Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at K87 (P = 0.2757); Loss of stability (P = 0.3582); Loss of ubiquitination at K87 (P = 0.3786)
17:44051776:G:T,P10636,E82D,0.116,Loss of methylation at K87 (P = 0.128); Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at K87 (P = 0.2757); Loss of stability (P = 0.3582); Loss of ubiquitination at K87 (P = 0.3786)
17:44051777:G:A,P10636,G83R,0.154,Loss of glycosylation at K87 (P = 0.0885); Loss of catalytic residue at G83 (P = 0.1173); Gain of solvent accessibility (P = 0.1319); Gain of methylation at K87 (P = 0.1456); Loss of ubiquitination at K87 (P = 0.3277)
17:44051777:G:C,P10636,G83R,0.154,Loss of glycosylation at K87 (P = 0.0885); Loss of catalytic residue at G83 (P = 0.1173); Gain of solvent accessibility (P = 0.1319); Gain of methylation at K87 (P = 0.1456); Loss of ubiquitination at K87 (P = 0.3277)
17:44051778:G:A,P10636,G83E,0.2,Gain of solvent accessibility (P = 0.0026); Gain of relative solvent accessibility (P = 0.0166); Gain of methylation at K87 (P = 0.0809); Loss of catalytic residue at G83 (P = 0.1231); Loss of glycosylation at K87 (P = 0.1801)
17:44051778:G:C,P10636,G83A,0.136,Loss of catalytic residue at G83 (P = 0.0248); Loss of methylation at K87 (P = 0.1056); Loss of stability (P = 0.1861); Loss of glycosylation at K87 (P = 0.273); Loss of ubiquitination at K87 (P = 0.3724)
17:44051778:G:T,P10636,G83V,0.124,Gain of methylation at K87 (P = 0.1408); Loss of glycosylation at K87 (P = 0.217); Loss of catalytic residue at D81 (P = 0.3121); Loss of ubiquitination at K87 (P = 0.3563); Loss of relative solvent accessibility (P = 0.5582)
17:44051780:G:A,P10636,A84T,0.104,Gain of phosphorylation at A84 (P = 0.007); Gain of glycosylation at A84 (P = 0.0507); Gain of methylation at K87 (P = 0.0936); Gain of relative solvent accessibility (P = 0.2629); Gain of catalytic residue at A84 (P = 0.2837)
17:44051780:G:C,P10636,A84P,0.139,Gain of methylation at K87 (P = 0.0594); Gain of catalytic residue at A84 (P = 0.0738); Gain of glycosylation at P85 (P = 0.1014); Loss of ubiquitination at K87 (P = 0.3724); Loss of stability (P = 0.4051)
17:44051780:G:T,P10636,A84S,0.09,Gain of phosphorylation at A84 (P = 0.026); Gain of glycosylation at A84 (P = 0.0283); Gain of methylation at K87 (P = 0.1111); Gain of relative solvent accessibility (P = 0.2629); Gain of catalytic residue at E82 (P = 0.3429)
17:44051781:C:A,P10636,A84D,0.106,Gain of relative solvent accessibility (P = 0.1066); Loss of methylation at K87 (P = 0.1182); Gain of solvent accessibility (P = 0.1422); Gain of glycosylation at K87 (P = 0.1974); Gain of ubiquitination at K87 (P = 0.3778)
17:44051781:C:G,P10636,A84G,0.137,Gain of catalytic residue at A84 (P = 0.0538); Gain of methylation at K87 (P = 0.1129); Gain of glycosylation at K87 (P = 0.2275); Gain of relative solvent accessibility (P = 0.2629); Loss of stability (P = 0.3032)
17:44051781:C:T,P10636,A84V,0.133,Gain of methylation at K87 (P = 0.0861); Gain of catalytic residue at A84 (P = 0.1725); Loss of glycosylation at K87 (P = 0.1747); Gain of ubiquitination at K87 (P = 0.3821); Gain of solvent accessibility (P = 0.4946)
17:44051783:C:A,P10636,P85T,0.126,Gain of phosphorylation at P85 (P = 0.0673); Loss of methylation at K87 (P = 0.0816); Gain of glycosylation at P85 (P = 0.0876); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1922)
17:44051783:C:G,P10636,P85A,0.159,Loss of methylation at K87 (P = 0.0655); Loss of solvent accessibility (P = 0.1322); Gain of catalytic residue at P85 (P = 0.1558); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at K87 (P = 0.2406)
17:44051783:C:T,P10636,P85S,0.145,Gain of glycosylation at P85 (P = 0.011); Gain of phosphorylation at P85 (P = 0.0469); Loss of methylation at K87 (P = 0.0776); Loss of ubiquitination at K87 (P = 0.3642); Loss of stability (P = 0.4084)
17:44051784:C:A,P10636,P85H,0.146,Loss of methylation at K87 (P = 0.073); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at E82 (P = 0.2157); Gain of glycosylation at K87 (P = 0.2788); Loss of solvent accessibility (P = 0.3103)
17:44051784:C:G,P10636,P85R,0.206,Loss of methylation at K87 (P = 0.0539); Loss of glycosylation at K87 (P = 0.0909); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at P85 (P = 0.2141); Gain of MoRF binding (P = 0.3252)
17:44051784:C:T,P10636,P85L,0.157,Loss of methylation at K87 (P = 0.071); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1362); Gain of glycosylation at K87 (P = 0.2058); Loss of ubiquitination at K87 (P = 0.348)
17:44051786:G:C,P10636,G86R,0.158,Gain of methylation at K87 (P = 0.0442); Gain of solvent accessibility (P = 0.1319); Loss of glycosylation at K87 (P = 0.1512); Loss of catalytic residue at G83 (P = 0.2716); Loss of ubiquitination at K87 (P = 0.3724)
17:44051786:G:T,P10636,G86C,0.15,Gain of catalytic residue at P85 (P = 0.0157); Gain of methylation at K87 (P = 0.0238); Loss of glycosylation at K87 (P = 0.1985); Loss of ubiquitination at K87 (P = 0.3165); Gain of solvent accessibility (P = 0.5843)
17:44051787:G:A,P10636,G86D,0.148,Gain of solvent accessibility (P = 0.0281); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at K87 (P = 0.1256); Loss of glycosylation at K87 (P = 0.2196); Loss of catalytic residue at G83 (P = 0.2866)
17:44051787:G:C,P10636,G86A,0.106,Loss of methylation at K87 (P = 0.11); Loss of glycosylation at K87 (P = 0.1756); Loss of catalytic residue at D81 (P = 0.2522); Gain of ubiquitination at K87 (P = 0.3821); Gain of solvent accessibility (P = 0.5093)
17:44051787:G:T,P10636,G86V,0.133,Gain of methylation at K87 (P = 0.0395); Loss of glycosylation at K87 (P = 0.1102); Loss of ubiquitination at K87 (P = 0.3724); Loss of catalytic residue at Q88 (P = 0.5108); Gain of solvent accessibility (P = 0.571)
17:44051789:A:C,P10636,K87Q,0.213,Loss of ubiquitination at K87 (P = 0.0022); Loss of glycosylation at K87 (P = 0.0189); Loss of methylation at K87 (P = 0.0205); Loss of solvent accessibility (P = 0.0561); Loss of relative solvent accessibility (P = 0.1807)
17:44051789:A:G,P10636,K87E,0.233,Loss of ubiquitination at K87 (P = 0.0022); Loss of glycosylation at K87 (P = 0.0189); Loss of methylation at K87 (P = 0.0205); Loss of solvent accessibility (P = 0.0219); Loss of relative solvent accessibility (P = 0.0981)
17:44051790:A:C,P10636,K87T,0.237,Loss of ubiquitination at K87 (P = 0.0022); Loss of solvent accessibility (P = 0.0155); Gain of phosphorylation at K87 (P = 0.0165); Loss of methylation at K87 (P = 0.0205); Loss of relative solvent accessibility (P = 0.0981)
17:44051790:A:G,P10636,K87R,0.233,Loss of ubiquitination at K87 (P = 0.0022); Loss of glycosylation at K87 (P = 0.0189); Loss of methylation at K87 (P = 0.0331); Loss of solvent accessibility (P = 0.0404); Loss of relative solvent accessibility (P = 0.0981)
17:44051790:A:T,P10636,K87M,0.284,Loss of ubiquitination at K87 (P = 0.0022); Loss of solvent accessibility (P = 0.0117); Loss of glycosylation at K87 (P = 0.0189); Loss of methylation at K87 (P = 0.0205); Loss of relative solvent accessibility (P = 0.0676)
17:44051791:G:C,P10636,K87N,0.229,Loss of ubiquitination at K87 (P = 0.0022); Loss of glycosylation at K87 (P = 0.0189); Loss of methylation at K87 (P = 0.0205); Loss of solvent accessibility (P = 0.0371); Loss of relative solvent accessibility (P = 0.1807)
17:44051791:G:T,P10636,K87N,0.229,Loss of ubiquitination at K87 (P = 0.0022); Loss of glycosylation at K87 (P = 0.0189); Loss of methylation at K87 (P = 0.0205); Loss of solvent accessibility (P = 0.0371); Loss of relative solvent accessibility (P = 0.1807)
17:44051792:C:A,P10636,Q88K,0.241,Gain of ubiquitination at Q88 (P = 0.0051); Gain of glycosylation at Q88 (P = 0.0172); Gain of methylation at Q88 (P = 0.0261); Gain of solvent accessibility (P = 0.0328); Gain of relative solvent accessibility (P = 0.0479)
17:44051792:C:G,P10636,Q88E,0.171,Gain of solvent accessibility (P = 0.0421); Gain of relative solvent accessibility (P = 0.0479); Loss of methylation at K87 (P = 0.0788); Gain of glycosylation at K87 (P = 0.2506); Loss of catalytic residue at Q88 (P = 0.3282)
17:44051793:A:C,P10636,Q88P,0.148,Gain of glycosylation at Q88 (P = 0.0986); Loss of methylation at K87 (P = 0.1304); Gain of catalytic residue at K87 (P = 0.2176); Loss of ubiquitination at K87 (P = 0.3724); Loss of solvent accessibility (P = 0.4141)
17:44051793:A:G,P10636,Q88R,0.191,Gain of methylation at K87 (P = 0.1118); Gain of catalytic residue at Q88 (P = 0.2057); Loss of glycosylation at K87 (P = 0.2727); Loss of ubiquitination at K87 (P = 0.3642); Gain of solvent accessibility (P = 0.3819)
17:44051793:A:T,P10636,Q88L,0.239,Gain of stability (P = 0.0212); Loss of methylation at K87 (P = 0.064); Loss of glycosylation at K87 (P = 0.1766); Loss of ubiquitination at K87 (P = 0.348); Gain of catalytic residue at K87 (P = 0.3693)
17:44051794:G:C,P10636,Q88H,0.127,Loss of methylation at K87 (P = 0.1163); Gain of glycosylation at K87 (P = 0.2358); Loss of catalytic residue at Q88 (P = 0.3279); Loss of ubiquitination at K87 (P = 0.3642); Gain of sheet (P = 0.6509)
17:44051794:G:T,P10636,Q88H,0.127,Loss of methylation at K87 (P = 0.1163); Gain of glycosylation at K87 (P = 0.2358); Loss of catalytic residue at Q88 (P = 0.3279); Loss of ubiquitination at K87 (P = 0.3642); Gain of sheet (P = 0.6509)
17:44051795:G:A,P10636,A89T,0.121,Gain of phosphorylation at A89 (P = 0.0261); Gain of methylation at K87 (P = 0.1009); Gain of glycosylation at A89 (P = 0.1022); Gain of ubiquitination at K87 (P = 0.3821); Gain of solvent accessibility (P = 0.4304)
17:44051795:G:C,P10636,A89P,0.144,Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0739); Gain of methylation at K87 (P = 0.0783); Gain of glycosylation at A89 (P = 0.0838); Loss of ubiquitination at K87 (P = 0.3786)
17:44051795:G:T,P10636,A89S,0.158,Gain of glycosylation at A89 (P = 0.0045); Gain of phosphorylation at A89 (P = 0.0607); Loss of methylation at K87 (P = 0.0974); Gain of ubiquitination at K87 (P = 0.3805); Gain of solvent accessibility (P = 0.4821)
17:44051796:C:A,P10636,A89D,0.173,Gain of solvent accessibility (P = 0.0354); Gain of relative solvent accessibility (P = 0.0479); Loss of methylation at K87 (P = 0.0826); Gain of catalytic residue at A89 (P = 0.1783); Loss of glycosylation at K87 (P = 0.2245)
17:44051796:C:G,P10636,A89G,0.111,Gain of catalytic residue at P85 (P = 0.0924); Gain of methylation at K87 (P = 0.1132); Loss of glycosylation at K87 (P = 0.1804); Gain of ubiquitination at K87 (P = 0.3821); Loss of sheet (P = 0.6423)
17:44051796:C:T,P10636,A89V,0.139,Gain of methylation at K87 (P = 0.0611); Gain of stability (P = 0.1144); Loss of glycosylation at K87 (P = 0.2084); Gain of ubiquitination at K87 (P = 0.3788); Loss of relative solvent accessibility (P = 0.5582)
17:44051798:G:A,P10636,A90T,0.129,Gain of glycosylation at A90 (P = 0.0046); Gain of phosphorylation at A90 (P = 0.0257); Gain of methylation at K87 (P = 0.0739); Gain of ubiquitination at K87 (P = 0.3778); Gain of solvent accessibility (P = 0.4304)
17:44051798:G:C,P10636,A90P,0.117,Gain of glycosylation at A90 (P = 0.0279); Gain of methylation at K87 (P = 0.0566); Gain of phosphorylation at T95 (P = 0.1126); Gain of ubiquitination at K87 (P = 0.3788); Loss of stability (P = 0.3987)
17:44051798:G:T,P10636,A90S,0.102,Gain of glycosylation at A90 (P = 0.0205); Gain of phosphorylation at A90 (P = 0.0537); Loss of methylation at K87 (P = 0.1244); Gain of ubiquitination at K87 (P = 0.3788); Gain of solvent accessibility (P = 0.4821)
17:44051799:C:A,P10636,A90D,0.121,Loss of methylation at K87 (P = 0.0926); Gain of solvent accessibility (P = 0.194); Loss of glycosylation at K87 (P = 0.2044); Gain of phosphorylation at T95 (P = 0.2356); Gain of relative solvent accessibility (P = 0.2363)
17:44051799:C:G,P10636,A90G,0.092,Gain of catalytic residue at A89 (P = 0.0982); Gain of methylation at K87 (P = 0.1143); Loss of stability (P = 0.1944); Gain of phosphorylation at T95 (P = 0.2263); Gain of glycosylation at K87 (P = 0.2417)
17:44051799:C:T,P10636,A90V,0.096,Gain of methylation at K87 (P = 0.0692); Loss of phosphorylation at T95 (P = 0.193); Loss of glycosylation at K87 (P = 0.2202); Loss of ubiquitination at K87 (P = 0.3786); Gain of sheet (P = 0.6509)
17:44051801:G:C,P10636,A91P,0.143,Gain of methylation at K87 (P = 0.0556); Gain of phosphorylation at T95 (P = 0.1193); Loss of stability (P = 0.1561); Gain of glycosylation at T95 (P = 0.2391); Gain of ubiquitination at K87 (P = 0.3788)
17:44051801:G:T,P10636,A91S,0.149,Gain of glycosylation at A91 (P = 0.0055); Gain of phosphorylation at A91 (P = 0.0449); Gain of methylation at K87 (P = 0.0537); Gain of solvent accessibility (P = 0.3089); Gain of ubiquitination at K87 (P = 0.3788)
17:44051802:C:A,P10636,A91E,0.141,Gain of methylation at K87 (P = 0.0617); Gain of solvent accessibility (P = 0.154); Gain of phosphorylation at T95 (P = 0.1716); Gain of glycosylation at K87 (P = 0.2214); Gain of catalytic residue at A91 (P = 0.3545)
17:44051802:C:G,P10636,A91G,0.1,Gain of methylation at K87 (P = 0.1036); Gain of catalytic residue at A90 (P = 0.1147); Loss of stability (P = 0.1885); Gain of phosphorylation at T95 (P = 0.2188); Gain of glycosylation at K87 (P = 0.2454)
17:44051802:C:T,P10636,A91V,0.133,Loss of relative solvent accessibility (P = 0.0404); Gain of methylation at K87 (P = 0.089); Loss of solvent accessibility (P = 0.1301); Loss of glycosylation at K87 (P = 0.1817); Loss of phosphorylation at T95 (P = 0.1849)
17:44051804:C:A,P10636,Q92K,0.273,Gain of ubiquitination at Q92 (P = 0.0018); Gain of methylation at Q92 (P = 0.0065); Gain of glycosylation at Q92 (P = 0.024); Gain of solvent accessibility (P = 0.0328); Gain of relative solvent accessibility (P = 0.0479)
17:44051804:C:G,P10636,Q92E,0.112,Gain of phosphorylation at T95 (P = 0.1505); Loss of methylation at K87 (P = 0.1541); Gain of glycosylation at K87 (P = 0.2342); Gain of ubiquitination at K87 (P = 0.3821); Gain of sheet (P = 0.6509)
17:44051805:A:C,P10636,Q92P,0.185,Gain of glycosylation at Q92 (P = 0.0493); Gain of methylation at K87 (P = 0.0583); Gain of catalytic residue at Q92 (P = 0.0664); Gain of phosphorylation at T95 (P = 0.1135); Loss of stability (P = 0.2465)
17:44051805:A:G,P10636,Q92R,0.197,Gain of phosphorylation at T95 (P = 0.0793); Loss of methylation at K87 (P = 0.0851); Loss of glycosylation at T95 (P = 0.1413); Gain of catalytic residue at Q92 (P = 0.1626); Loss of ubiquitination at K87 (P = 0.3786)
17:44051805:A:T,P10636,Q92L,0.203,Gain of methylation at K87 (P = 0.1095); Loss of phosphorylation at T95 (P = 0.1323); Gain of glycosylation at K87 (P = 0.2145); Gain of catalytic residue at Q88 (P = 0.3603); Loss of ubiquitination at K87 (P = 0.3724)
17:44051806:G:C,P10636,Q92H,0.102,Gain of methylation at K87 (P = 0.1139); Gain of glycosylation at T95 (P = 0.1852); Loss of phosphorylation at T95 (P = 0.257); Loss of ubiquitination at K87 (P = 0.3786); Gain of catalytic residue at Q88 (P = 0.3931)
17:44051806:G:T,P10636,Q92H,0.102,Gain of methylation at K87 (P = 0.1139); Gain of glycosylation at T95 (P = 0.1852); Loss of phosphorylation at T95 (P = 0.257); Loss of ubiquitination at K87 (P = 0.3786); Gain of catalytic residue at Q88 (P = 0.3931)
17:44051807:C:A,P10636,P93T,0.099,Gain of phosphorylation at P93 (P = 0.027); Gain of glycosylation at P93 (P = 0.0732); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.28); Loss of stability (P = 0.5393)
17:44051807:C:G,P10636,P93A,0.086,Loss of phosphorylation at T95 (P = 0.135); Loss of glycosylation at T95 (P = 0.1581); Loss of stability (P = 0.3633); Loss of catalytic residue at I97 (P = 0.6207); Gain of sheet (P = 0.6509)
17:44051807:C:T,P10636,P93S,0.08,Gain of glycosylation at P93 (P = 0.0332); Gain of phosphorylation at P93 (P = 0.0396); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1903); Loss of stability (P = 0.4685)
17:44051808:C:A,P10636,P93H,0.082,Loss of phosphorylation at T95 (P = 0.1094); Gain of glycosylation at T95 (P = 0.3327); Gain of catalytic residue at T95 (P = 0.4263); Loss of stability (P = 0.5052); Gain of solvent accessibility (P = 0.5093)
17:44051808:C:G,P10636,P93R,0.136,Gain of solvent accessibility (P = 0.0971); Gain of phosphorylation at T95 (P = 0.1271); Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at T95 (P = 0.1984); Loss of catalytic residue at E96 (P = 0.4761)
17:44051808:C:T,P10636,P93L,0.124,Loss of phosphorylation at T95 (P = 0.0932); Loss of glycosylation at T95 (P = 0.1079); Gain of catalytic residue at P93 (P = 0.3085); Gain of solvent accessibility (P = 0.571); Gain of sheet (P = 0.6509)
17:44051810:C:A,P10636,H94N,0.066,Loss of catalytic residue at E96 (P = 0.1189); Gain of glycosylation at T95 (P = 0.1593); Gain of phosphorylation at T95 (P = 0.2292); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.4304)
17:44051810:C:G,P10636,H94D,0.139,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0411); Gain of phosphorylation at T95 (P = 0.1168); Loss of catalytic residue at E96 (P = 0.1347); Gain of glycosylation at T95 (P = 0.1699)
17:44051810:C:T,P10636,H94Y,0.164,Gain of phosphorylation at H94 (P = 0.0069); Gain of catalytic residue at P98 (P = 0.0721); Gain of solvent accessibility (P = 0.2384); Gain of relative solvent accessibility (P = 0.2629); Gain of stability (P = 0.3068)
17:44051811:A:C,P10636,H94P,0.18,Gain of relative solvent accessibility (P = 0.0098); Gain of catalytic residue at P93 (P = 0.0112); Gain of solvent accessibility (P = 0.0354); Gain of glycosylation at H94 (P = 0.0506); Loss of loop (P = 0.0603)
17:44051811:A:G,P10636,H94R,0.111,Gain of phosphorylation at T95 (P = 0.1086); Loss of catalytic residue at E96 (P = 0.1544); Gain of solvent accessibility (P = 0.1903); Gain of relative solvent accessibility (P = 0.2629); Loss of glycosylation at T95 (P = 0.2732)
17:44051811:A:T,P10636,H94L,0.17,Gain of stability (P = 0.0061); Loss of catalytic residue at E96 (P = 0.1699); Loss of glycosylation at T95 (P = 0.1738); Loss of phosphorylation at T95 (P = 0.2555); Loss of sheet (P = 0.6423)
17:44051812:C:A,P10636,H94Q,0.124,Loss of loop (P = 0.0288); Gain of helix (P = 0.0349); Gain of relative solvent accessibility (P = 0.0507); Gain of solvent accessibility (P = 0.0584); Loss of catalytic residue at E96 (P = 0.1476)
17:44051812:C:G,P10636,H94Q,0.124,Loss of loop (P = 0.0288); Gain of helix (P = 0.0349); Gain of relative solvent accessibility (P = 0.0507); Gain of solvent accessibility (P = 0.0584); Loss of catalytic residue at E96 (P = 0.1476)
17:44051813:A:C,P10636,T95P,0.105,Loss of glycosylation at T95 (P = 0.0309); Loss of phosphorylation at T95 (P = 0.0541); Loss of stability (P = 0.479); Gain of catalytic residue at I97 (P = 0.6339); Loss of sheet (P = 0.6423)
17:44051813:A:G,P10636,T95A,0.117,Loss of glycosylation at T95 (P = 0.0135); Loss of phosphorylation at T95 (P = 0.0541); Loss of catalytic residue at T95 (P = 0.6257); Loss of sheet (P = 0.6423); Loss of stability (P = 0.7966)
17:44051813:A:T,P10636,T95S,0.135,Gain of phosphorylation at T95 (P = 0.0851); Gain of glycosylation at T95 (P = 0.0936); Loss of catalytic residue at T95 (P = 0.5356); Gain of sheet (P = 0.6509); Loss of stability (P = 0.6562)
17:44051814:C:A,P10636,T95K,0.217,Gain of ubiquitination at T95 (P = 0.0025); Gain of methylation at T95 (P = 0.0057); Gain of solvent accessibility (P = 0.0086); Gain of relative solvent accessibility (P = 0.0249); Loss of phosphorylation at T95 (P = 0.0541)
17:44051814:C:G,P10636,T95R,0.131,Loss of glycosylation at T95 (P = 0.0135); Loss of phosphorylation at T95 (P = 0.0541); Loss of catalytic residue at E96 (P = 0.2745); Gain of solvent accessibility (P = 0.3194); Loss of sheet (P = 0.6423)
17:44051816:G:A,P10636,E96K,0.208,Gain of ubiquitination at E96 (P = 0.0031); Gain of methylation at E96 (P = 0.0053); Gain of glycosylation at E96 (P = 0.0279); Loss of catalytic residue at E96 (P = 0.1258); Gain of phosphorylation at T95 (P = 0.2398)
17:44051816:G:C,P10636,E96Q,0.126,Loss of phosphorylation at T95 (P = 0.1632); Loss of catalytic residue at E96 (P = 0.1737); Gain of glycosylation at T95 (P = 0.2713); Loss of solvent accessibility (P = 0.4436); Loss of relative solvent accessibility (P = 0.5898)
17:44051817:A:C,P10636,E96A,0.18,Loss of solvent accessibility (P = 0.0224); Loss of catalytic residue at E96 (P = 0.1353); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at T95 (P = 0.2313); Loss of glycosylation at T95 (P = 0.3064)
17:44051817:A:G,P10636,E96G,0.154,Loss of solvent accessibility (P = 0.0299); Loss of glycosylation at T95 (P = 0.2043); Loss of phosphorylation at T95 (P = 0.242); Gain of catalytic residue at T95 (P = 0.2503); Loss of relative solvent accessibility (P = 0.3219)
17:44051817:A:T,P10636,E96V,0.224,Loss of solvent accessibility (P = 0.0431); Loss of phosphorylation at T95 (P = 0.1457); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T95 (P = 0.2687); Loss of catalytic residue at E96 (P = 0.2991)
17:44051818:G:C,P10636,E96D,0.104,Gain of phosphorylation at T95 (P = 0.2248); Loss of solvent accessibility (P = 0.2517); Loss of glycosylation at T95 (P = 0.2976); Loss of catalytic residue at E96 (P = 0.3383); Loss of relative solvent accessibility (P = 0.5898)
17:44051818:G:T,P10636,E96D,0.104,Gain of phosphorylation at T95 (P = 0.2248); Loss of solvent accessibility (P = 0.2517); Loss of glycosylation at T95 (P = 0.2976); Loss of catalytic residue at E96 (P = 0.3383); Loss of relative solvent accessibility (P = 0.5898)
17:44051819:A:C,P10636,I97L,0.122,Loss of catalytic residue at T102 (P = 0.208); Gain of glycosylation at T102 (P = 0.2085); Gain of phosphorylation at T102 (P = 0.2109); Gain of sheet (P = 0.6509); Loss of stability (P = 0.8327)
17:44051819:A:G,P10636,I97V,0.126,Gain of glycosylation at T95 (P = 0.1463); Gain of phosphorylation at T95 (P = 0.1716); Loss of catalytic residue at T102 (P = 0.2358); Loss of stability (P = 0.5304); Gain of disorder (P = 0.8652)
17:44051819:A:T,P10636,I97F,0.125,Gain of phosphorylation at T95 (P = 0.1625); Loss of catalytic residue at T102 (P = 0.1996); Gain of glycosylation at T95 (P = 0.213); Loss of stability (P = 0.2727); Gain of solvent accessibility (P = 0.571)
17:44051820:T:A,P10636,I97N,0.179,Gain of glycosylation at T102 (P = 0.0793); Loss of catalytic residue at E99 (P = 0.0905); Loss of stability (P = 0.11); Gain of phosphorylation at T95 (P = 0.1441); Gain of relative solvent accessibility (P = 0.1571)
17:44051820:T:C,P10636,I97T,0.213,Gain of phosphorylation at I97 (P = 0.0052); Gain of glycosylation at I97 (P = 0.0071); Gain of sheet (P = 0.0166); Loss of loop (P = 0.0288); Loss of stability (P = 0.0429)
17:44051820:T:G,P10636,I97S,0.205,Gain of glycosylation at I97 (P = 0.0095); Gain of phosphorylation at I97 (P = 0.0191); Loss of stability (P = 0.0741); Loss of catalytic residue at I97 (P = 0.0873); Gain of sheet (P = 0.6509)
17:44051821:C:G,P10636,I97M,0.131,Gain of phosphorylation at T102 (P = 0.0802); Gain of glycosylation at T102 (P = 0.1595); Loss of catalytic residue at E99 (P = 0.1895); Loss of stability (P = 0.4245); Gain of solvent accessibility (P = 0.5843)
17:44051822:C:A,P10636,P98T,0.195,Gain of glycosylation at P98 (P = 0.0104); Gain of phosphorylation at P98 (P = 0.0434); Gain of sheet (P = 0.0507); Loss of loop (P = 0.0603); Gain of catalytic residue at E96 (P = 0.42)
17:44051822:C:G,P10636,P98A,0.201,Gain of sheet (P = 0.0507); Loss of glycosylation at T95 (P = 0.0575); Loss of loop (P = 0.0603); Gain of helix (P = 0.0893); Loss of phosphorylation at T95 (P = 0.1899)
17:44051822:C:T,P10636,P98S,0.211,Gain of glycosylation at P98 (P = 0.0084); Gain of phosphorylation at P98 (P = 0.0558); Loss of stability (P = 0.563); Gain of catalytic residue at E96 (P = 0.6181); Loss of sheet (P = 0.6423)
17:44051823:C:A,P10636,P98Q,0.19,Loss of glycosylation at T95 (P = 0.0412); Loss of phosphorylation at T101 (P = 0.1339); Gain of solvent accessibility (P = 0.3418); Loss of sheet (P = 0.6423); Loss of stability (P = 0.6782)
17:44051823:C:G,P10636,P98R,0.235,Loss of glycosylation at T95 (P = 0.0241); Gain of phosphorylation at T95 (P = 0.1745); Gain of solvent accessibility (P = 0.2097); Loss of catalytic residue at E99 (P = 0.3626); Gain of methylation at P98 (P = 0.6065)
17:44051823:C:T,P10636,P98L,0.243,Loss of glycosylation at T95 (P = 0.0323); Loss of phosphorylation at T101 (P = 0.0681); Loss of catalytic residue at I97 (P = 0.5298); Loss of relative solvent accessibility (P = 0.5582); Loss of solvent accessibility (P = 0.5743)
17:44051825:G:A,P10636,E99K,0.21,Gain of ubiquitination at E99 (P = 0.0018); Gain of glycosylation at E99 (P = 0.0044); Gain of methylation at E99 (P = 0.0121); Loss of catalytic residue at E99 (P = 0.0655); Gain of phosphorylation at T102 (P = 0.1866)
17:44051825:G:C,P10636,E99Q,0.104,Loss of glycosylation at T95 (P = 0.1466); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.1846); Loss of phosphorylation at T101 (P = 0.187); Loss of stability (P = 0.6564)
17:44051826:A:C,P10636,E99A,0.131,Loss of solvent accessibility (P = 0.0224); Loss of catalytic residue at E99 (P = 0.0999); Gain of glycosylation at T102 (P = 0.1399); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at T101 (P = 0.1894)
17:44051826:A:G,P10636,E99G,0.096,Loss of solvent accessibility (P = 0.1434); Loss of stability (P = 0.1469); Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at T102 (P = 0.1763); Loss of phosphorylation at T101 (P = 0.2035)
17:44051826:A:T,P10636,E99V,0.195,Loss of solvent accessibility (P = 0.0146); Loss of relative solvent accessibility (P = 0.0676); Loss of phosphorylation at T101 (P = 0.1295); Gain of glycosylation at T102 (P = 0.1308); Gain of catalytic residue at E96 (P = 0.3152)
17:44051827:A:C,P10636,E99D,0.091,Loss of catalytic residue at E99 (P = 0.0419); Loss of solvent accessibility (P = 0.1177); Gain of phosphorylation at T102 (P = 0.1761); Loss of glycosylation at T101 (P = 0.2513); Loss of relative solvent accessibility (P = 0.3219)
17:44051827:A:T,P10636,E99D,0.091,Loss of catalytic residue at E99 (P = 0.0419); Loss of solvent accessibility (P = 0.1177); Gain of phosphorylation at T102 (P = 0.1761); Loss of glycosylation at T101 (P = 0.2513); Loss of relative solvent accessibility (P = 0.3219)
17:44051828:G:A,P10636,G100R,0.14,Gain of phosphorylation at T102 (P = 0.0992); Loss of glycosylation at T101 (P = 0.1185); Loss of relative solvent accessibility (P = 0.1807); Loss of catalytic residue at E99 (P = 0.2121); Gain of solvent accessibility (P = 0.3956)
17:44051828:G:C,P10636,G100R,0.14,Gain of phosphorylation at T102 (P = 0.0992); Loss of glycosylation at T101 (P = 0.1185); Loss of relative solvent accessibility (P = 0.1807); Loss of catalytic residue at E99 (P = 0.2121); Gain of solvent accessibility (P = 0.3956)
17:44051829:G:A,P10636,G100E,0.153,Loss of loop (P = 0.0128); Gain of helix (P = 0.0349); Gain of solvent accessibility (P = 0.0456); Gain of phosphorylation at T95 (P = 0.1705); Loss of glycosylation at T101 (P = 0.1743)
17:44051829:G:C,P10636,G100A,0.122,Loss of loop (P = 0.0128); Gain of helix (P = 0.0164); Loss of relative solvent accessibility (P = 0.0676); Gain of phosphorylation at T95 (P = 0.1232); Loss of glycosylation at T102 (P = 0.2334)
17:44051829:G:T,P10636,G100V,0.131,Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at T95 (P = 0.1703); Loss of phosphorylation at T101 (P = 0.187); Loss of catalytic residue at I97 (P = 0.3019); Loss of solvent accessibility (P = 0.4141)
17:44051831:A:C,P10636,T101P,0.114,Loss of glycosylation at T101 (P = 0.0253); Loss of phosphorylation at T101 (P = 0.0312); Loss of catalytic residue at T101 (P = 0.1955); Loss of stability (P = 0.608); Loss of sheet (P = 0.6423)
17:44051831:A:G,P10636,T101A,0.119,Loss of glycosylation at T101 (P = 0.0092); Loss of phosphorylation at T101 (P = 0.0312); Loss of catalytic residue at E99 (P = 0.2249); Loss of solvent accessibility (P = 0.5743); Loss of sheet (P = 0.6423)
17:44051831:A:T,P10636,T101S,0.126,Loss of glycosylation at T102 (P = 0.1295); Gain of phosphorylation at T101 (P = 0.1423); Loss of catalytic residue at T101 (P = 0.2013); Loss of sheet (P = 0.6423); Gain of disorder (P = 0.843)
17:44051832:C:A,P10636,T101N,0.123,Loss of glycosylation at T101 (P = 0.0092); Loss of phosphorylation at T101 (P = 0.0312); Loss of catalytic residue at T102 (P = 0.3045); Gain of solvent accessibility (P = 0.5334); Loss of sheet (P = 0.6423)
17:44051832:C:G,P10636,T101S,0.126,Loss of glycosylation at T102 (P = 0.1295); Gain of phosphorylation at T101 (P = 0.1423); Loss of catalytic residue at T101 (P = 0.2013); Loss of sheet (P = 0.6423); Gain of disorder (P = 0.843)
17:44051832:C:T,P10636,T101I,0.151,Loss of glycosylation at T101 (P = 0.0092); Loss of phosphorylation at T101 (P = 0.0312); Loss of catalytic residue at T101 (P = 0.1951); Loss of solvent accessibility (P = 0.5485); Loss of relative solvent accessibility (P = 0.5582)
17:44051834:A:C,P10636,T102P,0.131,Loss of glycosylation at T102 (P = 0.0442); Loss of catalytic residue at T102 (P = 0.048); Loss of phosphorylation at T102 (P = 0.0651); Gain of sheet (P = 0.6509); Loss of stability (P = 0.666)
17:44051834:A:G,P10636,T102A,0.155,Loss of glycosylation at T102 (P = 0.022); Loss of phosphorylation at T102 (P = 0.0651); Loss of catalytic residue at T102 (P = 0.1236); Loss of sheet (P = 0.6423); Loss of solvent accessibility (P = 0.7428)
17:44051834:A:T,P10636,T102S,0.145,Loss of catalytic residue at T102 (P = 0.0285); Gain of phosphorylation at T102 (P = 0.0728); Loss of glycosylation at T101 (P = 0.1452); Loss of sheet (P = 0.6423); Gain of disorder (P = 0.8345)
17:44051835:C:A,P10636,T102K,0.213,Gain of ubiquitination at T102 (P = 0.0029); Gain of solvent accessibility (P = 0.0156); Gain of methylation at T102 (P = 0.0229); Gain of relative solvent accessibility (P = 0.0479); Loss of glycosylation at T101 (P = 0.0587)
17:44051835:C:G,P10636,T102R,0.192,Loss of glycosylation at T102 (P = 0.022); Loss of phosphorylation at T102 (P = 0.0651); Gain of solvent accessibility (P = 0.0808); Loss of catalytic residue at T102 (P = 0.1481); Gain of relative solvent accessibility (P = 0.2363)
17:44051835:C:T,P10636,T102I,0.149,Loss of glycosylation at T102 (P = 0.022); Loss of phosphorylation at T102 (P = 0.0651); Loss of catalytic residue at T102 (P = 0.2468); Gain of sheet (P = 0.6509); Gain of stability (P = 0.7015)
17:44051837:G:A,P10636,A103T,0.136,Gain of glycosylation at A103 (P = 0.0091); Gain of phosphorylation at A103 (P = 0.0207); Gain of solvent accessibility (P = 0.4946); Gain of catalytic residue at E104 (P = 0.5369); Loss of sheet (P = 0.7751)
17:44051837:G:C,P10636,A103P,0.161,Gain of catalytic residue at A103 (P = 0.0571); Gain of phosphorylation at T102 (P = 0.0789); Gain of glycosylation at T102 (P = 0.1557); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.3418)
17:44051837:G:T,P10636,A103S,0.118,Gain of glycosylation at A103 (P = 0.0105); Gain of phosphorylation at A103 (P = 0.0261); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.348); Loss of sheet (P = 0.6423)
17:44055741:C:A,P10636,A103D,0.113,Gain of phosphorylation at T102 (P = 0.1721); Loss of glycosylation at T102 (P = 0.2044); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2689); Loss of catalytic residue at E104 (P = 0.4672)
17:44055741:C:G,P10636,A103G,0.096,Loss of glycosylation at T102 (P = 0.1112); Gain of phosphorylation at T102 (P = 0.2444); Gain of relative solvent accessibility (P = 0.2629); Gain of catalytic residue at E104 (P = 0.5308); Gain of solvent accessibility (P = 0.5485)
17:44055741:C:T,P10636,A103V,0.171,Gain of glycosylation at T102 (P = 0.1548); Loss of phosphorylation at T101 (P = 0.1995); Gain of stability (P = 0.2439); Gain of catalytic residue at A103 (P = 0.3469); Gain of sheet (P = 0.6509)
17:44055743:G:A,P10636,E104K,0.261,Gain of ubiquitination at E104 (P = 0.0025); Gain of glycosylation at E104 (P = 0.0113); Gain of methylation at E104 (P = 0.0118); Gain of solvent accessibility (P = 0.0314); Gain of relative solvent accessibility (P = 0.0479)
17:44055743:G:C,P10636,E104Q,0.139,Loss of glycosylation at T102 (P = 0.115); Loss of phosphorylation at T101 (P = 0.1559); Loss of catalytic residue at E104 (P = 0.3733); Gain of solvent accessibility (P = 0.5946); Gain of sheet (P = 0.6509)
17:44055744:A:G,P10636,E104G,0.162,Gain of catalytic residue at A103 (P = 0.0966); Gain of glycosylation at T102 (P = 0.1365); Loss of stability (P = 0.155); Loss of phosphorylation at T101 (P = 0.1632); Loss of solvent accessibility (P = 0.4011)
17:44055744:A:T,P10636,E104V,0.184,Loss of phosphorylation at T101 (P = 0.1114); Gain of glycosylation at T102 (P = 0.1734); Loss of solvent accessibility (P = 0.3136); Loss of catalytic residue at E104 (P = 0.3797); Loss of relative solvent accessibility (P = 0.5582)
17:44055745:A:C,P10636,E104D,0.124,Gain of phosphorylation at T102 (P = 0.1505); Gain of glycosylation at T102 (P = 0.2489); Loss of catalytic residue at E104 (P = 0.2597); Loss of stability (P = 0.5797); Gain of sheet (P = 0.6509)
17:44055745:A:T,P10636,E104D,0.124,Gain of phosphorylation at T102 (P = 0.1505); Gain of glycosylation at T102 (P = 0.2489); Loss of catalytic residue at E104 (P = 0.2597); Loss of stability (P = 0.5797); Gain of sheet (P = 0.6509)
17:44055746:G:A,P10636,E105K,0.245,Gain of ubiquitination at E105 (P = 0.001); Gain of methylation at E105 (P = 0.0075); Gain of glycosylation at E105 (P = 0.0218); Gain of solvent accessibility (P = 0.0314); Gain of relative solvent accessibility (P = 0.0479)
17:44055746:G:C,P10636,E105Q,0.114,Gain of glycosylation at T102 (P = 0.1482); Loss of phosphorylation at T101 (P = 0.1715); Gain of catalytic residue at E104 (P = 0.3584); Gain of solvent accessibility (P = 0.5946); Gain of sheet (P = 0.6509)
17:44055747:A:C,P10636,E105A,0.142,Gain of glycosylation at T102 (P = 0.0785); Loss of phosphorylation at T102 (P = 0.2157); Loss of catalytic residue at E105 (P = 0.3472); Loss of solvent accessibility (P = 0.4838); Loss of stability (P = 0.6402)
17:44055747:A:G,P10636,E105G,0.127,Gain of glycosylation at T102 (P = 0.1395); Loss of stability (P = 0.1828); Loss of phosphorylation at T102 (P = 0.2391); Gain of catalytic residue at A106 (P = 0.3379); Loss of solvent accessibility (P = 0.4011)
17:44055747:A:T,P10636,E105V,0.17,Gain of glycosylation at T102 (P = 0.113); Loss of phosphorylation at T101 (P = 0.1387); Gain of catalytic residue at E104 (P = 0.2554); Loss of solvent accessibility (P = 0.4274); Gain of sheet (P = 0.6509)
17:44055748:A:C,P10636,E105D,0.112,Gain of phosphorylation at T102 (P = 0.1455); Gain of glycosylation at T102 (P = 0.2524); Gain of catalytic residue at G107 (P = 0.4476); Gain of sheet (P = 0.6509); Loss of stability (P = 0.7127)
17:44055748:A:T,P10636,E105D,0.112,Gain of phosphorylation at T102 (P = 0.1455); Gain of glycosylation at T102 (P = 0.2524); Gain of catalytic residue at G107 (P = 0.4476); Gain of sheet (P = 0.6509); Loss of stability (P = 0.7127)
17:44055749:G:A,P10636,A106T,0.123,Gain of phosphorylation at A106 (P = 0.0124); Gain of glycosylation at T102 (P = 0.1383); Loss of stability (P = 0.2416); Gain of catalytic residue at E104 (P = 0.4224); Loss of sheet (P = 0.6423)
17:44055749:G:C,P10636,A106P,0.131,Loss of stability (P = 0.145); Gain of glycosylation at T102 (P = 0.1588); Loss of catalytic residue at A106 (P = 0.1872); Gain of phosphorylation at T102 (P = 0.1877); Gain of solvent accessibility (P = 0.5093)
17:44055749:G:T,P10636,A106S,0.154,Gain of glycosylation at A106 (P = 1e-04); Gain of phosphorylation at A106 (P = 0.025); Loss of catalytic residue at A106 (P = 0.1561); Loss of stability (P = 0.4685); Gain of solvent accessibility (P = 0.5334)
17:44055750:C:A,P10636,A106E,0.12,Gain of glycosylation at T102 (P = 0.1426); Gain of phosphorylation at T102 (P = 0.1783); Gain of solvent accessibility (P = 0.194); Gain of relative solvent accessibility (P = 0.2629); Loss of catalytic residue at E104 (P = 0.2941)
17:44055750:C:G,P10636,A106G,0.118,Loss of stability (P = 0.078); Loss of phosphorylation at T101 (P = 0.2018); Loss of glycosylation at T102 (P = 0.2345); Gain of catalytic residue at G107 (P = 0.3499); Loss of sheet (P = 0.6423)
17:44055750:C:T,P10636,A106V,0.107,Loss of phosphorylation at T101 (P = 0.1229); Loss of glycosylation at T102 (P = 0.2639); Gain of catalytic residue at E105 (P = 0.3868); Gain of solvent accessibility (P = 0.4946); Loss of stability (P = 0.6478)
17:44055752:G:A,P10636,G107S,0.142,Gain of glycosylation at G107 (P = 0.0026); Gain of phosphorylation at G107 (P = 0.015); Loss of stability (P = 0.1459); Loss of catalytic residue at A106 (P = 0.1516); Gain of solvent accessibility (P = 0.3956)
17:44055752:G:C,P10636,G107R,0.174,Gain of solvent accessibility (P = 0.1319); Loss of catalytic residue at A106 (P = 0.1374); Loss of glycosylation at T102 (P = 0.2286); Gain of phosphorylation at T102 (P = 0.2759); Loss of stability (P = 0.3739)
17:44055752:G:T,P10636,G107C,0.2,Loss of catalytic residue at A106 (P = 0.167); Loss of glycosylation at T102 (P = 0.2151); Loss of phosphorylation at T102 (P = 0.2157); Loss of stability (P = 0.4782); Gain of solvent accessibility (P = 0.5843)
17:44055753:G:C,P10636,G107A,0.121,Gain of phosphorylation at T102 (P = 0.1463); Loss of catalytic residue at A106 (P = 0.1524); Loss of stability (P = 0.2069); Gain of glycosylation at T102 (P = 0.2351); Gain of solvent accessibility (P = 0.5093)
17:44055753:G:T,P10636,G107V,0.202,Loss of catalytic residue at A106 (P = 0.1576); Loss of phosphorylation at T102 (P = 0.2096); Loss of glycosylation at T102 (P = 0.2467); Loss of stability (P = 0.5525); Loss of relative solvent accessibility (P = 0.5582)
17:44055755:A:C,P10636,I108L,0.122,Gain of glycosylation at S113 (P = 0.1349); Loss of phosphorylation at T111 (P = 0.2507); Loss of catalytic residue at E105 (P = 0.4942); Loss of sheet (P = 0.6423); Loss of solvent accessibility (P = 0.6935)
17:44055755:A:G,P10636,I108V,0.105,Gain of glycosylation at S113 (P = 0.1364); Gain of phosphorylation at S113 (P = 0.3103); Loss of stability (P = 0.4519); Loss of catalytic residue at E105 (P = 0.5864); Loss of sheet (P = 0.6423)
17:44055755:A:T,P10636,I108F,0.121,Gain of glycosylation at S113 (P = 0.1541); Loss of stability (P = 0.2788); Loss of catalytic residue at I108 (P = 0.2916); Gain of phosphorylation at S113 (P = 0.3077); Loss of sheet (P = 0.6423)
17:44055756:T:A,P10636,I108N,0.147,Loss of stability (P = 0.0799); Gain of glycosylation at S113 (P = 0.1899); Gain of relative solvent accessibility (P = 0.2629); Loss of catalytic residue at E104 (P = 0.2907); Loss of phosphorylation at S113 (P = 0.3063)
17:44055756:T:G,P10636,I108S,0.226,Gain of glycosylation at I108 (P = 2e-04); Gain of phosphorylation at I108 (P = 0.0103); Loss of catalytic residue at I108 (P = 0.026); Loss of stability (P = 0.1179); Gain of relative solvent accessibility (P = 0.2629)
17:44055757:T:G,P10636,I108M,0.132,Gain of glycosylation at S113 (P = 0.1755); Loss of catalytic residue at I108 (P = 0.2573); Gain of phosphorylation at S113 (P = 0.2828); Loss of stability (P = 0.3449); Gain of solvent accessibility (P = 0.5485)
17:44055758:G:A,P10636,G109R,0.182,Gain of solvent accessibility (P = 0.0971); Gain of catalytic residue at G109 (P = 0.1066); Loss of glycosylation at S113 (P = 0.1076); Gain of relative solvent accessibility (P = 0.2629); Loss of phosphorylation at S113 (P = 0.2971)
17:44055758:G:C,P10636,G109R,0.182,Gain of solvent accessibility (P = 0.0971); Gain of catalytic residue at G109 (P = 0.1066); Loss of glycosylation at S113 (P = 0.1076); Gain of relative solvent accessibility (P = 0.2629); Loss of phosphorylation at S113 (P = 0.2971)
17:44055759:G:A,P10636,G109E,0.171,Gain of solvent accessibility (P = 0.0074); Gain of relative solvent accessibility (P = 0.0249); Gain of phosphorylation at S113 (P = 0.2508); Loss of glycosylation at S113 (P = 0.2593); Loss of catalytic residue at I108 (P = 0.3179)
17:44055759:G:C,P10636,G109A,0.13,Gain of glycosylation at S113 (P = 0.1204); Loss of catalytic residue at I108 (P = 0.2609); Gain of phosphorylation at S113 (P = 0.3274); Gain of solvent accessibility (P = 0.5334); Gain of sheet (P = 0.6509)
17:44055759:G:T,P10636,G109V,0.183,Gain of catalytic residue at G109 (P = 0.1253); Gain of glycosylation at S113 (P = 0.1732); Loss of phosphorylation at T111 (P = 0.2397); Gain of solvent accessibility (P = 0.5946); Gain of sheet (P = 0.6509)
17:44055761:G:A,P10636,D110N,0.125,Gain of catalytic residue at D110 (P = 0.0516); Loss of phosphorylation at S113 (P = 0.1048); Loss of glycosylation at S113 (P = 0.1921); Loss of stability (P = 0.5193); Loss of sheet (P = 0.6423)
17:44055761:G:C,P10636,D110H,0.113,Gain of catalytic residue at D110 (P = 0.1222); Loss of phosphorylation at T111 (P = 0.1438); Gain of glycosylation at S113 (P = 0.2185); Gain of solvent accessibility (P = 0.4946); Loss of stability (P = 0.5682)
17:44055761:G:T,P10636,D110Y,0.177,Gain of phosphorylation at D110 (P = 0.0341); Gain of catalytic residue at D110 (P = 0.0568); Gain of glycosylation at S113 (P = 0.1845); Loss of solvent accessibility (P = 0.5485); Loss of relative solvent accessibility (P = 0.5582)
17:44055762:A:C,P10636,D110A,0.091,Gain of glycosylation at S113 (P = 0.1634); Loss of phosphorylation at T111 (P = 0.1992); Loss of catalytic residue at A106 (P = 0.3418); Loss of stability (P = 0.5497); Loss of solvent accessibility (P = 0.6392)
17:44055762:A:G,P10636,D110G,0.119,Gain of helix (P = 0.005); Loss of loop (P = 0.0073); Gain of glycosylation at S113 (P = 0.1961); Loss of phosphorylation at T111 (P = 0.2098); Loss of stability (P = 0.2568)
17:44055762:A:T,P10636,D110V,0.144,Gain of catalytic residue at D110 (P = 0.0862); Loss of phosphorylation at T111 (P = 0.1094); Gain of glycosylation at S113 (P = 0.193); Loss of solvent accessibility (P = 0.4218); Loss of relative solvent accessibility (P = 0.5582)
17:44055763:C:A,P10636,D110E,0.122,Gain of helix (P = 0.005); Loss of loop (P = 0.0073); Gain of glycosylation at S113 (P = 0.226); Gain of catalytic residue at D110 (P = 0.2659); Gain of phosphorylation at S113 (P = 0.2839)
17:44055763:C:G,P10636,D110E,0.122,Gain of helix (P = 0.005); Loss of loop (P = 0.0073); Gain of glycosylation at S113 (P = 0.226); Gain of catalytic residue at D110 (P = 0.2659); Gain of phosphorylation at S113 (P = 0.2839)
17:44055764:A:C,P10636,T111P,0.19,Loss of glycosylation at T111 (P = 0.0163); Loss of phosphorylation at T111 (P = 0.0217); Gain of catalytic residue at T111 (P = 0.0343); Loss of stability (P = 0.6316); Loss of sheet (P = 0.6423)
17:44055764:A:G,P10636,T111A,0.148,Loss of glycosylation at T111 (P = 0.0061); Loss of phosphorylation at T111 (P = 0.0217); Loss of sheet (P = 0.6423); Loss of catalytic residue at A106 (P = 0.6462); Loss of solvent accessibility (P = 0.7428)
17:44055764:A:T,P10636,T111S,0.179,Gain of glycosylation at S113 (P = 0.2239); Gain of phosphorylation at S113 (P = 0.2334); Gain of relative solvent accessibility (P = 0.2363); Gain of catalytic residue at G109 (P = 0.3072); Gain of solvent accessibility (P = 0.4137)
17:44055765:C:A,P10636,T111N,0.172,Loss of glycosylation at T111 (P = 0.0061); Loss of phosphorylation at T111 (P = 0.0217); Gain of solvent accessibility (P = 0.5334); Gain of catalytic residue at P112 (P = 0.6116); Loss of sheet (P = 0.6423)
17:44055765:C:G,P10636,T111S,0.179,Gain of glycosylation at S113 (P = 0.2239); Gain of phosphorylation at S113 (P = 0.2334); Gain of relative solvent accessibility (P = 0.2363); Gain of catalytic residue at G109 (P = 0.3072); Gain of solvent accessibility (P = 0.4137)
17:44055765:C:T,P10636,T111I,0.206,Loss of glycosylation at T111 (P = 0.0061); Loss of phosphorylation at T111 (P = 0.0217); Gain of catalytic residue at T111 (P = 0.3332); Loss of solvent accessibility (P = 0.5485); Loss of relative solvent accessibility (P = 0.5582)
17:44055767:C:A,P10636,P112T,0.189,Gain of glycosylation at P112 (P = 0.0322); Gain of phosphorylation at P112 (P = 0.0475); Loss of stability (P = 0.2524); Gain of catalytic residue at T111 (P = 0.4269); Gain of solvent accessibility (P = 0.5946)
17:44055767:C:G,P10636,P112A,0.206,Loss of phosphorylation at T111 (P = 0.0924); Gain of catalytic residue at D110 (P = 0.2381); Loss of glycosylation at S113 (P = 0.258); Loss of stability (P = 0.269); Gain of sheet (P = 0.6509)
17:44055767:C:T,P10636,P112S,0.173,Gain of phosphorylation at P112 (P = 0.0343); Gain of glycosylation at P112 (P = 0.0364); Gain of relative solvent accessibility (P = 0.2629); Loss of stability (P = 0.3723); Gain of solvent accessibility (P = 0.4137)
17:44055768:C:A,P10636,P112H,0.24,Loss of phosphorylation at T111 (P = 0.0734); Gain of catalytic residue at L114 (P = 0.1009); Loss of glycosylation at S113 (P = 0.1527); Loss of stability (P = 0.4342); Gain of sheet (P = 0.6509)
17:44055768:C:G,P10636,P112R,0.245,Gain of catalytic residue at P112 (P = 0.0568); Loss of glycosylation at S113 (P = 0.0764); Gain of solvent accessibility (P = 0.1422); Loss of phosphorylation at T111 (P = 0.1755); Gain of relative solvent accessibility (P = 0.2629)
17:44055768:C:T,P10636,P112L,0.262,Loss of phosphorylation at T111 (P = 0.0536); Loss of glycosylation at T111 (P = 0.0956); Gain of catalytic residue at P112 (P = 0.1069); Gain of solvent accessibility (P = 0.5334); Gain of sheet (P = 0.6509)
17:44055770:A:C,P10636,S113R,0.154,Loss of glycosylation at S113 (P = 0.0259); Loss of phosphorylation at S113 (P = 0.0274); Gain of solvent accessibility (P = 0.0766); Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at D116 (P = 0.4765)
17:44055770:A:G,P10636,S113G,0.173,Loss of glycosylation at S113 (P = 0.0259); Loss of phosphorylation at S113 (P = 0.0274); Gain of catalytic residue at L114 (P = 0.1145); Gain of relative solvent accessibility (P = 0.2363); Loss of stability (P = 0.4542)
17:44055770:A:T,P10636,S113C,0.222,Gain of catalytic residue at P112 (P = 0.0137); Loss of glycosylation at S113 (P = 0.0259); Loss of phosphorylation at S113 (P = 0.0274); Gain of solvent accessibility (P = 0.5946); Loss of sheet (P = 0.6423)
17:44055771:G:A,P10636,S113N,0.164,Loss of glycosylation at S113 (P = 0.0259); Loss of phosphorylation at S113 (P = 0.0274); Gain of catalytic residue at S113 (P = 0.145); Gain of solvent accessibility (P = 0.4821); Loss of sheet (P = 0.6423)
17:44055771:G:C,P10636,S113T,0.15,Gain of glycosylation at S113 (P = 0.0795); Gain of catalytic residue at S113 (P = 0.144); Gain of phosphorylation at S113 (P = 0.3332); Gain of solvent accessibility (P = 0.571); Gain of sheet (P = 0.6509)
17:44055771:G:T,P10636,S113I,0.2,Loss of glycosylation at S113 (P = 0.0259); Loss of phosphorylation at S113 (P = 0.0274); Gain of stability (P = 0.178); Gain of catalytic residue at D116 (P = 0.2123); Loss of sheet (P = 0.6423)
17:44055772:C:A,P10636,S113R,0.154,Loss of glycosylation at S113 (P = 0.0259); Loss of phosphorylation at S113 (P = 0.0274); Gain of solvent accessibility (P = 0.0766); Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at D116 (P = 0.4765)
17:44055772:C:G,P10636,S113R,0.154,Loss of glycosylation at S113 (P = 0.0259); Loss of phosphorylation at S113 (P = 0.0274); Gain of solvent accessibility (P = 0.0766); Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at D116 (P = 0.4765)
17:44055773:C:A,P10636,L114M,0.129,Loss of glycosylation at S113 (P = 0.0472); Loss of solvent accessibility (P = 0.0703); Loss of relative solvent accessibility (P = 0.0981); Gain of phosphorylation at S113 (P = 0.2856); Gain of catalytic residue at D116 (P = 0.4396)
17:44055773:C:G,P10636,L114V,0.118,Loss of solvent accessibility (P = 0.0533); Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at S113 (P = 0.138); Loss of stability (P = 0.2666); Gain of catalytic residue at D116 (P = 0.2984)
17:44055774:T:A,P10636,L114Q,0.12,Loss of glycosylation at S113 (P = 0.0599); Loss of solvent accessibility (P = 0.1651); Loss of stability (P = 0.1728); Loss of relative solvent accessibility (P = 0.1807); Gain of phosphorylation at S113 (P = 0.3146)
17:44055774:T:C,P10636,L114P,0.159,Loss of stability (P = 0.0389); Loss of solvent accessibility (P = 0.0509); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at L114 (P = 0.1135); Gain of phosphorylation at S113 (P = 0.1975)
17:44055774:T:G,P10636,L114R,0.157,Loss of glycosylation at S113 (P = 0.1214); Loss of stability (P = 0.1262); Loss of relative solvent accessibility (P = 0.1807); Gain of phosphorylation at S113 (P = 0.1834); Loss of solvent accessibility (P = 0.2882)
17:44055776:G:A,P10636,E115K,0.222,Gain of ubiquitination at E115 (P = 9e-04); Gain of methylation at E115 (P = 0.0198); Gain of glycosylation at E115 (P = 0.021); Loss of solvent accessibility (P = 0.0807); Loss of relative solvent accessibility (P = 0.1807)
17:44055776:G:C,P10636,E115Q,0.126,Loss of solvent accessibility (P = 0.0721); Loss of phosphorylation at S113 (P = 0.0947); Loss of glycosylation at S113 (P = 0.1118); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at D116 (P = 0.5829)
17:44055777:A:C,P10636,E115A,0.194,Loss of solvent accessibility (P = 0.0111); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at S113 (P = 0.0895); Loss of phosphorylation at S113 (P = 0.1697); Gain of catalytic residue at D116 (P = 0.4122)
17:44055777:A:G,P10636,E115G,0.146,Loss of solvent accessibility (P = 0.0187); Gain of glycosylation at S113 (P = 0.1159); Loss of stability (P = 0.1453); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S113 (P = 0.1899)
17:44055777:A:T,P10636,E115V,0.21,Loss of solvent accessibility (P = 0.0146); Loss of relative solvent accessibility (P = 0.0676); Loss of phosphorylation at S113 (P = 0.1103); Gain of glycosylation at S113 (P = 0.1912); Gain of catalytic residue at D116 (P = 0.2739)
17:44055778:A:C,P10636,E115D,0.131,Loss of solvent accessibility (P = 0.0509); Gain of glycosylation at S113 (P = 0.1562); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S113 (P = 0.2948); Loss of stability (P = 0.6017)
17:44055778:A:T,P10636,E115D,0.131,Loss of solvent accessibility (P = 0.0509); Gain of glycosylation at S113 (P = 0.1562); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S113 (P = 0.2948); Loss of stability (P = 0.6017)
17:44055779:G:A,P10636,D116N,0.126,Loss of solvent accessibility (P = 0.0595); Loss of relative solvent accessibility (P = 0.0981); Loss of phosphorylation at S113 (P = 0.1174); Gain of glycosylation at S113 (P = 0.2152); Loss of catalytic residue at D116 (P = 0.4696)
17:44055779:G:C,P10636,D116H,0.135,Loss of solvent accessibility (P = 0.0703); Loss of relative solvent accessibility (P = 0.0981); Loss of phosphorylation at S113 (P = 0.1476); Gain of glycosylation at S113 (P = 0.2455); Gain of catalytic residue at E115 (P = 0.2521)
17:44055779:G:T,P10636,D116Y,0.206,Gain of phosphorylation at D116 (P = 0.0102); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1115); Gain of glycosylation at S113 (P = 0.1811); Gain of catalytic residue at E115 (P = 0.185)
17:44055780:A:C,P10636,D116A,0.125,Loss of solvent accessibility (P = 0.0435); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at S113 (P = 0.1483); Loss of phosphorylation at S113 (P = 0.2197); Gain of catalytic residue at T111 (P = 0.4598)
17:44055780:A:G,P10636,D116G,0.138,Loss of solvent accessibility (P = 0.0364); Gain of catalytic residue at P112 (P = 0.0838); Gain of glycosylation at S113 (P = 0.0949); Loss of relative solvent accessibility (P = 0.0981); Loss of stability (P = 0.1813)
17:44055780:A:T,P10636,D116V,0.148,Loss of solvent accessibility (P = 0.0544); Loss of relative solvent accessibility (P = 0.0981); Loss of phosphorylation at S113 (P = 0.1368); Gain of glycosylation at S113 (P = 0.1526); Gain of catalytic residue at E115 (P = 0.5451)
17:44055781:C:A,P10636,D116E,0.133,Loss of glycosylation at S113 (P = 0.1671); Gain of phosphorylation at S113 (P = 0.2724); Gain of solvent accessibility (P = 0.3089); Loss of catalytic residue at H121 (P = 0.5061); Gain of sheet (P = 0.6509)
17:44055781:C:G,P10636,D116E,0.133,Loss of glycosylation at S113 (P = 0.1671); Gain of phosphorylation at S113 (P = 0.2724); Gain of solvent accessibility (P = 0.3089); Loss of catalytic residue at H121 (P = 0.5061); Gain of sheet (P = 0.6509)
17:44055782:G:C,P10636,E117Q,0.123,Loss of phosphorylation at S113 (P = 0.1527); Loss of glycosylation at S113 (P = 0.1685); Loss of solvent accessibility (P = 0.1868); Loss of relative solvent accessibility (P = 0.3219); Gain of catalytic residue at A119 (P = 0.466)
17:44055783:A:C,P10636,E117A,0.201,Loss of solvent accessibility (P = 0.0224); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S113 (P = 0.2017); Gain of glycosylation at S113 (P = 0.2272); Gain of catalytic residue at A119 (P = 0.3262)
17:44055783:A:G,P10636,E117G,0.155,Loss of solvent accessibility (P = 0.0187); Loss of stability (P = 0.1334); Loss of glycosylation at S113 (P = 0.148); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at A119 (P = 0.2249)
17:44055783:A:T,P10636,E117V,0.223,Loss of solvent accessibility (P = 0.0146); Loss of relative solvent accessibility (P = 0.0676); Loss of phosphorylation at S113 (P = 0.1357); Loss of glycosylation at S113 (P = 0.1364); Gain of catalytic residue at A119 (P = 0.2692)
17:44055784:A:C,P10636,E117D,0.107,Gain of glycosylation at S113 (P = 0.1792); Loss of phosphorylation at S113 (P = 0.311); Gain of catalytic residue at E117 (P = 0.4478); Loss of stability (P = 0.4768); Loss of solvent accessibility (P = 0.5485)
17:44055784:A:T,P10636,E117D,0.107,Gain of glycosylation at S113 (P = 0.1792); Loss of phosphorylation at S113 (P = 0.311); Gain of catalytic residue at E117 (P = 0.4478); Loss of stability (P = 0.4768); Loss of solvent accessibility (P = 0.5485)
17:44055785:G:A,P10636,A118T,0.089,Gain of phosphorylation at A118 (P = 0.0374); Gain of glycosylation at A118 (P = 0.0441); Loss of stability (P = 0.112); Gain of catalytic residue at A118 (P = 0.4814); Gain of solvent accessibility (P = 0.5334)
17:44055785:G:C,P10636,A118P,0.13,Loss of stability (P = 0.0315); Gain of phosphorylation at T123 (P = 0.1322); Loss of glycosylation at S113 (P = 0.1763); Gain of catalytic residue at L114 (P = 0.4594); Gain of solvent accessibility (P = 0.5485)
17:44055785:G:T,P10636,A118S,0.103,Gain of phosphorylation at A118 (P = 0.023); Gain of glycosylation at A118 (P = 0.0372); Gain of catalytic residue at L114 (P = 0.107); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1604)
17:44055786:C:A,P10636,A118D,0.121,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1045); Loss of glycosylation at S113 (P = 0.133); Loss of stability (P = 0.1817); Gain of phosphorylation at T123 (P = 0.2177)
17:44055786:C:T,P10636,A118V,0.09,Loss of glycosylation at S113 (P = 0.2114); Loss of phosphorylation at T123 (P = 0.2184); Gain of catalytic residue at E117 (P = 0.3836); Gain of solvent accessibility (P = 0.5334); Loss of stability (P = 0.5714)
17:44055788:G:A,P10636,A119T,0.066,Gain of glycosylation at A119 (P = 0.0073); Gain of phosphorylation at A119 (P = 0.0191); Gain of solvent accessibility (P = 0.4304); Gain of catalytic residue at E117 (P = 0.4718); Loss of stability (P = 0.5458)
17:44055788:G:C,P10636,A119P,0.07,Gain of phosphorylation at T123 (P = 0.1474); Loss of stability (P = 0.2489); Gain of glycosylation at T123 (P = 0.2572); Loss of catalytic residue at A119 (P = 0.4311); Gain of solvent accessibility (P = 0.4656)
17:44055788:G:T,P10636,A119S,0.069,Gain of glycosylation at A119 (P = 0.002); Gain of phosphorylation at A119 (P = 0.0323); Loss of catalytic residue at A119 (P = 0.3657); Gain of solvent accessibility (P = 0.4821); Loss of stability (P = 0.5052)
17:44055789:C:A,P10636,A119D,0.046,Gain of phosphorylation at T123 (P = 0.2344); Gain of glycosylation at T123 (P = 0.2716); Gain of solvent accessibility (P = 0.3602); Loss of stability (P = 0.5564); Loss of sheet (P = 0.6423)
17:44055789:C:G,P10636,A119G,0.035,Loss of stability (P = 0.1315); Gain of phosphorylation at T123 (P = 0.2252); Gain of catalytic residue at A118 (P = 0.2503); Loss of glycosylation at T123 (P = 0.2943); Loss of sheet (P = 0.6423)
17:44055789:C:T,P10636,A119V,0.06,Loss of phosphorylation at T123 (P = 0.2228); Loss of glycosylation at T123 (P = 0.2446); Gain of catalytic residue at E117 (P = 0.5509); Loss of relative solvent accessibility (P = 0.5582); Gain of sheet (P = 0.6509)
17:44055791:G:A,P10636,G120S,0.154,Gain of glycosylation at G120 (P = 0.0129); Gain of phosphorylation at G120 (P = 0.0311); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0971); Loss of stability (P = 0.12)
17:44055791:G:C,P10636,G120R,0.213,Gain of solvent accessibility (P = 0.0042); Gain of relative solvent accessibility (P = 0.09); Gain of phosphorylation at T123 (P = 0.1088); Loss of catalytic residue at H121 (P = 0.1412); Gain of glycosylation at T123 (P = 0.2346)
17:44055791:G:T,P10636,G120C,0.198,Gain of catalytic residue at V122 (P = 0.0977); Loss of phosphorylation at T123 (P = 0.1455); Gain of glycosylation at T123 (P = 0.2027); Loss of stability (P = 0.4647); Gain of solvent accessibility (P = 0.5334)
17:44055792:G:A,P10636,G120D,0.171,Gain of solvent accessibility (P = 0.039); Gain of relative solvent accessibility (P = 0.09); Gain of glycosylation at T123 (P = 0.1196); Gain of phosphorylation at T123 (P = 0.1944); Loss of catalytic residue at H121 (P = 0.2016)
17:44055792:G:C,P10636,G120A,0.135,Gain of glycosylation at T123 (P = 0.1353); Gain of phosphorylation at T123 (P = 0.2205); Loss of catalytic residue at H121 (P = 0.2395); Loss of stability (P = 0.2501); Loss of relative solvent accessibility (P = 0.3919)
17:44055792:G:T,P10636,G120V,0.168,Loss of phosphorylation at T123 (P = 0.1367); Gain of glycosylation at T123 (P = 0.1552); Loss of catalytic residue at H121 (P = 0.2764); Gain of solvent accessibility (P = 0.4946); Loss of stability (P = 0.5132)
17:44055794:C:A,P10636,H121N,0.12,Loss of phosphorylation at T123 (P = 0.1829); Loss of glycosylation at T123 (P = 0.2034); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.4304); Loss of catalytic residue at E125 (P = 0.443)
17:44055794:C:G,P10636,H121D,0.133,Gain of phosphorylation at T123 (P = 0.1316); Loss of catalytic residue at H121 (P = 0.1331); Loss of glycosylation at T123 (P = 0.147); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.4137)
17:44055794:C:T,P10636,H121Y,0.228,Gain of phosphorylation at H121 (P = 0.0041); Loss of glycosylation at T123 (P = 0.08); Gain of catalytic residue at A119 (P = 0.6169); Gain of sheet (P = 0.6509); Loss of disorder (P = 0.6798)
17:44055795:A:C,P10636,H121P,0.144,Gain of phosphorylation at T123 (P = 0.1012); Loss of catalytic residue at H121 (P = 0.1124); Gain of relative solvent accessibility (P = 0.2629); Gain of glycosylation at T123 (P = 0.3054); Gain of solvent accessibility (P = 0.5485)
17:44055795:A:G,P10636,H121R,0.155,Gain of phosphorylation at T123 (P = 0.094); Gain of solvent accessibility (P = 0.1903); Loss of catalytic residue at E125 (P = 0.2455); Loss of glycosylation at T123 (P = 0.2594); Gain of relative solvent accessibility (P = 0.2629)
17:44055795:A:T,P10636,H121L,0.224,Gain of stability (P = 0.0295); Loss of glycosylation at T123 (P = 0.1305); Loss of phosphorylation at T123 (P = 0.2414); Loss of catalytic residue at H121 (P = 0.2906); Loss of sheet (P = 0.6423)
17:44055796:C:A,P10636,H121Q,0.131,Loss of catalytic residue at H121 (P = 0.1167); Gain of phosphorylation at T123 (P = 0.2344); Gain of relative solvent accessibility (P = 0.2629); Loss of glycosylation at T123 (P = 0.2685); Gain of solvent accessibility (P = 0.2987)
17:44055796:C:G,P10636,H121Q,0.131,Loss of catalytic residue at H121 (P = 0.1167); Gain of phosphorylation at T123 (P = 0.2344); Gain of relative solvent accessibility (P = 0.2629); Loss of glycosylation at T123 (P = 0.2685); Gain of solvent accessibility (P = 0.2987)
17:44055797:G:A,P10636,V122M,0.078,Loss of phosphorylation at T123 (P = 0.2477); Gain of glycosylation at T123 (P = 0.2832); Loss of catalytic residue at E125 (P = 0.3008); Gain of solvent accessibility (P = 0.4656); Gain of sheet (P = 0.6509)
17:44055797:G:C,P10636,V122L,0.099,Loss of glycosylation at T123 (P = 0.1601); Loss of phosphorylation at T123 (P = 0.2458); Gain of relative solvent accessibility (P = 0.2629); Loss of catalytic residue at E125 (P = 0.2799); Gain of solvent accessibility (P = 0.3194)
17:44055797:G:T,P10636,V122L,0.099,Loss of glycosylation at T123 (P = 0.1601); Loss of phosphorylation at T123 (P = 0.2458); Gain of relative solvent accessibility (P = 0.2629); Loss of catalytic residue at E125 (P = 0.2799); Gain of solvent accessibility (P = 0.3194)
17:44055798:T:A,P10636,V122E,0.136,Loss of glycosylation at T123 (P = 0.0767); Gain of relative solvent accessibility (P = 0.1066); Gain of solvent accessibility (P = 0.1116); Gain of phosphorylation at T123 (P = 0.1265); Loss of catalytic residue at E125 (P = 0.2182)
17:44055798:T:C,P10636,V122A,0.081,Gain of phosphorylation at T123 (P = 0.1474); Gain of glycosylation at T123 (P = 0.1801); Loss of catalytic residue at E125 (P = 0.2535); Loss of stability (P = 0.6347); Loss of sheet (P = 0.6423)
17:44055798:T:G,P10636,V122G,0.102,Loss of stability (P = 0.0925); Gain of phosphorylation at T123 (P = 0.164); Gain of relative solvent accessibility (P = 0.2629); Gain of glycosylation at T123 (P = 0.2669); Loss of catalytic residue at E125 (P = 0.3188)
17:44055800:A:C,P10636,T123P,0.072,Loss of glycosylation at T123 (P = 0.0238); Loss of phosphorylation at T123 (P = 0.0405); Loss of catalytic residue at E125 (P = 0.3181); Gain of sheet (P = 0.6509); Loss of stability (P = 0.7604)
17:44055800:A:G,P10636,T123A,0.072,Loss of glycosylation at T123 (P = 0.0171); Loss of phosphorylation at T123 (P = 0.0405); Loss of catalytic residue at H121 (P = 0.3015); Loss of solvent accessibility (P = 0.5743); Loss of sheet (P = 0.6423)
17:44055800:A:T,P10636,T123S,0.103,Loss of glycosylation at T123 (P = 0.0464); Gain of phosphorylation at S128 (P = 0.1253); Loss of catalytic residue at H121 (P = 0.3198); Loss of sheet (P = 0.6423); Gain of MoRF binding (P = 0.7795)
17:44055801:C:A,P10636,T123N,0.071,Loss of glycosylation at T123 (P = 0.0171); Loss of phosphorylation at T123 (P = 0.0405); Loss of catalytic residue at H121 (P = 0.3064); Gain of solvent accessibility (P = 0.5334); Loss of sheet (P = 0.6423)
17:44055801:C:G,P10636,T123S,0.103,Loss of glycosylation at T123 (P = 0.0464); Gain of phosphorylation at S128 (P = 0.1253); Loss of catalytic residue at H121 (P = 0.3198); Loss of sheet (P = 0.6423); Gain of MoRF binding (P = 0.7795)
17:44055801:C:T,P10636,T123I,0.148,Loss of glycosylation at T123 (P = 0.0171); Loss of phosphorylation at T123 (P = 0.0405); Loss of catalytic residue at H121 (P = 0.241); Gain of stability (P = 0.3053); Loss of solvent accessibility (P = 0.5485)
17:44055803:C:A,P10636,Q124K,0.205,Gain of ubiquitination at Q124 (P = 4e-04); Gain of methylation at Q124 (P = 0.0271); Gain of glycosylation at Q124 (P = 0.0304); Gain of phosphorylation at S128 (P = 0.1298); Gain of relative solvent accessibility (P = 0.2363)
17:44055803:C:G,P10636,Q124E,0.092,Gain of phosphorylation at S128 (P = 0.141); Gain of glycosylation at S128 (P = 0.2543); Loss of catalytic residue at E125 (P = 0.5533); Loss of MoRF binding (P = 0.7627); Loss of sheet (P = 0.7751)
17:44055804:A:C,P10636,Q124P,0.108,Gain of phosphorylation at T123 (P = 0.094); Gain of glycosylation at T123 (P = 0.1332); Loss of solvent accessibility (P = 0.4141); Loss of stability (P = 0.4221); Gain of catalytic residue at E125 (P = 0.5471)
17:44055804:A:G,P10636,Q124R,0.117,Gain of phosphorylation at T123 (P = 0.1172); Gain of glycosylation at T123 (P = 0.2527); Gain of solvent accessibility (P = 0.3819); Loss of catalytic residue at E127 (P = 0.4024); Gain of methylation at Q124 (P = 0.481)
17:44055804:A:T,P10636,Q124L,0.175,Gain of catalytic residue at Q124 (P = 0.0769); Loss of glycosylation at T123 (P = 0.1149); Loss of phosphorylation at T123 (P = 0.1373); Loss of solvent accessibility (P = 0.4838); Gain of stability (P = 0.625)
17:44055805:A:C,P10636,Q124H,0.081,Gain of glycosylation at T123 (P = 0.1565); Loss of phosphorylation at S128 (P = 0.1766); Gain of catalytic residue at E125 (P = 0.3401); Loss of stability (P = 0.4099); Loss of solvent accessibility (P = 0.5288)
17:44055805:A:T,P10636,Q124H,0.081,Gain of glycosylation at T123 (P = 0.1565); Loss of phosphorylation at S128 (P = 0.1766); Gain of catalytic residue at E125 (P = 0.3401); Loss of stability (P = 0.4099); Loss of solvent accessibility (P = 0.5288)
17:44055806:G:A,P10636,E125K,0.187,Gain of ubiquitination at E125 (P = 9e-04); Gain of methylation at E125 (P = 0.0252); Gain of glycosylation at E125 (P = 0.0342); Gain of relative solvent accessibility (P = 0.0999); Gain of solvent accessibility (P = 0.1045)
17:44055806:G:C,P10636,E125Q,0.087,Loss of glycosylation at T123 (P = 0.1119); Loss of phosphorylation at S128 (P = 0.1133); Loss of catalytic residue at E125 (P = 0.1369); Gain of ubiquitination at K130 (P = 0.3503); Loss of methylation at K130 (P = 0.3693)
17:44060544:A:C,P10636,E125A,0.083,Loss of phosphorylation at S128 (P = 0.1471); Loss of glycosylation at T123 (P = 0.1526); Loss of methylation at K130 (P = 0.1939); Loss of catalytic residue at E125 (P = 0.2136); Loss of ubiquitination at K130 (P = 0.34)
17:44060544:A:G,P10636,E125G,0.078,Loss of stability (P = 0.1203); Loss of phosphorylation at T123 (P = 0.1393); Gain of glycosylation at K130 (P = 0.2259); Gain of catalytic residue at K130 (P = 0.2814); Loss of methylation at K130 (P = 0.2988)
17:44060544:A:T,P10636,E125V,0.101,Loss of phosphorylation at T123 (P = 0.1018); Loss of glycosylation at T123 (P = 0.1531); Loss of catalytic residue at E125 (P = 0.204); Loss of methylation at K130 (P = 0.2654); Loss of ubiquitination at K130 (P = 0.331)
17:44060545:G:C,P10636,E125D,0.055,Loss of glycosylation at S128 (P = 0.1616); Gain of phosphorylation at T123 (P = 0.1969); Loss of methylation at K130 (P = 0.3087); Loss of ubiquitination at K130 (P = 0.3494); Loss of catalytic residue at E125 (P = 0.5488)
17:44060545:G:T,P10636,E125D,0.055,Loss of glycosylation at S128 (P = 0.1616); Gain of phosphorylation at T123 (P = 0.1969); Loss of methylation at K130 (P = 0.3087); Loss of ubiquitination at K130 (P = 0.3494); Loss of catalytic residue at E125 (P = 0.5488)
17:44060546:C:A,P10636,P126T,0.256,Loss of glycosylation at T123 (P = 0.0494); Loss of phosphorylation at T123 (P = 0.0719); Gain of catalytic residue at P126 (P = 0.1952); Loss of methylation at K130 (P = 0.3211); Gain of ubiquitination at K130 (P = 0.3503)
17:44060546:C:G,P10636,P126A,0.246,Loss of glycosylation at T123 (P = 0.0634); Loss of methylation at K130 (P = 0.1082); Loss of phosphorylation at T123 (P = 0.1724); Gain of ubiquitination at K130 (P = 0.3476); Loss of catalytic residue at E125 (P = 0.4054)
17:44060546:C:T,P10636,P126S,0.219,Gain of phosphorylation at P126 (P = 0.0388); Loss of glycosylation at T123 (P = 0.0516); Gain of relative solvent accessibility (P = 0.2629); Loss of methylation at K130 (P = 0.312); Gain of ubiquitination at K130 (P = 0.3527)
17:44060547:C:A,P10636,P126H,0.231,Loss of glycosylation at T123 (P = 0.0527); Loss of phosphorylation at S128 (P = 0.1557); Gain of solvent accessibility (P = 0.2601); Gain of relative solvent accessibility (P = 0.2629); Loss of methylation at K130 (P = 0.3036)
17:44060547:C:G,P10636,P126R,0.244,Loss of glycosylation at T123 (P = 0.0296); Gain of phosphorylation at S128 (P = 0.0962); Gain of solvent accessibility (P = 0.1422); Gain of relative solvent accessibility (P = 0.2629); Gain of MoRF binding (P = 0.2943)
17:44060547:C:T,P10636,P126L,0.247,Loss of glycosylation at T123 (P = 0.0423); Loss of methylation at K130 (P = 0.0561); Loss of phosphorylation at T123 (P = 0.1023); Loss of ubiquitination at K130 (P = 0.34); Gain of stability (P = 0.3886)
17:44060549:G:A,P10636,E127K,0.166,Gain of ubiquitination at E127 (P = 0.0018); Gain of methylation at E127 (P = 0.021); Gain of glycosylation at E127 (P = 0.0372); Loss of phosphorylation at S128 (P = 0.1941); Gain of MoRF binding (P = 0.2962)
17:44060549:G:C,P10636,E127Q,0.065,Loss of glycosylation at T123 (P = 0.1148); Loss of phosphorylation at S128 (P = 0.1351); Loss of catalytic residue at E127 (P = 0.3005); Gain of ubiquitination at K130 (P = 0.3476); Gain of methylation at K130 (P = 0.3575)
17:44060550:A:C,P10636,E127A,0.09,Loss of phosphorylation at S128 (P = 0.1426); Loss of glycosylation at K130 (P = 0.1913); Loss of catalytic residue at E127 (P = 0.3028); Gain of ubiquitination at K130 (P = 0.3527); Loss of solvent accessibility (P = 0.3543)
17:44060550:A:G,P10636,E127G,0.079,Gain of glycosylation at S128 (P = 0.1385); Loss of phosphorylation at S128 (P = 0.2264); Loss of ubiquitination at K130 (P = 0.3494); Gain of catalytic residue at K130 (P = 0.3524); Gain of methylation at K130 (P = 0.3656)
17:44060550:A:T,P10636,E127V,0.101,Loss of glycosylation at K130 (P = 0.1206); Loss of phosphorylation at S128 (P = 0.1264); Gain of catalytic residue at K130 (P = 0.2599); Loss of ubiquitination at K130 (P = 0.3078); Loss of solvent accessibility (P = 0.3136)
17:44060551:A:C,P10636,E127D,0.055,Loss of phosphorylation at S128 (P = 0.1973); Loss of methylation at K130 (P = 0.1981); Loss of glycosylation at K130 (P = 0.2409); Loss of ubiquitination at K130 (P = 0.3494); Gain of catalytic residue at E125 (P = 0.5117)
17:44060551:A:T,P10636,E127D,0.055,Loss of phosphorylation at S128 (P = 0.1973); Loss of methylation at K130 (P = 0.1981); Loss of glycosylation at K130 (P = 0.2409); Loss of ubiquitination at K130 (P = 0.3494); Gain of catalytic residue at E125 (P = 0.5117)
17:44060552:A:C,P10636,S128R,0.117,Loss of glycosylation at S128 (P = 0.0132); Loss of phosphorylation at S128 (P = 0.0433); Gain of solvent accessibility (P = 0.1185); Loss of methylation at K130 (P = 0.3133); Gain of ubiquitination at K130 (P = 0.3527)
17:44060552:A:G,P10636,S128G,0.113,Loss of glycosylation at S128 (P = 0.0132); Loss of stability (P = 0.0226); Loss of phosphorylation at S128 (P = 0.0433); Loss of ubiquitination at K130 (P = 0.34); Gain of methylation at K130 (P = 0.3585)
17:44060552:A:T,P10636,S128C,0.163,Loss of glycosylation at S128 (P = 0.0132); Loss of phosphorylation at S128 (P = 0.0433); Loss of ubiquitination at K130 (P = 0.2767); Loss of relative solvent accessibility (P = 0.3219); Loss of stability (P = 0.3411)
17:44060553:G:A,P10636,S128N,0.123,Loss of glycosylation at S128 (P = 0.0132); Loss of phosphorylation at S128 (P = 0.0433); Loss of stability (P = 0.349); Loss of ubiquitination at K130 (P = 0.3494); Gain of methylation at K130 (P = 0.3653)
17:44060553:G:C,P10636,S128T,0.117,Loss of glycosylation at S128 (P = 0.0287); Gain of phosphorylation at S128 (P = 0.1114); Gain of methylation at K130 (P = 0.3517); Gain of ubiquitination at K130 (P = 0.3527); Loss of stability (P = 0.5099)
17:44060553:G:T,P10636,S128I,0.178,Loss of glycosylation at S128 (P = 0.0132); Gain of catalytic residue at S128 (P = 0.0386); Loss of phosphorylation at S128 (P = 0.0433); Loss of ubiquitination at K130 (P = 0.2936); Gain of methylation at K130 (P = 0.3154)
17:44060554:T:A,P10636,S128R,0.117,Loss of glycosylation at S128 (P = 0.0132); Loss of phosphorylation at S128 (P = 0.0433); Gain of solvent accessibility (P = 0.1185); Loss of methylation at K130 (P = 0.3133); Gain of ubiquitination at K130 (P = 0.3527)
17:44060554:T:G,P10636,S128R,0.117,Loss of glycosylation at S128 (P = 0.0132); Loss of phosphorylation at S128 (P = 0.0433); Gain of solvent accessibility (P = 0.1185); Loss of methylation at K130 (P = 0.3133); Gain of ubiquitination at K130 (P = 0.3527)
17:44060555:G:A,P10636,G129S,0.098,Gain of phosphorylation at G129 (P = 0.0337); Loss of glycosylation at S128 (P = 0.034); Loss of stability (P = 0.1768); Gain of ubiquitination at K130 (P = 0.3527); Gain of methylation at K130 (P = 0.3716)
17:44060555:G:C,P10636,G129R,0.106,Loss of glycosylation at S128 (P = 0.0429); Gain of phosphorylation at S128 (P = 0.1242); Gain of solvent accessibility (P = 0.1319); Loss of stability (P = 0.1853); Gain of methylation at K130 (P = 0.3357)
17:44060555:G:T,P10636,G129C,0.133,Loss of glycosylation at S128 (P = 0.0407); Gain of catalytic residue at V131 (P = 0.0977); Loss of phosphorylation at S128 (P = 0.1264); Gain of methylation at K130 (P = 0.2281); Loss of ubiquitination at K130 (P = 0.321)
17:44060556:G:A,P10636,G129D,0.089,Loss of glycosylation at S128 (P = 0.0336); Gain of phosphorylation at S128 (P = 0.1961); Gain of solvent accessibility (P = 0.2987); Gain of ubiquitination at K130 (P = 0.3459); Loss of methylation at K130 (P = 0.3472)
17:44060556:G:C,P10636,G129A,0.072,Loss of glycosylation at S128 (P = 0.0408); Loss of stability (P = 0.1115); Loss of phosphorylation at S128 (P = 0.1904); Loss of methylation at K130 (P = 0.2979); Gain of ubiquitination at K130 (P = 0.3459)
17:44060556:G:T,P10636,G129V,0.095,Loss of glycosylation at S128 (P = 0.0297); Loss of phosphorylation at S128 (P = 0.2022); Gain of methylation at K130 (P = 0.3144); Gain of ubiquitination at K130 (P = 0.3476); Loss of stability (P = 0.3893)
17:44060558:A:C,P10636,K130Q,0.177,Loss of ubiquitination at K130 (P = 0.0037); Loss of methylation at K130 (P = 0.0055); Loss of glycosylation at K130 (P = 0.0276); Loss of solvent accessibility (P = 0.0561); Loss of phosphorylation at S128 (P = 0.1573)
17:44060558:A:G,P10636,K130E,0.174,Loss of ubiquitination at K130 (P = 0.0037); Loss of methylation at K130 (P = 0.0055); Loss of solvent accessibility (P = 0.0219); Loss of glycosylation at K130 (P = 0.0276); Loss of relative solvent accessibility (P = 0.0981)
17:44060559:A:C,P10636,K130T,0.209,Loss of ubiquitination at K130 (P = 0.0037); Loss of methylation at K130 (P = 0.0055); Loss of solvent accessibility (P = 0.0155); Gain of phosphorylation at K130 (P = 0.0528); Loss of relative solvent accessibility (P = 0.0981)
17:44060559:A:G,P10636,K130R,0.159,Loss of ubiquitination at K130 (P = 0.0037); Loss of methylation at K130 (P = 0.0099); Loss of glycosylation at K130 (P = 0.0276); Loss of solvent accessibility (P = 0.1115); Gain of phosphorylation at S128 (P = 0.1351)
17:44060559:A:T,P10636,K130M,0.236,Loss of ubiquitination at K130 (P = 0.0037); Loss of methylation at K130 (P = 0.0055); Loss of solvent accessibility (P = 0.0217); Loss of glycosylation at K130 (P = 0.0276); Loss of relative solvent accessibility (P = 0.0981)
17:44060560:G:C,P10636,K130N,0.175,Loss of ubiquitination at K130 (P = 0.0037); Loss of methylation at K130 (P = 0.0055); Loss of glycosylation at K130 (P = 0.0276); Loss of solvent accessibility (P = 0.0371); Loss of phosphorylation at S128 (P = 0.1224)
17:44060560:G:T,P10636,K130N,0.175,Loss of ubiquitination at K130 (P = 0.0037); Loss of methylation at K130 (P = 0.0055); Loss of glycosylation at K130 (P = 0.0276); Loss of solvent accessibility (P = 0.0371); Loss of phosphorylation at S128 (P = 0.1224)
17:44060561:G:A,P10636,V131M,0.1,Loss of methylation at K130 (P = 0.0174); Loss of glycosylation at S128 (P = 0.1095); Gain of phosphorylation at S128 (P = 0.2041); Gain of solvent accessibility (P = 0.2601); Gain of relative solvent accessibility (P = 0.2629)
17:44060561:G:C,P10636,V131L,0.079,Loss of methylation at K130 (P = 0.0494); Loss of glycosylation at S128 (P = 0.0885); Loss of phosphorylation at S128 (P = 0.246); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.3194)
17:44060561:G:T,P10636,V131L,0.079,Loss of methylation at K130 (P = 0.0494); Loss of glycosylation at S128 (P = 0.0885); Loss of phosphorylation at S128 (P = 0.246); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.3194)
17:44060562:T:A,P10636,V131E,0.144,Gain of solvent accessibility (P = 0.0133); Gain of relative solvent accessibility (P = 0.0249); Loss of methylation at K130 (P = 0.0364); Loss of glycosylation at S128 (P = 0.0728); Gain of phosphorylation at S128 (P = 0.1062)
17:44060562:T:C,P10636,V131A,0.063,Loss of methylation at K130 (P = 0.0486); Loss of stability (P = 0.091); Gain of glycosylation at K130 (P = 0.1454); Gain of phosphorylation at S128 (P = 0.1946); Gain of relative solvent accessibility (P = 0.2629)
17:44060562:T:G,P10636,V131G,0.096,Loss of stability (P = 0.0242); Loss of methylation at K130 (P = 0.0496); Gain of glycosylation at K130 (P = 0.0759); Gain of relative solvent accessibility (P = 0.1066); Gain of phosphorylation at S128 (P = 0.1591)
17:44060564:G:C,P10636,V132L,0.073,Gain of glycosylation at K130 (P = 0.1789); Gain of phosphorylation at S128 (P = 0.2393); Loss of methylation at K130 (P = 0.2713); Loss of ubiquitination at K130 (P = 0.3494); Gain of stability (P = 0.528)
17:44060564:G:T,P10636,V132F,0.086,Gain of catalytic residue at V132 (P = 0.1804); Gain of glycosylation at K130 (P = 0.1805); Gain of phosphorylation at S128 (P = 0.2115); Gain of ubiquitination at K130 (P = 0.3476); Loss of methylation at K130 (P = 0.3756)
17:44060565:T:A,P10636,V132D,0.168,Gain of relative solvent accessibility (P = 0.0166); Gain of solvent accessibility (P = 0.0221); Loss of methylation at K130 (P = 0.0874); Gain of phosphorylation at S128 (P = 0.1614); Loss of glycosylation at K130 (P = 0.186)
17:44060565:T:C,P10636,V132A,0.073,Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at K130 (P = 0.1904); Gain of phosphorylation at S128 (P = 0.2053); Loss of stability (P = 0.2608); Loss of methylation at K130 (P = 0.2722)
17:44060565:T:G,P10636,V132G,0.093,Loss of stability (P = 0.0673); Gain of relative solvent accessibility (P = 0.1571); Gain of phosphorylation at S128 (P = 0.1711); Loss of glycosylation at S128 (P = 0.1993); Loss of methylation at K130 (P = 0.3002)
17:44060567:C:A,P10636,Q133K,0.216,Gain of ubiquitination at Q133 (P = 0.0022); Gain of methylation at Q133 (P = 0.0073); Gain of glycosylation at Q133 (P = 0.0552); Gain of phosphorylation at S128 (P = 0.16); Loss of catalytic residue at K130 (P = 0.5066)
17:44060567:C:G,P10636,Q133E,0.083,Gain of phosphorylation at S128 (P = 0.1398); Gain of glycosylation at K130 (P = 0.2061); Loss of methylation at K130 (P = 0.2305); Gain of relative solvent accessibility (P = 0.2363); Gain of solvent accessibility (P = 0.3089)
17:44060568:A:C,P10636,Q133P,0.088,Gain of phosphorylation at S128 (P = 0.1382); Gain of glycosylation at S128 (P = 0.2078); Gain of catalytic residue at K130 (P = 0.2153); Loss of solvent accessibility (P = 0.2953); Loss of methylation at K130 (P = 0.3506)
17:44060568:A:G,P10636,Q133R,0.111,Gain of glycosylation at K130 (P = 0.0977); Gain of phosphorylation at S128 (P = 0.141); Loss of ubiquitination at K130 (P = 0.331); Gain of methylation at K130 (P = 0.3704); Gain of solvent accessibility (P = 0.3819)
17:44060568:A:T,P10636,Q133L,0.161,Loss of methylation at K130 (P = 0.1016); Loss of glycosylation at K130 (P = 0.1471); Gain of stability (P = 0.1477); Gain of phosphorylation at S128 (P = 0.2452); Loss of solvent accessibility (P = 0.322)
17:44060569:G:C,P10636,Q133H,0.057,Gain of glycosylation at S128 (P = 0.2045); Gain of phosphorylation at S128 (P = 0.2452); Loss of methylation at K130 (P = 0.278); Gain of ubiquitination at K130 (P = 0.3527); Gain of catalytic residue at K130 (P = 0.5522)
17:44060569:G:T,P10636,Q133H,0.057,Gain of glycosylation at S128 (P = 0.2045); Gain of phosphorylation at S128 (P = 0.2452); Loss of methylation at K130 (P = 0.278); Gain of ubiquitination at K130 (P = 0.3527); Gain of catalytic residue at K130 (P = 0.5522)
17:44060570:G:A,P10636,E134K,0.274,Gain of ubiquitination at E134 (P = 0.0042); Gain of methylation at E134 (P = 0.0156); Gain of glycosylation at E134 (P = 0.0188); Gain of MoRF binding (P = 0.1023); Loss of catalytic residue at E134 (P = 0.1242)
17:44060570:G:C,P10636,E134Q,0.175,Loss of catalytic residue at E134 (P = 0.0777); Loss of glycosylation at K130 (P = 0.217); Loss of ubiquitination at K130 (P = 0.34); Loss of methylation at K130 (P = 0.3615); Gain of MoRF binding (P = 0.4504)
17:44060571:A:C,P10636,E134A,0.274,Loss of solvent accessibility (P = 0.0159); Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at K130 (P = 0.2498); Loss of methylation at K130 (P = 0.3156); Loss of ubiquitination at K130 (P = 0.331)
17:44060571:A:G,P10636,E134G,0.173,Loss of catalytic residue at E134 (P = 0.0441); Loss of solvent accessibility (P = 0.0769); Gain of glycosylation at K130 (P = 0.2354); Loss of stability (P = 0.2659); Loss of ubiquitination at K130 (P = 0.331)
17:44060571:A:T,P10636,E134V,0.29,Loss of solvent accessibility (P = 0.0199); Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at K130 (P = 0.156); Loss of catalytic residue at E134 (P = 0.1564); Loss of ubiquitination at K130 (P = 0.2767)
17:44060572:A:C,P10636,E134D,0.15,Loss of catalytic residue at E134 (P = 0.0681); Loss of glycosylation at K130 (P = 0.2364); Loss of methylation at K130 (P = 0.2657); Loss of ubiquitination at K130 (P = 0.34); Loss of solvent accessibility (P = 0.5485)
17:44060572:A:T,P10636,E134D,0.15,Loss of catalytic residue at E134 (P = 0.0681); Loss of glycosylation at K130 (P = 0.2364); Loss of methylation at K130 (P = 0.2657); Loss of ubiquitination at K130 (P = 0.34); Loss of solvent accessibility (P = 0.5485)
17:44060573:G:A,P10636,G135S,0.118,Gain of phosphorylation at G135 (P = 0.0209); Gain of glycosylation at P140 (P = 0.1607); Gain of methylation at K130 (P = 0.3305); Loss of ubiquitination at K130 (P = 0.34); Gain of solvent accessibility (P = 0.3956)
17:44060573:G:C,P10636,G135R,0.194,Loss of catalytic residue at F136 (P = 0.102); Gain of solvent accessibility (P = 0.1319); Loss of glycosylation at K130 (P = 0.1397); Loss of ubiquitination at K130 (P = 0.3494); Gain of MoRF binding (P = 0.3604)
17:44060573:G:T,P10636,G135C,0.233,Gain of glycosylation at P140 (P = 0.1547); Loss of ubiquitination at K130 (P = 0.34); Loss of methylation at K130 (P = 0.368); Loss of catalytic residue at F136 (P = 0.4908); Loss of relative solvent accessibility (P = 0.5582)
17:44060574:G:A,P10636,G135D,0.113,Gain of solvent accessibility (P = 0.0739); Gain of relative solvent accessibility (P = 0.0999); Loss of catalytic residue at E134 (P = 0.1661); Loss of glycosylation at P140 (P = 0.1881); Gain of ubiquitination at K130 (P = 0.3503)
17:44060574:G:C,P10636,G135A,0.137,Gain of glycosylation at P140 (P = 0.1668); Loss of methylation at K130 (P = 0.2911); Loss of ubiquitination at K130 (P = 0.3494); Loss of catalytic residue at L137 (P = 0.3828); Loss of relative solvent accessibility (P = 0.5582)
17:44060576:T:A,P10636,F136I,0.111,Loss of catalytic residue at F136 (P = 0.0805); Gain of glycosylation at P140 (P = 0.2665); Gain of relative solvent accessibility (P = 0.2751); Gain of solvent accessibility (P = 0.4496); Loss of methylation at R138 (P = 0.5619)
17:44060576:T:C,P10636,F136L,0.148,Gain of glycosylation at P140 (P = 0.2348); Loss of catalytic residue at F136 (P = 0.2518); Loss of methylation at R138 (P = 0.566); Loss of stability (P = 0.6562); Gain of MoRF binding (P = 0.6958)
17:44060576:T:G,P10636,F136V,0.12,Loss of glycosylation at P140 (P = 0.2358); Loss of catalytic residue at F136 (P = 0.2923); Loss of stability (P = 0.3066); Gain of methylation at R138 (P = 0.5454); Gain of MoRF binding (P = 0.65)
17:44060577:T:A,P10636,F136Y,0.151,Gain of phosphorylation at F136 (P = 0.0094); Loss of catalytic residue at F136 (P = 0.0682); Gain of glycosylation at P140 (P = 0.1405); Gain of relative solvent accessibility (P = 0.2751); Gain of solvent accessibility (P = 0.3194)
17:44060577:T:C,P10636,F136S,0.178,Gain of phosphorylation at F136 (P = 0.0084); Gain of glycosylation at F136 (P = 0.0823); Loss of stability (P = 0.1177); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at F136 (P = 0.2453)
17:44060577:T:G,P10636,F136C,0.117,Gain of catalytic residue at L137 (P = 0.1304); Loss of stability (P = 0.1881); Gain of glycosylation at P140 (P = 0.2533); Gain of relative solvent accessibility (P = 0.2751); Gain of methylation at R138 (P = 0.5273)
17:44060578:C:A,P10636,F136L,0.148,Gain of glycosylation at P140 (P = 0.2348); Loss of catalytic residue at F136 (P = 0.2518); Loss of methylation at R138 (P = 0.566); Loss of stability (P = 0.6562); Gain of MoRF binding (P = 0.6958)
17:44060578:C:G,P10636,F136L,0.148,Gain of glycosylation at P140 (P = 0.2348); Loss of catalytic residue at F136 (P = 0.2518); Loss of methylation at R138 (P = 0.566); Loss of stability (P = 0.6562); Gain of MoRF binding (P = 0.6958)
17:44060579:C:A,P10636,L137I,0.148,Loss of glycosylation at P140 (P = 0.1676); Gain of catalytic residue at E139 (P = 0.3545); Loss of stability (P = 0.5393); Loss of methylation at R138 (P = 0.5602); Loss of sheet (P = 0.6423)
17:44060579:C:G,P10636,L137V,0.116,Loss of glycosylation at P140 (P = 0.1597); Loss of catalytic residue at L137 (P = 0.2373); Loss of stability (P = 0.4759); Gain of methylation at R138 (P = 0.5161); Loss of solvent accessibility (P = 0.5743)
17:44060579:C:T,P10636,L137F,0.134,Loss of glycosylation at P142 (P = 0.1847); Gain of catalytic residue at L137 (P = 0.2584); Loss of stability (P = 0.2984); Gain of methylation at R138 (P = 0.5203); Loss of sheet (P = 0.6423)
17:44060580:T:A,P10636,L137H,0.134,Loss of stability (P = 0.062); Loss of glycosylation at P142 (P = 0.2551); Gain of catalytic residue at E139 (P = 0.3393); Gain of solvent accessibility (P = 0.5093); Loss of methylation at R138 (P = 0.5628)
17:44060580:T:C,P10636,L137P,0.188,Gain of glycosylation at L137 (P = 0.0382); Gain of relative solvent accessibility (P = 0.0479); Loss of stability (P = 0.0616); Gain of solvent accessibility (P = 0.1376); Gain of catalytic residue at L137 (P = 0.3359)
17:44060580:T:G,P10636,L137R,0.202,Loss of stability (P = 0.112); Loss of catalytic residue at F136 (P = 0.1435); Gain of methylation at L137 (P = 0.1721); Gain of glycosylation at P140 (P = 0.2037); Gain of solvent accessibility (P = 0.2863)
17:44060582:C:G,P10636,R138G,0.226,Gain of sheet (P = 0.0125); Loss of solvent accessibility (P = 0.0159); Loss of loop (P = 0.0288); Gain of glycosylation at P142 (P = 0.1738); Gain of catalytic residue at E139 (P = 0.2364)
17:44060583:G:C,P10636,R138P,0.257,Loss of solvent accessibility (P = 0.0036); Gain of sheet (P = 0.0266); Loss of loop (P = 0.0288); Gain of glycosylation at R138 (P = 0.052); Loss of relative solvent accessibility (P = 0.0981)
17:44060583:G:T,P10636,R138L,0.229,Loss of solvent accessibility (P = 0.1579); Gain of glycosylation at P142 (P = 0.1736); Gain of catalytic residue at E139 (P = 0.2439); Loss of methylation at R138 (P = 0.5471); Gain of stability (P = 0.6174)
17:44060585:G:A,P10636,E139K,0.23,Gain of methylation at E139 (P = 0.0053); Gain of ubiquitination at E139 (P = 0.0066); Gain of glycosylation at E139 (P = 0.0269); Loss of solvent accessibility (P = 0.0807); Loss of relative solvent accessibility (P = 0.1807)
17:44060585:G:C,P10636,E139Q,0.107,Loss of solvent accessibility (P = 0.0721); Loss of glycosylation at P140 (P = 0.1523); Loss of relative solvent accessibility (P = 0.1807); Loss of catalytic residue at E139 (P = 0.3374); Gain of MoRF binding (P = 0.4954)
17:44060586:A:C,P10636,E139A,0.172,Loss of solvent accessibility (P = 0.0224); Loss of glycosylation at P140 (P = 0.1756); Loss of relative solvent accessibility (P = 0.1807); Loss of catalytic residue at E139 (P = 0.3829); Gain of methylation at R138 (P = 0.3836)
17:44060586:A:G,P10636,E139G,0.202,Loss of solvent accessibility (P = 0.0098); Loss of stability (P = 0.0629); Loss of relative solvent accessibility (P = 0.0676); Gain of catalytic residue at E139 (P = 0.1518); Gain of methylation at R138 (P = 0.1607)
17:44060586:A:T,P10636,E139V,0.211,Loss of solvent accessibility (P = 0.0146); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at P140 (P = 0.09); Gain of catalytic residue at G144 (P = 0.2858); Gain of MoRF binding (P = 0.4257)
17:44060587:G:C,P10636,E139D,0.13,Loss of solvent accessibility (P = 0.0509); Gain of catalytic residue at E139 (P = 0.0971); Loss of glycosylation at P140 (P = 0.1633); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.5227)
17:44060587:G:T,P10636,E139D,0.13,Loss of solvent accessibility (P = 0.0509); Gain of catalytic residue at E139 (P = 0.0971); Loss of glycosylation at P140 (P = 0.1633); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.5227)
17:44060588:C:A,P10636,P140T,0.15,Gain of phosphorylation at P140 (P = 0.0534); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.0721); Loss of glycosylation at P140 (P = 0.0854); Loss of catalytic residue at L137 (P = 0.2683)
17:44060588:C:G,P10636,P140A,0.177,Loss of glycosylation at P140 (P = 0.0411); Loss of solvent accessibility (P = 0.0807); Loss of relative solvent accessibility (P = 0.107); Loss of catalytic residue at P140 (P = 0.1988); Loss of stability (P = 0.2196)
17:44060589:C:A,P10636,P140Q,0.17,Loss of glycosylation at P140 (P = 0.0411); Loss of catalytic residue at P140 (P = 0.0991); Gain of solvent accessibility (P = 0.1045); Loss of stability (P = 0.4213); Loss of methylation at R138 (P = 0.5624)
17:44060589:C:G,P10636,P140R,0.175,Loss of glycosylation at P140 (P = 0.0411); Gain of methylation at P140 (P = 0.0499); Loss of relative solvent accessibility (P = 0.107); Loss of catalytic residue at P140 (P = 0.2613); Gain of MoRF binding (P = 0.2669)
17:44060589:C:T,P10636,P140L,0.218,Loss of glycosylation at P140 (P = 0.0411); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1115); Loss of catalytic residue at L137 (P = 0.2503); Loss of methylation at R138 (P = 0.5634)
17:44060591:G:A,P10636,G141S,0.119,Gain of phosphorylation at G141 (P = 0.0075); Gain of glycosylation at G141 (P = 0.0312); Loss of catalytic residue at G141 (P = 0.1139); Gain of solvent accessibility (P = 0.3956); Loss of methylation at R138 (P = 0.5623)
17:44060591:G:C,P10636,G141R,0.113,Loss of glycosylation at P142 (P = 0.1317); Gain of solvent accessibility (P = 0.1319); Gain of phosphorylation at S146 (P = 0.2632); Gain of MoRF binding (P = 0.3898); Loss of catalytic residue at F136 (P = 0.4033)
17:44060591:G:T,P10636,G141C,0.114,Loss of glycosylation at P143 (P = 0.1328); Loss of phosphorylation at S146 (P = 0.1476); Loss of catalytic residue at G141 (P = 0.401); Loss of relative solvent accessibility (P = 0.5582); Loss of methylation at R138 (P = 0.5624)
17:44060592:G:A,P10636,G141D,0.137,Gain of solvent accessibility (P = 0.0281); Gain of relative solvent accessibility (P = 0.0479); Loss of glycosylation at P143 (P = 0.067); Loss of catalytic residue at G141 (P = 0.0868); Gain of phosphorylation at S146 (P = 0.2788)
17:44060592:G:C,P10636,G141A,0.095,Loss of catalytic residue at G141 (P = 0.1117); Loss of glycosylation at P142 (P = 0.2462); Loss of phosphorylation at S146 (P = 0.2477); Loss of relative solvent accessibility (P = 0.5582); Loss of methylation at R138 (P = 0.5655)
17:44060592:G:T,P10636,G141V,0.092,Loss of glycosylation at P140 (P = 0.0895); Loss of phosphorylation at S146 (P = 0.1782); Loss of catalytic residue at G141 (P = 0.258); Loss of relative solvent accessibility (P = 0.5582); Loss of methylation at R138 (P = 0.5631)
17:44060594:C:A,P10636,P142T,0.144,Gain of phosphorylation at P142 (P = 0.0124); Loss of glycosylation at P143 (P = 0.0618); Loss of catalytic residue at G141 (P = 0.1498); Loss of stability (P = 0.5145); Gain of MoRF binding (P = 0.5584)
17:44060594:C:G,P10636,P142A,0.121,Loss of glycosylation at P142 (P = 0.0384); Loss of catalytic residue at P142 (P = 0.0655); Loss of phosphorylation at S146 (P = 0.1829); Gain of MoRF binding (P = 0.5535); Gain of methylation at R138 (P = 0.5633)
17:44060594:C:T,P10636,P142S,0.127,Gain of phosphorylation at P142 (P = 0.0296); Loss of glycosylation at P143 (P = 0.0832); Loss of catalytic residue at G141 (P = 0.1786); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.4137)
17:44060595:C:A,P10636,P142H,0.125,Loss of glycosylation at P142 (P = 0.0384); Loss of phosphorylation at S146 (P = 0.1204); Loss of catalytic residue at G141 (P = 0.1442); Gain of solvent accessibility (P = 0.4656); Loss of stability (P = 0.5433)
17:44060595:C:G,P10636,P142R,0.15,Loss of glycosylation at P142 (P = 0.0384); Gain of methylation at P142 (P = 0.0414); Gain of MoRF binding (P = 0.0791); Loss of catalytic residue at G141 (P = 0.1242); Loss of phosphorylation at S146 (P = 0.1842)
17:44060595:C:T,P10636,P142L,0.143,Loss of glycosylation at P142 (P = 0.0384); Loss of catalytic residue at G141 (P = 0.1481); Loss of phosphorylation at S146 (P = 0.1852); Gain of stability (P = 0.5583); Loss of methylation at R138 (P = 0.5652)
17:44060597:C:A,P10636,P143T,0.176,Loss of catalytic residue at P142 (P = 0.0165); Gain of phosphorylation at P143 (P = 0.085); Loss of glycosylation at P142 (P = 0.095); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2384)
17:44060597:C:G,P10636,P143A,0.184,Loss of glycosylation at P143 (P = 0.0135); Loss of catalytic residue at P142 (P = 0.0165); Gain of relative solvent accessibility (P = 0.1571); Loss of phosphorylation at S146 (P = 0.1648); Gain of MoRF binding (P = 0.5397)
17:44060597:C:T,P10636,P143S,0.172,Loss of catalytic residue at P142 (P = 0.0165); Gain of phosphorylation at P143 (P = 0.0293); Loss of glycosylation at P143 (P = 0.112); Gain of MoRF binding (P = 0.5409); Gain of methylation at R138 (P = 0.5571)
17:44060598:C:A,P10636,P143Q,0.172,Loss of glycosylation at P143 (P = 0.0135); Loss of catalytic residue at P142 (P = 0.0165); Gain of solvent accessibility (P = 0.0411); Loss of phosphorylation at S146 (P = 0.1174); Gain of relative solvent accessibility (P = 0.1571)
17:44060598:C:G,P10636,P143R,0.212,Loss of glycosylation at P143 (P = 0.0135); Loss of catalytic residue at P142 (P = 0.0165); Gain of solvent accessibility (P = 0.0411); Gain of MoRF binding (P = 0.0785); Gain of phosphorylation at S146 (P = 0.1409)
17:44060598:C:T,P10636,P143L,0.204,Loss of glycosylation at P143 (P = 0.0135); Loss of catalytic residue at P142 (P = 0.0283); Gain of stability (P = 0.0871); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1362)
17:44060600:G:A,P10636,G144S,0.092,Gain of phosphorylation at G144 (P = 0.0194); Gain of glycosylation at G144 (P = 0.0268); Loss of catalytic residue at P140 (P = 0.0746); Gain of relative solvent accessibility (P = 0.1894); Gain of solvent accessibility (P = 0.194)
17:44060600:G:C,P10636,G144R,0.155,Gain of solvent accessibility (P = 0.019); Loss of catalytic residue at P140 (P = 0.0746); Gain of methylation at G144 (P = 0.0774); Gain of phosphorylation at S146 (P = 0.1244); Loss of glycosylation at P140 (P = 0.1762)
17:44060600:G:T,P10636,G144C,0.137,Gain of catalytic residue at P143 (P = 0.0312); Loss of phosphorylation at S146 (P = 0.1162); Loss of glycosylation at P140 (P = 0.1651); Loss of relative solvent accessibility (P = 0.3919); Loss of sheet (P = 0.6423)
17:44060601:G:A,P10636,G144D,0.106,Loss of catalytic residue at P140 (P = 0.0746); Gain of solvent accessibility (P = 0.1045); Loss of glycosylation at P143 (P = 0.1117); Gain of relative solvent accessibility (P = 0.1894); Gain of phosphorylation at S146 (P = 0.2661)
17:44060601:G:C,P10636,G144A,0.052,Loss of catalytic residue at P140 (P = 0.0746); Gain of glycosylation at P142 (P = 0.1148); Loss of phosphorylation at S146 (P = 0.2408); Loss of sheet (P = 0.6423); Gain of MoRF binding (P = 0.695)
17:44060601:G:T,P10636,G144V,0.088,Loss of catalytic residue at P140 (P = 0.0746); Loss of glycosylation at P143 (P = 0.0839); Loss of phosphorylation at S146 (P = 0.1441); Loss of relative solvent accessibility (P = 0.3219); Loss of solvent accessibility (P = 0.623)
17:44060603:C:A,P10636,L145M,0.1,Gain of glycosylation at P140 (P = 0.2048); Gain of phosphorylation at S146 (P = 0.2275); Gain of catalytic residue at G144 (P = 0.4925); Gain of solvent accessibility (P = 0.571); Gain of MoRF binding (P = 0.6367)
17:44060603:C:G,P10636,L145V,0.117,Loss of glycosylation at P143 (P = 0.1126); Loss of phosphorylation at S146 (P = 0.2498); Gain of catalytic residue at G144 (P = 0.5862); Gain of sheet (P = 0.6509); Gain of MoRF binding (P = 0.6591)
17:44060604:T:A,P10636,L145Q,0.097,Loss of catalytic residue at L145 (P = 0.0383); Gain of glycosylation at P140 (P = 0.1343); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.1751); Gain of phosphorylation at S146 (P = 0.2673)
17:44060604:T:C,P10636,L145P,0.156,Gain of glycosylation at L145 (P = 0.0106); Loss of catalytic residue at L145 (P = 0.0424); Gain of phosphorylation at S146 (P = 0.1633); Loss of stability (P = 0.2144); Gain of relative solvent accessibility (P = 0.2751)
17:44060604:T:G,P10636,L145R,0.2,Gain of methylation at L145 (P = 0.0242); Gain of solvent accessibility (P = 0.1071); Gain of phosphorylation at S146 (P = 0.1395); Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at P142 (P = 0.236)
17:44060606:A:G,P10636,S146G,0.056,Loss of phosphorylation at S146 (P = 0.0327); Loss of glycosylation at P143 (P = 0.0943); Loss of stability (P = 0.2536); Gain of catalytic residue at Q148 (P = 0.3743); Loss of solvent accessibility (P = 0.6134)
17:44060606:A:T,P10636,S146C,0.15,Loss of phosphorylation at S146 (P = 0.0327); Loss of glycosylation at P143 (P = 0.1583); Gain of catalytic residue at S146 (P = 0.1815); Loss of sheet (P = 0.6423); Loss of solvent accessibility (P = 0.6935)
17:44060607:G:A,P10636,S146N,0.098,Loss of phosphorylation at S146 (P = 0.0327); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917); Loss of glycosylation at P142 (P = 0.1921); Loss of catalytic residue at G144 (P = 0.4439)
17:44060607:G:C,P10636,S146T,0.075,Gain of glycosylation at S146 (P = 0.0941); Loss of phosphorylation at S151 (P = 0.1399); Gain of catalytic residue at S146 (P = 0.3347); Gain of solvent accessibility (P = 0.5334); Loss of stability (P = 0.5909)
17:44060607:G:T,P10636,S146I,0.207,Loss of phosphorylation at S146 (P = 0.0327); Loss of glycosylation at P143 (P = 0.0764); Gain of stability (P = 0.2735); Loss of relative solvent accessibility (P = 0.3919); Loss of catalytic residue at G144 (P = 0.5068)
17:44060608:C:A,P10636,S146R,0.119,Loss of phosphorylation at S146 (P = 0.0327); Loss of glycosylation at P142 (P = 0.1843); Gain of catalytic residue at S146 (P = 0.3101); Gain of solvent accessibility (P = 0.3304); Gain of MoRF binding (P = 0.3921)
17:44060608:C:G,P10636,S146R,0.119,Loss of phosphorylation at S146 (P = 0.0327); Loss of glycosylation at P142 (P = 0.1843); Gain of catalytic residue at S146 (P = 0.3101); Gain of solvent accessibility (P = 0.3304); Gain of MoRF binding (P = 0.3921)
17:44060609:C:A,P10636,H147N,0.109,Loss of catalytic residue at L149 (P = 0.1025); Gain of relative solvent accessibility (P = 0.1571); Gain of phosphorylation at S151 (P = 0.1834); Loss of glycosylation at P142 (P = 0.2583); Gain of solvent accessibility (P = 0.2863)
17:44060609:C:G,P10636,H147D,0.146,Gain of relative solvent accessibility (P = 0.09); Loss of catalytic residue at L149 (P = 0.1002); Gain of phosphorylation at S151 (P = 0.1245); Gain of solvent accessibility (P = 0.1456); Loss of glycosylation at P143 (P = 0.1859)
17:44060609:C:T,P10636,H147Y,0.258,Gain of phosphorylation at H147 (P = 0.0081); Loss of catalytic residue at L149 (P = 0.1112); Gain of glycosylation at P142 (P = 0.1318); Gain of solvent accessibility (P = 0.5485); Gain of sheet (P = 0.6509)
17:44060610:A:C,P10636,H147P,0.149,Gain of glycosylation at H147 (P = 0.0941); Gain of phosphorylation at S151 (P = 0.1076); Loss of catalytic residue at H147 (P = 0.1169); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.348)
17:44060610:A:G,P10636,H147R,0.225,Gain of catalytic residue at M150 (P = 0.0523); Loss of glycosylation at S151 (P = 0.1082); Gain of solvent accessibility (P = 0.1133); Gain of phosphorylation at S146 (P = 0.1301); Gain of relative solvent accessibility (P = 0.1571)
17:44060610:A:T,P10636,H147L,0.225,Loss of catalytic residue at L149 (P = 0.137); Gain of phosphorylation at S151 (P = 0.1387); Gain of glycosylation at P142 (P = 0.2041); Gain of stability (P = 0.2841); Gain of sheet (P = 0.6509)
17:44060611:C:A,P10636,H147Q,0.177,Gain of solvent accessibility (P = 0.0081); Gain of relative solvent accessibility (P = 0.0166); Loss of catalytic residue at L149 (P = 0.0997); Gain of phosphorylation at S151 (P = 0.1433); Loss of glycosylation at S151 (P = 0.1722)
17:44060611:C:G,P10636,H147Q,0.177,Gain of solvent accessibility (P = 0.0081); Gain of relative solvent accessibility (P = 0.0166); Loss of catalytic residue at L149 (P = 0.0997); Gain of phosphorylation at S151 (P = 0.1433); Loss of glycosylation at S151 (P = 0.1722)
17:44060612:C:A,P10636,Q148K,0.173,Gain of ubiquitination at Q148 (P = 0.0029); Gain of methylation at Q148 (P = 0.0122); Gain of glycosylation at Q148 (P = 0.0202); Gain of relative solvent accessibility (P = 0.1066); Gain of catalytic residue at Q148 (P = 0.1224)
17:44060612:C:G,P10636,Q148E,0.108,Gain of solvent accessibility (P = 0.0221); Gain of relative solvent accessibility (P = 0.0249); Gain of phosphorylation at S151 (P = 0.1081); Gain of catalytic residue at Q148 (P = 0.1338); Loss of glycosylation at P143 (P = 0.2876)
17:44060613:A:C,P10636,Q148P,0.083,Gain of glycosylation at Q148 (P = 0.0354); Gain of phosphorylation at S151 (P = 0.1041); Loss of stability (P = 0.1789); Gain of relative solvent accessibility (P = 0.2629); Gain of catalytic residue at Q148 (P = 0.2825)
17:44060613:A:G,P10636,Q148R,0.095,Gain of phosphorylation at S151 (P = 0.074); Loss of glycosylation at S151 (P = 0.1332); Gain of solvent accessibility (P = 0.204); Gain of relative solvent accessibility (P = 0.2629); Gain of methylation at Q148 (P = 0.2912)
17:44060613:A:T,P10636,Q148L,0.072,Gain of phosphorylation at S151 (P = 0.1624); Loss of glycosylation at P143 (P = 0.2316); Gain of catalytic residue at S146 (P = 0.2503); Loss of solvent accessibility (P = 0.5904); Gain of sheet (P = 0.6509)
17:44060614:G:C,P10636,Q148H,0.068,Gain of catalytic residue at M150 (P = 0.0525); Gain of phosphorylation at S151 (P = 0.1715); Loss of stability (P = 0.2024); Loss of glycosylation at P143 (P = 0.239); Gain of relative solvent accessibility (P = 0.2629)
17:44060614:G:T,P10636,Q148H,0.068,Gain of catalytic residue at M150 (P = 0.0525); Gain of phosphorylation at S151 (P = 0.1715); Loss of stability (P = 0.2024); Loss of glycosylation at P143 (P = 0.239); Gain of relative solvent accessibility (P = 0.2629)
17:44060615:C:A,P10636,L149I,0.174,Gain of catalytic residue at M153 (P = 0.0311); Gain of phosphorylation at S151 (P = 0.2179); Gain of glycosylation at S146 (P = 0.2667); Loss of stability (P = 0.5604); Gain of solvent accessibility (P = 0.5946)
17:44060615:C:G,P10636,L149V,0.187,Gain of catalytic residue at M153 (P = 0.0335); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1751); Gain of phosphorylation at S151 (P = 0.2154); Loss of stability (P = 0.2411)
17:44060615:C:T,P10636,L149F,0.149,Loss of stability (P = 0.1796); Loss of phosphorylation at S146 (P = 0.2035); Gain of glycosylation at S151 (P = 0.2764); Gain of solvent accessibility (P = 0.5485); Gain of catalytic residue at H147 (P = 0.6006)
17:44060616:T:A,P10636,L149H,0.188,Loss of stability (P = 0.0371); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0971); Gain of phosphorylation at S151 (P = 0.1607); Gain of glycosylation at S151 (P = 0.305)
17:44060616:T:C,P10636,L149P,0.247,Loss of catalytic residue at L149 (P = 0.0095); Loss of stability (P = 0.0187); Gain of relative solvent accessibility (P = 0.09); Gain of glycosylation at S146 (P = 0.0977); Gain of phosphorylation at S151 (P = 0.0999)
17:44060616:T:G,P10636,L149R,0.243,Gain of solvent accessibility (P = 0.0365); Loss of stability (P = 0.0427); Gain of phosphorylation at S151 (P = 0.0728); Gain of relative solvent accessibility (P = 0.09); Loss of glycosylation at S151 (P = 0.1177)
17:44060618:A:C,P10636,M150L,0.115,Loss of glycosylation at S151 (P = 0.208); Loss of phosphorylation at S151 (P = 0.2264); Loss of sheet (P = 0.6423); Loss of MoRF binding (P = 0.7001); Gain of catalytic residue at H147 (P = 0.7655)
17:44060618:A:G,P10636,M150V,0.097,Loss of phosphorylation at S151 (P = 0.1741); Gain of glycosylation at S151 (P = 0.3111); Gain of catalytic residue at M150 (P = 0.3872); Loss of sheet (P = 0.6423); Loss of MoRF binding (P = 0.7065)
17:44060618:A:T,P10636,M150L,0.115,Loss of glycosylation at S151 (P = 0.208); Loss of phosphorylation at S151 (P = 0.2264); Loss of sheet (P = 0.6423); Loss of MoRF binding (P = 0.7001); Gain of catalytic residue at H147 (P = 0.7655)
17:44060619:T:A,P10636,M150K,0.25,Gain of ubiquitination at M150 (P = 0.0018); Gain of glycosylation at M150 (P = 0.0448); Gain of methylation at M150 (P = 0.0494); Gain of solvent accessibility (P = 0.0789); Gain of relative solvent accessibility (P = 0.09)
17:44060619:T:C,P10636,M150T,0.092,Gain of phosphorylation at M150 (P = 0.0287); Gain of glycosylation at M150 (P = 0.0344); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.2008); Gain of catalytic residue at M150 (P = 0.2739)
17:44060619:T:G,P10636,M150R,0.181,Gain of methylation at M150 (P = 0.0252); Gain of solvent accessibility (P = 0.1133); Gain of phosphorylation at S151 (P = 0.1213); Loss of glycosylation at S151 (P = 0.1295); Gain of relative solvent accessibility (P = 0.1571)
17:44060620:G:A,P10636,M150I,0.114,Loss of phosphorylation at S151 (P = 0.1452); Gain of glycosylation at S151 (P = 0.2827); Gain of catalytic residue at S146 (P = 0.3948); Loss of sheet (P = 0.6423); Loss of MoRF binding (P = 0.7037)
17:44060620:G:C,P10636,M150I,0.114,Loss of phosphorylation at S151 (P = 0.1452); Gain of glycosylation at S151 (P = 0.2827); Gain of catalytic residue at S146 (P = 0.3948); Loss of sheet (P = 0.6423); Loss of MoRF binding (P = 0.7037)
17:44060620:G:T,P10636,M150I,0.114,Loss of phosphorylation at S151 (P = 0.1452); Gain of glycosylation at S151 (P = 0.2827); Gain of catalytic residue at S146 (P = 0.3948); Loss of sheet (P = 0.6423); Loss of MoRF binding (P = 0.7037)
17:44060621:T:A,P10636,S151T,0.086,Loss of glycosylation at S151 (P = 0.0863); Loss of phosphorylation at S146 (P = 0.1329); Gain of catalytic residue at S151 (P = 0.1918); Gain of solvent accessibility (P = 0.571); Loss of stability (P = 0.6665)
17:44060621:T:C,P10636,S151P,0.07,Loss of glycosylation at S151 (P = 0.0398); Loss of phosphorylation at S151 (P = 0.0459); Gain of catalytic residue at S151 (P = 0.2403); Loss of loop (P = 0.2897); Gain of sheet (P = 0.4423)
17:44060621:T:G,P10636,S151A,0.072,Loss of glycosylation at S151 (P = 0.0101); Loss of phosphorylation at S151 (P = 0.0459); Gain of catalytic residue at S151 (P = 0.2709); Loss of solvent accessibility (P = 0.623); Loss of sheet (P = 0.6423)
17:44060622:C:A,P10636,S151Y,0.189,Loss of glycosylation at S151 (P = 0.0101); Gain of catalytic residue at S151 (P = 0.0576); Gain of phosphorylation at S151 (P = 0.0615); Gain of solvent accessibility (P = 0.5334); Loss of sheet (P = 0.6423)
17:44060622:C:G,P10636,S151C,0.122,Loss of glycosylation at S151 (P = 0.0101); Loss of phosphorylation at S151 (P = 0.0459); Gain of catalytic residue at S151 (P = 0.1398); Loss of stability (P = 0.6781); Loss of MoRF binding (P = 0.6983)
17:44060622:C:T,P10636,S151F,0.124,Loss of glycosylation at S151 (P = 0.0101); Loss of phosphorylation at S151 (P = 0.0459); Gain of catalytic residue at S151 (P = 0.2943); Loss of MoRF binding (P = 0.7024); Loss of sheet (P = 0.7751)
17:44060624:G:A,P10636,G152S,0.071,Gain of phosphorylation at G152 (P = 0.0175); Loss of glycosylation at S151 (P = 0.0321); Loss of catalytic residue at G152 (P = 0.1548); Loss of stability (P = 0.1681); Gain of solvent accessibility (P = 0.4946)
17:44060624:G:C,P10636,G152R,0.114,Gain of solvent accessibility (P = 0.0306); Loss of glycosylation at S151 (P = 0.0421); Gain of phosphorylation at S151 (P = 0.1306); Gain of methylation at G152 (P = 0.1997); Loss of stability (P = 0.2357)
17:44060624:G:T,P10636,G152C,0.09,Gain of catalytic residue at M150 (P = 0.016); Loss of glycosylation at S151 (P = 0.0362); Loss of phosphorylation at S151 (P = 0.1247); Loss of stability (P = 0.354); Loss of relative solvent accessibility (P = 0.3589)
17:44060625:G:A,P10636,G152D,0.074,Loss of glycosylation at S151 (P = 0.0328); Gain of solvent accessibility (P = 0.0648); Loss of catalytic residue at G152 (P = 0.1021); Gain of relative solvent accessibility (P = 0.1684); Gain of phosphorylation at S151 (P = 0.2248)
17:44060625:G:C,P10636,G152A,0.063,Loss of glycosylation at S151 (P = 0.0372); Loss of catalytic residue at G152 (P = 0.0928); Loss of stability (P = 0.0948); Loss of phosphorylation at S151 (P = 0.1847); Gain of sheet (P = 0.6509)
17:44060625:G:T,P10636,G152V,0.086,Loss of glycosylation at S151 (P = 0.0235); Loss of phosphorylation at S151 (P = 0.1575); Loss of relative solvent accessibility (P = 0.1903); Loss of stability (P = 0.3537); Loss of catalytic residue at S151 (P = 0.488)
17:44060627:A:C,P10636,M153L,0.262,Gain of sheet (P = 0.0266); Loss of loop (P = 0.0288); Gain of catalytic residue at M153 (P = 0.06); Gain of phosphorylation at S151 (P = 0.2553); Loss of glycosylation at S151 (P = 0.3028)
17:44060627:A:G,P10636,M153V,0.252,Gain of catalytic residue at M153 (P = 0.0077); Loss of phosphorylation at S151 (P = 0.2008); Loss of glycosylation at P154 (P = 0.216); Loss of stability (P = 0.4315); Loss of sheet (P = 0.6423)
17:44060627:A:T,P10636,M153L,0.262,Gain of sheet (P = 0.0266); Loss of loop (P = 0.0288); Gain of catalytic residue at M153 (P = 0.06); Gain of phosphorylation at S151 (P = 0.2553); Loss of glycosylation at S151 (P = 0.3028)
17:44060628:T:A,P10636,M153K,0.35,Gain of ubiquitination at M153 (P = 0.0037); Gain of glycosylation at M153 (P = 0.0214); Gain of methylation at M153 (P = 0.0491); Gain of catalytic residue at M153 (P = 0.0578); Gain of solvent accessibility (P = 0.0789)
17:44060628:T:C,P10636,M153T,0.19,Gain of phosphorylation at M153 (P = 0.026); Gain of glycosylation at M153 (P = 0.0322); Gain of catalytic residue at M153 (P = 0.1117); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1712)
17:44060628:T:G,P10636,M153R,0.261,Gain of methylation at M153 (P = 0.0238); Gain of catalytic residue at M153 (P = 0.0355); Gain of phosphorylation at S151 (P = 0.1101); Gain of solvent accessibility (P = 0.1133); Gain of relative solvent accessibility (P = 0.1571)
17:44060629:G:A,P10636,M153I,0.158,Loss of phosphorylation at S151 (P = 0.1984); Loss of glycosylation at P154 (P = 0.202); Gain of catalytic residue at M153 (P = 0.2749); Loss of stability (P = 0.6191); Loss of sheet (P = 0.6423)
17:44060629:G:C,P10636,M153I,0.158,Loss of phosphorylation at S151 (P = 0.1984); Loss of glycosylation at P154 (P = 0.202); Gain of catalytic residue at M153 (P = 0.2749); Loss of stability (P = 0.6191); Loss of sheet (P = 0.6423)
17:44060629:G:T,P10636,M153I,0.158,Loss of phosphorylation at S151 (P = 0.1984); Loss of glycosylation at P154 (P = 0.202); Gain of catalytic residue at M153 (P = 0.2749); Loss of stability (P = 0.6191); Loss of sheet (P = 0.6423)
17:44060630:C:A,P10636,P154T,0.11,Gain of phosphorylation at P154 (P = 0.016); Gain of catalytic residue at P154 (P = 0.0634); Loss of glycosylation at S151 (P = 0.0966); Gain of MoRF binding (P = 0.5483); Gain of solvent accessibility (P = 0.5843)
17:44060630:C:G,P10636,P154A,0.091,Gain of catalytic residue at P154 (P = 0.0404); Loss of glycosylation at P154 (P = 0.0831); Loss of phosphorylation at S151 (P = 0.178); Gain of MoRF binding (P = 0.5623); Loss of stability (P = 0.6983)
17:44060630:C:T,P10636,P154S,0.095,Gain of phosphorylation at P154 (P = 0.0259); Gain of catalytic residue at P154 (P = 0.0355); Gain of glycosylation at P154 (P = 0.0587); Gain of MoRF binding (P = 0.5423); Gain of sheet (P = 0.6509)
17:44060631:C:A,P10636,P154H,0.082,Loss of glycosylation at P154 (P = 0.0831); Gain of catalytic residue at P154 (P = 0.1128); Loss of phosphorylation at S151 (P = 0.1503); Gain of solvent accessibility (P = 0.3819); Gain of MoRF binding (P = 0.5655)
17:44060631:C:G,P10636,P154R,0.137,Gain of methylation at P154 (P = 0.0244); Gain of MoRF binding (P = 0.0539); Loss of glycosylation at S151 (P = 0.0725); Gain of catalytic residue at P154 (P = 0.0797); Gain of phosphorylation at S151 (P = 0.1617)
17:44060631:C:T,P10636,P154L,0.138,Gain of stability (P = 0.0341); Loss of glycosylation at S151 (P = 0.0519); Loss of phosphorylation at S151 (P = 0.1497); Gain of catalytic residue at P154 (P = 0.1605); Loss of relative solvent accessibility (P = 0.5582)
17:44060633:G:A,P10636,G155R,0.275,Gain of solvent accessibility (P = 0.0014); Loss of catalytic residue at G152 (P = 0.1233); Gain of stability (P = 0.1295); Gain of relative solvent accessibility (P = 0.1571); Loss of phosphorylation at S151 (P = 0.1583)
17:44060633:G:C,P10636,G155R,0.275,Gain of solvent accessibility (P = 0.0014); Loss of catalytic residue at G152 (P = 0.1233); Gain of stability (P = 0.1295); Gain of relative solvent accessibility (P = 0.1571); Loss of phosphorylation at S151 (P = 0.1583)
17:44060633:G:T,P10636,G155W,0.217,Gain of catalytic residue at G155 (P = 0.0466); Loss of relative solvent accessibility (P = 0.0981); Loss of phosphorylation at S151 (P = 0.1334); Gain of glycosylation at P157 (P = 0.1584); Gain of stability (P = 0.2924)
17:44060634:G:A,P10636,G155E,0.159,Gain of solvent accessibility (P = 0.0456); Loss of catalytic residue at G152 (P = 0.1483); Gain of phosphorylation at S151 (P = 0.1857); Gain of stability (P = 0.2061); Loss of glycosylation at P157 (P = 0.3469)
17:44060634:G:C,P10636,G155A,0.099,Gain of relative solvent accessibility (P = 0.1571); Gain of stability (P = 0.1917); Gain of solvent accessibility (P = 0.204); Loss of catalytic residue at G152 (P = 0.2221); Gain of glycosylation at P157 (P = 0.2243)
17:44060634:G:T,P10636,G155V,0.162,Gain of stability (P = 0.0341); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at G155 (P = 0.1278); Loss of phosphorylation at S151 (P = 0.1703); Loss of glycosylation at P154 (P = 0.1724)
17:44060636:G:A,P10636,A156T,0.084,Gain of phosphorylation at A156 (P = 0.0207); Gain of glycosylation at A156 (P = 0.0263); Loss of stability (P = 0.3352); Gain of catalytic residue at A156 (P = 0.3675); Gain of solvent accessibility (P = 0.4946)
17:44060636:G:C,P10636,A156P,0.161,Gain of glycosylation at A156 (P = 0.0153); Gain of catalytic residue at A156 (P = 0.0514); Gain of phosphorylation at S151 (P = 0.1342); Loss of stability (P = 0.2971); Loss of sheet (P = 0.6423)
17:44060636:G:T,P10636,A156S,0.092,Gain of phosphorylation at A156 (P = 0.0096); Gain of glycosylation at A156 (P = 0.0625); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.348); Loss of stability (P = 0.4656)
17:44060637:C:A,P10636,A156D,0.134,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.026); Gain of phosphorylation at S151 (P = 0.1454); Loss of glycosylation at S151 (P = 0.2179); Gain of catalytic residue at L159 (P = 0.505)
17:44060637:C:G,P10636,A156G,0.101,Loss of stability (P = 0.1513); Gain of phosphorylation at S151 (P = 0.1727); Loss of glycosylation at S151 (P = 0.1796); Gain of catalytic residue at A156 (P = 0.192); Loss of sheet (P = 0.6423)
17:44060637:C:T,P10636,A156V,0.113,Gain of catalytic residue at A156 (P = 0.0714); Loss of glycosylation at S151 (P = 0.1688); Loss of phosphorylation at S151 (P = 0.2098); Loss of sheet (P = 0.6423); Gain of MoRF binding (P = 0.6842)
17:44060639:C:T,P10636,P157S,0.216,Gain of phosphorylation at P157 (P = 0.0319); Gain of catalytic residue at M153 (P = 0.0382); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.1116); Loss of glycosylation at P157 (P = 0.3227)
17:44060640:C:A,P10636,P157H,0.19,Loss of glycosylation at P157 (P = 0.0814); Gain of catalytic residue at L159 (P = 0.2285); Loss of stability (P = 0.4943); Gain of MoRF binding (P = 0.5818); Loss of sheet (P = 0.7751)
17:44060640:C:G,P10636,P157R,0.241,Gain of MoRF binding (P = 0.0609); Gain of solvent accessibility (P = 0.0789); Loss of glycosylation at P157 (P = 0.0814); Gain of methylation at P157 (P = 0.1977); Gain of relative solvent accessibility (P = 0.2363)
17:44060640:C:T,P10636,P157L,0.245,Loss of glycosylation at P157 (P = 0.0814); Gain of catalytic residue at P157 (P = 0.3351); Loss of relative solvent accessibility (P = 0.5582); Loss of solvent accessibility (P = 0.5743); Gain of MoRF binding (P = 0.6466)
17:44060642:C:A,P10636,L158I,0.13,Gain of catalytic residue at M153 (P = 0.0372); Loss of glycosylation at P157 (P = 0.2002); Gain of solvent accessibility (P = 0.5946); Loss of sheet (P = 0.6423); Gain of MoRF binding (P = 0.7087)
17:44060642:C:G,P10636,L158V,0.12,Gain of catalytic residue at M153 (P = 0.037); Loss of glycosylation at P157 (P = 0.2043); Loss of sheet (P = 0.6423); Gain of MoRF binding (P = 0.6821); Loss of stability (P = 0.6836)
17:44060642:C:T,P10636,L158F,0.122,Loss of catalytic residue at L158 (P = 0.1724); Loss of glycosylation at P163 (P = 0.2421); Gain of solvent accessibility (P = 0.4496); Loss of stability (P = 0.635); Loss of sheet (P = 0.6423)
17:44060643:T:A,P10636,L158H,0.158,Loss of stability (P = 0.184); Loss of glycosylation at P163 (P = 0.2232); Gain of relative solvent accessibility (P = 0.2363); Gain of solvent accessibility (P = 0.2601); Gain of catalytic residue at E161 (P = 0.4977)
17:44060643:T:C,P10636,L158P,0.132,Gain of glycosylation at L158 (P = 0.0186); Loss of stability (P = 0.0961); Gain of catalytic residue at P157 (P = 0.1534); Gain of relative solvent accessibility (P = 0.2363); Gain of solvent accessibility (P = 0.4821)
17:44060643:T:G,P10636,L158R,0.167,Gain of solvent accessibility (P = 0.1071); Loss of glycosylation at P163 (P = 0.1949); Gain of relative solvent accessibility (P = 0.2363); Gain of methylation at L158 (P = 0.2425); Gain of MoRF binding (P = 0.3016)
17:44060645:C:A,P10636,L159M,0.165,Gain of catalytic residue at L159 (P = 0.1715); Gain of glycosylation at P163 (P = 0.2804); Loss of stability (P = 0.2964); Loss of methylation at R164 (P = 0.4228); Gain of solvent accessibility (P = 0.571)
17:44060645:C:G,P10636,L159V,0.096,Loss of glycosylation at P157 (P = 0.2111); Loss of catalytic residue at L159 (P = 0.3957); Loss of stability (P = 0.4013); Gain of methylation at R164 (P = 0.4228); Gain of MoRF binding (P = 0.6921)
17:44060646:T:A,P10636,L159Q,0.111,Loss of stability (P = 0.0684); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.1751); Gain of glycosylation at P157 (P = 0.1956); Loss of catalytic residue at L159 (P = 0.198)
17:44060646:T:G,P10636,L159R,0.179,Gain of methylation at L159 (P = 0.0377); Loss of stability (P = 0.0523); Gain of solvent accessibility (P = 0.1071); Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at P163 (P = 0.1779)
17:44060648:C:A,P10636,P160T,0.157,Gain of glycosylation at P160 (P = 0.0138); Gain of phosphorylation at P160 (P = 0.0429); Loss of catalytic residue at P160 (P = 0.255); Loss of methylation at R164 (P = 0.4218); Gain of solvent accessibility (P = 0.5843)
17:44060648:C:G,P10636,P160A,0.15,Loss of catalytic residue at P160 (P = 0.1478); Loss of glycosylation at P160 (P = 0.1536); Gain of methylation at R164 (P = 0.3805); Gain of MoRF binding (P = 0.599); Loss of sheet (P = 0.7751)
17:44060648:C:T,P10636,P160S,0.152,Gain of phosphorylation at P160 (P = 0.0391); Loss of catalytic residue at P160 (P = 0.133); Loss of glycosylation at P163 (P = 0.2057); Gain of methylation at R164 (P = 0.4088); Gain of MoRF binding (P = 0.5674)
17:44060649:C:A,P10636,P160H,0.164,Loss of glycosylation at P160 (P = 0.1536); Loss of catalytic residue at P160 (P = 0.2495); Gain of solvent accessibility (P = 0.3819); Loss of methylation at R164 (P = 0.4219); Gain of MoRF binding (P = 0.606)
17:44060649:C:G,P10636,P160R,0.187,Gain of MoRF binding (P = 0.1016); Gain of glycosylation at P163 (P = 0.1323); Gain of solvent accessibility (P = 0.2097); Loss of catalytic residue at L159 (P = 0.2216); Loss of methylation at R164 (P = 0.419)
17:44060649:C:T,P10636,P160L,0.182,Loss of glycosylation at P163 (P = 0.1314); Loss of catalytic residue at L159 (P = 0.2562); Gain of methylation at R164 (P = 0.4069); Gain of solvent accessibility (P = 0.4656); Gain of MoRF binding (P = 0.6318)
17:44060651:G:A,P10636,E161K,0.245,Gain of glycosylation at E161 (P = 0.0023); Gain of methylation at E161 (P = 0.0084); Gain of ubiquitination at E161 (P = 0.0114); Gain of MoRF binding (P = 0.2251); Gain of catalytic residue at E161 (P = 0.3506)
17:44060651:G:C,P10636,E161Q,0.157,Gain of glycosylation at P157 (P = 0.285); Loss of methylation at R164 (P = 0.4016); Gain of MoRF binding (P = 0.5189); Gain of solvent accessibility (P = 0.5485); Gain of sheet (P = 0.6509)
17:44060652:A:C,P10636,E161A,0.143,Loss of loop (P = 0.0288); Loss of solvent accessibility (P = 0.0769); Gain of helix (P = 0.0893); Gain of glycosylation at P163 (P = 0.2076); Gain of methylation at R164 (P = 0.2345)
17:44060652:A:G,P10636,E161G,0.172,Loss of solvent accessibility (P = 0.0387); Gain of sheet (P = 0.0507); Loss of loop (P = 0.0603); Gain of methylation at R164 (P = 0.1531); Gain of glycosylation at P163 (P = 0.1816)
17:44060652:A:T,P10636,E161V,0.229,Loss of solvent accessibility (P = 0.0052); Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at P163 (P = 0.1688); Gain of methylation at R164 (P = 0.3591); Gain of MoRF binding (P = 0.5761)
17:44060653:G:C,P10636,E161D,0.133,Loss of glycosylation at P163 (P = 0.1101); Loss of solvent accessibility (P = 0.1813); Loss of methylation at R164 (P = 0.4164); Loss of relative solvent accessibility (P = 0.5582); Gain of catalytic residue at R164 (P = 0.6616)
17:44060653:G:T,P10636,E161D,0.133,Loss of glycosylation at P163 (P = 0.1101); Loss of solvent accessibility (P = 0.1813); Loss of methylation at R164 (P = 0.4164); Loss of relative solvent accessibility (P = 0.5582); Gain of catalytic residue at R164 (P = 0.6616)
17:44060654:G:A,P10636,G162S,0.277,Gain of phosphorylation at G162 (P = 0.0055); Gain of glycosylation at G162 (P = 0.0514); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2455); Loss of methylation at R164 (P = 0.4077)
17:44060654:G:C,P10636,G162R,0.34,Gain of solvent accessibility (P = 0.0789); Gain of glycosylation at P163 (P = 0.0963); Gain of relative solvent accessibility (P = 0.1571); Gain of methylation at R164 (P = 0.4176); Gain of MoRF binding (P = 0.5636)
17:44060654:G:T,P10636,G162C,0.298,Loss of glycosylation at P163 (P = 0.1986); Gain of catalytic residue at P163 (P = 0.3551); Loss of methylation at R164 (P = 0.4015); Gain of solvent accessibility (P = 0.5093); Loss of stability (P = 0.621)
17:44060655:G:A,P10636,G162D,0.345,Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at T167 (P = 0.188); Gain of solvent accessibility (P = 0.1903); Loss of methylation at R164 (P = 0.3889); Loss of stability (P = 0.5732)
17:44060655:G:C,P10636,G162A,0.327,Gain of glycosylation at P160 (P = 0.2107); Gain of relative solvent accessibility (P = 0.2751); Loss of catalytic residue at L159 (P = 0.4092); Loss of methylation at R164 (P = 0.4176); Gain of solvent accessibility (P = 0.4304)
17:44060655:G:T,P10636,G162V,0.309,Loss of glycosylation at P163 (P = 0.1175); Loss of methylation at R164 (P = 0.3971); Loss of catalytic residue at L159 (P = 0.4936); Gain of solvent accessibility (P = 0.4946); Gain of sheet (P = 0.6509)
17:44060657:C:A,P10636,P163T,0.305,Gain of phosphorylation at P163 (P = 0.007); Gain of glycosylation at P163 (P = 0.0507); Loss of stability (P = 0.379); Loss of catalytic residue at P160 (P = 0.4012); Gain of methylation at R164 (P = 0.409)
17:44060657:C:G,P10636,P163A,0.283,Loss of glycosylation at P163 (P = 0.0458); Gain of methylation at R164 (P = 0.2993); Loss of stability (P = 0.3246); Loss of catalytic residue at P160 (P = 0.4012); Gain of MoRF binding (P = 0.5952)
17:44060657:C:T,P10636,P163S,0.279,Gain of phosphorylation at P163 (P = 0.0051); Gain of glycosylation at P163 (P = 0.0773); Gain of catalytic residue at L159 (P = 0.2825); Gain of methylation at R164 (P = 0.4043); Loss of stability (P = 0.4831)
17:44060658:C:A,P10636,P163H,0.26,Loss of glycosylation at P163 (P = 0.0458); Gain of catalytic residue at P163 (P = 0.2302); Loss of methylation at R164 (P = 0.3988); Loss of stability (P = 0.452); Loss of relative solvent accessibility (P = 0.5582)
17:44060658:C:G,P10636,P163R,0.293,Gain of methylation at P163 (P = 0.0427); Loss of glycosylation at P163 (P = 0.0458); Gain of solvent accessibility (P = 0.2097); Gain of MoRF binding (P = 0.3516); Loss of catalytic residue at P160 (P = 0.4012)
17:44060658:C:T,P10636,P163L,0.294,Loss of glycosylation at P163 (P = 0.0458); Loss of methylation at R164 (P = 0.4192); Gain of stability (P = 0.5508); Loss of relative solvent accessibility (P = 0.5582); Loss of catalytic residue at L159 (P = 0.5631)
17:44060660:A:G,P10636,R164G,0.269,Loss of solvent accessibility (P = 0.0159); Gain of glycosylation at P163 (P = 0.1502); Gain of catalytic residue at G162 (P = 0.1607); Loss of loop (P = 0.2897); Loss of methylation at R164 (P = 0.3124)
17:44060661:G:A,P10636,R164K,0.302,Gain of ubiquitination at R164 (P = 0.0051); Gain of glycosylation at R164 (P = 0.0053); Gain of methylation at R164 (P = 0.0115); Loss of solvent accessibility (P = 0.4218); Loss of sheet (P = 0.6423)
17:44060661:G:C,P10636,R164T,0.27,Gain of glycosylation at R164 (P = 0.0044); Loss of solvent accessibility (P = 0.008); Gain of phosphorylation at R164 (P = 0.0101); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at R164 (P = 0.3124)
17:44060661:G:T,P10636,R164I,0.281,Loss of solvent accessibility (P = 0.01); Loss of glycosylation at P163 (P = 0.1001); Loss of relative solvent accessibility (P = 0.1807); Gain of stability (P = 0.2129); Gain of catalytic residue at E161 (P = 0.2603)
17:44060662:A:C,P10636,R164S,0.236,Gain of phosphorylation at R164 (P = 0.0264); Gain of glycosylation at R164 (P = 0.0308); Loss of solvent accessibility (P = 0.0606); Gain of catalytic residue at G162 (P = 0.2233); Loss of methylation at R164 (P = 0.3124)
17:44060662:A:T,P10636,R164S,0.236,Gain of phosphorylation at R164 (P = 0.0264); Gain of glycosylation at R164 (P = 0.0308); Loss of solvent accessibility (P = 0.0606); Gain of catalytic residue at G162 (P = 0.2233); Loss of methylation at R164 (P = 0.3124)
17:44060663:G:A,P10636,E165K,0.254,Gain of methylation at E165 (P = 0.001); Gain of glycosylation at E165 (P = 0.0098); Gain of ubiquitination at E165 (P = 0.0128); Gain of relative solvent accessibility (P = 0.1684); Gain of solvent accessibility (P = 0.1846)
17:44060663:G:C,P10636,E165Q,0.161,Loss of solvent accessibility (P = 0.1235); Loss of relative solvent accessibility (P = 0.1903); Gain of glycosylation at T167 (P = 0.192); Loss of methylation at R164 (P = 0.4099); Gain of catalytic residue at R164 (P = 0.4744)
17:44060664:A:C,P10636,E165A,0.186,Gain of methylation at R164 (P = 0.0578); Loss of solvent accessibility (P = 0.086); Gain of glycosylation at T167 (P = 0.1098); Loss of relative solvent accessibility (P = 0.3589); Gain of MoRF binding (P = 0.5586)
17:44060664:A:G,P10636,E165G,0.198,Gain of methylation at R164 (P = 0.0335); Loss of solvent accessibility (P = 0.0635); Gain of glycosylation at T167 (P = 0.1106); Loss of stability (P = 0.1418); Gain of catalytic residue at G162 (P = 0.2575)
17:44060664:A:T,P10636,E165V,0.219,Loss of solvent accessibility (P = 0.0509); Gain of methylation at R164 (P = 0.0889); Gain of glycosylation at T167 (P = 0.1061); Loss of relative solvent accessibility (P = 0.114); Gain of catalytic residue at R164 (P = 0.4175)
17:44060665:G:C,P10636,E165D,0.159,Loss of glycosylation at P163 (P = 0.1338); Gain of relative solvent accessibility (P = 0.1684); Gain of methylation at R164 (P = 0.4163); Gain of solvent accessibility (P = 0.4656); Gain of catalytic residue at R164 (P = 0.6017)
17:44060665:G:T,P10636,E165D,0.159,Loss of glycosylation at P163 (P = 0.1338); Gain of relative solvent accessibility (P = 0.1684); Gain of methylation at R164 (P = 0.4163); Gain of solvent accessibility (P = 0.4656); Gain of catalytic residue at R164 (P = 0.6017)
17:44060666:G:A,P10636,A166T,0.146,Gain of phosphorylation at A166 (P = 0.0103); Gain of glycosylation at A166 (P = 0.0128); Gain of relative solvent accessibility (P = 0.2751); Gain of solvent accessibility (P = 0.367); Loss of methylation at R164 (P = 0.422)
17:44060666:G:C,P10636,A166P,0.181,Gain of glycosylation at A166 (P = 0.026); Loss of methylation at R164 (P = 0.4142); Loss of stability (P = 0.4326); Gain of solvent accessibility (P = 0.5485); Gain of phosphorylation at S171 (P = 0.6246)
17:44060666:G:T,P10636,A166S,0.175,Gain of phosphorylation at A166 (P = 0.0023); Gain of glycosylation at A166 (P = 0.1062); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2689); Loss of methylation at R164 (P = 0.4222)
17:44060667:C:A,P10636,A166D,0.169,Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at T167 (P = 0.18); Gain of solvent accessibility (P = 0.199); Loss of methylation at R164 (P = 0.4111); Gain of phosphorylation at S171 (P = 0.6283)
17:44060667:C:G,P10636,A166G,0.18,Loss of stability (P = 0.1442); Loss of glycosylation at T167 (P = 0.1595); Gain of relative solvent accessibility (P = 0.2751); Gain of methylation at R164 (P = 0.389); Gain of solvent accessibility (P = 0.5485)
17:44060667:C:T,P10636,A166V,0.161,Loss of glycosylation at T167 (P = 0.1428); Loss of methylation at R164 (P = 0.4053); Gain of solvent accessibility (P = 0.5334); Loss of phosphorylation at S171 (P = 0.6134); Gain of MoRF binding (P = 0.7468)
17:44060669:A:C,P10636,T167P,0.174,Loss of phosphorylation at T167 (P = 0.0022); Loss of glycosylation at T167 (P = 0.0763); Loss of stability (P = 0.1084); Loss of methylation at R164 (P = 0.4195); Loss of catalytic residue at R168 (P = 0.6493)
17:44060669:A:G,P10636,T167A,0.196,Loss of phosphorylation at T167 (P = 0.0022); Loss of glycosylation at T167 (P = 0.0225); Loss of stability (P = 0.1124); Gain of relative solvent accessibility (P = 0.2363); Gain of methylation at R164 (P = 0.3075)
17:44060669:A:T,P10636,T167S,0.171,Loss of glycosylation at T167 (P = 0.1416); Gain of relative solvent accessibility (P = 0.2363); Loss of stability (P = 0.2554); Gain of solvent accessibility (P = 0.4137); Loss of methylation at R164 (P = 0.4217)
17:44060670:C:A,P10636,T167K,0.265,Loss of phosphorylation at T167 (P = 0.0022); Gain of solvent accessibility (P = 0.0044); Gain of ubiquitination at T167 (P = 0.0066); Gain of methylation at T167 (P = 0.008); Gain of relative solvent accessibility (P = 0.0166)
17:44060670:C:G,P10636,T167R,0.242,Loss of phosphorylation at T167 (P = 0.0022); Gain of solvent accessibility (P = 0.0058); Loss of glycosylation at T167 (P = 0.0225); Gain of relative solvent accessibility (P = 0.0479); Loss of stability (P = 0.3133)
17:44060670:C:T,P10636,T167I,0.206,Loss of phosphorylation at T167 (P = 0.0022); Loss of glycosylation at T167 (P = 0.0225); Gain of methylation at R164 (P = 0.411); Loss of stability (P = 0.5673); Gain of catalytic residue at S171 (P = 0.6451)
17:44060672:C:A,P10636,R168S,0.263,Gain of glycosylation at R168 (P = 0.0186); Gain of phosphorylation at R168 (P = 0.0266); Loss of catalytic residue at R168 (P = 0.0392); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.3418)
17:44060672:C:G,P10636,R168G,0.232,Loss of catalytic residue at R168 (P = 0.0551); Loss of solvent accessibility (P = 0.1744); Loss of glycosylation at T167 (P = 0.2006); Loss of phosphorylation at S171 (P = 0.2722); Loss of stability (P = 0.2833)
17:44060672:C:T,P10636,R168C,0.222,Loss of phosphorylation at S171 (P = 0.0775); Loss of catalytic residue at R168 (P = 0.0837); Gain of glycosylation at T167 (P = 0.112); Loss of solvent accessibility (P = 0.3854); Gain of methylation at R164 (P = 0.4204)
17:44060673:G:A,P10636,R168H,0.221,Loss of phosphorylation at S171 (P = 0.1229); Gain of glycosylation at T167 (P = 0.1315); Loss of catalytic residue at R168 (P = 0.1927); Loss of solvent accessibility (P = 0.3473); Gain of methylation at R164 (P = 0.4024)
17:44060673:G:C,P10636,R168P,0.256,Gain of relative solvent accessibility (P = 0.0479); Gain of glycosylation at T167 (P = 0.1037); Gain of solvent accessibility (P = 0.2987); Loss of stability (P = 0.3368); Loss of phosphorylation at S171 (P = 0.3707)
17:44060673:G:T,P10636,R168L,0.264,Loss of catalytic residue at R168 (P = 0.0761); Loss of phosphorylation at S171 (P = 0.1158); Loss of glycosylation at T167 (P = 0.1536); Loss of solvent accessibility (P = 0.1922); Gain of methylation at R164 (P = 0.3625)
17:44060675:C:A,P10636,Q169K,0.328,Gain of ubiquitination at Q169 (P = 0.0045); Gain of methylation at Q169 (P = 0.0074); Gain of glycosylation at Q169 (P = 0.0251); Gain of catalytic residue at Q169 (P = 0.0441); Gain of relative solvent accessibility (P = 0.2363)
17:44060675:C:G,P10636,Q169E,0.239,Gain of glycosylation at T167 (P = 0.1145); Loss of catalytic residue at R168 (P = 0.2451); Gain of methylation at R164 (P = 0.3954); Gain of phosphorylation at T173 (P = 0.5515); Loss of stability (P = 0.7321)
17:44060676:A:C,P10636,Q169P,0.289,Gain of catalytic residue at Q169 (P = 0.0154); Gain of glycosylation at T167 (P = 0.0814); Gain of methylation at R164 (P = 0.2747); Loss of stability (P = 0.2883); Gain of phosphorylation at T173 (P = 0.5304)
17:44060676:A:G,P10636,Q169R,0.243,Gain of glycosylation at T167 (P = 0.1053); Gain of methylation at R164 (P = 0.3098); Gain of solvent accessibility (P = 0.3819); Gain of catalytic residue at Q169 (P = 0.4409); Gain of phosphorylation at T173 (P = 0.5443)
17:44060676:A:T,P10636,Q169L,0.275,Gain of glycosylation at T167 (P = 0.1741); Gain of methylation at R164 (P = 0.2235); Loss of solvent accessibility (P = 0.322); Gain of catalytic residue at T173 (P = 0.4502); Loss of phosphorylation at T173 (P = 0.4574)
17:44060677:A:C,P10636,Q169H,0.251,Gain of glycosylation at T167 (P = 0.0683); Gain of methylation at R164 (P = 0.2738); Loss of solvent accessibility (P = 0.3543); Loss of stability (P = 0.3575); Loss of relative solvent accessibility (P = 0.5582)
17:44060677:A:T,P10636,Q169H,0.251,Gain of glycosylation at T167 (P = 0.0683); Gain of methylation at R164 (P = 0.2738); Loss of solvent accessibility (P = 0.3543); Loss of stability (P = 0.3575); Loss of relative solvent accessibility (P = 0.5582)
17:44060678:C:A,P10636,P170T,0.327,Gain of phosphorylation at P170 (P = 0.0165); Gain of glycosylation at P170 (P = 0.0468); Loss of catalytic residue at P170 (P = 0.0688); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1235)
17:44060678:C:G,P10636,P170A,0.342,Loss of solvent accessibility (P = 0.089); Loss of glycosylation at T167 (P = 0.0914); Loss of relative solvent accessibility (P = 0.0981); Loss of catalytic residue at P170 (P = 0.113); Loss of phosphorylation at T173 (P = 0.4875)
17:44060678:C:T,P10636,P170S,0.337,Gain of phosphorylation at P170 (P = 0.0063); Loss of catalytic residue at P170 (P = 0.0648); Loss of glycosylation at T167 (P = 0.0692); Loss of solvent accessibility (P = 0.1744); Loss of relative solvent accessibility (P = 0.1807)
17:44060679:C:A,P10636,P170H,0.31,Loss of glycosylation at T167 (P = 0.0777); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.3103); Loss of phosphorylation at T173 (P = 0.3392); Gain of catalytic residue at T173 (P = 0.4412)
17:44060679:C:G,P10636,P170R,0.352,Loss of glycosylation at T167 (P = 0.0517); Loss of relative solvent accessibility (P = 0.1807); Loss of catalytic residue at P170 (P = 0.2237); Gain of MoRF binding (P = 0.3802); Gain of methylation at P170 (P = 0.4929)
17:44060679:C:T,P10636,P170L,0.366,Loss of glycosylation at T167 (P = 0.0519); Loss of catalytic residue at P170 (P = 0.088); Loss of phosphorylation at T173 (P = 0.1001); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2517)
17:44060681:T:A,P10636,S171T,0.2,Loss of loop (P = 0.0288); Loss of glycosylation at S171 (P = 0.0293); Gain of helix (P = 0.0893); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2097)
17:44060681:T:C,P10636,S171P,0.164,Loss of phosphorylation at S171 (P = 0.0096); Loss of glycosylation at S171 (P = 0.0297); Loss of loop (P = 0.0603); Gain of helix (P = 0.0893); Gain of relative solvent accessibility (P = 0.1571)
17:44060681:T:G,P10636,S171A,0.152,Loss of glycosylation at S171 (P = 0.0017); Loss of phosphorylation at S171 (P = 0.0096); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at S171 (P = 0.1031); Loss of solvent accessibility (P = 0.1144)
17:44060682:C:G,P10636,S171W,0.215,Loss of glycosylation at S171 (P = 0.0017); Loss of phosphorylation at S171 (P = 0.0096); Gain of catalytic residue at S171 (P = 0.0513); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1322)
17:44060682:C:T,P10636,S171L,0.204,Loss of glycosylation at S171 (P = 0.0017); Loss of phosphorylation at S171 (P = 0.0096); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1551); Gain of stability (P = 0.1894)
17:44060684:G:A,P10636,G172R,0.203,Loss of glycosylation at S171 (P = 0.1299); Gain of solvent accessibility (P = 0.1319); Loss of catalytic residue at T173 (P = 0.2141); Gain of MoRF binding (P = 0.3867); Gain of phosphorylation at T173 (P = 0.5324)
17:44060684:G:C,P10636,G172R,0.203,Loss of glycosylation at S171 (P = 0.1299); Gain of solvent accessibility (P = 0.1319); Loss of catalytic residue at T173 (P = 0.2141); Gain of MoRF binding (P = 0.3867); Gain of phosphorylation at T173 (P = 0.5324)
17:44060684:G:T,P10636,G172W,0.231,Loss of glycosylation at S171 (P = 0.0149); Gain of catalytic residue at P175 (P = 0.0311); Loss of phosphorylation at T173 (P = 0.2008); Gain of solvent accessibility (P = 0.3304); Gain of MoRF binding (P = 0.5974)
17:44060685:G:A,P10636,G172E,0.172,Loss of glycosylation at S171 (P = 0.0615); Loss of catalytic residue at T173 (P = 0.2106); Gain of solvent accessibility (P = 0.2192); Gain of phosphorylation at T173 (P = 0.5591); Loss of methylation at R168 (P = 0.609)
17:44060685:G:C,P10636,G172A,0.156,Gain of glycosylation at T173 (P = 0.1106); Loss of catalytic residue at T173 (P = 0.2594); Loss of stability (P = 0.4899); Loss of phosphorylation at T173 (P = 0.5679); Loss of methylation at R168 (P = 0.6113)
17:44060685:G:T,P10636,G172V,0.177,Loss of glycosylation at S171 (P = 0.0853); Gain of catalytic residue at G172 (P = 0.2136); Loss of phosphorylation at T173 (P = 0.4825); Gain of solvent accessibility (P = 0.571); Loss of methylation at R168 (P = 0.6108)
17:44060687:A:C,P10636,T173P,0.256,Loss of phosphorylation at T173 (P = 0.013); Gain of relative solvent accessibility (P = 0.0275); Gain of glycosylation at T173 (P = 0.0758); Gain of solvent accessibility (P = 0.08); Loss of catalytic residue at T173 (P = 0.2182)
17:44060687:A:G,P10636,T173A,0.207,Loss of phosphorylation at T173 (P = 0.013); Loss of glycosylation at T173 (P = 0.0779); Gain of catalytic residue at T173 (P = 0.2725); Loss of solvent accessibility (P = 0.4653); Loss of stability (P = 0.5551)
17:44060687:A:T,P10636,T173S,0.259,Gain of glycosylation at T173 (P = 0.0188); Loss of catalytic residue at T173 (P = 0.2171); Gain of phosphorylation at T173 (P = 0.5393); Gain of methylation at R168 (P = 0.6019); Loss of stability (P = 0.7291)
17:44060688:C:A,P10636,T173K,0.313,Gain of ubiquitination at T173 (P = 0.0048); Gain of solvent accessibility (P = 0.007); Loss of phosphorylation at T173 (P = 0.013); Gain of methylation at T173 (P = 0.015); Gain of relative solvent accessibility (P = 0.0275)
17:44060688:C:G,P10636,T173R,0.259,Loss of phosphorylation at T173 (P = 0.013); Gain of methylation at T173 (P = 0.0602); Loss of glycosylation at T173 (P = 0.0779); Gain of catalytic residue at T173 (P = 0.254); Gain of solvent accessibility (P = 0.3819)
17:44060688:C:T,P10636,T173I,0.247,Loss of phosphorylation at T173 (P = 0.013); Gain of catalytic residue at P175 (P = 0.0379); Loss of glycosylation at T173 (P = 0.0779); Loss of relative solvent accessibility (P = 0.3919); Loss of solvent accessibility (P = 0.4995)
17:44060690:G:A,P10636,G174R,0.177,Loss of catalytic residue at P170 (P = 0.0914); Gain of glycosylation at T173 (P = 0.1166); Gain of solvent accessibility (P = 0.1319); Gain of methylation at G174 (P = 0.5245); Gain of phosphorylation at T173 (P = 0.5294)
17:44060690:G:C,P10636,G174R,0.177,Loss of catalytic residue at P170 (P = 0.0914); Gain of glycosylation at T173 (P = 0.1166); Gain of solvent accessibility (P = 0.1319); Gain of methylation at G174 (P = 0.5245); Gain of phosphorylation at T173 (P = 0.5294)
17:44060691:G:A,P10636,G174E,0.166,Loss of catalytic residue at P170 (P = 0.0914); Gain of glycosylation at T173 (P = 0.1516); Gain of solvent accessibility (P = 0.2192); Gain of phosphorylation at T173 (P = 0.5577); Loss of stability (P = 0.6783)
17:44060691:G:C,P10636,G174A,0.167,Gain of glycosylation at T173 (P = 0.0828); Loss of catalytic residue at P170 (P = 0.0914); Loss of stability (P = 0.5075); Loss of phosphorylation at T173 (P = 0.5659); Gain of MoRF binding (P = 0.7502)
17:44060691:G:T,P10636,G174V,0.191,Gain of glycosylation at T173 (P = 0.0547); Loss of catalytic residue at P170 (P = 0.0914); Loss of phosphorylation at T173 (P = 0.4767); Loss of relative solvent accessibility (P = 0.5582); Gain of sheet (P = 0.6509)
17:44060693:C:A,P10636,P175T,0.204,Gain of phosphorylation at P175 (P = 0.0269); Gain of glycosylation at P175 (P = 0.1588); Gain of catalytic residue at P175 (P = 0.2448); Gain of MoRF binding (P = 0.6874); Loss of solvent accessibility (P = 0.7225)
17:44060693:C:G,P10636,P175A,0.176,Loss of glycosylation at T178 (P = 0.2681); Loss of catalytic residue at G174 (P = 0.312); Loss of phosphorylation at T173 (P = 0.5015); Loss of solvent accessibility (P = 0.6134); Loss of stability (P = 0.6672)
17:44060693:C:T,P10636,P175S,0.195,Gain of phosphorylation at P175 (P = 0.0157); Gain of glycosylation at P175 (P = 0.0701); Loss of catalytic residue at G174 (P = 0.3257); Gain of MoRF binding (P = 0.667); Loss of stability (P = 0.7314)
17:44060694:C:A,P10636,P175H,0.179,Gain of catalytic residue at P175 (P = 0.0767); Gain of glycosylation at T173 (P = 0.188); Gain of solvent accessibility (P = 0.3819); Loss of phosphorylation at T173 (P = 0.4178); Gain of MoRF binding (P = 0.6723)
17:44060694:C:G,P10636,P175R,0.227,Gain of methylation at P175 (P = 0.1613); Gain of MoRF binding (P = 0.1978); Gain of solvent accessibility (P = 0.2097); Loss of catalytic residue at G174 (P = 0.2151); Loss of glycosylation at T178 (P = 0.2479)
17:44060694:C:T,P10636,P175L,0.201,Gain of catalytic residue at P175 (P = 0.1382); Loss of phosphorylation at T173 (P = 0.214); Loss of glycosylation at T173 (P = 0.2458); Gain of MoRF binding (P = 0.7147); Gain of stability (P = 0.7826)
17:44060696:G:A,P10636,E176K,0.237,Gain of ubiquitination at E176 (P = 0.0022); Gain of glycosylation at E176 (P = 0.0062); Gain of methylation at E176 (P = 0.0139); Gain of MoRF binding (P = 0.3775); Loss of catalytic residue at G174 (P = 0.4081)
17:44060696:G:C,P10636,E176Q,0.175,Gain of glycosylation at T173 (P = 0.1454); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.1846); Loss of catalytic residue at E176 (P = 0.2886); Loss of phosphorylation at T173 (P = 0.4875)
17:44060697:A:C,P10636,E176A,0.21,Loss of solvent accessibility (P = 0.0159); Gain of glycosylation at T173 (P = 0.061); Loss of relative solvent accessibility (P = 0.0981); Loss of catalytic residue at E176 (P = 0.2946); Loss of phosphorylation at T173 (P = 0.4255)
17:44060697:A:G,P10636,E176G,0.213,Loss of solvent accessibility (P = 0.0187); Gain of glycosylation at T178 (P = 0.1668); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at E179 (P = 0.2374); Loss of stability (P = 0.2427)
17:44060697:A:T,P10636,E176V,0.238,Loss of solvent accessibility (P = 0.0431); Gain of glycosylation at T173 (P = 0.0617); Gain of catalytic residue at E179 (P = 0.1002); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at T173 (P = 0.3093)
17:44060698:G:C,P10636,E176D,0.184,Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at G174 (P = 0.2791); Loss of glycosylation at T178 (P = 0.3147); Gain of solvent accessibility (P = 0.4946); Gain of phosphorylation at T173 (P = 0.5437)
17:44060698:G:T,P10636,E176D,0.184,Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at G174 (P = 0.2791); Loss of glycosylation at T178 (P = 0.3147); Gain of solvent accessibility (P = 0.4946); Gain of phosphorylation at T173 (P = 0.5437)
17:44060699:G:A,P10636,D177N,0.179,Loss of solvent accessibility (P = 0.1202); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at T178 (P = 0.2384); Gain of catalytic residue at D177 (P = 0.2746); Gain of methylation at R182 (P = 0.4144)
17:44060699:G:C,P10636,D177H,0.165,Gain of catalytic residue at D177 (P = 0.1426); Loss of solvent accessibility (P = 0.1473); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T178 (P = 0.3421); Gain of methylation at R182 (P = 0.3673)
17:44060699:G:T,P10636,D177Y,0.203,Gain of phosphorylation at D177 (P = 0.0054); Loss of solvent accessibility (P = 0.0509); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at P175 (P = 0.3055); Gain of catalytic residue at T173 (P = 0.3072)
17:44060700:A:C,P10636,D177A,0.173,Loss of solvent accessibility (P = 0.0435); Gain of glycosylation at T178 (P = 0.0854); Loss of relative solvent accessibility (P = 0.0981); Gain of methylation at R182 (P = 0.339); Gain of catalytic residue at E176 (P = 0.4352)
17:44060700:A:G,P10636,D177G,0.187,Loss of solvent accessibility (P = 0.0674); Gain of catalytic residue at D177 (P = 0.0909); Gain of glycosylation at T178 (P = 0.1821); Loss of stability (P = 0.2497); Loss of relative solvent accessibility (P = 0.3219)
17:44060700:A:T,P10636,D177V,0.185,Loss of solvent accessibility (P = 0.0544); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at T178 (P = 0.144); Gain of catalytic residue at E176 (P = 0.3132); Gain of methylation at R182 (P = 0.3623)
17:44060701:C:A,P10636,D177E,0.123,Gain of glycosylation at P175 (P = 0.1708); Gain of catalytic residue at T178 (P = 0.4643); Gain of methylation at R182 (P = 0.501); Gain of phosphorylation at T173 (P = 0.5701); Loss of relative solvent accessibility (P = 0.5898)
17:44060701:C:G,P10636,D177E,0.123,Gain of glycosylation at P175 (P = 0.1708); Gain of catalytic residue at T178 (P = 0.4643); Gain of methylation at R182 (P = 0.501); Gain of phosphorylation at T173 (P = 0.5701); Loss of relative solvent accessibility (P = 0.5898)
17:44060702:A:C,P10636,T178P,0.198,Loss of phosphorylation at T178 (P = 0.0075); Loss of glycosylation at T178 (P = 0.1765); Loss of stability (P = 0.4265); Loss of methylation at R182 (P = 0.5169); Loss of catalytic residue at E176 (P = 0.6104)
17:44060702:A:G,P10636,T178A,0.2,Loss of phosphorylation at T178 (P = 0.0075); Loss of glycosylation at T178 (P = 0.0893); Gain of catalytic residue at T173 (P = 0.4465); Gain of methylation at R182 (P = 0.4946); Loss of sheet (P = 0.6423)
17:44060702:A:T,P10636,T178S,0.201,Gain of glycosylation at T178 (P = 0.2262); Loss of phosphorylation at T178 (P = 0.3674); Loss of methylation at R182 (P = 0.5182); Loss of sheet (P = 0.6423); Loss of solvent accessibility (P = 0.6498)
17:44060703:C:A,P10636,T178K,0.322,Gain of ubiquitination at T178 (P = 0.0011); Loss of phosphorylation at T178 (P = 0.0075); Gain of methylation at T178 (P = 0.0393); Gain of glycosylation at T178 (P = 0.0779); Gain of solvent accessibility (P = 0.3418)
17:44060703:C:G,P10636,T178R,0.264,Loss of phosphorylation at T178 (P = 0.0075); Loss of glycosylation at T178 (P = 0.0893); Gain of solvent accessibility (P = 0.2291); Gain of methylation at T178 (P = 0.326); Loss of catalytic residue at E176 (P = 0.363)
17:44060703:C:T,P10636,T178I,0.232,Loss of phosphorylation at T178 (P = 0.0075); Loss of glycosylation at T178 (P = 0.0893); Gain of catalytic residue at T178 (P = 0.1221); Loss of methylation at R182 (P = 0.5153); Loss of solvent accessibility (P = 0.5485)
17:44060705:G:A,P10636,E179K,0.31,Gain of ubiquitination at E179 (P = 0.0029); Gain of glycosylation at E179 (P = 0.0068); Gain of methylation at E179 (P = 0.0421); Gain of solvent accessibility (P = 0.0739); Gain of relative solvent accessibility (P = 0.09)
17:44060705:G:C,P10636,E179Q,0.202,Gain of glycosylation at T178 (P = 0.2986); Loss of methylation at R182 (P = 0.5131); Gain of MoRF binding (P = 0.5185); Gain of catalytic residue at G174 (P = 0.5734); Gain of solvent accessibility (P = 0.5843)
17:44060706:A:C,P10636,E179A,0.226,Loss of solvent accessibility (P = 0.2106); Gain of catalytic residue at E179 (P = 0.2339); Gain of glycosylation at T178 (P = 0.3428); Gain of methylation at R182 (P = 0.3849); Gain of MoRF binding (P = 0.5706)
17:44060706:A:G,P10636,E179G,0.275,Gain of catalytic residue at P175 (P = 0.0776); Loss of solvent accessibility (P = 0.1868); Loss of stability (P = 0.1899); Loss of glycosylation at T178 (P = 0.3028); Gain of methylation at R182 (P = 0.3345)
17:44060706:A:T,P10636,E179V,0.236,Gain of glycosylation at T178 (P = 0.2964); Gain of catalytic residue at E176 (P = 0.334); Loss of solvent accessibility (P = 0.3368); Gain of methylation at R182 (P = 0.4652); Gain of MoRF binding (P = 0.5661)
17:44060707:G:C,P10636,E179D,0.209,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.199); Loss of glycosylation at T178 (P = 0.3008); Gain of catalytic residue at G174 (P = 0.5078); Loss of methylation at R182 (P = 0.517)
17:44060707:G:T,P10636,E179D,0.209,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.199); Loss of glycosylation at T178 (P = 0.3008); Gain of catalytic residue at G174 (P = 0.5078); Loss of methylation at R182 (P = 0.517)
17:44060708:G:A,P10636,G180S,0.192,Gain of phosphorylation at G180 (P = 0.0115); Gain of glycosylation at G180 (P = 0.0304); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2987); Gain of catalytic residue at R182 (P = 0.3362)
17:44060708:G:C,P10636,G180R,0.222,Gain of solvent accessibility (P = 0.0971); Gain of methylation at G180 (P = 0.0975); Gain of catalytic residue at G180 (P = 0.1531); Gain of relative solvent accessibility (P = 0.2629); Loss of glycosylation at T178 (P = 0.3051)
17:44060708:G:T,P10636,G180C,0.179,Loss of glycosylation at T178 (P = 0.1432); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2902); Loss of methylation at R182 (P = 0.5106); Loss of phosphorylation at T178 (P = 0.6165)
17:44060709:G:A,P10636,G180D,0.21,Gain of solvent accessibility (P = 0.2291); Gain of relative solvent accessibility (P = 0.2629); Loss of glycosylation at T178 (P = 0.3338); Loss of methylation at R182 (P = 0.503); Loss of catalytic residue at R182 (P = 0.6243)
17:44060709:G:C,P10636,G180A,0.177,Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.3819); Loss of glycosylation at T178 (P = 0.3836); Loss of methylation at R182 (P = 0.5161); Loss of catalytic residue at H183 (P = 0.6004)
17:44060709:G:T,P10636,G180V,0.174,Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.28); Gain of glycosylation at T178 (P = 0.3826); Gain of catalytic residue at E176 (P = 0.4231); Loss of methylation at R182 (P = 0.509)
17:44060711:G:A,P10636,G181S,0.176,Gain of phosphorylation at G181 (P = 0.0146); Gain of glycosylation at G181 (P = 0.0648); Loss of relative solvent accessibility (P = 0.0981); Loss of stability (P = 0.3729); Loss of solvent accessibility (P = 0.3854)
17:44060711:G:C,P10636,G181R,0.219,Gain of catalytic residue at G181 (P = 0.0427); Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at T178 (P = 0.2145); Gain of MoRF binding (P = 0.4598); Gain of methylation at G181 (P = 0.49)
17:44060711:G:T,P10636,G181C,0.166,Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at H183 (P = 0.3063); Loss of glycosylation at T178 (P = 0.3503); Loss of solvent accessibility (P = 0.4011); Loss of methylation at R182 (P = 0.5024)
17:44060712:G:C,P10636,G181A,0.186,Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at T178 (P = 0.1109); Loss of stability (P = 0.3319); Loss of solvent accessibility (P = 0.3368); Loss of methylation at R182 (P = 0.508)
17:44060712:G:T,P10636,G181V,0.213,Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at T178 (P = 0.1901); Gain of catalytic residue at G181 (P = 0.3688); Loss of solvent accessibility (P = 0.4141); Loss of methylation at R182 (P = 0.5024)
17:44060714:C:A,P10636,R182S,0.215,Gain of phosphorylation at R182 (P = 0.0233); Gain of relative solvent accessibility (P = 0.0249); Gain of glycosylation at R182 (P = 0.043); Gain of solvent accessibility (P = 0.154); Gain of catalytic residue at G180 (P = 0.2188)
17:44060714:C:G,P10636,R182G,0.207,Gain of relative solvent accessibility (P = 0.0249); Loss of stability (P = 0.1348); Gain of catalytic residue at G180 (P = 0.1686); Gain of glycosylation at T178 (P = 0.2497); Gain of solvent accessibility (P = 0.4304)
17:44060714:C:T,P10636,R182C,0.164,Gain of catalytic residue at E179 (P = 0.1959); Gain of glycosylation at T178 (P = 0.2394); Gain of relative solvent accessibility (P = 0.2629); Loss of methylation at R182 (P = 0.483); Loss of MoRF binding (P = 0.5827)
17:44060715:G:C,P10636,R182P,0.195,Gain of relative solvent accessibility (P = 0.0249); Gain of glycosylation at R182 (P = 0.1219); Gain of solvent accessibility (P = 0.1376); Gain of catalytic residue at G181 (P = 0.2364); Loss of stability (P = 0.4026)
17:44060715:G:T,P10636,R182L,0.217,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0674); Gain of catalytic residue at R182 (P = 0.1235); Gain of glycosylation at T178 (P = 0.1865); Loss of methylation at R182 (P = 0.483)
17:44060717:C:A,P10636,H183N,0.277,Gain of relative solvent accessibility (P = 0.1066); Gain of solvent accessibility (P = 0.2455); Gain of glycosylation at T178 (P = 0.3181); Gain of catalytic residue at H183 (P = 0.3251); Gain of methylation at R182 (P = 0.431)
17:44060717:C:G,P10636,H183D,0.279,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0411); Loss of catalytic residue at H183 (P = 0.3769); Gain of glycosylation at T178 (P = 0.4063); Gain of methylation at R182 (P = 0.5175)
17:44060717:C:T,P10636,H183Y,0.268,Gain of phosphorylation at H183 (P = 0.0178); Loss of glycosylation at T178 (P = 0.3571); Gain of methylation at R182 (P = 0.4067); Gain of MoRF binding (P = 0.6027); Gain of sheet (P = 0.6509)
17:44060718:A:C,P10636,H183P,0.269,Gain of glycosylation at H183 (P = 0.089); Gain of relative solvent accessibility (P = 0.1066); Gain of solvent accessibility (P = 0.3194); Gain of methylation at R182 (P = 0.4015); Loss of catalytic residue at H183 (P = 0.5125)
17:44060718:A:G,P10636,H183R,0.276,Gain of solvent accessibility (P = 0.0704); Gain of relative solvent accessibility (P = 0.1066); Gain of MoRF binding (P = 0.3222); Loss of glycosylation at T178 (P = 0.3779); Gain of methylation at R182 (P = 0.5148)
17:44060718:A:T,P10636,H183L,0.287,Gain of stability (P = 0.1727); Loss of glycosylation at T178 (P = 0.3281); Gain of methylation at R182 (P = 0.4061); Loss of catalytic residue at H183 (P = 0.5434); Gain of MoRF binding (P = 0.5962)
17:44060719:C:A,P10636,H183Q,0.237,Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2987); Loss of glycosylation at T178 (P = 0.345); Loss of methylation at R182 (P = 0.5151); Loss of catalytic residue at H183 (P = 0.5324)
17:44060719:C:G,P10636,H183Q,0.237,Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2987); Loss of glycosylation at T178 (P = 0.345); Loss of methylation at R182 (P = 0.5151); Loss of catalytic residue at H183 (P = 0.5324)
17:44060720:G:A,P10636,A184T,0.156,Gain of phosphorylation at A184 (P = 0.0111); Gain of methylation at K189 (P = 0.1037); Loss of glycosylation at K189 (P = 0.1968); Gain of ubiquitination at K189 (P = 0.3023); Gain of catalytic residue at A184 (P = 0.41)
17:44060720:G:C,P10636,A184P,0.269,Gain of catalytic residue at A184 (P = 0.0061); Gain of methylation at K189 (P = 0.0951); Gain of glycosylation at A184 (P = 0.1018); Gain of ubiquitination at K189 (P = 0.2865); Gain of solvent accessibility (P = 0.5485)
17:44060721:C:A,P10636,A184D,0.172,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1045); Loss of methylation at K189 (P = 0.1239); Loss of glycosylation at K189 (P = 0.1666); Gain of ubiquitination at K189 (P = 0.2923)
17:44060721:C:G,P10636,A184G,0.15,Gain of methylation at K189 (P = 0.1333); Gain of relative solvent accessibility (P = 0.1571); Gain of catalytic residue at A184 (P = 0.2235); Loss of stability (P = 0.2379); Gain of glycosylation at K189 (P = 0.2517)
17:44060721:C:T,P10636,A184V,0.128,Gain of methylation at K189 (P = 0.1016); Loss of glycosylation at K189 (P = 0.2098); Loss of ubiquitination at K189 (P = 0.2184); Gain of solvent accessibility (P = 0.5334); Gain of MoRF binding (P = 0.5813)
17:44060723:C:A,P10636,P185T,0.244,Gain of phosphorylation at P185 (P = 0.0514); Gain of methylation at K189 (P = 0.1631); Loss of ubiquitination at K189 (P = 0.2604); Loss of glycosylation at K189 (P = 0.2607); Loss of relative solvent accessibility (P = 0.3219)
17:44060723:C:G,P10636,P185A,0.229,Loss of methylation at K189 (P = 0.1089); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at K189 (P = 0.2629); Loss of ubiquitination at K189 (P = 0.2943)
17:44060723:C:T,P10636,P185S,0.225,Gain of phosphorylation at P185 (P = 0.0203); Loss of methylation at K189 (P = 0.1403); Loss of glycosylation at K189 (P = 0.2091); Loss of ubiquitination at K189 (P = 0.2604); Gain of MoRF binding (P = 0.4119)
17:44060724:C:A,P10636,P185H,0.23,Gain of catalytic residue at L187 (P = 0.1516); Loss of methylation at K189 (P = 0.1685); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at K189 (P = 0.2239); Loss of ubiquitination at K189 (P = 0.2604)
17:44060724:C:G,P10636,P185R,0.233,Gain of MoRF binding (P = 0.0564); Loss of methylation at K189 (P = 0.1026); Loss of relative solvent accessibility (P = 0.1807); Loss of ubiquitination at K189 (P = 0.1882); Loss of glycosylation at K189 (P = 0.2505)
17:44060724:C:T,P10636,P185L,0.288,Gain of catalytic residue at P185 (P = 0.0459); Loss of methylation at K189 (P = 0.0821); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at K189 (P = 0.1956); Loss of solvent accessibility (P = 0.2517)
17:44060726:G:A,P10636,E186K,0.257,Gain of ubiquitination at E186 (P = 0.0101); Gain of glycosylation at E186 (P = 0.0164); Gain of methylation at E186 (P = 0.0245); Gain of MoRF binding (P = 0.053); Loss of solvent accessibility (P = 0.4838)
17:44060726:G:C,P10636,E186Q,0.169,Gain of methylation at K189 (P = 0.0795); Gain of glycosylation at K189 (P = 0.2518); Loss of ubiquitination at K189 (P = 0.2943); Gain of MoRF binding (P = 0.3205); Loss of solvent accessibility (P = 0.4141)
17:44060727:A:C,P10636,E186A,0.194,Loss of solvent accessibility (P = 0.0404); Loss of methylation at K189 (P = 0.1851); Loss of glycosylation at K189 (P = 0.2628); Loss of ubiquitination at K189 (P = 0.2943); Gain of MoRF binding (P = 0.4108)
17:44060727:A:G,P10636,E186G,0.195,Loss of solvent accessibility (P = 0.0062); Loss of relative solvent accessibility (P = 0.107); Gain of methylation at K189 (P = 0.1473); Gain of catalytic residue at L187 (P = 0.1853); Gain of glycosylation at K189 (P = 0.2339)
17:44060727:A:T,P10636,E186V,0.308,Loss of solvent accessibility (P = 0.0052); Loss of relative solvent accessibility (P = 0.0404); Gain of methylation at K189 (P = 0.1072); Loss of glycosylation at K189 (P = 0.1469); Loss of ubiquitination at K189 (P = 0.2943)
17:44060728:G:C,P10636,E186D,0.127,Loss of methylation at K189 (P = 0.1235); Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at K189 (P = 0.2456); Gain of ubiquitination at K189 (P = 0.3023); Gain of catalytic residue at R182 (P = 0.5)
17:44060728:G:T,P10636,E186D,0.127,Loss of methylation at K189 (P = 0.1235); Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at K189 (P = 0.2456); Gain of ubiquitination at K189 (P = 0.3023); Gain of catalytic residue at R182 (P = 0.5)
17:44060729:C:A,P10636,L187M,0.21,Gain of methylation at K189 (P = 0.0713); Gain of glycosylation at K189 (P = 0.2467); Gain of ubiquitination at K189 (P = 0.2806); Loss of stability (P = 0.3001); Gain of MoRF binding (P = 0.4793)
17:44060729:C:G,P10636,L187V,0.169,Gain of methylation at K189 (P = 0.0562); Loss of stability (P = 0.1896); Loss of glycosylation at K189 (P = 0.2252); Gain of ubiquitination at K189 (P = 0.3023); Loss of solvent accessibility (P = 0.4141)
17:44060730:T:A,P10636,L187Q,0.234,Loss of stability (P = 0.0328); Gain of solvent accessibility (P = 0.0837); Gain of relative solvent accessibility (P = 0.0999); Gain of methylation at K189 (P = 0.1185); Loss of glycosylation at K189 (P = 0.1972)
17:44060730:T:C,P10636,L187P,0.266,Loss of stability (P = 0.0135); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at K189 (P = 0.0672); Gain of solvent accessibility (P = 0.1376); Gain of glycosylation at L187 (P = 0.1516)
17:44060730:T:G,P10636,L187R,0.271,Loss of stability (P = 0.0282); Gain of solvent accessibility (P = 0.1071); Loss of glycosylation at K189 (P = 0.1123); Gain of MoRF binding (P = 0.1204); Loss of methylation at K189 (P = 0.1236)
17:44060732:C:A,P10636,L188I,0.189,Gain of catalytic residue at L193 (P = 0.0245); Gain of methylation at K189 (P = 0.0405); Gain of glycosylation at K189 (P = 0.2631); Loss of ubiquitination at K189 (P = 0.3072); Gain of MoRF binding (P = 0.533)
17:44060732:C:G,P10636,L188V,0.153,Gain of methylation at K189 (P = 0.0304); Loss of glycosylation at K189 (P = 0.2236); Gain of ubiquitination at K189 (P = 0.3023); Loss of stability (P = 0.4663); Gain of MoRF binding (P = 0.5068)
17:44060732:C:T,P10636,L188F,0.163,Gain of methylation at K189 (P = 0.026); Loss of glycosylation at K189 (P = 0.2779); Gain of ubiquitination at K189 (P = 0.2865); Loss of stability (P = 0.3252); Loss of MoRF binding (P = 0.5785)
17:44060733:T:A,P10636,L188H,0.192,Loss of stability (P = 0.061); Gain of methylation at K189 (P = 0.1056); Gain of glycosylation at K189 (P = 0.1906); Gain of catalytic residue at L187 (P = 0.1966); Gain of ubiquitination at K189 (P = 0.297)
17:44060733:T:C,P10636,L188P,0.206,Loss of stability (P = 0.0472); Gain of methylation at K189 (P = 0.0732); Gain of glycosylation at L188 (P = 0.0997); Gain of relative solvent accessibility (P = 0.2363); Gain of ubiquitination at K189 (P = 0.2389)
17:44060733:T:G,P10636,L188R,0.212,Loss of stability (P = 0.1069); Gain of solvent accessibility (P = 0.1071); Loss of glycosylation at K189 (P = 0.1584); Gain of methylation at K189 (P = 0.1804); Gain of MoRF binding (P = 0.2089)
17:44060735:A:C,P10636,K189Q,0.257,Loss of ubiquitination at K189 (P = 0.0056); Loss of glycosylation at K189 (P = 0.0209); Loss of methylation at K189 (P = 0.0332); Gain of relative solvent accessibility (P = 0.0522); Gain of solvent accessibility (P = 0.0789)
17:44060735:A:G,P10636,K189E,0.263,Loss of ubiquitination at K189 (P = 0.0056); Loss of glycosylation at K189 (P = 0.0209); Loss of methylation at K189 (P = 0.0332); Gain of relative solvent accessibility (P = 0.1684); Gain of solvent accessibility (P = 0.2863)
17:44060736:A:C,P10636,K189T,0.273,Loss of ubiquitination at K189 (P = 0.0056); Loss of glycosylation at K189 (P = 0.0286); Loss of methylation at K189 (P = 0.0332); Loss of solvent accessibility (P = 0.1144); Loss of stability (P = 0.2535)
17:44060736:A:G,P10636,K189R,0.274,Loss of ubiquitination at K189 (P = 0.0056); Loss of glycosylation at K189 (P = 0.0209); Loss of methylation at K189 (P = 0.0397); Gain of MoRF binding (P = 0.4911); Loss of sheet (P = 0.6423)
17:44060736:A:T,P10636,K189M,0.314,Loss of ubiquitination at K189 (P = 0.0056); Loss of glycosylation at K189 (P = 0.0209); Loss of methylation at K189 (P = 0.0332); Loss of solvent accessibility (P = 0.0477); Loss of relative solvent accessibility (P = 0.114)
17:44060737:G:C,P10636,K189N,0.259,Loss of ubiquitination at K189 (P = 0.0056); Loss of glycosylation at K189 (P = 0.0209); Loss of methylation at K189 (P = 0.0332); Loss of solvent accessibility (P = 0.1301); Gain of catalytic residue at H190 (P = 0.232)
17:44060737:G:T,P10636,K189N,0.259,Loss of ubiquitination at K189 (P = 0.0056); Loss of glycosylation at K189 (P = 0.0209); Loss of methylation at K189 (P = 0.0332); Loss of solvent accessibility (P = 0.1301); Gain of catalytic residue at H190 (P = 0.232)
17:44060738:C:A,P10636,H190N,0.173,Gain of relative solvent accessibility (P = 0.1066); Loss of catalytic residue at L192 (P = 0.1082); Loss of methylation at K189 (P = 0.156); Loss of glycosylation at K189 (P = 0.16); Gain of solvent accessibility (P = 0.2455)
17:44060738:C:G,P10636,H190D,0.2,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0411); Loss of methylation at K189 (P = 0.0906); Loss of catalytic residue at L192 (P = 0.1062); Loss of glycosylation at K189 (P = 0.242)
17:44060738:C:T,P10636,H190Y,0.188,Gain of phosphorylation at H190 (P = 0.0336); Loss of catalytic residue at L192 (P = 0.1014); Loss of methylation at K189 (P = 0.1129); Loss of glycosylation at K189 (P = 0.1245); Loss of ubiquitination at K189 (P = 0.2943)
17:44060739:A:C,P10636,H190P,0.191,Gain of catalytic residue at H190 (P = 0.0554); Gain of methylation at K189 (P = 0.1686); Gain of glycosylation at K189 (P = 0.2542); Gain of ubiquitination at K189 (P = 0.3071); Loss of stability (P = 0.3575)
17:44060739:A:G,P10636,H190R,0.21,Loss of catalytic residue at L192 (P = 0.0867); Gain of MoRF binding (P = 0.0983); Gain of methylation at K189 (P = 0.1085); Gain of glycosylation at K189 (P = 0.2229); Loss of ubiquitination at K189 (P = 0.2604)
17:44060739:A:T,P10636,H190L,0.206,Loss of methylation at K189 (P = 0.0845); Loss of catalytic residue at L192 (P = 0.102); Loss of glycosylation at K189 (P = 0.1213); Loss of ubiquitination at K189 (P = 0.2184); Gain of stability (P = 0.3114)
17:44060740:C:A,P10636,H190Q,0.163,Loss of catalytic residue at L192 (P = 0.1061); Gain of methylation at K189 (P = 0.1627); Loss of glycosylation at K189 (P = 0.2513); Loss of ubiquitination at K189 (P = 0.2943); Gain of MoRF binding (P = 0.5337)
17:44060740:C:G,P10636,H190Q,0.163,Loss of catalytic residue at L192 (P = 0.1061); Gain of methylation at K189 (P = 0.1627); Loss of glycosylation at K189 (P = 0.2513); Loss of ubiquitination at K189 (P = 0.2943); Gain of MoRF binding (P = 0.5337)
17:44060741:C:A,P10636,Q191K,0.348,Gain of ubiquitination at Q191 (P = 0.0085); Gain of glycosylation at Q191 (P = 0.0211); Gain of solvent accessibility (P = 0.0328); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at Q191 (P = 0.0611)
17:44060741:C:G,P10636,Q191E,0.325,Gain of solvent accessibility (P = 0.0421); Gain of relative solvent accessibility (P = 0.0479); Loss of methylation at K189 (P = 0.1177); Gain of glycosylation at K189 (P = 0.1493); Loss of ubiquitination at K189 (P = 0.3072)
17:44060742:A:C,P10636,Q191P,0.293,Loss of stability (P = 0.1173); Gain of methylation at K189 (P = 0.1393); Gain of glycosylation at K189 (P = 0.1699); Gain of catalytic residue at Q191 (P = 0.2589); Loss of ubiquitination at K189 (P = 0.2797)
17:44060742:A:G,P10636,Q191R,0.302,Loss of methylation at K189 (P = 0.1129); Loss of glycosylation at K189 (P = 0.1293); Gain of solvent accessibility (P = 0.1505); Gain of MoRF binding (P = 0.2071); Gain of relative solvent accessibility (P = 0.2363)
17:44060742:A:T,P10636,Q191L,0.342,Loss of methylation at K189 (P = 0.1208); Gain of glycosylation at K189 (P = 0.1479); Loss of ubiquitination at K189 (P = 0.1882); Gain of catalytic residue at D195 (P = 0.4292); Loss of solvent accessibility (P = 0.4838)
17:44060743:G:C,P10636,Q191H,0.279,Gain of catalytic residue at L193 (P = 0.0553); Loss of methylation at K189 (P = 0.1487); Loss of stability (P = 0.1646); Gain of glycosylation at K189 (P = 0.1795); Loss of ubiquitination at K189 (P = 0.2604)
17:44060743:G:T,P10636,Q191H,0.279,Gain of catalytic residue at L193 (P = 0.0553); Loss of methylation at K189 (P = 0.1487); Loss of stability (P = 0.1646); Gain of glycosylation at K189 (P = 0.1795); Loss of ubiquitination at K189 (P = 0.2604)
17:44060744:C:A,P10636,L192I,0.335,Gain of methylation at K189 (P = 0.0615); Gain of glycosylation at K189 (P = 0.275); Gain of ubiquitination at K189 (P = 0.3023); Gain of catalytic residue at D195 (P = 0.3154); Loss of solvent accessibility (P = 0.4436)
17:44060744:C:G,P10636,L192V,0.381,Loss of catalytic residue at L192 (P = 0.0295); Gain of methylation at K189 (P = 0.072); Loss of glycosylation at K189 (P = 0.2234); Loss of stability (P = 0.2663); Gain of ubiquitination at K189 (P = 0.3023)
17:44060744:C:T,P10636,L192F,0.387,Loss of catalytic residue at L192 (P = 0.087); Gain of methylation at K189 (P = 0.1085); Loss of stability (P = 0.2563); Loss of glycosylation at K189 (P = 0.2712); Gain of ubiquitination at K189 (P = 0.2923)
17:44060745:T:A,P10636,L192H,0.355,Loss of catalytic residue at L192 (P = 0.0268); Loss of stability (P = 0.0414); Gain of methylation at K189 (P = 0.0824); Gain of glycosylation at K189 (P = 0.1405); Gain of ubiquitination at K189 (P = 0.3023)
17:44060745:T:C,P10636,L192P,0.349,Loss of catalytic residue at L192 (P = 0.0134); Loss of stability (P = 0.0135); Gain of methylation at K189 (P = 0.0474); Gain of glycosylation at K189 (P = 0.1777); Gain of relative solvent accessibility (P = 0.2363)
17:44060745:T:G,P10636,L192R,0.394,Loss of catalytic residue at L192 (P = 0.0648); Loss of ubiquitination at K189 (P = 0.071); Loss of stability (P = 0.08); Gain of glycosylation at K189 (P = 0.0988); Gain of solvent accessibility (P = 0.1071)
17:44060747:C:G,P10636,L193V,0.308,Gain of methylation at K189 (P = 0.0777); Loss of glycosylation at K189 (P = 0.225); Gain of ubiquitination at K189 (P = 0.3023); Gain of catalytic residue at D195 (P = 0.4246); Gain of MoRF binding (P = 0.4932)
17:44060748:T:A,P10636,L193Q,0.322,Loss of glycosylation at K189 (P = 0.1461); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1716); Gain of solvent accessibility (P = 0.1751); Loss of methylation at K189 (P = 0.1758)
17:44060748:T:C,P10636,L193P,0.319,Loss of stability (P = 0.0338); Gain of methylation at K189 (P = 0.1067); Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at K189 (P = 0.236); Gain of ubiquitination at K189 (P = 0.2923)
17:44060748:T:G,P10636,L193R,0.37,Gain of MoRF binding (P = 0.0565); Loss of glycosylation at K189 (P = 0.089); Gain of solvent accessibility (P = 0.1071); Loss of methylation at K189 (P = 0.1117); Loss of stability (P = 0.1397)
17:44060750:G:A,P10636,G194R,0.3,Loss of ubiquitination at K189 (P = 0.0607); Gain of MoRF binding (P = 0.088); Gain of methylation at K189 (P = 0.0991); Gain of solvent accessibility (P = 0.1319); Loss of glycosylation at K189 (P = 0.2334)
17:44060750:G:C,P10636,G194R,0.3,Loss of ubiquitination at K189 (P = 0.0607); Gain of MoRF binding (P = 0.088); Gain of methylation at K189 (P = 0.0991); Gain of solvent accessibility (P = 0.1319); Loss of glycosylation at K189 (P = 0.2334)
17:44060751:G:A,P10636,G194E,0.266,Gain of solvent accessibility (P = 0.012); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at K189 (P = 0.0936); Gain of glycosylation at K189 (P = 0.2375); Loss of ubiquitination at K189 (P = 0.2797)
17:44060751:G:C,P10636,G194A,0.257,Loss of methylation at K189 (P = 0.1305); Loss of glycosylation at K189 (P = 0.2349); Loss of stability (P = 0.2614); Loss of ubiquitination at K189 (P = 0.2943); Gain of solvent accessibility (P = 0.5093)
17:44060751:G:T,P10636,G194V,0.259,Loss of glycosylation at K189 (P = 0.132); Loss of methylation at K189 (P = 0.1786); Loss of ubiquitination at K189 (P = 0.2604); Gain of MoRF binding (P = 0.5512); Gain of solvent accessibility (P = 0.571)
17:44060753:G:A,P10636,D195N,0.342,Gain of MoRF binding (P = 0.335); Gain of catalytic residue at D195 (P = 0.3408); Loss of solvent accessibility (P = 0.4274); Loss of stability (P = 0.4753); Loss of relative solvent accessibility (P = 0.5898)
17:44060753:G:C,P10636,D195H,0.335,Loss of solvent accessibility (P = 0.1473); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at D195 (P = 0.2131); Loss of stability (P = 0.311); Gain of MoRF binding (P = 0.396)
17:44060753:G:T,P10636,D195Y,0.365,Gain of phosphorylation at D195 (P = 0.0341); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1115); Gain of catalytic residue at D195 (P = 0.2611); Gain of MoRF binding (P = 0.3963)
17:44060754:A:C,P10636,D195A,0.336,Loss of solvent accessibility (P = 0.1115); Loss of relative solvent accessibility (P = 0.3219); Gain of MoRF binding (P = 0.3342); Loss of stability (P = 0.5612); Gain of sheet (P = 0.6509)
17:44060754:A:G,P10636,D195G,0.36,Gain of helix (P = 0.0022); Loss of loop (P = 0.0022); Loss of solvent accessibility (P = 0.0674); Loss of stability (P = 0.1446); Gain of catalytic residue at L196 (P = 0.2532)
17:44060754:A:T,P10636,D195V,0.396,Loss of solvent accessibility (P = 0.0907); Gain of catalytic residue at D195 (P = 0.1491); Loss of relative solvent accessibility (P = 0.1807); Gain of MoRF binding (P = 0.3162); Gain of sheet (P = 0.6509)
17:44060755:C:A,P10636,D195E,0.328,Gain of solvent accessibility (P = 0.3089); Gain of catalytic residue at D195 (P = 0.31); Loss of MoRF binding (P = 0.5769); Gain of sheet (P = 0.6509); Loss of stability (P = 0.7438)
17:44060755:C:G,P10636,D195E,0.328,Gain of solvent accessibility (P = 0.3089); Gain of catalytic residue at D195 (P = 0.31); Loss of MoRF binding (P = 0.5769); Gain of sheet (P = 0.6509); Loss of stability (P = 0.7438)
17:44060756:C:A,P10636,L196M,0.309,Loss of catalytic residue at L196 (P = 0.1462); Loss of stability (P = 0.2445); Gain of glycosylation at P201 (P = 0.4337); Gain of MoRF binding (P = 0.4935); Gain of solvent accessibility (P = 0.571)
17:44060756:C:G,P10636,L196V,0.285,Loss of stability (P = 0.1691); Loss of catalytic residue at L196 (P = 0.1912); Loss of glycosylation at P201 (P = 0.3994); Gain of MoRF binding (P = 0.5039); Gain of sheet (P = 0.6509)
17:44060757:T:A,P10636,L196Q,0.304,Loss of stability (P = 0.0453); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.1751); Loss of catalytic residue at L196 (P = 0.217); Gain of glycosylation at P201 (P = 0.3891)
17:44060757:T:C,P10636,L196P,0.311,Loss of stability (P = 0.0149); Gain of catalytic residue at L193 (P = 0.1684); Gain of glycosylation at P201 (P = 0.4128); Loss of MoRF binding (P = 0.5553); Loss of sheet (P = 0.6423)
17:44060757:T:G,P10636,L196R,0.333,Loss of stability (P = 0.0351); Gain of solvent accessibility (P = 0.1071); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at E199 (P = 0.2552); Gain of MoRF binding (P = 0.2656)
17:44060759:C:A,P10636,H197N,0.18,Loss of catalytic residue at E199 (P = 0.1457); Gain of glycosylation at P201 (P = 0.4046); Loss of stability (P = 0.4585); Gain of MoRF binding (P = 0.5512); Loss of sheet (P = 0.6423)
17:44060759:C:G,P10636,H197D,0.213,Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0808); Loss of catalytic residue at L196 (P = 0.2235); Loss of glycosylation at P201 (P = 0.4221); Loss of MoRF binding (P = 0.5531)
17:44060759:C:T,P10636,H197Y,0.233,Gain of phosphorylation at H197 (P = 0.0068); Gain of glycosylation at P201 (P = 0.1884); Loss of catalytic residue at L196 (P = 0.2101); Gain of solvent accessibility (P = 0.4304); Loss of MoRF binding (P = 0.5786)
17:44060760:A:C,P10636,H197P,0.21,Loss of catalytic residue at E199 (P = 0.1024); Loss of stability (P = 0.2713); Gain of glycosylation at P201 (P = 0.2744); Loss of MoRF binding (P = 0.5604); Loss of sheet (P = 0.6423)
17:44060760:A:G,P10636,H197R,0.224,Gain of solvent accessibility (P = 0.1319); Gain of MoRF binding (P = 0.1474); Loss of catalytic residue at E199 (P = 0.1782); Gain of glycosylation at P201 (P = 0.2301); Gain of relative solvent accessibility (P = 0.2363)
17:44060760:A:T,P10636,H197L,0.236,Loss of catalytic residue at L196 (P = 0.2042); Gain of glycosylation at P201 (P = 0.36); Loss of solvent accessibility (P = 0.3646); Loss of relative solvent accessibility (P = 0.5582); Loss of MoRF binding (P = 0.5773)
17:44060761:C:A,P10636,H197Q,0.207,Loss of catalytic residue at L196 (P = 0.2224); Gain of glycosylation at P201 (P = 0.2469); Gain of MoRF binding (P = 0.5396); Gain of solvent accessibility (P = 0.5485); Loss of stability (P = 0.5995)
17:44060761:C:G,P10636,H197Q,0.207,Loss of catalytic residue at L196 (P = 0.2224); Gain of glycosylation at P201 (P = 0.2469); Gain of MoRF binding (P = 0.5396); Gain of solvent accessibility (P = 0.5485); Loss of stability (P = 0.5995)
17:44060762:C:A,P10636,Q198K,0.36,Gain of ubiquitination at Q198 (P = 0.0045); Gain of glycosylation at Q198 (P = 0.0271); Gain of methylation at Q198 (P = 0.0338); Gain of MoRF binding (P = 0.3599); Loss of solvent accessibility (P = 0.4218)
17:44060762:C:G,P10636,Q198E,0.297,Gain of catalytic residue at Q198 (P = 0.2789); Loss of glycosylation at P201 (P = 0.4262); Loss of MoRF binding (P = 0.5519); Gain of stability (P = 0.5909); Gain of sheet (P = 0.6509)
17:44060763:A:C,P10636,Q198P,0.288,Gain of glycosylation at P201 (P = 0.1772); Loss of solvent accessibility (P = 0.1868); Gain of catalytic residue at G200 (P = 0.3979); Loss of MoRF binding (P = 0.5543); Gain of sheet (P = 0.6509)
17:44060763:A:G,P10636,Q198R,0.337,Gain of MoRF binding (P = 0.2393); Gain of glycosylation at P201 (P = 0.4136); Loss of catalytic residue at E199 (P = 0.4417); Loss of relative solvent accessibility (P = 0.5582); Gain of methylation at Q198 (P = 0.5981)
17:44060763:A:T,P10636,Q198L,0.347,Loss of solvent accessibility (P = 0.0022); Loss of relative solvent accessibility (P = 0.0186); Gain of catalytic residue at Q198 (P = 0.05); Gain of stability (P = 0.0568); Gain of glycosylation at P201 (P = 0.3117)
17:44060764:G:C,P10636,Q198H,0.305,Loss of solvent accessibility (P = 0.0056); Loss of relative solvent accessibility (P = 0.0404); Gain of catalytic residue at Q198 (P = 0.3001); Loss of glycosylation at P201 (P = 0.3814); Loss of MoRF binding (P = 0.5704)
17:44060764:G:T,P10636,Q198H,0.305,Loss of solvent accessibility (P = 0.0056); Loss of relative solvent accessibility (P = 0.0404); Gain of catalytic residue at Q198 (P = 0.3001); Loss of glycosylation at P201 (P = 0.3814); Loss of MoRF binding (P = 0.5704)
17:44060765:G:A,P10636,E199K,0.378,Gain of glycosylation at E199 (P = 0.0185); Gain of methylation at E199 (P = 0.0225); Loss of ubiquitination at K204 (P = 0.0298); Gain of MoRF binding (P = 0.0899); Loss of solvent accessibility (P = 0.1579)
17:44060765:G:C,P10636,E199Q,0.36,Loss of solvent accessibility (P = 0.0174); Loss of relative solvent accessibility (P = 0.0676); Loss of catalytic residue at E199 (P = 0.1887); Loss of glycosylation at K204 (P = 0.2405); Loss of ubiquitination at K204 (P = 0.3054)
17:44060766:A:C,P10636,E199A,0.343,Loss of solvent accessibility (P = 0.0053); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K204 (P = 0.232); Loss of ubiquitination at K204 (P = 0.3303); Gain of MoRF binding (P = 0.3407)
17:44060766:A:G,P10636,E199G,0.347,Loss of solvent accessibility (P = 0.0036); Loss of relative solvent accessibility (P = 0.0676); Gain of catalytic residue at G200 (P = 0.2109); Loss of glycosylation at K204 (P = 0.261); Loss of ubiquitination at K204 (P = 0.3054)
17:44060766:A:T,P10636,E199V,0.375,Loss of solvent accessibility (P = 0.0022); Loss of relative solvent accessibility (P = 0.0186); Loss of glycosylation at K204 (P = 0.1471); Loss of catalytic residue at E199 (P = 0.2168); Gain of MoRF binding (P = 0.3032)
17:44060767:G:C,P10636,E199D,0.292,Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at K204 (P = 0.2623); Loss of catalytic residue at E199 (P = 0.3289); Loss of ubiquitination at K204 (P = 0.3733); Loss of methylation at K204 (P = 0.4508)
17:44060767:G:T,P10636,E199D,0.292,Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at K204 (P = 0.2623); Loss of catalytic residue at E199 (P = 0.3289); Loss of ubiquitination at K204 (P = 0.3733); Loss of methylation at K204 (P = 0.4508)
17:44060768:G:A,P10636,G200R,0.275,Gain of solvent accessibility (P = 0.0023); Gain of relative solvent accessibility (P = 0.0479); Loss of glycosylation at K204 (P = 0.1261); Gain of MoRF binding (P = 0.315); Loss of catalytic residue at G200 (P = 0.3169)
17:44060768:G:C,P10636,G200R,0.275,Gain of solvent accessibility (P = 0.0023); Gain of relative solvent accessibility (P = 0.0479); Loss of glycosylation at K204 (P = 0.1261); Gain of MoRF binding (P = 0.315); Loss of catalytic residue at G200 (P = 0.3169)
17:44060768:G:T,P10636,G200W,0.209,Loss of glycosylation at K204 (P = 0.2595); Loss of ubiquitination at K204 (P = 0.3654); Gain of MoRF binding (P = 0.3772); Gain of methylation at K204 (P = 0.4499); Loss of catalytic residue at L203 (P = 0.4973)
17:44060769:G:A,P10636,G200E,0.232,Gain of solvent accessibility (P = 0.0026); Gain of relative solvent accessibility (P = 0.0166); Gain of glycosylation at P201 (P = 0.2128); Loss of catalytic residue at E199 (P = 0.3416); Gain of ubiquitination at K204 (P = 0.3757)
17:44060769:G:C,P10636,G200A,0.17,Loss of catalytic residue at G200 (P = 0.2691); Loss of glycosylation at K204 (P = 0.2791); Gain of ubiquitination at K204 (P = 0.3757); Loss of methylation at K204 (P = 0.4366); Gain of solvent accessibility (P = 0.5093)
17:44060769:G:T,P10636,G200V,0.189,Loss of glycosylation at K204 (P = 0.1987); Loss of catalytic residue at G200 (P = 0.3193); Gain of ubiquitination at K204 (P = 0.3741); Gain of methylation at K204 (P = 0.451); Gain of MoRF binding (P = 0.5652)
17:44060771:C:A,P10636,P201T,0.401,Gain of phosphorylation at P201 (P = 0.0222); Loss of catalytic residue at P201 (P = 0.0925); Loss of glycosylation at P201 (P = 0.1687); Gain of relative solvent accessibility (P = 0.2629); Loss of stability (P = 0.3675)
17:44060771:C:G,P10636,P201A,0.395,Loss of catalytic residue at P201 (P = 0.0541); Loss of glycosylation at P201 (P = 0.1069); Gain of relative solvent accessibility (P = 0.2629); Loss of stability (P = 0.3277); Gain of ubiquitination at K204 (P = 0.3757)
17:44060771:C:T,P10636,P201S,0.4,Gain of phosphorylation at P201 (P = 0.0261); Loss of catalytic residue at P201 (P = 0.0423); Loss of glycosylation at P201 (P = 0.1948); Gain of relative solvent accessibility (P = 0.2629); Loss of methylation at K204 (P = 0.3233)
17:44060772:C:A,P10636,P201Q,0.422,Loss of catalytic residue at P201 (P = 0.0125); Loss of glycosylation at P201 (P = 0.1069); Gain of solvent accessibility (P = 0.2291); Gain of relative solvent accessibility (P = 0.2629); Loss of ubiquitination at K204 (P = 0.3584)
17:44060772:C:G,P10636,P201R,0.43,Gain of MoRF binding (P = 0.0266); Loss of catalytic residue at P201 (P = 0.0272); Gain of solvent accessibility (P = 0.0488); Gain of relative solvent accessibility (P = 0.1066); Loss of glycosylation at P201 (P = 0.1069)
17:44060774:C:A,P10636,P202T,0.513,Gain of phosphorylation at P202 (P = 0.0302); Loss of catalytic residue at P201 (P = 0.1966); Loss of glycosylation at K204 (P = 0.2317); Loss of ubiquitination at K204 (P = 0.3733); Loss of methylation at K204 (P = 0.4229)
17:44060774:C:G,P10636,P202A,0.499,Loss of catalytic residue at P201 (P = 0.1966); Gain of glycosylation at K204 (P = 0.2325); Loss of ubiquitination at K204 (P = 0.3733); Loss of methylation at K204 (P = 0.3988); Gain of MoRF binding (P = 0.4426)
17:44060774:C:T,P10636,P202S,0.491,Gain of phosphorylation at P202 (P = 0.0235); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.1116); Loss of glycosylation at K204 (P = 0.1601); Loss of catalytic residue at P201 (P = 0.1966)
17:44060775:C:A,P10636,P202Q,0.511,Loss of glycosylation at P201 (P = 0.1774); Loss of catalytic residue at P201 (P = 0.2509); Gain of solvent accessibility (P = 0.3418); Loss of ubiquitination at K204 (P = 0.3501); Gain of MoRF binding (P = 0.376)
17:44060775:C:G,P10636,P202R,0.52,Gain of MoRF binding (P = 0.0213); Loss of glycosylation at K204 (P = 0.0991); Loss of catalytic residue at P201 (P = 0.1966); Gain of solvent accessibility (P = 0.2097); Gain of methylation at P202 (P = 0.2266)
17:44060777:C:A,P10636,L203M,0.285,Loss of methylation at K204 (P = 0.0578); Loss of catalytic residue at L203 (P = 0.1687); Gain of glycosylation at K204 (P = 0.2189); Loss of ubiquitination at K204 (P = 0.3584); Gain of solvent accessibility (P = 0.5334)
17:44060777:C:G,P10636,L203V,0.249,Loss of glycosylation at K204 (P = 0.2089); Gain of relative solvent accessibility (P = 0.2629); Loss of catalytic residue at L203 (P = 0.3214); Gain of ubiquitination at K204 (P = 0.3757); Gain of methylation at K204 (P = 0.4157)
17:44060778:T:A,P10636,L203Q,0.298,Gain of solvent accessibility (P = 0.0137); Gain of relative solvent accessibility (P = 0.0249); Gain of glycosylation at P201 (P = 0.0856); Loss of stability (P = 0.2797); Loss of catalytic residue at L203 (P = 0.2844)
17:44060778:T:C,P10636,L203P,0.301,Gain of relative solvent accessibility (P = 0.0249); Gain of helix (P = 0.0349); Gain of glycosylation at L203 (P = 0.0443); Gain of catalytic residue at P202 (P = 0.0519); Loss of loop (P = 0.0603)
17:44060778:T:G,P10636,L203R,0.291,Gain of glycosylation at P201 (P = 0.0768); Gain of solvent accessibility (P = 0.1683); Loss of catalytic residue at G205 (P = 0.242); Loss of stability (P = 0.2504); Gain of relative solvent accessibility (P = 0.2629)
17:44060780:A:C,P10636,K204Q,0.344,Loss of ubiquitination at K204 (P = 0.0023); Loss of methylation at K204 (P = 0.0031); Loss of glycosylation at K204 (P = 0.0194); Loss of solvent accessibility (P = 0.0561); Loss of relative solvent accessibility (P = 0.1807)
17:44060780:A:G,P10636,K204E,0.331,Loss of ubiquitination at K204 (P = 0.0023); Loss of methylation at K204 (P = 0.0031); Loss of glycosylation at K204 (P = 0.0194); Loss of catalytic residue at K204 (P = 0.3926); Loss of MoRF binding (P = 0.6077)
17:44060781:A:C,P10636,K204T,0.37,Loss of ubiquitination at K204 (P = 0.0023); Loss of methylation at K204 (P = 0.0031); Gain of phosphorylation at K204 (P = 0.0129); Loss of solvent accessibility (P = 0.0249); Loss of glycosylation at K204 (P = 0.0564)
17:44060781:A:T,P10636,K204M,0.364,Loss of ubiquitination at K204 (P = 0.0023); Loss of methylation at K204 (P = 0.0031); Loss of glycosylation at K204 (P = 0.0194); Loss of solvent accessibility (P = 0.0217); Loss of relative solvent accessibility (P = 0.0981)
17:44060782:G:C,P10636,K204N,0.335,Loss of ubiquitination at K204 (P = 0.0023); Loss of methylation at K204 (P = 0.0031); Loss of glycosylation at K204 (P = 0.0194); Gain of catalytic residue at K204 (P = 0.3737); Loss of solvent accessibility (P = 0.3854)
17:44060782:G:T,P10636,K204N,0.335,Loss of ubiquitination at K204 (P = 0.0023); Loss of methylation at K204 (P = 0.0031); Loss of glycosylation at K204 (P = 0.0194); Gain of catalytic residue at K204 (P = 0.3737); Loss of solvent accessibility (P = 0.3854)
17:44060783:G:A,P10636,G205R,0.393,Loss of catalytic residue at G205 (P = 0.1667); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at K204 (P = 0.1862); Gain of MoRF binding (P = 0.241); Loss of ubiquitination at K204 (P = 0.3054)
17:44060783:G:C,P10636,G205R,0.393,Loss of catalytic residue at G205 (P = 0.1667); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at K204 (P = 0.1862); Gain of MoRF binding (P = 0.241); Loss of ubiquitination at K204 (P = 0.3054)
17:44060783:G:T,P10636,G205W,0.362,Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K204 (P = 0.0988); Gain of catalytic residue at L203 (P = 0.1365); Gain of ubiquitination at K209 (P = 0.3433); Gain of MoRF binding (P = 0.3557)
17:44060784:G:A,P10636,G205E,0.362,Gain of solvent accessibility (P = 0.0456); Loss of catalytic residue at G205 (P = 0.084); Loss of glycosylation at K204 (P = 0.1817); Gain of ubiquitination at K209 (P = 0.3263); Gain of methylation at K209 (P = 0.4381)
17:44060784:G:C,P10636,G205A,0.327,Loss of glycosylation at K204 (P = 0.1127); Loss of catalytic residue at G205 (P = 0.1485); Loss of relative solvent accessibility (P = 0.1807); Gain of ubiquitination at K209 (P = 0.3329); Loss of methylation at K209 (P = 0.4216)
17:44060784:G:T,P10636,G205V,0.32,Loss of glycosylation at K204 (P = 0.0808); Loss of relative solvent accessibility (P = 0.0981); Loss of catalytic residue at G205 (P = 0.1509); Gain of ubiquitination at K209 (P = 0.3215); Loss of solvent accessibility (P = 0.4141)
17:44060786:G:A,P10636,A206T,0.19,Gain of phosphorylation at A206 (P = 0.0086); Loss of catalytic residue at A206 (P = 0.1235); Loss of glycosylation at K204 (P = 0.1964); Gain of ubiquitination at K209 (P = 0.3459); Loss of methylation at K209 (P = 0.4375)
17:44060786:G:C,P10636,A206P,0.219,Gain of relative solvent accessibility (P = 0.0098); Gain of solvent accessibility (P = 0.0216); Loss of catalytic residue at A206 (P = 0.0348); Gain of glycosylation at A206 (P = 0.0485); Loss of ubiquitination at K209 (P = 0.3336)
17:44060786:G:T,P10636,A206S,0.203,Gain of phosphorylation at A206 (P = 0.0046); Gain of glycosylation at A206 (P = 0.0158); Loss of catalytic residue at A206 (P = 0.2516); Loss of ubiquitination at K209 (P = 0.3426); Loss of methylation at K209 (P = 0.3568)
17:44060787:C:A,P10636,A206E,0.266,Gain of solvent accessibility (P = 0.0023); Gain of relative solvent accessibility (P = 0.0098); Loss of catalytic residue at A206 (P = 0.1164); Gain of glycosylation at P201 (P = 0.2229); Loss of loop (P = 0.2897)
17:44060787:C:G,P10636,A206G,0.227,Gain of relative solvent accessibility (P = 0.0098); Gain of solvent accessibility (P = 0.11); Gain of catalytic residue at P202 (P = 0.1189); Loss of stability (P = 0.1375); Loss of glycosylation at K204 (P = 0.1597)
17:44060787:C:T,P10636,A206V,0.201,Loss of glycosylation at K209 (P = 0.2184); Gain of ubiquitination at K209 (P = 0.3407); Loss of catalytic residue at A206 (P = 0.3705); Gain of methylation at K209 (P = 0.4284); Gain of solvent accessibility (P = 0.4946)
17:44060789:G:A,P10636,G207R,0.283,Gain of methylation at G207 (P = 0.05); Loss of glycosylation at K209 (P = 0.1109); Loss of catalytic residue at A206 (P = 0.1131); Gain of solvent accessibility (P = 0.1319); Gain of MoRF binding (P = 0.2129)
17:44060789:G:C,P10636,G207R,0.283,Gain of methylation at G207 (P = 0.05); Loss of glycosylation at K209 (P = 0.1109); Loss of catalytic residue at A206 (P = 0.1131); Gain of solvent accessibility (P = 0.1319); Gain of MoRF binding (P = 0.2129)
17:44060789:G:T,P10636,G207W,0.304,Gain of glycosylation at P212 (P = 0.1242); Loss of catalytic residue at G205 (P = 0.2243); Gain of solvent accessibility (P = 0.3304); Loss of ubiquitination at K204 (P = 0.3401); Gain of MoRF binding (P = 0.3609)
17:44060790:G:A,P10636,G207E,0.274,Gain of solvent accessibility (P = 0.012); Gain of relative solvent accessibility (P = 0.0479); Loss of catalytic residue at A206 (P = 0.1014); Loss of glycosylation at K209 (P = 0.1682); Gain of ubiquitination at K209 (P = 0.3215)
17:44060790:G:C,P10636,G207A,0.282,Gain of catalytic residue at G207 (P = 0.1245); Loss of glycosylation at K209 (P = 0.1812); Loss of stability (P = 0.2792); Gain of ubiquitination at K209 (P = 0.3329); Loss of methylation at K204 (P = 0.4313)
17:44060790:G:T,P10636,G207V,0.244,Loss of glycosylation at K209 (P = 0.142); Loss of catalytic residue at A206 (P = 0.2001); Gain of ubiquitination at K209 (P = 0.3215); Gain of methylation at K209 (P = 0.4321); Loss of stability (P = 0.4702)
17:44060792:G:A,P10636,G208S,0.339,Gain of phosphorylation at G208 (P = 0.0022); Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at K209 (P = 0.1523); Loss of catalytic residue at G205 (P = 0.1684); Loss of ubiquitination at K209 (P = 0.3426)
17:44060792:G:C,P10636,G208R,0.344,Gain of methylation at G208 (P = 0.0329); Loss of catalytic residue at G205 (P = 0.1068); Gain of MoRF binding (P = 0.1643); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at K209 (P = 0.1863)
17:44060792:G:T,P10636,G208C,0.313,Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at G208 (P = 0.1359); Gain of glycosylation at P212 (P = 0.1613); Gain of ubiquitination at K209 (P = 0.3379); Gain of methylation at K209 (P = 0.379)
17:44060793:G:C,P10636,G208A,0.315,Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at K209 (P = 0.2009); Loss of catalytic residue at G205 (P = 0.2041); Gain of ubiquitination at K209 (P = 0.3355); Loss of solvent accessibility (P = 0.3368)
17:44060793:G:T,P10636,G208V,0.306,Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at K209 (P = 0.1425); Gain of catalytic residue at G208 (P = 0.1616); Gain of ubiquitination at K209 (P = 0.3181); Gain of methylation at K209 (P = 0.4059)
17:44060795:A:C,P10636,K209Q,0.303,Loss of methylation at K209 (P = 0.0033); Loss of ubiquitination at K209 (P = 0.0039); Loss of glycosylation at K209 (P = 0.0391); Loss of MoRF binding (P = 0.6312); Loss of sheet (P = 0.6423)
17:44060795:A:G,P10636,K209E,0.319,Loss of methylation at K209 (P = 0.0033); Loss of ubiquitination at K209 (P = 0.0039); Loss of glycosylation at K209 (P = 0.0391); Gain of stability (P = 0.2803); Loss of MoRF binding (P = 0.6138)
17:44060796:A:C,P10636,K209T,0.349,Loss of methylation at K209 (P = 0.0033); Loss of ubiquitination at K209 (P = 0.0039); Gain of phosphorylation at K209 (P = 0.0042); Gain of glycosylation at K209 (P = 0.0444); Loss of solvent accessibility (P = 0.4011)
17:44060796:A:G,P10636,K209R,0.298,Loss of ubiquitination at K209 (P = 0.0039); Loss of methylation at K209 (P = 0.0169); Loss of glycosylation at K209 (P = 0.0391); Gain of stability (P = 0.3568); Gain of solvent accessibility (P = 0.4067)
17:44060796:A:T,P10636,K209I,0.324,Loss of methylation at K209 (P = 0.0033); Loss of ubiquitination at K209 (P = 0.0039); Gain of stability (P = 0.0174); Loss of glycosylation at K209 (P = 0.0391); Gain of catalytic residue at K209 (P = 0.0891)
17:44060797:A:C,P10636,K209N,0.295,Loss of methylation at K209 (P = 0.0033); Loss of ubiquitination at K209 (P = 0.0039); Loss of glycosylation at K209 (P = 0.0391); Gain of catalytic residue at K209 (P = 0.5228); Loss of MoRF binding (P = 0.6287)
17:44060797:A:T,P10636,K209N,0.295,Loss of methylation at K209 (P = 0.0033); Loss of ubiquitination at K209 (P = 0.0039); Loss of glycosylation at K209 (P = 0.0391); Gain of catalytic residue at K209 (P = 0.5228); Loss of MoRF binding (P = 0.6287)
17:44060798:G:A,P10636,E210K,0.384,Gain of methylation at E210 (P = 0.0036); Gain of ubiquitination at E210 (P = 0.0155); Gain of glycosylation at E210 (P = 0.0327); Gain of catalytic residue at E210 (P = 0.1065); Gain of MoRF binding (P = 0.1744)
17:44060798:G:C,P10636,E210Q,0.309,Gain of glycosylation at P212 (P = 0.219); Gain of methylation at K215 (P = 0.2404); Loss of ubiquitination at K209 (P = 0.3426); Gain of MoRF binding (P = 0.3754); Gain of solvent accessibility (P = 0.5485)
17:44060799:A:C,P10636,E210A,0.335,Loss of solvent accessibility (P = 0.0769); Loss of methylation at K215 (P = 0.146); Loss of glycosylation at K209 (P = 0.1668); Gain of MoRF binding (P = 0.2988); Loss of stability (P = 0.3113)
17:44060799:A:G,P10636,E210G,0.346,Loss of solvent accessibility (P = 0.0187); Gain of methylation at R211 (P = 0.0538); Gain of glycosylation at K209 (P = 0.1819); Gain of catalytic residue at K209 (P = 0.2326); Loss of stability (P = 0.3341)
17:44060799:A:T,P10636,E210V,0.338,Loss of solvent accessibility (P = 0.0022); Loss of relative solvent accessibility (P = 0.0186); Loss of glycosylation at K209 (P = 0.1191); Loss of methylation at K215 (P = 0.2193); Gain of MoRF binding (P = 0.2283)
17:44060800:G:C,P10636,E210D,0.272,Loss of glycosylation at P212 (P = 0.1581); Loss of methylation at K215 (P = 0.2342); Gain of catalytic residue at K209 (P = 0.2869); Gain of ubiquitination at K209 (P = 0.3459); Loss of solvent accessibility (P = 0.4653)
17:44060800:G:T,P10636,E210D,0.272,Loss of glycosylation at P212 (P = 0.1581); Loss of methylation at K215 (P = 0.2342); Gain of catalytic residue at K209 (P = 0.2869); Gain of ubiquitination at K209 (P = 0.3459); Loss of solvent accessibility (P = 0.4653)
17:44060801:A:G,P10636,R211G,0.343,Gain of glycosylation at S214 (P = 0.0951); Loss of stability (P = 0.1127); Loss of solvent accessibility (P = 0.1744); Gain of catalytic residue at R211 (P = 0.202); Loss of methylation at K215 (P = 0.249)
17:44060801:A:T,P10636,R211W,0.326,Gain of glycosylation at K209 (P = 0.0824); Gain of methylation at K215 (P = 0.2357); Loss of ubiquitination at K209 (P = 0.3426); Loss of solvent accessibility (P = 0.4436); Gain of catalytic residue at R211 (P = 0.5507)
17:44060802:G:A,P10636,R211K,0.343,Gain of methylation at R211 (P = 0.008); Gain of ubiquitination at R211 (P = 0.0109); Gain of glycosylation at R211 (P = 0.0466); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0596)
17:44060802:G:C,P10636,R211T,0.34,Gain of phosphorylation at R211 (P = 0.0033); Gain of glycosylation at K209 (P = 0.1054); Gain of methylation at K215 (P = 0.2049); Loss of solvent accessibility (P = 0.2732); Gain of ubiquitination at K209 (P = 0.3379)
17:44060802:G:T,P10636,R211M,0.316,Gain of glycosylation at K209 (P = 0.0755); Gain of methylation at K215 (P = 0.2487); Gain of ubiquitination at K209 (P = 0.3355); Loss of solvent accessibility (P = 0.3543); Gain of catalytic residue at K209 (P = 0.452)
17:44060803:G:C,P10636,R211S,0.341,Gain of phosphorylation at R211 (P = 0.0046); Gain of glycosylation at K209 (P = 0.1486); Gain of methylation at K215 (P = 0.2468); Gain of ubiquitination at K209 (P = 0.3433); Loss of solvent accessibility (P = 0.3744)
17:44060803:G:T,P10636,R211S,0.341,Gain of phosphorylation at R211 (P = 0.0046); Gain of glycosylation at K209 (P = 0.1486); Gain of methylation at K215 (P = 0.2468); Gain of ubiquitination at K209 (P = 0.3433); Loss of solvent accessibility (P = 0.3744)
17:44060804:C:A,P10636,P212T,0.313,Gain of phosphorylation at P212 (P = 0.0071); Loss of glycosylation at P212 (P = 0.0816); Loss of methylation at K215 (P = 0.1603); Loss of stability (P = 0.3054); Gain of ubiquitination at K209 (P = 0.3407)
17:44060804:C:G,P10636,P212A,0.284,Loss of glycosylation at P212 (P = 0.0565); Loss of methylation at K215 (P = 0.0809); Gain of catalytic residue at P212 (P = 0.1246); Loss of stability (P = 0.2397); Loss of ubiquitination at K209 (P = 0.3426)
17:44060804:C:T,P10636,P212S,0.325,Gain of phosphorylation at P212 (P = 0.0031); Loss of methylation at K215 (P = 0.0865); Loss of glycosylation at P212 (P = 0.11); Gain of catalytic residue at P212 (P = 0.2548); Loss of ubiquitination at K209 (P = 0.3426)
17:44060805:C:A,P10636,P212Q,0.303,Loss of glycosylation at P212 (P = 0.0565); Gain of methylation at K215 (P = 0.2586); Gain of solvent accessibility (P = 0.3418); Gain of ubiquitination at K209 (P = 0.3433); Gain of MoRF binding (P = 0.4699)
17:44060805:C:G,P10636,P212R,0.304,Loss of glycosylation at P212 (P = 0.0565); Gain of MoRF binding (P = 0.1136); Loss of methylation at K215 (P = 0.2064); Gain of solvent accessibility (P = 0.2097); Gain of ubiquitination at K209 (P = 0.3433)
17:44060807:G:C,P10636,G213R,0.325,Gain of solvent accessibility (P = 0.0037); Loss of methylation at K215 (P = 0.0468); Loss of glycosylation at K215 (P = 0.0635); Gain of ubiquitination at K209 (P = 0.3459); Gain of MoRF binding (P = 0.3944)
17:44060807:G:T,P10636,G213W,0.329,Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at P212 (P = 0.1551); Gain of methylation at K215 (P = 0.2185); Gain of ubiquitination at K209 (P = 0.3459); Loss of solvent accessibility (P = 0.4274)
17:44060808:G:A,P10636,G213E,0.293,Gain of solvent accessibility (P = 0.024); Loss of methylation at K215 (P = 0.0697); Loss of glycosylation at K215 (P = 0.1042); Gain of ubiquitination at K209 (P = 0.3329); Gain of catalytic residue at G213 (P = 0.5325)
17:44060808:G:C,P10636,G213A,0.306,Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K215 (P = 0.1609); Loss of methylation at K215 (P = 0.2446); Loss of solvent accessibility (P = 0.2882); Gain of ubiquitination at K209 (P = 0.3355)
17:44060808:G:T,P10636,G213V,0.315,Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at K215 (P = 0.1294); Gain of methylation at K215 (P = 0.1939); Loss of solvent accessibility (P = 0.2668); Gain of ubiquitination at K209 (P = 0.3215)
17:44060810:A:C,P10636,S214R,0.222,Loss of phosphorylation at S214 (P = 8e-04); Gain of glycosylation at K215 (P = 0.1359); Gain of methylation at K215 (P = 0.1669); Gain of solvent accessibility (P = 0.204); Loss of ubiquitination at K209 (P = 0.3336)
17:44060810:A:G,P10636,S214G,0.198,Loss of phosphorylation at S214 (P = 8e-04); Loss of stability (P = 0.1099); Loss of glycosylation at P212 (P = 0.1355); Loss of methylation at K215 (P = 0.2168); Loss of ubiquitination at K209 (P = 0.3336)
17:44060810:A:T,P10636,S214C,0.219,Loss of phosphorylation at S214 (P = 8e-04); Gain of methylation at K215 (P = 0.0598); Gain of glycosylation at K215 (P = 0.1841); Loss of ubiquitination at K209 (P = 0.3426); Loss of stability (P = 0.3723)
17:44060811:G:A,P10636,S214N,0.212,Loss of phosphorylation at S214 (P = 8e-04); Loss of glycosylation at P212 (P = 0.1518); Gain of methylation at K215 (P = 0.2208); Loss of stability (P = 0.2879); Loss of ubiquitination at K209 (P = 0.3336)
17:44060811:G:C,P10636,S214T,0.223,Gain of glycosylation at K209 (P = 0.1925); Gain of methylation at K215 (P = 0.2304); Loss of stability (P = 0.2642); Gain of ubiquitination at K209 (P = 0.3407); Gain of solvent accessibility (P = 0.571)
17:44060811:G:T,P10636,S214I,0.208,Loss of phosphorylation at S214 (P = 8e-04); Loss of glycosylation at P212 (P = 0.161); Gain of methylation at K215 (P = 0.2007); Gain of ubiquitination at K209 (P = 0.3459); Gain of catalytic residue at K209 (P = 0.6176)
17:44060812:C:A,P10636,S214R,0.222,Loss of phosphorylation at S214 (P = 8e-04); Gain of glycosylation at K215 (P = 0.1359); Gain of methylation at K215 (P = 0.1669); Gain of solvent accessibility (P = 0.204); Loss of ubiquitination at K209 (P = 0.3336)
17:44060812:C:G,P10636,S214R,0.222,Loss of phosphorylation at S214 (P = 8e-04); Gain of glycosylation at K215 (P = 0.1359); Gain of methylation at K215 (P = 0.1669); Gain of solvent accessibility (P = 0.204); Loss of ubiquitination at K209 (P = 0.3336)
17:44060813:A:C,P10636,K215Q,0.214,Loss of ubiquitination at K215 (P = 0.0027); Loss of methylation at K215 (P = 0.0095); Loss of glycosylation at K215 (P = 0.0232); Loss of solvent accessibility (P = 0.0364); Loss of relative solvent accessibility (P = 0.107)
17:44060813:A:G,P10636,K215E,0.252,Loss of ubiquitination at K215 (P = 0.0027); Loss of methylation at K215 (P = 0.0095); Loss of glycosylation at K215 (P = 0.0232); Loss of solvent accessibility (P = 0.089); Loss of relative solvent accessibility (P = 0.1967)
17:44060814:A:C,P10636,K215T,0.262,Loss of ubiquitination at K215 (P = 0.0027); Loss of solvent accessibility (P = 0.0056); Gain of phosphorylation at K215 (P = 0.0067); Loss of methylation at K215 (P = 0.0095); Gain of glycosylation at S214 (P = 0.0595)
17:44060814:A:G,P10636,K215R,0.237,Loss of ubiquitination at K215 (P = 0.0027); Loss of methylation at K215 (P = 0.0114); Loss of solvent accessibility (P = 0.0217); Loss of glycosylation at K215 (P = 0.0232); Loss of relative solvent accessibility (P = 0.0676)
17:44060814:A:T,P10636,K215M,0.294,Loss of ubiquitination at K215 (P = 0.0027); Loss of methylation at K215 (P = 0.0095); Loss of solvent accessibility (P = 0.01); Loss of glycosylation at K215 (P = 0.0232); Loss of relative solvent accessibility (P = 0.0676)
17:44060815:G:C,P10636,K215N,0.236,Loss of ubiquitination at K215 (P = 0.0027); Loss of solvent accessibility (P = 0.0079); Loss of methylation at K215 (P = 0.0095); Loss of glycosylation at K215 (P = 0.0232); Loss of relative solvent accessibility (P = 0.0676)
17:44060815:G:T,P10636,K215N,0.236,Loss of ubiquitination at K215 (P = 0.0027); Loss of solvent accessibility (P = 0.0079); Loss of methylation at K215 (P = 0.0095); Loss of glycosylation at K215 (P = 0.0232); Loss of relative solvent accessibility (P = 0.0676)
17:44060816:G:A,P10636,E216K,0.242,Gain of ubiquitination at E216 (P = 0.0025); Gain of methylation at E216 (P = 0.0165); Gain of glycosylation at E216 (P = 0.0346); Loss of stability (P = 0.2483); Gain of MoRF binding (P = 0.3519)
17:44060816:G:C,P10636,E216Q,0.147,Gain of glycosylation at P212 (P = 0.1819); Gain of methylation at K215 (P = 0.1888); Gain of ubiquitination at K215 (P = 0.3643); Loss of solvent accessibility (P = 0.4141); Gain of MoRF binding (P = 0.5295)
17:44060817:A:C,P10636,E216A,0.183,Loss of solvent accessibility (P = 0.0023); Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at K215 (P = 0.166); Loss of methylation at K215 (P = 0.1933); Gain of ubiquitination at K215 (P = 0.3614)
17:44060817:A:G,P10636,E216G,0.145,Loss of solvent accessibility (P = 0.0387); Gain of catalytic residue at P212 (P = 0.0924); Loss of stability (P = 0.1171); Gain of glycosylation at K215 (P = 0.1624); Loss of methylation at K215 (P = 0.2218)
17:44060817:A:T,P10636,E216V,0.184,Loss of solvent accessibility (P = 0.0052); Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at K215 (P = 0.107); Gain of methylation at K215 (P = 0.1395); Gain of ubiquitination at K215 (P = 0.3629)
17:44060818:G:C,P10636,E216D,0.141,Loss of methylation at K215 (P = 0.1469); Loss of glycosylation at K215 (P = 0.2157); Gain of ubiquitination at K215 (P = 0.3685); Loss of solvent accessibility (P = 0.4653); Loss of stability (P = 0.5015)
17:44060818:G:T,P10636,E216D,0.141,Loss of methylation at K215 (P = 0.1469); Loss of glycosylation at K215 (P = 0.2157); Gain of ubiquitination at K215 (P = 0.3685); Loss of solvent accessibility (P = 0.4653); Loss of stability (P = 0.5015)
17:44060819:G:A,P10636,E217K,0.351,Gain of ubiquitination at E217 (P = 0.0037); Gain of methylation at E217 (P = 0.0145); Gain of glycosylation at E217 (P = 0.0682); Gain of solvent accessibility (P = 0.0739); Gain of relative solvent accessibility (P = 0.09)
17:44060819:G:C,P10636,E217Q,0.304,Loss of glycosylation at K215 (P = 0.1587); Gain of methylation at K215 (P = 0.1887); Gain of ubiquitination at K215 (P = 0.3643); Loss of solvent accessibility (P = 0.5485); Loss of stability (P = 0.5716)
17:44060820:A:C,P10636,E217A,0.31,Gain of glycosylation at S214 (P = 0.0785); Loss of stability (P = 0.2053); Loss of solvent accessibility (P = 0.2106); Loss of methylation at K215 (P = 0.2142); Gain of ubiquitination at K215 (P = 0.3614)
17:44060820:A:G,P10636,E217G,0.321,Gain of glycosylation at S214 (P = 0.0635); Loss of stability (P = 0.0719); Loss of solvent accessibility (P = 0.1868); Loss of methylation at K215 (P = 0.2505); Gain of ubiquitination at K215 (P = 0.3671)
17:44060820:A:T,P10636,E217V,0.302,Gain of glycosylation at S214 (P = 0.0589); Loss of solvent accessibility (P = 0.1986); Gain of methylation at K215 (P = 0.2257); Gain of ubiquitination at K215 (P = 0.3565); Loss of relative solvent accessibility (P = 0.3919)
17:44060821:G:C,P10636,E217D,0.309,Loss of methylation at K215 (P = 0.1542); Loss of glycosylation at K215 (P = 0.1597); Gain of ubiquitination at K215 (P = 0.3685); Loss of solvent accessibility (P = 0.4011); Loss of stability (P = 0.4442)
17:44060821:G:T,P10636,E217D,0.309,Loss of methylation at K215 (P = 0.1542); Loss of glycosylation at K215 (P = 0.1597); Gain of ubiquitination at K215 (P = 0.3685); Loss of solvent accessibility (P = 0.4011); Loss of stability (P = 0.4442)
17:44060822:G:A,P10636,V218M,0.233,Gain of glycosylation at K215 (P = 0.1654); Loss of stability (P = 0.2207); Gain of methylation at K215 (P = 0.2374); Loss of ubiquitination at K215 (P = 0.3326); Gain of solvent accessibility (P = 0.3956)
17:44060822:G:C,P10636,V218L,0.219,Loss of methylation at K215 (P = 0.1081); Gain of glycosylation at K215 (P = 0.1853); Loss of ubiquitination at K215 (P = 0.3603); Gain of solvent accessibility (P = 0.4946); Loss of stability (P = 0.5513)
17:44060822:G:T,P10636,V218L,0.219,Loss of methylation at K215 (P = 0.1081); Gain of glycosylation at K215 (P = 0.1853); Loss of ubiquitination at K215 (P = 0.3603); Gain of solvent accessibility (P = 0.4946); Loss of stability (P = 0.5513)
17:44060823:T:A,P10636,V218E,0.265,Gain of solvent accessibility (P = 0.006); Gain of relative solvent accessibility (P = 0.0166); Loss of stability (P = 0.0914); Gain of glycosylation at K215 (P = 0.1789); Gain of methylation at K215 (P = 0.2505)
17:44060823:T:C,P10636,V218A,0.259,Loss of stability (P = 0.044); Loss of methylation at K215 (P = 0.1739); Gain of glycosylation at K215 (P = 0.1744); Loss of ubiquitination at K215 (P = 0.3603); Loss of solvent accessibility (P = 0.7428)
17:44060823:T:G,P10636,V218G,0.282,Loss of stability (P = 0.0032); Gain of glycosylation at K215 (P = 0.148); Gain of methylation at K215 (P = 0.2618); Loss of ubiquitination at K215 (P = 0.3216); Loss of solvent accessibility (P = 0.6392)
17:44060825:G:A,P10636,D219N,0.148,Loss of solvent accessibility (P = 0.0595); Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at K215 (P = 0.2218); Loss of methylation at K215 (P = 0.2398); Gain of ubiquitination at K215 (P = 0.3671)
17:44060825:G:C,P10636,D219H,0.145,Loss of solvent accessibility (P = 0.1473); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at K215 (P = 0.1982); Loss of methylation at K215 (P = 0.2236); Gain of catalytic residue at D221 (P = 0.2361)
17:44060825:G:T,P10636,D219Y,0.232,Gain of phosphorylation at D219 (P = 2e-04); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2073); Gain of methylation at K215 (P = 0.2087); Loss of glycosylation at K215 (P = 0.2271)
17:44060826:A:C,P10636,D219A,0.135,Loss of solvent accessibility (P = 0.0595); Loss of methylation at K215 (P = 0.1067); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at K215 (P = 0.266); Gain of ubiquitination at K215 (P = 0.3685)
17:44060826:A:G,P10636,D219G,0.135,Loss of solvent accessibility (P = 0.0477); Loss of methylation at K215 (P = 0.1708); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at K215 (P = 0.2354); Loss of ubiquitination at K215 (P = 0.3673)
17:44060826:A:T,P10636,D219V,0.145,Loss of solvent accessibility (P = 0.0907); Loss of methylation at K215 (P = 0.1554); Loss of glycosylation at K215 (P = 0.1654); Loss of relative solvent accessibility (P = 0.1807); Gain of ubiquitination at K215 (P = 0.3614)
17:44060827:T:A,P10636,D219E,0.179,Loss of solvent accessibility (P = 0.1651); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at K215 (P = 0.2341); Gain of methylation at K215 (P = 0.247); Loss of ubiquitination at K215 (P = 0.3603)
17:44060827:T:G,P10636,D219E,0.179,Loss of solvent accessibility (P = 0.1651); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at K215 (P = 0.2341); Gain of methylation at K215 (P = 0.247); Loss of ubiquitination at K215 (P = 0.3603)
17:44060828:G:A,P10636,E220K,0.323,Gain of ubiquitination at E220 (P = 0.0054); Gain of solvent accessibility (P = 0.0314); Gain of methylation at E220 (P = 0.0453); Gain of relative solvent accessibility (P = 0.0479); Gain of glycosylation at E220 (P = 0.0559)
17:44060828:G:C,P10636,E220Q,0.295,Loss of stability (P = 0.1809); Loss of glycosylation at K215 (P = 0.2393); Gain of methylation at K215 (P = 0.249); Gain of ubiquitination at K215 (P = 0.366); Gain of solvent accessibility (P = 0.5946)
17:44060829:A:C,P10636,E220A,0.297,Loss of methylation at K215 (P = 0.0879); Loss of stability (P = 0.1415); Loss of glycosylation at K215 (P = 0.2217); Loss of solvent accessibility (P = 0.3543); Gain of ubiquitination at K215 (P = 0.3597)
17:44060829:A:G,P10636,E220G,0.298,Loss of stability (P = 0.0255); Loss of methylation at K215 (P = 0.1499); Loss of glycosylation at K215 (P = 0.2547); Loss of solvent accessibility (P = 0.3103); Gain of ubiquitination at K215 (P = 0.3685)
17:44060829:A:T,P10636,E220V,0.28,Loss of methylation at K215 (P = 0.128); Loss of glycosylation at K215 (P = 0.1378); Gain of ubiquitination at K215 (P = 0.358); Loss of solvent accessibility (P = 0.4274); Loss of stability (P = 0.4898)
17:44060830:A:C,P10636,E220D,0.299,Loss of stability (P = 0.1314); Loss of methylation at K215 (P = 0.2275); Loss of glycosylation at K215 (P = 0.2486); Gain of ubiquitination at K215 (P = 0.3696); Loss of solvent accessibility (P = 0.7699)
17:44060830:A:T,P10636,E220D,0.299,Loss of stability (P = 0.1314); Loss of methylation at K215 (P = 0.2275); Loss of glycosylation at K215 (P = 0.2486); Gain of ubiquitination at K215 (P = 0.3696); Loss of solvent accessibility (P = 0.7699)
17:44060831:G:A,P10636,D221N,0.293,Loss of stability (P = 0.1144); Gain of methylation at R222 (P = 0.661); Loss of helix (P = 0.7775); Gain of MoRF binding (P = 0.7907); Loss of solvent accessibility (P = 0.9548)
17:44060831:G:C,P10636,D221H,0.298,Loss of stability (P = 0.0592); Gain of methylation at R222 (P = 0.6774); Loss of solvent accessibility (P = 0.7091); Loss of helix (P = 0.7775); Gain of MoRF binding (P = 0.7919)
17:44060831:G:T,P10636,D221Y,0.301,Gain of phosphorylation at D221 (P = 0); Loss of stability (P = 0.1646); Loss of relative solvent accessibility (P = 0.3919); Loss of solvent accessibility (P = 0.5185); Gain of methylation at R222 (P = 0.6647)
17:44060832:A:C,P10636,D221A,0.31,Loss of stability (P = 0.0202); Loss of solvent accessibility (P = 0.3543); Gain of methylation at R222 (P = 0.6498); Gain of MoRF binding (P = 0.7353); Loss of helix (P = 0.7775)
17:44060832:A:G,P10636,D221G,0.286,Loss of stability (P = 0.0251); Loss of solvent accessibility (P = 0.2953); Gain of methylation at R222 (P = 0.6167); Gain of MoRF binding (P = 0.7522); Loss of helix (P = 0.7775)
17:44060832:A:T,P10636,D221V,0.293,Loss of solvent accessibility (P = 0.322); Loss of relative solvent accessibility (P = 0.3919); Gain of sheet (P = 0.6509); Gain of methylation at R222 (P = 0.662); Loss of stability (P = 0.6622)
17:44060833:C:A,P10636,D221E,0.27,Loss of stability (P = 0.1992); Gain of solvent accessibility (P = 0.4067); Gain of methylation at R222 (P = 0.6723); Gain of MoRF binding (P = 0.8695); Loss of helix (P = 0.9149)
17:44060833:C:G,P10636,D221E,0.27,Loss of stability (P = 0.1992); Gain of solvent accessibility (P = 0.4067); Gain of methylation at R222 (P = 0.6723); Gain of MoRF binding (P = 0.8695); Loss of helix (P = 0.9149)
17:44060834:C:G,P10636,R222G,0.357,Loss of stability (P = 0.0509); Loss of solvent accessibility (P = 0.1744); Gain of glycosylation at S227 (P = 0.3091); Loss of methylation at R222 (P = 0.6837); Loss of phosphorylation at S227 (P = 0.783)
17:44060834:C:T,P10636,R222C,0.349,Gain of catalytic residue at V224 (P = 0.0626); Gain of glycosylation at S227 (P = 0.1553); Loss of solvent accessibility (P = 0.1744); Loss of stability (P = 0.2382); Loss of relative solvent accessibility (P = 0.5582)
17:44060835:G:A,P10636,R222H,0.339,Loss of stability (P = 0.0887); Gain of glycosylation at S227 (P = 0.1335); Gain of catalytic residue at D221 (P = 0.266); Loss of solvent accessibility (P = 0.3473); Loss of methylation at R222 (P = 0.6837)
17:44060835:G:C,P10636,R222P,0.375,Loss of loop (P = 0.0603); Loss of stability (P = 0.0777); Gain of helix (P = 0.0893); Gain of glycosylation at S227 (P = 0.135); Gain of relative solvent accessibility (P = 0.2363)
17:44060835:G:T,P10636,R222L,0.382,Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.154); Gain of glycosylation at S227 (P = 0.1989); Gain of sheet (P = 0.6509); Loss of stability (P = 0.6593)
17:44060837:G:A,P10636,D223N,0.137,Loss of stability (P = 0.1812); Loss of glycosylation at S228 (P = 0.2653); Gain of methylation at R222 (P = 0.6599); Loss of phosphorylation at S227 (P = 0.7447); Gain of MoRF binding (P = 0.8691)
17:44060837:G:C,P10636,D223H,0.138,Loss of stability (P = 0.0811); Gain of glycosylation at S228 (P = 0.3006); Gain of catalytic residue at D221 (P = 0.3184); Gain of solvent accessibility (P = 0.4946); Gain of sheet (P = 0.6509)
17:44060837:G:T,P10636,D223Y,0.214,Gain of phosphorylation at D223 (P = 4e-04); Loss of stability (P = 0.1774); Loss of glycosylation at S228 (P = 0.2896); Gain of solvent accessibility (P = 0.348); Gain of sheet (P = 0.6509)
17:44060838:A:C,P10636,D223A,0.124,Loss of stability (P = 0.0768); Loss of glycosylation at S228 (P = 0.2916); Gain of catalytic residue at D221 (P = 0.3933); Loss of solvent accessibility (P = 0.6392); Gain of methylation at R222 (P = 0.6522)
17:44060838:A:G,P10636,D223G,0.166,Loss of stability (P = 0.0315); Loss of glycosylation at S228 (P = 0.1722); Gain of catalytic residue at V224 (P = 0.2261); Loss of solvent accessibility (P = 0.5288); Gain of methylation at R222 (P = 0.6231)
17:44060838:A:T,P10636,D223V,0.114,Loss of glycosylation at S228 (P = 0.2179); Loss of stability (P = 0.379); Loss of solvent accessibility (P = 0.5904); Gain of sheet (P = 0.6509); Gain of methylation at R222 (P = 0.6644)
17:44060839:C:A,P10636,D223E,0.13,Loss of glycosylation at S228 (P = 0.251); Loss of stability (P = 0.2781); Gain of solvent accessibility (P = 0.4496); Gain of methylation at R222 (P = 0.6724); Gain of phosphorylation at S227 (P = 0.794)
17:44060839:C:G,P10636,D223E,0.13,Loss of glycosylation at S228 (P = 0.251); Loss of stability (P = 0.2781); Gain of solvent accessibility (P = 0.4496); Gain of methylation at R222 (P = 0.6724); Gain of phosphorylation at S227 (P = 0.794)
17:44060840:G:A,P10636,V224I,0.133,Gain of glycosylation at S227 (P = 0.1947); Gain of catalytic residue at V224 (P = 0.21); Loss of stability (P = 0.5655); Gain of methylation at R222 (P = 0.68); Loss of phosphorylation at S227 (P = 0.7861)
17:44060840:G:C,P10636,V224L,0.125,Loss of glycosylation at S228 (P = 0.3121); Gain of solvent accessibility (P = 0.4946); Loss of stability (P = 0.6702); Gain of methylation at R222 (P = 0.6763); Gain of phosphorylation at S227 (P = 0.7936)
17:44060840:G:T,P10636,V224F,0.107,Gain of glycosylation at S227 (P = 0.1452); Loss of stability (P = 0.2041); Gain of catalytic residue at V224 (P = 0.3145); Gain of methylation at R222 (P = 0.6714); Loss of phosphorylation at S227 (P = 0.7875)
17:44060841:T:A,P10636,V224D,0.168,Gain of helix (P = 0.0349); Loss of loop (P = 0.0603); Gain of glycosylation at S228 (P = 0.0643); Loss of stability (P = 0.0679); Gain of solvent accessibility (P = 0.5093)
17:44060841:T:C,P10636,V224A,0.182,Loss of stability (P = 0.0434); Gain of glycosylation at S228 (P = 0.0879); Loss of solvent accessibility (P = 0.5743); Gain of methylation at R222 (P = 0.6607); Gain of phosphorylation at S227 (P = 0.7929)
17:44060843:G:A,P10636,D225N,0.25,Gain of glycosylation at S228 (P = 0.2879); Loss of stability (P = 0.3151); Gain of catalytic residue at D225 (P = 0.3717); Loss of solvent accessibility (P = 0.6392); Gain of methylation at R222 (P = 0.6551)
17:44060843:G:C,P10636,D225H,0.273,Gain of glycosylation at S228 (P = 0.2431); Loss of stability (P = 0.3059); Gain of solvent accessibility (P = 0.4946); Gain of sheet (P = 0.6509); Gain of methylation at R222 (P = 0.6522)
17:44060843:G:T,P10636,D225Y,0.325,Gain of phosphorylation at D225 (P = 2e-04); Gain of catalytic residue at P229 (P = 0.089); Gain of glycosylation at S227 (P = 0.1199); Loss of stability (P = 0.5881); Gain of sheet (P = 0.6509)
17:44060844:A:C,P10636,D225A,0.296,Gain of glycosylation at S228 (P = 0.1039); Loss of stability (P = 0.2569); Loss of solvent accessibility (P = 0.4838); Gain of methylation at R222 (P = 0.65); Loss of phosphorylation at S227 (P = 0.7605)
17:44060844:A:G,P10636,D225G,0.297,Loss of stability (P = 0.0907); Gain of glycosylation at S227 (P = 0.2156); Loss of solvent accessibility (P = 0.4141); Gain of methylation at R222 (P = 0.6468); Loss of phosphorylation at S227 (P = 0.765)
17:44060844:A:T,P10636,D225V,0.301,Gain of glycosylation at S228 (P = 0.0856); Loss of solvent accessibility (P = 0.5904); Gain of sheet (P = 0.6509); Gain of methylation at R222 (P = 0.6647); Loss of stability (P = 0.7061)
17:44060845:T:A,P10636,D225E,0.263,Gain of glycosylation at S227 (P = 0.1309); Gain of solvent accessibility (P = 0.4496); Loss of stability (P = 0.5384); Gain of methylation at R222 (P = 0.6671); Gain of phosphorylation at S227 (P = 0.7938)
17:44060845:T:G,P10636,D225E,0.263,Gain of glycosylation at S227 (P = 0.1309); Gain of solvent accessibility (P = 0.4496); Loss of stability (P = 0.5384); Gain of methylation at R222 (P = 0.6671); Gain of phosphorylation at S227 (P = 0.7938)
17:44060846:G:A,P10636,E226K,0.277,Gain of ubiquitination at E226 (P = 0.006); Gain of methylation at E226 (P = 0.0099); Gain of solvent accessibility (P = 0.0314); Gain of relative solvent accessibility (P = 0.0479); Loss of loop (P = 0.0603)
17:44060846:G:C,P10636,E226Q,0.236,Gain of solvent accessibility (P = 0.0367); Gain of relative solvent accessibility (P = 0.0479); Loss of loop (P = 0.0603); Gain of helix (P = 0.0893); Gain of glycosylation at S227 (P = 0.131)
17:44060847:A:C,P10636,E226A,0.216,Gain of glycosylation at S227 (P = 0.1508); Loss of solvent accessibility (P = 0.3543); Loss of stability (P = 0.6381); Gain of methylation at R222 (P = 0.6624); Loss of phosphorylation at S227 (P = 0.7605)
17:44060847:A:G,P10636,E226G,0.214,Gain of glycosylation at S227 (P = 0.1087); Loss of stability (P = 0.2694); Loss of solvent accessibility (P = 0.4011); Gain of methylation at R222 (P = 0.6625); Gain of catalytic residue at D221 (P = 0.752)
17:44060847:A:T,P10636,E226V,0.264,Gain of helix (P = 0.0164); Loss of loop (P = 0.0288); Gain of catalytic residue at E226 (P = 0.0502); Gain of glycosylation at S227 (P = 0.1547); Gain of relative solvent accessibility (P = 0.2363)
17:44060848:G:C,P10636,E226D,0.222,Gain of relative solvent accessibility (P = 0.0479); Gain of helix (P = 0.0893); Gain of solvent accessibility (P = 0.0917); Gain of glycosylation at S227 (P = 0.1211); Loss of loop (P = 0.2897)
17:44060848:G:T,P10636,E226D,0.222,Gain of relative solvent accessibility (P = 0.0479); Gain of helix (P = 0.0893); Gain of solvent accessibility (P = 0.0917); Gain of glycosylation at S227 (P = 0.1211); Loss of loop (P = 0.2897)
17:44060849:T:A,P10636,S227T,0.342,Gain of glycosylation at S232 (P = 0.1656); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2073); Gain of methylation at R222 (P = 0.6747); Loss of phosphorylation at S227 (P = 0.7345)
17:44060849:T:C,P10636,S227P,0.346,Loss of phosphorylation at S227 (P = 0.0028); Loss of glycosylation at S227 (P = 0.1229); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2455); Loss of stability (P = 0.3807)
17:44060849:T:G,P10636,S227A,0.323,Loss of phosphorylation at S227 (P = 0.0028); Loss of glycosylation at S227 (P = 0.0832); Loss of stability (P = 0.6064); Loss of solvent accessibility (P = 0.6392); Gain of methylation at R222 (P = 0.671)
17:44060850:C:A,P10636,S227Y,0.352,Loss of glycosylation at S227 (P = 0.0832); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.239); Gain of methylation at R222 (P = 0.6739); Loss of phosphorylation at S232 (P = 0.7885)
17:44060850:C:G,P10636,S227C,0.369,Loss of phosphorylation at S227 (P = 0.0028); Loss of glycosylation at S227 (P = 0.0832); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1986); Gain of methylation at R222 (P = 0.6783)
17:44060850:C:T,P10636,S227F,0.363,Loss of phosphorylation at S227 (P = 0.0028); Gain of glycosylation at S228 (P = 0.0735); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1952); Gain of sheet (P = 0.6509)
17:44060852:T:A,P10636,S228T,0.309,Gain of glycosylation at S227 (P = 0.0495); Loss of stability (P = 0.2675); Gain of catalytic residue at S228 (P = 0.5253); Loss of phosphorylation at S227 (P = 0.7417); Loss of solvent accessibility (P = 0.7428)
17:44060852:T:C,P10636,S228P,0.353,Loss of phosphorylation at S228 (P = 0.0013); Gain of catalytic residue at S228 (P = 0.005); Gain of glycosylation at S227 (P = 0.1201); Loss of stability (P = 0.1383); Gain of solvent accessibility (P = 0.5946)
17:44060852:T:G,P10636,S228A,0.319,Loss of phosphorylation at S228 (P = 0.0013); Loss of glycosylation at S228 (P = 0.0526); Loss of stability (P = 0.2396); Loss of solvent accessibility (P = 0.8212); Gain of MoRF binding (P = 0.9407)
17:44060853:C:A,P10636,S228Y,0.334,Loss of glycosylation at S228 (P = 0.0526); Loss of stability (P = 0.5056); Gain of solvent accessibility (P = 0.5334); Loss of phosphorylation at S228 (P = 0.6979); Loss of relative solvent accessibility (P = 0.93)
17:44060853:C:T,P10636,S228F,0.363,Loss of phosphorylation at S228 (P = 0.0013); Loss of glycosylation at S228 (P = 0.0526); Loss of relative solvent accessibility (P = 0.5582); Loss of solvent accessibility (P = 0.6498); Gain of sheet (P = 0.6509)
17:44060855:C:A,P10636,P229T,0.352,Gain of phosphorylation at P229 (P = 0.0078); Gain of glycosylation at P229 (P = 0.0116); Loss of stability (P = 0.1953); Loss of solvent accessibility (P = 0.7225); Gain of MoRF binding (P = 0.893)
17:44060855:C:G,P10636,P229A,0.36,Loss of stability (P = 0.092); Gain of glycosylation at S228 (P = 0.1283); Loss of solvent accessibility (P = 0.6134); Loss of phosphorylation at S227 (P = 0.77); Gain of MoRF binding (P = 0.8876)
17:44060856:C:A,P10636,P229H,0.341,Loss of glycosylation at P233 (P = 0.1795); Loss of stability (P = 0.2142); Gain of catalytic residue at P229 (P = 0.219); Loss of phosphorylation at S227 (P = 0.7481); Gain of MoRF binding (P = 0.8941)
17:44060856:C:G,P10636,P229R,0.362,Loss of glycosylation at S232 (P = 0.1176); Gain of solvent accessibility (P = 0.2097); Gain of catalytic residue at P229 (P = 0.2315); Loss of stability (P = 0.3323); Gain of methylation at P229 (P = 0.6063)
17:44060856:C:T,P10636,P229L,0.332,Gain of glycosylation at S228 (P = 0.1441); Loss of stability (P = 0.7255); Loss of phosphorylation at S227 (P = 0.7417); Loss of solvent accessibility (P = 0.8212); Gain of MoRF binding (P = 0.9033)
17:44060858:C:A,P10636,Q230K,0.29,Gain of methylation at Q230 (P = 0.0037); Gain of ubiquitination at Q230 (P = 0.0085); Gain of catalytic residue at Q230 (P = 0.0457); Gain of glycosylation at Q230 (P = 0.0502); Loss of stability (P = 0.2251)
17:44060858:C:G,P10636,Q230E,0.289,Gain of glycosylation at S232 (P = 0.1699); Gain of sheet (P = 0.6509); Loss of stability (P = 0.6829); Gain of phosphorylation at S235 (P = 0.7731); Gain of helix (P = 0.7803)
17:44060859:A:C,P10636,Q230P,0.33,Gain of catalytic residue at P229 (P = 0.018); Gain of glycosylation at Q230 (P = 0.0183); Loss of solvent accessibility (P = 0.1868); Loss of stability (P = 0.2942); Gain of phosphorylation at S235 (P = 0.7728)
17:44060859:A:T,P10636,Q230L,0.297,Loss of solvent accessibility (P = 0.0052); Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at S228 (P = 0.065); Gain of catalytic residue at Q230 (P = 0.1401); Loss of phosphorylation at S235 (P = 0.77)
17:44060860:A:C,P10636,Q230H,0.282,Loss of solvent accessibility (P = 0.0056); Loss of relative solvent accessibility (P = 0.0404); Gain of catalytic residue at Q230 (P = 0.1953); Loss of glycosylation at P233 (P = 0.1963); Loss of stability (P = 0.3355)
17:44060860:A:T,P10636,Q230H,0.282,Loss of solvent accessibility (P = 0.0056); Loss of relative solvent accessibility (P = 0.0404); Gain of catalytic residue at Q230 (P = 0.1953); Loss of glycosylation at P233 (P = 0.1963); Loss of stability (P = 0.3355)
17:44060861:G:A,P10636,D231N,0.273,Gain of glycosylation at P233 (P = 0.0844); Loss of methylation at K236 (P = 0.2522); Gain of ubiquitination at K236 (P = 0.2793); Loss of solvent accessibility (P = 0.4011); Gain of catalytic residue at D231 (P = 0.466)
17:44060861:G:C,P10636,D231H,0.271,Gain of glycosylation at P233 (P = 0.0974); Gain of catalytic residue at D231 (P = 0.1431); Loss of methylation at K236 (P = 0.2295); Gain of ubiquitination at K236 (P = 0.2713); Loss of relative solvent accessibility (P = 0.5582)
17:44060861:G:T,P10636,D231Y,0.324,Gain of phosphorylation at D231 (P = 0.0017); Gain of catalytic residue at D231 (P = 0.0117); Loss of solvent accessibility (P = 0.0352); Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at P233 (P = 0.0856)
17:44060862:A:C,P10636,D231A,0.268,Gain of glycosylation at P233 (P = 0.0954); Loss of solvent accessibility (P = 0.2073); Loss of methylation at K236 (P = 0.2152); Loss of ubiquitination at K236 (P = 0.2823); Loss of stability (P = 0.7447)
17:44060862:A:G,P10636,D231G,0.291,Loss of solvent accessibility (P = 0.0387); Gain of glycosylation at S228 (P = 0.0899); Loss of relative solvent accessibility (P = 0.1967); Gain of methylation at K236 (P = 0.2678); Loss of ubiquitination at K236 (P = 0.2823)
17:44060862:A:T,P10636,D231V,0.302,Loss of solvent accessibility (P = 0.0159); Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at S228 (P = 0.0935); Gain of methylation at K236 (P = 0.2513); Gain of ubiquitination at K236 (P = 0.2625)
17:44060863:C:A,P10636,D231E,0.28,Gain of glycosylation at P233 (P = 0.0817); Gain of methylation at K236 (P = 0.258); Loss of ubiquitination at K236 (P = 0.2662); Loss of relative solvent accessibility (P = 0.5582); Loss of catalytic residue at K236 (P = 0.6154)
17:44060863:C:G,P10636,D231E,0.28,Gain of glycosylation at P233 (P = 0.0817); Gain of methylation at K236 (P = 0.258); Loss of ubiquitination at K236 (P = 0.2662); Loss of relative solvent accessibility (P = 0.5582); Loss of catalytic residue at K236 (P = 0.6154)
17:44060864:T:A,P10636,S232T,0.225,Loss of glycosylation at P233 (P = 0.1413); Gain of ubiquitination at K236 (P = 0.2713); Gain of methylation at K236 (P = 0.2749); Gain of solvent accessibility (P = 0.571); Loss of stability (P = 0.6779)
17:44060864:T:C,P10636,S232P,0.289,Loss of phosphorylation at S232 (P = 0.0015); Gain of catalytic residue at S232 (P = 0.0071); Gain of glycosylation at P233 (P = 0.0682); Gain of methylation at K236 (P = 0.2689); Gain of ubiquitination at K236 (P = 0.2793)
17:44060864:T:G,P10636,S232A,0.211,Loss of phosphorylation at S232 (P = 0.0015); Loss of glycosylation at S232 (P = 0.0211); Loss of methylation at K236 (P = 0.1311); Gain of ubiquitination at K236 (P = 0.2568); Loss of solvent accessibility (P = 0.623)
17:44060865:C:A,P10636,S232Y,0.3,Gain of catalytic residue at S232 (P = 0.0087); Loss of glycosylation at S232 (P = 0.0211); Gain of ubiquitination at K236 (P = 0.2568); Gain of solvent accessibility (P = 0.2689); Gain of methylation at K236 (P = 0.2726)
17:44060865:C:G,P10636,S232C,0.253,Loss of phosphorylation at S232 (P = 0.0015); Loss of glycosylation at S232 (P = 0.0211); Gain of catalytic residue at S232 (P = 0.073); Loss of methylation at K236 (P = 0.2331); Gain of ubiquitination at K236 (P = 0.2713)
17:44060865:C:T,P10636,S232F,0.241,Loss of phosphorylation at S232 (P = 0.0015); Loss of glycosylation at S232 (P = 0.0211); Gain of ubiquitination at K236 (P = 0.2483); Loss of methylation at K236 (P = 0.2521); Loss of MoRF binding (P = 0.8489)
17:44060867:C:A,P10636,P233T,0.293,Gain of phosphorylation at P233 (P = 6e-04); Loss of catalytic residue at P233 (P = 0.0386); Loss of glycosylation at P234 (P = 0.0631); Loss of methylation at K236 (P = 0.184); Loss of stability (P = 0.225)
17:44060867:C:G,P10636,P233A,0.234,Loss of glycosylation at P233 (P = 0.0326); Loss of catalytic residue at P233 (P = 0.0361); Loss of methylation at K236 (P = 0.0692); Loss of stability (P = 0.1153); Gain of ubiquitination at K236 (P = 0.2568)
17:44060867:C:T,P10636,P233S,0.3,Gain of phosphorylation at P233 (P = 0.0025); Loss of catalytic residue at P233 (P = 0.0056); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.1116); Loss of glycosylation at S232 (P = 0.12)
17:44060868:C:A,P10636,P233H,0.22,Loss of glycosylation at P233 (P = 0.0326); Loss of catalytic residue at P233 (P = 0.0843); Loss of methylation at K236 (P = 0.2256); Loss of stability (P = 0.2397); Gain of ubiquitination at K236 (P = 0.2713)
17:44060868:C:G,P10636,P233R,0.265,Loss of glycosylation at P233 (P = 0.0326); Gain of solvent accessibility (P = 0.0789); Loss of catalytic residue at P233 (P = 0.1666); Gain of methylation at K236 (P = 0.2088); Gain of relative solvent accessibility (P = 0.2363)
17:44060868:C:T,P10636,P233L,0.202,Loss of glycosylation at P233 (P = 0.0326); Loss of methylation at K236 (P = 0.0537); Loss of catalytic residue at P233 (P = 0.0614); Gain of ubiquitination at K236 (P = 0.2198); Loss of phosphorylation at S235 (P = 0.6322)
17:44060870:C:A,P10636,P234T,0.336,Gain of phosphorylation at P234 (P = 0.0111); Loss of catalytic residue at P233 (P = 0.0131); Gain of glycosylation at P234 (P = 0.0718); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at K236 (P = 0.182)
17:44060870:C:G,P10636,P234A,0.324,Loss of catalytic residue at P233 (P = 0.0131); Loss of glycosylation at P234 (P = 0.0207); Loss of methylation at K236 (P = 0.1319); Gain of ubiquitination at K236 (P = 0.2713); Loss of stability (P = 0.5369)
17:44060870:C:T,P10636,P234S,0.365,Gain of phosphorylation at P234 (P = 0.0023); Loss of catalytic residue at P233 (P = 0.0188); Loss of methylation at K236 (P = 0.1115); Loss of glycosylation at S232 (P = 0.1217); Gain of relative solvent accessibility (P = 0.1571)
17:44060871:C:A,P10636,P234H,0.321,Loss of catalytic residue at P233 (P = 0.0131); Loss of glycosylation at P234 (P = 0.0207); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1551); Loss of methylation at K236 (P = 0.1644)
17:44060871:C:G,P10636,P234R,0.354,Loss of catalytic residue at P233 (P = 0.0131); Loss of glycosylation at P234 (P = 0.0207); Gain of solvent accessibility (P = 0.0411); Loss of methylation at K236 (P = 0.1758); Gain of ubiquitination at K236 (P = 0.2483)
17:44060871:C:T,P10636,P234L,0.359,Loss of catalytic residue at P233 (P = 0.0131); Loss of glycosylation at P234 (P = 0.0207); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.0807); Loss of methylation at K236 (P = 0.1626)
17:44060873:T:A,P10636,S235T,0.317,Loss of glycosylation at P233 (P = 0.1525); Gain of methylation at K236 (P = 0.2426); Loss of catalytic residue at K236 (P = 0.2694); Gain of ubiquitination at K236 (P = 0.2713); Gain of solvent accessibility (P = 0.5843)
17:44060873:T:C,P10636,S235P,0.305,Loss of phosphorylation at S235 (P = 0.0038); Gain of catalytic residue at P234 (P = 0.0621); Gain of glycosylation at K236 (P = 0.0957); Gain of methylation at K236 (P = 0.2207); Gain of ubiquitination at K236 (P = 0.2625)
17:44060873:T:G,P10636,S235A,0.326,Loss of phosphorylation at S235 (P = 0.0038); Loss of glycosylation at S235 (P = 0.0112); Loss of catalytic residue at K236 (P = 0.2054); Gain of ubiquitination at K236 (P = 0.239); Gain of methylation at K236 (P = 0.2759)
17:44060874:C:A,P10636,S235Y,0.356,Gain of catalytic residue at S235 (P = 0.0109); Loss of glycosylation at S235 (P = 0.0112); Gain of ubiquitination at K236 (P = 0.2483); Loss of methylation at K236 (P = 0.275); Gain of solvent accessibility (P = 0.348)
17:44060874:C:G,P10636,S235C,0.323,Loss of phosphorylation at S235 (P = 0.0038); Loss of glycosylation at S235 (P = 0.0112); Gain of catalytic residue at P234 (P = 0.0362); Gain of methylation at K236 (P = 0.0719); Gain of ubiquitination at K236 (P = 0.2713)
17:44060874:C:T,P10636,S235F,0.315,Loss of phosphorylation at S235 (P = 0.0038); Loss of glycosylation at S235 (P = 0.0112); Gain of methylation at K236 (P = 0.1015); Gain of ubiquitination at K236 (P = 0.2287); Loss of catalytic residue at K236 (P = 0.2552)
17:44060876:A:C,P10636,K236Q,0.292,Loss of ubiquitination at K236 (P = 0.0067); Loss of methylation at K236 (P = 0.0087); Loss of catalytic residue at K236 (P = 0.0873); Loss of glycosylation at K236 (P = 0.099); Gain of relative solvent accessibility (P = 0.1571)
17:44060876:A:G,P10636,K236E,0.315,Loss of ubiquitination at K236 (P = 0.0067); Loss of methylation at K236 (P = 0.0087); Loss of glycosylation at K236 (P = 0.099); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at K236 (P = 0.1785)
17:44060877:A:C,P10636,K236T,0.313,Gain of phosphorylation at K236 (P = 0.0026); Loss of ubiquitination at K236 (P = 0.0067); Loss of methylation at K236 (P = 0.0087); Gain of glycosylation at K236 (P = 0.0169); Loss of catalytic residue at K236 (P = 0.0864)
17:44060877:A:G,P10636,K236R,0.278,Loss of ubiquitination at K236 (P = 0.0067); Loss of methylation at K236 (P = 0.0138); Loss of catalytic residue at K236 (P = 0.0968); Loss of glycosylation at K236 (P = 0.099); Loss of solvent accessibility (P = 0.1115)
17:44060877:A:T,P10636,K236M,0.302,Loss of ubiquitination at K236 (P = 0.0067); Loss of methylation at K236 (P = 0.0087); Loss of solvent accessibility (P = 0.0217); Loss of glycosylation at S235 (P = 0.0403); Loss of catalytic residue at K236 (P = 0.0601)
17:44060878:G:C,P10636,K236N,0.279,Loss of ubiquitination at K236 (P = 0.0067); Loss of methylation at K236 (P = 0.0087); Loss of glycosylation at K236 (P = 0.099); Loss of catalytic residue at K236 (P = 0.3733); Loss of solvent accessibility (P = 0.3854)
17:44060878:G:T,P10636,K236N,0.279,Loss of ubiquitination at K236 (P = 0.0067); Loss of methylation at K236 (P = 0.0087); Loss of glycosylation at K236 (P = 0.099); Loss of catalytic residue at K236 (P = 0.3733); Loss of solvent accessibility (P = 0.3854)
17:44060879:G:A,P10636,A237T,0.298,Gain of phosphorylation at A237 (P = 0.0065); Gain of glycosylation at A237 (P = 0.0157); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.1301); Gain of methylation at K236 (P = 0.2146)
17:44060879:G:C,P10636,A237P,0.264,Gain of glycosylation at A237 (P = 0.0259); Gain of methylation at K236 (P = 0.2059); Gain of solvent accessibility (P = 0.2689); Loss of ubiquitination at K236 (P = 0.2823); Gain of catalytic residue at K236 (P = 0.4909)
17:44060879:G:T,P10636,A237S,0.274,Gain of phosphorylation at A237 (P = 0.0016); Gain of glycosylation at A237 (P = 0.1056); Loss of ubiquitination at K236 (P = 0.2479); Gain of methylation at K236 (P = 0.2569); Gain of solvent accessibility (P = 0.3089)
17:44060880:C:A,P10636,A237D,0.269,Gain of solvent accessibility (P = 0.1154); Gain of glycosylation at S232 (P = 0.1494); Gain of ubiquitination at K236 (P = 0.2625); Gain of methylation at K236 (P = 0.2711); Loss of MoRF binding (P = 0.6636)
17:44060880:C:G,P10636,A237G,0.243,Loss of glycosylation at P234 (P = 0.1174); Loss of ubiquitination at K236 (P = 0.2479); Gain of methylation at K236 (P = 0.2555); Loss of solvent accessibility (P = 0.3744); Loss of stability (P = 0.4599)
17:44060880:C:T,P10636,A237V,0.313,Loss of relative solvent accessibility (P = 0.0186); Loss of solvent accessibility (P = 0.0807); Loss of glycosylation at S232 (P = 0.0947); Gain of methylation at K236 (P = 0.132); Gain of ubiquitination at K236 (P = 0.2287)
17:44060882:T:A,P10636,S238T,0.148,Gain of methylation at K236 (P = 0.2234); Gain of glycosylation at P233 (P = 0.2611); Gain of ubiquitination at K236 (P = 0.2713); Gain of solvent accessibility (P = 0.5843); Loss of MoRF binding (P = 0.656)
17:44060882:T:C,P10636,S238P,0.176,Gain of catalytic residue at S238 (P = 0.0028); Loss of phosphorylation at S238 (P = 0.0048); Gain of glycosylation at P239 (P = 0.0977); Gain of methylation at K236 (P = 0.2095); Gain of ubiquitination at K236 (P = 0.2793)
17:44060882:T:G,P10636,S238A,0.125,Loss of phosphorylation at S238 (P = 0.0048); Loss of glycosylation at S238 (P = 0.0441); Gain of methylation at K236 (P = 0.2502); Gain of ubiquitination at K236 (P = 0.2713); Gain of catalytic residue at S238 (P = 0.5327)
17:44060883:C:A,P10636,S238Y,0.219,Gain of catalytic residue at S238 (P = 0.0368); Loss of glycosylation at S238 (P = 0.0441); Gain of methylation at K236 (P = 0.2187); Gain of ubiquitination at K236 (P = 0.2483); Gain of solvent accessibility (P = 0.348)
17:44060883:C:G,P10636,S238C,0.146,Loss of phosphorylation at S238 (P = 0.0048); Gain of catalytic residue at S238 (P = 0.0394); Loss of glycosylation at S238 (P = 0.0441); Gain of methylation at K236 (P = 0.2005); Loss of ubiquitination at K236 (P = 0.2823)
17:44060883:C:T,P10636,S238F,0.138,Loss of phosphorylation at S238 (P = 0.0048); Loss of glycosylation at S238 (P = 0.0441); Gain of methylation at K236 (P = 0.1772); Gain of ubiquitination at K236 (P = 0.2287); Gain of solvent accessibility (P = 0.4067)
17:44060885:C:A,P10636,P239T,0.429,Gain of phosphorylation at P239 (P = 0.0051); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.0721); Gain of glycosylation at S238 (P = 0.0801); Loss of catalytic residue at P239 (P = 0.2118)
17:44060885:C:G,P10636,P239A,0.418,Loss of glycosylation at P239 (P = 0.0962); Loss of methylation at K236 (P = 0.0999); Loss of catalytic residue at P239 (P = 0.1182); Gain of ubiquitination at K236 (P = 0.2287); Loss of solvent accessibility (P = 0.2732)
17:44060885:C:T,P10636,P239S,0.424,Gain of phosphorylation at P239 (P = 0.0055); Loss of catalytic residue at P239 (P = 0.0576); Loss of methylation at K236 (P = 0.1108); Loss of glycosylation at S238 (P = 0.1418); Gain of ubiquitination at K236 (P = 0.2793)
17:44060886:C:A,P10636,P239Q,0.411,Loss of glycosylation at S238 (P = 0.0919); Loss of catalytic residue at P239 (P = 0.1115); Loss of methylation at K236 (P = 0.2376); Gain of ubiquitination at K236 (P = 0.239); Gain of solvent accessibility (P = 0.3304)
17:44060886:C:G,P10636,P239R,0.405,Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at P239 (P = 0.0962); Loss of methylation at K236 (P = 0.1018); Gain of MoRF binding (P = 0.1058); Loss of catalytic residue at P239 (P = 0.1242)
17:44060886:C:T,P10636,P239L,0.412,Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Loss of catalytic residue at P239 (P = 0.075); Loss of methylation at K236 (P = 0.0778); Loss of glycosylation at P239 (P = 0.0962)
17:44060888:G:A,P10636,A240T,0.119,Gain of phosphorylation at A240 (P = 0.0046); Gain of glycosylation at A240 (P = 0.0207); Gain of methylation at K236 (P = 0.1738); Loss of ubiquitination at K236 (P = 0.2662); Loss of stability (P = 0.4789)
17:44060888:G:C,P10636,A240P,0.14,Gain of glycosylation at P239 (P = 0.1276); Loss of stability (P = 0.1864); Gain of methylation at K236 (P = 0.2126); Loss of ubiquitination at K236 (P = 0.2479); Gain of catalytic residue at P239 (P = 0.2639)
17:44060888:G:T,P10636,A240S,0.123,Gain of phosphorylation at A240 (P = 0.0059); Gain of glycosylation at A240 (P = 0.0583); Gain of methylation at K236 (P = 0.2124); Gain of relative solvent accessibility (P = 0.2629); Gain of ubiquitination at K236 (P = 0.2793)
17:44060889:C:G,P10636,A240G,0.085,Loss of glycosylation at S235 (P = 0.1811); Loss of stability (P = 0.2062); Loss of ubiquitination at K236 (P = 0.2479); Gain of methylation at K236 (P = 0.2502); Loss of MoRF binding (P = 0.6096)
17:44060889:C:T,P10636,A240V,0.112,Gain of glycosylation at S238 (P = 0.2218); Gain of methylation at K236 (P = 0.2389); Gain of ubiquitination at K236 (P = 0.239); Gain of catalytic residue at R244 (P = 0.2544); Gain of solvent accessibility (P = 0.4946)
17:44060891:C:A,P10636,Q241K,0.179,Gain of ubiquitination at Q241 (P = 0.006); Gain of methylation at Q241 (P = 0.0087); Gain of glycosylation at Q241 (P = 0.0361); Gain of catalytic residue at Q241 (P = 0.1629); Loss of stability (P = 0.1649)
17:44060891:C:G,P10636,Q241E,0.074,Gain of methylation at R244 (P = 0.177); Loss of glycosylation at S238 (P = 0.2422); Loss of ubiquitination at K236 (P = 0.2662); Loss of stability (P = 0.5129); Loss of MoRF binding (P = 0.578)
17:44060892:A:C,P10636,Q241P,0.135,Gain of relative solvent accessibility (P = 0.0166); Gain of helix (P = 0.0349); Loss of loop (P = 0.0603); Gain of methylation at R244 (P = 0.0709); Gain of solvent accessibility (P = 0.08)
17:44060892:A:G,P10636,Q241R,0.116,Gain of methylation at Q241 (P = 0.0823); Gain of glycosylation at S238 (P = 0.1773); Gain of ubiquitination at K236 (P = 0.2483); Gain of MoRF binding (P = 0.2837); Gain of solvent accessibility (P = 0.3819)
17:44060892:A:T,P10636,Q241L,0.097,Loss of methylation at K236 (P = 0.0941); Loss of glycosylation at S238 (P = 0.1653); Gain of ubiquitination at K236 (P = 0.2287); Gain of catalytic residue at Q241 (P = 0.2716); Loss of solvent accessibility (P = 0.4838)
17:44060893:A:C,P10636,Q241H,0.091,Gain of methylation at R244 (P = 0.0613); Gain of catalytic residue at D242 (P = 0.1626); Loss of stability (P = 0.2012); Gain of glycosylation at S238 (P = 0.2045); Gain of ubiquitination at K236 (P = 0.2568)
17:44060893:A:T,P10636,Q241H,0.091,Gain of methylation at R244 (P = 0.0613); Gain of catalytic residue at D242 (P = 0.1626); Loss of stability (P = 0.2012); Gain of glycosylation at S238 (P = 0.2045); Gain of ubiquitination at K236 (P = 0.2568)
17:44060894:G:A,P10636,D242N,0.132,Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at P245 (P = 0.166); Gain of methylation at R244 (P = 0.2349); Gain of solvent accessibility (P = 0.2902); Gain of MoRF binding (P = 0.3698)
17:44060894:G:C,P10636,D242H,0.164,Gain of catalytic residue at D242 (P = 0.059); Loss of solvent accessibility (P = 0.1473); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at R244 (P = 0.1817); Gain of glycosylation at P239 (P = 0.1908)
17:44060894:G:T,P10636,D242Y,0.233,Gain of phosphorylation at D242 (P = 0.002); Gain of catalytic residue at D242 (P = 0.0879); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1115); Gain of glycosylation at P239 (P = 0.12)
17:44060895:A:C,P10636,D242A,0.153,Loss of solvent accessibility (P = 0.0595); Gain of glycosylation at P245 (P = 0.1355); Gain of catalytic residue at D242 (P = 0.1631); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at R244 (P = 0.2426)
17:44060895:A:G,P10636,D242G,0.122,Loss of solvent accessibility (P = 0.0477); Gain of glycosylation at P245 (P = 0.1257); Gain of methylation at R244 (P = 0.1611); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at G243 (P = 0.2744)
17:44060895:A:T,P10636,D242V,0.187,Loss of solvent accessibility (P = 0.0544); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at S238 (P = 0.1918); Gain of catalytic residue at R244 (P = 0.2106); Gain of MoRF binding (P = 0.269)
17:44060896:T:A,P10636,D242E,0.108,Gain of glycosylation at P245 (P = 0.157); Gain of methylation at R244 (P = 0.2829); Gain of solvent accessibility (P = 0.3089); Gain of MoRF binding (P = 0.5804); Gain of phosphorylation at S238 (P = 0.7483)
17:44060896:T:G,P10636,D242E,0.108,Gain of glycosylation at P245 (P = 0.157); Gain of methylation at R244 (P = 0.2829); Gain of solvent accessibility (P = 0.3089); Gain of MoRF binding (P = 0.5804); Gain of phosphorylation at S238 (P = 0.7483)
17:44060897:G:A,P10636,G243R,0.223,Gain of solvent accessibility (P = 0.019); Gain of glycosylation at P245 (P = 0.0542); Loss of catalytic residue at P239 (P = 0.0914); Loss of methylation at R244 (P = 0.2792); Gain of MoRF binding (P = 0.3095)
17:44060897:G:C,P10636,G243R,0.223,Gain of solvent accessibility (P = 0.019); Gain of glycosylation at P245 (P = 0.0542); Loss of catalytic residue at P239 (P = 0.0914); Loss of methylation at R244 (P = 0.2792); Gain of MoRF binding (P = 0.3095)
17:44060897:G:T,P10636,G243W,0.247,Loss of relative solvent accessibility (P = 0.0186); Gain of catalytic residue at P246 (P = 0.0293); Loss of glycosylation at T248 (P = 0.1098); Loss of methylation at R244 (P = 0.2243); Loss of solvent accessibility (P = 0.2517)
17:44060898:G:A,P10636,G243E,0.22,Gain of solvent accessibility (P = 0.024); Loss of catalytic residue at P239 (P = 0.0914); Gain of glycosylation at S238 (P = 0.1389); Loss of methylation at R244 (P = 0.276); Loss of MoRF binding (P = 0.5632)
17:44060898:G:C,P10636,G243A,0.154,Loss of relative solvent accessibility (P = 0.0404); Loss of catalytic residue at P239 (P = 0.0914); Gain of glycosylation at S238 (P = 0.1198); Loss of solvent accessibility (P = 0.1952); Loss of methylation at R244 (P = 0.3337)
17:44060898:G:T,P10636,G243V,0.2,Loss of relative solvent accessibility (P = 0.0186); Loss of catalytic residue at P239 (P = 0.0914); Gain of glycosylation at S238 (P = 0.1413); Loss of solvent accessibility (P = 0.1744); Loss of methylation at R244 (P = 0.3123)
17:44060900:C:G,P10636,R244G,0.213,Gain of catalytic residue at R244 (P = 0.0439); Gain of glycosylation at T248 (P = 0.1655); Loss of methylation at R244 (P = 0.1946); Loss of solvent accessibility (P = 0.239); Loss of stability (P = 0.306)
17:44060901:G:C,P10636,R244P,0.225,Gain of glycosylation at P245 (P = 0.043); Gain of catalytic residue at R244 (P = 0.0826); Loss of methylation at R244 (P = 0.1946); Loss of stability (P = 0.3507); Loss of solvent accessibility (P = 0.3854)
17:44060901:G:T,P10636,R244L,0.213,Gain of glycosylation at T248 (P = 0.1379); Loss of methylation at R244 (P = 0.1946); Gain of catalytic residue at R244 (P = 0.201); Loss of solvent accessibility (P = 0.3103); Loss of MoRF binding (P = 0.5475)
17:44060903:C:A,P10636,P245T,0.172,Gain of phosphorylation at P245 (P = 0.0137); Loss of catalytic residue at P245 (P = 0.0612); Loss of glycosylation at T248 (P = 0.161); Loss of methylation at R244 (P = 0.3615); Gain of MoRF binding (P = 0.3928)
17:44060903:C:G,P10636,P245A,0.173,Loss of catalytic residue at P245 (P = 0.0361); Loss of glycosylation at P245 (P = 0.0676); Gain of methylation at R244 (P = 0.3057); Gain of MoRF binding (P = 0.3657); Loss of stability (P = 0.5084)
17:44060903:C:T,P10636,P245S,0.205,Gain of phosphorylation at P245 (P = 0.0099); Loss of catalytic residue at P245 (P = 0.0135); Loss of glycosylation at T248 (P = 0.1159); Gain of MoRF binding (P = 0.3501); Gain of methylation at R244 (P = 0.3667)
17:44060904:C:A,P10636,P245H,0.184,Loss of catalytic residue at P245 (P = 0.0407); Loss of glycosylation at P245 (P = 0.0676); Loss of methylation at R244 (P = 0.2997); Gain of solvent accessibility (P = 0.3819); Gain of MoRF binding (P = 0.421)
17:44060904:C:G,P10636,P245R,0.227,Gain of MoRF binding (P = 0.0481); Loss of glycosylation at T248 (P = 0.0601); Loss of catalytic residue at P245 (P = 0.0678); Gain of solvent accessibility (P = 0.2097); Loss of methylation at R244 (P = 0.323)
17:44060904:C:T,P10636,P245L,0.214,Loss of catalytic residue at P245 (P = 0.0209); Loss of glycosylation at P245 (P = 0.0676); Gain of stability (P = 0.1636); Loss of methylation at R244 (P = 0.3418); Gain of MoRF binding (P = 0.3769)
17:44060906:C:A,P10636,P246T,0.164,Gain of phosphorylation at P246 (P = 0.0126); Gain of glycosylation at P246 (P = 0.0171); Loss of catalytic residue at P245 (P = 0.0191); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.0721)
17:44060906:C:G,P10636,P246A,0.175,Loss of catalytic residue at P245 (P = 0.016); Loss of solvent accessibility (P = 0.0509); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at P246 (P = 0.1583); Gain of MoRF binding (P = 0.3468)
17:44060906:C:T,P10636,P246S,0.23,Gain of phosphorylation at P246 (P = 0.0058); Loss of catalytic residue at P245 (P = 0.016); Gain of glycosylation at P246 (P = 0.1275); Gain of methylation at R244 (P = 0.3187); Gain of MoRF binding (P = 0.3437)
17:44060907:C:A,P10636,P246H,0.194,Loss of catalytic residue at P245 (P = 0.016); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1301); Loss of glycosylation at P246 (P = 0.1583); Gain of methylation at R244 (P = 0.3577)
17:44060907:C:G,P10636,P246R,0.241,Loss of catalytic residue at P245 (P = 0.0175); Loss of relative solvent accessibility (P = 0.0676); Gain of MoRF binding (P = 0.0821); Gain of glycosylation at P245 (P = 0.1225); Gain of methylation at R244 (P = 0.2377)
17:44060907:C:T,P10636,P246L,0.224,Loss of catalytic residue at P245 (P = 0.016); Gain of stability (P = 0.0341); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Loss of glycosylation at P246 (P = 0.1583)
17:44060909:C:A,P10636,Q247K,0.246,Gain of ubiquitination at Q247 (P = 0.0042); Gain of methylation at Q247 (P = 0.0068); Gain of solvent accessibility (P = 0.0328); Gain of glycosylation at Q247 (P = 0.0351); Gain of relative solvent accessibility (P = 0.0479)
17:44060909:C:G,P10636,Q247E,0.12,Gain of glycosylation at P246 (P = 0.1173); Gain of methylation at R244 (P = 0.1583); Loss of MoRF binding (P = 0.5586); Loss of catalytic residue at R244 (P = 0.7357); Gain of phosphorylation at T248 (P = 0.8001)
17:44060910:A:C,P10636,Q247P,0.155,Gain of glycosylation at Q247 (P = 0.0153); Gain of catalytic residue at P246 (P = 0.0539); Gain of methylation at R244 (P = 0.0888); Loss of MoRF binding (P = 0.562); Loss of solvent accessibility (P = 0.6134)
17:44060910:A:G,P10636,Q247R,0.16,Gain of glycosylation at P246 (P = 0.0838); Gain of methylation at Q247 (P = 0.157); Gain of catalytic residue at Q247 (P = 0.225); Gain of MoRF binding (P = 0.2418); Gain of solvent accessibility (P = 0.3819)
17:44060910:A:T,P10636,Q247L,0.173,Gain of stability (P = 0.0182); Gain of glycosylation at P246 (P = 0.0867); Gain of methylation at R244 (P = 0.2004); Gain of catalytic residue at R244 (P = 0.3769); Loss of solvent accessibility (P = 0.4838)
17:44060911:G:C,P10636,Q247H,0.114,Gain of methylation at R244 (P = 0.1128); Gain of glycosylation at P246 (P = 0.1261); Gain of catalytic residue at E252 (P = 0.4696); Loss of MoRF binding (P = 0.5838); Loss of phosphorylation at T248 (P = 0.7938)
17:44060911:G:T,P10636,Q247H,0.114,Gain of methylation at R244 (P = 0.1128); Gain of glycosylation at P246 (P = 0.1261); Gain of catalytic residue at E252 (P = 0.4696); Loss of MoRF binding (P = 0.5838); Loss of phosphorylation at T248 (P = 0.7938)
17:44060912:A:G,P10636,T248A,0.181,Loss of phosphorylation at T248 (P = 0.0023); Loss of glycosylation at T248 (P = 0.0308); Loss of solvent accessibility (P = 0.1177); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at R244 (P = 0.329)
17:44060912:A:T,P10636,T248S,0.172,Gain of glycosylation at T248 (P = 0.0834); Loss of solvent accessibility (P = 0.2517); Gain of methylation at R244 (P = 0.3094); Loss of relative solvent accessibility (P = 0.3219); Loss of catalytic residue at T248 (P = 0.4371)
17:44060913:C:A,P10636,T248K,0.261,Loss of phosphorylation at T248 (P = 0.0023); Gain of methylation at T248 (P = 0.004); Gain of ubiquitination at T248 (P = 0.009); Gain of solvent accessibility (P = 0.039); Gain of relative solvent accessibility (P = 0.1571)
17:44060913:C:G,P10636,T248R,0.213,Loss of phosphorylation at T248 (P = 0.0023); Loss of glycosylation at T248 (P = 0.0308); Gain of solvent accessibility (P = 0.0503); Gain of MoRF binding (P = 0.1103); Loss of methylation at R244 (P = 0.3682)
17:44060913:C:T,P10636,T248I,0.181,Loss of phosphorylation at T248 (P = 0.0023); Loss of glycosylation at T248 (P = 0.0308); Gain of stability (P = 0.1303); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2034)
17:44060915:G:A,P10636,A249T,0.153,Gain of phosphorylation at A249 (P = 0.0041); Gain of glycosylation at A249 (P = 0.012); Gain of methylation at R244 (P = 0.3674); Gain of solvent accessibility (P = 0.4304); Gain of catalytic residue at R244 (P = 0.5159)
17:44060915:G:C,P10636,A249P,0.155,Gain of glycosylation at A249 (P = 0.0255); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0739); Gain of methylation at R244 (P = 0.3545); Loss of stability (P = 0.4623)
17:44060915:G:T,P10636,A249S,0.123,Gain of phosphorylation at A249 (P = 0.0102); Gain of glycosylation at A249 (P = 0.0154); Gain of catalytic residue at R251 (P = 0.2462); Gain of methylation at R244 (P = 0.2982); Gain of solvent accessibility (P = 0.4821)
17:44060916:C:A,P10636,A249D,0.109,Loss of glycosylation at T248 (P = 0.1514); Gain of solvent accessibility (P = 0.3602); Loss of methylation at R244 (P = 0.3605); Loss of MoRF binding (P = 0.5608); Loss of phosphorylation at T254 (P = 0.5615)
17:44060916:C:G,P10636,A249G,0.061,Loss of glycosylation at T248 (P = 0.1143); Loss of stability (P = 0.3329); Gain of methylation at R244 (P = 0.3656); Gain of catalytic residue at T248 (P = 0.3681); Gain of phosphorylation at T254 (P = 0.5589)
17:44060916:C:T,P10636,A249V,0.119,Loss of glycosylation at T248 (P = 0.202); Gain of catalytic residue at R244 (P = 0.2548); Loss of methylation at R244 (P = 0.3505); Loss of phosphorylation at T254 (P = 0.4539); Gain of MoRF binding (P = 0.5355)
17:44060918:G:C,P10636,A250P,0.114,Gain of glycosylation at A250 (P = 0.0448); Loss of stability (P = 0.1926); Gain of phosphorylation at S255 (P = 0.2545); Loss of methylation at R251 (P = 0.453); Loss of MoRF binding (P = 0.5648)
17:44060918:G:T,P10636,A250S,0.109,Gain of glycosylation at A250 (P = 0.0071); Gain of phosphorylation at A250 (P = 0.0172); Loss of stability (P = 0.2061); Loss of methylation at R251 (P = 0.451); Gain of solvent accessibility (P = 0.4821)
17:44060919:C:A,P10636,A250D,0.143,Gain of solvent accessibility (P = 0.0354); Gain of relative solvent accessibility (P = 0.0479); Gain of glycosylation at T254 (P = 0.1172); Gain of phosphorylation at S255 (P = 0.3018); Loss of stability (P = 0.3268)
17:44060919:C:G,P10636,A250G,0.065,Loss of stability (P = 0.1194); Gain of catalytic residue at P246 (P = 0.1206); Gain of glycosylation at T254 (P = 0.1897); Gain of phosphorylation at S255 (P = 0.3084); Gain of methylation at R251 (P = 0.3167)
17:44060919:C:T,P10636,A250V,0.077,Loss of phosphorylation at S255 (P = 0.2134); Loss of glycosylation at T248 (P = 0.2226); Gain of solvent accessibility (P = 0.4304); Loss of methylation at R251 (P = 0.4469); Gain of catalytic residue at T254 (P = 0.5199)
17:44060921:A:G,P10636,R251G,0.203,Loss of solvent accessibility (P = 0.0023); Gain of catalytic residue at A250 (P = 0.0643); Gain of glycosylation at T248 (P = 0.0754); Loss of stability (P = 0.1807); Loss of relative solvent accessibility (P = 0.1807)
17:44060922:G:A,P10636,R251K,0.268,Gain of ubiquitination at R251 (P = 0.0025); Gain of methylation at R251 (P = 0.0116); Gain of glycosylation at R251 (P = 0.0286); Loss of solvent accessibility (P = 0.1434); Gain of phosphorylation at S255 (P = 0.2149)
17:44060922:G:C,P10636,R251T,0.226,Gain of glycosylation at R251 (P = 0.0053); Loss of solvent accessibility (P = 0.008); Gain of phosphorylation at R251 (P = 0.0876); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at E252 (P = 0.3392)
17:44060922:G:T,P10636,R251I,0.252,Loss of solvent accessibility (P = 0.01); Gain of glycosylation at T254 (P = 0.0582); Loss of phosphorylation at T254 (P = 0.0703); Gain of catalytic residue at E252 (P = 0.1396); Loss of relative solvent accessibility (P = 0.1807)
17:44060923:A:C,P10636,R251S,0.187,Gain of phosphorylation at R251 (P = 0.0226); Gain of glycosylation at R251 (P = 0.0256); Loss of solvent accessibility (P = 0.0606); Loss of methylation at R251 (P = 0.3914); Gain of catalytic residue at E252 (P = 0.4252)
17:44060923:A:T,P10636,R251S,0.187,Gain of phosphorylation at R251 (P = 0.0226); Gain of glycosylation at R251 (P = 0.0256); Loss of solvent accessibility (P = 0.0606); Loss of methylation at R251 (P = 0.3914); Gain of catalytic residue at E252 (P = 0.4252)
17:44060924:G:A,P10636,E252K,0.229,Gain of methylation at E252 (P = 0.0036); Gain of ubiquitination at E252 (P = 0.0054); Gain of glycosylation at E252 (P = 0.039); Gain of MoRF binding (P = 0.0684); Gain of relative solvent accessibility (P = 0.1684)
17:44060924:G:C,P10636,E252Q,0.092,Loss of phosphorylation at S255 (P = 0.1211); Gain of relative solvent accessibility (P = 0.1684); Loss of glycosylation at T248 (P = 0.1913); Gain of solvent accessibility (P = 0.2097); Gain of MoRF binding (P = 0.3264)
17:44060925:A:C,P10636,E252A,0.07,Loss of solvent accessibility (P = 0.0576); Gain of glycosylation at T254 (P = 0.152); Loss of relative solvent accessibility (P = 0.1903); Gain of methylation at R251 (P = 0.2285); Loss of stability (P = 0.2329)
17:44060925:A:G,P10636,E252G,0.101,Loss of stability (P = 0.0328); Loss of solvent accessibility (P = 0.0635); Gain of methylation at R251 (P = 0.0676); Gain of glycosylation at T254 (P = 0.12); Gain of catalytic residue at A253 (P = 0.2273)
17:44060925:A:T,P10636,E252V,0.188,Loss of solvent accessibility (P = 0.0509); Loss of phosphorylation at S255 (P = 0.1019); Loss of relative solvent accessibility (P = 0.114); Loss of glycosylation at T248 (P = 0.1973); Gain of MoRF binding (P = 0.2337)
17:44060926:A:C,P10636,E252D,0.082,Loss of glycosylation at T254 (P = 0.1606); Gain of relative solvent accessibility (P = 0.1684); Loss of stability (P = 0.213); Loss of phosphorylation at S255 (P = 0.2576); Loss of methylation at R251 (P = 0.4599)
17:44060926:A:T,P10636,E252D,0.082,Loss of glycosylation at T254 (P = 0.1606); Gain of relative solvent accessibility (P = 0.1684); Loss of stability (P = 0.213); Loss of phosphorylation at S255 (P = 0.2576); Loss of methylation at R251 (P = 0.4599)
17:44060927:G:A,P10636,A253T,0.062,Gain of glycosylation at A253 (P = 0.0318); Gain of phosphorylation at A253 (P = 0.0485); Gain of catalytic residue at A253 (P = 0.1802); Loss of stability (P = 0.312); Loss of methylation at R251 (P = 0.4518)
17:44060927:G:C,P10636,A253P,0.072,Gain of glycosylation at T254 (P = 0.0609); Gain of phosphorylation at S255 (P = 0.2352); Loss of stability (P = 0.2441); Loss of methylation at R251 (P = 0.4521); Gain of solvent accessibility (P = 0.5093)
17:44060927:G:T,P10636,A253S,0.104,Gain of phosphorylation at A253 (P = 0.0087); Gain of glycosylation at A253 (P = 0.0119); Gain of catalytic residue at T254 (P = 0.2403); Loss of stability (P = 0.3973); Loss of methylation at R251 (P = 0.4567)
17:44060928:C:A,P10636,A253D,0.083,Gain of glycosylation at T248 (P = 0.2044); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2689); Gain of catalytic residue at A253 (P = 0.2819); Gain of phosphorylation at S255 (P = 0.285)
17:44060928:C:G,P10636,A253G,0.074,Loss of stability (P = 0.0446); Gain of glycosylation at T248 (P = 0.2339); Gain of relative solvent accessibility (P = 0.2629); Gain of catalytic residue at A253 (P = 0.2748); Gain of phosphorylation at S255 (P = 0.299)
17:44060928:C:T,P10636,A253V,0.077,Loss of glycosylation at T254 (P = 0.1321); Loss of phosphorylation at S255 (P = 0.1697); Loss of methylation at R251 (P = 0.4482); Loss of catalytic residue at I256 (P = 0.4734); Gain of solvent accessibility (P = 0.4946)
17:44060930:A:C,P10636,T254P,0.109,Loss of phosphorylation at T254 (P = 0.0138); Loss of glycosylation at T254 (P = 0.07); Gain of catalytic residue at T254 (P = 0.1569); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1641)
17:44060930:A:G,P10636,T254A,0.089,Loss of phosphorylation at T254 (P = 0.0138); Loss of glycosylation at T254 (P = 0.0334); Gain of methylation at R251 (P = 0.3977); Loss of stability (P = 0.4378); Loss of catalytic residue at T254 (P = 0.4849)
17:44060930:A:T,P10636,T254S,0.119,Gain of glycosylation at T254 (P = 0.0739); Gain of relative solvent accessibility (P = 0.1571); Gain of phosphorylation at S255 (P = 0.206); Gain of solvent accessibility (P = 0.3819); Loss of stability (P = 0.3843)
17:44060931:C:A,P10636,T254N,0.136,Loss of phosphorylation at T254 (P = 0.0138); Loss of glycosylation at T254 (P = 0.0334); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.1846); Loss of stability (P = 0.2059)
17:44060931:C:G,P10636,T254S,0.119,Gain of glycosylation at T254 (P = 0.0739); Gain of relative solvent accessibility (P = 0.1571); Gain of phosphorylation at S255 (P = 0.206); Gain of solvent accessibility (P = 0.3819); Loss of stability (P = 0.3843)
17:44060931:C:T,P10636,T254I,0.151,Loss of phosphorylation at T254 (P = 0.0138); Loss of glycosylation at T254 (P = 0.0334); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1235); Loss of methylation at R251 (P = 0.4393)
17:44060933:A:C,P10636,S255R,0.182,Loss of glycosylation at S255 (P = 0.0062); Loss of phosphorylation at S255 (P = 0.0285); Gain of solvent accessibility (P = 0.1505); Gain of MoRF binding (P = 0.2101); Gain of catalytic residue at S255 (P = 0.3592)
17:44060933:A:G,P10636,S255G,0.12,Loss of glycosylation at S255 (P = 0.0062); Loss of phosphorylation at S255 (P = 0.0285); Loss of stability (P = 0.1551); Loss of solvent accessibility (P = 0.2732); Gain of catalytic residue at T254 (P = 0.3403)
17:44060933:A:T,P10636,S255C,0.284,Loss of glycosylation at S255 (P = 0.0062); Loss of phosphorylation at S255 (P = 0.0285); Gain of catalytic residue at E252 (P = 0.1965); Loss of methylation at R251 (P = 0.4432); Gain of solvent accessibility (P = 0.5485)
17:44060934:G:A,P10636,S255N,0.145,Loss of glycosylation at S255 (P = 0.0062); Gain of catalytic residue at S255 (P = 0.0252); Loss of phosphorylation at S255 (P = 0.0285); Loss of stability (P = 0.4221); Loss of methylation at R251 (P = 0.4568)
17:44060934:G:C,P10636,S255T,0.149,Gain of catalytic residue at S255 (P = 0.0618); Gain of glycosylation at T254 (P = 0.0755); Gain of phosphorylation at S255 (P = 0.2334); Loss of stability (P = 0.3726); Loss of methylation at R251 (P = 0.4549)
17:44060934:G:T,P10636,S255I,0.275,Loss of glycosylation at S255 (P = 0.0062); Loss of phosphorylation at S255 (P = 0.0285); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at S255 (P = 0.2505); Loss of solvent accessibility (P = 0.2953)
17:44060935:C:A,P10636,S255R,0.182,Loss of glycosylation at S255 (P = 0.0062); Loss of phosphorylation at S255 (P = 0.0285); Gain of solvent accessibility (P = 0.1505); Gain of MoRF binding (P = 0.2101); Gain of catalytic residue at S255 (P = 0.3592)
17:44060935:C:G,P10636,S255R,0.182,Loss of glycosylation at S255 (P = 0.0062); Loss of phosphorylation at S255 (P = 0.0285); Gain of solvent accessibility (P = 0.1505); Gain of MoRF binding (P = 0.2101); Gain of catalytic residue at S255 (P = 0.3592)
17:44060936:A:C,P10636,I256L,0.074,Gain of glycosylation at T254 (P = 0.1786); Loss of catalytic residue at I256 (P = 0.2151); Loss of phosphorylation at S255 (P = 0.2667); Gain of relative solvent accessibility (P = 0.2751); Gain of methylation at R251 (P = 0.4011)
17:44060936:A:G,P10636,I256V,0.077,Gain of glycosylation at T254 (P = 0.0961); Loss of phosphorylation at S255 (P = 0.2406); Gain of relative solvent accessibility (P = 0.2751); Loss of catalytic residue at I256 (P = 0.3148); Gain of methylation at R251 (P = 0.3926)
17:44060936:A:T,P10636,I256F,0.082,Loss of glycosylation at S255 (P = 0.1358); Loss of catalytic residue at I256 (P = 0.1538); Loss of phosphorylation at S255 (P = 0.2134); Gain of methylation at R251 (P = 0.3948); Loss of stability (P = 0.4452)
17:44060937:T:A,P10636,I256N,0.136,Gain of glycosylation at T254 (P = 0.0767); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1718); Loss of phosphorylation at S255 (P = 0.1762); Gain of solvent accessibility (P = 0.2689)
17:44060937:T:C,P10636,I256T,0.142,Gain of glycosylation at I256 (P = 0.0073); Gain of phosphorylation at I256 (P = 0.0143); Loss of stability (P = 0.0956); Gain of catalytic residue at F259 (P = 0.1383); Gain of relative solvent accessibility (P = 0.1571)
17:44060937:T:G,P10636,I256S,0.164,Gain of glycosylation at I256 (P = 0.0029); Gain of phosphorylation at I256 (P = 0.0296); Loss of stability (P = 0.0975); Loss of catalytic residue at I256 (P = 0.1082); Gain of relative solvent accessibility (P = 0.2751)
17:44060938:C:G,P10636,I256M,0.086,Loss of glycosylation at S255 (P = 0.0492); Loss of catalytic residue at I256 (P = 0.1458); Gain of phosphorylation at S255 (P = 0.3142); Gain of methylation at R251 (P = 0.4166); Gain of MoRF binding (P = 0.5765)
17:44060939:C:A,P10636,P257T,0.343,Gain of glycosylation at P257 (P = 0.0171); Gain of phosphorylation at P257 (P = 0.0592); Loss of stability (P = 0.1871); Loss of catalytic residue at P257 (P = 0.2559); Gain of solvent accessibility (P = 0.5334)
17:44060939:C:G,P10636,P257A,0.275,Loss of glycosylation at T254 (P = 0.0947); Loss of stability (P = 0.1189); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S255 (P = 0.2339)
17:44060939:C:T,P10636,P257S,0.303,Gain of glycosylation at P257 (P = 0.0059); Gain of phosphorylation at P257 (P = 0.0587); Loss of catalytic residue at P257 (P = 0.0856); Loss of stability (P = 0.2131); Gain of MoRF binding (P = 0.5317)
17:44060940:C:A,P10636,P257Q,0.337,Loss of glycosylation at S255 (P = 0.0584); Loss of phosphorylation at S255 (P = 0.1174); Gain of solvent accessibility (P = 0.1505); Loss of stability (P = 0.2578); Gain of catalytic residue at P257 (P = 0.4275)
17:44060940:C:G,P10636,P257R,0.384,Gain of solvent accessibility (P = 0.0411); Loss of glycosylation at T254 (P = 0.0454); Gain of MoRF binding (P = 0.1992); Gain of phosphorylation at S255 (P = 0.2631); Loss of stability (P = 0.3464)
17:44060940:C:T,P10636,P257L,0.329,Loss of glycosylation at T254 (P = 0.058); Loss of phosphorylation at S255 (P = 0.1211); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2517); Loss of catalytic residue at G258 (P = 0.2615)
17:44060942:G:A,P10636,G258S,0.079,Gain of glycosylation at G258 (P = 0.0156); Gain of phosphorylation at G258 (P = 0.0333); Loss of catalytic residue at I256 (P = 0.2076); Gain of solvent accessibility (P = 0.2192); Loss of stability (P = 0.4319)
17:44060942:G:C,P10636,G258R,0.144,Gain of solvent accessibility (P = 0.0471); Loss of glycosylation at S255 (P = 0.0641); Loss of catalytic residue at I256 (P = 0.1663); Gain of phosphorylation at S255 (P = 0.2022); Gain of MoRF binding (P = 0.2731)
17:44060942:G:T,P10636,G258C,0.148,Loss of glycosylation at S255 (P = 0.0868); Loss of phosphorylation at S255 (P = 0.0952); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at P257 (P = 0.2445); Loss of solvent accessibility (P = 0.4011)
17:44060943:G:A,P10636,G258D,0.095,Gain of solvent accessibility (P = 0.1014); Loss of glycosylation at S255 (P = 0.1571); Loss of catalytic residue at I256 (P = 0.1902); Gain of phosphorylation at S255 (P = 0.2625); Gain of sheet (P = 0.6509)
17:44060943:G:T,P10636,G258V,0.148,Loss of relative solvent accessibility (P = 0.0981); Loss of catalytic residue at I256 (P = 0.1425); Loss of phosphorylation at S255 (P = 0.2063); Loss of glycosylation at S255 (P = 0.25); Loss of solvent accessibility (P = 0.4141)
17:44060945:T:A,P10636,F259I,0.064,Gain of glycosylation at T254 (P = 0.1873); Loss of catalytic residue at P257 (P = 0.249); Gain of phosphorylation at S255 (P = 0.3032); Loss of stability (P = 0.4361); Gain of sheet (P = 0.6509)
17:44060945:T:C,P10636,F259L,0.1,Loss of catalytic residue at P257 (P = 0.1393); Gain of glycosylation at T254 (P = 0.1783); Gain of phosphorylation at S255 (P = 0.3121); Loss of stability (P = 0.5349); Gain of sheet (P = 0.6509)
17:44060945:T:G,P10636,F259V,0.078,Loss of catalytic residue at P257 (P = 0.1393); Gain of glycosylation at T254 (P = 0.1614); Loss of stability (P = 0.2421); Gain of phosphorylation at S255 (P = 0.3274); Gain of MoRF binding (P = 0.6526)
17:44060946:T:A,P10636,F259Y,0.105,Gain of phosphorylation at F259 (P = 0.0199); Loss of catalytic residue at P257 (P = 0.1393); Gain of glycosylation at T254 (P = 0.162); Loss of stability (P = 0.2427); Gain of solvent accessibility (P = 0.5334)
17:44060946:T:C,P10636,F259S,0.173,Gain of glycosylation at F259 (P = 0.003); Gain of phosphorylation at F259 (P = 0.0236); Loss of stability (P = 0.1149); Loss of catalytic residue at P257 (P = 0.1752); Gain of relative solvent accessibility (P = 0.2629)
17:44060946:T:G,P10636,F259C,0.085,Loss of catalytic residue at P257 (P = 0.1393); Loss of stability (P = 0.1666); Gain of glycosylation at T254 (P = 0.1797); Loss of phosphorylation at S255 (P = 0.277); Gain of sheet (P = 0.6509)
17:44060947:C:A,P10636,F259L,0.1,Loss of catalytic residue at P257 (P = 0.1393); Gain of glycosylation at T254 (P = 0.1783); Gain of phosphorylation at S255 (P = 0.3121); Loss of stability (P = 0.5349); Gain of sheet (P = 0.6509)
17:44060947:C:G,P10636,F259L,0.1,Loss of catalytic residue at P257 (P = 0.1393); Gain of glycosylation at T254 (P = 0.1783); Gain of phosphorylation at S255 (P = 0.3121); Loss of stability (P = 0.5349); Gain of sheet (P = 0.6509)
17:44060948:C:A,P10636,P260T,0.178,Gain of phosphorylation at P260 (P = 0.0584); Gain of glycosylation at P260 (P = 0.0597); Loss of relative solvent accessibility (P = 0.3219); Loss of solvent accessibility (P = 0.3473); Gain of catalytic residue at E262 (P = 0.3884)
17:44060948:C:G,P10636,P260A,0.211,Loss of solvent accessibility (P = 0.1322); Gain of catalytic residue at P260 (P = 0.148); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S255 (P = 0.2361); Gain of glycosylation at S255 (P = 0.5383)
17:44060948:C:T,P10636,P260S,0.171,Gain of glycosylation at P260 (P = 0.0281); Gain of phosphorylation at P260 (P = 0.0649); Gain of catalytic residue at G258 (P = 0.1842); Gain of MoRF binding (P = 0.6468); Gain of sheet (P = 0.6509)
17:44060949:C:A,P10636,P260Q,0.195,Loss of phosphorylation at S255 (P = 0.1459); Loss of glycosylation at S255 (P = 0.1756); Gain of catalytic residue at P260 (P = 0.3036); Loss of relative solvent accessibility (P = 0.3219); Loss of disorder (P = 0.6091)
17:44060949:C:G,P10636,P260R,0.232,Loss of glycosylation at S255 (P = 0.0748); Gain of methylation at P260 (P = 0.2004); Gain of catalytic residue at P260 (P = 0.205); Loss of phosphorylation at S255 (P = 0.2836); Loss of relative solvent accessibility (P = 0.3219)
17:44060949:C:T,P10636,P260L,0.303,Gain of catalytic residue at P260 (P = 0.0761); Loss of phosphorylation at S255 (P = 0.1355); Gain of stability (P = 0.1424); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2517)
17:44060951:G:A,P10636,A261T,0.14,Gain of glycosylation at A261 (P = 0.0182); Gain of phosphorylation at A261 (P = 0.0458); Gain of catalytic residue at A261 (P = 0.2611); Gain of solvent accessibility (P = 0.28); Gain of sheet (P = 0.6509)
17:44060951:G:C,P10636,A261P,0.139,Gain of catalytic residue at P260 (P = 0.0377); Gain of glycosylation at A261 (P = 0.0971); Gain of solvent accessibility (P = 0.1456); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.6052)
17:44060951:G:T,P10636,A261S,0.098,Gain of glycosylation at A261 (P = 0.0197); Gain of phosphorylation at A261 (P = 0.0388); Loss of catalytic residue at A261 (P = 0.2597); Gain of solvent accessibility (P = 0.3602); Gain of sheet (P = 0.6509)
17:44060952:C:A,P10636,A261E,0.154,Gain of solvent accessibility (P = 0.08); Loss of catalytic residue at G258 (P = 0.3892); Gain of glycosylation at P257 (P = 0.553); Gain of sheet (P = 0.6509); Gain of disorder (P = 0.6725)
17:44060952:C:G,P10636,A261G,0.099,Gain of catalytic residue at G258 (P = 0.1799); Loss of stability (P = 0.4055); Gain of glycosylation at P257 (P = 0.5429); Loss of solvent accessibility (P = 0.6498); Gain of sheet (P = 0.6509)
17:44060952:C:T,P10636,A261V,0.179,Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.2517); Gain of catalytic residue at A261 (P = 0.4116); Loss of disorder (P = 0.5951); Loss of glycosylation at P257 (P = 0.6194)
17:44060954:G:A,P10636,E262K,0.324,Gain of methylation at E262 (P = 0.0038); Gain of ubiquitination at E262 (P = 0.0109); Gain of glycosylation at E262 (P = 0.0275); Gain of catalytic residue at E262 (P = 0.2801); Loss of stability (P = 0.2839)
17:44060954:G:C,P10636,E262Q,0.217,Loss of solvent accessibility (P = 0.0721); Gain of catalytic residue at E262 (P = 0.1243); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.5327); Gain of glycosylation at P257 (P = 0.609)
17:44060955:A:C,P10636,E262A,0.283,Loss of solvent accessibility (P = 0.0224); Gain of catalytic residue at E262 (P = 0.0554); Loss of relative solvent accessibility (P = 0.1807); Loss of disorder (P = 0.632); Loss of glycosylation at P257 (P = 0.6381)
17:44060955:A:G,P10636,E262G,0.249,Loss of solvent accessibility (P = 0.0187); Gain of catalytic residue at A261 (P = 0.088); Loss of stability (P = 0.0949); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at P257 (P = 0.6425)
17:44060955:A:T,P10636,E262V,0.303,Loss of solvent accessibility (P = 0.0199); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at E262 (P = 0.157); Loss of disorder (P = 0.3773); Loss of glycosylation at P257 (P = 0.5975)
17:44060956:G:C,P10636,E262D,0.151,Loss of solvent accessibility (P = 0.1177); Loss of relative solvent accessibility (P = 0.3219); Gain of catalytic residue at A261 (P = 0.4281); Loss of stability (P = 0.5467); Loss of glycosylation at P257 (P = 0.6279)
17:44060956:G:T,P10636,E262D,0.151,Loss of solvent accessibility (P = 0.1177); Loss of relative solvent accessibility (P = 0.3219); Gain of catalytic residue at A261 (P = 0.4281); Loss of stability (P = 0.5467); Loss of glycosylation at P257 (P = 0.6279)
17:44060957:G:A,P10636,G263S,0.159,Gain of glycosylation at G263 (P = 0.0216); Gain of phosphorylation at G263 (P = 0.0343); Loss of catalytic residue at G263 (P = 0.0769); Gain of solvent accessibility (P = 0.1014); Gain of relative solvent accessibility (P = 0.1571)
17:44060957:G:C,P10636,G263R,0.182,Gain of solvent accessibility (P = 0.0471); Loss of catalytic residue at G263 (P = 0.163); Gain of methylation at G263 (P = 0.5428); Loss of relative solvent accessibility (P = 0.5898); Gain of sheet (P = 0.6509)
17:44060957:G:T,P10636,G263C,0.225,Loss of relative solvent accessibility (P = 0.0981); Loss of catalytic residue at I265 (P = 0.206); Loss of solvent accessibility (P = 0.4011); Loss of disorder (P = 0.5463); Gain of glycosylation at P260 (P = 0.6303)
17:44060958:G:A,P10636,G263D,0.193,Gain of solvent accessibility (P = 0.0354); Loss of catalytic residue at G263 (P = 0.1298); Gain of relative solvent accessibility (P = 0.1571); Gain of sheet (P = 0.6509); Gain of disorder (P = 0.6628)
17:44060958:G:C,P10636,G263A,0.118,Loss of catalytic residue at I265 (P = 0.1951); Gain of solvent accessibility (P = 0.367); Gain of glycosylation at P260 (P = 0.4924); Gain of sheet (P = 0.6509); Gain of disorder (P = 0.6785)
17:44060958:G:T,P10636,G263V,0.261,Loss of relative solvent accessibility (P = 0.0981); Loss of catalytic residue at A264 (P = 0.1972); Loss of solvent accessibility (P = 0.4141); Loss of disorder (P = 0.5398); Gain of sheet (P = 0.6509)
17:44060960:G:A,P10636,A264T,0.138,Gain of glycosylation at A264 (P = 0.0312); Gain of phosphorylation at A264 (P = 0.0392); Gain of solvent accessibility (P = 0.28); Gain of catalytic residue at E262 (P = 0.3086); Gain of disorder (P = 0.6329)
17:44060960:G:C,P10636,A264P,0.157,Loss of catalytic residue at A264 (P = 0.2353); Gain of solvent accessibility (P = 0.3194); Gain of glycosylation at A264 (P = 0.5347); Loss of stability (P = 0.5364); Gain of disorder (P = 0.5762)
17:44060960:G:T,P10636,A264S,0.156,Gain of glycosylation at A264 (P = 0.013); Gain of phosphorylation at A264 (P = 0.0276); Loss of catalytic residue at A264 (P = 0.1626); Gain of solvent accessibility (P = 0.3602); Gain of disorder (P = 0.5908)
17:44060961:C:A,P10636,A264D,0.174,Gain of solvent accessibility (P = 0.1708); Loss of catalytic residue at A264 (P = 0.3615); Gain of disorder (P = 0.6132); Gain of sheet (P = 0.6509); Loss of glycosylation at P260 (P = 0.7206)
17:44060961:C:G,P10636,A264G,0.159,Gain of catalytic residue at P260 (P = 0.0864); Loss of stability (P = 0.3516); Gain of disorder (P = 0.6258); Loss of solvent accessibility (P = 0.6498); Gain of glycosylation at P260 (P = 0.7237)
17:44060961:C:T,P10636,A264V,0.213,Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1651); Gain of catalytic residue at A264 (P = 0.2469); Loss of disorder (P = 0.5054); Gain of sheet (P = 0.6509)
17:44060963:A:C,P10636,I265L,0.145,Loss of catalytic residue at L267 (P = 0.322); Gain of glycosylation at P266 (P = 0.4469); Gain of disorder (P = 0.5836); Gain of sheet (P = 0.6509); Loss of stability (P = 0.8662)
17:44060963:A:G,P10636,I265V,0.142,Loss of catalytic residue at L267 (P = 0.3382); Gain of disorder (P = 0.5867); Loss of solvent accessibility (P = 0.6498); Gain of sheet (P = 0.6509); Loss of glycosylation at P260 (P = 0.7469)
17:44060963:A:T,P10636,I265F,0.136,Loss of catalytic residue at L267 (P = 0.3019); Gain of solvent accessibility (P = 0.5093); Loss of stability (P = 0.5325); Gain of disorder (P = 0.5898); Gain of sheet (P = 0.6509)
17:44060964:T:A,P10636,I265N,0.174,Loss of stability (P = 0.1254); Gain of relative solvent accessibility (P = 0.2629); Loss of catalytic residue at L267 (P = 0.3082); Gain of solvent accessibility (P = 0.3956); Gain of glycosylation at P260 (P = 0.4926)
17:44060964:T:C,P10636,I265T,0.177,Gain of glycosylation at I265 (P = 0.01); Gain of phosphorylation at I265 (P = 0.03); Loss of stability (P = 0.0914); Gain of relative solvent accessibility (P = 0.2629); Loss of catalytic residue at L267 (P = 0.3247)
17:44060964:T:G,P10636,I265S,0.19,Gain of glycosylation at I265 (P = 0.0157); Gain of phosphorylation at I265 (P = 0.0216); Loss of stability (P = 0.0965); Loss of catalytic residue at I265 (P = 0.1521); Gain of relative solvent accessibility (P = 0.2629)
17:44060965:C:G,P10636,I265M,0.171,Loss of catalytic residue at I265 (P = 0.1538); Gain of disorder (P = 0.566); Gain of glycosylation at P260 (P = 0.6052); Gain of sheet (P = 0.6509); Loss of stability (P = 0.6998)
17:44060966:C:A,P10636,P266T,0.281,Loss of catalytic residue at L267 (P = 0.2168); Gain of phosphorylation at P266 (P = 0.2524); Loss of disorder (P = 0.303); Gain of glycosylation at P266 (P = 0.3518); Loss of relative solvent accessibility (P = 0.5582)
17:44060966:C:G,P10636,P266A,0.293,Loss of catalytic residue at L267 (P = 0.1409); Loss of stability (P = 0.1544); Loss of solvent accessibility (P = 0.2732); Loss of disorder (P = 0.2869); Loss of relative solvent accessibility (P = 0.5582)
17:44060967:C:A,P10636,P266H,0.37,Loss of disorder (P = 0.1059); Gain of catalytic residue at P266 (P = 0.1812); Loss of stability (P = 0.4262); Gain of solvent accessibility (P = 0.4496); Loss of relative solvent accessibility (P = 0.5582)
17:44060967:C:G,P10636,P266R,0.332,Gain of solvent accessibility (P = 0.1045); Loss of catalytic residue at L267 (P = 0.1271); Gain of MoRF binding (P = 0.3542); Loss of disorder (P = 0.452); Loss of relative solvent accessibility (P = 0.5582)
17:44060967:C:T,P10636,P266L,0.395,Loss of disorder (P = 0.0769); Loss of catalytic residue at L267 (P = 0.2191); Loss of relative solvent accessibility (P = 0.5582); Gain of sheet (P = 0.6509); Gain of MoRF binding (P = 0.8409)
17:44060969:C:A,P10636,L267I,0.181,Gain of catalytic residue at L272 (P = 0.0428); Gain of disorder (P = 0.5828); Gain of sheet (P = 0.6509); Loss of stability (P = 0.7169); Loss of solvent accessibility (P = 0.7225)
17:44060969:C:G,P10636,L267V,0.17,Loss of catalytic residue at L267 (P = 0.1113); Loss of stability (P = 0.4986); Gain of disorder (P = 0.5645); Loss of sheet (P = 0.6423); Gain of MoRF binding (P = 0.8504)
17:44060969:C:T,P10636,L267F,0.188,Loss of catalytic residue at L267 (P = 0.1221); Loss of stability (P = 0.4528); Gain of disorder (P = 0.5649); Gain of sheet (P = 0.6509); Loss of solvent accessibility (P = 0.792)
17:44060970:T:A,P10636,L267H,0.205,Loss of stability (P = 0.05); Loss of catalytic residue at L267 (P = 0.0714); Gain of disorder (P = 0.5418); Gain of solvent accessibility (P = 0.5485); Gain of sheet (P = 0.6509)
17:44060970:T:C,P10636,L267P,0.292,Gain of catalytic residue at P266 (P = 0.0149); Gain of relative solvent accessibility (P = 0.0249); Loss of stability (P = 0.0404); Gain of solvent accessibility (P = 0.0766); Gain of glycosylation at L267 (P = 0.322)
17:44060970:T:G,P10636,L267R,0.25,Gain of solvent accessibility (P = 0.0155); Gain of relative solvent accessibility (P = 0.0507); Loss of stability (P = 0.1172); Loss of catalytic residue at L267 (P = 0.1183); Gain of disorder (P = 0.4754)
17:44060972:C:A,P10636,P268T,0.332,Gain of glycosylation at P268 (P = 0.0354); Gain of phosphorylation at P268 (P = 0.0681); Gain of catalytic residue at F271 (P = 0.121); Loss of disorder (P = 0.2549); Loss of stability (P = 0.3663)
17:44060972:C:G,P10636,P268A,0.276,Loss of catalytic residue at L267 (P = 0.0974); Loss of disorder (P = 0.2221); Loss of glycosylation at S273 (P = 0.2269); Loss of stability (P = 0.2612); Loss of phosphorylation at S273 (P = 0.282)
17:44060972:C:T,P10636,P268S,0.287,Gain of glycosylation at P268 (P = 0.0611); Gain of phosphorylation at P268 (P = 0.0731); Loss of catalytic residue at L267 (P = 0.1583); Loss of stability (P = 0.3773); Loss of disorder (P = 0.5465)
17:44060973:C:A,P10636,P268H,0.353,Loss of disorder (P = 0.093); Loss of glycosylation at S273 (P = 0.0963); Gain of catalytic residue at D270 (P = 0.17); Loss of phosphorylation at S273 (P = 0.2286); Loss of stability (P = 0.2672)
17:44060973:C:G,P10636,P268R,0.348,Gain of catalytic residue at P268 (P = 0.0177); Loss of glycosylation at S273 (P = 0.0833); Gain of solvent accessibility (P = 0.2097); Loss of phosphorylation at S273 (P = 0.327); Loss of disorder (P = 0.3868)
17:44060973:C:T,P10636,P268L,0.326,Loss of disorder (P = 0.0623); Loss of glycosylation at S273 (P = 0.1251); Loss of catalytic residue at L267 (P = 0.1257); Loss of phosphorylation at S273 (P = 0.2625); Loss of relative solvent accessibility (P = 0.5582)
17:44060975:G:A,P10636,V269M,0.113,Gain of methylation at K274 (P = 0.1888); Loss of glycosylation at S273 (P = 0.1913); Gain of phosphorylation at S273 (P = 0.263); Gain of ubiquitination at K274 (P = 0.3247); Gain of solvent accessibility (P = 0.4656)
17:44060975:G:C,P10636,V269L,0.182,Gain of solvent accessibility (P = 0.0086); Gain of relative solvent accessibility (P = 0.0098); Gain of catalytic residue at V269 (P = 0.0566); Loss of methylation at K274 (P = 0.1091); Loss of glycosylation at S273 (P = 0.2397)
17:44060975:G:T,P10636,V269L,0.182,Gain of solvent accessibility (P = 0.0086); Gain of relative solvent accessibility (P = 0.0098); Gain of catalytic residue at V269 (P = 0.0566); Loss of methylation at K274 (P = 0.1091); Loss of glycosylation at S273 (P = 0.2397)
17:44060976:T:A,P10636,V269E,0.234,Gain of solvent accessibility (P = 0.0039); Gain of relative solvent accessibility (P = 0.0098); Gain of glycosylation at S273 (P = 0.1016); Gain of phosphorylation at S273 (P = 0.1281); Gain of methylation at K274 (P = 0.2106)
17:44060976:T:C,P10636,V269A,0.177,Gain of relative solvent accessibility (P = 0.0098); Gain of solvent accessibility (P = 0.0713); Gain of glycosylation at S273 (P = 0.137); Loss of methylation at K274 (P = 0.1519); Gain of phosphorylation at S273 (P = 0.239)
17:44060976:T:G,P10636,V269G,0.22,Gain of relative solvent accessibility (P = 0.0098); Loss of stability (P = 0.0189); Gain of solvent accessibility (P = 0.1422); Gain of methylation at K274 (P = 0.2176); Gain of phosphorylation at S273 (P = 0.2225)
17:44060978:G:A,P10636,D270N,0.217,Gain of catalytic residue at D270 (P = 0.0286); Loss of stability (P = 0.0825); Loss of methylation at K274 (P = 0.1307); Loss of glycosylation at S273 (P = 0.1477); Loss of phosphorylation at S273 (P = 0.1816)
17:44060978:G:C,P10636,D270H,0.235,Loss of stability (P = 0.0613); Gain of catalytic residue at L272 (P = 0.0691); Loss of glycosylation at S273 (P = 0.1265); Loss of methylation at K274 (P = 0.1496); Loss of phosphorylation at S273 (P = 0.2083)
17:44060978:G:T,P10636,D270Y,0.357,Gain of catalytic residue at D270 (P = 0.012); Gain of phosphorylation at D270 (P = 0.032); Loss of disorder (P = 0.0394); Loss of glycosylation at S273 (P = 0.0845); Loss of relative solvent accessibility (P = 0.0981)
17:44060979:A:C,P10636,D270A,0.228,Loss of stability (P = 0.0629); Loss of solvent accessibility (P = 0.1115); Loss of methylation at K274 (P = 0.1454); Gain of glycosylation at S273 (P = 0.1483); Loss of phosphorylation at S273 (P = 0.2617)
17:44060979:A:G,P10636,D270G,0.191,Loss of stability (P = 0.0123); Gain of catalytic residue at P266 (P = 0.0654); Loss of solvent accessibility (P = 0.0674); Gain of glycosylation at S273 (P = 0.1822); Loss of methylation at K274 (P = 0.2048)
17:44060979:A:T,P10636,D270V,0.256,Loss of solvent accessibility (P = 0.0544); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at K274 (P = 0.1781); Loss of disorder (P = 0.1842); Loss of phosphorylation at S273 (P = 0.2015)
17:44060980:T:A,P10636,D270E,0.164,Loss of stability (P = 0.1671); Gain of methylation at K274 (P = 0.1949); Gain of glycosylation at S273 (P = 0.1961); Gain of phosphorylation at S273 (P = 0.204); Gain of solvent accessibility (P = 0.3089)
17:44060980:T:G,P10636,D270E,0.164,Loss of stability (P = 0.1671); Gain of methylation at K274 (P = 0.1949); Gain of glycosylation at S273 (P = 0.1961); Gain of phosphorylation at S273 (P = 0.204); Gain of solvent accessibility (P = 0.3089)
17:44060981:T:A,P10636,F271I,0.244,Loss of glycosylation at S273 (P = 0.113); Gain of catalytic residue at F271 (P = 0.113); Gain of methylation at K274 (P = 0.1505); Gain of phosphorylation at S276 (P = 0.2368); Loss of ubiquitination at K274 (P = 0.3114)
17:44060981:T:C,P10636,F271L,0.166,Loss of methylation at K274 (P = 0.113); Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at S273 (P = 0.1802); Gain of phosphorylation at S276 (P = 0.2147); Gain of solvent accessibility (P = 0.28)
17:44060981:T:G,P10636,F271V,0.171,Gain of methylation at K274 (P = 0.1969); Gain of catalytic residue at K274 (P = 0.2156); Gain of glycosylation at S276 (P = 0.2183); Gain of phosphorylation at S276 (P = 0.2265); Loss of stability (P = 0.2687)
17:44060982:T:A,P10636,F271Y,0.224,Gain of phosphorylation at F271 (P = 0.0381); Loss of methylation at K274 (P = 0.1243); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.1583); Loss of glycosylation at S273 (P = 0.1921)
17:44060982:T:C,P10636,F271S,0.228,Gain of glycosylation at F271 (P = 0.0234); Gain of phosphorylation at F271 (P = 0.0302); Loss of stability (P = 0.1267); Gain of relative solvent accessibility (P = 0.1571); Gain of methylation at K274 (P = 0.2097)
17:44060982:T:G,P10636,F271C,0.203,Gain of catalytic residue at L272 (P = 0.0435); Loss of glycosylation at S273 (P = 0.0723); Gain of relative solvent accessibility (P = 0.1571); Loss of methylation at K274 (P = 0.2048); Loss of phosphorylation at S276 (P = 0.2295)
17:44060983:C:A,P10636,F271L,0.166,Loss of methylation at K274 (P = 0.113); Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at S273 (P = 0.1802); Gain of phosphorylation at S276 (P = 0.2147); Gain of solvent accessibility (P = 0.28)
17:44060983:C:G,P10636,F271L,0.166,Loss of methylation at K274 (P = 0.113); Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at S273 (P = 0.1802); Gain of phosphorylation at S276 (P = 0.2147); Gain of solvent accessibility (P = 0.28)
17:44060984:C:A,P10636,L272I,0.258,Loss of solvent accessibility (P = 0.0606); Gain of glycosylation at S273 (P = 0.084); Loss of relative solvent accessibility (P = 0.0981); Gain of methylation at K274 (P = 0.0989); Loss of phosphorylation at S276 (P = 0.2423)
17:44060984:C:G,P10636,L272V,0.225,Gain of glycosylation at S273 (P = 0.0797); Loss of solvent accessibility (P = 0.089); Gain of methylation at K274 (P = 0.1451); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at K274 (P = 0.2262)
17:44060984:C:T,P10636,L272F,0.243,Gain of glycosylation at S273 (P = 0.0739); Loss of solvent accessibility (P = 0.0769); Loss of relative solvent accessibility (P = 0.0981); Gain of methylation at K274 (P = 0.1567); Loss of stability (P = 0.1748)
17:44060985:T:A,P10636,L272H,0.251,Loss of stability (P = 0.0152); Gain of glycosylation at S273 (P = 0.1078); Loss of methylation at K274 (P = 0.1192); Loss of solvent accessibility (P = 0.1459); Loss of phosphorylation at S276 (P = 0.1806)
17:44060985:T:C,P10636,L272P,0.262,Loss of stability (P = 0.0097); Gain of glycosylation at S273 (P = 0.0602); Gain of phosphorylation at S273 (P = 0.1156); Gain of methylation at K274 (P = 0.1567); Gain of disorder (P = 0.231)
17:44060985:T:G,P10636,L272R,0.266,Loss of stability (P = 0.0246); Gain of glycosylation at S273 (P = 0.0827); Gain of phosphorylation at S273 (P = 0.0913); Gain of catalytic residue at L272 (P = 0.0987); Loss of methylation at K274 (P = 0.1351)
17:44060987:T:A,P10636,S273T,0.2,Loss of glycosylation at S273 (P = 0.0604); Gain of phosphorylation at S273 (P = 0.0666); Loss of stability (P = 0.0989); Gain of methylation at K274 (P = 0.1793); Loss of ubiquitination at K274 (P = 0.221)
17:44060987:T:C,P10636,S273P,0.147,Loss of glycosylation at S273 (P = 0.0453); Loss of stability (P = 0.0785); Loss of phosphorylation at S273 (P = 0.0923); Gain of methylation at K274 (P = 0.1154); Gain of catalytic residue at L272 (P = 0.2005)
17:44060987:T:G,P10636,S273A,0.199,Loss of glycosylation at S273 (P = 0.0281); Loss of phosphorylation at S273 (P = 0.0923); Loss of disorder (P = 0.1791); Loss of stability (P = 0.1875); Loss of methylation at K274 (P = 0.1956)
17:44060988:C:A,P10636,S273Y,0.315,Loss of disorder (P = 0.0061); Gain of catalytic residue at S273 (P = 0.0205); Loss of glycosylation at S273 (P = 0.0281); Gain of phosphorylation at S273 (P = 0.053); Loss of relative solvent accessibility (P = 0.0981)
17:44060988:C:G,P10636,S273C,0.322,Loss of glycosylation at S273 (P = 0.0281); Loss of disorder (P = 0.0315); Gain of methylation at K274 (P = 0.0427); Loss of ubiquitination at K274 (P = 0.0508); Gain of catalytic residue at V275 (P = 0.0898)
17:44060988:C:T,P10636,S273F,0.274,Loss of glycosylation at S273 (P = 0.0281); Loss of disorder (P = 0.0351); Gain of methylation at K274 (P = 0.0726); Loss of phosphorylation at S273 (P = 0.0923); Loss of relative solvent accessibility (P = 0.0981)
17:44060990:A:C,P10636,K274Q,0.2,Loss of ubiquitination at K274 (P = 0.0047); Loss of methylation at K274 (P = 0.0112); Loss of glycosylation at S273 (P = 0.0886); Loss of phosphorylation at T277 (P = 0.1646); Loss of solvent accessibility (P = 0.4218)
17:44060990:A:G,P10636,K274E,0.205,Loss of ubiquitination at K274 (P = 0.0047); Loss of methylation at K274 (P = 0.0112); Gain of phosphorylation at S273 (P = 0.1076); Gain of glycosylation at S276 (P = 0.13); Gain of catalytic residue at K274 (P = 0.205)
17:44060991:A:C,P10636,K274T,0.279,Loss of ubiquitination at K274 (P = 0.0047); Loss of methylation at K274 (P = 0.0112); Gain of glycosylation at K274 (P = 0.029); Loss of phosphorylation at T277 (P = 0.1898); Loss of solvent accessibility (P = 0.1922)
17:44060991:A:G,P10636,K274R,0.199,Loss of ubiquitination at K274 (P = 0.0047); Loss of methylation at K274 (P = 0.0126); Gain of phosphorylation at S273 (P = 0.0985); Loss of glycosylation at S276 (P = 0.1537); Gain of catalytic residue at K274 (P = 0.4187)
17:44060991:A:T,P10636,K274I,0.354,Loss of ubiquitination at K274 (P = 0.0047); Loss of methylation at K274 (P = 0.0112); Loss of disorder (P = 0.048); Gain of catalytic residue at V275 (P = 0.0939); Loss of phosphorylation at T277 (P = 0.1056)
17:44060992:A:C,P10636,K274N,0.218,Loss of ubiquitination at K274 (P = 0.0047); Loss of methylation at K274 (P = 0.0112); Loss of phosphorylation at S276 (P = 0.113); Gain of glycosylation at T277 (P = 0.1959); Loss of solvent accessibility (P = 0.239)
17:44060992:A:T,P10636,K274N,0.218,Loss of ubiquitination at K274 (P = 0.0047); Loss of methylation at K274 (P = 0.0112); Loss of phosphorylation at S276 (P = 0.113); Gain of glycosylation at T277 (P = 0.1959); Loss of solvent accessibility (P = 0.239)
17:44060993:G:A,P10636,V275I,0.211,Loss of relative solvent accessibility (P = 0.0186); Loss of solvent accessibility (P = 0.0231); Loss of methylation at K274 (P = 0.0713); Loss of phosphorylation at T277 (P = 0.2106); Gain of glycosylation at S273 (P = 0.2317)
17:44060993:G:C,P10636,V275L,0.173,Loss of methylation at K274 (P = 0.0342); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0442); Loss of glycosylation at S276 (P = 0.0985); Loss of catalytic residue at E278 (P = 0.1862)
17:44060993:G:T,P10636,V275F,0.182,Loss of relative solvent accessibility (P = 0.0186); Loss of solvent accessibility (P = 0.0299); Loss of glycosylation at T277 (P = 0.1292); Gain of methylation at K274 (P = 0.1488); Loss of catalytic residue at E278 (P = 0.205)
17:44060994:T:A,P10636,V275D,0.239,Loss of methylation at K274 (P = 0.0312); Gain of phosphorylation at S273 (P = 0.1205); Loss of stability (P = 0.1209); Gain of glycosylation at S273 (P = 0.1475); Loss of catalytic residue at E278 (P = 0.2111)
17:44060994:T:C,P10636,V275A,0.208,Loss of methylation at K274 (P = 0.0393); Loss of stability (P = 0.05); Loss of catalytic residue at E278 (P = 0.1396); Gain of glycosylation at S273 (P = 0.1735); Gain of phosphorylation at S276 (P = 0.1807)
17:44060994:T:G,P10636,V275G,0.251,Loss of stability (P = 0.0086); Loss of methylation at K274 (P = 0.0401); Gain of glycosylation at K274 (P = 0.0914); Gain of phosphorylation at S276 (P = 0.141); Loss of solvent accessibility (P = 0.2034)
17:44060996:T:A,P10636,S276T,0.17,Loss of phosphorylation at S276 (P = 0.087); Loss of glycosylation at S276 (P = 0.1081); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at K274 (P = 0.1903); Loss of disorder (P = 0.1942)
17:44060996:T:C,P10636,S276P,0.148,Loss of glycosylation at S276 (P = 0.0248); Loss of phosphorylation at S276 (P = 0.039); Gain of methylation at K274 (P = 0.1197); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1986)
17:44060996:T:G,P10636,S276A,0.204,Loss of glycosylation at S276 (P = 0.0148); Loss of phosphorylation at S276 (P = 0.039); Loss of disorder (P = 0.1332); Loss of solvent accessibility (P = 0.1473); Gain of methylation at K274 (P = 0.1643)
17:44060997:C:A,P10636,S276Y,0.337,Loss of disorder (P = 0.0028); Loss of glycosylation at S276 (P = 0.0148); Loss of ubiquitination at K274 (P = 0.0508); Gain of phosphorylation at S276 (P = 0.0704); Gain of catalytic residue at P280 (P = 0.073)
17:44060997:C:G,P10636,S276C,0.315,Loss of disorder (P = 0.0137); Loss of glycosylation at S276 (P = 0.0148); Loss of phosphorylation at S276 (P = 0.039); Loss of ubiquitination at K274 (P = 0.0415); Gain of methylation at K274 (P = 0.1136)
17:44060997:C:T,P10636,S276F,0.295,Loss of glycosylation at S276 (P = 0.0148); Loss of disorder (P = 0.0169); Loss of phosphorylation at S276 (P = 0.039); Loss of ubiquitination at K274 (P = 0.0508); Loss of relative solvent accessibility (P = 0.0676)
17:44060999:A:C,P10636,T277P,0.195,Loss of glycosylation at T277 (P = 0.0296); Loss of phosphorylation at T277 (P = 0.0321); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1903); Gain of methylation at K274 (P = 0.1983)
17:44060999:A:G,P10636,T277A,0.147,Loss of glycosylation at T277 (P = 0.0131); Loss of phosphorylation at T277 (P = 0.0321); Loss of methylation at K274 (P = 0.0944); Gain of ubiquitination at K274 (P = 0.3121); Loss of solvent accessibility (P = 0.3473)
17:44060999:A:T,P10636,T277S,0.2,Loss of glycosylation at S276 (P = 0.0586); Gain of relative solvent accessibility (P = 0.09); Gain of phosphorylation at S273 (P = 0.1151); Loss of methylation at K274 (P = 0.1214); Gain of solvent accessibility (P = 0.2097)
17:44061000:C:A,P10636,T277K,0.264,Gain of ubiquitination at T277 (P = 0.0045); Gain of solvent accessibility (P = 0.007); Gain of methylation at T277 (P = 0.0245); Gain of relative solvent accessibility (P = 0.0275); Loss of phosphorylation at T277 (P = 0.0321)
17:44061000:C:G,P10636,T277R,0.231,Gain of solvent accessibility (P = 0.0086); Loss of glycosylation at T277 (P = 0.0131); Loss of phosphorylation at T277 (P = 0.0321); Gain of catalytic residue at T277 (P = 0.0452); Gain of relative solvent accessibility (P = 0.09)
17:44061000:C:T,P10636,T277I,0.228,Loss of glycosylation at T277 (P = 0.0131); Loss of phosphorylation at T277 (P = 0.0321); Loss of disorder (P = 0.0982); Gain of methylation at K274 (P = 0.2083); Loss of ubiquitination at K274 (P = 0.2976)
17:44061002:G:A,P10636,E278K,0.219,Gain of ubiquitination at E278 (P = 0.0054); Gain of methylation at E278 (P = 0.0264); Loss of glycosylation at S273 (P = 0.0845); Loss of phosphorylation at S276 (P = 0.1641); Loss of catalytic residue at E278 (P = 0.2744)
17:44061002:G:C,P10636,E278Q,0.158,Loss of phosphorylation at S276 (P = 0.0917); Loss of glycosylation at S273 (P = 0.0963); Loss of catalytic residue at E278 (P = 0.1298); Loss of methylation at K274 (P = 0.2044); Loss of ubiquitination at K274 (P = 0.2839)
17:44061003:A:C,P10636,E278A,0.209,Loss of catalytic residue at E278 (P = 0.0706); Loss of methylation at K274 (P = 0.1334); Loss of phosphorylation at S276 (P = 0.1347); Loss of solvent accessibility (P = 0.1459); Loss of disorder (P = 0.1572)
17:44061003:A:G,P10636,E278G,0.187,Loss of catalytic residue at E278 (P = 0.0422); Loss of solvent accessibility (P = 0.0769); Loss of glycosylation at S273 (P = 0.0984); Loss of phosphorylation at S276 (P = 0.1438); Loss of methylation at K274 (P = 0.1716)
17:44061003:A:T,P10636,E278V,0.32,Loss of disorder (P = 0.0205); Loss of solvent accessibility (P = 0.0721); Loss of phosphorylation at S276 (P = 0.1082); Loss of glycosylation at S273 (P = 0.1277); Loss of ubiquitination at K274 (P = 0.1287)
17:44061004:G:C,P10636,E278D,0.119,Loss of catalytic residue at E278 (P = 0.1476); Loss of methylation at K274 (P = 0.1821); Loss of phosphorylation at S276 (P = 0.2202); Loss of glycosylation at T277 (P = 0.2386); Loss of ubiquitination at K274 (P = 0.3231)
17:44061004:G:T,P10636,E278D,0.119,Loss of catalytic residue at E278 (P = 0.1476); Loss of methylation at K274 (P = 0.1821); Loss of phosphorylation at S276 (P = 0.2202); Loss of glycosylation at T277 (P = 0.2386); Loss of ubiquitination at K274 (P = 0.3231)
17:44061005:A:C,P10636,I279L,0.129,Loss of methylation at K274 (P = 0.0603); Loss of glycosylation at S276 (P = 0.089); Loss of catalytic residue at I279 (P = 0.2073); Gain of phosphorylation at S276 (P = 0.2182); Gain of ubiquitination at K274 (P = 0.3213)
17:44061005:A:G,P10636,I279V,0.096,Loss of methylation at K274 (P = 0.1337); Gain of glycosylation at T277 (P = 0.16); Gain of phosphorylation at S276 (P = 0.2033); Loss of catalytic residue at I279 (P = 0.2555); Gain of ubiquitination at K274 (P = 0.3213)
17:44061005:A:T,P10636,I279F,0.11,Loss of methylation at K274 (P = 0.1256); Gain of glycosylation at P280 (P = 0.1713); Gain of phosphorylation at T277 (P = 0.2192); Loss of catalytic residue at I279 (P = 0.2207); Gain of ubiquitination at K274 (P = 0.3166)
17:44061006:T:A,P10636,I279N,0.169,Loss of glycosylation at S282 (P = 0.0966); Loss of methylation at K274 (P = 0.1276); Loss of stability (P = 0.1285); Gain of phosphorylation at T277 (P = 0.189); Gain of ubiquitination at K274 (P = 0.2948)
17:44061006:T:C,P10636,I279T,0.171,Gain of phosphorylation at I279 (P = 0.0163); Gain of glycosylation at I279 (P = 0.0177); Loss of stability (P = 0.0674); Gain of methylation at K274 (P = 0.1752); Loss of catalytic residue at I279 (P = 0.1841)
17:44061006:T:G,P10636,I279S,0.199,Gain of phosphorylation at I279 (P = 0.0176); Gain of glycosylation at I279 (P = 0.0672); Loss of stability (P = 0.0765); Gain of methylation at K274 (P = 0.1662); Gain of disorder (P = 0.192)
17:44061007:C:G,P10636,I279M,0.139,Gain of catalytic residue at V275 (P = 0.0161); Loss of glycosylation at S276 (P = 0.1327); Loss of methylation at K274 (P = 0.162); Gain of phosphorylation at S276 (P = 0.1788); Gain of ubiquitination at K274 (P = 0.3121)
17:44061008:C:A,P10636,P280T,0.232,Gain of phosphorylation at P280 (P = 0.0381); Loss of glycosylation at T277 (P = 0.0503); Loss of disorder (P = 0.2098); Gain of catalytic residue at D285 (P = 0.4763); Loss of stability (P = 0.5276)
17:44061008:C:G,P10636,P280A,0.212,Loss of glycosylation at T277 (P = 0.0601); Loss of disorder (P = 0.1501); Loss of phosphorylation at T277 (P = 0.1697); Gain of catalytic residue at D285 (P = 0.4101); Loss of stability (P = 0.5542)
17:44061008:C:T,P10636,P280S,0.171,Gain of phosphorylation at P280 (P = 0.0187); Gain of glycosylation at P280 (P = 0.0665); Gain of disorder (P = 0.4825); Gain of catalytic residue at D285 (P = 0.5519); Gain of sheet (P = 0.6509)
17:44061009:C:A,P10636,P280Q,0.197,Loss of glycosylation at T277 (P = 0.0436); Loss of phosphorylation at T277 (P = 0.1274); Loss of disorder (P = 0.2768); Gain of solvent accessibility (P = 0.3418); Loss of catalytic residue at E278 (P = 0.3793)
17:44061009:C:G,P10636,P280R,0.235,Loss of glycosylation at S282 (P = 0.0271); Gain of solvent accessibility (P = 0.0789); Loss of phosphorylation at S276 (P = 0.13); Gain of relative solvent accessibility (P = 0.2363); Gain of catalytic residue at P280 (P = 0.2776)
17:44061009:C:T,P10636,P280L,0.281,Loss of glycosylation at T277 (P = 0.0306); Loss of disorder (P = 0.0355); Loss of phosphorylation at S282 (P = 0.1134); Gain of catalytic residue at D285 (P = 0.349); Gain of solvent accessibility (P = 0.4656)
17:44061011:G:A,P10636,A281T,0.167,Gain of glycosylation at A281 (P = 0.0016); Gain of phosphorylation at A281 (P = 0.0387); Gain of solvent accessibility (P = 0.2291); Gain of disorder (P = 0.4544); Loss of stability (P = 0.6507)
17:44061011:G:C,P10636,A281P,0.218,Gain of catalytic residue at P280 (P = 0.0112); Gain of glycosylation at A281 (P = 0.0158); Gain of phosphorylation at S276 (P = 0.1492); Gain of solvent accessibility (P = 0.2689); Gain of disorder (P = 0.3287)
17:44061011:G:T,P10636,A281S,0.134,Gain of phosphorylation at A281 (P = 0.0235); Gain of glycosylation at A281 (P = 0.0478); Gain of solvent accessibility (P = 0.3089); Gain of disorder (P = 0.3362); Loss of catalytic residue at E283 (P = 0.5688)
17:44061012:C:A,P10636,A281D,0.161,Gain of solvent accessibility (P = 0.1154); Loss of glycosylation at S282 (P = 0.1399); Gain of phosphorylation at S276 (P = 0.1419); Loss of catalytic residue at E283 (P = 0.4062); Gain of disorder (P = 0.4071)
17:44061012:C:G,P10636,A281G,0.087,Loss of glycosylation at S276 (P = 0.1596); Gain of phosphorylation at S276 (P = 0.2182); Loss of stability (P = 0.338); Gain of catalytic residue at I279 (P = 0.4215); Gain of disorder (P = 0.4483)
17:44061012:C:T,P10636,A281V,0.145,Loss of relative solvent accessibility (P = 0.0676); Gain of catalytic residue at A281 (P = 0.1149); Loss of glycosylation at S276 (P = 0.1977); Loss of solvent accessibility (P = 0.1986); Loss of phosphorylation at S276 (P = 0.2438)
17:44061014:T:A,P10636,S282T,0.187,Loss of glycosylation at S282 (P = 0.0728); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2073); Loss of disorder (P = 0.252); Loss of phosphorylation at T277 (P = 0.2744)
17:44061014:T:C,P10636,S282P,0.249,Gain of catalytic residue at S282 (P = 0.0061); Loss of phosphorylation at S282 (P = 0.0221); Loss of glycosylation at S282 (P = 0.0646); Loss of stability (P = 0.1542); Loss of relative solvent accessibility (P = 0.1807)
17:44061014:T:G,P10636,S282A,0.23,Loss of glycosylation at S282 (P = 0.0116); Loss of phosphorylation at S282 (P = 0.0221); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1144); Loss of disorder (P = 0.1935)
17:44061017:G:A,P10636,E283K,0.21,Gain of ubiquitination at E283 (P = 0.0048); Gain of methylation at E283 (P = 0.0571); Gain of glycosylation at E283 (P = 0.106); Loss of phosphorylation at S282 (P = 0.1732); Gain of catalytic residue at E283 (P = 0.3802)
17:44061017:G:C,P10636,E283Q,0.126,Loss of phosphorylation at S282 (P = 0.1677); Loss of glycosylation at S282 (P = 0.2033); Loss of catalytic residue at E283 (P = 0.3588); Loss of disorder (P = 0.4497); Loss of stability (P = 0.566)
17:44061018:A:C,P10636,E283A,0.15,Loss of phosphorylation at S282 (P = 0.1971); Gain of glycosylation at S282 (P = 0.198); Loss of stability (P = 0.2282); Loss of disorder (P = 0.3235); Gain of catalytic residue at E283 (P = 0.398)
17:44061018:A:G,P10636,E283G,0.135,Gain of glycosylation at S282 (P = 0.1018); Loss of stability (P = 0.1786); Loss of phosphorylation at S282 (P = 0.2995); Loss of solvent accessibility (P = 0.4011); Gain of catalytic residue at D285 (P = 0.4203)
17:44061018:A:T,P10636,E283V,0.22,Loss of disorder (P = 0.103); Loss of glycosylation at S282 (P = 0.1416); Loss of phosphorylation at S282 (P = 0.1607); Gain of catalytic residue at E283 (P = 0.3275); Loss of solvent accessibility (P = 0.4274)
17:44061019:G:C,P10636,E283D,0.114,Gain of glycosylation at S288 (P = 0.1928); Loss of phosphorylation at S282 (P = 0.4088); Gain of catalytic residue at E283 (P = 0.4836); Loss of disorder (P = 0.5219); Loss of stability (P = 0.5925)
17:44061019:G:T,P10636,E283D,0.114,Gain of glycosylation at S288 (P = 0.1928); Loss of phosphorylation at S282 (P = 0.4088); Gain of catalytic residue at E283 (P = 0.4836); Loss of disorder (P = 0.5219); Loss of stability (P = 0.5925)
17:44061020:C:A,P10636,P284T,0.213,Gain of phosphorylation at P284 (P = 0.0143); Gain of glycosylation at P284 (P = 0.047); Loss of stability (P = 0.2381); Loss of disorder (P = 0.3637); Gain of catalytic residue at P284 (P = 0.4185)
17:44061020:C:G,P10636,P284A,0.147,Loss of solvent accessibility (P = 0.0509); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at P284 (P = 0.1851); Loss of phosphorylation at S282 (P = 0.2833); Loss of disorder (P = 0.307)
17:44061020:C:T,P10636,P284S,0.184,Gain of phosphorylation at P284 (P = 0.0169); Loss of glycosylation at S282 (P = 0.1159); Loss of stability (P = 0.2132); Loss of catalytic residue at E283 (P = 0.5477); Gain of disorder (P = 0.5667)
17:44061021:C:A,P10636,P284H,0.202,Loss of glycosylation at S282 (P = 0.0605); Gain of catalytic residue at D285 (P = 0.0769); Gain of solvent accessibility (P = 0.1583); Loss of phosphorylation at S282 (P = 0.1641); Loss of stability (P = 0.2282)
17:44061021:C:G,P10636,P284R,0.228,Gain of solvent accessibility (P = 0.0216); Loss of glycosylation at S282 (P = 0.0393); Loss of catalytic residue at E283 (P = 0.1649); Gain of methylation at P284 (P = 0.2492); Gain of phosphorylation at S282 (P = 0.3612)
17:44061021:C:T,P10636,P284L,0.253,Gain of catalytic residue at P284 (P = 0.0065); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Loss of glycosylation at S282 (P = 0.0735); Loss of disorder (P = 0.0915)
17:44061023:G:C,P10636,D285H,0.19,Loss of solvent accessibility (P = 0.0217); Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at S288 (P = 0.1814); Loss of phosphorylation at S282 (P = 0.1925); Gain of catalytic residue at D285 (P = 0.3012)
17:44061023:G:T,P10636,D285Y,0.323,Gain of phosphorylation at D285 (P = 0.0219); Loss of solvent accessibility (P = 0.0352); Loss of relative solvent accessibility (P = 0.0404); Gain of catalytic residue at D285 (P = 0.0591); Loss of disorder (P = 0.0769)
17:44061024:A:C,P10636,D285A,0.212,Loss of solvent accessibility (P = 0.0174); Loss of relative solvent accessibility (P = 0.0676); Gain of catalytic residue at D285 (P = 0.084); Gain of glycosylation at S288 (P = 0.122); Loss of phosphorylation at S282 (P = 0.3342)
17:44061024:A:G,P10636,D285G,0.181,Loss of solvent accessibility (P = 0.0595); Gain of catalytic residue at D285 (P = 0.1302); Gain of glycosylation at S288 (P = 0.1348); Loss of stability (P = 0.336); Loss of phosphorylation at S282 (P = 0.3648)
17:44061024:A:T,P10636,D285V,0.225,Loss of solvent accessibility (P = 0.0159); Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at S288 (P = 0.13); Loss of phosphorylation at S282 (P = 0.2083); Loss of disorder (P = 0.2592)
17:44061025:C:A,P10636,D285E,0.187,Gain of glycosylation at P284 (P = 0.095); Gain of solvent accessibility (P = 0.2601); Gain of catalytic residue at D285 (P = 0.3212); Gain of phosphorylation at S282 (P = 0.3588); Gain of disorder (P = 0.4968)
17:44061025:C:G,P10636,D285E,0.187,Gain of glycosylation at P284 (P = 0.095); Gain of solvent accessibility (P = 0.2601); Gain of catalytic residue at D285 (P = 0.3212); Gain of phosphorylation at S282 (P = 0.3588); Gain of disorder (P = 0.4968)
17:44061026:G:A,P10636,G286R,0.201,Loss of glycosylation at S282 (P = 0.0846); Gain of solvent accessibility (P = 0.1319); Loss of phosphorylation at S282 (P = 0.2806); Loss of catalytic residue at G286 (P = 0.2913); Loss of methylation at R291 (P = 0.3238)
17:44061026:G:C,P10636,G286R,0.201,Loss of glycosylation at S282 (P = 0.0846); Gain of solvent accessibility (P = 0.1319); Loss of phosphorylation at S282 (P = 0.2806); Loss of catalytic residue at G286 (P = 0.2913); Loss of methylation at R291 (P = 0.3238)
17:44061026:G:T,P10636,G286W,0.304,Loss of catalytic residue at G286 (P = 0.0205); Loss of disorder (P = 0.039); Loss of glycosylation at S288 (P = 0.1413); Loss of phosphorylation at S282 (P = 0.1856); Loss of methylation at R291 (P = 0.211)
17:44061027:G:A,P10636,G286E,0.182,Loss of catalytic residue at G286 (P = 0.0368); Gain of glycosylation at P284 (P = 0.123); Gain of solvent accessibility (P = 0.2192); Loss of methylation at R291 (P = 0.2744); Gain of phosphorylation at S282 (P = 0.3453)
17:44061027:G:C,P10636,G286A,0.164,Loss of catalytic residue at G286 (P = 0.0257); Gain of glycosylation at P284 (P = 0.1646); Gain of methylation at R291 (P = 0.2675); Gain of phosphorylation at S282 (P = 0.4086); Loss of disorder (P = 0.5087)
17:44061027:G:T,P10636,G286V,0.18,Loss of catalytic residue at G286 (P = 0.0241); Gain of glycosylation at S288 (P = 0.2629); Loss of disorder (P = 0.2781); Gain of methylation at R291 (P = 0.3229); Loss of phosphorylation at S282 (P = 0.3497)
17:44061029:C:A,P10636,P287T,0.253,Gain of phosphorylation at P287 (P = 0.0233); Gain of glycosylation at P287 (P = 0.0339); Loss of stability (P = 0.1328); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2384)
17:44061029:C:G,P10636,P287A,0.164,Gain of catalytic residue at P287 (P = 0.0478); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at R291 (P = 0.1999); Loss of stability (P = 0.2038)
17:44061029:C:T,P10636,P287S,0.169,Gain of glycosylation at P287 (P = 0.0317); Gain of phosphorylation at P287 (P = 0.0339); Gain of methylation at R291 (P = 0.3123); Loss of stability (P = 0.323); Gain of disorder (P = 0.4926)
17:44061030:C:A,P10636,P287H,0.171,Gain of catalytic residue at P287 (P = 0.0598); Loss of glycosylation at S288 (P = 0.1555); Loss of phosphorylation at S282 (P = 0.1773); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at R291 (P = 0.2531)
17:44061030:C:G,P10636,P287R,0.205,Gain of methylation at P287 (P = 0.0524); Loss of glycosylation at S282 (P = 0.0611); Gain of catalytic residue at P287 (P = 0.1647); Loss of relative solvent accessibility (P = 0.3219); Loss of disorder (P = 0.4011)
17:44061030:C:T,P10636,P287L,0.204,Loss of disorder (P = 0.0753); Loss of glycosylation at S288 (P = 0.0949); Gain of catalytic residue at P287 (P = 0.1806); Loss of phosphorylation at S282 (P = 0.1957); Gain of methylation at R291 (P = 0.2334)
17:44061032:A:C,P10636,S288R,0.226,Loss of phosphorylation at S288 (P = 0.0171); Gain of solvent accessibility (P = 0.0365); Loss of glycosylation at S288 (P = 0.0424); Gain of catalytic residue at S288 (P = 0.0461); Loss of ubiquitination at K293 (P = 0.1287)
17:44061032:A:G,P10636,S288G,0.175,Loss of phosphorylation at S288 (P = 0.0171); Loss of glycosylation at S288 (P = 0.0424); Gain of catalytic residue at P284 (P = 0.0665); Gain of relative solvent accessibility (P = 0.1571); Gain of methylation at R291 (P = 0.2183)
17:44061032:A:T,P10636,S288C,0.28,Gain of catalytic residue at P287 (P = 0.009); Loss of phosphorylation at S288 (P = 0.0171); Loss of glycosylation at S288 (P = 0.0424); Loss of disorder (P = 0.0514); Loss of relative solvent accessibility (P = 0.0981)
17:44061033:G:A,P10636,S288N,0.204,Loss of phosphorylation at S288 (P = 0.0171); Loss of glycosylation at S288 (P = 0.0424); Gain of catalytic residue at S288 (P = 0.1101); Gain of solvent accessibility (P = 0.1376); Gain of relative solvent accessibility (P = 0.1571)
17:44061033:G:C,P10636,S288T,0.201,Gain of glycosylation at S288 (P = 0.0513); Loss of phosphorylation at S288 (P = 0.2053); Gain of methylation at K293 (P = 0.2732); Loss of disorder (P = 0.2814); Loss of ubiquitination at K293 (P = 0.3114)
17:44061033:G:T,P10636,S288I,0.294,Loss of phosphorylation at S288 (P = 0.0171); Gain of stability (P = 0.0258); Loss of disorder (P = 0.0407); Loss of glycosylation at S288 (P = 0.0424); Gain of catalytic residue at S288 (P = 0.0461)
17:44061034:T:A,P10636,S288R,0.226,Loss of phosphorylation at S288 (P = 0.0171); Gain of solvent accessibility (P = 0.0365); Loss of glycosylation at S288 (P = 0.0424); Gain of catalytic residue at S288 (P = 0.0461); Loss of ubiquitination at K293 (P = 0.1287)
17:44061034:T:G,P10636,S288R,0.226,Loss of phosphorylation at S288 (P = 0.0171); Gain of solvent accessibility (P = 0.0365); Loss of glycosylation at S288 (P = 0.0424); Gain of catalytic residue at S288 (P = 0.0461); Loss of ubiquitination at K293 (P = 0.1287)
17:44061035:G:A,P10636,V289I,0.152,Gain of catalytic residue at V289 (P = 0.1009); Gain of glycosylation at S288 (P = 0.1231); Gain of methylation at K293 (P = 0.1974); Loss of ubiquitination at K293 (P = 0.2669); Loss of disorder (P = 0.3392)
17:44061035:G:C,P10636,V289L,0.078,Gain of glycosylation at S288 (P = 0.1375); Loss of methylation at K293 (P = 0.217); Loss of ubiquitination at K293 (P = 0.2839); Loss of catalytic residue at G290 (P = 0.2898); Gain of disorder (P = 0.3923)
17:44061035:G:T,P10636,V289L,0.078,Gain of glycosylation at S288 (P = 0.1375); Loss of methylation at K293 (P = 0.217); Loss of ubiquitination at K293 (P = 0.2839); Loss of catalytic residue at G290 (P = 0.2898); Gain of disorder (P = 0.3923)
17:44061036:T:A,P10636,V289E,0.162,Gain of glycosylation at S288 (P = 0.1483); Gain of disorder (P = 0.1504); Gain of solvent accessibility (P = 0.2384); Loss of methylation at K293 (P = 0.2617); Gain of relative solvent accessibility (P = 0.2629)
17:44061036:T:G,P10636,V289G,0.171,Gain of glycosylation at S288 (P = 0.03); Loss of stability (P = 0.0445); Gain of methylation at R291 (P = 0.1252); Gain of disorder (P = 0.2167); Gain of catalytic residue at G290 (P = 0.2513)
17:44061038:G:A,P10636,G290R,0.255,Gain of solvent accessibility (P = 0.0037); Loss of ubiquitination at K293 (P = 0.1041); Gain of methylation at K293 (P = 0.1582); Loss of glycosylation at S288 (P = 0.1871); Loss of catalytic residue at R291 (P = 0.3107)
17:44061038:G:C,P10636,G290R,0.255,Gain of solvent accessibility (P = 0.0037); Loss of ubiquitination at K293 (P = 0.1041); Gain of methylation at K293 (P = 0.1582); Loss of glycosylation at S288 (P = 0.1871); Loss of catalytic residue at R291 (P = 0.3107)
17:44061038:G:T,P10636,G290W,0.367,Loss of disorder (P = 0.015); Loss of relative solvent accessibility (P = 0.0404); Loss of methylation at R291 (P = 0.1381); Loss of glycosylation at S288 (P = 0.1507); Loss of phosphorylation at S288 (P = 0.2053)
17:44061039:G:A,P10636,G290E,0.216,Gain of solvent accessibility (P = 0.024); Loss of methylation at R291 (P = 0.2039); Loss of catalytic residue at A292 (P = 0.2071); Loss of glycosylation at S288 (P = 0.2075); Gain of disorder (P = 0.2559)
17:44061039:G:C,P10636,G290A,0.11,Gain of glycosylation at S288 (P = 0.1847); Loss of catalytic residue at G290 (P = 0.2078); Loss of methylation at K293 (P = 0.2478); Loss of ubiquitination at K293 (P = 0.3231); Loss of disorder (P = 0.3492)
17:44061039:G:T,P10636,G290V,0.178,Loss of relative solvent accessibility (P = 0.0404); Loss of disorder (P = 0.1184); Loss of catalytic residue at G290 (P = 0.1993); Gain of glycosylation at S288 (P = 0.2041); Loss of methylation at R291 (P = 0.2232)
17:44061041:C:G,P10636,R291G,0.246,Loss of solvent accessibility (P = 0.0159); Loss of stability (P = 0.0595); Gain of glycosylation at K293 (P = 0.0596); Gain of catalytic residue at P287 (P = 0.0678); Loss of methylation at R291 (P = 0.1032)
17:44061041:C:T,P10636,R291W,0.345,Loss of solvent accessibility (P = 0.0087); Loss of disorder (P = 0.0149); Gain of methylation at K293 (P = 0.089); Loss of phosphorylation at S288 (P = 0.0958); Loss of relative solvent accessibility (P = 0.0981)
17:44061042:G:A,P10636,R291Q,0.192,Loss of catalytic residue at R291 (P = 0.0808); Gain of methylation at K293 (P = 0.1009); Gain of glycosylation at K293 (P = 0.142); Loss of phosphorylation at S288 (P = 0.1508); Gain of disorder (P = 0.2471)
17:44061042:G:C,P10636,R291P,0.253,Loss of catalytic residue at R291 (P = 0.0304); Gain of methylation at K293 (P = 0.0496); Gain of glycosylation at S288 (P = 0.0555); Loss of solvent accessibility (P = 0.0703); Loss of stability (P = 0.1281)
17:44061042:G:T,P10636,R291L,0.282,Gain of glycosylation at K293 (P = 0.0871); Loss of methylation at R291 (P = 0.1032); Loss of disorder (P = 0.1062); Loss of phosphorylation at S288 (P = 0.1402); Loss of solvent accessibility (P = 0.1579)
17:44061044:G:A,P10636,A292T,0.147,Gain of phosphorylation at A292 (P = 0.0147); Gain of glycosylation at A292 (P = 0.0292); Gain of methylation at K293 (P = 0.1252); Gain of disorder (P = 0.2184); Loss of catalytic residue at A292 (P = 0.2291)
17:44061044:G:C,P10636,A292P,0.194,Gain of disorder (P = 0.0837); Gain of methylation at K293 (P = 0.0895); Gain of glycosylation at K293 (P = 0.0969); Loss of catalytic residue at A292 (P = 0.1347); Loss of stability (P = 0.2147)
17:44061044:G:T,P10636,A292S,0.167,Gain of glycosylation at A292 (P = 0.0245); Gain of phosphorylation at A292 (P = 0.0385); Loss of catalytic residue at A292 (P = 0.0926); Gain of disorder (P = 0.0978); Gain of methylation at K293 (P = 0.1863)
17:44061045:C:A,P10636,A292D,0.153,Loss of catalytic residue at A292 (P = 0.1578); Gain of disorder (P = 0.159); Loss of methylation at R291 (P = 0.2101); Gain of glycosylation at K293 (P = 0.2231); Gain of relative solvent accessibility (P = 0.2629)
17:44061045:C:G,P10636,A292G,0.121,Gain of methylation at R291 (P = 0.1078); Loss of stability (P = 0.145); Loss of glycosylation at S288 (P = 0.1766); Gain of disorder (P = 0.1924); Loss of catalytic residue at A292 (P = 0.2825)
17:44061045:C:T,P10636,A292V,0.139,Gain of methylation at K293 (P = 0.0375); Loss of disorder (P = 0.1194); Loss of catalytic residue at A292 (P = 0.1457); Loss of glycosylation at S288 (P = 0.2078); Loss of ubiquitination at K293 (P = 0.3231)
17:44061047:A:C,P10636,K293Q,0.185,Loss of ubiquitination at K293 (P = 0.0047); Loss of methylation at K293 (P = 0.064); Loss of glycosylation at K293 (P = 0.0907); Loss of catalytic residue at K293 (P = 0.0915); Gain of relative solvent accessibility (P = 0.1571)
17:44061047:A:G,P10636,K293E,0.192,Loss of ubiquitination at K293 (P = 0.0047); Loss of methylation at K293 (P = 0.064); Loss of glycosylation at K293 (P = 0.0907); Gain of relative solvent accessibility (P = 0.1571); Gain of disorder (P = 0.1777)
17:44061048:A:C,P10636,K293T,0.189,Loss of ubiquitination at K293 (P = 0.0047); Gain of phosphorylation at K293 (P = 0.0248); Loss of methylation at K293 (P = 0.064); Gain of glycosylation at S288 (P = 0.1003); Loss of disorder (P = 0.217)
17:44061048:A:T,P10636,K293I,0.294,Loss of ubiquitination at K293 (P = 0.0047); Loss of disorder (P = 0.0182); Loss of solvent accessibility (P = 0.0431); Loss of methylation at K293 (P = 0.064); Loss of glycosylation at K293 (P = 0.0907)
17:44061049:A:C,P10636,K293N,0.211,Loss of ubiquitination at K293 (P = 0.0047); Loss of methylation at K293 (P = 0.064); Loss of catalytic residue at K293 (P = 0.0763); Loss of glycosylation at K293 (P = 0.0907); Loss of disorder (P = 0.1696)
17:44061049:A:T,P10636,K293N,0.211,Loss of ubiquitination at K293 (P = 0.0047); Loss of methylation at K293 (P = 0.064); Loss of catalytic residue at K293 (P = 0.0763); Loss of glycosylation at K293 (P = 0.0907); Loss of disorder (P = 0.1696)
17:44061050:G:A,P10636,G294R,0.282,Loss of relative solvent accessibility (P = 0.0676); Loss of ubiquitination at K293 (P = 0.1041); Gain of methylation at K293 (P = 0.1333); Gain of disorder (P = 0.1612); Loss of catalytic residue at L299 (P = 0.2052)
17:44061050:G:C,P10636,G294R,0.282,Loss of relative solvent accessibility (P = 0.0676); Loss of ubiquitination at K293 (P = 0.1041); Gain of methylation at K293 (P = 0.1333); Gain of disorder (P = 0.1612); Loss of catalytic residue at L299 (P = 0.2052)
17:44061050:G:T,P10636,G294W,0.42,Loss of disorder (P = 0.0045); Loss of relative solvent accessibility (P = 0.0186); Gain of methylation at K293 (P = 0.0627); Loss of glycosylation at K293 (P = 0.2144); Loss of catalytic residue at L299 (P = 0.228)
17:44061051:G:A,P10636,G294E,0.252,Gain of solvent accessibility (P = 0.0789); Gain of disorder (P = 0.0877); Loss of catalytic residue at K293 (P = 0.0928); Loss of methylation at R291 (P = 0.242); Gain of ubiquitination at K293 (P = 0.3213)
17:44061051:G:C,P10636,G294A,0.237,Loss of catalytic residue at L299 (P = 0.2031); Loss of disorder (P = 0.2419); Loss of methylation at K293 (P = 0.2603); Loss of glycosylation at K293 (P = 0.2633); Loss of stability (P = 0.2884)
17:44061051:G:T,P10636,G294V,0.339,Loss of relative solvent accessibility (P = 0.0186); Gain of methylation at K293 (P = 0.0353); Loss of disorder (P = 0.0661); Loss of solvent accessibility (P = 0.1744); Loss of glycosylation at K293 (P = 0.2064)
17:44061053:C:A,P10636,Q295K,0.267,Gain of ubiquitination at Q295 (P = 0.0094); Gain of methylation at Q295 (P = 0.0391); Gain of relative solvent accessibility (P = 0.0999); Gain of solvent accessibility (P = 0.1071); Gain of disorder (P = 0.1593)
17:44061053:C:G,P10636,Q295E,0.245,Gain of solvent accessibility (P = 0.0421); Gain of relative solvent accessibility (P = 0.0479); Gain of disorder (P = 0.1133); Loss of catalytic residue at Q295 (P = 0.1493); Gain of glycosylation at K293 (P = 0.1679)
17:44061054:A:C,P10636,Q295P,0.234,Gain of disorder (P = 0.0927); Gain of methylation at K293 (P = 0.1537); Loss of catalytic residue at Q295 (P = 0.1562); Gain of glycosylation at Q295 (P = 0.2388); Gain of ubiquitination at K293 (P = 0.3121)
17:44061054:A:G,P10636,Q295R,0.182,Loss of ubiquitination at K293 (P = 0.0828); Gain of methylation at R291 (P = 0.1057); Gain of disorder (P = 0.2111); Loss of glycosylation at K293 (P = 0.3277); Gain of solvent accessibility (P = 0.3819)
17:44061054:A:T,P10636,Q295L,0.276,Loss of disorder (P = 0.0448); Loss of ubiquitination at K293 (P = 0.1904); Gain of methylation at K293 (P = 0.2645); Gain of stability (P = 0.3023); Gain of glycosylation at K293 (P = 0.3121)
17:44061055:G:C,P10636,Q295H,0.222,Gain of catalytic residue at D296 (P = 0.0679); Gain of methylation at R291 (P = 0.1857); Loss of disorder (P = 0.2481); Gain of glycosylation at K293 (P = 0.2688); Gain of ubiquitination at K293 (P = 0.3247)
17:44061055:G:T,P10636,Q295H,0.222,Gain of catalytic residue at D296 (P = 0.0679); Gain of methylation at R291 (P = 0.1857); Loss of disorder (P = 0.2481); Gain of glycosylation at K293 (P = 0.2688); Gain of ubiquitination at K293 (P = 0.3247)
17:44061056:G:A,P10636,D296N,0.269,Gain of catalytic residue at D296 (P = 0.0143); Gain of methylation at K293 (P = 0.1126); Loss of ubiquitination at K293 (P = 0.1613); Loss of disorder (P = 0.2041); Loss of glycosylation at K293 (P = 0.3269)
17:44061056:G:C,P10636,D296H,0.243,Loss of solvent accessibility (P = 0.0509); Loss of relative solvent accessibility (P = 0.0676); Gain of methylation at K293 (P = 0.0825); Loss of ubiquitination at K293 (P = 0.1904); Gain of disorder (P = 0.207)
17:44061056:G:T,P10636,D296Y,0.353,Loss of disorder (P = 0.0101); Gain of phosphorylation at D296 (P = 0.0292); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.0721); Gain of methylation at K293 (P = 0.0903)
17:44061057:A:C,P10636,D296A,0.232,Loss of solvent accessibility (P = 0.1202); Loss of ubiquitination at K293 (P = 0.1287); Gain of methylation at R291 (P = 0.1512); Loss of disorder (P = 0.1567); Gain of glycosylation at P298 (P = 0.2434)
17:44061057:A:G,P10636,D296G,0.242,Loss of solvent accessibility (P = 0.0595); Gain of catalytic residue at D296 (P = 0.0736); Gain of methylation at R291 (P = 0.1136); Loss of ubiquitination at K293 (P = 0.1613); Gain of disorder (P = 0.2056)
17:44061057:A:T,P10636,D296V,0.316,Loss of solvent accessibility (P = 0.0299); Loss of disorder (P = 0.0372); Loss of relative solvent accessibility (P = 0.0676); Gain of methylation at K293 (P = 0.0988); Gain of stability (P = 0.1689)
17:44061058:T:A,P10636,D296E,0.257,Gain of disorder (P = 0.077); Gain of glycosylation at P298 (P = 0.1874); Gain of methylation at K293 (P = 0.1989); Loss of catalytic residue at A292 (P = 0.241); Gain of solvent accessibility (P = 0.2601)
17:44061058:T:G,P10636,D296E,0.257,Gain of disorder (P = 0.077); Gain of glycosylation at P298 (P = 0.1874); Gain of methylation at K293 (P = 0.1989); Loss of catalytic residue at A292 (P = 0.241); Gain of solvent accessibility (P = 0.2601)
17:44061059:G:A,P10636,A297T,0.167,Gain of phosphorylation at A297 (P = 0.0709); Gain of methylation at K293 (P = 0.1125); Gain of disorder (P = 0.1619); Loss of stability (P = 0.312); Gain of ubiquitination at K293 (P = 0.3213)
17:44061059:G:C,P10636,A297P,0.332,Gain of catalytic residue at A297 (P = 0.012); Gain of relative solvent accessibility (P = 0.0249); Gain of disorder (P = 0.0399); Gain of solvent accessibility (P = 0.0503); Gain of glycosylation at A297 (P = 0.0532)
17:44061059:G:T,P10636,A297S,0.254,Gain of relative solvent accessibility (P = 0.0249); Gain of phosphorylation at A297 (P = 0.0478); Gain of disorder (P = 0.0528); Gain of solvent accessibility (P = 0.0611); Gain of methylation at K293 (P = 0.1237)
17:44061060:C:A,P10636,A297D,0.257,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.026); Gain of disorder (P = 0.0832); Gain of methylation at K293 (P = 0.2263); Gain of ubiquitination at K293 (P = 0.3121)
17:44061060:C:G,P10636,A297G,0.229,Loss of stability (P = 0.0889); Gain of disorder (P = 0.124); Gain of catalytic residue at A297 (P = 0.1472); Gain of methylation at K293 (P = 0.2323); Gain of ubiquitination at K293 (P = 0.3247)
17:44061062:C:A,P10636,P298T,0.287,Gain of phosphorylation at P298 (P = 0.0637); Loss of disorder (P = 0.0841); Loss of stability (P = 0.1559); Loss of methylation at K293 (P = 0.2749); Loss of catalytic residue at L299 (P = 0.2836)
17:44061062:C:G,P10636,P298A,0.326,Loss of disorder (P = 0.0659); Loss of stability (P = 0.1079); Loss of catalytic residue at L299 (P = 0.2235); Loss of methylation at K293 (P = 0.2457); Loss of ubiquitination at K293 (P = 0.3114)
17:44061062:C:T,P10636,P298S,0.297,Loss of stability (P = 0.1481); Loss of catalytic residue at P298 (P = 0.1808); Loss of methylation at K293 (P = 0.2171); Loss of disorder (P = 0.2172); Loss of ubiquitination at K293 (P = 0.221)
17:44061063:C:A,P10636,P298H,0.285,Loss of disorder (P = 0.0829); Loss of stability (P = 0.164); Loss of methylation at K293 (P = 0.2348); Loss of ubiquitination at K293 (P = 0.2471); Loss of catalytic residue at P298 (P = 0.2601)
17:44061063:C:G,P10636,P298R,0.3,Loss of ubiquitination at K293 (P = 0.0467); Loss of disorder (P = 0.1265); Loss of methylation at K293 (P = 0.1467); Loss of catalytic residue at K293 (P = 0.1943); Gain of solvent accessibility (P = 0.2097)
17:44061063:C:T,P10636,P298L,0.404,Loss of disorder (P = 0.0161); Loss of catalytic residue at P298 (P = 0.2124); Loss of methylation at K293 (P = 0.2514); Loss of ubiquitination at K293 (P = 0.3114); Loss of glycosylation at K293 (P = 0.3983)
17:44061065:C:A,P10636,L299M,0.234,Loss of solvent accessibility (P = 0.0217); Loss of relative solvent accessibility (P = 0.0404); Gain of disorder (P = 0.0876); Gain of phosphorylation at T302 (P = 0.2922); Gain of glycosylation at T302 (P = 0.4804)
17:44061065:C:G,P10636,L299V,0.273,Loss of solvent accessibility (P = 0.0155); Loss of relative solvent accessibility (P = 0.0404); Gain of disorder (P = 0.1627); Gain of phosphorylation at T302 (P = 0.2493); Loss of catalytic residue at L299 (P = 0.2725)
17:44061066:T:A,P10636,L299Q,0.298,Gain of disorder (P = 0.0173); Gain of phosphorylation at T302 (P = 0.1701); Gain of solvent accessibility (P = 0.2346); Loss of catalytic residue at L299 (P = 0.3366); Gain of glycosylation at T302 (P = 0.4193)
17:44061066:T:C,P10636,L299P,0.33,Gain of disorder (P = 0.0095); Gain of glycosylation at L299 (P = 0.045); Gain of phosphorylation at T302 (P = 0.0769); Gain of catalytic residue at P298 (P = 0.145); Loss of stability (P = 0.1855)
17:44061066:T:G,P10636,L299R,0.335,Gain of disorder (P = 0.0222); Gain of phosphorylation at T302 (P = 0.0566); Gain of solvent accessibility (P = 0.2346); Loss of catalytic residue at Q295 (P = 0.3076); Gain of MoRF binding (P = 0.3942)
17:44061068:G:A,P10636,E300K,0.443,Gain of methylation at E300 (P = 0.0075); Gain of ubiquitination at E300 (P = 0.0138); Loss of catalytic residue at E300 (P = 0.063); Loss of solvent accessibility (P = 0.1579); Loss of stability (P = 0.1912)
17:44061068:G:C,P10636,E300Q,0.336,Loss of catalytic residue at E300 (P = 0.157); Loss of disorder (P = 0.1653); Loss of stability (P = 0.3703); Loss of solvent accessibility (P = 0.4141); Loss of phosphorylation at T302 (P = 0.5246)
17:44061069:A:C,P10636,E300A,0.411,Loss of solvent accessibility (P = 0.0053); Loss of catalytic residue at E300 (P = 0.0494); Loss of disorder (P = 0.0637); Loss of relative solvent accessibility (P = 0.0676); Loss of stability (P = 0.344)
17:44061069:A:G,P10636,E300G,0.402,Loss of solvent accessibility (P = 0.0111); Loss of catalytic residue at E300 (P = 0.0255); Loss of stability (P = 0.0326); Loss of disorder (P = 0.0983); Loss of relative solvent accessibility (P = 0.1967)
17:44061069:A:T,P10636,E300V,0.48,Loss of solvent accessibility (P = 0.0089); Loss of disorder (P = 0.0165); Loss of relative solvent accessibility (P = 0.0676); Loss of catalytic residue at E300 (P = 0.1607); Loss of phosphorylation at T302 (P = 0.5174)
17:44061070:G:C,P10636,E300D,0.339,Loss of catalytic residue at E300 (P = 0.0338); Loss of disorder (P = 0.1447); Loss of solvent accessibility (P = 0.1813); Loss of stability (P = 0.2424); Gain of phosphorylation at T302 (P = 0.5233)
17:44061070:G:T,P10636,E300D,0.339,Loss of catalytic residue at E300 (P = 0.0338); Loss of disorder (P = 0.1447); Loss of solvent accessibility (P = 0.1813); Loss of stability (P = 0.2424); Gain of phosphorylation at T302 (P = 0.5233)
17:44061071:T:A,P10636,F301I,0.304,Loss of catalytic residue at F301 (P = 0.155); Loss of disorder (P = 0.1973); Gain of glycosylation at T302 (P = 0.2518); Loss of stability (P = 0.5408); Loss of phosphorylation at T302 (P = 0.5485)
17:44061071:T:C,P10636,F301L,0.234,Gain of disorder (P = 0.1923); Loss of phosphorylation at T302 (P = 0.5471); Gain of glycosylation at T302 (P = 0.5509); Loss of catalytic residue at F301 (P = 0.6121); Loss of stability (P = 0.6391)
17:44061071:T:G,P10636,F301V,0.276,Loss of catalytic residue at F301 (P = 0.1531); Gain of glycosylation at T302 (P = 0.1569); Gain of disorder (P = 0.1828); Loss of stability (P = 0.2706); Gain of phosphorylation at T302 (P = 0.5431)
17:44061072:T:A,P10636,F301Y,0.303,Gain of phosphorylation at F301 (P = 0.012); Loss of disorder (P = 0.0909); Loss of catalytic residue at F301 (P = 0.1539); Loss of stability (P = 0.2252); Gain of relative solvent accessibility (P = 0.2629)
17:44061072:T:C,P10636,F301S,0.381,Gain of disorder (P = 0.0134); Gain of glycosylation at F301 (P = 0.0357); Loss of stability (P = 0.0656); Loss of catalytic residue at F301 (P = 0.1193); Gain of relative solvent accessibility (P = 0.2629)
17:44061072:T:G,P10636,F301C,0.298,Loss of stability (P = 0.1334); Loss of catalytic residue at F301 (P = 0.1428); Gain of disorder (P = 0.2152); Gain of phosphorylation at T302 (P = 0.5403); Gain of glycosylation at T302 (P = 0.5695)
17:44061073:C:A,P10636,F301L,0.234,Gain of disorder (P = 0.1923); Loss of phosphorylation at T302 (P = 0.5471); Gain of glycosylation at T302 (P = 0.5509); Loss of catalytic residue at F301 (P = 0.6121); Loss of stability (P = 0.6391)
17:44061073:C:G,P10636,F301L,0.234,Gain of disorder (P = 0.1923); Loss of phosphorylation at T302 (P = 0.5471); Gain of glycosylation at T302 (P = 0.5509); Loss of catalytic residue at F301 (P = 0.6121); Loss of stability (P = 0.6391)
17:44061074:A:C,P10636,T302P,0.307,Gain of disorder (P = 0.0407); Loss of stability (P = 0.0809); Gain of catalytic residue at L299 (P = 0.2541); Loss of phosphorylation at T302 (P = 0.4302); Loss of glycosylation at T302 (P = 0.5895)
17:44061074:A:G,P10636,T302A,0.286,Loss of stability (P = 0.1364); Loss of solvent accessibility (P = 0.1744); Gain of disorder (P = 0.237); Loss of glycosylation at T302 (P = 0.3172); Loss of relative solvent accessibility (P = 0.3219)
17:44061074:A:T,P10636,T302S,0.272,Gain of disorder (P = 0.0592); Loss of stability (P = 0.2098); Loss of catalytic residue at E300 (P = 0.3969); Gain of phosphorylation at T302 (P = 0.5176); Loss of glycosylation at T302 (P = 0.5434)
17:44061075:C:A,P10636,T302K,0.402,Gain of methylation at T302 (P = 0.0058); Gain of ubiquitination at T302 (P = 0.0109); Loss of stability (P = 0.063); Gain of disorder (P = 0.0638); Gain of solvent accessibility (P = 0.1505)
17:44061075:C:G,P10636,T302R,0.356,Gain of disorder (P = 0.1185); Gain of catalytic residue at T302 (P = 0.1341); Gain of solvent accessibility (P = 0.199); Loss of stability (P = 0.2243); Gain of methylation at T302 (P = 0.2588)
17:44061075:C:T,P10636,T302M,0.315,Loss of disorder (P = 0.1332); Loss of glycosylation at T302 (P = 0.3172); Loss of relative solvent accessibility (P = 0.3219); Loss of phosphorylation at T302 (P = 0.4302); Loss of solvent accessibility (P = 0.5185)
17:44061077:T:A,P10636,F303I,0.279,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.039); Loss of catalytic residue at F303 (P = 0.1144); Loss of disorder (P = 0.1931); Loss of stability (P = 0.2092)
17:44061077:T:C,P10636,F303L,0.187,Loss of stability (P = 0.1638); Gain of disorder (P = 0.1952); Gain of glycosylation at T308 (P = 0.2995); Gain of phosphorylation at T308 (P = 0.3201); Gain of catalytic residue at F303 (P = 0.4994)
17:44061077:T:G,P10636,F303V,0.247,Loss of stability (P = 0.0853); Gain of glycosylation at T302 (P = 0.1404); Loss of catalytic residue at F303 (P = 0.1711); Gain of disorder (P = 0.1845); Gain of phosphorylation at T308 (P = 0.2603)
17:44061078:T:A,P10636,F303Y,0.294,Gain of phosphorylation at F303 (P = 0.0351); Loss of stability (P = 0.0638); Loss of disorder (P = 0.0923); Loss of glycosylation at T308 (P = 0.1585); Loss of catalytic residue at F303 (P = 0.1862)
17:44061078:T:C,P10636,F303S,0.377,Loss of stability (P = 0.0118); Gain of disorder (P = 0.0151); Gain of relative solvent accessibility (P = 0.0249); Gain of phosphorylation at F303 (P = 0.0921); Loss of catalytic residue at F303 (P = 0.0929)
17:44061078:T:G,P10636,F303C,0.294,Loss of stability (P = 0.0373); Gain of catalytic residue at V305 (P = 0.0959); Gain of glycosylation at T302 (P = 0.1317); Gain of disorder (P = 0.2151); Gain of phosphorylation at T308 (P = 0.3173)
17:44061079:T:A,P10636,F303L,0.187,Loss of stability (P = 0.1638); Gain of disorder (P = 0.1952); Gain of glycosylation at T308 (P = 0.2995); Gain of phosphorylation at T308 (P = 0.3201); Gain of catalytic residue at F303 (P = 0.4994)
17:44061079:T:G,P10636,F303L,0.187,Loss of stability (P = 0.1638); Gain of disorder (P = 0.1952); Gain of glycosylation at T308 (P = 0.2995); Gain of phosphorylation at T308 (P = 0.3201); Gain of catalytic residue at F303 (P = 0.4994)
17:44061080:C:A,P10636,H304N,0.211,Gain of disorder (P = 0.1796); Loss of catalytic residue at E306 (P = 0.2432); Gain of glycosylation at T308 (P = 0.2894); Loss of phosphorylation at T308 (P = 0.3273); Gain of sheet (P = 0.6509)
17:44061080:C:G,P10636,H304D,0.249,Gain of disorder (P = 0.1041); Gain of phosphorylation at T302 (P = 0.1492); Gain of catalytic residue at H304 (P = 0.201); Gain of relative solvent accessibility (P = 0.2363); Loss of glycosylation at T308 (P = 0.3143)
17:44061080:C:T,P10636,H304Y,0.404,Gain of phosphorylation at H304 (P = 0.0145); Loss of disorder (P = 0.0262); Loss of glycosylation at T308 (P = 0.1048); Gain of catalytic residue at L299 (P = 0.1757); Gain of solvent accessibility (P = 0.4304)
17:44061081:A:C,P10636,H304P,0.302,Gain of disorder (P = 0.0392); Gain of relative solvent accessibility (P = 0.0999); Loss of catalytic residue at E306 (P = 0.1002); Gain of phosphorylation at T308 (P = 0.1101); Gain of glycosylation at T308 (P = 0.2901)
17:44061081:A:G,P10636,H304R,0.257,Gain of disorder (P = 0.1037); Gain of phosphorylation at T302 (P = 0.1396); Loss of glycosylation at T308 (P = 0.2381); Gain of catalytic residue at H304 (P = 0.2675); Gain of solvent accessibility (P = 0.3418)
17:44061081:A:T,P10636,H304L,0.32,Loss of disorder (P = 0.0857); Loss of glycosylation at T308 (P = 0.1306); Gain of stability (P = 0.1394); Loss of catalytic residue at F303 (P = 0.2848); Loss of phosphorylation at T308 (P = 0.3328)
17:44061082:C:A,P10636,H304Q,0.235,Gain of disorder (P = 0.0812); Loss of glycosylation at T308 (P = 0.2079); Gain of phosphorylation at T308 (P = 0.2557); Loss of catalytic residue at F301 (P = 0.3771); Gain of solvent accessibility (P = 0.5485)
17:44061082:C:G,P10636,H304Q,0.235,Gain of disorder (P = 0.0812); Loss of glycosylation at T308 (P = 0.2079); Gain of phosphorylation at T308 (P = 0.2557); Loss of catalytic residue at F301 (P = 0.3771); Gain of solvent accessibility (P = 0.5485)
17:44061083:G:A,P10636,V305M,0.205,Loss of relative solvent accessibility (P = 0.0981); Gain of disorder (P = 0.1146); Loss of solvent accessibility (P = 0.1362); Gain of catalytic residue at H304 (P = 0.2081); Loss of glycosylation at T308 (P = 0.3019)
17:44061083:G:C,P10636,V305L,0.229,Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1202); Gain of disorder (P = 0.2076); Loss of phosphorylation at T308 (P = 0.2444); Loss of glycosylation at T308 (P = 0.2579)
17:44061083:G:T,P10636,V305L,0.229,Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1202); Gain of disorder (P = 0.2076); Loss of phosphorylation at T308 (P = 0.2444); Loss of glycosylation at T308 (P = 0.2579)
17:44061084:T:A,P10636,V305E,0.296,Gain of disorder (P = 0.0168); Gain of solvent accessibility (P = 0.0611); Gain of phosphorylation at T308 (P = 0.1362); Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at T308 (P = 0.2901)
17:44061084:T:C,P10636,V305A,0.198,Gain of disorder (P = 0.0562); Gain of phosphorylation at T308 (P = 0.1497); Loss of glycosylation at T308 (P = 0.3173); Loss of solvent accessibility (P = 0.4995); Gain of catalytic residue at I307 (P = 0.5572)
17:44061084:T:G,P10636,V305G,0.241,Gain of disorder (P = 0.0392); Loss of stability (P = 0.0428); Loss of glycosylation at T308 (P = 0.1151); Gain of phosphorylation at T308 (P = 0.1357); Gain of relative solvent accessibility (P = 0.1571)
17:44061086:G:A,P10636,E306K,0.316,Gain of methylation at E306 (P = 0.0047); Gain of ubiquitination at E306 (P = 0.0121); Loss of catalytic residue at E306 (P = 0.0608); Loss of glycosylation at T308 (P = 0.0853); Loss of disorder (P = 0.2208)
17:44061086:G:C,P10636,E306Q,0.223,Loss of catalytic residue at E306 (P = 0.1447); Loss of disorder (P = 0.2005); Loss of glycosylation at T308 (P = 0.263); Loss of phosphorylation at T308 (P = 0.3153); Loss of solvent accessibility (P = 0.4436)
17:44061087:A:C,P10636,E306A,0.26,Loss of solvent accessibility (P = 0.0721); Loss of disorder (P = 0.0786); Loss of catalytic residue at E306 (P = 0.1199); Loss of glycosylation at T308 (P = 0.2872); Loss of phosphorylation at T308 (P = 0.3153)
17:44061087:A:G,P10636,E306G,0.285,Loss of catalytic residue at E306 (P = 0.0155); Loss of solvent accessibility (P = 0.0769); Loss of disorder (P = 0.116); Loss of stability (P = 0.1688); Gain of glycosylation at T308 (P = 0.233)
17:44061087:A:T,P10636,E306V,0.369,Loss of disorder (P = 0.0255); Loss of solvent accessibility (P = 0.0431); Loss of catalytic residue at E306 (P = 0.0772); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at T308 (P = 0.2729)
17:44061088:A:C,P10636,E306D,0.227,Loss of disorder (P = 0.1429); Loss of glycosylation at T308 (P = 0.1684); Loss of solvent accessibility (P = 0.2517); Gain of phosphorylation at T308 (P = 0.2536); Gain of catalytic residue at F303 (P = 0.5728)
17:44061088:A:T,P10636,E306D,0.227,Loss of disorder (P = 0.1429); Loss of glycosylation at T308 (P = 0.1684); Loss of solvent accessibility (P = 0.2517); Gain of phosphorylation at T308 (P = 0.2536); Gain of catalytic residue at F303 (P = 0.5728)
17:44061089:A:C,P10636,I307L,0.186,Loss of catalytic residue at P309 (P = 0.0303); Gain of disorder (P = 0.0889); Loss of glycosylation at T308 (P = 0.1142); Gain of phosphorylation at T308 (P = 0.2536); Gain of sheet (P = 0.6509)
17:44061089:A:G,P10636,I307V,0.197,Loss of catalytic residue at P309 (P = 0.0333); Gain of disorder (P = 0.0818); Gain of phosphorylation at T308 (P = 0.2316); Gain of glycosylation at T308 (P = 0.2515); Loss of stability (P = 0.3923)
17:44061089:A:T,P10636,I307F,0.215,Loss of catalytic residue at P309 (P = 0.0303); Gain of disorder (P = 0.0848); Loss of glycosylation at T308 (P = 0.1528); Gain of phosphorylation at T308 (P = 0.1717); Loss of stability (P = 0.4403)
17:44061090:T:A,P10636,I307N,0.319,Gain of disorder (P = 0.0291); Loss of catalytic residue at P309 (P = 0.0333); Gain of relative solvent accessibility (P = 0.0507); Loss of stability (P = 0.0923); Gain of solvent accessibility (P = 0.11)
17:44061090:T:C,P10636,I307T,0.318,Gain of glycosylation at I307 (P = 0.0164); Loss of stability (P = 0.0236); Gain of disorder (P = 0.0245); Loss of catalytic residue at P309 (P = 0.0333); Gain of phosphorylation at I307 (P = 0.1238)
17:44061090:T:G,P10636,I307S,0.321,Gain of disorder (P = 0.0114); Loss of catalytic residue at P309 (P = 0.0303); Gain of glycosylation at I307 (P = 0.037); Loss of stability (P = 0.0698); Gain of phosphorylation at T308 (P = 0.112)
17:44061091:C:G,P10636,I307M,0.228,Loss of catalytic residue at P309 (P = 0.0303); Gain of disorder (P = 0.0501); Gain of phosphorylation at T308 (P = 0.2422); Loss of glycosylation at T308 (P = 0.2959); Loss of stability (P = 0.3919)
17:44061092:A:C,P10636,T308P,0.261,Gain of catalytic residue at T308 (P = 0.0146); Loss of glycosylation at T308 (P = 0.0323); Gain of disorder (P = 0.0633); Loss of phosphorylation at T308 (P = 0.1097); Loss of stability (P = 0.1376)
17:44061092:A:G,P10636,T308A,0.195,Loss of glycosylation at T308 (P = 0.016); Loss of phosphorylation at T308 (P = 0.1097); Loss of methylation at K313 (P = 0.1701); Loss of stability (P = 0.1891); Gain of disorder (P = 0.2543)
17:44061092:A:T,P10636,T308S,0.161,Gain of disorder (P = 0.1003); Loss of glycosylation at T308 (P = 0.1159); Loss of phosphorylation at T308 (P = 0.2653); Gain of ubiquitination at K313 (P = 0.2682); Loss of methylation at K313 (P = 0.3236)
17:44061093:C:A,P10636,T308K,0.314,Gain of solvent accessibility (P = 0.007); Gain of methylation at T308 (P = 0.0079); Gain of ubiquitination at T308 (P = 0.0082); Gain of relative solvent accessibility (P = 0.0275); Loss of glycosylation at T308 (P = 0.0308)
17:44061093:C:G,P10636,T308R,0.214,Loss of glycosylation at T308 (P = 0.016); Loss of phosphorylation at T308 (P = 0.1097); Gain of disorder (P = 0.1477); Gain of solvent accessibility (P = 0.1505); Loss of methylation at K313 (P = 0.2412)
17:44061093:C:T,P10636,T308I,0.214,Loss of glycosylation at T308 (P = 0.016); Loss of disorder (P = 0.059); Loss of phosphorylation at T308 (P = 0.1097); Loss of ubiquitination at K313 (P = 0.2991); Gain of methylation at K313 (P = 0.3143)
17:44061095:C:A,P10636,P309T,0.278,Gain of glycosylation at P309 (P = 0.0211); Loss of disorder (P = 0.0909); Loss of phosphorylation at T308 (P = 0.1509); Loss of stability (P = 0.2012); Loss of ubiquitination at K313 (P = 0.2027)
17:44061095:C:G,P10636,P309A,0.268,Loss of catalytic residue at P309 (P = 0.0258); Loss of disorder (P = 0.0769); Loss of glycosylation at T308 (P = 0.1431); Loss of methylation at K313 (P = 0.1693); Loss of phosphorylation at T308 (P = 0.1792)
17:44061095:C:T,P10636,P309S,0.197,Gain of glycosylation at P309 (P = 0.0648); Loss of catalytic residue at P309 (P = 0.1718); Loss of phosphorylation at T308 (P = 0.1943); Loss of stability (P = 0.1969); Loss of methylation at K313 (P = 0.2208)
17:44061096:C:A,P10636,P309H,0.268,Loss of catalytic residue at P309 (P = 0.0277); Loss of disorder (P = 0.0963); Loss of glycosylation at T308 (P = 0.1772); Loss of phosphorylation at T308 (P = 0.183); Loss of stability (P = 0.2202)
17:44061096:C:G,P10636,P309R,0.248,Loss of glycosylation at T308 (P = 0.0882); Gain of solvent accessibility (P = 0.1045); Loss of methylation at K313 (P = 0.1343); Loss of disorder (P = 0.1468); Loss of ubiquitination at K313 (P = 0.2681)
17:44061096:C:T,P10636,P309L,0.372,Loss of disorder (P = 0.0237); Loss of glycosylation at T308 (P = 0.0579); Loss of catalytic residue at P309 (P = 0.0699); Loss of methylation at K313 (P = 0.1036); Loss of phosphorylation at T308 (P = 0.1509)
17:44061098:A:C,P10636,N310H,0.156,Gain of disorder (P = 0.1599); Loss of solvent accessibility (P = 0.1744); Gain of glycosylation at K313 (P = 0.1789); Loss of relative solvent accessibility (P = 0.1807); Gain of phosphorylation at T308 (P = 0.2859)
17:44061098:A:G,P10636,N310D,0.171,Gain of phosphorylation at T308 (P = 0.0974); Gain of disorder (P = 0.1358); Loss of methylation at K313 (P = 0.2263); Gain of glycosylation at K313 (P = 0.2734); Gain of ubiquitination at K313 (P = 0.2872)
17:44061098:A:T,P10636,N310Y,0.262,Loss of disorder (P = 0.0519); Gain of phosphorylation at N310 (P = 0.0736); Loss of glycosylation at T308 (P = 0.1356); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2668)
17:44061099:A:C,P10636,N310T,0.18,Gain of glycosylation at N310 (P = 0.0227); Gain of phosphorylation at N310 (P = 0.0794); Loss of solvent accessibility (P = 0.1177); Gain of disorder (P = 0.1663); Loss of relative solvent accessibility (P = 0.1807)
17:44061099:A:G,P10636,N310S,0.201,Gain of phosphorylation at N310 (P = 0.0792); Gain of disorder (P = 0.0819); Gain of glycosylation at N310 (P = 0.1048); Gain of ubiquitination at K313 (P = 0.2682); Loss of methylation at K313 (P = 0.3215)
17:44061099:A:T,P10636,N310I,0.265,Loss of solvent accessibility (P = 0.0721); Loss of relative solvent accessibility (P = 0.0981); Loss of disorder (P = 0.111); Loss of glycosylation at T308 (P = 0.1112); Gain of catalytic residue at V311 (P = 0.2076)
17:44061100:C:A,P10636,N310K,0.274,Gain of ubiquitination at N310 (P = 0.0082); Gain of methylation at N310 (P = 0.0126); Gain of glycosylation at N310 (P = 0.089); Gain of disorder (P = 0.0971); Gain of phosphorylation at T308 (P = 0.1337)
17:44061100:C:G,P10636,N310K,0.274,Gain of ubiquitination at N310 (P = 0.0082); Gain of methylation at N310 (P = 0.0126); Gain of glycosylation at N310 (P = 0.089); Gain of disorder (P = 0.0971); Gain of phosphorylation at T308 (P = 0.1337)
17:44061101:G:A,P10636,V311M,0.094,Gain of disorder (P = 0.2525); Gain of ubiquitination at K313 (P = 0.2682); Gain of glycosylation at K313 (P = 0.2797); Gain of methylation at K313 (P = 0.319); Loss of phosphorylation at T308 (P = 0.3485)
17:44061101:G:C,P10636,V311L,0.109,Loss of glycosylation at T308 (P = 0.1743); Gain of relative solvent accessibility (P = 0.2629); Loss of methylation at K313 (P = 0.2677); Gain of ubiquitination at K313 (P = 0.2682); Gain of solvent accessibility (P = 0.3194)
17:44061101:G:T,P10636,V311L,0.109,Loss of glycosylation at T308 (P = 0.1743); Gain of relative solvent accessibility (P = 0.2629); Loss of methylation at K313 (P = 0.2677); Gain of ubiquitination at K313 (P = 0.2682); Gain of solvent accessibility (P = 0.3194)
17:44061102:T:A,P10636,V311E,0.277,Gain of solvent accessibility (P = 0.0133); Gain of relative solvent accessibility (P = 0.0249); Gain of disorder (P = 0.0781); Gain of glycosylation at P309 (P = 0.1002); Gain of phosphorylation at T308 (P = 0.1273)
17:44061102:T:C,P10636,V311A,0.154,Loss of stability (P = 0.0516); Gain of disorder (P = 0.1822); Gain of glycosylation at T308 (P = 0.1853); Gain of ubiquitination at K313 (P = 0.2182); Gain of phosphorylation at T308 (P = 0.2221)
17:44061102:T:G,P10636,V311G,0.197,Loss of stability (P = 0.0119); Gain of glycosylation at K313 (P = 0.1084); Gain of disorder (P = 0.1466); Gain of phosphorylation at T308 (P = 0.1946); Gain of ubiquitination at K313 (P = 0.2182)
17:44061104:C:A,P10636,Q312K,0.37,Gain of methylation at Q312 (P = 0.0038); Gain of ubiquitination at Q312 (P = 0.0082); Gain of solvent accessibility (P = 0.0216); Gain of relative solvent accessibility (P = 0.0275); Gain of glycosylation at Q312 (P = 0.1871)
17:44061104:C:G,P10636,Q312E,0.251,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1045); Gain of glycosylation at T308 (P = 0.1828); Gain of phosphorylation at T308 (P = 0.1912); Gain of ubiquitination at K313 (P = 0.2754)
17:44061105:A:C,P10636,Q312P,0.247,Gain of glycosylation at Q312 (P = 0.0427); Gain of catalytic residue at N310 (P = 0.1273); Gain of phosphorylation at T308 (P = 0.1786); Gain of disorder (P = 0.2573); Gain of ubiquitination at K313 (P = 0.2754)
17:44061105:A:G,P10636,Q312R,0.251,Gain of phosphorylation at T308 (P = 0.1898); Gain of glycosylation at T308 (P = 0.2613); Gain of ubiquitination at K313 (P = 0.2812); Gain of methylation at K313 (P = 0.3025); Gain of disorder (P = 0.3744)
17:44061105:A:T,P10636,Q312L,0.294,Gain of catalytic residue at Q312 (P = 0.0432); Loss of disorder (P = 0.0676); Loss of methylation at K313 (P = 0.155); Loss of solvent accessibility (P = 0.2073); Loss of glycosylation at T308 (P = 0.2483)
17:44061106:G:C,P10636,Q312H,0.245,Loss of ubiquitination at K313 (P = 0.2027); Gain of phosphorylation at T308 (P = 0.2921); Gain of glycosylation at T308 (P = 0.2971); Loss of disorder (P = 0.3176); Gain of methylation at K313 (P = 0.3238)
17:44061106:G:T,P10636,Q312H,0.245,Loss of ubiquitination at K313 (P = 0.2027); Gain of phosphorylation at T308 (P = 0.2921); Gain of glycosylation at T308 (P = 0.2971); Loss of disorder (P = 0.3176); Gain of methylation at K313 (P = 0.3238)
17:44061107:A:C,P10636,K313Q,0.219,Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.007); Loss of solvent accessibility (P = 0.0561); Loss of glycosylation at K313 (P = 0.1426); Loss of relative solvent accessibility (P = 0.1807)
17:44061107:A:G,P10636,K313E,0.223,Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.007); Loss of glycosylation at K313 (P = 0.1426); Gain of phosphorylation at S318 (P = 0.1535); Gain of disorder (P = 0.312)
17:44061108:A:C,P10636,K313T,0.253,Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.007); Loss of solvent accessibility (P = 0.0249); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S318 (P = 0.1897)
17:44061108:A:G,P10636,K313R,0.218,Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.0087); Loss of solvent accessibility (P = 0.1115); Loss of glycosylation at K313 (P = 0.1426); Loss of relative solvent accessibility (P = 0.1807)
17:44061108:A:T,P10636,K313M,0.262,Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.007); Loss of solvent accessibility (P = 0.0217); Gain of stability (P = 0.0795); Loss of relative solvent accessibility (P = 0.0981)
17:44061109:G:C,P10636,K313N,0.238,Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.007); Loss of solvent accessibility (P = 0.0371); Loss of glycosylation at K313 (P = 0.1426); Loss of phosphorylation at S318 (P = 0.1733)
17:44061109:G:T,P10636,K313N,0.238,Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.007); Loss of solvent accessibility (P = 0.0371); Loss of glycosylation at K313 (P = 0.1426); Loss of phosphorylation at S318 (P = 0.1733)
17:44061110:G:A,P10636,E314K,0.344,Gain of ubiquitination at E314 (P = 0.0051); Gain of methylation at E314 (P = 0.0101); Gain of glycosylation at E314 (P = 0.1256); Loss of phosphorylation at S318 (P = 0.259); Gain of MoRF binding (P = 0.3056)
17:44061110:G:C,P10636,E314Q,0.225,Loss of phosphorylation at S318 (P = 0.1625); Loss of catalytic residue at E314 (P = 0.2525); Gain of methylation at K313 (P = 0.2917); Loss of ubiquitination at K313 (P = 0.2991); Loss of disorder (P = 0.413)
17:44061111:A:C,P10636,E314A,0.222,Loss of solvent accessibility (P = 0.0769); Loss of phosphorylation at S318 (P = 0.1724); Loss of methylation at K313 (P = 0.1857); Loss of disorder (P = 0.196); Loss of catalytic residue at E314 (P = 0.2433)
17:44061111:A:G,P10636,E314G,0.297,Loss of solvent accessibility (P = 0.0187); Loss of stability (P = 0.1173); Loss of phosphorylation at S318 (P = 0.1785); Loss of methylation at K313 (P = 0.2527); Gain of glycosylation at K313 (P = 0.2615)
17:44061111:A:T,P10636,E314V,0.359,Loss of solvent accessibility (P = 0.0089); Loss of disorder (P = 0.0587); Loss of relative solvent accessibility (P = 0.0676); Loss of phosphorylation at S318 (P = 0.1392); Loss of ubiquitination at K313 (P = 0.1393)
17:44061112:G:C,P10636,E314D,0.199,Loss of ubiquitination at K313 (P = 0.1675); Loss of methylation at K313 (P = 0.1878); Loss of phosphorylation at S318 (P = 0.2033); Loss of disorder (P = 0.2687); Loss of catalytic residue at E314 (P = 0.3763)
17:44061112:G:T,P10636,E314D,0.199,Loss of ubiquitination at K313 (P = 0.1675); Loss of methylation at K313 (P = 0.1878); Loss of phosphorylation at S318 (P = 0.2033); Loss of disorder (P = 0.2687); Loss of catalytic residue at E314 (P = 0.3763)
17:44061113:C:A,P10636,Q315K,0.185,Gain of ubiquitination at Q315 (P = 0.0031); Gain of methylation at Q315 (P = 0.0157); Gain of glycosylation at Q315 (P = 0.0649); Gain of phosphorylation at S318 (P = 0.1218); Loss of stability (P = 0.4254)
17:44061113:C:G,P10636,Q315E,0.17,Gain of phosphorylation at S318 (P = 0.0913); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2291); Gain of glycosylation at K313 (P = 0.2345); Gain of ubiquitination at K313 (P = 0.2527)
17:44061114:A:C,P10636,Q315P,0.157,Gain of glycosylation at Q315 (P = 0.0591); Gain of phosphorylation at S318 (P = 0.1077); Gain of relative solvent accessibility (P = 0.1571); Gain of ubiquitination at K313 (P = 0.2682); Gain of methylation at K313 (P = 0.2683)
17:44061114:A:G,P10636,Q315R,0.196,Gain of phosphorylation at S318 (P = 0.0673); Gain of catalytic residue at Q315 (P = 0.0964); Gain of solvent accessibility (P = 0.199); Gain of ubiquitination at K313 (P = 0.2932); Gain of methylation at K313 (P = 0.3065)
17:44061114:A:T,P10636,Q315L,0.228,Loss of solvent accessibility (P = 0.0217); Loss of relative solvent accessibility (P = 0.0981); Loss of disorder (P = 0.1197); Gain of phosphorylation at S318 (P = 0.1874); Loss of ubiquitination at K313 (P = 0.2027)
17:44061115:G:C,P10636,Q315H,0.143,Gain of phosphorylation at S318 (P = 0.1579); Loss of ubiquitination at K313 (P = 0.228); Gain of methylation at K313 (P = 0.3035); Gain of glycosylation at K313 (P = 0.329); Gain of catalytic residue at Q315 (P = 0.3518)
17:44061115:G:T,P10636,Q315H,0.143,Gain of phosphorylation at S318 (P = 0.1579); Loss of ubiquitination at K313 (P = 0.228); Gain of methylation at K313 (P = 0.3035); Gain of glycosylation at K313 (P = 0.329); Gain of catalytic residue at Q315 (P = 0.3518)
17:44061116:G:C,P10636,A316P,0.172,Gain of glycosylation at A316 (P = 0.0571); Gain of phosphorylation at S318 (P = 0.1555); Loss of stability (P = 0.1813); Gain of ubiquitination at K313 (P = 0.2075); Gain of methylation at K313 (P = 0.2305)
17:44061116:G:T,P10636,A316S,0.147,Gain of phosphorylation at A316 (P = 0.0378); Gain of ubiquitination at K313 (P = 0.2182); Gain of methylation at K313 (P = 0.2598); Gain of disorder (P = 0.4267); Loss of glycosylation at K313 (P = 0.473)
17:44061117:C:A,P10636,A316E,0.173,Gain of solvent accessibility (P = 0.0261); Gain of relative solvent accessibility (P = 0.09); Gain of phosphorylation at S318 (P = 0.1213); Gain of ubiquitination at K313 (P = 0.2182); Gain of methylation at K313 (P = 0.26)
17:44061117:C:G,P10636,A316G,0.13,Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.1789); Gain of phosphorylation at S318 (P = 0.2102); Gain of ubiquitination at K313 (P = 0.2182); Gain of methylation at K313 (P = 0.2982)
17:44061117:C:T,P10636,A316V,0.113,Loss of ubiquitination at K313 (P = 0.0756); Loss of phosphorylation at S318 (P = 0.1905); Gain of catalytic residue at E319 (P = 0.2031); Gain of methylation at K313 (P = 0.2915); Loss of disorder (P = 0.3313)
17:44061119:C:A,P10636,H317N,0.236,Loss of phosphorylation at S318 (P = 0.2387); Gain of ubiquitination at K313 (P = 0.2812); Loss of catalytic residue at E314 (P = 0.3077); Gain of methylation at K313 (P = 0.3209); Loss of glycosylation at K313 (P = 0.4114)
17:44061119:C:G,P10636,H317D,0.196,Gain of phosphorylation at S318 (P = 0.1458); Gain of ubiquitination at K313 (P = 0.2599); Gain of methylation at K313 (P = 0.2882); Loss of catalytic residue at E314 (P = 0.3128); Loss of glycosylation at K313 (P = 0.444)
17:44061119:C:T,P10636,H317Y,0.308,Gain of phosphorylation at H317 (P = 0.007); Loss of solvent accessibility (P = 0.0561); Loss of disorder (P = 0.0744); Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K313 (P = 0.1675)
17:44061120:A:C,P10636,H317P,0.198,Gain of glycosylation at H317 (P = 0.0364); Gain of phosphorylation at S318 (P = 0.1317); Gain of ubiquitination at K313 (P = 0.2182); Gain of methylation at K313 (P = 0.2427); Loss of catalytic residue at E314 (P = 0.3004)
17:44061120:A:G,P10636,H317R,0.216,Gain of phosphorylation at S318 (P = 0.0944); Gain of solvent accessibility (P = 0.1456); Gain of MoRF binding (P = 0.2504); Gain of ubiquitination at K313 (P = 0.2754); Loss of catalytic residue at E314 (P = 0.2896)
17:44061120:A:T,P10636,H317L,0.269,Loss of solvent accessibility (P = 0.0371); Loss of ubiquitination at K313 (P = 0.0909); Loss of relative solvent accessibility (P = 0.0981); Gain of phosphorylation at S318 (P = 0.2574); Loss of catalytic residue at E314 (P = 0.2893)
17:44061121:C:A,P10636,H317Q,0.192,Gain of phosphorylation at S318 (P = 0.2252); Gain of ubiquitination at K313 (P = 0.2682); Loss of catalytic residue at E314 (P = 0.2879); Gain of methylation at K313 (P = 0.301); Loss of glycosylation at K313 (P = 0.4379)
17:44061121:C:G,P10636,H317Q,0.192,Gain of phosphorylation at S318 (P = 0.2252); Gain of ubiquitination at K313 (P = 0.2682); Loss of catalytic residue at E314 (P = 0.2879); Gain of methylation at K313 (P = 0.301); Loss of glycosylation at K313 (P = 0.4379)
17:44061122:T:A,P10636,S318T,0.163,Gain of glycosylation at S318 (P = 0.0588); Gain of phosphorylation at S318 (P = 0.1166); Loss of relative solvent accessibility (P = 0.1807); Loss of ubiquitination at K313 (P = 0.2027); Loss of solvent accessibility (P = 0.2073)
17:44061122:T:C,P10636,S318P,0.181,Loss of phosphorylation at S318 (P = 0.0545); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1986); Gain of glycosylation at S318 (P = 0.2673); Gain of ubiquitination at K313 (P = 0.2682)
17:44061122:T:G,P10636,S318A,0.185,Loss of phosphorylation at S318 (P = 0.0545); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.0703); Loss of methylation at K313 (P = 0.1086); Loss of ubiquitination at K313 (P = 0.228)
17:44061123:C:G,P10636,S318W,0.312,Loss of disorder (P = 0.0349); Loss of phosphorylation at S318 (P = 0.0545); Loss of relative solvent accessibility (P = 0.0676); Loss of methylation at K313 (P = 0.0837); Gain of catalytic residue at S318 (P = 0.1117)
17:44061125:G:A,P10636,E319K,0.333,Gain of ubiquitination at E319 (P = 0.0039); Gain of glycosylation at E319 (P = 0.0483); Gain of methylation at E319 (P = 0.052); Loss of phosphorylation at S318 (P = 0.1248); Gain of MoRF binding (P = 0.2364)
17:44061125:G:C,P10636,E319Q,0.166,Loss of phosphorylation at S318 (P = 0.1392); Loss of methylation at R324 (P = 0.3895); Gain of MoRF binding (P = 0.4889); Loss of glycosylation at S318 (P = 0.5468); Loss of disorder (P = 0.5611)
17:44061126:A:C,P10636,E319A,0.169,Loss of phosphorylation at S318 (P = 0.1374); Gain of relative solvent accessibility (P = 0.1571); Loss of solvent accessibility (P = 0.2882); Gain of methylation at R324 (P = 0.2994); Loss of catalytic residue at E319 (P = 0.3176)
17:44061126:A:G,P10636,E319G,0.165,Gain of glycosylation at S318 (P = 0.0367); Loss of solvent accessibility (P = 0.1434); Gain of relative solvent accessibility (P = 0.1571); Loss of phosphorylation at S318 (P = 0.163); Loss of stability (P = 0.2233)
17:44061126:A:T,P10636,E319V,0.311,Loss of solvent accessibility (P = 0.0146); Loss of relative solvent accessibility (P = 0.0676); Loss of phosphorylation at S318 (P = 0.1191); Loss of disorder (P = 0.1402); Gain of methylation at R324 (P = 0.3805)
17:44061127:G:C,P10636,E319D,0.123,Loss of phosphorylation at S318 (P = 0.1937); Loss of methylation at R324 (P = 0.3755); Loss of disorder (P = 0.4411); Loss of solvent accessibility (P = 0.5485); Loss of glycosylation at S318 (P = 0.5783)
17:44061127:G:T,P10636,E319D,0.123,Loss of phosphorylation at S318 (P = 0.1937); Loss of methylation at R324 (P = 0.3755); Loss of disorder (P = 0.4411); Loss of solvent accessibility (P = 0.5485); Loss of glycosylation at S318 (P = 0.5783)
17:44061128:G:A,P10636,E320K,0.343,Gain of ubiquitination at E320 (P = 0.0031); Gain of glycosylation at E320 (P = 0.0416); Loss of stability (P = 0.072); Loss of phosphorylation at S318 (P = 0.1625); Gain of MoRF binding (P = 0.1766)
17:44061128:G:C,P10636,E320Q,0.202,Loss of solvent accessibility (P = 0.0174); Loss of relative solvent accessibility (P = 0.0676); Loss of phosphorylation at S318 (P = 0.1159); Loss of stability (P = 0.1508); Loss of methylation at R324 (P = 0.3875)
17:44061129:A:C,P10636,E320A,0.242,Loss of solvent accessibility (P = 0.0023); Loss of relative solvent accessibility (P = 0.0404); Loss of stability (P = 0.0799); Loss of phosphorylation at S318 (P = 0.1494); Gain of catalytic residue at E319 (P = 0.2126)
17:44061129:A:G,P10636,E320G,0.231,Loss of solvent accessibility (P = 0.0036); Loss of stability (P = 0.0135); Loss of relative solvent accessibility (P = 0.0676); Gain of catalytic residue at H321 (P = 0.1194); Loss of phosphorylation at S318 (P = 0.1531)
17:44061129:A:T,P10636,E320V,0.308,Loss of solvent accessibility (P = 0.0052); Loss of relative solvent accessibility (P = 0.0404); Loss of phosphorylation at S318 (P = 0.1148); Gain of catalytic residue at E319 (P = 0.1169); Loss of disorder (P = 0.1716)
17:44061130:G:C,P10636,E320D,0.147,Loss of stability (P = 0.1418); Loss of phosphorylation at S318 (P = 0.1814); Loss of methylation at R324 (P = 0.3763); Loss of solvent accessibility (P = 0.4653); Loss of disorder (P = 0.4758)
17:44061130:G:T,P10636,E320D,0.147,Loss of stability (P = 0.1418); Loss of phosphorylation at S318 (P = 0.1814); Loss of methylation at R324 (P = 0.3763); Loss of solvent accessibility (P = 0.4653); Loss of disorder (P = 0.4758)
17:44061131:C:A,P10636,H321N,0.111,Loss of phosphorylation at S318 (P = 0.2317); Loss of methylation at R324 (P = 0.3802); Loss of catalytic residue at E319 (P = 0.4797); Gain of disorder (P = 0.5943); Gain of glycosylation at S318 (P = 0.5948)
17:44061131:C:G,P10636,H321D,0.131,Gain of phosphorylation at S318 (P = 0.1384); Loss of methylation at R324 (P = 0.3449); Loss of catalytic residue at E319 (P = 0.4782); Gain of glycosylation at S318 (P = 0.5731); Gain of disorder (P = 0.5897)
17:44061132:A:C,P10636,H321P,0.159,Gain of glycosylation at S318 (P = 0.1195); Gain of phosphorylation at S318 (P = 0.1351); Loss of solvent accessibility (P = 0.3744); Loss of methylation at R324 (P = 0.3793); Loss of catalytic residue at E319 (P = 0.4996)
17:44061132:A:G,P10636,H321R,0.156,Gain of phosphorylation at S318 (P = 0.096); Gain of MoRF binding (P = 0.3508); Loss of methylation at R324 (P = 0.3592); Loss of catalytic residue at E319 (P = 0.4477); Gain of solvent accessibility (P = 0.5093)
17:44061132:A:T,P10636,H321L,0.274,Loss of solvent accessibility (P = 0.0371); Loss of relative solvent accessibility (P = 0.0981); Gain of stability (P = 0.1568); Loss of phosphorylation at S318 (P = 0.248); Loss of methylation at R324 (P = 0.3534)
17:44061133:T:A,P10636,H321Q,0.127,Loss of solvent accessibility (P = 0.239); Loss of phosphorylation at S318 (P = 0.26); Loss of relative solvent accessibility (P = 0.3219); Loss of methylation at R324 (P = 0.3384); Loss of catalytic residue at E319 (P = 0.4408)
17:44061133:T:G,P10636,H321Q,0.127,Loss of solvent accessibility (P = 0.239); Loss of phosphorylation at S318 (P = 0.26); Loss of relative solvent accessibility (P = 0.3219); Loss of methylation at R324 (P = 0.3384); Loss of catalytic residue at E319 (P = 0.4408)
17:44061134:T:A,P10636,L322M,0.083,Gain of phosphorylation at S318 (P = 0.2022); Gain of methylation at R324 (P = 0.3168); Gain of glycosylation at S318 (P = 0.4389); Gain of catalytic residue at H321 (P = 0.4936); Gain of disorder (P = 0.5767)
17:44061134:T:G,P10636,L322V,0.091,Gain of phosphorylation at S318 (P = 0.2475); Gain of methylation at R324 (P = 0.3188); Gain of catalytic residue at F327 (P = 0.421); Loss of stability (P = 0.5486); Gain of glycosylation at S318 (P = 0.57)
17:44061135:T:C,P10636,L322S,0.17,Gain of glycosylation at L322 (P = 0.0054); Gain of phosphorylation at L322 (P = 0.018); Gain of methylation at R324 (P = 0.124); Loss of stability (P = 0.1315); Gain of catalytic residue at L322 (P = 0.2411)
17:44061135:T:G,P10636,L322W,0.218,Gain of catalytic residue at L322 (P = 0.0054); Loss of phosphorylation at S318 (P = 0.1847); Loss of stability (P = 0.2735); Loss of methylation at R324 (P = 0.3062); Loss of disorder (P = 0.3784)
17:44061136:G:C,P10636,L322F,0.093,Gain of phosphorylation at S318 (P = 0.1911); Gain of methylation at R324 (P = 0.3611); Gain of catalytic residue at E319 (P = 0.4863); Gain of solvent accessibility (P = 0.4946); Loss of stability (P = 0.5044)
17:44061136:G:T,P10636,L322F,0.093,Gain of phosphorylation at S318 (P = 0.1911); Gain of methylation at R324 (P = 0.3611); Gain of catalytic residue at E319 (P = 0.4863); Gain of solvent accessibility (P = 0.4946); Loss of stability (P = 0.5044)
17:44061137:G:A,P10636,G323R,0.203,Gain of solvent accessibility (P = 0.019); Gain of phosphorylation at S318 (P = 0.1562); Gain of glycosylation at P328 (P = 0.1824); Loss of methylation at R324 (P = 0.3238); Gain of MoRF binding (P = 0.5287)
17:44061137:G:C,P10636,G323R,0.203,Gain of solvent accessibility (P = 0.019); Gain of phosphorylation at S318 (P = 0.1562); Gain of glycosylation at P328 (P = 0.1824); Loss of methylation at R324 (P = 0.3238); Gain of MoRF binding (P = 0.5287)
17:44061138:G:C,P10636,G323A,0.103,Gain of phosphorylation at S318 (P = 0.2207); Gain of glycosylation at P328 (P = 0.271); Loss of methylation at R324 (P = 0.3574); Loss of relative solvent accessibility (P = 0.5582); Loss of catalytic residue at A325 (P = 0.5707)
17:44061138:G:T,P10636,G323V,0.22,Loss of relative solvent accessibility (P = 0.0676); Loss of phosphorylation at S318 (P = 0.2117); Loss of methylation at R324 (P = 0.3331); Gain of glycosylation at P328 (P = 0.3416); Loss of solvent accessibility (P = 0.4011)
17:44061140:A:G,P10636,R324G,0.212,Loss of solvent accessibility (P = 0.0159); Gain of catalytic residue at F327 (P = 0.1392); Gain of glycosylation at P328 (P = 0.209); Loss of stability (P = 0.2292); Loss of methylation at R324 (P = 0.2421)
17:44061140:A:T,P10636,R324W,0.436,Gain of catalytic residue at L322 (P = 0.0016); Loss of solvent accessibility (P = 0.0036); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at P328 (P = 0.0891); Loss of disorder (P = 0.0964)
17:44061141:G:A,P10636,R324K,0.264,Gain of ubiquitination at R324 (P = 0.0048); Gain of glycosylation at R324 (P = 0.0123); Gain of methylation at R324 (P = 0.0463); Loss of stability (P = 0.4107); Loss of solvent accessibility (P = 0.4218)
17:44061141:G:C,P10636,R324T,0.21,Gain of glycosylation at R324 (P = 0.0038); Gain of phosphorylation at R324 (P = 0.0283); Gain of catalytic residue at F327 (P = 0.0573); Loss of solvent accessibility (P = 0.089); Loss of methylation at R324 (P = 0.2421)
17:44061141:G:T,P10636,R324M,0.225,Gain of glycosylation at P328 (P = 0.1073); Loss of methylation at R324 (P = 0.2421); Gain of catalytic residue at F327 (P = 0.2654); Loss of solvent accessibility (P = 0.2953); Loss of disorder (P = 0.581)
17:44061142:G:C,P10636,R324S,0.205,Gain of glycosylation at R324 (P = 0.0044); Gain of phosphorylation at R324 (P = 0.041); Loss of solvent accessibility (P = 0.0606); Loss of methylation at R324 (P = 0.2421); Gain of catalytic residue at F327 (P = 0.3749)
17:44061142:G:T,P10636,R324S,0.205,Gain of glycosylation at R324 (P = 0.0044); Gain of phosphorylation at R324 (P = 0.041); Loss of solvent accessibility (P = 0.0606); Loss of methylation at R324 (P = 0.2421); Gain of catalytic residue at F327 (P = 0.3749)
17:44061143:G:A,P10636,A325T,0.134,Gain of glycosylation at A325 (P = 0.0153); Gain of phosphorylation at A325 (P = 0.0449); Gain of solvent accessibility (P = 0.28); Loss of methylation at R324 (P = 0.3711); Loss of stability (P = 0.4356)
17:44061143:G:C,P10636,A325P,0.187,Gain of catalytic residue at A325 (P = 0.1102); Gain of solvent accessibility (P = 0.1456); Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at A325 (P = 0.2176); Loss of stability (P = 0.3563)
17:44061143:G:T,P10636,A325S,0.12,Gain of glycosylation at A325 (P = 0.0141); Gain of phosphorylation at A325 (P = 0.0325); Gain of solvent accessibility (P = 0.3602); Loss of methylation at R324 (P = 0.3838); Loss of stability (P = 0.4461)
17:44061144:C:A,P10636,A325D,0.161,Gain of solvent accessibility (P = 0.1708); Loss of glycosylation at P328 (P = 0.2656); Loss of methylation at R324 (P = 0.3476); Loss of catalytic residue at G329 (P = 0.3622); Loss of sheet (P = 0.6423)
17:44061144:C:G,P10636,A325G,0.128,Loss of stability (P = 0.0921); Gain of methylation at R324 (P = 0.1677); Gain of catalytic residue at A326 (P = 0.2518); Loss of glycosylation at P328 (P = 0.3011); Loss of sheet (P = 0.6423)
17:44061144:C:T,P10636,A325V,0.219,Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.2517); Loss of glycosylation at P328 (P = 0.2953); Loss of methylation at R324 (P = 0.3728); Loss of catalytic residue at A325 (P = 0.5547)
17:44061146:G:A,P10636,A326T,0.164,Gain of phosphorylation at A326 (P = 0.0164); Gain of glycosylation at A326 (P = 0.0334); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1986); Loss of stability (P = 0.2236)
17:44061146:G:C,P10636,A326P,0.154,Loss of stability (P = 0.0511); Gain of glycosylation at P328 (P = 0.2665); Gain of solvent accessibility (P = 0.2689); Gain of methylation at R324 (P = 0.3789); Gain of catalytic residue at R324 (P = 0.6344)
17:44061146:G:T,P10636,A326S,0.155,Gain of phosphorylation at A326 (P = 0.0087); Gain of glycosylation at A326 (P = 0.023); Loss of stability (P = 0.1971); Gain of catalytic residue at L322 (P = 0.2674); Gain of methylation at R324 (P = 0.3515)
17:44061147:C:A,P10636,A326E,0.16,Gain of solvent accessibility (P = 0.154); Gain of catalytic residue at A326 (P = 0.2241); Gain of methylation at R324 (P = 0.3393); Loss of stability (P = 0.3429); Loss of glycosylation at P328 (P = 0.3562)
17:44061147:C:G,P10636,A326G,0.152,Loss of stability (P = 0.0528); Gain of catalytic residue at A325 (P = 0.1539); Loss of glycosylation at P328 (P = 0.3123); Gain of methylation at R324 (P = 0.317); Loss of solvent accessibility (P = 0.3744)
17:44061147:C:T,P10636,A326V,0.231,Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1986); Loss of glycosylation at P328 (P = 0.2904); Loss of methylation at R324 (P = 0.3614); Loss of stability (P = 0.3771)
17:44061149:T:A,P10636,F327I,0.06,Loss of glycosylation at P328 (P = 0.2702); Loss of stability (P = 0.2777); Loss of methylation at R324 (P = 0.3643); Loss of catalytic residue at A330 (P = 0.5649); Loss of disorder (P = 0.6808)
17:44061149:T:C,P10636,F327L,0.129,Loss of stability (P = 0.3677); Loss of methylation at R324 (P = 0.3847); Gain of glycosylation at P328 (P = 0.3937); Loss of catalytic residue at A330 (P = 0.5174); Gain of sheet (P = 0.6509)
17:44061149:T:G,P10636,F327V,0.095,Loss of stability (P = 0.1131); Loss of glycosylation at P328 (P = 0.2547); Gain of methylation at R324 (P = 0.374); Loss of catalytic residue at A330 (P = 0.4872); Gain of disorder (P = 0.6899)
17:44061150:T:A,P10636,F327Y,0.228,Gain of solvent accessibility (P = 0.0081); Gain of relative solvent accessibility (P = 0.0249); Gain of phosphorylation at F327 (P = 0.044); Gain of catalytic residue at F327 (P = 0.046); Loss of stability (P = 0.1262)
17:44061150:T:C,P10636,F327S,0.194,Gain of phosphorylation at F327 (P = 0.0051); Gain of relative solvent accessibility (P = 0.0249); Gain of glycosylation at F327 (P = 0.0359); Loss of stability (P = 0.0495); Gain of solvent accessibility (P = 0.11)
17:44061150:T:G,P10636,F327C,0.097,Loss of stability (P = 0.1595); Loss of glycosylation at P328 (P = 0.3345); Gain of methylation at R324 (P = 0.3931); Gain of catalytic residue at G329 (P = 0.4714); Loss of sheet (P = 0.6423)
17:44061151:T:A,P10636,F327L,0.129,Loss of stability (P = 0.3677); Loss of methylation at R324 (P = 0.3847); Gain of glycosylation at P328 (P = 0.3937); Loss of catalytic residue at A330 (P = 0.5174); Gain of sheet (P = 0.6509)
17:44061151:T:G,P10636,F327L,0.129,Loss of stability (P = 0.3677); Loss of methylation at R324 (P = 0.3847); Gain of glycosylation at P328 (P = 0.3937); Loss of catalytic residue at A330 (P = 0.5174); Gain of sheet (P = 0.6509)
17:44061152:C:A,P10636,P328T,0.255,Gain of glycosylation at P328 (P = 0.0257); Gain of phosphorylation at P328 (P = 0.0382); Loss of catalytic residue at P328 (P = 0.1204); Loss of methylation at R324 (P = 0.3846); Gain of solvent accessibility (P = 0.5334)
17:44061152:C:G,P10636,P328A,0.198,Loss of glycosylation at P328 (P = 0.0825); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of catalytic residue at P328 (P = 0.3294); Loss of methylation at R324 (P = 0.3846)
17:44061152:C:T,P10636,P328S,0.232,Gain of glycosylation at P328 (P = 0.0166); Gain of phosphorylation at P328 (P = 0.0287); Loss of catalytic residue at P328 (P = 0.1547); Loss of solvent accessibility (P = 0.2953); Loss of relative solvent accessibility (P = 0.3219)
17:44061153:C:A,P10636,P328Q,0.224,Loss of glycosylation at P328 (P = 0.0825); Loss of catalytic residue at P328 (P = 0.1224); Gain of solvent accessibility (P = 0.1505); Loss of methylation at R324 (P = 0.3725); Gain of MoRF binding (P = 0.6015)
17:44061153:C:G,P10636,P328R,0.243,Gain of methylation at P328 (P = 0.0346); Loss of glycosylation at P328 (P = 0.0825); Loss of catalytic residue at G329 (P = 0.1663); Gain of MoRF binding (P = 0.2123); Loss of relative solvent accessibility (P = 0.3219)
17:44061153:C:T,P10636,P328L,0.269,Loss of glycosylation at P328 (P = 0.0825); Gain of stability (P = 0.0932); Loss of catalytic residue at G329 (P = 0.1738); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2517)
17:44061155:G:A,P10636,G329R,0.24,Gain of solvent accessibility (P = 0.019); Gain of methylation at G329 (P = 0.0334); Loss of catalytic residue at G329 (P = 0.1606); Gain of glycosylation at P328 (P = 0.1858); Gain of MoRF binding (P = 0.5363)
17:44061155:G:C,P10636,G329R,0.24,Gain of solvent accessibility (P = 0.019); Gain of methylation at G329 (P = 0.0334); Loss of catalytic residue at G329 (P = 0.1606); Gain of glycosylation at P328 (P = 0.1858); Gain of MoRF binding (P = 0.5363)
17:44061156:G:A,P10636,G329E,0.191,Gain of solvent accessibility (P = 0.0789); Gain of glycosylation at P328 (P = 0.241); Loss of catalytic residue at A330 (P = 0.3272); Loss of methylation at R324 (P = 0.3858); Loss of relative solvent accessibility (P = 0.5582)
17:44061156:G:C,P10636,G329A,0.137,Loss of catalytic residue at G329 (P = 0.105); Gain of glycosylation at P328 (P = 0.2508); Gain of solvent accessibility (P = 0.3304); Loss of methylation at R324 (P = 0.3886); Gain of disorder (P = 0.7406)
17:44061156:G:T,P10636,G329V,0.19,Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at P328 (P = 0.1861); Loss of catalytic residue at G329 (P = 0.2393); Loss of solvent accessibility (P = 0.2668); Loss of methylation at R324 (P = 0.378)
17:44061158:G:A,P10636,A330T,0.116,Gain of phosphorylation at A330 (P = 0.0058); Gain of glycosylation at A330 (P = 0.0105); Gain of catalytic residue at A330 (P = 0.2762); Loss of stability (P = 0.3629); Gain of solvent accessibility (P = 0.4304)
17:44061158:G:C,P10636,A330P,0.169,Gain of glycosylation at A330 (P = 0.0287); Gain of catalytic residue at A330 (P = 0.0555); Loss of stability (P = 0.1541); Gain of solvent accessibility (P = 0.4656); Loss of sheet (P = 0.6423)
17:44061158:G:T,P10636,A330S,0.117,Gain of glycosylation at A330 (P = 0.0056); Gain of phosphorylation at A330 (P = 0.0119); Loss of stability (P = 0.4333); Gain of solvent accessibility (P = 0.4821); Loss of sheet (P = 0.6423)
17:44061159:C:A,P10636,A330D,0.098,Loss of glycosylation at P328 (P = 0.193); Gain of solvent accessibility (P = 0.3602); Gain of catalytic residue at G332 (P = 0.46); Loss of stability (P = 0.4872); Loss of sheet (P = 0.6423)
17:44061159:C:G,P10636,A330G,0.133,Gain of catalytic residue at A330 (P = 0.0696); Loss of stability (P = 0.1254); Gain of glycosylation at P331 (P = 0.1688); Gain of disorder (P = 0.754); Loss of sheet (P = 0.7751)
17:44061159:C:T,P10636,A330V,0.092,Loss of glycosylation at P328 (P = 0.1852); Gain of catalytic residue at A330 (P = 0.2597); Gain of sheet (P = 0.6509); Loss of stability (P = 0.6534); Loss of disorder (P = 0.6813)
17:44061161:C:A,P10636,P331T,0.225,Gain of glycosylation at P331 (P = 0.0436); Gain of phosphorylation at P331 (P = 0.0517); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.0721); Gain of catalytic residue at P331 (P = 0.122)
17:44061161:C:G,P10636,P331A,0.217,Loss of solvent accessibility (P = 0.0509); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at P331 (P = 0.101); Gain of catalytic residue at P331 (P = 0.1453); Loss of stability (P = 0.3165)
17:44061161:C:T,P10636,P331S,0.212,Gain of glycosylation at P331 (P = 0.0182); Gain of phosphorylation at P331 (P = 0.0226); Loss of relative solvent accessibility (P = 0.107); Loss of solvent accessibility (P = 0.1279); Gain of catalytic residue at E333 (P = 0.4554)
17:44061162:C:A,P10636,P331H,0.229,Loss of relative solvent accessibility (P = 0.0676); Gain of catalytic residue at P331 (P = 0.0741); Loss of glycosylation at P331 (P = 0.101); Loss of solvent accessibility (P = 0.1301); Loss of stability (P = 0.4672)
17:44061162:C:G,P10636,P331R,0.259,Gain of methylation at P331 (P = 0.0111); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at P331 (P = 0.101); Loss of catalytic residue at G329 (P = 0.2306); Loss of solvent accessibility (P = 0.2517)
17:44061162:C:T,P10636,P331L,0.233,Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at P331 (P = 0.101); Loss of solvent accessibility (P = 0.1115); Gain of catalytic residue at E333 (P = 0.312); Gain of stability (P = 0.3871)
17:44061164:G:A,P10636,G332R,0.206,Gain of methylation at G332 (P = 0.0529); Loss of catalytic residue at P328 (P = 0.0852); Gain of stability (P = 0.1288); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at P328 (P = 0.2438)
17:44061164:G:C,P10636,G332R,0.206,Gain of methylation at G332 (P = 0.0529); Loss of catalytic residue at P328 (P = 0.0852); Gain of stability (P = 0.1288); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at P328 (P = 0.2438)
17:44061165:G:A,P10636,G332E,0.189,Loss of catalytic residue at P328 (P = 0.0852); Gain of stability (P = 0.1212); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at P328 (P = 0.2555); Loss of sheet (P = 0.7751)
17:44061165:G:C,P10636,G332A,0.148,Loss of catalytic residue at P328 (P = 0.0852); Gain of stability (P = 0.2083); Gain of glycosylation at P331 (P = 0.2749); Gain of solvent accessibility (P = 0.367); Loss of sheet (P = 0.7751)
17:44061165:G:T,P10636,G332V,0.197,Loss of catalytic residue at P328 (P = 0.0852); Loss of relative solvent accessibility (P = 0.0981); Gain of stability (P = 0.1455); Loss of glycosylation at P331 (P = 0.1858); Loss of solvent accessibility (P = 0.4141)
17:44061167:G:A,P10636,E333K,0.234,Gain of ubiquitination at E333 (P = 0.0066); Gain of glycosylation at E333 (P = 0.0157); Gain of methylation at E333 (P = 0.028); Gain of catalytic residue at E333 (P = 0.1955); Loss of solvent accessibility (P = 0.4838)
17:44061167:G:C,P10636,E333Q,0.153,Loss of methylation at R338 (P = 0.3135); Gain of glycosylation at P328 (P = 0.3452); Loss of solvent accessibility (P = 0.4141); Gain of catalytic residue at G332 (P = 0.4917); Loss of relative solvent accessibility (P = 0.5582)
17:44061168:A:C,P10636,E333A,0.186,Loss of solvent accessibility (P = 0.0404); Gain of catalytic residue at E333 (P = 0.1519); Gain of methylation at R338 (P = 0.1657); Gain of glycosylation at P328 (P = 0.2103); Loss of relative solvent accessibility (P = 0.5582)
17:44061168:A:G,P10636,E333G,0.196,Loss of solvent accessibility (P = 0.0387); Gain of catalytic residue at E333 (P = 0.0763); Gain of methylation at R338 (P = 0.1533); Gain of glycosylation at P328 (P = 0.1962); Loss of stability (P = 0.3874)
17:44061168:A:T,P10636,E333V,0.267,Loss of solvent accessibility (P = 0.0052); Loss of relative solvent accessibility (P = 0.0404); Gain of catalytic residue at E333 (P = 0.0598); Loss of glycosylation at P331 (P = 0.2017); Gain of methylation at R338 (P = 0.2789)
17:44061169:G:C,P10636,E333D,0.174,Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at P331 (P = 0.248); Loss of methylation at R338 (P = 0.2993); Gain of catalytic residue at G332 (P = 0.3657); Loss of relative solvent accessibility (P = 0.5582)
17:44061169:G:T,P10636,E333D,0.174,Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at P331 (P = 0.248); Loss of methylation at R338 (P = 0.2993); Gain of catalytic residue at G332 (P = 0.3657); Loss of relative solvent accessibility (P = 0.5582)
17:44061170:G:A,P10636,G334R,0.211,Gain of solvent accessibility (P = 0.1319); Loss of catalytic residue at G334 (P = 0.1486); Gain of methylation at G334 (P = 0.1581); Gain of glycosylation at P335 (P = 0.3065); Gain of MoRF binding (P = 0.6547)
17:44061170:G:C,P10636,G334R,0.211,Gain of solvent accessibility (P = 0.1319); Loss of catalytic residue at G334 (P = 0.1486); Gain of methylation at G334 (P = 0.1581); Gain of glycosylation at P335 (P = 0.3065); Gain of MoRF binding (P = 0.6547)
17:44061170:G:T,P10636,G334W,0.175,Loss of methylation at R338 (P = 0.1598); Loss of catalytic residue at G334 (P = 0.1871); Gain of solvent accessibility (P = 0.3304); Gain of glycosylation at P331 (P = 0.3892); Loss of disorder (P = 0.6448)
17:44061171:G:A,P10636,G334E,0.193,Gain of glycosylation at P335 (P = 0.1276); Loss of catalytic residue at G334 (P = 0.1655); Gain of solvent accessibility (P = 0.2192); Loss of methylation at R338 (P = 0.2854); Gain of stability (P = 0.8311)
17:44061171:G:C,P10636,G334A,0.167,Loss of catalytic residue at G334 (P = 0.0366); Gain of glycosylation at P331 (P = 0.1956); Gain of methylation at R338 (P = 0.3062); Gain of solvent accessibility (P = 0.5093); Gain of stability (P = 0.6561)
17:44061171:G:T,P10636,G334V,0.183,Loss of catalytic residue at G334 (P = 0.1098); Gain of stability (P = 0.2667); Loss of methylation at R338 (P = 0.3042); Loss of glycosylation at P335 (P = 0.3111); Gain of solvent accessibility (P = 0.3602)
17:44061173:C:A,P10636,P335T,0.201,Gain of phosphorylation at P335 (P = 0.0019); Loss of catalytic residue at G334 (P = 0.1792); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1922); Gain of methylation at R338 (P = 0.3085)
17:44061173:C:G,P10636,P335A,0.138,Loss of catalytic residue at P335 (P = 0.1115); Loss of glycosylation at P335 (P = 0.1528); Gain of methylation at R338 (P = 0.1585); Loss of solvent accessibility (P = 0.5743); Gain of MoRF binding (P = 0.7901)
17:44061173:C:T,P10636,P335S,0.183,Gain of phosphorylation at P335 (P = 0.0031); Gain of glycosylation at P335 (P = 0.0325); Loss of catalytic residue at P335 (P = 0.0528); Loss of solvent accessibility (P = 0.1744); Loss of relative solvent accessibility (P = 0.1807)
17:44061174:C:A,P10636,P335Q,0.146,Loss of catalytic residue at P335 (P = 0.0747); Loss of glycosylation at P335 (P = 0.1528); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at R338 (P = 0.2412); Loss of solvent accessibility (P = 0.3473)
17:44061174:C:G,P10636,P335R,0.179,Gain of methylation at P335 (P = 0.0474); Loss of catalytic residue at G334 (P = 0.0771); Loss of glycosylation at P335 (P = 0.1528); Loss of relative solvent accessibility (P = 0.1807); Gain of MoRF binding (P = 0.5036)
17:44061174:C:T,P10636,P335L,0.198,Gain of stability (P = 0.0197); Loss of relative solvent accessibility (P = 0.0981); Loss of catalytic residue at G334 (P = 0.1169); Loss of solvent accessibility (P = 0.1362); Loss of glycosylation at P335 (P = 0.1528)
17:44061176:G:A,P10636,E336K,0.236,Gain of methylation at E336 (P = 0.0039); Gain of ubiquitination at E336 (P = 0.0069); Gain of glycosylation at E336 (P = 0.0172); Gain of catalytic residue at E336 (P = 0.2794); Loss of solvent accessibility (P = 0.5124)
17:44061176:G:C,P10636,E336Q,0.113,Loss of solvent accessibility (P = 0.0721); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at R338 (P = 0.2676); Loss of glycosylation at S341 (P = 0.3046); Loss of catalytic residue at E336 (P = 0.4087)
17:44061177:A:C,P10636,E336A,0.137,Loss of solvent accessibility (P = 0.0224); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at R338 (P = 0.1946); Gain of glycosylation at S341 (P = 0.2089); Gain of catalytic residue at G339 (P = 0.4957)
17:44061177:A:G,P10636,E336G,0.12,Loss of solvent accessibility (P = 0.0769); Gain of methylation at R338 (P = 0.1355); Gain of catalytic residue at R338 (P = 0.2664); Gain of glycosylation at P335 (P = 0.2666); Loss of stability (P = 0.3831)
17:44061177:A:T,P10636,E336V,0.181,Loss of solvent accessibility (P = 0.0199); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at R338 (P = 0.3072); Loss of glycosylation at P335 (P = 0.3419); Loss of catalytic residue at E336 (P = 0.4416)
17:44061178:G:C,P10636,E336D,0.095,Loss of catalytic residue at G334 (P = 0.223); Loss of solvent accessibility (P = 0.2517); Gain of glycosylation at S341 (P = 0.2683); Loss of methylation at R338 (P = 0.2904); Loss of relative solvent accessibility (P = 0.5898)
17:44061178:G:T,P10636,E336D,0.095,Loss of catalytic residue at G334 (P = 0.223); Loss of solvent accessibility (P = 0.2517); Gain of glycosylation at S341 (P = 0.2683); Loss of methylation at R338 (P = 0.2904); Loss of relative solvent accessibility (P = 0.5898)
17:44061179:G:A,P10636,A337T,0.18,Gain of phosphorylation at A337 (P = 0.0031); Gain of glycosylation at A337 (P = 0.0085); Gain of solvent accessibility (P = 0.28); Loss of methylation at R338 (P = 0.2802); Loss of catalytic residue at G332 (P = 0.4873)
17:44061179:G:C,P10636,A337P,0.161,Gain of glycosylation at A337 (P = 0.0887); Gain of solvent accessibility (P = 0.1456); Gain of relative solvent accessibility (P = 0.1571); Loss of methylation at R338 (P = 0.285); Loss of stability (P = 0.3409)
17:44061179:G:T,P10636,A337S,0.171,Gain of phosphorylation at A337 (P = 0.0026); Gain of glycosylation at A337 (P = 0.0143); Loss of methylation at R338 (P = 0.2793); Gain of solvent accessibility (P = 0.3602); Loss of catalytic residue at G332 (P = 0.4528)
17:44061180:C:A,P10636,A337D,0.164,Gain of glycosylation at S341 (P = 0.1578); Gain of solvent accessibility (P = 0.1708); Loss of methylation at R338 (P = 0.2166); Loss of catalytic residue at E336 (P = 0.3929); Loss of stability (P = 0.6481)
17:44061180:C:G,P10636,A337G,0.171,Gain of methylation at R338 (P = 0.1168); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1589); Gain of catalytic residue at L342 (P = 0.1859); Loss of glycosylation at S341 (P = 0.2886)
17:44061180:C:T,P10636,A337V,0.165,Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at R338 (P = 0.2912); Loss of glycosylation at S341 (P = 0.2975); Gain of catalytic residue at E336 (P = 0.3693); Loss of solvent accessibility (P = 0.3854)
17:44061182:C:G,P10636,R338G,0.185,Loss of solvent accessibility (P = 0.0159); Gain of glycosylation at S341 (P = 0.0711); Loss of methylation at R338 (P = 0.1016); Loss of stability (P = 0.137); Gain of catalytic residue at A337 (P = 0.1674)
17:44061182:C:T,P10636,R338W,0.278,Loss of solvent accessibility (P = 0.0087); Gain of catalytic residue at R338 (P = 0.0715); Gain of glycosylation at S341 (P = 0.0732); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at R338 (P = 0.1016)
17:44061183:G:A,P10636,R338Q,0.18,Loss of methylation at R338 (P = 0.1016); Gain of glycosylation at S341 (P = 0.1114); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.4458); Loss of phosphorylation at S341 (P = 0.5867)
17:44061183:G:C,P10636,R338P,0.178,Gain of glycosylation at R338 (P = 0.0677); Loss of methylation at R338 (P = 0.1016); Gain of relative solvent accessibility (P = 0.1571); Loss of solvent accessibility (P = 0.1868); Loss of stability (P = 0.2135)
17:44061183:G:T,P10636,R338L,0.212,Gain of glycosylation at S341 (P = 0.0736); Loss of methylation at R338 (P = 0.1016); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at G339 (P = 0.2311); Loss of solvent accessibility (P = 0.4218)
17:44061185:G:A,P10636,G339S,0.141,Gain of phosphorylation at G339 (P = 0.0055); Loss of catalytic residue at P335 (P = 0.0775); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at R338 (P = 0.2279); Gain of glycosylation at P335 (P = 0.2864)
17:44061185:G:C,P10636,G339R,0.205,Loss of catalytic residue at P335 (P = 0.0775); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at R338 (P = 0.1979); Loss of glycosylation at S341 (P = 0.2344); Gain of solvent accessibility (P = 0.3956)
17:44061185:G:T,P10636,G339C,0.195,Loss of relative solvent accessibility (P = 0.0676); Loss of catalytic residue at P335 (P = 0.0775); Loss of methylation at R338 (P = 0.2154); Loss of glycosylation at S341 (P = 0.2197); Loss of solvent accessibility (P = 0.2882)
17:44061186:G:A,P10636,G339D,0.163,Loss of catalytic residue at P335 (P = 0.0775); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at R338 (P = 0.1852); Loss of glycosylation at S341 (P = 0.3511); Loss of solvent accessibility (P = 0.7225)
17:44061186:G:C,P10636,G339A,0.136,Loss of catalytic residue at P335 (P = 0.0775); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at R338 (P = 0.2641); Gain of glycosylation at S341 (P = 0.3096); Loss of solvent accessibility (P = 0.3368)
17:44061186:G:T,P10636,G339V,0.166,Loss of catalytic residue at P335 (P = 0.0775); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at R338 (P = 0.2308); Gain of glycosylation at S341 (P = 0.3332); Loss of solvent accessibility (P = 0.4141)
17:44061188:C:A,P10636,P340T,0.204,Gain of phosphorylation at P340 (P = 0.0075); Gain of glycosylation at P340 (P = 0.0152); Gain of catalytic residue at S341 (P = 0.1821); Gain of methylation at R338 (P = 0.3035); Loss of stability (P = 0.373)
17:44061188:C:G,P10636,P340A,0.211,Loss of solvent accessibility (P = 0.089); Loss of relative solvent accessibility (P = 0.0981); Gain of methylation at R338 (P = 0.2732); Loss of catalytic residue at G339 (P = 0.2946); Loss of glycosylation at S341 (P = 0.3429)
17:44061188:C:T,P10636,P340S,0.228,Gain of phosphorylation at P340 (P = 0.0023); Gain of glycosylation at P340 (P = 0.0322); Gain of relative solvent accessibility (P = 0.1571); Gain of methylation at R338 (P = 0.2779); Loss of catalytic residue at G339 (P = 0.3129)
17:44061189:C:A,P10636,P340H,0.23,Gain of catalytic residue at P340 (P = 0.0862); Gain of methylation at R338 (P = 0.1743); Gain of solvent accessibility (P = 0.204); Loss of glycosylation at S341 (P = 0.3001); Loss of stability (P = 0.6277)
17:44061189:C:G,P10636,P340R,0.22,Gain of methylation at R338 (P = 0.0905); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S341 (P = 0.2021); Loss of catalytic residue at G339 (P = 0.2859); Loss of solvent accessibility (P = 0.5288)
17:44061191:T:A,P10636,S341T,0.147,Gain of glycosylation at S341 (P = 0.0439); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1362); Gain of methylation at R338 (P = 0.3122); Loss of catalytic residue at G339 (P = 0.4524)
17:44061191:T:C,P10636,S341P,0.13,Loss of phosphorylation at S341 (P = 0.002); Gain of catalytic residue at P340 (P = 0.0133); Loss of glycosylation at S341 (P = 0.1418); Gain of methylation at R338 (P = 0.321); Loss of stability (P = 0.5141)
17:44061191:T:G,P10636,S341A,0.131,Loss of phosphorylation at S341 (P = 0.002); Loss of glycosylation at S341 (P = 0.0764); Gain of relative solvent accessibility (P = 0.1571); Gain of methylation at R338 (P = 0.2179); Loss of catalytic residue at G339 (P = 0.4946)
17:44061192:C:A,P10636,S341Y,0.228,Gain of solvent accessibility (P = 0.0155); Loss of glycosylation at S341 (P = 0.0764); Gain of relative solvent accessibility (P = 0.1571); Loss of methylation at R338 (P = 0.3055); Gain of catalytic residue at E344 (P = 0.3553)
17:44061192:C:G,P10636,S341C,0.185,Loss of phosphorylation at S341 (P = 0.002); Gain of catalytic residue at P340 (P = 0.0086); Loss of glycosylation at S341 (P = 0.0764); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1322)
17:44061192:C:T,P10636,S341F,0.158,Loss of phosphorylation at S341 (P = 0.002); Loss of glycosylation at S341 (P = 0.0764); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at R338 (P = 0.2943); Gain of catalytic residue at E344 (P = 0.3159)
17:44061194:T:A,P10636,L342M,0.149,Gain of methylation at K347 (P = 0.0941); Loss of glycosylation at S341 (P = 0.1319); Loss of stability (P = 0.251); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2902)
17:44061194:T:G,P10636,L342V,0.106,Gain of methylation at K347 (P = 0.1008); Loss of glycosylation at K347 (P = 0.2056); Loss of stability (P = 0.2997); Loss of ubiquitination at K347 (P = 0.4063); Gain of phosphorylation at T346 (P = 0.6419)
17:44061195:T:C,P10636,L342S,0.179,Gain of glycosylation at L342 (P = 0.0045); Gain of phosphorylation at L342 (P = 0.0073); Loss of stability (P = 0.032); Gain of methylation at K347 (P = 0.0854); Gain of relative solvent accessibility (P = 0.2629)
17:44061195:T:G,P10636,L342W,0.178,Loss of stability (P = 0.0578); Gain of methylation at K347 (P = 0.0896); Loss of glycosylation at S341 (P = 0.1281); Loss of ubiquitination at K347 (P = 0.3842); Gain of solvent accessibility (P = 0.4067)
17:44061196:G:C,P10636,L342F,0.116,Gain of methylation at K347 (P = 0.1098); Loss of stability (P = 0.1778); Gain of catalytic residue at P340 (P = 0.205); Gain of glycosylation at K347 (P = 0.2456); Loss of ubiquitination at K347 (P = 0.4063)
17:44061196:G:T,P10636,L342F,0.116,Gain of methylation at K347 (P = 0.1098); Loss of stability (P = 0.1778); Gain of catalytic residue at P340 (P = 0.205); Gain of glycosylation at K347 (P = 0.2456); Loss of ubiquitination at K347 (P = 0.4063)
17:44061197:G:A,P10636,G343R,0.135,Loss of glycosylation at K347 (P = 0.0924); Gain of catalytic residue at G343 (P = 0.1788); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at K347 (P = 0.185); Loss of ubiquitination at K347 (P = 0.395)
17:44061197:G:C,P10636,G343R,0.135,Loss of glycosylation at K347 (P = 0.0924); Gain of catalytic residue at G343 (P = 0.1788); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at K347 (P = 0.185); Loss of ubiquitination at K347 (P = 0.395)
17:44061198:G:A,P10636,G343E,0.135,Gain of solvent accessibility (P = 0.0456); Gain of glycosylation at T346 (P = 0.1036); Loss of methylation at K347 (P = 0.2241); Loss of ubiquitination at K347 (P = 0.395); Loss of catalytic residue at G339 (P = 0.5417)
17:44061198:G:C,P10636,G343A,0.09,Gain of glycosylation at T346 (P = 0.0976); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at K347 (P = 0.2444); Loss of stability (P = 0.3093); Loss of ubiquitination at K347 (P = 0.4063)
17:44061198:G:T,P10636,G343V,0.093,Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at T346 (P = 0.1037); Gain of methylation at K347 (P = 0.1607); Loss of ubiquitination at K347 (P = 0.4093); Loss of solvent accessibility (P = 0.4141)
17:44061200:G:A,P10636,E344K,0.284,Gain of ubiquitination at E344 (P = 0.0011); Gain of methylation at E344 (P = 0.016); Gain of glycosylation at E344 (P = 0.0235); Loss of stability (P = 0.0651); Gain of solvent accessibility (P = 0.4496)
17:44061200:G:C,P10636,E344Q,0.151,Loss of solvent accessibility (P = 0.0174); Loss of relative solvent accessibility (P = 0.0676); Gain of methylation at K347 (P = 0.1046); Gain of glycosylation at K347 (P = 0.1891); Loss of stability (P = 0.2196)
17:44061201:A:C,P10636,E344A,0.179,Loss of solvent accessibility (P = 0.0023); Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at S341 (P = 0.0941); Loss of stability (P = 0.1055); Loss of methylation at K347 (P = 0.235)
17:44061201:A:G,P10636,E344G,0.197,Loss of solvent accessibility (P = 0.0187); Loss of stability (P = 0.0304); Gain of glycosylation at S341 (P = 0.0564); Gain of catalytic residue at P340 (P = 0.0924); Loss of methylation at K347 (P = 0.2529)
17:44061201:A:T,P10636,E344V,0.2,Loss of solvent accessibility (P = 0.0052); Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at S341 (P = 0.0858); Gain of methylation at K347 (P = 0.2343); Gain of catalytic residue at E344 (P = 0.312)
17:44061202:G:C,P10636,E344D,0.137,Gain of glycosylation at S341 (P = 0.1794); Loss of solvent accessibility (P = 0.1813); Loss of methylation at K347 (P = 0.2102); Loss of stability (P = 0.289); Loss of catalytic residue at E344 (P = 0.3206)
17:44061202:G:T,P10636,E344D,0.137,Gain of glycosylation at S341 (P = 0.1794); Loss of solvent accessibility (P = 0.1813); Loss of methylation at K347 (P = 0.2102); Loss of stability (P = 0.289); Loss of catalytic residue at E344 (P = 0.3206)
17:44061203:G:A,P10636,D345N,0.143,Gain of methylation at K347 (P = 0.0928); Loss of glycosylation at K347 (P = 0.1738); Gain of catalytic residue at E344 (P = 0.301); Loss of stability (P = 0.354); Loss of ubiquitination at K347 (P = 0.4063)
17:44061203:G:C,P10636,D345H,0.144,Gain of methylation at K347 (P = 0.0577); Loss of solvent accessibility (P = 0.0703); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at E344 (P = 0.1529); Gain of glycosylation at K347 (P = 0.1639)
17:44061203:G:T,P10636,D345Y,0.206,Gain of phosphorylation at D345 (P = 9e-04); Gain of methylation at K347 (P = 0.0739); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1115); Gain of catalytic residue at E344 (P = 0.1565)
17:44061204:A:C,P10636,D345A,0.118,Gain of methylation at K347 (P = 0.0936); Loss of stability (P = 0.1608); Gain of glycosylation at T346 (P = 0.175); Loss of solvent accessibility (P = 0.3136); Loss of ubiquitination at K347 (P = 0.3993)
17:44061204:A:G,P10636,D345G,0.133,Loss of stability (P = 0.0335); Gain of methylation at K347 (P = 0.0801); Gain of glycosylation at K347 (P = 0.1087); Gain of relative solvent accessibility (P = 0.1571); Gain of catalytic residue at E344 (P = 0.1987)
17:44061204:A:T,P10636,D345V,0.138,Gain of methylation at K347 (P = 0.0446); Loss of solvent accessibility (P = 0.0544); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at E344 (P = 0.1825); Loss of glycosylation at K347 (P = 0.2497)
17:44061205:C:A,P10636,D345E,0.113,Gain of methylation at K347 (P = 0.1684); Gain of glycosylation at K347 (P = 0.2137); Gain of solvent accessibility (P = 0.3089); Loss of ubiquitination at K347 (P = 0.3993); Loss of stability (P = 0.4432)
17:44061205:C:G,P10636,D345E,0.113,Gain of methylation at K347 (P = 0.1684); Gain of glycosylation at K347 (P = 0.2137); Gain of solvent accessibility (P = 0.3089); Loss of ubiquitination at K347 (P = 0.3993); Loss of stability (P = 0.4432)
17:44061206:A:C,P10636,T346P,0.104,Loss of phosphorylation at T346 (P = 0.0093); Gain of glycosylation at K347 (P = 0.1014); Gain of methylation at K347 (P = 0.184); Loss of ubiquitination at K347 (P = 0.3777); Loss of stability (P = 0.4132)
17:44061206:A:G,P10636,T346A,0.098,Loss of phosphorylation at T346 (P = 0.0093); Loss of glycosylation at T346 (P = 0.0761); Loss of methylation at K347 (P = 0.2073); Loss of ubiquitination at K347 (P = 0.4093); Loss of solvent accessibility (P = 0.4995)
17:44061206:A:T,P10636,T346S,0.129,Loss of glycosylation at K347 (P = 0.2061); Loss of methylation at K347 (P = 0.2209); Gain of catalytic residue at L342 (P = 0.2424); Loss of ubiquitination at K347 (P = 0.3842); Loss of stability (P = 0.6055)
17:44061207:C:A,P10636,T346K,0.209,Gain of ubiquitination at T346 (P = 0.0025); Loss of phosphorylation at T346 (P = 0.0093); Gain of methylation at T346 (P = 0.0656); Gain of glycosylation at T346 (P = 0.0848); Gain of solvent accessibility (P = 0.1505)
17:44061207:C:G,P10636,T346R,0.143,Loss of phosphorylation at T346 (P = 0.0093); Gain of solvent accessibility (P = 0.0503); Loss of glycosylation at T346 (P = 0.0761); Gain of methylation at K347 (P = 0.1654); Loss of ubiquitination at K347 (P = 0.39)
17:44061207:C:T,P10636,T346I,0.122,Loss of phosphorylation at T346 (P = 0.0093); Loss of glycosylation at T346 (P = 0.0761); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at T346 (P = 0.1112); Loss of solvent accessibility (P = 0.1235)
17:44061209:A:C,P10636,K347Q,0.195,Loss of ubiquitination at K347 (P = 9e-04); Loss of glycosylation at K347 (P = 0.0294); Loss of methylation at K347 (P = 0.0541); Loss of solvent accessibility (P = 0.0561); Loss of relative solvent accessibility (P = 0.1807)
17:44061209:A:G,P10636,K347E,0.218,Loss of ubiquitination at K347 (P = 9e-04); Loss of glycosylation at K347 (P = 0.0294); Loss of methylation at K347 (P = 0.0541); Gain of catalytic residue at E344 (P = 0.5025); Loss of phosphorylation at T346 (P = 0.6096)
17:44061210:A:C,P10636,K347T,0.235,Loss of ubiquitination at K347 (P = 9e-04); Gain of phosphorylation at K347 (P = 0.0102); Loss of solvent accessibility (P = 0.0249); Loss of methylation at K347 (P = 0.0541); Gain of glycosylation at T346 (P = 0.0547)
17:44061210:A:G,P10636,K347R,0.204,Loss of ubiquitination at K347 (P = 9e-04); Loss of glycosylation at K347 (P = 0.0294); Loss of methylation at K347 (P = 0.1261); Loss of solvent accessibility (P = 0.2953); Loss of relative solvent accessibility (P = 0.3219)
17:44061210:A:T,P10636,K347I,0.24,Loss of ubiquitination at K347 (P = 9e-04); Loss of solvent accessibility (P = 0.0111); Loss of glycosylation at K347 (P = 0.0294); Loss of methylation at K347 (P = 0.0541); Loss of relative solvent accessibility (P = 0.0676)
17:44061211:A:C,P10636,K347N,0.206,Loss of ubiquitination at K347 (P = 9e-04); Loss of glycosylation at K347 (P = 0.0294); Loss of solvent accessibility (P = 0.0371); Loss of methylation at K347 (P = 0.0541); Loss of relative solvent accessibility (P = 0.1807)
17:44061211:A:T,P10636,K347N,0.206,Loss of ubiquitination at K347 (P = 9e-04); Loss of glycosylation at K347 (P = 0.0294); Loss of solvent accessibility (P = 0.0371); Loss of methylation at K347 (P = 0.0541); Loss of relative solvent accessibility (P = 0.1807)
17:44061212:G:A,P10636,E348K,0.198,Gain of ubiquitination at E348 (P = 0.0025); Gain of methylation at E348 (P = 0.0183); Gain of glycosylation at E348 (P = 0.0271); Gain of solvent accessibility (P = 0.4821); Gain of catalytic residue at K347 (P = 0.6236)
17:44061212:G:C,P10636,E348Q,0.105,Gain of methylation at K347 (P = 0.103); Loss of solvent accessibility (P = 0.1868); Loss of glycosylation at T346 (P = 0.218); Loss of relative solvent accessibility (P = 0.3219); Loss of ubiquitination at K347 (P = 0.4063)
17:44061213:A:C,P10636,E348A,0.114,Loss of solvent accessibility (P = 0.0224); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at K347 (P = 0.2327); Gain of glycosylation at K347 (P = 0.2352); Loss of ubiquitination at K347 (P = 0.4033)
17:44061213:A:G,P10636,E348G,0.113,Loss of solvent accessibility (P = 0.0187); Gain of glycosylation at K347 (P = 0.0971); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at K347 (P = 0.1871); Loss of ubiquitination at K347 (P = 0.4033)
17:44061213:A:T,P10636,E348V,0.169,Loss of solvent accessibility (P = 0.0199); Gain of methylation at K347 (P = 0.0312); Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at K347 (P = 0.2003); Gain of catalytic residue at E344 (P = 0.256)
17:44061214:G:C,P10636,E348D,0.095,Loss of methylation at K347 (P = 0.1956); Loss of glycosylation at K347 (P = 0.1987); Loss of ubiquitination at K347 (P = 0.4033); Loss of solvent accessibility (P = 0.5485); Gain of catalytic residue at K347 (P = 0.6101)
17:44061214:G:T,P10636,E348D,0.095,Loss of methylation at K347 (P = 0.1956); Loss of glycosylation at K347 (P = 0.1987); Loss of ubiquitination at K347 (P = 0.4033); Loss of solvent accessibility (P = 0.5485); Gain of catalytic residue at K347 (P = 0.6101)
17:44061215:G:A,P10636,A349T,0.147,Gain of phosphorylation at A349 (P = 0.002); Gain of glycosylation at A349 (P = 0.0597); Gain of solvent accessibility (P = 0.1154); Gain of relative solvent accessibility (P = 0.1571); Gain of methylation at K347 (P = 0.1683)
17:44061215:G:C,P10636,A349P,0.122,Gain of glycosylation at T346 (P = 0.0714); Gain of methylation at K347 (P = 0.1039); Gain of solvent accessibility (P = 0.1456); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.2277)
17:44061215:G:T,P10636,A349S,0.147,Gain of phosphorylation at A349 (P = 0.0026); Gain of glycosylation at P354 (P = 0.191); Gain of methylation at K347 (P = 0.2111); Loss of stability (P = 0.2622); Gain of solvent accessibility (P = 0.3602)
17:44061216:C:A,P10636,A349D,0.116,Gain of solvent accessibility (P = 0.1708); Loss of glycosylation at T346 (P = 0.1753); Loss of methylation at K347 (P = 0.1916); Loss of stability (P = 0.3374); Loss of ubiquitination at K347 (P = 0.39)
17:44061216:C:G,P10636,A349G,0.087,Loss of stability (P = 0.0535); Loss of glycosylation at K347 (P = 0.1813); Gain of methylation at K347 (P = 0.2226); Loss of ubiquitination at K347 (P = 0.3704); Gain of catalytic residue at E344 (P = 0.49)
17:44061216:C:T,P10636,A349V,0.094,Gain of methylation at K347 (P = 0.1022); Loss of glycosylation at K347 (P = 0.1681); Gain of solvent accessibility (P = 0.28); Loss of ubiquitination at K347 (P = 0.4033); Gain of catalytic residue at E353 (P = 0.5239)
17:44061218:G:A,P10636,D350N,0.126,Gain of catalytic residue at D350 (P = 0.0309); Gain of methylation at K347 (P = 0.1068); Loss of solvent accessibility (P = 0.1202); Gain of glycosylation at P354 (P = 0.1724); Loss of relative solvent accessibility (P = 0.1807)
17:44061218:G:C,P10636,D350H,0.107,Gain of methylation at K347 (P = 0.1114); Gain of glycosylation at P354 (P = 0.1252); Loss of solvent accessibility (P = 0.1473); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.2379)
17:44061218:G:T,P10636,D350Y,0.163,Gain of phosphorylation at D350 (P = 0.0019); Gain of glycosylation at P354 (P = 0.0823); Gain of catalytic residue at P354 (P = 0.0867); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2073)
17:44061219:A:C,P10636,D350A,0.129,Loss of solvent accessibility (P = 0.0595); Gain of glycosylation at P354 (P = 0.0782); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at K347 (P = 0.2127); Loss of ubiquitination at K347 (P = 0.4063)
17:44061219:A:G,P10636,D350G,0.098,Gain of glycosylation at P354 (P = 0.1049); Gain of methylation at K347 (P = 0.138); Loss of stability (P = 0.1627); Loss of solvent accessibility (P = 0.1813); Loss of ubiquitination at K347 (P = 0.4063)
17:44061219:A:T,P10636,D350V,0.112,Loss of solvent accessibility (P = 0.0544); Gain of glycosylation at P354 (P = 0.0775); Gain of methylation at K347 (P = 0.0897); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at E353 (P = 0.3757)
17:44061220:C:A,P10636,D350E,0.121,Gain of glycosylation at P354 (P = 0.1366); Gain of methylation at K347 (P = 0.1493); Gain of solvent accessibility (P = 0.3089); Loss of ubiquitination at K347 (P = 0.3777); Gain of phosphorylation at T346 (P = 0.6479)
17:44061220:C:G,P10636,D350E,0.121,Gain of glycosylation at P354 (P = 0.1366); Gain of methylation at K347 (P = 0.1493); Gain of solvent accessibility (P = 0.3089); Loss of ubiquitination at K347 (P = 0.3777); Gain of phosphorylation at T346 (P = 0.6479)
17:44061221:C:A,P10636,L351I,0.131,Loss of catalytic residue at L351 (P = 0.0622); Gain of methylation at K347 (P = 0.0842); Loss of glycosylation at P354 (P = 0.1537); Loss of ubiquitination at K347 (P = 0.4063); Loss of stability (P = 0.5845)
17:44061221:C:G,P10636,L351V,0.145,Loss of catalytic residue at L351 (P = 0.0474); Gain of methylation at K347 (P = 0.108); Loss of glycosylation at P354 (P = 0.1591); Loss of ubiquitination at K347 (P = 0.4063); Loss of stability (P = 0.473)
17:44061221:C:T,P10636,L351F,0.163,Loss of catalytic residue at L351 (P = 0.0781); Gain of methylation at K347 (P = 0.1425); Loss of glycosylation at S355 (P = 0.2072); Loss of ubiquitination at K347 (P = 0.4033); Loss of stability (P = 0.4057)
17:44061222:T:A,P10636,L351H,0.19,Loss of catalytic residue at L351 (P = 0.0468); Loss of stability (P = 0.0701); Gain of methylation at K347 (P = 0.1096); Gain of glycosylation at K347 (P = 0.1171); Gain of relative solvent accessibility (P = 0.2629)
17:44061222:T:C,P10636,L351P,0.201,Loss of stability (P = 0.0465); Gain of glycosylation at L351 (P = 0.0551); Gain of methylation at K347 (P = 0.0609); Gain of relative solvent accessibility (P = 0.2629); Loss of ubiquitination at K347 (P = 0.3704)
17:44061222:T:G,P10636,L351R,0.203,Loss of catalytic residue at L351 (P = 0.0397); Gain of methylation at K347 (P = 0.0487); Loss of glycosylation at S355 (P = 0.1314); Loss of stability (P = 0.1649); Gain of solvent accessibility (P = 0.1683)
17:44061224:C:A,P10636,P352T,0.157,Gain of phosphorylation at P352 (P = 0.0108); Gain of glycosylation at P352 (P = 0.0745); Gain of methylation at K347 (P = 0.1983); Loss of ubiquitination at K357 (P = 0.3296); Loss of catalytic residue at L351 (P = 0.3758)
17:44061224:C:G,P10636,P352A,0.115,Gain of glycosylation at S355 (P = 0.113); Loss of methylation at K357 (P = 0.117); Loss of catalytic residue at L351 (P = 0.2278); Loss of solvent accessibility (P = 0.2732); Gain of ubiquitination at K357 (P = 0.3325)
17:44061224:C:T,P10636,P352S,0.174,Gain of phosphorylation at P352 (P = 0.006); Loss of solvent accessibility (P = 0.0635); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K347 (P = 0.1741); Loss of methylation at K357 (P = 0.1792)
17:44061225:C:A,P10636,P352Q,0.119,Loss of glycosylation at K347 (P = 0.19); Loss of methylation at K347 (P = 0.2236); Gain of solvent accessibility (P = 0.3304); Gain of ubiquitination at K357 (P = 0.3325); Loss of catalytic residue at L351 (P = 0.4055)
17:44061225:C:G,P10636,P352R,0.226,Gain of solvent accessibility (P = 0.0216); Loss of glycosylation at K347 (P = 0.1123); Loss of methylation at K347 (P = 0.1649); Gain of MoRF binding (P = 0.3077); Gain of ubiquitination at K357 (P = 0.3291)
17:44061225:C:T,P10636,P352L,0.187,Loss of methylation at K357 (P = 0.0704); Gain of catalytic residue at P352 (P = 0.1523); Gain of glycosylation at S355 (P = 0.1541); Gain of solvent accessibility (P = 0.2863); Gain of ubiquitination at K357 (P = 0.3291)
17:44061227:G:A,P10636,E353K,0.219,Gain of ubiquitination at E353 (P = 0.0022); Gain of glycosylation at E353 (P = 0.0135); Gain of methylation at E353 (P = 0.0191); Gain of MoRF binding (P = 0.2145); Loss of solvent accessibility (P = 0.5124)
17:44061227:G:C,P10636,E353Q,0.124,Loss of glycosylation at P354 (P = 0.1443); Gain of methylation at K357 (P = 0.2527); Gain of ubiquitination at K357 (P = 0.3325); Gain of MoRF binding (P = 0.4152); Gain of solvent accessibility (P = 0.571)
17:44061228:A:C,P10636,E353A,0.145,Loss of solvent accessibility (P = 0.0159); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at S355 (P = 0.1223); Loss of methylation at K357 (P = 0.1864); Loss of ubiquitination at K357 (P = 0.3061)
17:44061228:A:G,P10636,E353G,0.162,Loss of solvent accessibility (P = 0.0769); Gain of catalytic residue at E353 (P = 0.0874); Loss of glycosylation at P354 (P = 0.2327); Loss of methylation at K357 (P = 0.2578); Loss of stability (P = 0.2987)
17:44061228:A:T,P10636,E353V,0.123,Loss of solvent accessibility (P = 0.0199); Gain of glycosylation at S355 (P = 0.0933); Loss of relative solvent accessibility (P = 0.0981); Gain of methylation at K357 (P = 0.2722); Gain of ubiquitination at K357 (P = 0.3257)
17:44061229:G:C,P10636,E353D,0.123,Loss of glycosylation at S355 (P = 0.1426); Loss of methylation at K357 (P = 0.2615); Gain of ubiquitination at K357 (P = 0.3291); Loss of solvent accessibility (P = 0.5485); Loss of MoRF binding (P = 0.5754)
17:44061229:G:T,P10636,E353D,0.123,Loss of glycosylation at S355 (P = 0.1426); Loss of methylation at K357 (P = 0.2615); Gain of ubiquitination at K357 (P = 0.3291); Loss of solvent accessibility (P = 0.5485); Loss of MoRF binding (P = 0.5754)
17:44061230:C:A,P10636,P354T,0.157,Gain of phosphorylation at P354 (P = 0.013); Loss of glycosylation at P354 (P = 0.1261); Loss of methylation at K357 (P = 0.1677); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1922)
17:44061230:C:G,P10636,P354A,0.176,Loss of glycosylation at P354 (P = 0.0361); Loss of solvent accessibility (P = 0.089); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at K357 (P = 0.1051); Loss of stability (P = 0.235)
17:44061230:C:T,P10636,P354S,0.2,Gain of phosphorylation at P354 (P = 0.0069); Loss of methylation at K357 (P = 0.0888); Loss of glycosylation at P354 (P = 0.1303); Loss of solvent accessibility (P = 0.1744); Loss of relative solvent accessibility (P = 0.1807)
17:44061231:C:A,P10636,P354H,0.136,Loss of glycosylation at P354 (P = 0.0361); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at K357 (P = 0.2193); Loss of stability (P = 0.2401); Loss of solvent accessibility (P = 0.3103)
17:44061231:C:G,P10636,P354R,0.207,Loss of glycosylation at P354 (P = 0.0361); Gain of MoRF binding (P = 0.0493); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at K357 (P = 0.2406); Loss of catalytic residue at L351 (P = 0.2591)
17:44061231:C:T,P10636,P354L,0.177,Loss of glycosylation at P354 (P = 0.0361); Loss of methylation at K357 (P = 0.0725); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1362); Gain of ubiquitination at K357 (P = 0.3221)
17:44061233:T:A,P10636,S355T,0.186,Gain of glycosylation at S355 (P = 0.0505); Gain of methylation at K357 (P = 0.2364); Loss of catalytic residue at L351 (P = 0.2814); Gain of ubiquitination at K357 (P = 0.3325); Loss of MoRF binding (P = 0.3569)
17:44061233:T:C,P10636,S355P,0.201,Loss of phosphorylation at S355 (P = 0.0069); Gain of catalytic residue at P354 (P = 0.0168); Gain of sheet (P = 0.0507); Loss of loop (P = 0.0603); Gain of glycosylation at S355 (P = 0.1106)
17:44061233:T:G,P10636,S355A,0.187,Loss of phosphorylation at S355 (P = 0.0069); Loss of glycosylation at S355 (P = 0.0363); Gain of sheet (P = 0.0507); Loss of loop (P = 0.0603); Gain of helix (P = 0.0893)
17:44061234:C:A,P10636,S355Y,0.22,Loss of glycosylation at S355 (P = 0.0363); Loss of relative solvent accessibility (P = 0.0404); Gain of catalytic residue at P359 (P = 0.089); Loss of solvent accessibility (P = 0.1115); Gain of methylation at K357 (P = 0.2492)
17:44061234:C:G,P10636,S355C,0.185,Loss of phosphorylation at S355 (P = 0.0069); Gain of catalytic residue at P354 (P = 0.0073); Loss of glycosylation at S355 (P = 0.0363); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.086)
17:44061234:C:T,P10636,S355F,0.226,Loss of phosphorylation at S355 (P = 0.0069); Loss of relative solvent accessibility (P = 0.0186); Loss of glycosylation at S355 (P = 0.0363); Loss of solvent accessibility (P = 0.045); Gain of catalytic residue at S355 (P = 0.0645)
17:44061236:G:A,P10636,E356K,0.25,Gain of ubiquitination at E356 (P = 0.0094); Gain of catalytic residue at E356 (P = 0.0116); Gain of methylation at E356 (P = 0.0127); Gain of MoRF binding (P = 0.0251); Gain of glycosylation at E356 (P = 0.0279)
17:44061236:G:C,P10636,E356Q,0.108,Loss of solvent accessibility (P = 0.0721); Gain of MoRF binding (P = 0.0782); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S355 (P = 0.1891); Gain of methylation at K357 (P = 0.2202)
17:44061237:A:C,P10636,E356A,0.124,Loss of solvent accessibility (P = 0.0224); Gain of glycosylation at S355 (P = 0.0638); Gain of MoRF binding (P = 0.0701); Loss of methylation at K357 (P = 0.1264); Loss of relative solvent accessibility (P = 0.1807)
17:44061237:A:G,P10636,E356G,0.15,Loss of solvent accessibility (P = 0.0187); Gain of glycosylation at S355 (P = 0.0332); Loss of stability (P = 0.0506); Gain of MoRF binding (P = 0.0718); Gain of catalytic residue at P352 (P = 0.0833)
17:44061237:A:T,P10636,E356V,0.146,Loss of solvent accessibility (P = 0.0146); Gain of MoRF binding (P = 0.0594); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at S355 (P = 0.1002); Gain of methylation at K357 (P = 0.1792)
17:44061238:A:C,P10636,E356D,0.11,Loss of glycosylation at P354 (P = 0.1168); Loss of methylation at K357 (P = 0.1853); Loss of MoRF binding (P = 0.2682); Loss of stability (P = 0.295); Gain of ubiquitination at K357 (P = 0.3291)
17:44061238:A:T,P10636,E356D,0.11,Loss of glycosylation at P354 (P = 0.1168); Loss of methylation at K357 (P = 0.1853); Loss of MoRF binding (P = 0.2682); Loss of stability (P = 0.295); Gain of ubiquitination at K357 (P = 0.3291)
17:44061239:A:C,P10636,K357Q,0.194,Loss of ubiquitination at K357 (P = 0.0043); Loss of methylation at K357 (P = 0.0087); Loss of glycosylation at K357 (P = 0.0326); Gain of helix (P = 0.0893); Loss of MoRF binding (P = 0.1005)
17:44061239:A:G,P10636,K357E,0.197,Loss of ubiquitination at K357 (P = 0.0043); Loss of methylation at K357 (P = 0.0087); Loss of glycosylation at K357 (P = 0.0326); Loss of MoRF binding (P = 0.0726); Gain of helix (P = 0.0893)
17:44061240:A:C,P10636,K357T,0.221,Loss of ubiquitination at K357 (P = 0.0043); Gain of phosphorylation at K357 (P = 0.0056); Loss of methylation at K357 (P = 0.0087); Loss of MoRF binding (P = 0.0913); Loss of glycosylation at P354 (P = 0.1107)
17:44061240:A:G,P10636,K357R,0.186,Loss of ubiquitination at K357 (P = 0.0043); Loss of methylation at K357 (P = 0.0157); Loss of glycosylation at K357 (P = 0.0326); Gain of MoRF binding (P = 0.0986); Loss of solvent accessibility (P = 0.1115)
17:44061240:A:T,P10636,K357M,0.207,Loss of ubiquitination at K357 (P = 0.0043); Loss of methylation at K357 (P = 0.0087); Loss of solvent accessibility (P = 0.0217); Loss of glycosylation at K357 (P = 0.0326); Loss of relative solvent accessibility (P = 0.0981)
17:44061241:G:C,P10636,K357N,0.196,Loss of ubiquitination at K357 (P = 0.0043); Loss of methylation at K357 (P = 0.0087); Loss of glycosylation at K357 (P = 0.0326); Loss of MoRF binding (P = 0.0949); Gain of catalytic residue at K357 (P = 0.1477)
17:44061241:G:T,P10636,K357N,0.196,Loss of ubiquitination at K357 (P = 0.0043); Loss of methylation at K357 (P = 0.0087); Loss of glycosylation at K357 (P = 0.0326); Loss of MoRF binding (P = 0.0949); Gain of catalytic residue at K357 (P = 0.1477)
17:44061242:C:A,P10636,Q358K,0.242,Gain of ubiquitination at Q358 (P = 0.0045); Gain of methylation at Q358 (P = 0.0199); Gain of glycosylation at Q358 (P = 0.0241); Gain of MoRF binding (P = 0.0649); Gain of helix (P = 0.0893)
17:44061242:C:G,P10636,Q358E,0.169,Loss of MoRF binding (P = 0.0784); Loss of methylation at K357 (P = 0.1255); Loss of solvent accessibility (P = 0.1551); Gain of glycosylation at P359 (P = 0.1558); Loss of loop (P = 0.2897)
17:44061243:A:C,P10636,Q358P,0.267,Gain of catalytic residue at Q358 (P = 0.011); Gain of glycosylation at Q358 (P = 0.0446); Loss of MoRF binding (P = 0.0998); Gain of methylation at K357 (P = 0.2712); Loss of solvent accessibility (P = 0.2814)
17:44061243:A:G,P10636,Q358R,0.148,Gain of MoRF binding (P = 0.0542); Gain of glycosylation at P359 (P = 0.126); Gain of methylation at K357 (P = 0.2754); Gain of ubiquitination at K357 (P = 0.3187); Loss of relative solvent accessibility (P = 0.3219)
17:44061243:A:T,P10636,Q358L,0.216,Loss of solvent accessibility (P = 0.0128); Loss of relative solvent accessibility (P = 0.0676); Loss of methylation at K357 (P = 0.0768); Gain of MoRF binding (P = 0.1); Loss of glycosylation at P354 (P = 0.1428)
17:44061244:G:C,P10636,Q358H,0.137,Loss of solvent accessibility (P = 0.0576); Gain of glycosylation at S355 (P = 0.1309); Loss of MoRF binding (P = 0.1489); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at K357 (P = 0.2173)
17:44061244:G:T,P10636,Q358H,0.137,Loss of solvent accessibility (P = 0.0576); Gain of glycosylation at S355 (P = 0.1309); Loss of MoRF binding (P = 0.1489); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at K357 (P = 0.2173)
17:44061245:C:A,P10636,P359T,0.152,Gain of phosphorylation at P359 (P = 0.0101); Gain of MoRF binding (P = 0.059); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.0721); Gain of glycosylation at P359 (P = 0.1194)
17:44061245:C:G,P10636,P359A,0.172,Loss of solvent accessibility (P = 0.0509); Gain of MoRF binding (P = 0.0599); Loss of relative solvent accessibility (P = 0.0676); Loss of methylation at K357 (P = 0.0711); Loss of glycosylation at P359 (P = 0.137)
17:44061245:C:T,P10636,P359S,0.16,Gain of phosphorylation at P359 (P = 0.0119); Gain of glycosylation at P359 (P = 0.0492); Gain of MoRF binding (P = 0.0551); Loss of solvent accessibility (P = 0.0635); Loss of relative solvent accessibility (P = 0.0676)
17:44061246:C:A,P10636,P359H,0.161,Gain of MoRF binding (P = 0.0651); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1301); Loss of glycosylation at P359 (P = 0.137); Gain of methylation at R364 (P = 0.16)
17:44061246:C:G,P10636,P359R,0.196,Gain of MoRF binding (P = 0.0068); Loss of relative solvent accessibility (P = 0.0676); Loss of methylation at K357 (P = 0.0891); Loss of glycosylation at S355 (P = 0.0938); Loss of solvent accessibility (P = 0.2517)
17:44061246:C:T,P10636,P359L,0.196,Gain of stability (P = 0.025); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Gain of MoRF binding (P = 0.0618); Loss of methylation at K357 (P = 0.0629)
17:44061248:G:A,P10636,A360T,0.191,Gain of glycosylation at A360 (P = 0.002); Gain of phosphorylation at A360 (P = 0.0238); Gain of MoRF binding (P = 0.1123); Loss of methylation at R364 (P = 0.1568); Gain of ubiquitination at K357 (P = 0.3291)
17:44061248:G:C,P10636,A360P,0.216,Gain of glycosylation at A360 (P = 0.018); Gain of catalytic residue at P359 (P = 0.0216); Loss of MoRF binding (P = 0.0766); Loss of methylation at R364 (P = 0.1652); Gain of relative solvent accessibility (P = 0.2629)
17:44061248:G:T,P10636,A360S,0.184,Gain of phosphorylation at A360 (P = 0.018); Gain of glycosylation at A360 (P = 0.055); Gain of MoRF binding (P = 0.0972); Loss of methylation at R364 (P = 0.1402); Gain of relative solvent accessibility (P = 0.2629)
17:44061249:C:A,P10636,A360D,0.239,Gain of solvent accessibility (P = 0.007); Gain of relative solvent accessibility (P = 0.0098); Loss of MoRF binding (P = 0.0788); Loss of methylation at R364 (P = 0.0877); Loss of glycosylation at S355 (P = 0.1827)
17:44061249:C:G,P10636,A360G,0.165,Gain of MoRF binding (P = 0.139); Loss of glycosylation at S355 (P = 0.1414); Gain of methylation at R364 (P = 0.1704); Gain of ubiquitination at K357 (P = 0.3325); Loss of stability (P = 0.4342)
17:44061249:C:T,P10636,A360V,0.196,Gain of MoRF binding (P = 0.1187); Gain of catalytic residue at A360 (P = 0.1381); Loss of methylation at R364 (P = 0.1505); Loss of glycosylation at S355 (P = 0.1868); Gain of ubiquitination at K357 (P = 0.3291)
17:44061251:G:A,P10636,A361T,0.215,Gain of phosphorylation at A361 (P = 0.005); Gain of glycosylation at A361 (P = 0.0426); Gain of methylation at K366 (P = 0.0807); Gain of ubiquitination at K366 (P = 0.1204); Gain of MoRF binding (P = 0.1379)
17:44061251:G:C,P10636,A361P,0.24,Gain of glycosylation at A361 (P = 0.0281); Loss of MoRF binding (P = 0.0693); Gain of catalytic residue at A361 (P = 0.0714); Gain of methylation at K366 (P = 0.086); Loss of ubiquitination at K366 (P = 0.1381)
17:44061251:G:T,P10636,A361S,0.235,Gain of phosphorylation at A361 (P = 0.0054); Gain of glycosylation at A361 (P = 0.0163); Gain of methylation at K366 (P = 0.1123); Gain of MoRF binding (P = 0.1255); Loss of ubiquitination at K366 (P = 0.1381)
17:44061252:C:A,P10636,A361D,0.232,Loss of MoRF binding (P = 0.066); Loss of methylation at R364 (P = 0.0768); Gain of ubiquitination at K366 (P = 0.0797); Gain of solvent accessibility (P = 0.1154); Loss of glycosylation at P363 (P = 0.1858)
17:44061252:C:G,P10636,A361G,0.167,Gain of methylation at K366 (P = 0.128); Loss of ubiquitination at K366 (P = 0.1381); Loss of MoRF binding (P = 0.1403); Gain of glycosylation at K357 (P = 0.2047); Loss of stability (P = 0.2641)
17:44061252:C:T,P10636,A361V,0.184,Loss of relative solvent accessibility (P = 0.0404); Gain of MoRF binding (P = 0.0984); Loss of methylation at R364 (P = 0.1091); Loss of solvent accessibility (P = 0.1301); Loss of ubiquitination at K366 (P = 0.1381)
17:44061254:G:A,P10636,A362T,0.162,Gain of phosphorylation at A362 (P = 0.0034); Gain of glycosylation at A362 (P = 0.0128); Gain of methylation at K366 (P = 0.1122); Gain of ubiquitination at K366 (P = 0.1204); Gain of MoRF binding (P = 0.1319)
17:44061254:G:C,P10636,A362P,0.302,Gain of glycosylation at A362 (P = 0.0291); Loss of stability (P = 0.0316); Gain of catalytic residue at A362 (P = 0.0435); Loss of MoRF binding (P = 0.0672); Gain of methylation at K366 (P = 0.1203)
17:44061254:G:T,P10636,A362S,0.163,Gain of phosphorylation at A362 (P = 0.0051); Gain of glycosylation at A362 (P = 0.0331); Gain of ubiquitination at K366 (P = 0.1204); Gain of MoRF binding (P = 0.1212); Loss of methylation at R364 (P = 0.1255)
17:44061255:C:A,P10636,A362D,0.237,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.026); Loss of MoRF binding (P = 0.0666); Gain of ubiquitination at K366 (P = 0.0719); Loss of methylation at R364 (P = 0.0792)
17:44061255:C:G,P10636,A362G,0.198,Gain of relative solvent accessibility (P = 0.0249); Loss of stability (P = 0.0386); Gain of ubiquitination at K366 (P = 0.1204); Gain of catalytic residue at A362 (P = 0.1239); Gain of methylation at R364 (P = 0.124)
17:44061255:C:T,P10636,A362V,0.137,Gain of methylation at K366 (P = 0.0889); Gain of MoRF binding (P = 0.1034); Loss of ubiquitination at K366 (P = 0.1381); Loss of glycosylation at K357 (P = 0.221); Loss of stability (P = 0.4899)
17:44061257:C:A,P10636,P363T,0.143,Gain of phosphorylation at P363 (P = 0.0172); Gain of MoRF binding (P = 0.0505); Loss of methylation at K366 (P = 0.1153); Loss of ubiquitination at K366 (P = 0.1216); Gain of glycosylation at P363 (P = 0.3195)
17:44061257:C:G,P10636,P363A,0.207,Gain of MoRF binding (P = 0.0539); Loss of methylation at K366 (P = 0.0659); Loss of glycosylation at P363 (P = 0.098); Loss of ubiquitination at K366 (P = 0.1216); Loss of stability (P = 0.1743)
17:44061257:C:T,P10636,P363S,0.174,Gain of phosphorylation at P363 (P = 0.0081); Gain of MoRF binding (P = 0.0477); Loss of methylation at K366 (P = 0.0696); Loss of ubiquitination at K366 (P = 0.1216); Loss of stability (P = 0.286)
17:44061258:C:A,P10636,P363Q,0.171,Gain of MoRF binding (P = 0.0451); Loss of methylation at R364 (P = 0.0812); Loss of glycosylation at P363 (P = 0.098); Loss of ubiquitination at K366 (P = 0.1216); Gain of solvent accessibility (P = 0.3418)
17:44061258:C:G,P10636,P363R,0.216,Gain of MoRF binding (P = 0.0066); Gain of methylation at P363 (P = 0.0391); Loss of ubiquitination at K366 (P = 0.0672); Loss of glycosylation at P363 (P = 0.098); Gain of solvent accessibility (P = 0.2097)
17:44061258:C:T,P10636,P363L,0.201,Loss of methylation at K366 (P = 0.0548); Gain of MoRF binding (P = 0.0551); Loss of glycosylation at P363 (P = 0.098); Loss of ubiquitination at K366 (P = 0.1062); Gain of catalytic residue at K366 (P = 0.4592)
17:44061260:C:G,P10636,R364G,0.212,Loss of methylation at R364 (P = 0.0297); Loss of solvent accessibility (P = 0.0329); Loss of MoRF binding (P = 0.045); Gain of glycosylation at K366 (P = 0.0836); Loss of ubiquitination at K366 (P = 0.1216)
17:44061260:C:T,P10636,R364W,0.253,Loss of solvent accessibility (P = 0.0087); Gain of catalytic residue at P367 (P = 0.0259); Loss of methylation at R364 (P = 0.0297); Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K366 (P = 0.1062)
17:44061261:G:A,P10636,R364Q,0.229,Loss of methylation at R364 (P = 0.0297); Loss of MoRF binding (P = 0.0491); Gain of ubiquitination at K366 (P = 0.0719); Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at K366 (P = 0.2002)
17:44061261:G:C,P10636,R364P,0.272,Loss of MoRF binding (P = 0.0107); Gain of glycosylation at R364 (P = 0.0113); Gain of catalytic residue at P363 (P = 0.018); Loss of methylation at R364 (P = 0.0297); Gain of ubiquitination at K366 (P = 0.1204)
17:44061261:G:T,P10636,R364L,0.225,Loss of solvent accessibility (P = 0.0052); Loss of methylation at R364 (P = 0.0297); Loss of MoRF binding (P = 0.0507); Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K366 (P = 0.1216)
17:44061263:G:A,P10636,G365R,0.188,Gain of solvent accessibility (P = 0.019); Gain of glycosylation at P363 (P = 0.0384); Loss of methylation at R364 (P = 0.0513); Gain of MoRF binding (P = 0.0522); Loss of ubiquitination at K366 (P = 0.0615)
17:44061263:G:C,P10636,G365R,0.188,Gain of solvent accessibility (P = 0.019); Gain of glycosylation at P363 (P = 0.0384); Loss of methylation at R364 (P = 0.0513); Gain of MoRF binding (P = 0.0522); Loss of ubiquitination at K366 (P = 0.0615)
17:44061263:G:T,P10636,G365W,0.191,Loss of methylation at R364 (P = 0.0388); Loss of relative solvent accessibility (P = 0.0404); Gain of MoRF binding (P = 0.043); Gain of glycosylation at P363 (P = 0.0745); Loss of ubiquitination at K366 (P = 0.0811)
17:44061264:G:A,P10636,G365E,0.193,Loss of MoRF binding (P = 0.0432); Loss of methylation at R364 (P = 0.0491); Gain of solvent accessibility (P = 0.0789); Gain of glycosylation at P363 (P = 0.086); Loss of ubiquitination at K366 (P = 0.093)
17:44061264:G:C,P10636,G365A,0.122,Gain of glycosylation at P363 (P = 0.0776); Loss of methylation at R364 (P = 0.0907); Gain of ubiquitination at K366 (P = 0.1204); Gain of MoRF binding (P = 0.1351); Loss of stability (P = 0.3259)
17:44061264:G:T,P10636,G365V,0.172,Loss of relative solvent accessibility (P = 0.0186); Gain of methylation at K366 (P = 0.0474); Loss of ubiquitination at K366 (P = 0.0811); Gain of MoRF binding (P = 0.0956); Loss of solvent accessibility (P = 0.1744)
17:44061266:A:C,P10636,K366Q,0.188,Loss of methylation at K366 (P = 0.0143); Loss of ubiquitination at K366 (P = 0.021); Loss of MoRF binding (P = 0.0552); Gain of glycosylation at S369 (P = 0.0658); Loss of catalytic residue at K366 (P = 0.2269)
17:44061266:A:G,P10636,K366E,0.235,Loss of MoRF binding (P = 0.0071); Loss of methylation at K366 (P = 0.0143); Loss of ubiquitination at K366 (P = 0.021); Loss of glycosylation at K366 (P = 0.0742); Loss of catalytic residue at R370 (P = 0.4974)
17:44061267:A:C,P10636,K366T,0.248,Gain of phosphorylation at K366 (P = 0.0101); Loss of methylation at K366 (P = 0.0143); Loss of ubiquitination at K366 (P = 0.021); Loss of MoRF binding (P = 0.0457); Gain of glycosylation at S369 (P = 0.0685)
17:44061267:A:G,P10636,K366R,0.211,Loss of ubiquitination at K366 (P = 0.021); Loss of methylation at K366 (P = 0.0455); Loss of glycosylation at K366 (P = 0.0742); Gain of MoRF binding (P = 0.0867); Gain of solvent accessibility (P = 0.1583)
17:44061267:A:T,P10636,K366M,0.226,Loss of methylation at K366 (P = 0.0143); Loss of ubiquitination at K366 (P = 0.021); Loss of MoRF binding (P = 0.0606); Loss of glycosylation at K366 (P = 0.0742); Loss of catalytic residue at K366 (P = 0.2933)
17:44061268:G:C,P10636,K366N,0.227,Loss of methylation at K366 (P = 0.0143); Loss of ubiquitination at K366 (P = 0.021); Loss of MoRF binding (P = 0.0501); Gain of glycosylation at S369 (P = 0.0627); Gain of catalytic residue at K366 (P = 0.2821)
17:44061268:G:T,P10636,K366N,0.227,Loss of methylation at K366 (P = 0.0143); Loss of ubiquitination at K366 (P = 0.021); Loss of MoRF binding (P = 0.0501); Gain of glycosylation at S369 (P = 0.0627); Gain of catalytic residue at K366 (P = 0.2821)
17:44061269:C:A,P10636,P367T,0.21,Gain of phosphorylation at P367 (P = 0.0057); Gain of MoRF binding (P = 0.0585); Loss of ubiquitination at K366 (P = 0.1216); Gain of methylation at R364 (P = 0.1355); Loss of glycosylation at S369 (P = 0.213)
17:44061269:C:G,P10636,P367A,0.212,Gain of MoRF binding (P = 0.0576); Gain of methylation at R364 (P = 0.0645); Loss of ubiquitination at K366 (P = 0.1062); Loss of glycosylation at S369 (P = 0.2576); Loss of catalytic residue at K366 (P = 0.3666)
17:44061269:C:T,P10636,P367S,0.235,Gain of phosphorylation at P367 (P = 0.002); Gain of MoRF binding (P = 0.0565); Loss of methylation at K366 (P = 0.0926); Loss of ubiquitination at K366 (P = 0.1216); Loss of glycosylation at S369 (P = 0.2179)
17:44061270:C:A,P10636,P367H,0.214,Gain of MoRF binding (P = 0.0641); Gain of methylation at R364 (P = 0.1011); Loss of ubiquitination at K366 (P = 0.1381); Loss of glycosylation at S369 (P = 0.2032); Gain of solvent accessibility (P = 0.204)
17:44061270:C:G,P10636,P367R,0.255,Gain of MoRF binding (P = 0.0153); Gain of solvent accessibility (P = 0.0411); Gain of methylation at P367 (P = 0.0573); Loss of ubiquitination at K366 (P = 0.0615); Loss of glycosylation at S369 (P = 0.1431)
17:44061270:C:T,P10636,P367L,0.22,Gain of MoRF binding (P = 0.062); Loss of methylation at K366 (P = 0.0804); Loss of ubiquitination at K366 (P = 0.093); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S369 (P = 0.197)
17:44061272:G:A,P10636,V368I,0.132,Loss of methylation at R364 (P = 0.1197); Gain of ubiquitination at K366 (P = 0.1204); Loss of MoRF binding (P = 0.1294); Gain of glycosylation at K366 (P = 0.1934); Gain of stability (P = 0.2833)
17:44061272:G:C,P10636,V368L,0.125,Loss of methylation at K366 (P = 0.0747); Loss of MoRF binding (P = 0.1104); Loss of ubiquitination at K366 (P = 0.1216); Loss of glycosylation at S369 (P = 0.185); Gain of solvent accessibility (P = 0.5485)
17:44061272:G:T,P10636,V368F,0.123,Loss of MoRF binding (P = 0.0989); Loss of ubiquitination at K366 (P = 0.1216); Loss of methylation at K366 (P = 0.1294); Gain of glycosylation at K366 (P = 0.2558); Gain of solvent accessibility (P = 0.4304)
17:44061273:T:A,P10636,V368D,0.254,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0314); Loss of methylation at K366 (P = 0.0452); Loss of MoRF binding (P = 0.0514); Loss of ubiquitination at K366 (P = 0.1216)
17:44061273:T:C,P10636,V368A,0.125,Loss of methylation at K366 (P = 0.0781); Loss of MoRF binding (P = 0.1273); Loss of ubiquitination at K366 (P = 0.1381); Gain of glycosylation at P367 (P = 0.1505); Gain of relative solvent accessibility (P = 0.2629)
17:44061273:T:G,P10636,V368G,0.158,Loss of stability (P = 0.0667); Loss of methylation at K366 (P = 0.0853); Loss of MoRF binding (P = 0.1112); Gain of ubiquitination at K366 (P = 0.1204); Gain of glycosylation at P367 (P = 0.1298)
17:44061275:A:C,P10636,S369R,0.173,Loss of phosphorylation at S369 (P = 0.0103); Gain of MoRF binding (P = 0.0534); Gain of glycosylation at K366 (P = 0.0644); Loss of methylation at R364 (P = 0.0681); Loss of ubiquitination at K366 (P = 0.1062)
17:44061275:A:G,P10636,S369G,0.159,Loss of phosphorylation at S369 (P = 0.0103); Loss of glycosylation at S369 (P = 0.0716); Loss of methylation at K366 (P = 0.1082); Loss of MoRF binding (P = 0.1324); Loss of ubiquitination at K366 (P = 0.1381)
17:44061275:A:T,P10636,S369C,0.222,Loss of phosphorylation at S369 (P = 0.0103); Loss of glycosylation at S369 (P = 0.0716); Loss of MoRF binding (P = 0.0833); Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K366 (P = 0.1062)
17:44061276:G:A,P10636,S369N,0.157,Loss of phosphorylation at S369 (P = 0.0103); Loss of glycosylation at S369 (P = 0.0716); Gain of ubiquitination at K366 (P = 0.1047); Loss of MoRF binding (P = 0.1225); Loss of methylation at R364 (P = 0.1371)
17:44061276:G:C,P10636,S369T,0.164,Gain of glycosylation at S369 (P = 0.0447); Gain of ubiquitination at K366 (P = 0.1204); Loss of MoRF binding (P = 0.1317); Gain of methylation at K366 (P = 0.1467); Gain of solvent accessibility (P = 0.4656)
17:44061276:G:T,P10636,S369I,0.267,Loss of phosphorylation at S369 (P = 0.0103); Gain of catalytic residue at L374 (P = 0.0441); Loss of glycosylation at S369 (P = 0.0716); Loss of ubiquitination at K366 (P = 0.093); Loss of relative solvent accessibility (P = 0.0981)
17:44061277:C:A,P10636,S369R,0.173,Loss of phosphorylation at S369 (P = 0.0103); Gain of MoRF binding (P = 0.0534); Gain of glycosylation at K366 (P = 0.0644); Loss of methylation at R364 (P = 0.0681); Loss of ubiquitination at K366 (P = 0.1062)
17:44061277:C:G,P10636,S369R,0.173,Loss of phosphorylation at S369 (P = 0.0103); Gain of MoRF binding (P = 0.0534); Gain of glycosylation at K366 (P = 0.0644); Loss of methylation at R364 (P = 0.0681); Loss of ubiquitination at K366 (P = 0.1062)
17:44061278:C:G,P10636,R370G,0.275,Loss of solvent accessibility (P = 0.0159); Loss of MoRF binding (P = 0.0239); Gain of catalytic residue at V371 (P = 0.0243); Gain of glycosylation at S369 (P = 0.0409); Gain of methylation at K375 (P = 0.0833)
17:44061279:G:A,P10636,R370Q,0.271,Loss of MoRF binding (P = 0.0393); Gain of methylation at K366 (P = 0.0916); Loss of catalytic residue at R370 (P = 0.0977); Loss of ubiquitination at K366 (P = 0.1216); Gain of relative solvent accessibility (P = 0.1571)
17:44061279:G:C,P10636,R370P,0.296,Loss of MoRF binding (P = 0.0039); Gain of methylation at K375 (P = 0.0627); Loss of ubiquitination at K366 (P = 0.1062); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at R370 (P = 0.1706)
17:44061279:G:T,P10636,R370L,0.308,Loss of MoRF binding (P = 0.0176); Loss of ubiquitination at K366 (P = 0.1381); Gain of methylation at K375 (P = 0.1477); Loss of solvent accessibility (P = 0.1579); Loss of glycosylation at S369 (P = 0.2573)
17:44061281:G:A,P10636,V371I,0.16,Gain of methylation at K375 (P = 0.0992); Gain of ubiquitination at K366 (P = 0.1204); Loss of MoRF binding (P = 0.2041); Gain of glycosylation at K366 (P = 0.2309); Gain of catalytic residue at V371 (P = 0.4609)
17:44061281:G:C,P10636,V371L,0.14,Loss of methylation at K366 (P = 0.085); Gain of ubiquitination at K366 (P = 0.1204); Loss of MoRF binding (P = 0.1721); Gain of glycosylation at K366 (P = 0.2521); Gain of phosphorylation at S369 (P = 0.6238)
17:44061281:G:T,P10636,V371F,0.142,Loss of methylation at K366 (P = 0.1346); Loss of ubiquitination at K366 (P = 0.1381); Loss of MoRF binding (P = 0.1449); Gain of glycosylation at K366 (P = 0.2617); Loss of stability (P = 0.3526)
17:44061282:T:A,P10636,V371D,0.198,Loss of MoRF binding (P = 0.0659); Gain of methylation at K366 (P = 0.0877); Gain of relative solvent accessibility (P = 0.1066); Loss of ubiquitination at K366 (P = 0.1381); Loss of stability (P = 0.1521)
17:44061282:T:C,P10636,V371A,0.165,Loss of stability (P = 0.0818); Loss of methylation at K375 (P = 0.1206); Loss of ubiquitination at K366 (P = 0.1381); Gain of MoRF binding (P = 0.2189); Gain of glycosylation at K366 (P = 0.2339)
17:44061282:T:G,P10636,V371G,0.231,Loss of stability (P = 0.0034); Gain of catalytic residue at V371 (P = 0.0718); Gain of ubiquitination at K366 (P = 0.1204); Loss of methylation at K375 (P = 0.149); Gain of glycosylation at K366 (P = 0.1918)
17:44061284:C:A,P10636,P372T,0.244,Gain of phosphorylation at P372 (P = 0.0226); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1235); Loss of methylation at K375 (P = 0.1244); Gain of ubiquitination at K375 (P = 0.1797)
17:44061284:C:G,P10636,P372A,0.222,Loss of methylation at K375 (P = 0.1039); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of ubiquitination at K375 (P = 0.1881); Gain of MoRF binding (P = 0.2258)
17:44061284:C:T,P10636,P372S,0.24,Gain of phosphorylation at P372 (P = 0.0026); Loss of methylation at K375 (P = 0.0831); Loss of solvent accessibility (P = 0.1744); Gain of ubiquitination at K375 (P = 0.1797); Loss of relative solvent accessibility (P = 0.1807)
17:44061285:C:A,P10636,P372H,0.25,Loss of methylation at K375 (P = 0.1458); Gain of catalytic residue at L374 (P = 0.163); Gain of ubiquitination at K375 (P = 0.1797); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S369 (P = 0.2219)
17:44061285:C:G,P10636,P372R,0.262,Loss of methylation at K375 (P = 0.1232); Loss of glycosylation at S369 (P = 0.1306); Gain of MoRF binding (P = 0.1687); Loss of relative solvent accessibility (P = 0.1807); Loss of ubiquitination at K375 (P = 0.1881)
17:44061285:C:T,P10636,P372L,0.309,Gain of stability (P = 0.0417); Loss of methylation at K375 (P = 0.0891); Gain of ubiquitination at K375 (P = 0.1278); Loss of glycosylation at S369 (P = 0.1489); Loss of relative solvent accessibility (P = 0.1807)
17:44061287:C:A,P10636,Q373K,0.199,Gain of ubiquitination at Q373 (P = 0.0289); Gain of glycosylation at P372 (P = 0.0656); Loss of methylation at K375 (P = 0.1276); Gain of catalytic residue at Q373 (P = 0.2859); Gain of MoRF binding (P = 0.2921)
17:44061287:C:G,P10636,Q373E,0.163,Loss of methylation at K375 (P = 0.0981); Gain of ubiquitination at K375 (P = 0.1278); Loss of MoRF binding (P = 0.1598); Gain of glycosylation at S369 (P = 0.2317); Loss of catalytic residue at R370 (P = 0.5658)
17:44061288:A:G,P10636,Q373R,0.162,Gain of methylation at Q373 (P = 0.0694); Gain of ubiquitination at K375 (P = 0.1504); Gain of glycosylation at P372 (P = 0.1729); Gain of MoRF binding (P = 0.2728); Loss of relative solvent accessibility (P = 0.5898)
17:44061288:A:T,P10636,Q373L,0.218,Loss of solvent accessibility (P = 0.0468); Gain of stability (P = 0.0697); Loss of methylation at K375 (P = 0.0947); Loss of ubiquitination at K375 (P = 0.1268); Gain of glycosylation at S369 (P = 0.1488)
17:44061289:A:C,P10636,Q373H,0.166,Gain of glycosylation at S369 (P = 0.1107); Loss of methylation at K375 (P = 0.1741); Loss of ubiquitination at K375 (P = 0.2053); Loss of MoRF binding (P = 0.3066); Loss of phosphorylation at S369 (P = 0.6153)
17:44061289:A:T,P10636,Q373H,0.166,Gain of glycosylation at S369 (P = 0.1107); Loss of methylation at K375 (P = 0.1741); Loss of ubiquitination at K375 (P = 0.2053); Loss of MoRF binding (P = 0.3066); Loss of phosphorylation at S369 (P = 0.6153)
17:44061290:C:A,P10636,L374I,0.174,Gain of methylation at K375 (P = 0.0449); Loss of ubiquitination at K375 (P = 0.2053); Gain of catalytic residue at R377 (P = 0.2271); Loss of glycosylation at S369 (P = 0.3201); Gain of MoRF binding (P = 0.4403)
17:44061290:C:G,P10636,L374V,0.19,Gain of methylation at K375 (P = 0.0327); Gain of catalytic residue at L374 (P = 0.1713); Loss of ubiquitination at K375 (P = 0.2053); Gain of glycosylation at S369 (P = 0.3104); Gain of MoRF binding (P = 0.4324)
17:44061290:C:T,P10636,L374F,0.187,Gain of methylation at K375 (P = 0.0278); Loss of ubiquitination at K375 (P = 0.2053); Gain of catalytic residue at L374 (P = 0.2229); Loss of glycosylation at S369 (P = 0.3128); Loss of MoRF binding (P = 0.4311)
17:44061291:T:A,P10636,L374H,0.173,Gain of methylation at K375 (P = 0.0564); Loss of stability (P = 0.1059); Gain of glycosylation at S369 (P = 0.1642); Loss of ubiquitination at K375 (P = 0.2053); Gain of MoRF binding (P = 0.4372)
17:44061291:T:C,P10636,L374P,0.241,Gain of relative solvent accessibility (P = 0.0249); Gain of glycosylation at L374 (P = 0.0362); Gain of methylation at K375 (P = 0.0626); Gain of solvent accessibility (P = 0.0766); Loss of stability (P = 0.0937)
17:44061291:T:G,P10636,L374R,0.187,Gain of methylation at K375 (P = 0.0425); Loss of stability (P = 0.1531); Gain of solvent accessibility (P = 0.1683); Loss of ubiquitination at K375 (P = 0.1881); Gain of relative solvent accessibility (P = 0.2629)
17:44061293:A:C,P10636,K375Q,0.209,Loss of methylation at K375 (P = 0.0303); Loss of ubiquitination at K375 (P = 0.0309); Loss of solvent accessibility (P = 0.1434); Loss of relative solvent accessibility (P = 0.3219); Loss of MoRF binding (P = 0.4115)
17:44061293:A:G,P10636,K375E,0.26,Loss of methylation at K375 (P = 0.0303); Loss of ubiquitination at K375 (P = 0.0309); Loss of solvent accessibility (P = 0.0544); Loss of relative solvent accessibility (P = 0.1807); Loss of MoRF binding (P = 0.2002)
17:44061294:A:C,P10636,K375T,0.237,Loss of methylation at K375 (P = 0.0303); Loss of ubiquitination at K375 (P = 0.0309); Gain of phosphorylation at K375 (P = 0.0331); Loss of solvent accessibility (P = 0.2814); Loss of MoRF binding (P = 0.4095)
17:44061294:A:G,P10636,K375R,0.255,Loss of ubiquitination at K375 (P = 0.0309); Loss of methylation at K375 (P = 0.0667); Loss of solvent accessibility (P = 0.2953); Loss of relative solvent accessibility (P = 0.3219); Gain of catalytic residue at K375 (P = 0.3835)
17:44061294:A:T,P10636,K375I,0.353,Gain of stability (P = 0.0227); Loss of methylation at K375 (P = 0.0303); Loss of ubiquitination at K375 (P = 0.0309); Loss of solvent accessibility (P = 0.0431); Loss of relative solvent accessibility (P = 0.1807)
17:44061295:A:C,P10636,K375N,0.218,Loss of methylation at K375 (P = 0.0303); Loss of ubiquitination at K375 (P = 0.0309); Loss of solvent accessibility (P = 0.3854); Loss of MoRF binding (P = 0.394); Loss of phosphorylation at S380 (P = 0.5793)
17:44061295:A:T,P10636,K375N,0.218,Loss of methylation at K375 (P = 0.0303); Loss of ubiquitination at K375 (P = 0.0309); Loss of solvent accessibility (P = 0.3854); Loss of MoRF binding (P = 0.394); Loss of phosphorylation at S380 (P = 0.5793)
17:44061296:G:A,P10636,A376T,0.205,Gain of phosphorylation at A376 (P = 0.0339); Gain of methylation at K375 (P = 0.0586); Gain of glycosylation at A376 (P = 0.161); Gain of ubiquitination at K375 (P = 0.1797); Loss of stability (P = 0.4573)
17:44061296:G:C,P10636,A376P,0.21,Gain of methylation at K375 (P = 0.0587); Gain of ubiquitination at K375 (P = 0.1278); Gain of solvent accessibility (P = 0.2689); Loss of stability (P = 0.3063); Gain of catalytic residue at L374 (P = 0.3584)
17:44061296:G:T,P10636,A376S,0.222,Gain of phosphorylation at A376 (P = 0.0093); Gain of methylation at K375 (P = 0.0854); Gain of glycosylation at A376 (P = 0.1368); Gain of ubiquitination at K375 (P = 0.1797); Gain of solvent accessibility (P = 0.3089)
17:44064406:C:A,P10636,A376D,0.203,Gain of solvent accessibility (P = 0.1154); Gain of ubiquitination at K375 (P = 0.1278); Gain of methylation at K375 (P = 0.169); Loss of MoRF binding (P = 0.3132); Gain of glycosylation at K381 (P = 0.4555)
17:44064406:C:G,P10636,A376G,0.207,Gain of catalytic residue at P372 (P = 0.1142); Gain of methylation at K375 (P = 0.1412); Gain of ubiquitination at K375 (P = 0.1504); Loss of stability (P = 0.2254); Gain of glycosylation at K375 (P = 0.4956)
17:44064406:C:T,P10636,A376V,0.299,Loss of relative solvent accessibility (P = 0.0186); Gain of methylation at K375 (P = 0.0377); Loss of solvent accessibility (P = 0.0807); Gain of ubiquitination at K375 (P = 0.1278); Gain of MoRF binding (P = 0.5546)
17:44064408:C:A,P10636,R377S,0.307,Loss of solvent accessibility (P = 0.0094); Gain of phosphorylation at R377 (P = 0.0201); Loss of stability (P = 0.0453); Gain of methylation at K375 (P = 0.0546); Loss of MoRF binding (P = 0.0778)
17:44064408:C:G,P10636,R377G,0.335,Loss of solvent accessibility (P = 3e-04); Loss of stability (P = 0.0072); Gain of methylation at K375 (P = 0.0499); Loss of MoRF binding (P = 0.0626); Loss of relative solvent accessibility (P = 0.0676)
17:44064408:C:T,P10636,R377C,0.38,Loss of solvent accessibility (P = 8e-04); Loss of MoRF binding (P = 0.0235); Gain of methylation at K375 (P = 0.0398); Loss of relative solvent accessibility (P = 0.0676); Gain of catalytic residue at V379 (P = 0.0817)
17:44064409:G:C,P10636,R377P,0.316,Loss of solvent accessibility (P = 0.0111); Loss of MoRF binding (P = 0.0144); Gain of methylation at K375 (P = 0.0394); Loss of stability (P = 0.067); Gain of catalytic residue at V379 (P = 0.1029)
17:44064409:G:T,P10636,R377L,0.318,Loss of solvent accessibility (P = 0.0013); Loss of MoRF binding (P = 0.0385); Gain of methylation at K375 (P = 0.0529); Loss of relative solvent accessibility (P = 0.0676); Gain of catalytic residue at V379 (P = 0.0932)
17:44064411:A:C,P10636,M378L,0.186,Loss of methylation at K383 (P = 0.0863); Loss of ubiquitination at K383 (P = 0.1741); Gain of glycosylation at S382 (P = 0.2948); Loss of catalytic residue at M378 (P = 0.3255); Loss of MoRF binding (P = 0.3909)
17:44064411:A:G,P10636,M378V,0.179,Loss of methylation at K375 (P = 0.1506); Loss of ubiquitination at K383 (P = 0.1741); Gain of glycosylation at S382 (P = 0.2393); Loss of catalytic residue at M378 (P = 0.2711); Loss of stability (P = 0.4121)
17:44064411:A:T,P10636,M378L,0.186,Loss of methylation at K383 (P = 0.0863); Loss of ubiquitination at K383 (P = 0.1741); Gain of glycosylation at S382 (P = 0.2948); Loss of catalytic residue at M378 (P = 0.3255); Loss of MoRF binding (P = 0.3909)
17:44064412:T:A,P10636,M378K,0.273,Gain of solvent accessibility (P = 0.0137); Loss of ubiquitination at K381 (P = 0.0224); Gain of methylation at M378 (P = 0.0236); Gain of relative solvent accessibility (P = 0.0249); Loss of stability (P = 0.0791)
17:44064412:T:C,P10636,M378T,0.187,Gain of phosphorylation at M378 (P = 0.026); Gain of methylation at K383 (P = 0.0905); Gain of relative solvent accessibility (P = 0.1066); Gain of ubiquitination at K375 (P = 0.1504); Gain of glycosylation at S382 (P = 0.1561)
17:44064412:T:G,P10636,M378R,0.217,Loss of ubiquitination at K381 (P = 0.0272); Gain of methylation at K375 (P = 0.05); Gain of solvent accessibility (P = 0.194); Gain of glycosylation at K375 (P = 0.2086); Gain of relative solvent accessibility (P = 0.2629)
17:44064413:G:A,P10636,M378I,0.23,Gain of methylation at K383 (P = 0.1128); Loss of ubiquitination at K383 (P = 0.1576); Gain of catalytic residue at V379 (P = 0.1837); Loss of glycosylation at S382 (P = 0.3879); Loss of MoRF binding (P = 0.4252)
17:44064413:G:C,P10636,M378I,0.23,Gain of methylation at K383 (P = 0.1128); Loss of ubiquitination at K383 (P = 0.1576); Gain of catalytic residue at V379 (P = 0.1837); Loss of glycosylation at S382 (P = 0.3879); Loss of MoRF binding (P = 0.4252)
17:44064413:G:T,P10636,M378I,0.23,Gain of methylation at K383 (P = 0.1128); Loss of ubiquitination at K383 (P = 0.1576); Gain of catalytic residue at V379 (P = 0.1837); Loss of glycosylation at S382 (P = 0.3879); Loss of MoRF binding (P = 0.4252)
17:44064414:G:A,P10636,V379I,0.13,Gain of methylation at K383 (P = 0.09); Loss of ubiquitination at K381 (P = 0.1537); Gain of glycosylation at S382 (P = 0.2607); Loss of MoRF binding (P = 0.4167); Gain of catalytic residue at L374 (P = 0.4756)
17:44064414:G:C,P10636,V379L,0.168,Loss of methylation at K383 (P = 0.0905); Gain of ubiquitination at K375 (P = 0.1278); Loss of glycosylation at S382 (P = 0.3276); Loss of catalytic residue at V379 (P = 0.3743); Loss of MoRF binding (P = 0.3897)
17:44064414:G:T,P10636,V379F,0.142,Loss of ubiquitination at K383 (P = 0.1403); Loss of methylation at K375 (P = 0.1624); Gain of glycosylation at S382 (P = 0.3196); Loss of MoRF binding (P = 0.3606); Loss of stability (P = 0.4221)
17:44064415:T:A,P10636,V379D,0.266,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0314); Loss of stability (P = 0.0332); Gain of ubiquitination at K383 (P = 0.0369); Loss of methylation at K383 (P = 0.0998)
17:44064415:T:C,P10636,V379A,0.187,Loss of stability (P = 0.0604); Gain of relative solvent accessibility (P = 0.1066); Loss of methylation at K383 (P = 0.1103); Gain of ubiquitination at K375 (P = 0.1504); Gain of glycosylation at S382 (P = 0.3478)
17:44064415:T:G,P10636,V379G,0.244,Loss of stability (P = 0.002); Gain of relative solvent accessibility (P = 0.1066); Gain of ubiquitination at K375 (P = 0.1278); Loss of methylation at K383 (P = 0.1366); Gain of catalytic residue at M378 (P = 0.1458)
17:44064417:A:C,P10636,S380R,0.261,Loss of phosphorylation at S380 (P = 0.0061); Loss of ubiquitination at K381 (P = 0.0248); Gain of solvent accessibility (P = 0.0837); Gain of methylation at K383 (P = 0.1111); Loss of glycosylation at S382 (P = 0.2875)
17:44064417:A:G,P10636,S380G,0.199,Loss of phosphorylation at S380 (P = 0.0061); Loss of stability (P = 0.0866); Loss of methylation at K375 (P = 0.0901); Loss of ubiquitination at K383 (P = 0.1741); Loss of solvent accessibility (P = 0.3103)
17:44064417:A:T,P10636,S380C,0.241,Loss of phosphorylation at S380 (P = 0.0061); Gain of methylation at K381 (P = 0.0131); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Gain of catalytic residue at M378 (P = 0.0592)
17:44064418:G:C,P10636,S380T,0.182,Gain of methylation at K383 (P = 0.0835); Loss of phosphorylation at S380 (P = 0.0983); Loss of ubiquitination at K383 (P = 0.1741); Loss of catalytic residue at K383 (P = 0.3432); Loss of MoRF binding (P = 0.403)
17:44064418:G:T,P10636,S380I,0.254,Loss of phosphorylation at S380 (P = 0.0061); Gain of methylation at K383 (P = 0.0442); Loss of ubiquitination at K381 (P = 0.1264); Gain of solvent accessibility (P = 0.204); Loss of glycosylation at S382 (P = 0.3238)
17:44064419:T:A,P10636,S380R,0.261,Loss of phosphorylation at S380 (P = 0.0061); Loss of ubiquitination at K381 (P = 0.0248); Gain of solvent accessibility (P = 0.0837); Gain of methylation at K383 (P = 0.1111); Loss of glycosylation at S382 (P = 0.2875)
17:44064419:T:G,P10636,S380R,0.261,Loss of phosphorylation at S380 (P = 0.0061); Loss of ubiquitination at K381 (P = 0.0248); Gain of solvent accessibility (P = 0.0837); Gain of methylation at K383 (P = 0.1111); Loss of glycosylation at S382 (P = 0.2875)
17:44064420:A:C,P10636,K381Q,0.253,Loss of ubiquitination at K381 (P = 0.0063); Loss of catalytic residue at K381 (P = 0.0496); Gain of methylation at K383 (P = 0.1253); Loss of MoRF binding (P = 0.1398); Gain of relative solvent accessibility (P = 0.1571)
17:44064420:A:G,P10636,K381E,0.297,Loss of ubiquitination at K381 (P = 0.0063); Loss of MoRF binding (P = 0.0135); Loss of catalytic residue at K381 (P = 0.0276); Loss of methylation at K383 (P = 0.1146); Gain of relative solvent accessibility (P = 0.1571)
17:44064421:A:C,P10636,K381T,0.24,Loss of ubiquitination at K381 (P = 0.0063); Loss of solvent accessibility (P = 0.0249); Gain of phosphorylation at K381 (P = 0.0293); Loss of catalytic residue at K381 (P = 0.0645); Loss of MoRF binding (P = 0.0978)
17:44064421:A:G,P10636,K381R,0.207,Loss of ubiquitination at K381 (P = 0.0063); Loss of solvent accessibility (P = 0.1115); Gain of methylation at K383 (P = 0.1539); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S382 (P = 0.2702)
17:44064421:A:T,P10636,K381I,0.267,Loss of ubiquitination at K381 (P = 0.0063); Loss of solvent accessibility (P = 0.0187); Loss of catalytic residue at K381 (P = 0.0222); Gain of methylation at K383 (P = 0.0548); Loss of relative solvent accessibility (P = 0.0981)
17:44064422:A:C,P10636,K381N,0.251,Loss of ubiquitination at K381 (P = 0.0063); Loss of catalytic residue at K381 (P = 0.0208); Loss of MoRF binding (P = 0.109); Loss of methylation at K383 (P = 0.1634); Loss of glycosylation at S382 (P = 0.3143)
17:44064422:A:T,P10636,K381N,0.251,Loss of ubiquitination at K381 (P = 0.0063); Loss of catalytic residue at K381 (P = 0.0208); Loss of MoRF binding (P = 0.109); Loss of methylation at K383 (P = 0.1634); Loss of glycosylation at S382 (P = 0.3143)
17:44064423:A:C,P10636,S382R,0.168,Loss of phosphorylation at S382 (P = 0.0106); Loss of ubiquitination at K381 (P = 0.0235); Gain of methylation at K383 (P = 0.0487); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at S382 (P = 0.0888)
17:44064423:A:G,P10636,S382G,0.17,Loss of phosphorylation at S382 (P = 0.0106); Loss of stability (P = 0.0341); Loss of glycosylation at S382 (P = 0.0888); Gain of ubiquitination at K383 (P = 0.1497); Gain of methylation at K383 (P = 0.1584)
17:44064423:A:T,P10636,S382C,0.163,Loss of phosphorylation at S382 (P = 0.0106); Gain of methylation at K381 (P = 0.0143); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Loss of ubiquitination at K381 (P = 0.0825)
17:44064424:G:A,P10636,S382N,0.157,Loss of phosphorylation at S382 (P = 0.0106); Loss of catalytic residue at K383 (P = 0.0711); Loss of glycosylation at S382 (P = 0.0888); Gain of methylation at K383 (P = 0.097); Loss of stability (P = 0.1361)
17:44064424:G:C,P10636,S382T,0.165,Gain of methylation at K383 (P = 0.0945); Loss of stability (P = 0.1409); Loss of glycosylation at S382 (P = 0.1446); Gain of ubiquitination at K383 (P = 0.1497); Gain of MoRF binding (P = 0.3723)
17:44064424:G:T,P10636,S382I,0.221,Loss of phosphorylation at S382 (P = 0.0106); Loss of relative solvent accessibility (P = 0.0186); Loss of solvent accessibility (P = 0.0431); Gain of methylation at K383 (P = 0.0547); Loss of ubiquitination at K381 (P = 0.0714)
17:44064425:C:A,P10636,S382R,0.168,Loss of phosphorylation at S382 (P = 0.0106); Loss of ubiquitination at K381 (P = 0.0235); Gain of methylation at K383 (P = 0.0487); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at S382 (P = 0.0888)
17:44064425:C:G,P10636,S382R,0.168,Loss of phosphorylation at S382 (P = 0.0106); Loss of ubiquitination at K381 (P = 0.0235); Gain of methylation at K383 (P = 0.0487); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at S382 (P = 0.0888)
17:44064426:A:C,P10636,K383Q,0.207,Loss of solvent accessibility (P = 0.0117); Loss of ubiquitination at K383 (P = 0.027); Loss of methylation at K383 (P = 0.0289); Loss of relative solvent accessibility (P = 0.0676); Loss of catalytic residue at K383 (P = 0.0908)
17:44064426:A:G,P10636,K383E,0.247,Loss of solvent accessibility (P = 0.0111); Loss of MoRF binding (P = 0.0115); Loss of ubiquitination at K383 (P = 0.027); Loss of methylation at K383 (P = 0.0289); Loss of relative solvent accessibility (P = 0.0676)
17:44064427:A:C,P10636,K383T,0.243,Loss of solvent accessibility (P = 0.0022); Loss of ubiquitination at K383 (P = 0.027); Gain of phosphorylation at K383 (P = 0.0288); Loss of methylation at K383 (P = 0.0289); Loss of relative solvent accessibility (P = 0.0404)
17:44064427:A:G,P10636,K383R,0.196,Loss of ubiquitination at K383 (P = 0.027); Loss of methylation at K383 (P = 0.044); Loss of glycosylation at S382 (P = 0.2987); Gain of MoRF binding (P = 0.329); Loss of stability (P = 0.3853)
17:44064427:A:T,P10636,K383I,0.215,Loss of solvent accessibility (P = 0.0036); Loss of ubiquitination at K383 (P = 0.027); Loss of methylation at K383 (P = 0.0289); Loss of relative solvent accessibility (P = 0.0404); Loss of catalytic residue at K383 (P = 0.1659)
17:44064428:A:C,P10636,K383N,0.228,Loss of solvent accessibility (P = 0.0079); Loss of ubiquitination at K383 (P = 0.027); Loss of methylation at K383 (P = 0.0289); Loss of relative solvent accessibility (P = 0.0676); Loss of catalytic residue at K383 (P = 0.0715)
17:44064428:A:T,P10636,K383N,0.228,Loss of solvent accessibility (P = 0.0079); Loss of ubiquitination at K383 (P = 0.027); Loss of methylation at K383 (P = 0.0289); Loss of relative solvent accessibility (P = 0.0676); Loss of catalytic residue at K383 (P = 0.0715)
17:44064429:G:A,P10636,D384N,0.171,Loss of ubiquitination at K381 (P = 0.0289); Loss of solvent accessibility (P = 0.0595); Gain of methylation at K383 (P = 0.0653); Loss of relative solvent accessibility (P = 0.0981); Loss of stability (P = 0.2292)
17:44064429:G:C,P10636,D384H,0.179,Loss of ubiquitination at K381 (P = 0.0248); Gain of methylation at K383 (P = 0.0613); Loss of solvent accessibility (P = 0.0703); Loss of relative solvent accessibility (P = 0.0981); Loss of stability (P = 0.1415)
17:44064429:G:T,P10636,D384Y,0.209,Gain of phosphorylation at D384 (P = 0.0134); Loss of ubiquitination at K381 (P = 0.0235); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1115); Gain of methylation at K383 (P = 0.1247)
17:44064430:A:C,P10636,D384A,0.212,Loss of ubiquitination at K381 (P = 0.0272); Loss of solvent accessibility (P = 0.0435); Loss of stability (P = 0.0942); Loss of relative solvent accessibility (P = 0.0981); Gain of methylation at K383 (P = 0.1105)
17:44064430:A:G,P10636,D384G,0.223,Loss of ubiquitination at K381 (P = 0.0289); Gain of catalytic residue at D384 (P = 0.0724); Loss of stability (P = 0.084); Gain of methylation at K383 (P = 0.103); Loss of solvent accessibility (P = 0.1813)
17:44064430:A:T,P10636,D384V,0.192,Loss of ubiquitination at K381 (P = 0.0246); Gain of methylation at K383 (P = 0.031); Loss of solvent accessibility (P = 0.0544); Gain of catalytic residue at S388 (P = 0.0905); Loss of relative solvent accessibility (P = 0.0981)
17:44064431:C:A,P10636,D384E,0.156,Gain of ubiquitination at K383 (P = 0.0797); Gain of methylation at K383 (P = 0.102); Loss of catalytic residue at K383 (P = 0.2418); Loss of stability (P = 0.2723); Gain of solvent accessibility (P = 0.3089)
17:44064431:C:G,P10636,D384E,0.156,Gain of ubiquitination at K383 (P = 0.0797); Gain of methylation at K383 (P = 0.102); Loss of catalytic residue at K383 (P = 0.2418); Loss of stability (P = 0.2723); Gain of solvent accessibility (P = 0.3089)
17:44064432:G:A,P10636,G385R,0.217,Loss of ubiquitination at K381 (P = 0.0272); Gain of methylation at K383 (P = 0.1139); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S382 (P = 0.2266); Gain of MoRF binding (P = 0.2471)
17:44064432:G:C,P10636,G385R,0.217,Loss of ubiquitination at K381 (P = 0.0272); Gain of methylation at K383 (P = 0.1139); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S382 (P = 0.2266); Gain of MoRF binding (P = 0.2471)
17:44064432:G:T,P10636,G385W,0.191,Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K383 (P = 0.0982); Gain of methylation at K383 (P = 0.1539); Loss of glycosylation at S382 (P = 0.2702); Gain of MoRF binding (P = 0.2752)
17:44064433:G:A,P10636,G385E,0.224,Gain of ubiquitination at K383 (P = 0.0303); Loss of MoRF binding (P = 0.0898); Loss of methylation at K383 (P = 0.1425); Loss of glycosylation at S382 (P = 0.1911); Gain of solvent accessibility (P = 0.3194)
17:44064433:G:C,P10636,G385A,0.165,Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at K383 (P = 0.1522); Loss of ubiquitination at K383 (P = 0.1741); Gain of glycosylation at S388 (P = 0.2817); Loss of solvent accessibility (P = 0.3368)
17:44064433:G:T,P10636,G385V,0.175,Gain of methylation at K383 (P = 0.0932); Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K383 (P = 0.1576); Loss of glycosylation at S382 (P = 0.3167); Gain of MoRF binding (P = 0.333)
17:44064435:A:C,P10636,T386P,0.172,Loss of phosphorylation at T386 (P = 0.0028); Gain of glycosylation at T386 (P = 0.0578); Gain of methylation at K383 (P = 0.124); Loss of MoRF binding (P = 0.1394); Gain of relative solvent accessibility (P = 0.1571)
17:44064435:A:G,P10636,T386A,0.21,Loss of phosphorylation at T386 (P = 0.0028); Loss of methylation at K391 (P = 0.0677); Gain of catalytic residue at T386 (P = 0.0755); Gain of relative solvent accessibility (P = 0.1571); Loss of ubiquitination at K383 (P = 0.1741)
17:44064435:A:T,P10636,T386S,0.211,Gain of glycosylation at T386 (P = 0.0154); Loss of methylation at K391 (P = 0.1291); Gain of relative solvent accessibility (P = 0.1571); Loss of ubiquitination at K383 (P = 0.1576); Gain of MoRF binding (P = 0.3552)
17:44064436:C:A,P10636,T386N,0.155,Loss of phosphorylation at T386 (P = 0.0028); Loss of methylation at K391 (P = 0.1185); Loss of ubiquitination at K383 (P = 0.1741); Loss of glycosylation at S382 (P = 0.3174); Loss of MoRF binding (P = 0.3553)
17:44064436:C:G,P10636,T386S,0.211,Gain of glycosylation at T386 (P = 0.0154); Loss of methylation at K391 (P = 0.1291); Gain of relative solvent accessibility (P = 0.1571); Loss of ubiquitination at K383 (P = 0.1576); Gain of MoRF binding (P = 0.3552)
17:44064436:C:T,P10636,T386I,0.154,Loss of phosphorylation at T386 (P = 0.0028); Loss of relative solvent accessibility (P = 0.0981); Gain of methylation at K383 (P = 0.1185); Loss of solvent accessibility (P = 0.1235); Loss of ubiquitination at K383 (P = 0.1741)
17:44064438:G:A,P10636,G387R,0.309,Gain of catalytic residue at G387 (P = 0.0292); Gain of methylation at K383 (P = 0.0699); Gain of solvent accessibility (P = 0.1319); Gain of ubiquitination at K383 (P = 0.1497); Gain of MoRF binding (P = 0.2229)
17:44064438:G:C,P10636,G387R,0.309,Gain of catalytic residue at G387 (P = 0.0292); Gain of methylation at K383 (P = 0.0699); Gain of solvent accessibility (P = 0.1319); Gain of ubiquitination at K383 (P = 0.1497); Gain of MoRF binding (P = 0.2229)
17:44064439:G:A,P10636,G387E,0.259,Gain of solvent accessibility (P = 0.012); Gain of ubiquitination at K383 (P = 0.0325); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at K383 (P = 0.0869); Loss of MoRF binding (P = 0.1172)
17:44064439:G:C,P10636,G387A,0.173,Loss of methylation at K392 (P = 0.1131); Gain of glycosylation at S382 (P = 0.1431); Loss of ubiquitination at K383 (P = 0.1741); Gain of MoRF binding (P = 0.3476); Loss of catalytic residue at K383 (P = 0.4007)
17:44064439:G:T,P10636,G387V,0.247,Gain of catalytic residue at G387 (P = 0.0333); Gain of methylation at K392 (P = 0.1147); Gain of ubiquitination at K392 (P = 0.143); Gain of glycosylation at S382 (P = 0.1828); Gain of MoRF binding (P = 0.3424)
17:44064441:A:C,P10636,S388R,0.177,Loss of phosphorylation at S388 (P = 0.0057); Loss of methylation at K383 (P = 0.0621); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at S388 (P = 0.1738); Loss of ubiquitination at K383 (P = 0.1741)
17:44064441:A:G,P10636,S388G,0.151,Loss of phosphorylation at S388 (P = 0.0057); Loss of solvent accessibility (P = 0.0477); Loss of relative solvent accessibility (P = 0.0676); Gain of methylation at K391 (P = 0.1118); Loss of glycosylation at S388 (P = 0.1738)
17:44064441:A:T,P10636,S388C,0.149,Loss of phosphorylation at S388 (P = 0.0057); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Gain of methylation at K391 (P = 0.0908); Loss of ubiquitination at K383 (P = 0.1576)
17:44064442:G:A,P10636,S388N,0.157,Loss of phosphorylation at S388 (P = 0.0057); Loss of methylation at K383 (P = 0.0798); Gain of ubiquitination at K392 (P = 0.1679); Loss of glycosylation at S388 (P = 0.1738); Gain of solvent accessibility (P = 0.2902)
17:44064442:G:C,P10636,S388T,0.17,Gain of methylation at K391 (P = 0.0988); Loss of ubiquitination at K383 (P = 0.1741); Loss of glycosylation at S388 (P = 0.2754); Loss of MoRF binding (P = 0.3257); Loss of relative solvent accessibility (P = 0.5582)
17:44064442:G:T,P10636,S388I,0.181,Loss of phosphorylation at S388 (P = 0.0057); Loss of relative solvent accessibility (P = 0.0186); Loss of solvent accessibility (P = 0.0431); Gain of methylation at K391 (P = 0.0656); Loss of ubiquitination at K392 (P = 0.1612)
17:44064443:C:A,P10636,S388R,0.177,Loss of phosphorylation at S388 (P = 0.0057); Loss of methylation at K383 (P = 0.0621); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at S388 (P = 0.1738); Loss of ubiquitination at K383 (P = 0.1741)
17:44064443:C:G,P10636,S388R,0.177,Loss of phosphorylation at S388 (P = 0.0057); Loss of methylation at K383 (P = 0.0621); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at S388 (P = 0.1738); Loss of ubiquitination at K383 (P = 0.1741)
17:44064444:G:A,P10636,D389N,0.198,Loss of ubiquitination at K394 (P = 0.0365); Loss of solvent accessibility (P = 0.0387); Gain of methylation at K391 (P = 0.0582); Loss of relative solvent accessibility (P = 0.0676); Loss of stability (P = 0.2324)
17:44064444:G:C,P10636,D389H,0.223,Loss of ubiquitination at K394 (P = 0.0387); Gain of methylation at K391 (P = 0.05); Loss of solvent accessibility (P = 0.0509); Loss of relative solvent accessibility (P = 0.0676); Loss of stability (P = 0.181)
17:44064444:G:T,P10636,D389Y,0.241,Gain of phosphorylation at D389 (P = 0.0205); Loss of solvent accessibility (P = 0.0352); Loss of ubiquitination at K394 (P = 0.0387); Loss of relative solvent accessibility (P = 0.0404); Gain of methylation at K394 (P = 0.0464)
17:44064445:A:C,P10636,D389A,0.242,Loss of solvent accessibility (P = 0.0174); Loss of ubiquitination at K394 (P = 0.0426); Loss of relative solvent accessibility (P = 0.0676); Gain of methylation at K391 (P = 0.0862); Gain of glycosylation at S388 (P = 0.1012)
17:44064445:A:G,P10636,D389G,0.245,Gain of glycosylation at S388 (P = 0.0205); Loss of ubiquitination at K394 (P = 0.0401); Loss of stability (P = 0.0428); Gain of methylation at K391 (P = 0.0662); Loss of solvent accessibility (P = 0.1177)
17:44064445:A:T,P10636,D389V,0.248,Loss of solvent accessibility (P = 0.0159); Loss of ubiquitination at K394 (P = 0.0401); Loss of relative solvent accessibility (P = 0.0404); Gain of methylation at K391 (P = 0.0548); Gain of MoRF binding (P = 0.2361)
17:44064446:T:A,P10636,D389E,0.14,Gain of methylation at K391 (P = 0.0778); Gain of ubiquitination at K394 (P = 0.102); Loss of stability (P = 0.2994); Gain of MoRF binding (P = 0.3594); Gain of glycosylation at K392 (P = 0.4678)
17:44064446:T:G,P10636,D389E,0.14,Gain of methylation at K391 (P = 0.0778); Gain of ubiquitination at K394 (P = 0.102); Loss of stability (P = 0.2994); Gain of MoRF binding (P = 0.3594); Gain of glycosylation at K392 (P = 0.4678)
17:44064447:G:A,P10636,D390N,0.188,Loss of ubiquitination at K394 (P = 0.0373); Gain of methylation at K391 (P = 0.0612); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.2502); Gain of MoRF binding (P = 0.2715)
17:44064447:G:C,P10636,D390H,0.171,Loss of ubiquitination at K394 (P = 0.0387); Gain of methylation at K392 (P = 0.055); Loss of solvent accessibility (P = 0.0703); Loss of relative solvent accessibility (P = 0.0981); Loss of stability (P = 0.2047)
17:44064447:G:T,P10636,D390Y,0.195,Gain of phosphorylation at D390 (P = 0.0131); Loss of ubiquitination at K394 (P = 0.0426); Gain of methylation at K394 (P = 0.08); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2073)
17:44064448:A:C,P10636,D390A,0.202,Loss of solvent accessibility (P = 0.0435); Loss of ubiquitination at K394 (P = 0.051); Loss of methylation at K394 (P = 0.0766); Loss of relative solvent accessibility (P = 0.0981); Loss of stability (P = 0.1544)
17:44064448:A:G,P10636,D390G,0.199,Loss of ubiquitination at K394 (P = 0.051); Loss of stability (P = 0.0649); Gain of methylation at K392 (P = 0.0862); Loss of solvent accessibility (P = 0.1813); Gain of MoRF binding (P = 0.27)
17:44064448:A:T,P10636,D390V,0.187,Gain of methylation at K391 (P = 0.0365); Loss of ubiquitination at K394 (P = 0.0437); Loss of solvent accessibility (P = 0.0907); Loss of relative solvent accessibility (P = 0.1807); Gain of MoRF binding (P = 0.2524)
17:44064449:C:A,P10636,D390E,0.174,Gain of methylation at K392 (P = 0.0816); Gain of ubiquitination at K394 (P = 0.0898); Gain of solvent accessibility (P = 0.1014); Gain of relative solvent accessibility (P = 0.1571); Loss of MoRF binding (P = 0.3522)
17:44064449:C:G,P10636,D390E,0.174,Gain of methylation at K392 (P = 0.0816); Gain of ubiquitination at K394 (P = 0.0898); Gain of solvent accessibility (P = 0.1014); Gain of relative solvent accessibility (P = 0.1571); Loss of MoRF binding (P = 0.3522)
17:44064450:A:C,P10636,K391Q,0.245,Loss of solvent accessibility (P = 0.0117); Gain of ubiquitination at K392 (P = 0.0193); Loss of methylation at K391 (P = 0.0225); Loss of relative solvent accessibility (P = 0.0676); Loss of MoRF binding (P = 0.0885)
17:44064450:A:G,P10636,K391E,0.276,Loss of MoRF binding (P = 0.0036); Gain of ubiquitination at K392 (P = 0.017); Loss of methylation at K391 (P = 0.0225); Loss of glycosylation at K391 (P = 0.2303); Loss of solvent accessibility (P = 0.2814)
17:44064451:A:C,P10636,K391T,0.276,Gain of phosphorylation at K391 (P = 0.0033); Loss of solvent accessibility (P = 0.0056); Gain of ubiquitination at K392 (P = 0.0204); Loss of methylation at K391 (P = 0.0225); Loss of MoRF binding (P = 0.0655)
17:44064451:A:G,P10636,K391R,0.213,Loss of solvent accessibility (P = 0.0217); Loss of methylation at K391 (P = 0.0355); Loss of ubiquitination at K391 (P = 0.0381); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K391 (P = 0.2303)
17:44064451:A:T,P10636,K391I,0.246,Loss of solvent accessibility (P = 0.0036); Gain of ubiquitination at K392 (P = 0.0212); Loss of methylation at K391 (P = 0.0225); Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at S388 (P = 0.0762)
17:44064452:A:C,P10636,K391N,0.237,Loss of solvent accessibility (P = 0.0079); Gain of ubiquitination at K392 (P = 0.0185); Loss of methylation at K391 (P = 0.0225); Loss of relative solvent accessibility (P = 0.0676); Loss of MoRF binding (P = 0.0787)
17:44064452:A:T,P10636,K391N,0.237,Loss of solvent accessibility (P = 0.0079); Gain of ubiquitination at K392 (P = 0.0185); Loss of methylation at K391 (P = 0.0225); Loss of relative solvent accessibility (P = 0.0676); Loss of MoRF binding (P = 0.0787)
17:44064453:A:C,P10636,K392Q,0.269,Loss of solvent accessibility (P = 0.0117); Gain of ubiquitination at K391 (P = 0.0185); Loss of methylation at K392 (P = 0.0209); Loss of relative solvent accessibility (P = 0.0676); Loss of MoRF binding (P = 0.1165)
17:44064453:A:G,P10636,K392E,0.32,Loss of MoRF binding (P = 0.0084); Loss of solvent accessibility (P = 0.0111); Gain of ubiquitination at K391 (P = 0.017); Loss of methylation at K392 (P = 0.0209); Loss of relative solvent accessibility (P = 0.0676)
17:44064454:A:C,P10636,K392T,0.275,Loss of solvent accessibility (P = 0.0056); Gain of ubiquitination at K391 (P = 0.0192); Loss of methylation at K392 (P = 0.0209); Gain of phosphorylation at K392 (P = 0.0216); Loss of relative solvent accessibility (P = 0.0676)
17:44064454:A:G,P10636,K392R,0.237,Loss of solvent accessibility (P = 0.0217); Loss of ubiquitination at K392 (P = 0.0297); Loss of methylation at K392 (P = 0.0411); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K392 (P = 0.2034)
17:44064454:A:T,P10636,K392I,0.265,Loss of solvent accessibility (P = 0.0036); Gain of ubiquitination at K391 (P = 0.0193); Loss of methylation at K392 (P = 0.0209); Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at K392 (P = 0.2034)
17:44064455:A:C,P10636,K392N,0.28,Loss of solvent accessibility (P = 0.0155); Gain of ubiquitination at K391 (P = 0.0192); Loss of methylation at K392 (P = 0.0209); Loss of MoRF binding (P = 0.1008); Loss of relative solvent accessibility (P = 0.107)
17:44064455:A:T,P10636,K392N,0.28,Loss of solvent accessibility (P = 0.0155); Gain of ubiquitination at K391 (P = 0.0192); Loss of methylation at K392 (P = 0.0209); Loss of MoRF binding (P = 0.1008); Loss of relative solvent accessibility (P = 0.107)
17:44064456:G:A,P10636,A393T,0.181,Gain of phosphorylation at A393 (P = 0.002); Gain of methylation at K391 (P = 0.0636); Loss of ubiquitination at K394 (P = 0.0962); Gain of glycosylation at S388 (P = 0.1399); Gain of relative solvent accessibility (P = 0.2629)
17:44064456:G:C,P10636,A393P,0.207,Gain of relative solvent accessibility (P = 0.0098); Gain of solvent accessibility (P = 0.0216); Gain of glycosylation at A393 (P = 0.0309); Gain of methylation at K391 (P = 0.0499); Loss of ubiquitination at K394 (P = 0.0853)
17:44064456:G:T,P10636,A393S,0.236,Gain of phosphorylation at A393 (P = 0.0027); Gain of relative solvent accessibility (P = 0.0249); Gain of glycosylation at A393 (P = 0.0269); Gain of solvent accessibility (P = 0.0611); Gain of methylation at K391 (P = 0.0705)
17:44064457:C:A,P10636,A393D,0.27,Gain of solvent accessibility (P = 0.007); Gain of relative solvent accessibility (P = 0.0098); Gain of ubiquitination at K392 (P = 0.0416); Loss of MoRF binding (P = 0.0542); Gain of methylation at K394 (P = 0.1292)
17:44064457:C:G,P10636,A393G,0.148,Gain of methylation at K391 (P = 0.103); Loss of stability (P = 0.1137); Gain of ubiquitination at K394 (P = 0.1162); Gain of glycosylation at K392 (P = 0.1764); Gain of relative solvent accessibility (P = 0.2629)
17:44064457:C:T,P10636,A393V,0.126,Gain of methylation at K394 (P = 0.0357); Loss of ubiquitination at K394 (P = 0.0853); Loss of glycosylation at T397 (P = 0.3222); Gain of MoRF binding (P = 0.3407); Gain of catalytic residue at S396 (P = 0.358)
17:44064459:A:C,P10636,K394Q,0.211,Loss of ubiquitination at K394 (P = 0.0167); Loss of methylation at K394 (P = 0.0303); Loss of MoRF binding (P = 0.1033); Loss of solvent accessibility (P = 0.1434); Loss of catalytic residue at K394 (P = 0.1629)
17:44064459:A:G,P10636,K394E,0.296,Loss of MoRF binding (P = 0.0079); Loss of ubiquitination at K394 (P = 0.0167); Loss of methylation at K394 (P = 0.0303); Loss of catalytic residue at K394 (P = 0.1206); Gain of relative solvent accessibility (P = 0.1571)
17:44064460:A:C,P10636,K394T,0.275,Loss of ubiquitination at K394 (P = 0.0167); Gain of glycosylation at K394 (P = 0.0237); Loss of methylation at K394 (P = 0.0303); Loss of solvent accessibility (P = 0.0561); Gain of phosphorylation at K394 (P = 0.072)
17:44064460:A:G,P10636,K394R,0.169,Loss of ubiquitination at K394 (P = 0.0167); Loss of methylation at K394 (P = 0.0424); Loss of solvent accessibility (P = 0.1115); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T397 (P = 0.2534)
17:44064460:A:T,P10636,K394M,0.22,Loss of ubiquitination at K394 (P = 0.0167); Loss of methylation at K394 (P = 0.0303); Loss of solvent accessibility (P = 0.0509); Loss of catalytic residue at K394 (P = 0.1228); Loss of phosphorylation at T397 (P = 0.1535)
17:44064461:G:C,P10636,K394N,0.248,Loss of ubiquitination at K394 (P = 0.0167); Loss of methylation at K394 (P = 0.0303); Loss of MoRF binding (P = 0.0901); Gain of glycosylation at T397 (P = 0.1116); Gain of relative solvent accessibility (P = 0.1571)
17:44064461:G:T,P10636,K394N,0.248,Loss of ubiquitination at K394 (P = 0.0167); Loss of methylation at K394 (P = 0.0303); Loss of MoRF binding (P = 0.0901); Gain of glycosylation at T397 (P = 0.1116); Gain of relative solvent accessibility (P = 0.1571)
17:44067244:A:C,P10636,T395P,0.18,Loss of phosphorylation at T395 (P = 0.0096); Gain of glycosylation at T395 (P = 0.0829); Loss of methylation at K391 (P = 0.1088); Loss of ubiquitination at K394 (P = 0.1139); Loss of MoRF binding (P = 0.2157)
17:44067244:A:G,P10636,T395A,0.136,Loss of phosphorylation at T395 (P = 0.0096); Loss of methylation at K391 (P = 0.0558); Gain of ubiquitination at K394 (P = 0.102); Loss of glycosylation at S396 (P = 0.2034); Gain of MoRF binding (P = 0.3668)
17:44067244:A:T,P10636,T395S,0.199,Gain of ubiquitination at K394 (P = 0.0737); Loss of methylation at K392 (P = 0.1219); Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at S396 (P = 0.186); Gain of MoRF binding (P = 0.363)
17:44067245:C:A,P10636,T395K,0.203,Loss of phosphorylation at T395 (P = 0.0096); Gain of ubiquitination at T395 (P = 0.0337); Gain of methylation at T395 (P = 0.0391); Loss of glycosylation at S396 (P = 0.0636); Gain of solvent accessibility (P = 0.1505)
17:44067245:C:G,P10636,T395R,0.207,Loss of phosphorylation at T395 (P = 0.0096); Loss of ubiquitination at K394 (P = 0.0437); Gain of solvent accessibility (P = 0.0503); Loss of glycosylation at S396 (P = 0.058); Loss of methylation at K391 (P = 0.0722)
17:44067245:C:T,P10636,T395I,0.154,Loss of phosphorylation at T395 (P = 0.0096); Gain of methylation at K394 (P = 0.0537); Loss of ubiquitination at K394 (P = 0.0755); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at T397 (P = 0.1033)
17:44067247:T:A,P10636,S396T,0.184,Loss of glycosylation at S396 (P = 0.0661); Gain of methylation at K392 (P = 0.1047); Gain of ubiquitination at K394 (P = 0.1162); Loss of phosphorylation at T395 (P = 0.2901); Loss of MoRF binding (P = 0.3651)
17:44067247:T:C,P10636,S396P,0.187,Loss of phosphorylation at S396 (P = 0.0041); Gain of methylation at K394 (P = 0.0702); Loss of glycosylation at S396 (P = 0.0955); Loss of ubiquitination at K394 (P = 0.1322); Loss of MoRF binding (P = 0.2161)
17:44067247:T:G,P10636,S396A,0.205,Loss of phosphorylation at S396 (P = 0.0041); Loss of glycosylation at S396 (P = 0.006); Loss of methylation at K391 (P = 0.0676); Gain of ubiquitination at K394 (P = 0.0686); Loss of catalytic residue at R398 (P = 0.3514)
17:44067248:C:A,P10636,S396Y,0.196,Loss of glycosylation at S396 (P = 0.006); Gain of methylation at K392 (P = 0.0512); Loss of phosphorylation at S396 (P = 0.1077); Gain of ubiquitination at K394 (P = 0.1162); Gain of catalytic residue at S396 (P = 0.293)
17:44067248:C:G,P10636,S396C,0.208,Loss of phosphorylation at S396 (P = 0.0041); Loss of glycosylation at S396 (P = 0.006); Gain of methylation at K394 (P = 0.0828); Loss of ubiquitination at K394 (P = 0.0853); Gain of catalytic residue at S400 (P = 0.1538)
17:44067248:C:T,P10636,S396F,0.229,Loss of phosphorylation at S396 (P = 0.0041); Loss of glycosylation at S396 (P = 0.006); Gain of methylation at K394 (P = 0.0718); Gain of ubiquitination at K394 (P = 0.1162); Loss of MoRF binding (P = 0.3328)
17:44067250:A:C,P10636,T397P,0.191,Loss of phosphorylation at T397 (P = 0.0169); Gain of glycosylation at T397 (P = 0.0542); Loss of ubiquitination at K394 (P = 0.0962); Loss of methylation at K392 (P = 0.1018); Loss of MoRF binding (P = 0.2726)
17:44067250:A:G,P10636,T397A,0.198,Loss of phosphorylation at T397 (P = 0.0169); Loss of methylation at K392 (P = 0.052); Loss of glycosylation at T397 (P = 0.0574); Gain of ubiquitination at K394 (P = 0.0898); Loss of stability (P = 0.3635)
17:44067250:A:T,P10636,T397S,0.265,Loss of glycosylation at S396 (P = 0.045); Gain of ubiquitination at K394 (P = 0.1162); Gain of catalytic residue at T397 (P = 0.1262); Loss of methylation at K392 (P = 0.1348); Gain of phosphorylation at T397 (P = 0.362)
17:44067251:C:A,P10636,T397K,0.271,Loss of phosphorylation at T397 (P = 0.0169); Loss of ubiquitination at K394 (P = 0.0346); Loss of glycosylation at S396 (P = 0.0702); Gain of methylation at K402 (P = 0.0938); Gain of solvent accessibility (P = 0.1014)
17:44067251:C:G,P10636,T397R,0.2,Loss of phosphorylation at T397 (P = 0.0169); Loss of ubiquitination at K394 (P = 0.0426); Loss of glycosylation at T397 (P = 0.0574); Gain of methylation at K402 (P = 0.0788); Gain of solvent accessibility (P = 0.1154)
17:44067251:C:T,P10636,T397I,0.196,Loss of phosphorylation at T397 (P = 0.0169); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.045); Loss of glycosylation at S396 (P = 0.0522); Loss of methylation at K392 (P = 0.0757)
17:44067253:C:A,P10636,R398S,0.345,Gain of phosphorylation at R398 (P = 0.0042); Loss of MoRF binding (P = 0.0444); Gain of methylation at K394 (P = 0.0449); Gain of glycosylation at R398 (P = 0.0555); Loss of solvent accessibility (P = 0.0606)
17:44067253:C:G,P10636,R398G,0.288,Loss of solvent accessibility (P = 0.0159); Loss of MoRF binding (P = 0.0327); Gain of methylation at K394 (P = 0.0493); Gain of ubiquitination at K394 (P = 0.0598); Gain of glycosylation at T395 (P = 0.1285)
17:44067253:C:T,P10636,R398C,0.312,Loss of MoRF binding (P = 0.0076); Gain of methylation at K394 (P = 0.0474); Gain of ubiquitination at K394 (P = 0.0598); Gain of catalytic residue at S400 (P = 0.0635); Gain of glycosylation at T397 (P = 0.0674)
17:44067254:G:A,P10636,R398H,0.292,Loss of MoRF binding (P = 0.0388); Gain of methylation at K394 (P = 0.0497); Gain of ubiquitination at K394 (P = 0.0598); Gain of glycosylation at T395 (P = 0.0682); Loss of phosphorylation at T397 (P = 0.2119)
17:44067254:G:C,P10636,R398P,0.299,Loss of MoRF binding (P = 0.0039); Gain of glycosylation at R398 (P = 0.0208); Gain of methylation at K394 (P = 0.0415); Loss of catalytic residue at R398 (P = 0.0601); Loss of solvent accessibility (P = 0.0703)
17:44067254:G:T,P10636,R398L,0.305,Loss of solvent accessibility (P = 0.0052); Loss of MoRF binding (P = 0.0169); Loss of catalytic residue at R398 (P = 0.021); Gain of ubiquitination at K394 (P = 0.0566); Gain of methylation at K394 (P = 0.0877)
17:44067256:T:A,P10636,S399T,0.151,Gain of methylation at K394 (P = 0.1048); Gain of ubiquitination at K394 (P = 0.1162); Gain of glycosylation at S400 (P = 0.1756); Loss of catalytic residue at S399 (P = 0.2956); Loss of phosphorylation at T403 (P = 0.3025)
17:44067256:T:C,P10636,S399P,0.198,Loss of phosphorylation at S399 (P = 0.0088); Gain of glycosylation at S399 (P = 0.0354); Gain of methylation at K402 (P = 0.0753); Gain of relative solvent accessibility (P = 0.09); Loss of ubiquitination at K394 (P = 0.1322)
17:44067256:T:G,P10636,S399A,0.163,Loss of phosphorylation at S399 (P = 0.0088); Loss of methylation at K394 (P = 0.0845); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K394 (P = 0.102); Gain of glycosylation at S400 (P = 0.1392)
17:44067257:C:A,P10636,S399Y,0.175,Loss of phosphorylation at S399 (P = 0.0506); Gain of methylation at K394 (P = 0.0858); Loss of ubiquitination at K394 (P = 0.1322); Loss of glycosylation at T397 (P = 0.2916); Loss of MoRF binding (P = 0.3091)
17:44067257:C:G,P10636,S399C,0.17,Loss of phosphorylation at S399 (P = 0.0088); Loss of glycosylation at T397 (P = 0.0949); Gain of methylation at K402 (P = 0.1049); Loss of ubiquitination at K394 (P = 0.1139); Loss of MoRF binding (P = 0.2432)
17:44067257:C:T,P10636,S399F,0.184,Loss of phosphorylation at S399 (P = 0.0088); Loss of methylation at K394 (P = 0.0975); Gain of ubiquitination at K394 (P = 0.102); Gain of glycosylation at S400 (P = 0.1454); Loss of MoRF binding (P = 0.2811)
17:44067259:T:A,P10636,S400T,0.174,Gain of glycosylation at S399 (P = 0.0601); Gain of methylation at K402 (P = 0.1283); Loss of phosphorylation at T397 (P = 0.1497); Loss of ubiquitination at K402 (P = 0.2258); Loss of MoRF binding (P = 0.2463)
17:44067259:T:C,P10636,S400P,0.193,Loss of phosphorylation at S400 (P = 0.0032); Gain of glycosylation at T397 (P = 0.0649); Gain of methylation at K402 (P = 0.0759); Loss of MoRF binding (P = 0.1166); Loss of ubiquitination at K402 (P = 0.198)
17:44067259:T:G,P10636,S400A,0.167,Loss of phosphorylation at S400 (P = 0.0032); Loss of methylation at K405 (P = 0.0781); Loss of glycosylation at S400 (P = 0.0787); Loss of ubiquitination at K402 (P = 0.212); Gain of MoRF binding (P = 0.2491)
17:44067260:C:A,P10636,S400Y,0.226,Gain of catalytic residue at S400 (P = 0.0444); Loss of glycosylation at S400 (P = 0.0787); Loss of methylation at K402 (P = 0.1368); Loss of relative solvent accessibility (P = 0.1807); Loss of ubiquitination at K402 (P = 0.1815)
17:44067260:C:G,P10636,S400C,0.192,Loss of phosphorylation at S400 (P = 0.0032); Loss of glycosylation at S400 (P = 0.0787); Gain of methylation at K402 (P = 0.0849); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1322)
17:44067260:C:T,P10636,S400F,0.22,Loss of phosphorylation at S400 (P = 0.0032); Gain of catalytic residue at S400 (P = 0.0576); Gain of methylation at K402 (P = 0.0769); Loss of glycosylation at S400 (P = 0.0787); Loss of ubiquitination at K402 (P = 0.1516)
17:44067262:G:A,P10636,A401T,0.203,Gain of phosphorylation at A401 (P = 0.0099); Gain of methylation at K405 (P = 0.0798); Gain of glycosylation at S400 (P = 0.0881); Loss of stability (P = 0.0906); Loss of MoRF binding (P = 0.1604)
17:44067262:G:C,P10636,A401P,0.257,Gain of glycosylation at A401 (P = 0.0142); Gain of methylation at K402 (P = 0.0706); Loss of stability (P = 0.0711); Loss of MoRF binding (P = 0.078); Loss of ubiquitination at K402 (P = 0.198)
17:44067262:G:T,P10636,A401S,0.238,Gain of phosphorylation at A401 (P = 0.0035); Gain of glycosylation at A401 (P = 0.0517); Gain of methylation at K405 (P = 0.0854); Loss of stability (P = 0.1301); Loss of MoRF binding (P = 0.1821)
17:44067263:C:A,P10636,A401D,0.242,Loss of MoRF binding (P = 0.0644); Gain of methylation at K405 (P = 0.1051); Gain of ubiquitination at K402 (P = 0.2033); Loss of glycosylation at S400 (P = 0.2153); Loss of stability (P = 0.2212)
17:44067263:C:G,P10636,A401G,0.202,Loss of stability (P = 0.0418); Gain of glycosylation at S400 (P = 0.0493); Gain of methylation at K405 (P = 0.1336); Loss of MoRF binding (P = 0.1875); Loss of ubiquitination at K402 (P = 0.2258)
17:44067263:C:T,P10636,A401V,0.192,Loss of relative solvent accessibility (P = 0.0186); Gain of methylation at K402 (P = 0.0343); Loss of solvent accessibility (P = 0.0807); Loss of stability (P = 0.1495); Loss of ubiquitination at K402 (P = 0.1668)
17:44067265:A:C,P10636,K402Q,0.193,Loss of methylation at K402 (P = 0.0329); Loss of ubiquitination at K402 (P = 0.0341); Loss of MoRF binding (P = 0.0659); Loss of solvent accessibility (P = 0.1434); Loss of glycosylation at S400 (P = 0.2437)
17:44067265:A:G,P10636,K402E,0.276,Loss of MoRF binding (P = 0.0094); Loss of methylation at K402 (P = 0.0329); Loss of ubiquitination at K402 (P = 0.0341); Gain of glycosylation at T397 (P = 0.1887); Loss of catalytic residue at K402 (P = 0.2539)
17:44067266:A:C,P10636,K402T,0.275,Gain of glycosylation at K402 (P = 0.032); Loss of methylation at K402 (P = 0.0329); Loss of ubiquitination at K402 (P = 0.0341); Loss of MoRF binding (P = 0.0537); Gain of phosphorylation at K402 (P = 0.0652)
17:44067266:A:G,P10636,K402R,0.207,Loss of ubiquitination at K402 (P = 0.0341); Loss of methylation at K402 (P = 0.0637); Gain of MoRF binding (P = 0.0901); Loss of glycosylation at T403 (P = 0.2392); Loss of solvent accessibility (P = 0.2953)
17:44067266:A:T,P10636,K402I,0.26,Loss of solvent accessibility (P = 0.0187); Loss of methylation at K402 (P = 0.0329); Loss of ubiquitination at K402 (P = 0.0341); Loss of MoRF binding (P = 0.0563); Gain of glycosylation at S400 (P = 0.0718)
17:44067267:A:C,P10636,K402N,0.221,Loss of methylation at K402 (P = 0.0329); Loss of ubiquitination at K402 (P = 0.0341); Loss of MoRF binding (P = 0.0591); Gain of glycosylation at T403 (P = 0.1351); Loss of solvent accessibility (P = 0.1579)
17:44067267:A:T,P10636,K402N,0.221,Loss of methylation at K402 (P = 0.0329); Loss of ubiquitination at K402 (P = 0.0341); Loss of MoRF binding (P = 0.0591); Gain of glycosylation at T403 (P = 0.1351); Loss of solvent accessibility (P = 0.1579)
17:44067268:A:C,P10636,T403P,0.194,Loss of phosphorylation at T403 (P = 0.0188); Gain of catalytic residue at T403 (P = 0.0626); Loss of MoRF binding (P = 0.0712); Loss of stability (P = 0.0723); Gain of methylation at K405 (P = 0.1398)
17:44067268:A:G,P10636,T403A,0.126,Loss of phosphorylation at T403 (P = 0.0188); Loss of glycosylation at T403 (P = 0.0853); Loss of stability (P = 0.0906); Loss of methylation at K405 (P = 0.0985); Gain of MoRF binding (P = 0.1382)
17:44067268:A:T,P10636,T403S,0.112,Loss of methylation at K402 (P = 0.1224); Gain of MoRF binding (P = 0.1316); Gain of glycosylation at P408 (P = 0.2055); Loss of ubiquitination at K402 (P = 0.2258); Loss of stability (P = 0.3334)
17:44067269:C:A,P10636,T403N,0.118,Loss of phosphorylation at T403 (P = 0.0188); Loss of glycosylation at T403 (P = 0.0853); Loss of methylation at K405 (P = 0.1214); Gain of MoRF binding (P = 0.1382); Gain of ubiquitination at K402 (P = 0.1725)
17:44067269:C:G,P10636,T403S,0.112,Loss of methylation at K402 (P = 0.1224); Gain of MoRF binding (P = 0.1316); Gain of glycosylation at P408 (P = 0.2055); Loss of ubiquitination at K402 (P = 0.2258); Loss of stability (P = 0.3334)
17:44067271:T:A,P10636,L404M,0.155,Loss of methylation at K405 (P = 0.0342); Gain of MoRF binding (P = 0.0831); Gain of glycosylation at T403 (P = 0.1127); Gain of ubiquitination at K405 (P = 0.2122); Loss of stability (P = 0.4075)
17:44067271:T:G,P10636,L404V,0.121,Gain of methylation at K405 (P = 0.0474); Gain of glycosylation at T403 (P = 0.0848); Gain of MoRF binding (P = 0.0918); Gain of ubiquitination at K402 (P = 0.1725); Loss of stability (P = 0.1837)
17:44067272:T:C,P10636,L404S,0.234,Gain of phosphorylation at L404 (P = 0.007); Gain of relative solvent accessibility (P = 0.0249); Loss of stability (P = 0.027); Gain of glycosylation at T403 (P = 0.0822); Gain of solvent accessibility (P = 0.0837)
17:44067272:T:G,P10636,L404W,0.196,Gain of MoRF binding (P = 0.051); Gain of methylation at K402 (P = 0.0764); Loss of stability (P = 0.085); Gain of glycosylation at S400 (P = 0.1425); Gain of ubiquitination at K405 (P = 0.1827)
17:44067273:G:C,P10636,L404F,0.12,Gain of methylation at K405 (P = 0.0424); Loss of MoRF binding (P = 0.1358); Loss of ubiquitination at K402 (P = 0.198); Gain of glycosylation at T403 (P = 0.2299); Loss of stability (P = 0.3895)
17:44067273:G:T,P10636,L404F,0.12,Gain of methylation at K405 (P = 0.0424); Loss of MoRF binding (P = 0.1358); Loss of ubiquitination at K402 (P = 0.198); Gain of glycosylation at T403 (P = 0.2299); Loss of stability (P = 0.3895)
17:44067274:A:C,P10636,K405Q,0.37,Loss of methylation at K405 (P = 0.0131); Loss of ubiquitination at K405 (P = 0.0496); Loss of MoRF binding (P = 0.0664); Loss of catalytic residue at K405 (P = 0.2024); Loss of glycosylation at T403 (P = 0.2458)
17:44067274:A:G,P10636,K405E,0.396,Loss of MoRF binding (P = 0.0095); Loss of methylation at K405 (P = 0.0131); Loss of ubiquitination at K405 (P = 0.0496); Loss of glycosylation at P408 (P = 0.1683); Loss of catalytic residue at K405 (P = 0.173)
17:44067275:A:C,P10636,K405T,0.379,Loss of methylation at K405 (P = 0.0131); Loss of solvent accessibility (P = 0.0249); Gain of phosphorylation at K405 (P = 0.0297); Gain of glycosylation at K405 (P = 0.0353); Loss of ubiquitination at K405 (P = 0.0496)
17:44067275:A:G,P10636,K405R,0.315,Loss of methylation at K405 (P = 0.0295); Loss of ubiquitination at K405 (P = 0.0496); Gain of MoRF binding (P = 0.0899); Loss of glycosylation at P408 (P = 0.2929); Loss of solvent accessibility (P = 0.2953)
17:44067275:A:T,P10636,K405I,0.398,Loss of methylation at K405 (P = 0.0131); Loss of solvent accessibility (P = 0.0431); Loss of ubiquitination at K405 (P = 0.0496); Loss of MoRF binding (P = 0.0713); Loss of glycosylation at P408 (P = 0.1578)
17:44067276:A:C,P10636,K405N,0.377,Loss of methylation at K405 (P = 0.0131); Loss of ubiquitination at K405 (P = 0.0496); Loss of MoRF binding (P = 0.0591); Gain of glycosylation at T403 (P = 0.1479); Loss of catalytic residue at K405 (P = 0.1789)
17:44067276:A:T,P10636,K405N,0.377,Loss of methylation at K405 (P = 0.0131); Loss of ubiquitination at K405 (P = 0.0496); Loss of MoRF binding (P = 0.0591); Gain of glycosylation at T403 (P = 0.1479); Loss of catalytic residue at K405 (P = 0.1789)
17:44067277:A:C,P10636,N406H,0.314,Loss of MoRF binding (P = 0.1192); Gain of methylation at K405 (P = 0.1443); Loss of ubiquitination at K402 (P = 0.212); Loss of glycosylation at P408 (P = 0.2785); Gain of solvent accessibility (P = 0.3418)
17:44067277:A:G,P10636,N406D,0.345,Loss of MoRF binding (P = 0.0637); Loss of methylation at K405 (P = 0.0694); Loss of glycosylation at P408 (P = 0.1384); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2192)
17:44067277:A:T,P10636,N406Y,0.342,Gain of phosphorylation at N406 (P = 0.0203); Gain of solvent accessibility (P = 0.0354); Gain of methylation at K402 (P = 0.061); Loss of MoRF binding (P = 0.106); Gain of relative solvent accessibility (P = 0.1571)
17:44067278:A:C,P10636,N406T,0.337,Gain of phosphorylation at N406 (P = 0.0573); Gain of glycosylation at N406 (P = 0.0724); Loss of MoRF binding (P = 0.1288); Loss of methylation at K405 (P = 0.1511); Gain of relative solvent accessibility (P = 0.1571)
17:44067278:A:G,P10636,N406S,0.329,Gain of phosphorylation at N406 (P = 0.0104); Gain of glycosylation at N406 (P = 0.0257); Loss of methylation at K405 (P = 0.1314); Loss of MoRF binding (P = 0.1439); Gain of relative solvent accessibility (P = 0.1571)
17:44067278:A:T,P10636,N406I,0.349,Loss of solvent accessibility (P = 0.0721); Loss of phosphorylation at T403 (P = 0.0847); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at K402 (P = 0.1092); Loss of glycosylation at P408 (P = 0.1217)
17:44067279:T:A,P10636,N406K,0.346,Gain of methylation at N406 (P = 0.0132); Gain of MoRF binding (P = 0.0503); Gain of solvent accessibility (P = 0.0638); Gain of glycosylation at P408 (P = 0.0868); Gain of ubiquitination at N406 (P = 0.1008)
17:44067279:T:G,P10636,N406K,0.346,Gain of methylation at N406 (P = 0.0132); Gain of MoRF binding (P = 0.0503); Gain of solvent accessibility (P = 0.0638); Gain of glycosylation at P408 (P = 0.0868); Gain of ubiquitination at N406 (P = 0.1008)
17:44067280:A:G,P10636,R407G,0.442,Loss of stability (P = 0.04); Loss of MoRF binding (P = 0.0512); Loss of methylation at R407 (P = 0.0699); Gain of ubiquitination at K402 (P = 0.1472); Loss of glycosylation at P408 (P = 0.1748)
17:44067280:A:T,P10636,R407W,0.448,Loss of catalytic residue at R407 (P = 0.0448); Loss of methylation at R407 (P = 0.0699); Gain of glycosylation at P412 (P = 0.093); Loss of MoRF binding (P = 0.1424); Gain of ubiquitination at K402 (P = 0.1725)
17:44067281:G:A,P10636,R407K,0.435,Gain of methylation at R407 (P = 0.0157); Gain of ubiquitination at R407 (P = 0.0592); Loss of MoRF binding (P = 0.0958); Gain of glycosylation at R407 (P = 0.1246); Loss of stability (P = 0.126)
17:44067281:G:C,P10636,R407T,0.451,Gain of phosphorylation at R407 (P = 0.0169); Loss of catalytic residue at R407 (P = 0.0231); Loss of MoRF binding (P = 0.0477); Loss of methylation at R407 (P = 0.0699); Gain of glycosylation at S411 (P = 0.1018)
17:44067281:G:T,P10636,R407M,0.411,Loss of MoRF binding (P = 0.0694); Loss of methylation at R407 (P = 0.0699); Gain of glycosylation at P412 (P = 0.1322); Gain of ubiquitination at K402 (P = 0.1725); Loss of solvent accessibility (P = 0.3543)
17:44067282:G:C,P10636,R407S,0.455,Gain of phosphorylation at R407 (P = 0.0167); Loss of catalytic residue at R407 (P = 0.0222); Gain of glycosylation at R407 (P = 0.0293); Loss of MoRF binding (P = 0.0504); Loss of methylation at R407 (P = 0.0699)
17:44067282:G:T,P10636,R407S,0.455,Gain of phosphorylation at R407 (P = 0.0167); Loss of catalytic residue at R407 (P = 0.0222); Gain of glycosylation at R407 (P = 0.0293); Loss of MoRF binding (P = 0.0504); Loss of methylation at R407 (P = 0.0699)
17:44067283:C:A,P10636,P408T,0.26,Loss of catalytic residue at P408 (P = 0.0197); Gain of phosphorylation at P408 (P = 0.0275); Loss of stability (P = 0.0537); Gain of MoRF binding (P = 0.0566); Loss of glycosylation at P408 (P = 0.1022)
17:44067283:C:G,P10636,P408A,0.291,Loss of catalytic residue at P408 (P = 0.0148); Gain of MoRF binding (P = 0.0459); Loss of stability (P = 0.0476); Loss of glycosylation at P408 (P = 0.0485); Loss of methylation at K405 (P = 0.0744)
17:44067283:C:T,P10636,P408S,0.278,Gain of phosphorylation at P408 (P = 0.017); Loss of catalytic residue at P408 (P = 0.0502); Gain of MoRF binding (P = 0.0552); Loss of stability (P = 0.0809); Loss of methylation at K405 (P = 0.083)
17:44067284:C:A,P10636,P408H,0.24,Loss of glycosylation at P408 (P = 0.0485); Gain of MoRF binding (P = 0.0672); Loss of stability (P = 0.0684); Loss of catalytic residue at P408 (P = 0.0912); Loss of methylation at K405 (P = 0.164)
17:44067284:C:G,P10636,P408R,0.272,Gain of MoRF binding (P = 0.0186); Loss of ubiquitination at K413 (P = 0.0246); Loss of catalytic residue at P408 (P = 0.0428); Loss of glycosylation at P408 (P = 0.0485); Loss of methylation at K405 (P = 0.113)
17:44067284:C:T,P10636,P408L,0.232,Loss of glycosylation at P408 (P = 0.0485); Loss of methylation at K405 (P = 0.0501); Gain of MoRF binding (P = 0.0509); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1362)
17:44067286:T:A,P10636,C409S,0.392,Gain of phosphorylation at C409 (P = 0.0024); Gain of glycosylation at C409 (P = 0.0297); Loss of catalytic residue at C409 (P = 0.0512); Gain of MoRF binding (P = 0.0678); Loss of methylation at K405 (P = 0.1781)
17:44067286:T:C,P10636,C409R,0.383,Gain of MoRF binding (P = 0.0081); Loss of ubiquitination at K413 (P = 0.0246); Gain of methylation at C409 (P = 0.0249); Loss of catalytic residue at L410 (P = 0.0331); Gain of glycosylation at P408 (P = 0.0892)
17:44067286:T:G,P10636,C409G,0.353,Gain of MoRF binding (P = 0.0789); Loss of catalytic residue at C409 (P = 0.0905); Gain of methylation at R407 (P = 0.113); Loss of glycosylation at P412 (P = 0.1397); Loss of stability (P = 0.1446)
17:44067287:G:A,P10636,C409Y,0.354,Gain of phosphorylation at C409 (P = 0.0288); Loss of catalytic residue at L410 (P = 0.0466); Gain of methylation at K405 (P = 0.0634); Gain of MoRF binding (P = 0.0868); Loss of relative solvent accessibility (P = 0.1807)
17:44067287:G:C,P10636,C409S,0.392,Gain of phosphorylation at C409 (P = 0.0024); Gain of glycosylation at C409 (P = 0.0297); Loss of catalytic residue at C409 (P = 0.0512); Gain of MoRF binding (P = 0.0678); Loss of methylation at K405 (P = 0.1781)
17:44067287:G:T,P10636,C409F,0.345,Loss of catalytic residue at L410 (P = 0.0434); Loss of relative solvent accessibility (P = 0.0981); Gain of MoRF binding (P = 0.1115); Gain of methylation at K405 (P = 0.1217); Loss of solvent accessibility (P = 0.1744)
17:44067288:C:G,P10636,C409W,0.379,Gain of catalytic residue at P412 (P = 0.0256); Gain of MoRF binding (P = 0.0273); Loss of relative solvent accessibility (P = 0.0981); Gain of methylation at K405 (P = 0.1298); Gain of glycosylation at P412 (P = 0.1573)
17:44067289:C:A,P10636,L410I,0.254,Loss of catalytic residue at L410 (P = 0.0047); Gain of methylation at K405 (P = 0.0804); Gain of glycosylation at S411 (P = 0.1033); Gain of MoRF binding (P = 0.1104); Loss of ubiquitination at K413 (P = 0.2335)
17:44067289:C:G,P10636,L410V,0.224,Loss of catalytic residue at L410 (P = 0.0096); Gain of MoRF binding (P = 0.0913); Gain of methylation at K405 (P = 0.1016); Loss of glycosylation at P408 (P = 0.1342); Gain of ubiquitination at K413 (P = 0.1982)
17:44067290:T:A,P10636,L410H,0.216,Loss of stability (P = 0.0585); Gain of methylation at K405 (P = 0.0772); Loss of catalytic residue at L410 (P = 0.1053); Gain of MoRF binding (P = 0.1095); Gain of glycosylation at K413 (P = 0.1309)
17:44067290:T:C,P10636,L410P,0.272,Gain of glycosylation at L410 (P = 0.0154); Gain of relative solvent accessibility (P = 0.0249); Loss of stability (P = 0.0641); Gain of methylation at K405 (P = 0.0669); Gain of solvent accessibility (P = 0.0766)
17:44067290:T:G,P10636,L410R,0.307,Gain of MoRF binding (P = 0.0162); Loss of ubiquitination at K413 (P = 0.0283); Gain of methylation at L410 (P = 0.0457); Gain of solvent accessibility (P = 0.0611); Gain of relative solvent accessibility (P = 0.1066)
17:44067292:A:C,P10636,S411R,0.28,Loss of phosphorylation at S411 (P = 0.0203); Loss of ubiquitination at K413 (P = 0.0255); Gain of MoRF binding (P = 0.0343); Gain of methylation at S411 (P = 0.0596); Loss of glycosylation at P415 (P = 0.1571)
17:44067292:A:G,P10636,S411G,0.26,Loss of phosphorylation at S411 (P = 0.0203); Loss of stability (P = 0.0496); Gain of glycosylation at K413 (P = 0.0775); Loss of MoRF binding (P = 0.1357); Gain of ubiquitination at K413 (P = 0.2106)
17:44067292:A:T,P10636,S411C,0.255,Loss of phosphorylation at S411 (P = 0.0203); Loss of ubiquitination at K413 (P = 0.0742); Loss of MoRF binding (P = 0.0804); Gain of glycosylation at K413 (P = 0.1378); Gain of catalytic residue at S411 (P = 0.2246)
17:44067293:G:A,P10636,S411N,0.249,Loss of phosphorylation at S411 (P = 0.0203); Loss of MoRF binding (P = 0.1224); Loss of glycosylation at P415 (P = 0.1835); Loss of ubiquitination at K413 (P = 0.2335); Gain of methylation at K413 (P = 0.262)
17:44067293:G:C,P10636,S411T,0.261,Gain of glycosylation at S411 (P = 0.0647); Loss of MoRF binding (P = 0.1269); Loss of ubiquitination at K413 (P = 0.2113); Gain of catalytic residue at S411 (P = 0.2192); Gain of methylation at K413 (P = 0.251)
17:44067293:G:T,P10636,S411I,0.27,Loss of phosphorylation at S411 (P = 0.0203); Loss of glycosylation at P412 (P = 0.0862); Gain of MoRF binding (P = 0.1262); Gain of methylation at K413 (P = 0.1907); Loss of ubiquitination at K413 (P = 0.2335)
17:44067294:C:A,P10636,S411R,0.28,Loss of phosphorylation at S411 (P = 0.0203); Loss of ubiquitination at K413 (P = 0.0255); Gain of MoRF binding (P = 0.0343); Gain of methylation at S411 (P = 0.0596); Loss of glycosylation at P415 (P = 0.1571)
17:44067294:C:G,P10636,S411R,0.28,Loss of phosphorylation at S411 (P = 0.0203); Loss of ubiquitination at K413 (P = 0.0255); Gain of MoRF binding (P = 0.0343); Gain of methylation at S411 (P = 0.0596); Loss of glycosylation at P415 (P = 0.1571)
17:44067295:C:A,P10636,P412T,0.22,Gain of phosphorylation at P412 (P = 0.0178); Gain of MoRF binding (P = 0.0601); Gain of glycosylation at P412 (P = 0.0787); Loss of stability (P = 0.2174); Gain of ubiquitination at K413 (P = 0.2244)
17:44067295:C:G,P10636,P412A,0.207,Loss of glycosylation at P412 (P = 0.0243); Gain of MoRF binding (P = 0.0509); Loss of methylation at K413 (P = 0.142); Loss of phosphorylation at S411 (P = 0.1554); Gain of ubiquitination at K413 (P = 0.1557)
17:44067295:C:T,P10636,P412S,0.189,Gain of phosphorylation at P412 (P = 0.021); Gain of MoRF binding (P = 0.0585); Loss of glycosylation at K413 (P = 0.1057); Loss of methylation at K413 (P = 0.1391); Loss of stability (P = 0.1842)
17:44067296:C:A,P10636,P412H,0.214,Loss of glycosylation at P412 (P = 0.0243); Gain of MoRF binding (P = 0.0679); Loss of phosphorylation at S411 (P = 0.159); Loss of stability (P = 0.2202); Loss of methylation at K413 (P = 0.2243)
17:44067296:C:G,P10636,P412R,0.252,Gain of MoRF binding (P = 0.0081); Loss of ubiquitination at K413 (P = 0.0233); Loss of glycosylation at P412 (P = 0.0243); Gain of methylation at P412 (P = 0.0745); Gain of catalytic residue at P412 (P = 0.0856)
17:44067296:C:T,P10636,P412L,0.227,Loss of glycosylation at P412 (P = 0.0243); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Gain of MoRF binding (P = 0.059); Loss of methylation at K413 (P = 0.1101)
17:44067298:A:C,P10636,K413Q,0.352,Loss of methylation at K413 (P = 0.0087); Loss of ubiquitination at K413 (P = 0.0087); Loss of glycosylation at K413 (P = 0.0334); Loss of MoRF binding (P = 0.0712); Loss of catalytic residue at K413 (P = 0.1517)
17:44067298:A:G,P10636,K413E,0.343,Loss of methylation at K413 (P = 0.0087); Loss of ubiquitination at K413 (P = 0.0087); Loss of glycosylation at K413 (P = 0.0334); Loss of MoRF binding (P = 0.0382); Gain of phosphorylation at S411 (P = 0.4383)
17:44067299:A:C,P10636,K413T,0.344,Loss of methylation at K413 (P = 0.0087); Loss of ubiquitination at K413 (P = 0.0087); Gain of glycosylation at K413 (P = 0.0631); Gain of phosphorylation at K413 (P = 0.0647); Loss of MoRF binding (P = 0.0672)
17:44067299:A:G,P10636,K413R,0.308,Loss of ubiquitination at K413 (P = 0.0087); Loss of methylation at K413 (P = 0.0164); Loss of glycosylation at K413 (P = 0.0334); Gain of MoRF binding (P = 0.0825); Gain of phosphorylation at S411 (P = 0.3749)
17:44067299:A:T,P10636,K413I,0.395,Loss of solvent accessibility (P = 0.0017); Loss of methylation at K413 (P = 0.0087); Loss of ubiquitination at K413 (P = 0.0087); Loss of relative solvent accessibility (P = 0.0186); Loss of glycosylation at K413 (P = 0.0334)
17:44067300:A:C,P10636,K413N,0.362,Loss of methylation at K413 (P = 0.0087); Loss of ubiquitination at K413 (P = 0.0087); Loss of glycosylation at K413 (P = 0.0334); Loss of MoRF binding (P = 0.0674); Loss of phosphorylation at S411 (P = 0.1712)
17:44067300:A:T,P10636,K413N,0.362,Loss of methylation at K413 (P = 0.0087); Loss of ubiquitination at K413 (P = 0.0087); Loss of glycosylation at K413 (P = 0.0334); Loss of MoRF binding (P = 0.0674); Loss of phosphorylation at S411 (P = 0.1712)
17:44067301:C:A,P10636,H414N,0.214,Gain of relative solvent accessibility (P = 0.0507); Gain of solvent accessibility (P = 0.1154); Loss of glycosylation at K413 (P = 0.139); Gain of MoRF binding (P = 0.1413); Loss of catalytic residue at H414 (P = 0.1428)
17:44067301:C:G,P10636,H414D,0.261,Gain of relative solvent accessibility (P = 0.0507); Loss of MoRF binding (P = 0.09); Loss of methylation at K413 (P = 0.0995); Loss of glycosylation at T416 (P = 0.1067); Gain of solvent accessibility (P = 0.1071)
17:44067301:C:T,P10636,H414Y,0.201,Gain of phosphorylation at H414 (P = 0.0598); Loss of methylation at K413 (P = 0.0979); Loss of glycosylation at T416 (P = 0.1067); Gain of MoRF binding (P = 0.1699); Gain of ubiquitination at K413 (P = 0.2244)
17:44067302:A:C,P10636,H414P,0.286,Gain of glycosylation at H414 (P = 0.0127); Loss of MoRF binding (P = 0.1075); Gain of catalytic residue at H414 (P = 0.1457); Loss of ubiquitination at K413 (P = 0.2113); Gain of relative solvent accessibility (P = 0.2629)
17:44067302:A:G,P10636,H414R,0.242,Loss of ubiquitination at K413 (P = 0.022); Gain of MoRF binding (P = 0.0245); Loss of glycosylation at S419 (P = 0.1026); Gain of solvent accessibility (P = 0.1903); Gain of methylation at K413 (P = 0.2609)
17:44067302:A:T,P10636,H414L,0.22,Loss of methylation at K413 (P = 0.0778); Loss of glycosylation at S419 (P = 0.1323); Gain of MoRF binding (P = 0.1706); Gain of ubiquitination at K413 (P = 0.2244); Gain of catalytic residue at H414 (P = 0.3482)
17:44067303:C:A,P10636,H414Q,0.198,Gain of MoRF binding (P = 0.1213); Loss of glycosylation at S419 (P = 0.1285); Loss of ubiquitination at K413 (P = 0.1557); Loss of catalytic residue at K413 (P = 0.2374); Gain of methylation at K413 (P = 0.2547)
17:44067303:C:G,P10636,H414Q,0.198,Gain of MoRF binding (P = 0.1213); Loss of glycosylation at S419 (P = 0.1285); Loss of ubiquitination at K413 (P = 0.1557); Loss of catalytic residue at K413 (P = 0.2374); Gain of methylation at K413 (P = 0.2547)
17:44067304:C:A,P10636,P415T,0.398,Gain of phosphorylation at P415 (P = 0.0588); Gain of MoRF binding (P = 0.0952); Loss of glycosylation at P412 (P = 0.1231); Loss of methylation at K413 (P = 0.1547); Gain of ubiquitination at K413 (P = 0.2244)
17:44067304:C:G,P10636,P415A,0.413,Loss of glycosylation at P415 (P = 0.0372); Gain of MoRF binding (P = 0.0737); Gain of ubiquitination at K413 (P = 0.1283); Loss of methylation at K413 (P = 0.1542); Loss of phosphorylation at S411 (P = 0.3027)
17:44067304:C:T,P10636,P415S,0.428,Gain of phosphorylation at P415 (P = 0.011); Gain of glycosylation at P415 (P = 0.0541); Gain of MoRF binding (P = 0.0859); Loss of methylation at K413 (P = 0.1312); Gain of ubiquitination at K413 (P = 0.1832)
17:44067305:C:A,P10636,P415H,0.389,Loss of glycosylation at P415 (P = 0.0372); Loss of relative solvent accessibility (P = 0.0676); Gain of MoRF binding (P = 0.1171); Loss of solvent accessibility (P = 0.1301); Loss of methylation at K413 (P = 0.2162)
17:44067305:C:G,P10636,P415R,0.435,Gain of MoRF binding (P = 0.0132); Loss of ubiquitination at K413 (P = 0.0233); Loss of glycosylation at P415 (P = 0.0372); Gain of solvent accessibility (P = 0.1045); Gain of catalytic residue at P415 (P = 0.1437)
17:44067305:C:T,P10636,P415L,0.396,Loss of glycosylation at P415 (P = 0.0372); Gain of catalytic residue at P415 (P = 0.0886); Gain of MoRF binding (P = 0.0919); Loss of methylation at K413 (P = 0.1086); Gain of stability (P = 0.1523)
17:44067307:A:C,P10636,T416P,0.292,Loss of phosphorylation at T416 (P = 0.0059); Gain of catalytic residue at P415 (P = 0.0276); Gain of glycosylation at P415 (P = 0.0592); Loss of ubiquitination at K413 (P = 0.1557); Gain of methylation at K413 (P = 0.2589)
17:44067307:A:G,P10636,T416A,0.272,Loss of phosphorylation at T416 (P = 0.0059); Loss of glycosylation at T416 (P = 0.0153); Loss of solvent accessibility (P = 0.1177); Loss of methylation at K413 (P = 0.1713); Loss of relative solvent accessibility (P = 0.1807)
17:44067307:A:T,P10636,T416S,0.305,Loss of glycosylation at T416 (P = 0.0861); Loss of catalytic residue at T416 (P = 0.1421); Loss of methylation at K413 (P = 0.1683); Loss of ubiquitination at K413 (P = 0.2335); Loss of solvent accessibility (P = 0.2517)
17:44067308:C:A,P10636,T416N,0.289,Loss of phosphorylation at T416 (P = 0.0059); Loss of glycosylation at T416 (P = 0.0153); Loss of methylation at K413 (P = 0.2038); Loss of ubiquitination at K413 (P = 0.2335); Gain of MoRF binding (P = 0.283)
17:44067308:C:G,P10636,T416S,0.305,Loss of glycosylation at T416 (P = 0.0861); Loss of catalytic residue at T416 (P = 0.1421); Loss of methylation at K413 (P = 0.1683); Loss of ubiquitination at K413 (P = 0.2335); Loss of solvent accessibility (P = 0.2517)
17:44067310:C:A,P10636,P417T,0.246,Gain of phosphorylation at P417 (P = 0.0128); Gain of glycosylation at T416 (P = 0.1248); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1922); Gain of ubiquitination at K413 (P = 0.2244)
17:44067310:C:G,P10636,P417A,0.306,Gain of catalytic residue at P417 (P = 0.0171); Loss of glycosylation at P417 (P = 0.0236); Loss of solvent accessibility (P = 0.089); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at K413 (P = 0.1186)
17:44067310:C:T,P10636,P417S,0.267,Gain of phosphorylation at P417 (P = 0.0069); Gain of glycosylation at P417 (P = 0.0426); Gain of ubiquitination at K413 (P = 0.2106); Gain of MoRF binding (P = 0.2624); Gain of methylation at K413 (P = 0.2793)
17:44067311:C:A,P10636,P417H,0.25,Loss of glycosylation at P417 (P = 0.0236); Gain of catalytic residue at P417 (P = 0.0782); Loss of relative solvent accessibility (P = 0.1807); Loss of ubiquitination at K413 (P = 0.2335); Loss of methylation at K413 (P = 0.2407)
17:44067311:C:G,P10636,P417R,0.296,Loss of ubiquitination at K413 (P = 0.0236); Loss of glycosylation at P417 (P = 0.0236); Gain of catalytic residue at P417 (P = 0.0237); Gain of MoRF binding (P = 0.0243); Loss of methylation at K413 (P = 0.1419)
17:44067311:C:T,P10636,P417L,0.286,Loss of glycosylation at P417 (P = 0.0236); Gain of catalytic residue at P417 (P = 0.0414); Loss of methylation at K413 (P = 0.0696); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1362)
17:44067313:G:A,P10636,G418S,0.306,Gain of phosphorylation at G418 (P = 0.0078); Gain of glycosylation at P415 (P = 0.0682); Gain of solvent accessibility (P = 0.1014); Gain of relative solvent accessibility (P = 0.1571); Loss of ubiquitination at K413 (P = 0.1852)
17:44067313:G:C,P10636,G418R,0.331,Gain of solvent accessibility (P = 0.0097); Loss of ubiquitination at K413 (P = 0.0233); Gain of glycosylation at P415 (P = 0.0825); Gain of methylation at G418 (P = 0.0976); Gain of MoRF binding (P = 0.1497)
17:44067313:G:T,P10636,G418C,0.319,Gain of catalytic residue at P417 (P = 0.009); Loss of glycosylation at T416 (P = 0.0476); Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K413 (P = 0.1852); Loss of methylation at K413 (P = 0.2384)
17:44067314:G:A,P10636,G418D,0.304,Gain of solvent accessibility (P = 0.0354); Gain of glycosylation at P415 (P = 0.1224); Gain of ubiquitination at K413 (P = 0.1283); Loss of methylation at K413 (P = 0.1431); Gain of relative solvent accessibility (P = 0.1571)
17:44067314:G:C,P10636,G418A,0.303,Gain of glycosylation at P415 (P = 0.1401); Loss of methylation at K413 (P = 0.2154); Gain of ubiquitination at K413 (P = 0.2244); Gain of solvent accessibility (P = 0.367); Loss of catalytic residue at H414 (P = 0.4188)
17:44067314:G:T,P10636,G418V,0.299,Loss of glycosylation at P417 (P = 0.0767); Loss of relative solvent accessibility (P = 0.0981); Gain of ubiquitination at K413 (P = 0.1982); Gain of methylation at K413 (P = 0.2618); Loss of solvent accessibility (P = 0.4141)
17:44067316:A:C,P10636,S419R,0.242,Loss of phosphorylation at S419 (P = 0.0089); Loss of glycosylation at S419 (P = 0.032); Gain of catalytic residue at S419 (P = 0.1317); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at S419 (P = 0.235)
17:44067316:A:G,P10636,S419G,0.223,Loss of phosphorylation at S419 (P = 0.0089); Loss of glycosylation at S419 (P = 0.032); Gain of catalytic residue at P415 (P = 0.0752); Loss of solvent accessibility (P = 0.1279); Loss of relative solvent accessibility (P = 0.1807)
17:44067316:A:T,P10636,S419C,0.231,Loss of phosphorylation at S419 (P = 0.0089); Loss of glycosylation at S419 (P = 0.032); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1322); Gain of catalytic residue at S419 (P = 0.149)
17:44067317:G:A,P10636,S419N,0.226,Loss of phosphorylation at S419 (P = 0.0089); Loss of glycosylation at S419 (P = 0.032); Gain of catalytic residue at S419 (P = 0.3036); Gain of solvent accessibility (P = 0.3304); Loss of MoRF binding (P = 0.5799)
17:44067317:G:C,P10636,S419T,0.231,Gain of glycosylation at S419 (P = 0.0464); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2073); Loss of phosphorylation at T416 (P = 0.4256); Loss of MoRF binding (P = 0.5783)
17:44067317:G:T,P10636,S419I,0.245,Loss of phosphorylation at S419 (P = 0.0089); Loss of glycosylation at S419 (P = 0.032); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1115); Gain of MoRF binding (P = 0.5722)
17:44067318:C:A,P10636,S419R,0.242,Loss of phosphorylation at S419 (P = 0.0089); Loss of glycosylation at S419 (P = 0.032); Gain of catalytic residue at S419 (P = 0.1317); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at S419 (P = 0.235)
17:44067318:C:G,P10636,S419R,0.242,Loss of phosphorylation at S419 (P = 0.0089); Loss of glycosylation at S419 (P = 0.032); Gain of catalytic residue at S419 (P = 0.1317); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at S419 (P = 0.235)
17:44067319:T:A,P10636,S420T,0.129,Gain of glycosylation at S420 (P = 0.0436); Gain of catalytic residue at S420 (P = 0.275); Loss of phosphorylation at S420 (P = 0.3362); Gain of solvent accessibility (P = 0.4496); Loss of stability (P = 0.5426)
17:44067319:T:C,P10636,S420P,0.085,Loss of phosphorylation at S420 (P = 0.0113); Gain of glycosylation at S419 (P = 0.0887); Loss of stability (P = 0.4967); Gain of solvent accessibility (P = 0.5334); Gain of sheet (P = 0.6509)
17:44067319:T:G,P10636,S420A,0.089,Loss of phosphorylation at S420 (P = 0.0113); Loss of glycosylation at S420 (P = 0.0704); Loss of solvent accessibility (P = 0.5485); Gain of MoRF binding (P = 0.6759); Loss of stability (P = 0.6779)
17:44067320:C:T,P10636,S420L,0.151,Loss of phosphorylation at S420 (P = 0.0113); Loss of relative solvent accessibility (P = 0.0186); Loss of solvent accessibility (P = 0.0404); Gain of glycosylation at S419 (P = 0.0673); Gain of catalytic residue at S420 (P = 0.2963)
17:44067322:G:A,P10636,D421N,0.216,Loss of stability (P = 0.0222); Gain of glycosylation at S420 (P = 0.1328); Loss of phosphorylation at S420 (P = 0.3687); Gain of catalytic residue at P422 (P = 0.5175); Loss of solvent accessibility (P = 0.5743)
17:44067322:G:C,P10636,D421H,0.202,Loss of stability (P = 0.0865); Gain of catalytic residue at D421 (P = 0.1505); Loss of glycosylation at S419 (P = 0.1604); Loss of relative solvent accessibility (P = 0.3919); Loss of solvent accessibility (P = 0.4141)
17:44067322:G:T,P10636,D421Y,0.204,Gain of phosphorylation at D421 (P = 0.0146); Gain of glycosylation at S419 (P = 0.1135); Gain of catalytic residue at D421 (P = 0.1136); Loss of stability (P = 0.2155); Gain of sheet (P = 0.6509)
17:44067323:A:C,P10636,D421A,0.205,Loss of stability (P = 0.1303); Gain of glycosylation at S419 (P = 0.1414); Gain of catalytic residue at D421 (P = 0.2619); Loss of solvent accessibility (P = 0.2668); Loss of relative solvent accessibility (P = 0.3919)
17:44067323:A:G,P10636,D421G,0.226,Loss of stability (P = 0.031); Gain of glycosylation at S420 (P = 0.032); Gain of catalytic residue at P417 (P = 0.0678); Loss of solvent accessibility (P = 0.2953); Loss of phosphorylation at S420 (P = 0.5931)
17:44067323:A:T,P10636,D421V,0.197,Gain of glycosylation at S419 (P = 0.0876); Loss of solvent accessibility (P = 0.322); Loss of stability (P = 0.337); Loss of relative solvent accessibility (P = 0.3919); Loss of phosphorylation at S420 (P = 0.4567)
17:44067324:C:A,P10636,D421E,0.219,Loss of stability (P = 0.159); Gain of glycosylation at P417 (P = 0.162); Gain of solvent accessibility (P = 0.1751); Gain of relative solvent accessibility (P = 0.1894); Loss of catalytic residue at S419 (P = 0.4179)
17:44067324:C:G,P10636,D421E,0.219,Loss of stability (P = 0.159); Gain of glycosylation at P417 (P = 0.162); Gain of solvent accessibility (P = 0.1751); Gain of relative solvent accessibility (P = 0.1894); Loss of catalytic residue at S419 (P = 0.4179)
17:44067325:C:A,P10636,P422T,0.265,Gain of phosphorylation at P422 (P = 0.0499); Loss of glycosylation at S419 (P = 0.1828); Loss of stability (P = 0.2732); Loss of relative solvent accessibility (P = 0.3219); Loss of solvent accessibility (P = 0.3473)
17:44067325:C:G,P10636,P422A,0.264,Loss of glycosylation at P422 (P = 0.064); Loss of stability (P = 0.362); Loss of phosphorylation at S420 (P = 0.4623); Loss of solvent accessibility (P = 0.5743); Gain of sheet (P = 0.6509)
17:44067325:C:T,P10636,P422S,0.289,Gain of phosphorylation at P422 (P = 0.0194); Gain of glycosylation at P422 (P = 0.0597); Loss of solvent accessibility (P = 0.1744); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.3228)
17:44067326:C:A,P10636,P422H,0.279,Loss of glycosylation at P422 (P = 0.064); Gain of catalytic residue at D421 (P = 0.1547); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.2792); Loss of solvent accessibility (P = 0.3103)
17:44067326:C:G,P10636,P422R,0.316,Loss of glycosylation at P422 (P = 0.064); Gain of catalytic residue at P422 (P = 0.0796); Gain of solvent accessibility (P = 0.1708); Gain of MoRF binding (P = 0.5235); Loss of stability (P = 0.5266)
17:44067326:C:T,P10636,P422L,0.344,Gain of catalytic residue at P422 (P = 0.0245); Loss of glycosylation at P422 (P = 0.064); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.2517); Loss of phosphorylation at S420 (P = 0.4019)
17:44067328:C:A,P10636,L423M,0.369,Loss of catalytic residue at L423 (P = 0.0024); Loss of glycosylation at S419 (P = 0.2144); Loss of stability (P = 0.5378); Loss of relative solvent accessibility (P = 0.5582); Gain of phosphorylation at S427 (P = 0.5653)
17:44067328:C:G,P10636,L423V,0.345,Loss of catalytic residue at L423 (P = 0.0396); Loss of solvent accessibility (P = 0.0561); Gain of glycosylation at S420 (P = 0.1047); Loss of relative solvent accessibility (P = 0.107); Gain of phosphorylation at S427 (P = 0.5707)
17:44067329:T:A,P10636,L423Q,0.354,Loss of catalytic residue at L423 (P = 0.005); Loss of relative solvent accessibility (P = 0.107); Loss of stability (P = 0.1143); Loss of solvent accessibility (P = 0.1434); Loss of glycosylation at P422 (P = 0.1617)
17:44067329:T:C,P10636,L423P,0.366,Gain of catalytic residue at P422 (P = 0.0112); Loss of stability (P = 0.0376); Gain of glycosylation at L423 (P = 0.0624); Loss of solvent accessibility (P = 0.2106); Gain of phosphorylation at S427 (P = 0.5397)
17:44067329:T:G,P10636,L423R,0.354,Loss of stability (P = 0.1069); Loss of glycosylation at S419 (P = 0.2196); Gain of solvent accessibility (P = 0.2346); Gain of catalytic residue at G418 (P = 0.358); Loss of relative solvent accessibility (P = 0.5582)
17:44067331:A:C,P10636,I424L,0.284,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0365); Gain of catalytic residue at I424 (P = 0.0652); Gain of glycosylation at P422 (P = 0.1357); Gain of phosphorylation at S427 (P = 0.5473)
17:44067331:A:G,P10636,I424V,0.274,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0674); Gain of glycosylation at S419 (P = 0.1305); Gain of phosphorylation at S427 (P = 0.5581); Loss of sheet (P = 0.6423)
17:44067331:A:T,P10636,I424F,0.26,Gain of catalytic residue at I424 (P = 0.0778); Gain of glycosylation at P422 (P = 0.1376); Loss of stability (P = 0.3865); Gain of solvent accessibility (P = 0.5093); Gain of phosphorylation at S427 (P = 0.571)
17:44067332:T:A,P10636,I424N,0.328,Gain of catalytic residue at I424 (P = 0.0055); Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0421); Loss of stability (P = 0.104); Loss of glycosylation at S427 (P = 0.112)
17:44067332:T:C,P10636,I424T,0.328,Gain of phosphorylation at I424 (P = 0.0025); Gain of relative solvent accessibility (P = 0.0098); Gain of glycosylation at I424 (P = 0.0103); Gain of solvent accessibility (P = 0.0263); Loss of stability (P = 0.0326)
17:44067332:T:G,P10636,I424S,0.313,Gain of phosphorylation at I424 (P = 0.0068); Gain of glycosylation at I424 (P = 0.0183); Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0854); Loss of stability (P = 0.0866)
17:44067333:C:G,P10636,I424M,0.282,Loss of glycosylation at S427 (P = 0.1028); Gain of relative solvent accessibility (P = 0.2629); Gain of solvent accessibility (P = 0.2987); Loss of stability (P = 0.4013); Gain of phosphorylation at S427 (P = 0.5397)
17:44067334:C:A,P10636,Q425K,0.291,Gain of methylation at Q425 (P = 0.0078); Gain of ubiquitination at Q425 (P = 0.009); Gain of glycosylation at Q425 (P = 0.0623); Gain of relative solvent accessibility (P = 0.1684); Gain of solvent accessibility (P = 0.194)
17:44067334:C:G,P10636,Q425E,0.269,Gain of catalytic residue at Q425 (P = 0.1661); Gain of relative solvent accessibility (P = 0.1684); Gain of glycosylation at S420 (P = 0.217); Gain of solvent accessibility (P = 0.2455); Gain of phosphorylation at S427 (P = 0.5375)
17:44067335:A:C,P10636,Q425P,0.278,Gain of catalytic residue at Q425 (P = 0.0159); Gain of glycosylation at Q425 (P = 0.0201); Loss of solvent accessibility (P = 0.1202); Loss of loop (P = 0.2897); Loss of relative solvent accessibility (P = 0.3589)
17:44067335:A:G,P10636,Q425R,0.267,Gain of catalytic residue at Q425 (P = 0.0676); Loss of glycosylation at S427 (P = 0.2402); Loss of relative solvent accessibility (P = 0.3589); Loss of solvent accessibility (P = 0.3646); Gain of phosphorylation at S427 (P = 0.503)
17:44067335:A:T,P10636,Q425L,0.328,Loss of solvent accessibility (P = 0.0807); Gain of catalytic residue at Q425 (P = 0.0997); Gain of glycosylation at S420 (P = 0.1159); Loss of relative solvent accessibility (P = 0.1903); Loss of phosphorylation at S427 (P = 0.5237)
17:44067336:A:C,P10636,Q425H,0.277,Gain of glycosylation at S420 (P = 0.1338); Loss of solvent accessibility (P = 0.1922); Gain of catalytic residue at Q425 (P = 0.2967); Loss of relative solvent accessibility (P = 0.3589); Gain of phosphorylation at S427 (P = 0.5717)
17:44067336:A:T,P10636,Q425H,0.277,Gain of glycosylation at S420 (P = 0.1338); Loss of solvent accessibility (P = 0.1922); Gain of catalytic residue at Q425 (P = 0.2967); Loss of relative solvent accessibility (P = 0.3589); Gain of phosphorylation at S427 (P = 0.5717)
17:44067337:C:A,P10636,P426T,0.258,Loss of catalytic residue at P426 (P = 0.0077); Gain of glycosylation at P426 (P = 0.012); Gain of phosphorylation at P426 (P = 0.0534); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1922)
17:44067337:C:G,P10636,P426A,0.255,Loss of catalytic residue at P426 (P = 0.0077); Loss of glycosylation at S428 (P = 0.1542); Loss of phosphorylation at S427 (P = 0.4368); Loss of solvent accessibility (P = 0.5743); Loss of stability (P = 0.6007)
17:44067337:C:T,P10636,P426S,0.226,Gain of phosphorylation at P426 (P = 0.0185); Gain of glycosylation at P426 (P = 0.0219); Loss of catalytic residue at P426 (P = 0.086); Loss of stability (P = 0.5952); Gain of sheet (P = 0.6509)
17:44067338:C:A,P10636,P426H,0.245,Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at I424 (P = 0.12); Loss of solvent accessibility (P = 0.1551); Loss of glycosylation at S428 (P = 0.1936); Loss of phosphorylation at S427 (P = 0.3154)
17:44067338:C:G,P10636,P426R,0.262,Gain of solvent accessibility (P = 0.0411); Loss of glycosylation at S428 (P = 0.1292); Gain of phosphorylation at S428 (P = 0.5554); Loss of catalytic residue at D421 (P = 0.5583); Gain of methylation at P426 (P = 0.6493)
17:44067338:C:T,P10636,P426L,0.219,Loss of glycosylation at S427 (P = 0.069); Loss of relative solvent accessibility (P = 0.0981); Loss of catalytic residue at P426 (P = 0.0993); Loss of solvent accessibility (P = 0.1362); Loss of phosphorylation at S428 (P = 0.242)
17:44067340:T:A,P10636,S427T,0.304,Gain of glycosylation at S427 (P = 0.278); Loss of phosphorylation at S427 (P = 0.359); Gain of solvent accessibility (P = 0.4496); Loss of sheet (P = 0.6423); Gain of catalytic residue at S427 (P = 0.7875)
17:44067340:T:C,P10636,S427P,0.246,Loss of phosphorylation at S427 (P = 0.013); Loss of glycosylation at S427 (P = 0.0587); Loss of loop (P = 0.0603); Gain of sheet (P = 0.1451); Gain of helix (P = 0.4875)
17:44067340:T:G,P10636,S427A,0.256,Loss of glycosylation at S427 (P = 0.0088); Loss of phosphorylation at S427 (P = 0.013); Gain of catalytic residue at S427 (P = 0.1459); Loss of solvent accessibility (P = 0.5485); Loss of sheet (P = 0.6423)
17:44067341:C:A,P10636,S427Y,0.345,Loss of glycosylation at S427 (P = 0.0088); Gain of catalytic residue at S427 (P = 0.0189); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.1115); Loss of phosphorylation at S428 (P = 0.3695)
17:44067341:C:G,P10636,S427C,0.314,Loss of glycosylation at S427 (P = 0.0088); Loss of phosphorylation at S427 (P = 0.013); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Gain of catalytic residue at S427 (P = 0.0547)
17:44067343:A:C,P10636,S428R,0.298,Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Gain of catalytic residue at S428 (P = 0.0314); Gain of solvent accessibility (P = 0.3304); Loss of stability (P = 0.5068)
17:44067343:A:G,P10636,S428G,0.303,Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Loss of stability (P = 0.0936); Gain of catalytic residue at S428 (P = 0.419); Loss of solvent accessibility (P = 0.6134)
17:44067343:A:T,P10636,S428C,0.34,Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Gain of catalytic residue at S428 (P = 0.0455); Loss of relative solvent accessibility (P = 0.3919); Loss of solvent accessibility (P = 0.4838)
17:44067344:G:A,P10636,S428N,0.31,Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Loss of stability (P = 0.4455); Gain of catalytic residue at P429 (P = 0.5451); Gain of sheet (P = 0.6509)
17:44067344:G:C,P10636,S428T,0.288,Gain of catalytic residue at S428 (P = 0.1192); Gain of glycosylation at S427 (P = 0.2069); Loss of phosphorylation at S427 (P = 0.3653); Gain of sheet (P = 0.6509); Loss of stability (P = 0.6986)
17:44067344:G:T,P10636,S428I,0.292,Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Loss of relative solvent accessibility (P = 0.3219); Loss of solvent accessibility (P = 0.3854); Loss of catalytic residue at V431 (P = 0.5013)
17:44067345:C:A,P10636,S428R,0.298,Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Gain of catalytic residue at S428 (P = 0.0314); Gain of solvent accessibility (P = 0.3304); Loss of stability (P = 0.5068)
17:44067345:C:G,P10636,S428R,0.298,Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Gain of catalytic residue at S428 (P = 0.0314); Gain of solvent accessibility (P = 0.3304); Loss of stability (P = 0.5068)
17:44067346:C:A,P10636,P429T,0.284,Gain of glycosylation at P429 (P = 0.0218); Gain of phosphorylation at P429 (P = 0.0457); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1235); Gain of catalytic residue at P429 (P = 0.1752)
17:44067346:C:G,P10636,P429A,0.27,Loss of solvent accessibility (P = 0.089); Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at P429 (P = 0.1667); Loss of phosphorylation at S428 (P = 0.3257); Loss of stability (P = 0.4292)
17:44067346:C:T,P10636,P429S,0.262,Gain of phosphorylation at P429 (P = 0.0172); Gain of glycosylation at P429 (P = 0.0722); Loss of solvent accessibility (P = 0.1744); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.3711)
17:44067347:C:A,P10636,P429H,0.265,Loss of glycosylation at S427 (P = 0.0873); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at P429 (P = 0.1114); Loss of solvent accessibility (P = 0.1551); Loss of phosphorylation at S428 (P = 0.2788)
17:44067347:C:G,P10636,P429R,0.289,Loss of glycosylation at S427 (P = 0.0853); Gain of catalytic residue at P429 (P = 0.1382); Loss of relative solvent accessibility (P = 0.1807); Gain of methylation at P429 (P = 0.2658); Loss of solvent accessibility (P = 0.5288)
17:44067347:C:T,P10636,P429L,0.291,Gain of catalytic residue at P429 (P = 0.0244); Loss of glycosylation at S427 (P = 0.0944); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1362); Loss of phosphorylation at S428 (P = 0.3373)
17:44067349:G:A,P10636,A430T,0.278,Gain of glycosylation at A430 (P = 0.0044); Gain of phosphorylation at A430 (P = 0.0152); Gain of solvent accessibility (P = 0.28); Loss of sheet (P = 0.6423); Loss of stability (P = 0.6731)
17:44067349:G:C,P10636,A430P,0.31,Gain of catalytic residue at P429 (P = 0.0207); Gain of glycosylation at A430 (P = 0.0215); Gain of solvent accessibility (P = 0.1456); Gain of relative solvent accessibility (P = 0.1571); Loss of loop (P = 0.2897)
17:44067349:G:T,P10636,A430S,0.307,Gain of phosphorylation at A430 (P = 0.0052); Gain of glycosylation at A430 (P = 0.0239); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.1708); Loss of loop (P = 0.2897)
17:44067350:C:A,P10636,A430D,0.286,Loss of glycosylation at P433 (P = 0.1007); Gain of solvent accessibility (P = 0.1708); Loss of catalytic residue at V431 (P = 0.4825); Gain of phosphorylation at S427 (P = 0.5458); Loss of sheet (P = 0.6423)
17:44067350:C:G,P10636,A430G,0.274,Gain of relative solvent accessibility (P = 0.1571); Loss of glycosylation at P433 (P = 0.1829); Gain of catalytic residue at V431 (P = 0.2034); Loss of stability (P = 0.2246); Gain of phosphorylation at S427 (P = 0.5626)
17:44067350:C:T,P10636,A430V,0.326,Gain of sheet (P = 0.0125); Loss of loop (P = 0.0288); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at P433 (P = 0.1428); Loss of solvent accessibility (P = 0.1651)
17:44067352:G:C,P10636,V431L,0.321,Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1202); Gain of glycosylation at P429 (P = 0.1288); Gain of catalytic residue at V431 (P = 0.3326); Gain of phosphorylation at S427 (P = 0.5616)
17:44067352:G:T,P10636,V431L,0.321,Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1202); Gain of glycosylation at P429 (P = 0.1288); Gain of catalytic residue at V431 (P = 0.3326); Gain of phosphorylation at S427 (P = 0.5616)
17:44067353:T:A,P10636,V431E,0.339,Loss of glycosylation at S428 (P = 0.0706); Gain of solvent accessibility (P = 0.194); Loss of stability (P = 0.2473); Loss of loop (P = 0.2897); Loss of catalytic residue at E434 (P = 0.3638)
17:44067353:T:C,P10636,V431A,0.363,Loss of stability (P = 0.094); Gain of glycosylation at P429 (P = 0.1023); Gain of relative solvent accessibility (P = 0.1571); Loss of loop (P = 0.2897); Loss of catalytic residue at V431 (P = 0.332)
17:44067353:T:G,P10636,V431G,0.33,Loss of stability (P = 0.0135); Gain of catalytic residue at A430 (P = 0.0648); Loss of glycosylation at S427 (P = 0.2547); Loss of solvent accessibility (P = 0.3103); Gain of phosphorylation at S427 (P = 0.5554)
17:44067355:T:A,P10636,C432S,0.286,Gain of phosphorylation at C432 (P = 0.0012); Loss of catalytic residue at C432 (P = 0.0088); Gain of glycosylation at C432 (P = 0.012); Loss of stability (P = 0.5421); Loss of sheet (P = 0.6423)
17:44067355:T:C,P10636,C432R,0.201,Loss of glycosylation at S437 (P = 0.0641); Gain of solvent accessibility (P = 0.0789); Gain of methylation at C432 (P = 0.1076); Loss of catalytic residue at P433 (P = 0.2222); Gain of relative solvent accessibility (P = 0.2363)
17:44067355:T:G,P10636,C432G,0.186,Loss of glycosylation at S437 (P = 0.1552); Loss of stability (P = 0.2012); Loss of catalytic residue at P433 (P = 0.2222); Gain of phosphorylation at S427 (P = 0.5529); Loss of sheet (P = 0.6423)
17:44067356:G:A,P10636,C432Y,0.194,Gain of phosphorylation at C432 (P = 0.0081); Gain of glycosylation at P433 (P = 0.1852); Gain of catalytic residue at P436 (P = 0.211); Gain of solvent accessibility (P = 0.5485); Loss of sheet (P = 0.6423)
17:44067356:G:C,P10636,C432S,0.286,Gain of phosphorylation at C432 (P = 0.0012); Loss of catalytic residue at C432 (P = 0.0088); Gain of glycosylation at C432 (P = 0.012); Loss of stability (P = 0.5421); Loss of sheet (P = 0.6423)
17:44067356:G:T,P10636,C432F,0.162,Loss of glycosylation at S437 (P = 0.1575); Loss of catalytic residue at P433 (P = 0.2222); Gain of phosphorylation at S427 (P = 0.5623); Gain of MoRF binding (P = 0.7645); Loss of sheet (P = 0.7751)
17:44067357:C:G,P10636,C432W,0.176,Loss of catalytic residue at C432 (P = 0.0919); Gain of glycosylation at P433 (P = 0.175); Gain of solvent accessibility (P = 0.2601); Loss of phosphorylation at S427 (P = 0.5616); Gain of MoRF binding (P = 0.6496)
17:44067358:C:A,P10636,P433T,0.204,Gain of phosphorylation at P433 (P = 0.0155); Gain of glycosylation at P433 (P = 0.1165); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2384); Loss of catalytic residue at P433 (P = 0.2654)
17:44067358:C:G,P10636,P433A,0.196,Loss of glycosylation at P433 (P = 0.022); Loss of catalytic residue at P433 (P = 0.1388); Loss of phosphorylation at S428 (P = 0.4823); Loss of solvent accessibility (P = 0.5743); Gain of MoRF binding (P = 0.6308)
17:44067359:C:A,P10636,P433Q,0.206,Loss of glycosylation at P433 (P = 0.022); Gain of solvent accessibility (P = 0.1505); Loss of catalytic residue at P433 (P = 0.1948); Loss of phosphorylation at S428 (P = 0.4136); Gain of MoRF binding (P = 0.6082)
17:44067359:C:G,P10636,P433R,0.24,Loss of glycosylation at P433 (P = 0.022); Gain of solvent accessibility (P = 0.0411); Gain of MoRF binding (P = 0.3367); Loss of catalytic residue at V431 (P = 0.3844); Gain of methylation at P433 (P = 0.4119)
17:44067359:C:T,P10636,P433L,0.274,Loss of glycosylation at P433 (P = 0.022); Gain of stability (P = 0.0795); Gain of catalytic residue at P433 (P = 0.2221); Gain of solvent accessibility (P = 0.3194); Loss of phosphorylation at S428 (P = 0.4249)
17:44067361:G:A,P10636,E434K,0.342,Gain of methylation at E434 (P = 0.0062); Gain of ubiquitination at E434 (P = 0.009); Gain of glycosylation at E434 (P = 0.0415); Gain of solvent accessibility (P = 0.1505); Gain of relative solvent accessibility (P = 0.1571)
17:44067361:G:C,P10636,E434Q,0.356,Loss of catalytic residue at E434 (P = 0.046); Loss of solvent accessibility (P = 0.0721); Loss of glycosylation at P433 (P = 0.0831); Loss of relative solvent accessibility (P = 0.1807); Gain of MoRF binding (P = 0.431)
17:44067362:A:C,P10636,E434A,0.389,Loss of solvent accessibility (P = 0.0111); Loss of catalytic residue at E434 (P = 0.0341); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at S437 (P = 0.0909); Loss of loop (P = 0.2897)
17:44067362:A:G,P10636,E434G,0.336,Loss of solvent accessibility (P = 0.0187); Gain of glycosylation at S437 (P = 0.1411); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.1928); Loss of catalytic residue at E434 (P = 0.3704)
17:44067362:A:T,P10636,E434V,0.375,Loss of solvent accessibility (P = 0.0146); Loss of loop (P = 0.0288); Loss of relative solvent accessibility (P = 0.0676); Gain of glycosylation at S437 (P = 0.0755); Gain of sheet (P = 0.1451)
17:44067363:G:C,P10636,E434D,0.34,Loss of catalytic residue at E434 (P = 0.0682); Loss of glycosylation at P433 (P = 0.1419); Loss of solvent accessibility (P = 0.5485); Loss of MoRF binding (P = 0.5639); Loss of phosphorylation at S437 (P = 0.7029)
17:44067363:G:T,P10636,E434D,0.34,Loss of catalytic residue at E434 (P = 0.0682); Loss of glycosylation at P433 (P = 0.1419); Loss of solvent accessibility (P = 0.5485); Loss of MoRF binding (P = 0.5639); Loss of phosphorylation at S437 (P = 0.7029)
17:44067364:C:A,P10636,P435T,0.264,Gain of phosphorylation at P435 (P = 0.0087); Loss of glycosylation at P435 (P = 0.0577); Loss of catalytic residue at P435 (P = 0.0593); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1922)
17:44067364:C:G,P10636,P435A,0.281,Loss of catalytic residue at P435 (P = 0.0067); Loss of glycosylation at P435 (P = 0.0072); Loss of methylation at K440 (P = 0.0916); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807)
17:44067364:C:T,P10636,P435S,0.257,Gain of phosphorylation at P435 (P = 0.0053); Loss of catalytic residue at P435 (P = 0.0227); Loss of glycosylation at P435 (P = 0.08); Loss of solvent accessibility (P = 0.1744); Loss of relative solvent accessibility (P = 0.1807)
17:44067365:C:A,P10636,P435Q,0.254,Loss of glycosylation at P435 (P = 0.0072); Loss of catalytic residue at P435 (P = 0.03); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at K440 (P = 0.2715); Loss of solvent accessibility (P = 0.3473)
17:44067365:C:G,P10636,P435R,0.263,Loss of glycosylation at P435 (P = 0.0072); Loss of catalytic residue at P435 (P = 0.0976); Loss of methylation at K440 (P = 0.1551); Gain of MoRF binding (P = 0.1561); Loss of relative solvent accessibility (P = 0.1807)
17:44067365:C:T,P10636,P435L,0.234,Loss of glycosylation at P435 (P = 0.0072); Loss of methylation at K440 (P = 0.0682); Loss of catalytic residue at P435 (P = 0.0954); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1362)
17:44067367:C:A,P10636,P436T,0.328,Gain of phosphorylation at P436 (P = 0.0152); Loss of catalytic residue at P435 (P = 0.0165); Loss of glycosylation at P435 (P = 0.0885); Gain of MoRF binding (P = 0.2593); Gain of methylation at K440 (P = 0.3016)
17:44067367:C:G,P10636,P436A,0.325,Loss of glycosylation at P436 (P = 0.0044); Loss of catalytic residue at P435 (P = 0.0165); Loss of methylation at K440 (P = 0.0837); Gain of MoRF binding (P = 0.257); Loss of ubiquitination at K440 (P = 0.3733)
17:44067367:C:T,P10636,P436S,0.381,Gain of phosphorylation at P436 (P = 0.0055); Loss of catalytic residue at P435 (P = 0.0389); Gain of sheet (P = 0.0507); Loss of loop (P = 0.0603); Loss of glycosylation at P436 (P = 0.1092)
17:44067368:C:A,P10636,P436H,0.329,Loss of glycosylation at P436 (P = 0.0044); Loss of catalytic residue at P435 (P = 0.0165); Gain of solvent accessibility (P = 0.1583); Loss of methylation at K440 (P = 0.1743); Gain of MoRF binding (P = 0.2628)
17:44067368:C:G,P10636,P436R,0.359,Loss of glycosylation at P436 (P = 0.0044); Loss of catalytic residue at P435 (P = 0.0165); Gain of solvent accessibility (P = 0.0216); Gain of MoRF binding (P = 0.0234); Loss of ubiquitination at K440 (P = 0.228)
17:44067368:C:T,P10636,P436L,0.346,Loss of glycosylation at P436 (P = 0.0044); Loss of catalytic residue at P435 (P = 0.0165); Loss of methylation at K440 (P = 0.0587); Gain of stability (P = 0.1788); Gain of solvent accessibility (P = 0.2863)
17:44067370:T:A,P10636,S437T,0.169,Loss of glycosylation at P433 (P = 0.1725); Gain of MoRF binding (P = 0.2764); Gain of methylation at K440 (P = 0.289); Gain of catalytic residue at S437 (P = 0.3609); Loss of ubiquitination at K440 (P = 0.3733)
17:44067370:T:C,P10636,S437P,0.229,Loss of phosphorylation at S437 (P = 0.0065); Gain of sheet (P = 0.0073); Loss of loop (P = 0.0128); Gain of glycosylation at S437 (P = 0.0606); Gain of catalytic residue at P436 (P = 0.1238)
17:44067370:T:G,P10636,S437A,0.155,Loss of phosphorylation at S437 (P = 0.0065); Loss of glycosylation at S437 (P = 0.0215); Loss of methylation at K440 (P = 0.2631); Gain of MoRF binding (P = 0.2699); Loss of catalytic residue at K440 (P = 0.3529)
17:44067371:C:A,P10636,S437Y,0.231,Loss of glycosylation at S437 (P = 0.0215); Gain of catalytic residue at S437 (P = 0.0438); Loss of relative solvent accessibility (P = 0.0676); Loss of methylation at K440 (P = 0.1046); Loss of solvent accessibility (P = 0.1301)
17:44067371:C:G,P10636,S437C,0.18,Loss of phosphorylation at S437 (P = 0.0065); Loss of glycosylation at S437 (P = 0.0215); Gain of catalytic residue at P436 (P = 0.0545); Loss of MoRF binding (P = 0.245); Gain of methylation at K440 (P = 0.2796)
17:44067371:C:T,P10636,S437F,0.205,Loss of phosphorylation at S437 (P = 0.0065); Loss of glycosylation at S437 (P = 0.0215); Gain of catalytic residue at S437 (P = 0.1031); Gain of solvent accessibility (P = 0.1376); Loss of MoRF binding (P = 0.2549)
17:44067373:T:A,P10636,S438T,0.287,Gain of catalytic residue at S438 (P = 0.0506); Gain of glycosylation at S437 (P = 0.0685); Loss of phosphorylation at S438 (P = 0.1423); Gain of MoRF binding (P = 0.2187); Gain of methylation at K440 (P = 0.2889)
17:44067373:T:C,P10636,S438P,0.337,Gain of catalytic residue at S438 (P = 0.0011); Loss of phosphorylation at S438 (P = 0.0034); Gain of sheet (P = 0.0073); Loss of loop (P = 0.0128); Gain of glycosylation at S437 (P = 0.0874)
17:44067373:T:G,P10636,S438A,0.258,Loss of phosphorylation at S438 (P = 0.0034); Loss of glycosylation at S438 (P = 0.0063); Gain of MoRF binding (P = 0.1836); Loss of methylation at K440 (P = 0.2698); Loss of stability (P = 0.3507)
17:44067374:C:A,P10636,S438Y,0.323,Gain of catalytic residue at S438 (P = 0.0024); Loss of glycosylation at S438 (P = 0.0063); Loss of phosphorylation at S438 (P = 0.1165); Loss of methylation at K440 (P = 0.1628); Loss of MoRF binding (P = 0.2103)
17:44067374:C:G,P10636,S438C,0.312,Loss of phosphorylation at S438 (P = 0.0034); Loss of glycosylation at S438 (P = 0.0063); Gain of catalytic residue at S438 (P = 0.0443); Loss of MoRF binding (P = 0.164); Gain of methylation at K440 (P = 0.2735)
17:44067374:C:T,P10636,S438F,0.276,Loss of phosphorylation at S438 (P = 0.0034); Loss of glycosylation at S438 (P = 0.0063); Loss of MoRF binding (P = 0.2058); Gain of catalytic residue at S438 (P = 0.2454); Gain of methylation at K440 (P = 0.2846)
17:44067376:C:A,P10636,P439T,0.172,Gain of phosphorylation at P439 (P = 0.0137); Gain of MoRF binding (P = 0.0698); Gain of catalytic residue at S444 (P = 0.1295); Loss of stability (P = 0.1471); Gain of glycosylation at S443 (P = 0.2189)
17:44067376:C:G,P10636,P439A,0.168,Loss of glycosylation at P439 (P = 0.0115); Loss of stability (P = 0.0576); Gain of MoRF binding (P = 0.0601); Loss of methylation at K440 (P = 0.1059); Gain of relative solvent accessibility (P = 0.1571)
17:44067376:C:T,P10636,P439S,0.201,Gain of phosphorylation at P439 (P = 0.0096); Gain of MoRF binding (P = 0.0695); Loss of glycosylation at S437 (P = 0.1174); Loss of stability (P = 0.1319); Loss of methylation at K440 (P = 0.1424)
17:44067377:C:A,P10636,P439H,0.168,Loss of glycosylation at P439 (P = 0.0115); Gain of catalytic residue at S444 (P = 0.0767); Gain of MoRF binding (P = 0.0794); Loss of relative solvent accessibility (P = 0.0981); Loss of stability (P = 0.1094)
17:44067377:C:G,P10636,P439R,0.246,Loss of glycosylation at P439 (P = 0.0115); Gain of MoRF binding (P = 0.014); Gain of solvent accessibility (P = 0.0411); Gain of catalytic residue at S444 (P = 0.0483); Loss of ubiquitination at K440 (P = 0.0579)
17:44067377:C:T,P10636,P439L,0.161,Loss of glycosylation at P439 (P = 0.0115); Gain of MoRF binding (P = 0.0671); Loss of methylation at K440 (P = 0.0821); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at P439 (P = 0.1163)
17:44067379:A:C,P10636,K440Q,0.35,Loss of ubiquitination at K440 (P = 0.0023); Loss of methylation at K440 (P = 0.0075); Loss of glycosylation at P439 (P = 0.0532); Loss of MoRF binding (P = 0.0665); Loss of catalytic residue at K440 (P = 0.093)
17:44067379:A:G,P10636,K440E,0.394,Loss of ubiquitination at K440 (P = 0.0023); Gain of sheet (P = 0.0073); Loss of loop (P = 0.0073); Loss of methylation at K440 (P = 0.0075); Loss of MoRF binding (P = 0.0318)
17:44067380:A:C,P10636,K440T,0.412,Loss of solvent accessibility (P = 0.0022); Loss of ubiquitination at K440 (P = 0.0023); Gain of sheet (P = 0.0073); Loss of loop (P = 0.0073); Loss of methylation at K440 (P = 0.0075)
17:44067380:A:G,P10636,K440R,0.316,Loss of ubiquitination at K440 (P = 0.0023); Loss of methylation at K440 (P = 0.0174); Gain of MoRF binding (P = 0.0781); Gain of glycosylation at S443 (P = 0.1018); Gain of catalytic residue at Y441 (P = 0.2817)
17:44067380:A:T,P10636,K440I,0.38,Loss of ubiquitination at K440 (P = 0.0023); Loss of solvent accessibility (P = 0.0036); Loss of methylation at K440 (P = 0.0075); Loss of relative solvent accessibility (P = 0.0404); Loss of MoRF binding (P = 0.0547)
17:44067381:A:C,P10636,K440N,0.35,Loss of ubiquitination at K440 (P = 0.0023); Loss of methylation at K440 (P = 0.0075); Loss of MoRF binding (P = 0.0619); Gain of glycosylation at S443 (P = 0.0639); Loss of solvent accessibility (P = 0.1177)
17:44067381:A:T,P10636,K440N,0.35,Loss of ubiquitination at K440 (P = 0.0023); Loss of methylation at K440 (P = 0.0075); Loss of MoRF binding (P = 0.0619); Gain of glycosylation at S443 (P = 0.0639); Loss of solvent accessibility (P = 0.1177)
17:44067382:T:A,P10636,Y441N,0.164,Loss of phosphorylation at Y441 (P = 0.0109); Gain of glycosylation at T446 (P = 0.0927); Gain of MoRF binding (P = 0.099); Loss of stability (P = 0.1742); Gain of relative solvent accessibility (P = 0.2363)
17:44067382:T:G,P10636,Y441D,0.223,Loss of phosphorylation at Y441 (P = 0.0109); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0735); Loss of glycosylation at P439 (P = 0.0745); Loss of methylation at K440 (P = 0.1057)
17:44067383:A:C,P10636,Y441S,0.257,Loss of loop (P = 0.0128); Gain of sheet (P = 0.0166); Gain of glycosylation at Y441 (P = 0.018); Loss of stability (P = 0.1008); Gain of MoRF binding (P = 0.1089)
17:44067383:A:G,P10636,Y441C,0.191,Loss of phosphorylation at Y441 (P = 0.0109); Loss of glycosylation at S443 (P = 0.0921); Loss of MoRF binding (P = 0.0989); Gain of methylation at K440 (P = 0.0996); Gain of catalytic residue at S443 (P = 0.1314)
17:44067383:A:T,P10636,Y441F,0.165,Loss of phosphorylation at Y441 (P = 0.0109); Loss of glycosylation at S437 (P = 0.1074); Loss of MoRF binding (P = 0.1248); Gain of methylation at K440 (P = 0.1426); Gain of catalytic residue at P439 (P = 0.1578)
17:44067385:G:A,P10636,V442I,0.16,Gain of MoRF binding (P = 0.1396); Loss of glycosylation at S437 (P = 0.1701); Loss of phosphorylation at T446 (P = 0.2244); Gain of methylation at K440 (P = 0.2628); Gain of catalytic residue at S444 (P = 0.2881)
17:44067385:G:C,P10636,V442L,0.167,Loss of glycosylation at S443 (P = 0.0924); Loss of MoRF binding (P = 0.1137); Loss of methylation at K440 (P = 0.1234); Loss of phosphorylation at T446 (P = 0.1955); Loss of catalytic residue at T446 (P = 0.3219)
17:44067385:G:T,P10636,V442F,0.169,Loss of MoRF binding (P = 0.0981); Loss of glycosylation at S437 (P = 0.2021); Loss of phosphorylation at T446 (P = 0.2538); Loss of methylation at K440 (P = 0.2815); Loss of catalytic residue at T446 (P = 0.3257)
17:44067386:T:A,P10636,V442D,0.275,Gain of relative solvent accessibility (P = 0.0166); Gain of solvent accessibility (P = 0.0171); Loss of MoRF binding (P = 0.0404); Loss of methylation at K440 (P = 0.0878); Loss of glycosylation at S443 (P = 0.134)
17:44067386:T:C,P10636,V442A,0.156,Loss of MoRF binding (P = 0.1312); Gain of glycosylation at S437 (P = 0.1346); Loss of methylation at K440 (P = 0.158); Loss of stability (P = 0.1589); Gain of relative solvent accessibility (P = 0.2363)
17:44067386:T:G,P10636,V442G,0.201,Loss of stability (P = 0.0224); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.1136); Gain of catalytic residue at S443 (P = 0.1549); Loss of methylation at K440 (P = 0.1878)
17:44067388:T:A,P10636,S443T,0.215,Loss of MoRF binding (P = 0.1389); Loss of phosphorylation at S443 (P = 0.1459); Gain of methylation at R448 (P = 0.1707); Gain of glycosylation at T446 (P = 0.2243); Loss of ubiquitination at K440 (P = 0.3733)
17:44067388:T:C,P10636,S443P,0.219,Loss of phosphorylation at S443 (P = 0.0123); Loss of glycosylation at S443 (P = 0.0699); Loss of MoRF binding (P = 0.0701); Gain of methylation at R448 (P = 0.1329); Loss of ubiquitination at K440 (P = 0.3733)
17:44067388:T:G,P10636,S443A,0.277,Loss of phosphorylation at S443 (P = 0.0123); Loss of glycosylation at S443 (P = 0.0265); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0435); Gain of MoRF binding (P = 0.1134)
17:44067389:C:A,P10636,S443Y,0.317,Loss of glycosylation at S443 (P = 0.0265); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.1115); Loss of MoRF binding (P = 0.1172); Gain of catalytic residue at S443 (P = 0.1413)
17:44067389:C:G,P10636,S443C,0.327,Loss of phosphorylation at S443 (P = 0.0123); Loss of glycosylation at S443 (P = 0.0265); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Gain of catalytic residue at S447 (P = 0.0606)
17:44067389:C:T,P10636,S443F,0.341,Loss of phosphorylation at S443 (P = 0.0123); Loss of glycosylation at S443 (P = 0.0265); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0807); Loss of MoRF binding (P = 0.1152)
17:44067391:T:A,P10636,S444T,0.246,Gain of glycosylation at S443 (P = 0.0592); Loss of MoRF binding (P = 0.1309); Gain of methylation at R448 (P = 0.1736); Loss of phosphorylation at S444 (P = 0.1758); Gain of catalytic residue at S443 (P = 0.2331)
17:44067391:T:C,P10636,S444P,0.277,Loss of phosphorylation at S444 (P = 0.0176); Loss of glycosylation at S444 (P = 0.0283); Loss of MoRF binding (P = 0.0641); Gain of methylation at R448 (P = 0.1326); Loss of relative solvent accessibility (P = 0.1807)
17:44067391:T:G,P10636,S444A,0.237,Loss of glycosylation at S444 (P = 0.0096); Loss of phosphorylation at S444 (P = 0.0176); Loss of MoRF binding (P = 0.1283); Gain of methylation at R448 (P = 0.1326); Loss of solvent accessibility (P = 0.1473)
17:44067392:C:A,P10636,S444Y,0.363,Loss of glycosylation at S444 (P = 0.0096); Gain of catalytic residue at S444 (P = 0.0643); Loss of relative solvent accessibility (P = 0.0981); Loss of MoRF binding (P = 0.1016); Loss of methylation at R448 (P = 0.1684)
17:44067392:C:G,P10636,S444C,0.342,Loss of glycosylation at S444 (P = 0.0096); Loss of phosphorylation at S444 (P = 0.0176); Loss of MoRF binding (P = 0.0773); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1322)
17:44067392:C:T,P10636,S444F,0.363,Loss of glycosylation at S444 (P = 0.0096); Loss of phosphorylation at S444 (P = 0.0176); Loss of MoRF binding (P = 0.079); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at R448 (P = 0.1679)
17:44067394:G:A,P10636,V445I,0.268,Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.045); Loss of methylation at R448 (P = 0.1157); Gain of MoRF binding (P = 0.1414); Loss of phosphorylation at T446 (P = 0.1766)
17:44067394:G:C,P10636,V445L,0.28,Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0442); Loss of MoRF binding (P = 0.1124); Loss of glycosylation at T446 (P = 0.1199); Loss of methylation at K440 (P = 0.1335)
17:44067394:G:T,P10636,V445F,0.321,Loss of relative solvent accessibility (P = 0.0186); Loss of solvent accessibility (P = 0.0299); Loss of MoRF binding (P = 0.0959); Loss of glycosylation at T446 (P = 0.1159); Gain of catalytic residue at V445 (P = 0.1752)
17:44067395:T:A,P10636,V445D,0.314,Loss of MoRF binding (P = 0.0442); Loss of glycosylation at T446 (P = 0.105); Loss of methylation at R448 (P = 0.1096); Gain of phosphorylation at T446 (P = 0.1545); Loss of catalytic residue at T449 (P = 0.2145)
17:44067395:T:C,P10636,V445A,0.244,Gain of methylation at R448 (P = 0.0981); Loss of MoRF binding (P = 0.1319); Loss of stability (P = 0.1431); Gain of phosphorylation at T449 (P = 0.184); Gain of glycosylation at T446 (P = 0.1948)
17:44067395:T:G,P10636,V445G,0.279,Loss of stability (P = 0.0131); Gain of methylation at R448 (P = 0.0849); Loss of MoRF binding (P = 0.1106); Gain of glycosylation at S444 (P = 0.1263); Gain of phosphorylation at T449 (P = 0.1589)
17:44067397:A:C,P10636,T446P,0.263,Loss of phosphorylation at T446 (P = 0.0334); Loss of MoRF binding (P = 0.0679); Loss of catalytic residue at S451 (P = 0.1304); Gain of glycosylation at S443 (P = 0.1604); Loss of methylation at R448 (P = 0.174)
17:44067397:A:G,P10636,T446A,0.289,Loss of phosphorylation at T446 (P = 0.0334); Loss of glycosylation at T446 (P = 0.0346); Gain of MoRF binding (P = 0.098); Loss of solvent accessibility (P = 0.1177); Gain of methylation at R448 (P = 0.1188)
17:44067397:A:T,P10636,T446S,0.361,Gain of sheet (P = 0.0036); Loss of loop (P = 0.0073); Loss of relative solvent accessibility (P = 0.0306); Loss of solvent accessibility (P = 0.0352); Gain of phosphorylation at T446 (P = 0.0826)
17:44067398:C:A,P10636,T446N,0.267,Loss of phosphorylation at T446 (P = 0.0334); Loss of glycosylation at T446 (P = 0.0346); Gain of methylation at R448 (P = 0.1384); Loss of MoRF binding (P = 0.1398); Loss of relative solvent accessibility (P = 0.1807)
17:44067398:C:G,P10636,T446S,0.361,Gain of sheet (P = 0.0036); Loss of loop (P = 0.0073); Loss of relative solvent accessibility (P = 0.0306); Loss of solvent accessibility (P = 0.0352); Gain of phosphorylation at T446 (P = 0.0826)
17:44067398:C:T,P10636,T446I,0.314,Loss of phosphorylation at T446 (P = 0.0334); Loss of glycosylation at T446 (P = 0.0346); Loss of solvent accessibility (P = 0.0674); Loss of relative solvent accessibility (P = 0.0676); Gain of MoRF binding (P = 0.0878)
17:44067400:T:A,P10636,S447T,0.198,Loss of glycosylation at S447 (P = 0.0863); Loss of phosphorylation at T446 (P = 0.0975); Loss of MoRF binding (P = 0.1319); Loss of stability (P = 0.1608); Gain of methylation at R448 (P = 0.1696)
17:44067400:T:G,P10636,S447A,0.208,Loss of glycosylation at S447 (P = 0.0047); Loss of phosphorylation at S447 (P = 0.0053); Loss of stability (P = 0.0275); Gain of methylation at R448 (P = 0.0803); Gain of MoRF binding (P = 0.1222)
17:44067401:C:A,P10636,S447Y,0.251,Loss of glycosylation at S447 (P = 0.0047); Loss of MoRF binding (P = 0.1177); Loss of methylation at R448 (P = 0.1573); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S452 (P = 0.1885)
17:44067401:C:G,P10636,S447C,0.255,Loss of glycosylation at S447 (P = 0.0047); Loss of phosphorylation at S447 (P = 0.0053); Loss of MoRF binding (P = 0.0831); Gain of catalytic residue at S447 (P = 0.175); Loss of methylation at R448 (P = 0.1778)
17:44067401:C:T,P10636,S447F,0.291,Loss of glycosylation at S447 (P = 0.0047); Loss of phosphorylation at S447 (P = 0.0053); Loss of relative solvent accessibility (P = 0.0981); Loss of MoRF binding (P = 0.1082); Gain of methylation at R448 (P = 0.1424)
17:44067403:C:G,P10636,R448G,0.432,Loss of MoRF binding (P = 0.0065); Loss of solvent accessibility (P = 0.0159); Loss of methylation at R448 (P = 0.0322); Gain of glycosylation at T446 (P = 0.0928); Loss of stability (P = 0.0985)
17:44067404:G:C,P10636,R448P,0.423,Loss of MoRF binding (P = 5e-04); Loss of catalytic residue at R448 (P = 0.0317); Loss of methylation at R448 (P = 0.0322); Gain of glycosylation at T449 (P = 0.0446); Loss of phosphorylation at T446 (P = 0.1498)
17:44067404:G:T,P10636,R448L,0.454,Loss of MoRF binding (P = 0.0056); Loss of methylation at R448 (P = 0.0322); Loss of glycosylation at S447 (P = 0.0477); Loss of phosphorylation at T446 (P = 0.0609); Loss of solvent accessibility (P = 0.1579)
17:44067406:A:C,P10636,T449P,0.248,Loss of phosphorylation at T449 (P = 0.0363); Gain of glycosylation at T449 (P = 0.0503); Loss of MoRF binding (P = 0.0718); Loss of solvent accessibility (P = 0.1473); Loss of stability (P = 0.176)
17:44067406:A:G,P10636,T449A,0.238,Loss of phosphorylation at T449 (P = 0.0363); Gain of methylation at R448 (P = 0.0882); Gain of MoRF binding (P = 0.0958); Gain of glycosylation at S452 (P = 0.1788); Loss of stability (P = 0.2365)
17:44067406:A:T,P10636,T449S,0.269,Gain of phosphorylation at T449 (P = 0.0794); Gain of glycosylation at T449 (P = 0.081); Gain of MoRF binding (P = 0.1344); Gain of methylation at R448 (P = 0.1638); Loss of stability (P = 0.3723)
17:44067407:C:A,P10636,T449N,0.246,Loss of phosphorylation at T449 (P = 0.0363); Loss of glycosylation at S447 (P = 0.1226); Loss of MoRF binding (P = 0.1378); Loss of methylation at R448 (P = 0.1798); Loss of stability (P = 0.2963)
17:44067407:C:G,P10636,T449S,0.269,Gain of phosphorylation at T449 (P = 0.0794); Gain of glycosylation at T449 (P = 0.081); Gain of MoRF binding (P = 0.1344); Gain of methylation at R448 (P = 0.1638); Loss of stability (P = 0.3723)
17:44067407:C:T,P10636,T449I,0.281,Loss of phosphorylation at T449 (P = 0.0363); Loss of methylation at R448 (P = 0.0761); Gain of MoRF binding (P = 0.0856); Loss of glycosylation at S444 (P = 0.0941); Loss of relative solvent accessibility (P = 0.0981)
17:44067409:G:A,P10636,G450S,0.265,Gain of phosphorylation at G450 (P = 0.0041); Loss of catalytic residue at G450 (P = 0.0817); Loss of relative solvent accessibility (P = 0.107); Loss of methylation at R448 (P = 0.1283); Gain of glycosylation at G450 (P = 0.1351)
17:44067409:G:C,P10636,G450R,0.24,Gain of methylation at G450 (P = 0.0321); Gain of MoRF binding (P = 0.0524); Gain of glycosylation at T446 (P = 0.0925); Loss of ubiquitination at K455 (P = 0.1055); Loss of relative solvent accessibility (P = 0.107)
17:44067409:G:T,P10636,G450C,0.251,Loss of relative solvent accessibility (P = 0.0404); Loss of MoRF binding (P = 0.085); Loss of glycosylation at S452 (P = 0.0959); Loss of methylation at R448 (P = 0.1098); Loss of phosphorylation at T449 (P = 0.1469)
17:44067410:G:A,P10636,G450D,0.243,Gain of ubiquitination at K455 (P = 0.0356); Loss of MoRF binding (P = 0.0487); Loss of relative solvent accessibility (P = 0.0676); Loss of methylation at R448 (P = 0.0857); Loss of catalytic residue at S452 (P = 0.1012)
17:44067410:G:C,P10636,G450A,0.188,Loss of relative solvent accessibility (P = 0.0404); Loss of catalytic residue at G450 (P = 0.0427); Gain of MoRF binding (P = 0.1189); Loss of ubiquitination at K455 (P = 0.1498); Loss of methylation at R448 (P = 0.1684)
17:44067410:G:T,P10636,G450V,0.196,Loss of relative solvent accessibility (P = 0.0404); Gain of MoRF binding (P = 0.1008); Loss of methylation at R448 (P = 0.1056); Gain of ubiquitination at K455 (P = 0.1295); Gain of glycosylation at T449 (P = 0.1346)
17:44067412:A:C,P10636,S451R,0.325,Loss of phosphorylation at S451 (P = 0.0084); Gain of methylation at S451 (P = 0.0199); Gain of solvent accessibility (P = 0.0365); Gain of MoRF binding (P = 0.0385); Loss of glycosylation at S452 (P = 0.0969)
17:44067412:A:G,P10636,S451G,0.237,Loss of phosphorylation at S451 (P = 0.0084); Gain of glycosylation at S452 (P = 0.0834); Gain of methylation at R448 (P = 0.0902); Loss of MoRF binding (P = 0.1207); Gain of ubiquitination at K455 (P = 0.1295)
17:44067412:A:T,P10636,S451C,0.297,Loss of phosphorylation at S451 (P = 0.0084); Loss of glycosylation at S452 (P = 0.0679); Loss of MoRF binding (P = 0.0806); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1322)
17:44067413:G:A,P10636,S451N,0.279,Loss of phosphorylation at S451 (P = 0.0084); Loss of glycosylation at S452 (P = 0.1039); Gain of ubiquitination at K455 (P = 0.1295); Gain of MoRF binding (P = 0.1327); Gain of methylation at R448 (P = 0.1543)
17:44067413:G:C,P10636,S451T,0.291,Gain of glycosylation at S451 (P = 0.0559); Gain of ubiquitination at K455 (P = 0.1295); Loss of MoRF binding (P = 0.136); Gain of methylation at R448 (P = 0.1817); Loss of catalytic residue at S451 (P = 0.2326)
17:44067413:G:T,P10636,S451I,0.288,Loss of phosphorylation at S451 (P = 0.0084); Loss of methylation at R448 (P = 0.0975); Loss of relative solvent accessibility (P = 0.0981); Loss of MoRF binding (P = 0.116); Loss of glycosylation at S447 (P = 0.1467)
17:44067414:T:A,P10636,S451R,0.325,Loss of phosphorylation at S451 (P = 0.0084); Gain of methylation at S451 (P = 0.0199); Gain of solvent accessibility (P = 0.0365); Gain of MoRF binding (P = 0.0385); Loss of glycosylation at S452 (P = 0.0969)
17:44067414:T:G,P10636,S451R,0.325,Loss of phosphorylation at S451 (P = 0.0084); Gain of methylation at S451 (P = 0.0199); Gain of solvent accessibility (P = 0.0365); Gain of MoRF binding (P = 0.0385); Loss of glycosylation at S452 (P = 0.0969)
17:44067415:T:A,P10636,S452T,0.251,Gain of glycosylation at S451 (P = 0.066); Loss of phosphorylation at S452 (P = 0.0818); Loss of ubiquitination at K455 (P = 0.1498); Gain of methylation at R448 (P = 0.1561); Loss of MoRF binding (P = 0.1649)
17:44067415:T:C,P10636,S452P,0.267,Loss of phosphorylation at S452 (P = 0.0157); Loss of MoRF binding (P = 0.0749); Loss of catalytic residue at S452 (P = 0.0828); Gain of glycosylation at T449 (P = 0.0867); Gain of methylation at R448 (P = 0.1391)
17:44067415:T:G,P10636,S452A,0.222,Loss of phosphorylation at S452 (P = 0.0157); Loss of glycosylation at S452 (P = 0.0372); Gain of methylation at R448 (P = 0.0791); Loss of ubiquitination at K455 (P = 0.1498); Loss of MoRF binding (P = 0.1811)
17:44067416:C:A,P10636,S452Y,0.307,Loss of glycosylation at S452 (P = 0.0372); Gain of solvent accessibility (P = 0.039); Loss of phosphorylation at S452 (P = 0.0818); Loss of ubiquitination at K455 (P = 0.0924); Gain of methylation at R448 (P = 0.1377)
17:44067416:C:G,P10636,S452C,0.319,Loss of phosphorylation at S452 (P = 0.0157); Loss of glycosylation at S452 (P = 0.0372); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Loss of MoRF binding (P = 0.0848)
17:44067416:C:T,P10636,S452F,0.303,Loss of phosphorylation at S452 (P = 0.0157); Loss of relative solvent accessibility (P = 0.0186); Loss of glycosylation at S452 (P = 0.0372); Loss of solvent accessibility (P = 0.045); Gain of methylation at R448 (P = 0.0878)
17:44067418:G:A,P10636,G453R,0.343,Gain of solvent accessibility (P = 0.0097); Gain of methylation at G453 (P = 0.0247); Loss of ubiquitination at K455 (P = 0.0694); Loss of glycosylation at S452 (P = 0.0751); Gain of MoRF binding (P = 0.0792)
17:44067418:G:C,P10636,G453R,0.343,Gain of solvent accessibility (P = 0.0097); Gain of methylation at G453 (P = 0.0247); Loss of ubiquitination at K455 (P = 0.0694); Loss of glycosylation at S452 (P = 0.0751); Gain of MoRF binding (P = 0.0792)
17:44067419:G:A,P10636,G453E,0.318,Gain of ubiquitination at K455 (P = 0.0398); Gain of solvent accessibility (P = 0.0456); Loss of glycosylation at S452 (P = 0.0564); Loss of MoRF binding (P = 0.0577); Loss of catalytic residue at S451 (P = 0.1259)
17:44067419:G:C,P10636,G453A,0.255,Loss of glycosylation at S452 (P = 0.07); Gain of ubiquitination at K455 (P = 0.1295); Gain of methylation at R448 (P = 0.1497); Loss of relative solvent accessibility (P = 0.1807); Gain of MoRF binding (P = 0.2044)
17:44067419:G:T,P10636,G453V,0.326,Gain of catalytic residue at G453 (P = 0.0219); Loss of glycosylation at S452 (P = 0.0505); Loss of ubiquitination at K455 (P = 0.1202); Loss of methylation at R448 (P = 0.1578); Gain of solvent accessibility (P = 0.1683)
17:44067421:G:A,P10636,A454T,0.137,Gain of phosphorylation at A454 (P = 0.0243); Gain of glycosylation at A454 (P = 0.0483); Loss of ubiquitination at K455 (P = 0.1351); Loss of stability (P = 0.1613); Gain of methylation at K455 (P = 0.1797)
17:44067421:G:C,P10636,A454P,0.191,Gain of glycosylation at A454 (P = 0.0602); Loss of MoRF binding (P = 0.0822); Gain of methylation at K455 (P = 0.1037); Loss of stability (P = 0.1061); Loss of ubiquitination at K455 (P = 0.1351)
17:44067421:G:T,P10636,A454S,0.164,Gain of phosphorylation at A454 (P = 0.0155); Loss of ubiquitination at K455 (P = 0.1202); Loss of glycosylation at S452 (P = 0.1241); Loss of stability (P = 0.1872); Loss of MoRF binding (P = 0.2351)
17:44067422:C:A,P10636,A454E,0.269,Gain of solvent accessibility (P = 0.0145); Gain of ubiquitination at K455 (P = 0.0398); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0491); Loss of glycosylation at S452 (P = 0.0874)
17:44067422:C:G,P10636,A454G,0.168,Loss of stability (P = 0.0672); Loss of ubiquitination at K455 (P = 0.1351); Loss of glycosylation at S452 (P = 0.1584); Loss of MoRF binding (P = 0.233); Loss of phosphorylation at T449 (P = 0.2479)
17:44067422:C:T,P10636,A454V,0.155,Gain of methylation at K455 (P = 0.039); Loss of ubiquitination at K455 (P = 0.1055); Loss of phosphorylation at T449 (P = 0.1557); Loss of glycosylation at S452 (P = 0.1689); Gain of MoRF binding (P = 0.2465)
17:44067424:A:C,P10636,K455Q,0.317,Loss of ubiquitination at K455 (P = 0.0233); Loss of MoRF binding (P = 0.0779); Loss of glycosylation at K455 (P = 0.0977); Loss of methylation at K455 (P = 0.1208); Loss of phosphorylation at S452 (P = 0.2791)
17:44067424:A:G,P10636,K455E,0.377,Loss of MoRF binding (P = 0.0034); Gain of ubiquitination at K458 (P = 0.0219); Loss of glycosylation at K455 (P = 0.0977); Loss of methylation at K455 (P = 0.1208); Gain of relative solvent accessibility (P = 0.1571)
17:44067425:A:C,P10636,K455T,0.329,Loss of ubiquitination at K455 (P = 0.0233); Gain of phosphorylation at K455 (P = 0.0305); Loss of MoRF binding (P = 0.0596); Gain of glycosylation at S452 (P = 0.0887); Loss of methylation at K455 (P = 0.1208)
17:44067425:A:G,P10636,K455R,0.302,Loss of ubiquitination at K455 (P = 0.0233); Gain of glycosylation at S452 (P = 0.095); Gain of methylation at K455 (P = 0.1804); Gain of MoRF binding (P = 0.2552); Loss of catalytic residue at S452 (P = 0.2677)
17:44067425:A:T,P10636,K455M,0.336,Loss of solvent accessibility (P = 0.0217); Loss of ubiquitination at K455 (P = 0.0233); Loss of MoRF binding (P = 0.0803); Loss of glycosylation at K455 (P = 0.0977); Loss of relative solvent accessibility (P = 0.0981)
17:44067426:G:C,P10636,K455N,0.306,Loss of ubiquitination at K455 (P = 0.0233); Loss of MoRF binding (P = 0.0694); Loss of glycosylation at K455 (P = 0.0977); Loss of methylation at K455 (P = 0.1208); Loss of phosphorylation at S452 (P = 0.2691)
17:44067426:G:T,P10636,K455N,0.306,Loss of ubiquitination at K455 (P = 0.0233); Loss of MoRF binding (P = 0.0694); Loss of glycosylation at K455 (P = 0.0977); Loss of methylation at K455 (P = 0.1208); Loss of phosphorylation at S452 (P = 0.2691)
17:44067427:G:A,P10636,E456K,0.285,Loss of ubiquitination at K455 (P = 0.0483); Loss of solvent accessibility (P = 0.0807); Gain of glycosylation at S452 (P = 0.1438); Loss of relative solvent accessibility (P = 0.1807); Gain of MoRF binding (P = 0.2358)
17:44067427:G:C,P10636,E456Q,0.243,Loss of ubiquitination at K455 (P = 0.0694); Gain of methylation at K455 (P = 0.1827); Gain of glycosylation at S452 (P = 0.2617); Gain of MoRF binding (P = 0.273); Loss of phosphorylation at S452 (P = 0.4682)
17:44067428:A:C,P10636,E456A,0.254,Loss of ubiquitination at K455 (P = 0.0694); Gain of glycosylation at S452 (P = 0.0914); Loss of solvent accessibility (P = 0.1459); Gain of MoRF binding (P = 0.2761); Gain of methylation at K455 (P = 0.3075)
17:44067428:A:G,P10636,E456G,0.246,Loss of solvent accessibility (P = 0.0477); Loss of ubiquitination at K455 (P = 0.0694); Gain of glycosylation at K455 (P = 0.1166); Gain of catalytic residue at K455 (P = 0.208); Loss of stability (P = 0.2329)
17:44067428:A:T,P10636,E456V,0.294,Gain of methylation at K455 (P = 0.0334); Loss of solvent accessibility (P = 0.0431); Loss of ubiquitination at K455 (P = 0.0818); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S452 (P = 0.2365)
17:44067429:G:C,P10636,E456D,0.219,Loss of ubiquitination at K455 (P = 0.0924); Gain of glycosylation at S452 (P = 0.1339); Loss of methylation at K455 (P = 0.2997); Gain of MoRF binding (P = 0.3485); Gain of catalytic residue at K460 (P = 0.4457)
17:44067429:G:T,P10636,E456D,0.219,Loss of ubiquitination at K455 (P = 0.0924); Gain of glycosylation at S452 (P = 0.1339); Loss of methylation at K455 (P = 0.2997); Gain of MoRF binding (P = 0.3485); Gain of catalytic residue at K460 (P = 0.4457)
17:44067430:A:C,P10636,M457L,0.318,Gain of relative solvent accessibility (P = 0.0098); Gain of solvent accessibility (P = 0.0137); Gain of ubiquitination at K455 (P = 0.0954); Loss of glycosylation at S452 (P = 0.1835); Loss of MoRF binding (P = 0.2768)
17:44067430:A:G,P10636,M457V,0.255,Gain of methylation at K458 (P = 0.0283); Gain of ubiquitination at K455 (P = 0.1103); Loss of glycosylation at S452 (P = 0.175); Loss of stability (P = 0.3483); Loss of MoRF binding (P = 0.3601)
17:44067430:A:T,P10636,M457L,0.318,Gain of relative solvent accessibility (P = 0.0098); Gain of solvent accessibility (P = 0.0137); Gain of ubiquitination at K455 (P = 0.0954); Loss of glycosylation at S452 (P = 0.1835); Loss of MoRF binding (P = 0.2768)
17:44067431:T:A,P10636,M457K,0.36,Gain of solvent accessibility (P = 0.0137); Gain of relative solvent accessibility (P = 0.0249); Gain of methylation at K458 (P = 0.0354); Gain of ubiquitination at M457 (P = 0.0592); Loss of stability (P = 0.0674)
17:44067431:T:C,P10636,M457T,0.272,Gain of phosphorylation at M457 (P = 0.0238); Gain of methylation at K458 (P = 0.0551); Loss of stability (P = 0.1006); Gain of glycosylation at S452 (P = 0.1061); Loss of ubiquitination at K455 (P = 0.1498)
17:44067431:T:G,P10636,M457R,0.317,Gain of methylation at K458 (P = 0.028); Loss of ubiquitination at K455 (P = 0.1055); Gain of glycosylation at K460 (P = 0.1208); Loss of stability (P = 0.1427); Gain of solvent accessibility (P = 0.194)
17:44067432:G:A,P10636,M457I,0.254,Gain of methylation at K458 (P = 0.0537); Gain of ubiquitination at K455 (P = 0.0954); Loss of glycosylation at S452 (P = 0.1256); Loss of MoRF binding (P = 0.3378); Gain of catalytic residue at K460 (P = 0.3556)
17:44067432:G:C,P10636,M457I,0.254,Gain of methylation at K458 (P = 0.0537); Gain of ubiquitination at K455 (P = 0.0954); Loss of glycosylation at S452 (P = 0.1256); Loss of MoRF binding (P = 0.3378); Gain of catalytic residue at K460 (P = 0.3556)
17:44067432:G:T,P10636,M457I,0.254,Gain of methylation at K458 (P = 0.0537); Gain of ubiquitination at K455 (P = 0.0954); Loss of glycosylation at S452 (P = 0.1256); Loss of MoRF binding (P = 0.3378); Gain of catalytic residue at K460 (P = 0.3556)
17:44067433:A:C,P10636,K458Q,0.343,Gain of ubiquitination at K455 (P = 0.0252); Loss of catalytic residue at K458 (P = 0.057); Loss of glycosylation at K458 (P = 0.0846); Loss of solvent accessibility (P = 0.1434); Loss of MoRF binding (P = 0.1615)
17:44067433:A:G,P10636,K458E,0.362,Loss of MoRF binding (P = 0.0084); Gain of ubiquitination at K455 (P = 0.023); Loss of catalytic residue at K458 (P = 0.0365); Loss of glycosylation at K458 (P = 0.0846); Gain of methylation at K455 (P = 0.3269)
17:44067434:A:C,P10636,K458T,0.327,Gain of ubiquitination at K455 (P = 0.0268); Gain of phosphorylation at K458 (P = 0.0502); Loss of catalytic residue at K458 (P = 0.0612); Gain of methylation at K455 (P = 0.0804); Loss of glycosylation at K458 (P = 0.1348)
17:44067434:A:G,P10636,K458R,0.31,Loss of ubiquitination at K458 (P = 0.0381); Gain of methylation at K458 (P = 0.0691); Loss of glycosylation at K458 (P = 0.0846); Loss of catalytic residue at K458 (P = 0.2261); Loss of solvent accessibility (P = 0.2953)
17:44067434:A:T,P10636,K458I,0.387,Loss of solvent accessibility (P = 0.0187); Gain of ubiquitination at K455 (P = 0.0301); Gain of methylation at K455 (P = 0.0334); Loss of catalytic residue at K458 (P = 0.0494); Gain of glycosylation at K460 (P = 0.0821)
17:44067435:A:C,P10636,K458N,0.322,Gain of ubiquitination at K455 (P = 0.026); Loss of solvent accessibility (P = 0.0674); Loss of glycosylation at K458 (P = 0.0846); Loss of MoRF binding (P = 0.1256); Gain of methylation at K455 (P = 0.2516)
17:44067435:A:T,P10636,K458N,0.322,Gain of ubiquitination at K455 (P = 0.026); Loss of solvent accessibility (P = 0.0674); Loss of glycosylation at K458 (P = 0.0846); Loss of MoRF binding (P = 0.1256); Gain of methylation at K455 (P = 0.2516)
17:44067436:C:A,P10636,L459I,0.198,Gain of methylation at K455 (P = 0.0981); Gain of ubiquitination at K455 (P = 0.1295); Loss of glycosylation at K460 (P = 0.3583); Gain of MoRF binding (P = 0.3866); Loss of stability (P = 0.4614)
17:44067436:C:G,P10636,L459V,0.217,Gain of methylation at K460 (P = 0.0976); Loss of ubiquitination at K455 (P = 0.1498); Loss of stability (P = 0.2382); Loss of glycosylation at K460 (P = 0.3172); Gain of MoRF binding (P = 0.3754)
17:44067436:C:T,P10636,L459F,0.221,Gain of methylation at K460 (P = 0.0487); Loss of ubiquitination at K455 (P = 0.1498); Gain of catalytic residue at L459 (P = 0.2141); Loss of stability (P = 0.3104); Loss of glycosylation at K460 (P = 0.3359)
17:44067437:T:A,P10636,L459H,0.252,Loss of stability (P = 0.0309); Gain of methylation at K455 (P = 0.0636); Gain of glycosylation at K460 (P = 0.1256); Gain of ubiquitination at K455 (P = 0.1295); Gain of MoRF binding (P = 0.3879)
17:44067437:T:C,P10636,L459P,0.273,Loss of stability (P = 0.0173); Gain of methylation at K455 (P = 0.0611); Gain of glycosylation at K460 (P = 0.0871); Gain of ubiquitination at K460 (P = 0.1434); Loss of MoRF binding (P = 0.2851)
17:44067437:T:G,P10636,L459R,0.343,Gain of solvent accessibility (P = 0.0039); Gain of relative solvent accessibility (P = 0.0249); Gain of methylation at L459 (P = 0.025); Gain of glycosylation at K458 (P = 0.0782); Loss of stability (P = 0.0786)
17:44067439:A:C,P10636,K460Q,0.361,Gain of ubiquitination at K455 (P = 0.0248); Loss of glycosylation at K460 (P = 0.0716); Loss of MoRF binding (P = 0.145); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.2346)
17:44067439:A:G,P10636,K460E,0.381,Loss of MoRF binding (P = 0.0095); Gain of ubiquitination at K465 (P = 0.0185); Loss of glycosylation at K460 (P = 0.0716); Gain of methylation at K455 (P = 0.3032); Loss of catalytic residue at K460 (P = 0.3158)
17:44067440:A:C,P10636,K460T,0.339,Gain of phosphorylation at K460 (P = 0.0219); Gain of ubiquitination at K455 (P = 0.0252); Loss of MoRF binding (P = 0.1044); Gain of methylation at K455 (P = 0.1057); Loss of glycosylation at K460 (P = 0.1154)
17:44067440:A:G,P10636,K460R,0.303,Loss of ubiquitination at K460 (P = 0.0381); Loss of glycosylation at K460 (P = 0.0716); Gain of methylation at K460 (P = 0.0767); Loss of solvent accessibility (P = 0.2953); Loss of relative solvent accessibility (P = 0.3219)
17:44067440:A:T,P10636,K460M,0.341,Loss of solvent accessibility (P = 0.0217); Gain of ubiquitination at K455 (P = 0.028); Loss of glycosylation at K460 (P = 0.0716); Loss of relative solvent accessibility (P = 0.0981); Loss of MoRF binding (P = 0.22)
17:44067441:G:C,P10636,K460N,0.318,Gain of ubiquitination at K455 (P = 0.0248); Loss of solvent accessibility (P = 0.0674); Loss of glycosylation at K460 (P = 0.0716); Loss of MoRF binding (P = 0.1121); Loss of catalytic residue at K460 (P = 0.3173)
17:44067441:G:T,P10636,K460N,0.318,Gain of ubiquitination at K455 (P = 0.0248); Loss of solvent accessibility (P = 0.0674); Loss of glycosylation at K460 (P = 0.0716); Loss of MoRF binding (P = 0.1121); Loss of catalytic residue at K460 (P = 0.3173)
17:44068826:G:A,P10636,G461R,0.278,Gain of solvent accessibility (P = 0.019); Gain of methylation at G461 (P = 0.0323); Gain of glycosylation at K458 (P = 0.1038); Loss of ubiquitination at K465 (P = 0.2258); Gain of MoRF binding (P = 0.2461)
17:44068826:G:C,P10636,G461R,0.278,Gain of solvent accessibility (P = 0.019); Gain of methylation at G461 (P = 0.0323); Gain of glycosylation at K458 (P = 0.1038); Loss of ubiquitination at K465 (P = 0.2258); Gain of MoRF binding (P = 0.2461)
17:44068826:G:T,P10636,G461W,0.32,Gain of catalytic residue at L459 (P = 0.0042); Loss of relative solvent accessibility (P = 0.0404); Loss of ubiquitination at K465 (P = 0.198); Loss of glycosylation at K460 (P = 0.2039); Loss of phosphorylation at T466 (P = 0.2595)
17:44068827:G:A,P10636,G461E,0.279,Gain of solvent accessibility (P = 0.024); Gain of ubiquitination at K460 (P = 0.0415); Loss of MoRF binding (P = 0.082); Gain of methylation at K465 (P = 0.2458); Loss of glycosylation at K460 (P = 0.246)
17:44068827:G:C,P10636,G461A,0.204,Loss of relative solvent accessibility (P = 0.0676); Loss of ubiquitination at K465 (P = 0.1815); Loss of glycosylation at K460 (P = 0.2194); Loss of stability (P = 0.2446); Loss of solvent accessibility (P = 0.2882)
17:44068827:G:T,P10636,G461V,0.223,Loss of relative solvent accessibility (P = 0.0404); Gain of methylation at K460 (P = 0.1114); Loss of ubiquitination at K465 (P = 0.1668); Loss of glycosylation at K460 (P = 0.1716); Loss of solvent accessibility (P = 0.2668)
17:44068829:G:A,P10636,A462T,0.225,Gain of phosphorylation at A462 (P = 0.012); Gain of methylation at K467 (P = 0.0637); Loss of relative solvent accessibility (P = 0.0981); Loss of stability (P = 0.1513); Loss of ubiquitination at K465 (P = 0.1815)
17:44068829:G:C,P10636,A462P,0.248,Gain of methylation at K467 (P = 0.0582); Gain of glycosylation at A462 (P = 0.0586); Loss of MoRF binding (P = 0.1123); Gain of solvent accessibility (P = 0.1456); Gain of relative solvent accessibility (P = 0.1571)
17:44068829:G:T,P10636,A462S,0.211,Gain of phosphorylation at A462 (P = 0.0134); Gain of methylation at K467 (P = 0.0667); Gain of glycosylation at A462 (P = 0.0933); Gain of ubiquitination at K467 (P = 0.1278); Loss of relative solvent accessibility (P = 0.1807)
17:44068830:C:A,P10636,A462D,0.267,Gain of ubiquitination at K460 (P = 0.047); Loss of MoRF binding (P = 0.0743); Gain of methylation at K467 (P = 0.0885); Gain of solvent accessibility (P = 0.1708); Loss of glycosylation at T466 (P = 0.2015)
17:44068830:C:G,P10636,A462G,0.313,Gain of catalytic residue at A462 (P = 0.0014); Loss of stability (P = 0.0591); Gain of methylation at K467 (P = 0.1072); Gain of relative solvent accessibility (P = 0.1571); Loss of ubiquitination at K467 (P = 0.2053)
17:44068830:C:T,P10636,A462V,0.257,Gain of catalytic residue at A462 (P = 0.0393); Gain of ubiquitination at K467 (P = 0.107); Gain of methylation at K467 (P = 0.1168); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at T466 (P = 0.2558)
17:44068832:G:A,P10636,D463N,0.28,Gain of methylation at K465 (P = 0.1548); Gain of MoRF binding (P = 0.1742); Gain of glycosylation at T466 (P = 0.1952); Gain of ubiquitination at K458 (P = 0.1989); Loss of phosphorylation at T466 (P = 0.2731)
17:44068832:G:C,P10636,D463H,0.292,Gain of methylation at K465 (P = 0.1233); Loss of ubiquitination at K465 (P = 0.1668); Gain of MoRF binding (P = 0.1899); Gain of glycosylation at K460 (P = 0.2432); Loss of stability (P = 0.251)
17:44068832:G:T,P10636,D463Y,0.36,Gain of catalytic residue at D463 (P = 0.0011); Gain of phosphorylation at D463 (P = 0.0327); Gain of methylation at K467 (P = 0.0773); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1115)
17:44068833:A:C,P10636,D463A,0.317,Loss of ubiquitination at K465 (P = 0.1375); Loss of glycosylation at T466 (P = 0.1531); Loss of methylation at K467 (P = 0.1738); Gain of MoRF binding (P = 0.1789); Gain of catalytic residue at G461 (P = 0.2245)
17:44068833:A:G,P10636,D463G,0.335,Loss of stability (P = 0.0613); Gain of catalytic residue at G461 (P = 0.0966); Loss of glycosylation at T466 (P = 0.0991); Gain of methylation at K465 (P = 0.1493); Loss of ubiquitination at K465 (P = 0.1516)
17:44068834:T:A,P10636,D463E,0.255,Gain of methylation at K467 (P = 0.1287); Loss of ubiquitination at K467 (P = 0.2053); Loss of glycosylation at T466 (P = 0.2153); Gain of MoRF binding (P = 0.2635); Gain of solvent accessibility (P = 0.3089)
17:44068834:T:G,P10636,D463E,0.255,Gain of methylation at K467 (P = 0.1287); Loss of ubiquitination at K467 (P = 0.2053); Loss of glycosylation at T466 (P = 0.2153); Gain of MoRF binding (P = 0.2635); Gain of solvent accessibility (P = 0.3089)
17:44068835:G:A,P10636,G464S,0.269,Gain of phosphorylation at G464 (P = 0.0218); Gain of glycosylation at G464 (P = 0.0714); Gain of methylation at K467 (P = 0.144); Loss of ubiquitination at K465 (P = 0.1668); Gain of solvent accessibility (P = 0.2192)
17:44068835:G:C,P10636,G464R,0.347,Gain of solvent accessibility (P = 0.0014); Gain of methylation at K467 (P = 0.0493); Gain of ubiquitination at K460 (P = 0.0825); Gain of MoRF binding (P = 0.0927); Loss of glycosylation at T466 (P = 0.1168)
17:44068835:G:T,P10636,G464C,0.323,Gain of methylation at K465 (P = 0.014); Loss of relative solvent accessibility (P = 0.0981); Loss of MoRF binding (P = 0.1233); Loss of glycosylation at T466 (P = 0.147); Loss of ubiquitination at K465 (P = 0.1516)
17:44068836:G:A,P10636,G464D,0.309,Gain of ubiquitination at K460 (P = 0.047); Loss of MoRF binding (P = 0.0679); Gain of solvent accessibility (P = 0.1014); Loss of glycosylation at T466 (P = 0.1378); Loss of methylation at K467 (P = 0.1823)
17:44068836:G:C,P10636,G464A,0.243,Loss of methylation at K467 (P = 0.1468); Loss of ubiquitination at K467 (P = 0.1704); Gain of MoRF binding (P = 0.2452); Loss of glycosylation at T466 (P = 0.2845); Loss of relative solvent accessibility (P = 0.3219)
17:44068836:G:T,P10636,G464V,0.274,Gain of methylation at K465 (P = 0.0454); Loss of ubiquitination at K465 (P = 0.1668); Loss of relative solvent accessibility (P = 0.1807); Gain of MoRF binding (P = 0.2325); Loss of glycosylation at K460 (P = 0.2646)
17:44068838:A:C,P10636,K465Q,0.337,Gain of ubiquitination at K460 (P = 0.0325); Loss of MoRF binding (P = 0.0695); Gain of methylation at K467 (P = 0.1); Loss of glycosylation at K465 (P = 0.1073); Loss of phosphorylation at T466 (P = 0.317)
17:44068838:A:G,P10636,K465E,0.388,Loss of MoRF binding (P = 0.0056); Gain of ubiquitination at K467 (P = 0.0185); Loss of glycosylation at K465 (P = 0.1073); Loss of methylation at K465 (P = 0.1555); Loss of catalytic residue at K465 (P = 0.2952)
17:44068839:A:C,P10636,K465T,0.336,Loss of solvent accessibility (P = 0.0249); Gain of ubiquitination at K460 (P = 0.0291); Gain of phosphorylation at K465 (P = 0.0456); Gain of glycosylation at T466 (P = 0.0476); Loss of MoRF binding (P = 0.0579)
17:44068839:A:G,P10636,K465R,0.301,Gain of methylation at K465 (P = 0.0244); Loss of ubiquitination at K465 (P = 0.0341); Loss of glycosylation at K465 (P = 0.1073); Gain of MoRF binding (P = 0.1675); Loss of solvent accessibility (P = 0.2953)
17:44068839:A:T,P10636,K465I,0.382,Loss of solvent accessibility (P = 0.0187); Gain of ubiquitination at K460 (P = 0.0291); Gain of methylation at K467 (P = 0.0432); Loss of MoRF binding (P = 0.0656); Loss of glycosylation at T470 (P = 0.0862)
17:44068840:A:C,P10636,K465N,0.322,Gain of ubiquitination at K460 (P = 0.0314); Loss of MoRF binding (P = 0.0628); Gain of glycosylation at T466 (P = 0.0914); Loss of methylation at K465 (P = 0.1555); Loss of solvent accessibility (P = 0.1579)
17:44068840:A:T,P10636,K465N,0.322,Gain of ubiquitination at K460 (P = 0.0314); Loss of MoRF binding (P = 0.0628); Gain of glycosylation at T466 (P = 0.0914); Loss of methylation at K465 (P = 0.1555); Loss of solvent accessibility (P = 0.1579)
17:44068841:A:C,P10636,T466P,0.253,Loss of phosphorylation at T466 (P = 0.0182); Loss of MoRF binding (P = 0.0777); Gain of methylation at K467 (P = 0.1286); Gain of glycosylation at K467 (P = 0.1565); Gain of relative solvent accessibility (P = 0.1571)
17:44068841:A:G,P10636,T466A,0.257,Loss of phosphorylation at T466 (P = 0.0182); Loss of glycosylation at T466 (P = 0.0561); Loss of solvent accessibility (P = 0.1177); Loss of methylation at K467 (P = 0.1183); Loss of relative solvent accessibility (P = 0.1807)
17:44068841:A:T,P10636,T466S,0.229,Gain of glycosylation at T466 (P = 0.1089); Loss of methylation at K467 (P = 0.1653); Gain of ubiquitination at K467 (P = 0.1797); Gain of MoRF binding (P = 0.2008); Loss of phosphorylation at T466 (P = 0.4526)
17:44068842:C:A,P10636,T466K,0.294,Loss of phosphorylation at T466 (P = 0.0182); Gain of methylation at T466 (P = 0.0508); Gain of ubiquitination at T466 (P = 0.0539); Gain of MoRF binding (P = 0.0831); Gain of solvent accessibility (P = 0.1505)
17:44068842:C:G,P10636,T466R,0.276,Loss of phosphorylation at T466 (P = 0.0182); Gain of methylation at K467 (P = 0.0448); Loss of glycosylation at T466 (P = 0.0561); Gain of MoRF binding (P = 0.0679); Loss of relative solvent accessibility (P = 0.1807)
17:44068844:A:C,P10636,K467Q,0.275,Loss of ubiquitination at K467 (P = 0.0309); Loss of methylation at K467 (P = 0.035); Loss of MoRF binding (P = 0.0596); Loss of solvent accessibility (P = 0.1434); Loss of glycosylation at K467 (P = 0.1499)
17:44068844:A:G,P10636,K467E,0.324,Loss of MoRF binding (P = 0.0038); Gain of ubiquitination at K465 (P = 0.0198); Loss of methylation at K467 (P = 0.035); Loss of catalytic residue at K467 (P = 0.1176); Loss of solvent accessibility (P = 0.1322)
17:44068845:A:C,P10636,K467T,0.316,Loss of solvent accessibility (P = 0.0249); Loss of ubiquitination at K467 (P = 0.0309); Loss of methylation at K467 (P = 0.035); Loss of MoRF binding (P = 0.0464); Gain of phosphorylation at K467 (P = 0.0491)
17:44068845:A:G,P10636,K467R,0.259,Loss of ubiquitination at K467 (P = 0.0309); Gain of glycosylation at T466 (P = 0.0787); Gain of MoRF binding (P = 0.1187); Loss of methylation at K467 (P = 0.189); Gain of phosphorylation at T466 (P = 0.4466)
17:44068845:A:T,P10636,K467M,0.32,Loss of solvent accessibility (P = 0.0217); Loss of ubiquitination at K467 (P = 0.0309); Loss of methylation at K467 (P = 0.035); Loss of catalytic residue at K467 (P = 0.0502); Loss of MoRF binding (P = 0.0791)
17:44068846:G:C,P10636,K467N,0.256,Loss of ubiquitination at K467 (P = 0.0309); Loss of methylation at K467 (P = 0.035); Loss of solvent accessibility (P = 0.0371); Loss of MoRF binding (P = 0.053); Loss of catalytic residue at K467 (P = 0.0731)
17:44068846:G:T,P10636,K467N,0.256,Loss of ubiquitination at K467 (P = 0.0309); Loss of methylation at K467 (P = 0.035); Loss of solvent accessibility (P = 0.0371); Loss of MoRF binding (P = 0.053); Loss of catalytic residue at K467 (P = 0.0731)
17:44068847:A:C,P10636,I468L,0.143,Loss of methylation at K467 (P = 0.0836); Loss of MoRF binding (P = 0.1575); Loss of glycosylation at T470 (P = 0.1884); Loss of ubiquitination at K467 (P = 0.2053); Loss of phosphorylation at T466 (P = 0.4526)
17:44068847:A:G,P10636,I468V,0.133,Gain of methylation at K467 (P = 0.0594); Gain of glycosylation at T466 (P = 0.103); Gain of MoRF binding (P = 0.1504); Loss of ubiquitination at K467 (P = 0.2053); Gain of phosphorylation at T466 (P = 0.4411)
17:44068847:A:T,P10636,I468F,0.162,Gain of methylation at K467 (P = 0.0397); Loss of glycosylation at T470 (P = 0.0766); Loss of MoRF binding (P = 0.1152); Loss of ubiquitination at K467 (P = 0.1881); Loss of catalytic residue at R472 (P = 0.2978)
17:44068848:T:A,P10636,I468N,0.186,Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0421); Gain of MoRF binding (P = 0.1275); Loss of methylation at K467 (P = 0.1315); Gain of ubiquitination at K467 (P = 0.1797)
17:44068848:T:G,P10636,I468S,0.193,Gain of relative solvent accessibility (P = 0.0249); Gain of phosphorylation at I468 (P = 0.0292); Gain of solvent accessibility (P = 0.0854); Gain of glycosylation at I468 (P = 0.0863); Loss of methylation at K467 (P = 0.103)
17:44068849:C:G,P10636,I468M,0.166,Loss of methylation at K467 (P = 0.0444); Gain of MoRF binding (P = 0.0983); Loss of glycosylation at T470 (P = 0.1538); Loss of ubiquitination at K467 (P = 0.2053); Loss of catalytic residue at R472 (P = 0.2318)
17:44068850:G:C,P10636,A469P,0.331,Gain of catalytic residue at A469 (P = 0.0226); Loss of MoRF binding (P = 0.0601); Gain of glycosylation at T466 (P = 0.0673); Gain of relative solvent accessibility (P = 0.09); Gain of methylation at K467 (P = 0.0977)
17:44068850:G:T,P10636,A469S,0.23,Gain of phosphorylation at A469 (P = 0.0153); Gain of glycosylation at A469 (P = 0.0162); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K467 (P = 0.1278); Gain of solvent accessibility (P = 0.1319)
17:44068851:C:A,P10636,A469D,0.269,Loss of MoRF binding (P = 0.0582); Gain of solvent accessibility (P = 0.0596); Gain of ubiquitination at K467 (P = 0.0704); Gain of relative solvent accessibility (P = 0.09); Loss of methylation at K467 (P = 0.1068)
17:44068851:C:G,P10636,A469G,0.228,Gain of relative solvent accessibility (P = 0.09); Gain of catalytic residue at I468 (P = 0.1542); Loss of MoRF binding (P = 0.156); Loss of ubiquitination at K467 (P = 0.1704); Gain of methylation at K467 (P = 0.1732)
17:44068851:C:T,P10636,A469V,0.234,Gain of methylation at K467 (P = 0.0778); Loss of glycosylation at T470 (P = 0.1572); Gain of MoRF binding (P = 0.1587); Loss of ubiquitination at K465 (P = 0.1668); Gain of catalytic residue at A469 (P = 0.2046)
17:44068853:A:C,P10636,T470P,0.281,Loss of phosphorylation at T470 (P = 0.0028); Gain of catalytic residue at T470 (P = 0.0186); Loss of MoRF binding (P = 0.0569); Loss of stability (P = 0.058); Loss of glycosylation at T470 (P = 0.0828)
17:44068853:A:G,P10636,T470A,0.202,Loss of phosphorylation at T470 (P = 0.0028); Loss of glycosylation at T470 (P = 0.032); Loss of methylation at K467 (P = 0.1296); Gain of MoRF binding (P = 0.146); Loss of ubiquitination at K467 (P = 0.1704)
17:44068853:A:T,P10636,T470S,0.181,Loss of methylation at K467 (P = 0.1371); Gain of MoRF binding (P = 0.1474); Loss of phosphorylation at T466 (P = 0.1575); Loss of glycosylation at T470 (P = 0.1704); Gain of ubiquitination at K467 (P = 0.1797)
17:44068854:C:A,P10636,T470K,0.258,Loss of phosphorylation at T470 (P = 0.0028); Gain of ubiquitination at T470 (P = 0.0494); Gain of MoRF binding (P = 0.0528); Loss of glycosylation at T470 (P = 0.1079); Loss of stability (P = 0.1242)
17:44068854:C:G,P10636,T470R,0.283,Loss of phosphorylation at T470 (P = 0.0028); Gain of methylation at T470 (P = 0.0124); Loss of glycosylation at T470 (P = 0.032); Gain of MoRF binding (P = 0.0386); Gain of catalytic residue at T470 (P = 0.1496)
17:44068854:C:T,P10636,T470I,0.246,Loss of phosphorylation at T470 (P = 0.0028); Loss of glycosylation at T470 (P = 0.032); Gain of methylation at K467 (P = 0.0836); Gain of MoRF binding (P = 0.1359); Loss of ubiquitination at K467 (P = 0.1564)
17:44068856:C:A,P10636,P471T,0.251,Gain of glycosylation at P471 (P = 0.0184); Gain of phosphorylation at P471 (P = 0.0191); Gain of MoRF binding (P = 0.0664); Gain of methylation at K467 (P = 0.1182); Loss of ubiquitination at K467 (P = 0.2053)
17:44068856:C:G,P10636,P471A,0.246,Gain of MoRF binding (P = 0.0599); Loss of methylation at K467 (P = 0.1114); Loss of stability (P = 0.1181); Loss of glycosylation at T470 (P = 0.1413); Loss of ubiquitination at K467 (P = 0.1881)
17:44068856:C:T,P10636,P471S,0.298,Gain of phosphorylation at P471 (P = 0.0147); Gain of glycosylation at P471 (P = 0.0202); Gain of catalytic residue at P471 (P = 0.0246); Gain of MoRF binding (P = 0.0606); Loss of methylation at K467 (P = 0.1935)
17:44068857:C:A,P10636,P471Q,0.24,Gain of MoRF binding (P = 0.0607); Loss of glycosylation at T470 (P = 0.1314); Loss of methylation at R472 (P = 0.1448); Loss of ubiquitination at K467 (P = 0.2053); Loss of phosphorylation at T466 (P = 0.2342)
17:44068857:C:G,P10636,P471R,0.304,Gain of methylation at P471 (P = 0.0143); Gain of MoRF binding (P = 0.0205); Gain of catalytic residue at P471 (P = 0.0994); Gain of solvent accessibility (P = 0.1045); Loss of glycosylation at T470 (P = 0.1809)
17:44068857:C:T,P10636,P471L,0.285,Gain of MoRF binding (P = 0.061); Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at T470 (P = 0.0778); Loss of methylation at K467 (P = 0.0918); Loss of solvent accessibility (P = 0.1115)
17:44068859:C:G,P10636,R472G,0.391,Gain of sheet (P = 0.0016); Loss of solvent accessibility (P = 0.0044); Loss of methylation at R472 (P = 0.0058); Loss of loop (P = 0.0073); Loss of MoRF binding (P = 0.0098)
17:44068860:G:A,P10636,R472Q,0.346,Loss of methylation at R472 (P = 0.0058); Loss of MoRF binding (P = 0.0154); Loss of solvent accessibility (P = 0.0703); Gain of ubiquitination at K467 (P = 0.0898); Loss of glycosylation at T470 (P = 0.1262)
17:44068860:G:C,P10636,R472P,0.376,Loss of MoRF binding (P = 6e-04); Gain of sheet (P = 0.0036); Loss of methylation at R472 (P = 0.0058); Loss of loop (P = 0.0073); Gain of catalytic residue at P471 (P = 0.0112)
17:44068860:G:T,P10636,R472L,0.392,Loss of solvent accessibility (P = 6e-04); Loss of methylation at R472 (P = 0.0058); Loss of MoRF binding (P = 0.0094); Loss of relative solvent accessibility (P = 0.0404); Gain of stability (P = 0.0417)
17:44068862:G:A,P10636,G473R,0.346,Gain of solvent accessibility (P = 0.0042); Gain of methylation at G473 (P = 0.0202); Gain of MoRF binding (P = 0.0337); Loss of glycosylation at T470 (P = 0.0738); Gain of relative solvent accessibility (P = 0.09)
17:44068862:G:C,P10636,G473R,0.346,Gain of solvent accessibility (P = 0.0042); Gain of methylation at G473 (P = 0.0202); Gain of MoRF binding (P = 0.0337); Loss of glycosylation at T470 (P = 0.0738); Gain of relative solvent accessibility (P = 0.09)
17:44068863:G:A,P10636,G473E,0.333,Loss of MoRF binding (P = 0.0369); Loss of methylation at R472 (P = 0.0504); Gain of solvent accessibility (P = 0.0596); Loss of glycosylation at T470 (P = 0.1047); Gain of relative solvent accessibility (P = 0.1894)
17:44068863:G:C,P10636,G473A,0.27,Gain of glycosylation at T470 (P = 0.0872); Loss of methylation at R472 (P = 0.1583); Gain of MoRF binding (P = 0.1619); Loss of catalytic residue at A474 (P = 0.3264); Loss of relative solvent accessibility (P = 0.3919)
17:44068863:G:T,P10636,G473V,0.227,Loss of methylation at R472 (P = 0.0563); Gain of MoRF binding (P = 0.1098); Gain of glycosylation at T470 (P = 0.1461); Loss of catalytic residue at A474 (P = 0.3241); Loss of relative solvent accessibility (P = 0.3919)
17:44068865:G:A,P10636,A474T,0.205,Gain of glycosylation at A474 (P = 0.0028); Gain of phosphorylation at A474 (P = 0.0203); Loss of MoRF binding (P = 0.1493); Gain of solvent accessibility (P = 0.2291); Loss of methylation at R472 (P = 0.2904)
17:44068865:G:C,P10636,A474P,0.272,Gain of glycosylation at A474 (P = 0.0076); Loss of MoRF binding (P = 0.0431); Gain of catalytic residue at A474 (P = 0.1625); Gain of solvent accessibility (P = 0.2689); Loss of methylation at R472 (P = 0.3099)
17:44068865:G:T,P10636,A474S,0.177,Gain of phosphorylation at A474 (P = 0.0092); Gain of glycosylation at A474 (P = 0.0154); Gain of MoRF binding (P = 0.1597); Loss of methylation at R472 (P = 0.3021); Loss of relative solvent accessibility (P = 0.5582)
17:44068866:C:A,P10636,A474E,0.25,Loss of MoRF binding (P = 0.0269); Gain of solvent accessibility (P = 0.0456); Gain of glycosylation at T470 (P = 0.1087); Loss of methylation at R472 (P = 0.2421); Loss of catalytic residue at A474 (P = 0.2978)
17:44068866:C:G,P10636,A474G,0.178,Loss of MoRF binding (P = 0.1428); Loss of glycosylation at P476 (P = 0.2334); Gain of methylation at R472 (P = 0.3388); Gain of catalytic residue at A475 (P = 0.3504); Loss of stability (P = 0.4886)
17:44068866:C:T,P10636,A474V,0.198,Gain of MoRF binding (P = 0.1156); Loss of glycosylation at P476 (P = 0.1433); Loss of methylation at R472 (P = 0.1918); Gain of solvent accessibility (P = 0.2291); Gain of catalytic residue at A474 (P = 0.5243)
17:44068868:G:A,P10636,A475T,0.246,Gain of phosphorylation at A475 (P = 0.017); Gain of glycosylation at A475 (P = 0.0188); Gain of methylation at K480 (P = 0.1107); Gain of ubiquitination at K480 (P = 0.1375); Gain of MoRF binding (P = 0.1541)
17:44068868:G:C,P10636,A475P,0.351,Gain of glycosylation at A475 (P = 0.0106); Gain of catalytic residue at A475 (P = 0.0255); Loss of MoRF binding (P = 0.0486); Loss of stability (P = 0.1002); Gain of methylation at K480 (P = 0.1111)
17:44068868:G:T,P10636,A475S,0.258,Gain of phosphorylation at A475 (P = 0.0068); Gain of glycosylation at A475 (P = 0.0089); Gain of MoRF binding (P = 0.126); Gain of ubiquitination at K480 (P = 0.1375); Gain of methylation at K480 (P = 0.1558)
17:44068869:C:A,P10636,A475D,0.312,Gain of ubiquitination at K480 (P = 0.0261); Loss of MoRF binding (P = 0.0531); Loss of glycosylation at P477 (P = 0.0755); Loss of methylation at R472 (P = 0.1325); Gain of solvent accessibility (P = 0.1708)
17:44068869:C:G,P10636,A475G,0.28,Gain of catalytic residue at A475 (P = 0.0309); Loss of stability (P = 0.0843); Loss of MoRF binding (P = 0.1504); Gain of methylation at K480 (P = 0.1598); Loss of ubiquitination at K480 (P = 0.1601)
17:44068869:C:T,P10636,A475V,0.221,Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at P476 (P = 0.1209); Gain of MoRF binding (P = 0.1303); Gain of ubiquitination at K480 (P = 0.1375); Gain of methylation at K480 (P = 0.1561)
17:44068871:C:A,P10636,P476T,0.351,Gain of phosphorylation at P476 (P = 0.0257); Gain of MoRF binding (P = 0.0529); Loss of catalytic residue at P476 (P = 0.0757); Gain of glycosylation at P476 (P = 0.1031); Gain of ubiquitination at K480 (P = 0.1128)
17:44068871:C:G,P10636,P476A,0.376,Loss of catalytic residue at P476 (P = 0.0076); Loss of glycosylation at P476 (P = 0.0375); Gain of MoRF binding (P = 0.0591); Loss of methylation at K480 (P = 0.0888); Loss of solvent accessibility (P = 0.1322)
17:44068871:C:T,P10636,P476S,0.352,Loss of catalytic residue at P476 (P = 0.0025); Gain of phosphorylation at P476 (P = 0.0322); Gain of MoRF binding (P = 0.048); Gain of glycosylation at P476 (P = 0.0678); Gain of ubiquitination at K480 (P = 0.0972)
17:44068872:C:A,P10636,P476H,0.374,Loss of glycosylation at P476 (P = 0.0375); Gain of MoRF binding (P = 0.0563); Loss of catalytic residue at P476 (P = 0.1107); Gain of ubiquitination at K480 (P = 0.1375); Loss of methylation at K480 (P = 0.1625)
17:44068872:C:G,P10636,P476R,0.388,Gain of MoRF binding (P = 0.0087); Gain of methylation at P476 (P = 0.0264); Loss of glycosylation at P476 (P = 0.0375); Gain of solvent accessibility (P = 0.0411); Loss of ubiquitination at K480 (P = 0.0877)
17:44068872:C:T,P10636,P476L,0.351,Loss of glycosylation at P476 (P = 0.0375); Gain of MoRF binding (P = 0.0653); Loss of methylation at K480 (P = 0.0666); Gain of ubiquitination at K480 (P = 0.0972); Loss of relative solvent accessibility (P = 0.0981)
17:44068874:C:A,P10636,P477T,0.288,Loss of catalytic residue at P476 (P = 0.0138); Gain of phosphorylation at P477 (P = 0.0187); Loss of glycosylation at P477 (P = 0.0308); Gain of MoRF binding (P = 0.0565); Loss of methylation at K480 (P = 0.1052)
17:44068874:C:G,P10636,P477A,0.245,Loss of glycosylation at P477 (P = 0.0092); Loss of catalytic residue at P476 (P = 0.0205); Loss of solvent accessibility (P = 0.0509); Gain of MoRF binding (P = 0.056); Loss of relative solvent accessibility (P = 0.0676)
17:44068874:C:T,P10636,P477S,0.277,Loss of catalytic residue at P476 (P = 0.0138); Gain of phosphorylation at P477 (P = 0.0293); Gain of MoRF binding (P = 0.0534); Loss of methylation at K480 (P = 0.0605); Gain of ubiquitination at K480 (P = 0.0972)
17:44068875:C:A,P10636,P477Q,0.281,Loss of glycosylation at P477 (P = 0.0092); Loss of catalytic residue at P476 (P = 0.0255); Gain of MoRF binding (P = 0.0548); Gain of solvent accessibility (P = 0.1045); Gain of ubiquitination at K480 (P = 0.1128)
17:44068875:C:G,P10636,P477R,0.34,Loss of glycosylation at P477 (P = 0.0092); Loss of catalytic residue at P476 (P = 0.0138); Gain of MoRF binding (P = 0.0139); Gain of solvent accessibility (P = 0.0216); Gain of methylation at P477 (P = 0.035)
17:44068875:C:T,P10636,P477L,0.319,Loss of glycosylation at P477 (P = 0.0092); Loss of catalytic residue at P476 (P = 0.0138); Gain of stability (P = 0.0197); Gain of MoRF binding (P = 0.0584); Loss of methylation at K480 (P = 0.0788)
17:44068877:G:A,P10636,G478S,0.265,Gain of glycosylation at G478 (P = 0.0037); Gain of phosphorylation at G478 (P = 0.0235); Loss of catalytic residue at G478 (P = 0.0506); Gain of ubiquitination at K480 (P = 0.1375); Loss of methylation at K480 (P = 0.1455)
17:44068877:G:C,P10636,G478R,0.305,Gain of solvent accessibility (P = 0.0037); Gain of MoRF binding (P = 0.0477); Gain of methylation at G478 (P = 0.0679); Loss of glycosylation at K480 (P = 0.0944); Loss of ubiquitination at K480 (P = 0.1423)
17:44068877:G:T,P10636,G478C,0.29,Loss of relative solvent accessibility (P = 0.0676); Loss of MoRF binding (P = 0.08); Loss of ubiquitination at K480 (P = 0.1423); Gain of methylation at K480 (P = 0.1593); Loss of glycosylation at K480 (P = 0.1698)
17:44068878:G:A,P10636,G478D,0.312,Gain of ubiquitination at K480 (P = 0.0247); Loss of MoRF binding (P = 0.0317); Loss of catalytic residue at G478 (P = 0.0592); Loss of methylation at K480 (P = 0.0624); Gain of solvent accessibility (P = 0.0638)
17:44068878:G:C,P10636,G478A,0.223,Loss of relative solvent accessibility (P = 0.0404); Loss of catalytic residue at G478 (P = 0.082); Gain of glycosylation at P476 (P = 0.1027); Gain of ubiquitination at K480 (P = 0.1128); Gain of MoRF binding (P = 0.1453)
17:44068878:G:T,P10636,G478V,0.228,Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at P477 (P = 0.0648); Gain of ubiquitination at K480 (P = 0.0972); Gain of MoRF binding (P = 0.0977); Loss of catalytic residue at G478 (P = 0.1086)
17:44068880:C:A,P10636,Q479K,0.33,Gain of methylation at Q479 (P = 0.0192); Gain of ubiquitination at Q479 (P = 0.0388); Gain of glycosylation at Q479 (P = 0.0448); Gain of MoRF binding (P = 0.053); Loss of solvent accessibility (P = 0.1868)
17:44068880:C:G,P10636,Q479E,0.338,Gain of ubiquitination at K480 (P = 0.0251); Loss of MoRF binding (P = 0.031); Loss of methylation at K480 (P = 0.0994); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at Q479 (P = 0.187)
17:44068881:A:C,P10636,Q479P,0.329,Gain of glycosylation at Q479 (P = 0.0169); Loss of solvent accessibility (P = 0.0352); Loss of MoRF binding (P = 0.0398); Loss of ubiquitination at K480 (P = 0.1264); Loss of relative solvent accessibility (P = 0.1807)
17:44068881:A:G,P10636,Q479R,0.311,Gain of methylation at Q479 (P = 0.0133); Gain of MoRF binding (P = 0.0356); Loss of ubiquitination at K480 (P = 0.0957); Gain of solvent accessibility (P = 0.199); Loss of glycosylation at K480 (P = 0.2618)
17:44068881:A:T,P10636,Q479L,0.315,Loss of solvent accessibility (P = 0.0217); Loss of methylation at K480 (P = 0.0496); Loss of relative solvent accessibility (P = 0.0981); Loss of MoRF binding (P = 0.1006); Loss of glycosylation at P476 (P = 0.1045)
17:44068882:G:C,P10636,Q479H,0.29,Loss of solvent accessibility (P = 0.0576); Loss of MoRF binding (P = 0.1101); Loss of ubiquitination at K480 (P = 0.1423); Loss of glycosylation at P476 (P = 0.1501); Loss of methylation at K480 (P = 0.154)
17:44068882:G:T,P10636,Q479H,0.29,Loss of solvent accessibility (P = 0.0576); Loss of MoRF binding (P = 0.1101); Loss of ubiquitination at K480 (P = 0.1423); Loss of glycosylation at P476 (P = 0.1501); Loss of methylation at K480 (P = 0.154)
17:44068883:A:C,P10636,K480Q,0.368,Loss of methylation at K480 (P = 0.0121); Loss of glycosylation at K480 (P = 0.0175); Loss of ubiquitination at K480 (P = 0.0244); Loss of MoRF binding (P = 0.0295); Loss of solvent accessibility (P = 0.1077)
17:44068883:A:G,P10636,K480E,0.378,Loss of MoRF binding (P = 6e-04); Loss of methylation at K480 (P = 0.0121); Loss of glycosylation at K480 (P = 0.0175); Loss of ubiquitination at K480 (P = 0.0244); Gain of stability (P = 0.2121)
17:44068884:A:C,P10636,K480T,0.373,Loss of methylation at K480 (P = 0.0121); Gain of phosphorylation at K480 (P = 0.018); Loss of MoRF binding (P = 0.0227); Loss of ubiquitination at K480 (P = 0.0244); Gain of helix (P = 0.0496)
17:44068884:A:G,P10636,K480R,0.365,Loss of glycosylation at K480 (P = 0.0175); Loss of ubiquitination at K480 (P = 0.0244); Loss of methylation at K480 (P = 0.0862); Gain of MoRF binding (P = 0.0932); Gain of catalytic residue at K480 (P = 0.1356)
17:44068884:A:T,P10636,K480M,0.39,Loss of solvent accessibility (P = 0.0045); Loss of methylation at K480 (P = 0.0121); Loss of glycosylation at K480 (P = 0.0175); Loss of ubiquitination at K480 (P = 0.0244); Gain of stability (P = 0.025)
17:44068885:G:C,P10636,K480N,0.366,Loss of methylation at K480 (P = 0.0121); Loss of glycosylation at K480 (P = 0.0175); Loss of ubiquitination at K480 (P = 0.0244); Loss of MoRF binding (P = 0.0279); Loss of solvent accessibility (P = 0.1177)
17:44068885:G:T,P10636,K480N,0.366,Loss of methylation at K480 (P = 0.0121); Loss of glycosylation at K480 (P = 0.0175); Loss of ubiquitination at K480 (P = 0.0244); Loss of MoRF binding (P = 0.0279); Loss of solvent accessibility (P = 0.1177)
17:44068886:G:A,P10636,G481S,0.291,Gain of glycosylation at G481 (P = 0.0151); Gain of phosphorylation at G481 (P = 0.0293); Gain of solvent accessibility (P = 0.1014); Loss of catalytic residue at P477 (P = 0.1103); Loss of ubiquitination at K480 (P = 0.1423)
17:44068886:G:C,P10636,G481R,0.324,Gain of solvent accessibility (P = 0.0014); Gain of methylation at G481 (P = 0.044); Gain of MoRF binding (P = 0.058); Loss of ubiquitination at K480 (P = 0.0877); Loss of catalytic residue at P477 (P = 0.1103)
17:44068886:G:T,P10636,G481C,0.291,Gain of methylation at K480 (P = 0.0379); Loss of MoRF binding (P = 0.0803); Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K480 (P = 0.1091); Loss of catalytic residue at P477 (P = 0.1103)
17:44068887:G:A,P10636,G481D,0.297,Gain of ubiquitination at K480 (P = 0.0239); Loss of MoRF binding (P = 0.0291); Gain of solvent accessibility (P = 0.0354); Loss of methylation at K480 (P = 0.0676); Loss of catalytic residue at P477 (P = 0.1103)
17:44068887:G:C,P10636,G481A,0.245,Loss of catalytic residue at P477 (P = 0.1103); Loss of glycosylation at K480 (P = 0.1112); Loss of methylation at K480 (P = 0.1505); Gain of relative solvent accessibility (P = 0.1571); Gain of MoRF binding (P = 0.1579)
17:44068887:G:T,P10636,G481V,0.23,Gain of methylation at K480 (P = 0.0678); Loss of glycosylation at K480 (P = 0.083); Loss of relative solvent accessibility (P = 0.0981); Loss of catalytic residue at P477 (P = 0.1103); Gain of ubiquitination at K480 (P = 0.1128)
17:44068889:C:A,P10636,Q482K,0.24,Gain of methylation at Q482 (P = 0.0085); Gain of ubiquitination at Q482 (P = 0.03); Gain of glycosylation at Q482 (P = 0.0449); Gain of MoRF binding (P = 0.0625); Loss of solvent accessibility (P = 0.1868)
17:44068889:C:G,P10636,Q482E,0.229,Gain of ubiquitination at K480 (P = 0.0268); Loss of MoRF binding (P = 0.0357); Loss of methylation at K480 (P = 0.1086); Gain of glycosylation at K480 (P = 0.1819); Gain of sheet (P = 0.1945)
17:44068890:A:C,P10636,Q482P,0.251,Gain of glycosylation at Q482 (P = 0.0342); Loss of MoRF binding (P = 0.0585); Gain of methylation at R487 (P = 0.1389); Loss of ubiquitination at K480 (P = 0.1423); Gain of catalytic residue at G481 (P = 0.1627)
17:44068890:A:G,P10636,Q482R,0.263,Gain of methylation at Q482 (P = 0.0094); Gain of MoRF binding (P = 0.0526); Gain of catalytic residue at Q482 (P = 0.0953); Loss of ubiquitination at K480 (P = 0.1091); Loss of glycosylation at K480 (P = 0.1466)
17:44068890:A:T,P10636,Q482L,0.24,Loss of solvent accessibility (P = 0.0217); Loss of methylation at K480 (P = 0.0655); Loss of relative solvent accessibility (P = 0.0981); Loss of MoRF binding (P = 0.134); Gain of ubiquitination at K480 (P = 0.1375)
17:44068891:G:C,P10636,Q482H,0.208,Gain of methylation at R487 (P = 0.1001); Loss of MoRF binding (P = 0.1254); Loss of ubiquitination at K480 (P = 0.1601); Gain of glycosylation at K480 (P = 0.1911); Gain of catalytic residue at K480 (P = 0.2625)
17:44068891:G:T,P10636,Q482H,0.208,Gain of methylation at R487 (P = 0.1001); Loss of MoRF binding (P = 0.1254); Loss of ubiquitination at K480 (P = 0.1601); Gain of glycosylation at K480 (P = 0.1911); Gain of catalytic residue at K480 (P = 0.2625)
17:44068892:G:A,P10636,A483T,0.247,Gain of glycosylation at A483 (P = 0.0293); Gain of phosphorylation at A483 (P = 0.0535); Loss of relative solvent accessibility (P = 0.0981); Gain of ubiquitination at K480 (P = 0.1128); Loss of methylation at R487 (P = 0.1238)
17:44068892:G:C,P10636,A483P,0.273,Loss of MoRF binding (P = 0.0603); Gain of methylation at K480 (P = 0.0917); Gain of ubiquitination at K480 (P = 0.1128); Gain of glycosylation at A483 (P = 0.1182); Loss of relative solvent accessibility (P = 0.1807)
17:44068892:G:T,P10636,A483S,0.269,Gain of phosphorylation at A483 (P = 0.0551); Gain of MoRF binding (P = 0.1112); Gain of ubiquitination at K480 (P = 0.1128); Loss of methylation at R487 (P = 0.1181); Loss of glycosylation at K480 (P = 0.2611)
17:44068893:C:A,P10636,A483D,0.281,Gain of ubiquitination at K480 (P = 0.0251); Loss of MoRF binding (P = 0.0567); Loss of methylation at R487 (P = 0.0703); Gain of solvent accessibility (P = 0.1708); Gain of glycosylation at K480 (P = 0.1891)
17:44068893:C:G,P10636,A483G,0.261,Loss of relative solvent accessibility (P = 0.0981); Loss of glycosylation at T486 (P = 0.1258); Loss of MoRF binding (P = 0.1438); Loss of solvent accessibility (P = 0.1579); Loss of stability (P = 0.1598)
17:44068893:C:T,P10636,A483V,0.255,Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K480 (P = 0.1264); Gain of MoRF binding (P = 0.1382); Gain of methylation at K480 (P = 0.1536); Loss of phosphorylation at T486 (P = 0.1705)
17:44068895:A:C,P10636,N484H,0.297,Gain of ubiquitination at K480 (P = 0.0972); Loss of MoRF binding (P = 0.1157); Gain of methylation at R487 (P = 0.1303); Loss of solvent accessibility (P = 0.1744); Gain of glycosylation at K480 (P = 0.1798)
17:44068895:A:G,P10636,N484D,0.295,Gain of ubiquitination at K480 (P = 0.0276); Loss of MoRF binding (P = 0.0469); Loss of methylation at R487 (P = 0.1017); Gain of phosphorylation at T486 (P = 0.1629); Loss of glycosylation at T486 (P = 0.2378)
17:44068895:A:T,P10636,N484Y,0.304,Gain of phosphorylation at N484 (P = 0.0101); Gain of methylation at K480 (P = 0.0953); Gain of catalytic residue at N484 (P = 0.1019); Loss of MoRF binding (P = 0.1075); Gain of glycosylation at P489 (P = 0.1249)
17:44068896:A:C,P10636,N484T,0.343,Gain of phosphorylation at N484 (P = 0.0155); Loss of loop (P = 0.0288); Gain of sheet (P = 0.0477); Gain of glycosylation at N484 (P = 0.0682); Gain of methylation at K480 (P = 0.0988)
17:44068896:A:T,P10636,N484I,0.362,Gain of stability (P = 0.0553); Loss of solvent accessibility (P = 0.0721); Loss of methylation at R487 (P = 0.0857); Gain of glycosylation at P489 (P = 0.0933); Loss of relative solvent accessibility (P = 0.0981)
17:44068897:C:A,P10636,N484K,0.343,Gain of methylation at N484 (P = 0.0087); Loss of loop (P = 0.0288); Gain of ubiquitination at N484 (P = 0.0289); Gain of glycosylation at N484 (P = 0.0346); Gain of MoRF binding (P = 0.041)
17:44068897:C:G,P10636,N484K,0.343,Gain of methylation at N484 (P = 0.0087); Loss of loop (P = 0.0288); Gain of ubiquitination at N484 (P = 0.0289); Gain of glycosylation at N484 (P = 0.0346); Gain of MoRF binding (P = 0.041)
17:44068898:G:A,P10636,A485T,0.323,Gain of glycosylation at A485 (P = 0.0067); Gain of phosphorylation at A485 (P = 0.0596); Gain of catalytic residue at A485 (P = 0.0825); Gain of methylation at K480 (P = 0.0962); Loss of MoRF binding (P = 0.1086)
17:44068898:G:C,P10636,A485P,0.317,Loss of MoRF binding (P = 0.0453); Gain of methylation at K480 (P = 0.0916); Gain of glycosylation at A485 (P = 0.0954); Gain of ubiquitination at K480 (P = 0.0972); Loss of stability (P = 0.2037)
17:44068898:G:T,P10636,A485S,0.289,Gain of glycosylation at A485 (P = 0.0104); Gain of phosphorylation at A485 (P = 0.03); Gain of methylation at K480 (P = 0.0767); Gain of ubiquitination at K480 (P = 0.1128); Loss of MoRF binding (P = 0.1357)
17:44068899:C:G,P10636,A485G,0.262,Gain of ubiquitination at K480 (P = 0.0972); Gain of methylation at R487 (P = 0.1308); Loss of MoRF binding (P = 0.1386); Loss of stability (P = 0.2329); Gain of glycosylation at K480 (P = 0.2585)
17:44068899:C:T,P10636,A485V,0.293,Gain of MoRF binding (P = 0.0979); Loss of methylation at R487 (P = 0.1128); Loss of ubiquitination at K480 (P = 0.1601); Loss of glycosylation at K480 (P = 0.2044); Loss of phosphorylation at T486 (P = 0.2313)
17:44068901:A:C,P10636,T486P,0.286,Loss of glycosylation at T486 (P = 0.0259); Loss of phosphorylation at T486 (P = 0.0294); Loss of MoRF binding (P = 0.053); Loss of ubiquitination at K491 (P = 0.0992); Loss of stability (P = 0.1047)
17:44068901:A:G,P10636,T486A,0.252,Loss of glycosylation at T486 (P = 0.0077); Loss of phosphorylation at T486 (P = 0.0294); Gain of methylation at R487 (P = 0.0701); Loss of ubiquitination at K491 (P = 0.0877); Gain of MoRF binding (P = 0.1335)
17:44068901:A:T,P10636,T486S,0.257,Loss of ubiquitination at K491 (P = 0.1151); Gain of MoRF binding (P = 0.1168); Gain of phosphorylation at T486 (P = 0.1322); Gain of methylation at R487 (P = 0.1513); Gain of relative solvent accessibility (P = 0.1684)
17:44068902:C:A,P10636,T486N,0.247,Loss of glycosylation at T486 (P = 0.0077); Loss of phosphorylation at T486 (P = 0.0294); Loss of ubiquitination at K491 (P = 0.1322); Loss of MoRF binding (P = 0.1413); Gain of methylation at R487 (P = 0.1608)
17:44068902:C:G,P10636,T486S,0.257,Loss of ubiquitination at K491 (P = 0.1151); Gain of MoRF binding (P = 0.1168); Gain of phosphorylation at T486 (P = 0.1322); Gain of methylation at R487 (P = 0.1513); Gain of relative solvent accessibility (P = 0.1684)
17:44068902:C:T,P10636,T486I,0.327,Loss of glycosylation at T486 (P = 0.0077); Loss of phosphorylation at T486 (P = 0.0294); Loss of methylation at R487 (P = 0.0797); Gain of ubiquitination at K491 (P = 0.0985); Loss of relative solvent accessibility (P = 0.0995)
17:44068904:A:G,P10636,R487G,0.412,Loss of MoRF binding (P = 0.0033); Loss of methylation at R487 (P = 0.0309); Gain of ubiquitination at K491 (P = 0.0312); Gain of relative solvent accessibility (P = 0.0479); Loss of catalytic residue at R487 (P = 0.0582)
17:44068904:A:T,P10636,R487W,0.433,Loss of methylation at R487 (P = 0.0309); Gain of ubiquitination at K491 (P = 0.0312); Loss of MoRF binding (P = 0.0426); Loss of phosphorylation at T486 (P = 0.0704); Loss of catalytic residue at R487 (P = 0.0735)
17:44068905:G:A,P10636,R487K,0.351,Gain of methylation at R487 (P = 0.021); Gain of ubiquitination at R487 (P = 0.03); Loss of MoRF binding (P = 0.0738); Gain of glycosylation at R487 (P = 0.0973); Loss of catalytic residue at R487 (P = 0.1478)
17:44068905:G:C,P10636,R487T,0.397,Gain of glycosylation at R487 (P = 0.0035); Loss of MoRF binding (P = 0.0044); Gain of phosphorylation at R487 (P = 0.0293); Loss of methylation at R487 (P = 0.0309); Gain of ubiquitination at K491 (P = 0.0312)
17:44068905:G:T,P10636,R487M,0.404,Loss of MoRF binding (P = 0.0089); Loss of methylation at R487 (P = 0.0309); Gain of ubiquitination at K491 (P = 0.0312); Loss of catalytic residue at R487 (P = 0.0739); Loss of phosphorylation at T486 (P = 0.1009)
17:44068906:G:C,P10636,R487S,0.394,Loss of MoRF binding (P = 0.0071); Gain of glycosylation at R487 (P = 0.0075); Gain of phosphorylation at R487 (P = 0.0286); Gain of ubiquitination at K491 (P = 0.0303); Loss of methylation at R487 (P = 0.0309)
17:44068906:G:T,P10636,R487S,0.394,Loss of MoRF binding (P = 0.0071); Gain of glycosylation at R487 (P = 0.0075); Gain of phosphorylation at R487 (P = 0.0286); Gain of ubiquitination at K491 (P = 0.0303); Loss of methylation at R487 (P = 0.0309)
17:44068907:A:C,P10636,I488L,0.357,Gain of methylation at R487 (P = 0.0588); Loss of MoRF binding (P = 0.1068); Gain of glycosylation at P489 (P = 0.1161); Loss of ubiquitination at K491 (P = 0.1322); Gain of sheet (P = 0.1945)
17:44068907:A:G,P10636,I488V,0.345,Gain of methylation at R487 (P = 0.0448); Loss of ubiquitination at K491 (P = 0.0992); Gain of MoRF binding (P = 0.1273); Loss of glycosylation at P493 (P = 0.2403); Gain of phosphorylation at T486 (P = 0.2547)
17:44068907:A:T,P10636,I488F,0.376,Gain of methylation at R487 (P = 0.0433); Loss of MoRF binding (P = 0.0975); Gain of glycosylation at P489 (P = 0.1063); Loss of ubiquitination at K491 (P = 0.1322); Gain of phosphorylation at T486 (P = 0.2526)
17:44068908:T:A,P10636,I488N,0.364,Gain of methylation at R487 (P = 0.0662); Loss of MoRF binding (P = 0.1026); Loss of ubiquitination at K491 (P = 0.1151); Gain of glycosylation at P489 (P = 0.1322); Loss of stability (P = 0.1504)
17:44068908:T:C,P10636,I488T,0.322,Gain of phosphorylation at I488 (P = 0.0012); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at R487 (P = 0.0528); Loss of stability (P = 0.0791); Gain of solvent accessibility (P = 0.0917)
17:44068908:T:G,P10636,I488S,0.316,Gain of phosphorylation at I488 (P = 0.0081); Gain of methylation at R487 (P = 0.0539); Loss of stability (P = 0.0604); Gain of glycosylation at I488 (P = 0.0658); Gain of relative solvent accessibility (P = 0.09)
17:44068909:T:G,P10636,I488M,0.371,Gain of methylation at R487 (P = 0.0475); Gain of MoRF binding (P = 0.0979); Loss of ubiquitination at K491 (P = 0.0992); Gain of glycosylation at P489 (P = 0.1176); Gain of phosphorylation at T486 (P = 0.2699)
17:44068910:C:A,P10636,P489T,0.269,Gain of phosphorylation at P489 (P = 0.0257); Gain of relative solvent accessibility (P = 0.0479); Gain of MoRF binding (P = 0.0507); Gain of glycosylation at P489 (P = 0.0684); Gain of solvent accessibility (P = 0.0917)
17:44068910:C:G,P10636,P489A,0.311,Gain of MoRF binding (P = 0.0454); Loss of glycosylation at P489 (P = 0.067); Loss of ubiquitination at K491 (P = 0.0992); Loss of loop (P = 0.1242); Gain of methylation at R487 (P = 0.1644)
17:44068910:C:T,P10636,P489S,0.238,Gain of phosphorylation at P489 (P = 0.0137); Gain of MoRF binding (P = 0.0412); Gain of relative solvent accessibility (P = 0.0479); Loss of glycosylation at T486 (P = 0.0775); Gain of solvent accessibility (P = 0.11)
17:44068911:C:A,P10636,P489Q,0.257,Gain of MoRF binding (P = 0.045); Loss of ubiquitination at K491 (P = 0.0587); Loss of glycosylation at P489 (P = 0.067); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917)
17:44068911:C:G,P10636,P489R,0.304,Gain of MoRF binding (P = 0.0084); Gain of methylation at P489 (P = 0.0385); Loss of ubiquitination at K491 (P = 0.052); Loss of glycosylation at T492 (P = 0.0584); Gain of solvent accessibility (P = 0.0584)
17:44068911:C:T,P10636,P489L,0.28,Loss of glycosylation at T486 (P = 0.0371); Gain of MoRF binding (P = 0.048); Loss of ubiquitination at K491 (P = 0.052); Loss of methylation at R487 (P = 0.0875); Loss of phosphorylation at T486 (P = 0.1175)
17:44068913:G:A,P10636,A490T,0.203,Gain of relative solvent accessibility (P = 0.0023); Gain of phosphorylation at A490 (P = 0.0025); Gain of glycosylation at A490 (P = 0.0055); Gain of solvent accessibility (P = 0.0068); Loss of ubiquitination at K491 (P = 0.0777)
17:44068913:G:C,P10636,A490P,0.237,Gain of relative solvent accessibility (P = 0.0023); Gain of solvent accessibility (P = 0.0078); Gain of glycosylation at A490 (P = 0.0095); Gain of catalytic residue at P489 (P = 0.0112); Loss of MoRF binding (P = 0.0581)
17:44068913:G:T,P10636,A490S,0.184,Gain of relative solvent accessibility (P = 0.0023); Gain of phosphorylation at A490 (P = 0.0061); Gain of glycosylation at A490 (P = 0.0073); Gain of solvent accessibility (P = 0.0104); Loss of methylation at R487 (P = 0.1045)
17:44068914:C:A,P10636,A490E,0.251,Gain of solvent accessibility (P = 9e-04); Gain of relative solvent accessibility (P = 0.0023); Gain of ubiquitination at K491 (P = 0.034); Loss of MoRF binding (P = 0.049); Loss of methylation at R487 (P = 0.0725)
17:44068914:C:G,P10636,A490G,0.149,Gain of relative solvent accessibility (P = 0.0023); Gain of solvent accessibility (P = 0.0514); Loss of ubiquitination at K491 (P = 0.0877); Gain of methylation at R487 (P = 0.1249); Gain of MoRF binding (P = 0.1331)
17:44068914:C:T,P10636,A490V,0.146,Loss of ubiquitination at K491 (P = 0.0637); Gain of MoRF binding (P = 0.1117); Gain of relative solvent accessibility (P = 0.1259); Loss of glycosylation at P493 (P = 0.1275); Loss of methylation at R487 (P = 0.1437)
17:44068916:A:C,P10636,K491Q,0.286,Loss of methylation at K491 (P = 0.0015); Loss of ubiquitination at K491 (P = 0.0183); Loss of MoRF binding (P = 0.0457); Loss of catalytic residue at K491 (P = 0.0612); Loss of glycosylation at K491 (P = 0.0828)
17:44068916:A:G,P10636,K491E,0.309,Loss of methylation at K491 (P = 0.0015); Loss of MoRF binding (P = 0.0052); Loss of ubiquitination at K491 (P = 0.0183); Loss of glycosylation at K491 (P = 0.0828); Loss of catalytic residue at K491 (P = 0.114)
17:44068917:A:C,P10636,K491T,0.317,Loss of methylation at K491 (P = 0.0015); Gain of glycosylation at K491 (P = 0.0135); Loss of ubiquitination at K491 (P = 0.0183); Loss of MoRF binding (P = 0.0279); Gain of phosphorylation at K491 (P = 0.031)
17:44068917:A:G,P10636,K491R,0.207,Loss of ubiquitination at K491 (P = 0.0183); Loss of methylation at K491 (P = 0.0186); Gain of MoRF binding (P = 0.0699); Gain of solvent accessibility (P = 0.0789); Loss of glycosylation at K491 (P = 0.0828)
17:44068917:A:T,P10636,K491I,0.294,Loss of methylation at K491 (P = 0.0015); Loss of ubiquitination at K491 (P = 0.0183); Loss of catalytic residue at K491 (P = 0.0236); Loss of MoRF binding (P = 0.025); Loss of glycosylation at K491 (P = 0.0828)
17:44068918:A:C,P10636,K491N,0.285,Loss of methylation at K491 (P = 0.0015); Loss of ubiquitination at K491 (P = 0.0183); Loss of MoRF binding (P = 0.0383); Loss of glycosylation at K491 (P = 0.0828); Gain of relative solvent accessibility (P = 0.1684)
17:44068918:A:T,P10636,K491N,0.285,Loss of methylation at K491 (P = 0.0015); Loss of ubiquitination at K491 (P = 0.0183); Loss of MoRF binding (P = 0.0383); Loss of glycosylation at K491 (P = 0.0828); Gain of relative solvent accessibility (P = 0.1684)
17:44068919:A:C,P10636,T492P,0.276,Loss of phosphorylation at T492 (P = 0.0034); Gain of catalytic residue at T492 (P = 0.0055); Loss of MoRF binding (P = 0.0688); Gain of glycosylation at P493 (P = 0.0846); Gain of ubiquitination at K491 (P = 0.115)
17:44068919:A:G,P10636,T492A,0.199,Loss of phosphorylation at T492 (P = 0.0034); Loss of glycosylation at T492 (P = 0.0098); Loss of ubiquitination at K491 (P = 0.0877); Gain of MoRF binding (P = 0.0974); Gain of methylation at R487 (P = 0.1381)
17:44068919:A:T,P10636,T492S,0.211,Loss of glycosylation at T492 (P = 0.0632); Loss of ubiquitination at K491 (P = 0.1151); Gain of MoRF binding (P = 0.1168); Gain of relative solvent accessibility (P = 0.1571); Loss of methylation at R487 (P = 0.1677)
17:44068920:C:A,P10636,T492N,0.225,Loss of phosphorylation at T492 (P = 0.0034); Loss of glycosylation at T492 (P = 0.0098); Gain of ubiquitination at K491 (P = 0.115); Loss of MoRF binding (P = 0.126); Gain of relative solvent accessibility (P = 0.1571)
17:44068920:C:G,P10636,T492S,0.211,Loss of glycosylation at T492 (P = 0.0632); Loss of ubiquitination at K491 (P = 0.1151); Gain of MoRF binding (P = 0.1168); Gain of relative solvent accessibility (P = 0.1571); Loss of methylation at R487 (P = 0.1677)
17:44068920:C:T,P10636,T492I,0.227,Loss of phosphorylation at T492 (P = 0.0034); Loss of glycosylation at T492 (P = 0.0098); Gain of catalytic residue at P494 (P = 0.0576); Loss of ubiquitination at K491 (P = 0.0777); Gain of MoRF binding (P = 0.0781)
17:44068922:C:A,P10636,P493T,0.244,Gain of phosphorylation at P493 (P = 0.0011); Loss of catalytic residue at P493 (P = 0.0281); Gain of MoRF binding (P = 0.0552); Gain of glycosylation at P493 (P = 0.0916); Gain of ubiquitination at K497 (P = 0.1215)
17:44068922:C:G,P10636,P493A,0.221,Loss of glycosylation at P493 (P = 0.018); Loss of catalytic residue at P493 (P = 0.0226); Gain of MoRF binding (P = 0.0512); Loss of ubiquitination at K491 (P = 0.0709); Loss of sheet (P = 0.371)
17:44068922:C:T,P10636,P493S,0.242,Loss of catalytic residue at P493 (P = 0.004); Gain of phosphorylation at P493 (P = 0.0086); Gain of relative solvent accessibility (P = 0.0249); Gain of MoRF binding (P = 0.0462); Gain of solvent accessibility (P = 0.0739)
17:44068923:C:A,P10636,P493Q,0.31,Gain of solvent accessibility (P = 0.0026); Gain of relative solvent accessibility (P = 0.0098); Loss of catalytic residue at P493 (P = 0.0138); Loss of glycosylation at P493 (P = 0.018); Gain of MoRF binding (P = 0.0427)
17:44068923:C:T,P10636,P493L,0.221,Loss of glycosylation at P493 (P = 0.018); Gain of MoRF binding (P = 0.0565); Loss of ubiquitination at K491 (P = 0.0709); Gain of stability (P = 0.3144); Loss of sheet (P = 0.371)
17:44068925:C:A,P10636,P494T,0.267,Gain of phosphorylation at P494 (P = 9e-04); Loss of catalytic residue at P493 (P = 0.0191); Loss of glycosylation at P494 (P = 0.0559); Gain of MoRF binding (P = 0.056); Gain of ubiquitination at K491 (P = 0.115)
17:44068925:C:G,P10636,P494A,0.227,Loss of glycosylation at P494 (P = 0.0078); Loss of catalytic residue at P493 (P = 0.0537); Gain of MoRF binding (P = 0.0593); Loss of ubiquitination at K491 (P = 0.0637); Loss of solvent accessibility (P = 0.2732)
17:44068925:C:T,P10636,P494S,0.27,Gain of phosphorylation at P494 (P = 0.0069); Loss of catalytic residue at P493 (P = 0.0219); Gain of MoRF binding (P = 0.0466); Loss of glycosylation at P494 (P = 0.0471); Loss of ubiquitination at K491 (P = 0.0877)
17:44068926:C:A,P10636,P494H,0.281,Loss of glycosylation at P494 (P = 0.0078); Loss of catalytic residue at P493 (P = 0.0219); Gain of MoRF binding (P = 0.0552); Loss of ubiquitination at K491 (P = 0.0877); Gain of solvent accessibility (P = 0.1583)
17:44068926:C:G,P10636,P494R,0.32,Gain of MoRF binding (P = 0.0011); Loss of glycosylation at P494 (P = 0.0078); Loss of catalytic residue at P493 (P = 0.0219); Loss of ubiquitination at K491 (P = 0.0587); Gain of solvent accessibility (P = 0.1045)
17:44068926:C:T,P10636,P494L,0.253,Loss of glycosylation at P494 (P = 0.0078); Loss of catalytic residue at P493 (P = 0.0219); Gain of stability (P = 0.0311); Loss of ubiquitination at K491 (P = 0.0587); Gain of MoRF binding (P = 0.0744)
17:44068928:G:C,P10636,A495P,0.275,Gain of glycosylation at A495 (P = 0.0015); Gain of catalytic residue at A495 (P = 0.0213); Loss of MoRF binding (P = 0.0866); Gain of ubiquitination at K491 (P = 0.115); Gain of relative solvent accessibility (P = 0.1259)
17:44068928:G:T,P10636,A495S,0.232,Gain of phosphorylation at A495 (P = 0.0016); Gain of glycosylation at A495 (P = 0.0038); Gain of ubiquitination at K491 (P = 0.0985); Gain of relative solvent accessibility (P = 0.1259); Gain of MoRF binding (P = 0.1491)
17:44068929:C:A,P10636,A495D,0.241,Gain of ubiquitination at K497 (P = 0.0301); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0704); Loss of MoRF binding (P = 0.0762); Loss of glycosylation at T492 (P = 0.0825)
17:44068929:C:G,P10636,A495G,0.226,Loss of glycosylation at T498 (P = 0.0885); Loss of stability (P = 0.1137); Loss of ubiquitination at K491 (P = 0.1322); Gain of MoRF binding (P = 0.1656); Gain of relative solvent accessibility (P = 0.2363)
17:44068929:C:T,P10636,A495V,0.193,Loss of glycosylation at P493 (P = 0.0598); Gain of ubiquitination at K497 (P = 0.1025); Gain of MoRF binding (P = 0.1544); Gain of relative solvent accessibility (P = 0.2363); Gain of solvent accessibility (P = 0.3602)
17:44068931:C:A,P10636,P496T,0.238,Gain of phosphorylation at P496 (P = 0.0033); Gain of relative solvent accessibility (P = 0.0479); Gain of MoRF binding (P = 0.0737); Gain of solvent accessibility (P = 0.0808); Loss of ubiquitination at K491 (P = 0.0992)
17:44068931:C:G,P10636,P496A,0.234,Loss of glycosylation at P496 (P = 0.0079); Gain of relative solvent accessibility (P = 0.0479); Gain of MoRF binding (P = 0.0599); Loss of ubiquitination at K491 (P = 0.0877); Loss of stability (P = 0.1484)
17:44068931:C:T,P10636,P496S,0.241,Gain of phosphorylation at P496 (P = 0.0042); Gain of relative solvent accessibility (P = 0.0479); Gain of MoRF binding (P = 0.0663); Loss of ubiquitination at K491 (P = 0.0709); Loss of glycosylation at K497 (P = 0.1007)
17:44068932:C:A,P10636,P496Q,0.263,Loss of glycosylation at P496 (P = 0.0079); Gain of solvent accessibility (P = 0.0202); Gain of relative solvent accessibility (P = 0.0479); Gain of MoRF binding (P = 0.0694); Loss of ubiquitination at K491 (P = 0.0992)
17:44068932:C:G,P10636,P496R,0.283,Loss of glycosylation at P496 (P = 0.0079); Gain of MoRF binding (P = 0.0105); Gain of solvent accessibility (P = 0.0246); Gain of methylation at P496 (P = 0.0436); Loss of ubiquitination at K491 (P = 0.0992)
17:44068932:C:T,P10636,P496L,0.208,Loss of glycosylation at P496 (P = 0.0079); Gain of MoRF binding (P = 0.0658); Gain of ubiquitination at K497 (P = 0.0856); Loss of catalytic residue at K497 (P = 0.3248); Loss of methylation at K491 (P = 0.3685)
17:44068934:A:C,P10636,K497Q,0.376,Loss of methylation at K497 (P = 6e-04); Loss of ubiquitination at K497 (P = 0.0255); Loss of glycosylation at K497 (P = 0.0297); Loss of catalytic residue at K497 (P = 0.0722); Gain of relative solvent accessibility (P = 0.09)
17:44068934:A:G,P10636,K497E,0.378,Loss of methylation at K497 (P = 6e-04); Loss of ubiquitination at K497 (P = 0.0255); Loss of glycosylation at K497 (P = 0.0297); Loss of MoRF binding (P = 0.0873); Gain of relative solvent accessibility (P = 0.09)
17:44068935:A:C,P10636,K497T,0.365,Loss of methylation at K497 (P = 6e-04); Gain of phosphorylation at K497 (P = 0.017); Loss of ubiquitination at K497 (P = 0.0255); Gain of glycosylation at K497 (P = 0.0296); Gain of relative solvent accessibility (P = 0.09)
17:44068935:A:G,P10636,K497R,0.315,Loss of methylation at K497 (P = 0.0152); Loss of ubiquitination at K497 (P = 0.0255); Loss of glycosylation at K497 (P = 0.0297); Gain of MoRF binding (P = 0.1226); Gain of stability (P = 0.1962)
17:44068935:A:T,P10636,K497M,0.401,Loss of methylation at K497 (P = 6e-04); Loss of ubiquitination at K497 (P = 0.0255); Loss of glycosylation at K497 (P = 0.0297); Loss of catalytic residue at K497 (P = 0.0481); Gain of stability (P = 0.0523)
17:44068936:G:C,P10636,K497N,0.368,Loss of methylation at K497 (P = 6e-04); Loss of ubiquitination at K497 (P = 0.0255); Loss of glycosylation at K497 (P = 0.0297); Gain of relative solvent accessibility (P = 0.09); Loss of MoRF binding (P = 0.1309)
17:44068936:G:T,P10636,K497N,0.368,Loss of methylation at K497 (P = 6e-04); Loss of ubiquitination at K497 (P = 0.0255); Loss of glycosylation at K497 (P = 0.0297); Gain of relative solvent accessibility (P = 0.09); Loss of MoRF binding (P = 0.1309)
17:44068937:A:C,P10636,T498P,0.298,Loss of phosphorylation at T498 (P = 8e-04); Gain of catalytic residue at T498 (P = 0.0071); Gain of glycosylation at P500 (P = 0.113); Gain of ubiquitination at K497 (P = 0.1446); Gain of relative solvent accessibility (P = 0.1571)
17:44068937:A:G,P10636,T498A,0.268,Loss of phosphorylation at T498 (P = 8e-04); Loss of glycosylation at T498 (P = 0.0288); Loss of ubiquitination at K497 (P = 0.1647); Gain of MoRF binding (P = 0.2654); Gain of relative solvent accessibility (P = 0.2751)
17:44068937:A:T,P10636,T498S,0.292,Gain of glycosylation at T498 (P = 0.0615); Gain of ubiquitination at K497 (P = 0.1446); Gain of relative solvent accessibility (P = 0.1571); Gain of MoRF binding (P = 0.261); Gain of solvent accessibility (P = 0.3089)
17:44068938:C:A,P10636,T498K,0.377,Loss of phosphorylation at T498 (P = 8e-04); Gain of methylation at T498 (P = 0.0016); Gain of solvent accessibility (P = 0.006); Gain of relative solvent accessibility (P = 0.0166); Gain of ubiquitination at T498 (P = 0.0325)
17:44068938:C:G,P10636,T498R,0.349,Loss of phosphorylation at T498 (P = 8e-04); Loss of glycosylation at T498 (P = 0.0288); Gain of MoRF binding (P = 0.0337); Gain of methylation at T498 (P = 0.0446); Gain of solvent accessibility (P = 0.1014)
17:44068938:C:T,P10636,T498I,0.291,Loss of phosphorylation at T498 (P = 8e-04); Loss of glycosylation at T498 (P = 0.0288); Gain of catalytic residue at P500 (P = 0.0535); Gain of ubiquitination at K497 (P = 0.1215); Gain of relative solvent accessibility (P = 0.1571)
17:44068940:C:A,P10636,P499T,0.288,Gain of phosphorylation at P499 (P = 0.0013); Loss of catalytic residue at P499 (P = 0.0024); Loss of glycosylation at P500 (P = 0.0914); Loss of ubiquitination at K497 (P = 0.1473); Gain of MoRF binding (P = 0.2498)
17:44068940:C:G,P10636,P499A,0.264,Loss of catalytic residue at P499 (P = 0.0012); Loss of glycosylation at P499 (P = 0.0127); Loss of ubiquitination at K497 (P = 0.1296); Gain of MoRF binding (P = 0.2001); Gain of relative solvent accessibility (P = 0.2629)
17:44068940:C:T,P10636,P499S,0.285,Loss of catalytic residue at P499 (P = 4e-04); Gain of phosphorylation at P499 (P = 0.0025); Loss of glycosylation at P499 (P = 0.0821); Gain of relative solvent accessibility (P = 0.1066); Loss of ubiquitination at K497 (P = 0.1473)
17:44068941:C:A,P10636,P499Q,0.275,Loss of catalytic residue at P499 (P = 0.0051); Loss of glycosylation at P499 (P = 0.0127); Gain of solvent accessibility (P = 0.1045); Gain of relative solvent accessibility (P = 0.1066); Loss of ubiquitination at K497 (P = 0.1647)
17:44068941:C:G,P10636,P499R,0.293,Loss of glycosylation at P499 (P = 0.0127); Loss of catalytic residue at P499 (P = 0.0175); Gain of MoRF binding (P = 0.0348); Gain of solvent accessibility (P = 0.0488); Gain of methylation at P499 (P = 0.0539)
17:44068941:C:T,P10636,P499L,0.244,Loss of glycosylation at P499 (P = 0.0127); Loss of catalytic residue at P499 (P = 0.0592); Gain of ubiquitination at K497 (P = 0.1215); Gain of MoRF binding (P = 0.2354); Gain of relative solvent accessibility (P = 0.2629)
17:44068943:C:A,P10636,P500T,0.181,Gain of phosphorylation at P500 (P = 0.0043); Gain of glycosylation at P500 (P = 0.0882); Loss of ubiquitination at K497 (P = 0.1296); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1922)
17:44068943:C:G,P10636,P500A,0.182,Loss of glycosylation at P500 (P = 0.0234); Loss of solvent accessibility (P = 0.1322); Loss of ubiquitination at K497 (P = 0.1473); Loss of relative solvent accessibility (P = 0.1807); Loss of catalytic residue at K497 (P = 0.2592)
17:44068943:C:T,P10636,P500S,0.249,Gain of phosphorylation at P500 (P = 0.003); Loss of glycosylation at P500 (P = 0.0716); Loss of ubiquitination at K497 (P = 0.1296); Loss of catalytic residue at K497 (P = 0.2755); Gain of MoRF binding (P = 0.3021)
17:44068944:C:A,P10636,P500H,0.223,Loss of glycosylation at P500 (P = 0.0234); Gain of ubiquitination at K497 (P = 0.1446); Gain of solvent accessibility (P = 0.204); Gain of catalytic residue at P500 (P = 0.2483); Gain of MoRF binding (P = 0.3289)
17:44068944:C:G,P10636,P500R,0.274,Gain of MoRF binding (P = 0.0215); Loss of glycosylation at P500 (P = 0.0234); Gain of methylation at P500 (P = 0.0522); Gain of ubiquitination at K497 (P = 0.0762); Loss of catalytic residue at K497 (P = 0.216)
17:44068944:C:T,P10636,P500L,0.208,Loss of glycosylation at P500 (P = 0.0234); Gain of stability (P = 0.1015); Gain of ubiquitination at K497 (P = 0.1215); Loss of catalytic residue at K497 (P = 0.2582); Gain of solvent accessibility (P = 0.3194)
17:44068946:A:C,P10636,S501R,0.348,Loss of phosphorylation at S501 (P = 0.0011); Gain of solvent accessibility (P = 0.0014); Gain of relative solvent accessibility (P = 0.0166); Loss of glycosylation at S501 (P = 0.0228); Gain of methylation at S501 (P = 0.0402)
17:44068946:A:G,P10636,S501G,0.273,Loss of phosphorylation at S501 (P = 0.0011); Gain of relative solvent accessibility (P = 0.005); Loss of glycosylation at S501 (P = 0.0228); Gain of solvent accessibility (P = 0.0854); Gain of ubiquitination at K497 (P = 0.1215)
17:44068946:A:T,P10636,S501C,0.291,Loss of phosphorylation at S501 (P = 0.0011); Gain of catalytic residue at S501 (P = 0.0068); Loss of glycosylation at S501 (P = 0.0228); Loss of ubiquitination at K497 (P = 0.1296); Gain of relative solvent accessibility (P = 0.2751)
17:44068947:G:A,P10636,S501N,0.308,Loss of phosphorylation at S501 (P = 0.0011); Gain of relative solvent accessibility (P = 0.0166); Loss of glycosylation at S501 (P = 0.0228); Gain of solvent accessibility (P = 0.0246); Loss of ubiquitination at K497 (P = 0.1647)
17:44068947:G:C,P10636,S501T,0.267,Gain of relative solvent accessibility (P = 0.005); Gain of solvent accessibility (P = 0.0129); Gain of glycosylation at S501 (P = 0.0862); Loss of ubiquitination at K497 (P = 0.1647); Loss of sheet (P = 0.5184)
17:44068947:G:T,P10636,S501I,0.244,Loss of phosphorylation at S501 (P = 0.0011); Loss of glycosylation at S501 (P = 0.0228); Gain of catalytic residue at S501 (P = 0.15); Loss of ubiquitination at K497 (P = 0.1647); Gain of relative solvent accessibility (P = 0.2751)
17:44068948:C:A,P10636,S501R,0.348,Loss of phosphorylation at S501 (P = 0.0011); Gain of solvent accessibility (P = 0.0014); Gain of relative solvent accessibility (P = 0.0166); Loss of glycosylation at S501 (P = 0.0228); Gain of methylation at S501 (P = 0.0402)
17:44068948:C:G,P10636,S501R,0.348,Loss of phosphorylation at S501 (P = 0.0011); Gain of solvent accessibility (P = 0.0014); Gain of relative solvent accessibility (P = 0.0166); Loss of glycosylation at S501 (P = 0.0228); Gain of methylation at S501 (P = 0.0402)
17:44068949:T:A,P10636,S502T,0.267,Gain of glycosylation at S501 (P = 0.0625); Gain of relative solvent accessibility (P = 0.1571); Loss of ubiquitination at K497 (P = 0.1647); Gain of solvent accessibility (P = 0.2097); Gain of catalytic residue at S502 (P = 0.3707)
17:44068949:T:C,P10636,S502P,0.284,Loss of phosphorylation at S502 (P = 0.0014); Loss of glycosylation at S502 (P = 0.0421); Gain of relative solvent accessibility (P = 0.1571); Loss of ubiquitination at K497 (P = 0.1647); Gain of solvent accessibility (P = 0.2455)
17:44068949:T:G,P10636,S502A,0.287,Loss of glycosylation at S502 (P = 6e-04); Loss of phosphorylation at S502 (P = 0.0014); Loss of solvent accessibility (P = 0.1473); Loss of ubiquitination at K497 (P = 0.1647); Loss of relative solvent accessibility (P = 0.1807)
17:44068950:C:A,P10636,S502Y,0.326,Loss of glycosylation at S502 (P = 6e-04); Gain of catalytic residue at S502 (P = 0.0227); Gain of solvent accessibility (P = 0.0739); Loss of ubiquitination at K497 (P = 0.1045); Gain of methylation at K507 (P = 0.4867)
17:44068950:C:G,P10636,S502C,0.341,Loss of glycosylation at S502 (P = 6e-04); Loss of phosphorylation at S502 (P = 0.0014); Gain of catalytic residue at S502 (P = 0.0068); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.086)
17:44068950:C:T,P10636,S502F,0.295,Loss of glycosylation at S502 (P = 6e-04); Loss of phosphorylation at S502 (P = 0.0014); Gain of solvent accessibility (P = 0.1376); Loss of ubiquitination at K497 (P = 0.1647); Gain of catalytic residue at P500 (P = 0.2513)
17:44068952:G:A,P10636,G503S,0.305,Gain of phosphorylation at G503 (P = 7e-04); Gain of glycosylation at G503 (P = 0.0113); Gain of solvent accessibility (P = 0.1683); Loss of ubiquitination at K507 (P = 0.321); Gain of methylation at K507 (P = 0.4965)
17:44068952:G:C,P10636,G503R,0.295,Gain of solvent accessibility (P = 0.019); Gain of glycosylation at P506 (P = 0.0724); Gain of MoRF binding (P = 0.153); Gain of catalytic residue at G503 (P = 0.1623); Loss of ubiquitination at K507 (P = 0.2767)
17:44068952:G:T,P10636,G503C,0.306,Loss of relative solvent accessibility (P = 0.0404); Gain of catalytic residue at G503 (P = 0.0912); Gain of glycosylation at P500 (P = 0.137); Loss of solvent accessibility (P = 0.2517); Loss of ubiquitination at K507 (P = 0.3494)
17:44073765:G:A,P10636,G503D,0.285,Loss of glycosylation at S502 (P = 0.073); Gain of solvent accessibility (P = 0.1683); Loss of ubiquitination at K507 (P = 0.2583); Gain of methylation at K507 (P = 0.4945); Loss of catalytic residue at E504 (P = 0.507)
17:44073765:G:C,P10636,G503A,0.224,Gain of glycosylation at P500 (P = 0.1168); Gain of solvent accessibility (P = 0.3304); Gain of ubiquitination at K507 (P = 0.3527); Loss of methylation at K507 (P = 0.4654); Gain of MoRF binding (P = 0.5216)
17:44073765:G:T,P10636,G503V,0.218,Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at S501 (P = 0.118); Loss of solvent accessibility (P = 0.2668); Gain of ubiquitination at K507 (P = 0.3503); Loss of methylation at K507 (P = 0.488)
17:44073767:G:A,P10636,E504K,0.261,Gain of methylation at E504 (P = 0.0022); Loss of ubiquitination at K507 (P = 0.0211); Gain of MoRF binding (P = 0.033); Gain of glycosylation at E504 (P = 0.0338); Loss of stability (P = 0.2069)
17:44073767:G:C,P10636,E504Q,0.156,Gain of glycosylation at S501 (P = 0.195); Gain of MoRF binding (P = 0.2533); Loss of ubiquitination at K507 (P = 0.2936); Loss of catalytic residue at E504 (P = 0.3319); Gain of methylation at K507 (P = 0.4963)
17:44073768:A:C,P10636,E504A,0.14,Gain of glycosylation at S508 (P = 0.1284); Loss of ubiquitination at K507 (P = 0.2767); Loss of stability (P = 0.277); Gain of MoRF binding (P = 0.3332); Loss of solvent accessibility (P = 0.3543)
17:44073768:A:G,P10636,E504G,0.214,Gain of relative solvent accessibility (P = 0.09); Gain of glycosylation at S501 (P = 0.0952); Loss of stability (P = 0.1077); Gain of catalytic residue at P500 (P = 0.1189); Loss of ubiquitination at K507 (P = 0.2767)
17:44073768:A:T,P10636,E504V,0.204,Gain of glycosylation at S501 (P = 0.0999); Gain of catalytic residue at E504 (P = 0.2864); Loss of ubiquitination at K507 (P = 0.321); Loss of solvent accessibility (P = 0.3368); Gain of MoRF binding (P = 0.3477)
17:44073769:A:C,P10636,E504D,0.137,Loss of glycosylation at P506 (P = 0.1241); Loss of catalytic residue at E504 (P = 0.2312); Gain of ubiquitination at K507 (P = 0.3503); Loss of methylation at K507 (P = 0.4442); Gain of MoRF binding (P = 0.5093)
17:44073769:A:T,P10636,E504D,0.137,Loss of glycosylation at P506 (P = 0.1241); Loss of catalytic residue at E504 (P = 0.2312); Gain of ubiquitination at K507 (P = 0.3503); Loss of methylation at K507 (P = 0.4442); Gain of MoRF binding (P = 0.5093)
17:44073770:C:A,P10636,P505T,0.265,Loss of catalytic residue at P505 (P = 0.0018); Gain of phosphorylation at P505 (P = 0.0019); Loss of glycosylation at P506 (P = 0.1042); Gain of MoRF binding (P = 0.2966); Loss of stability (P = 0.308)
17:44073770:C:G,P10636,P505A,0.259,Loss of catalytic residue at P505 (P = 0.003); Loss of glycosylation at P505 (P = 0.0584); Loss of stability (P = 0.1421); Gain of MoRF binding (P = 0.255); Loss of ubiquitination at K507 (P = 0.3494)
17:44073770:C:T,P10636,P505S,0.274,Gain of phosphorylation at P505 (P = 0.0011); Loss of catalytic residue at P505 (P = 0.0016); Loss of glycosylation at P506 (P = 0.1467); Loss of stability (P = 0.2359); Gain of MoRF binding (P = 0.2984)
17:44073771:C:A,P10636,P505H,0.243,Loss of catalytic residue at P505 (P = 0.005); Loss of glycosylation at P505 (P = 0.0584); Loss of stability (P = 0.28); Loss of ubiquitination at K507 (P = 0.34); Gain of MoRF binding (P = 0.3407)
17:44073771:C:G,P10636,P505R,0.256,Gain of MoRF binding (P = 0.047); Loss of glycosylation at P505 (P = 0.0584); Loss of catalytic residue at P505 (P = 0.1169); Gain of solvent accessibility (P = 0.2097); Loss of ubiquitination at K507 (P = 0.2767)
17:44073771:C:T,P10636,P505L,0.208,Loss of catalytic residue at P505 (P = 0.0473); Loss of glycosylation at P505 (P = 0.0584); Gain of MoRF binding (P = 0.2907); Loss of methylation at K507 (P = 0.3494); Loss of ubiquitination at K507 (P = 0.3494)
17:44073773:C:A,P10636,P506T,0.168,Gain of phosphorylation at P506 (P = 0.0065); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0808); Loss of glycosylation at S508 (P = 0.135); Gain of MoRF binding (P = 0.2451)
17:44073773:C:G,P10636,P506A,0.16,Loss of glycosylation at P506 (P = 0.0456); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.199); Gain of MoRF binding (P = 0.2068); Loss of catalytic residue at P505 (P = 0.248)
17:44073773:C:T,P10636,P506S,0.18,Gain of phosphorylation at P506 (P = 9e-04); Gain of glycosylation at P506 (P = 0.1076); Gain of MoRF binding (P = 0.2479); Loss of ubiquitination at K507 (P = 0.321); Loss of catalytic residue at P505 (P = 0.3848)
17:44073774:C:A,P10636,P506Q,0.205,Gain of solvent accessibility (P = 0.0055); Gain of relative solvent accessibility (P = 0.0166); Loss of glycosylation at P506 (P = 0.0456); Gain of MoRF binding (P = 0.2435); Loss of catalytic residue at P505 (P = 0.248)
17:44073774:C:G,P10636,P506R,0.203,Gain of MoRF binding (P = 0.0267); Loss of glycosylation at P506 (P = 0.0456); Gain of methylation at P506 (P = 0.1056); Gain of solvent accessibility (P = 0.2097); Loss of catalytic residue at P505 (P = 0.248)
17:44073774:C:T,P10636,P506L,0.142,Loss of glycosylation at P506 (P = 0.0456); Loss of catalytic residue at P505 (P = 0.248); Gain of MoRF binding (P = 0.2483); Loss of ubiquitination at K507 (P = 0.321); Loss of methylation at K507 (P = 0.3823)
17:44073776:A:C,P10636,K507Q,0.279,Loss of methylation at K507 (P = 0.0021); Loss of ubiquitination at K507 (P = 0.0037); Loss of glycosylation at K507 (P = 0.0457); Loss of catalytic residue at K507 (P = 0.2722); Loss of MoRF binding (P = 0.324)
17:44073776:A:G,P10636,K507E,0.258,Loss of methylation at K507 (P = 0.0021); Loss of ubiquitination at K507 (P = 0.0037); Loss of glycosylation at K507 (P = 0.0457); Loss of MoRF binding (P = 0.2806); Loss of catalytic residue at K507 (P = 0.3476)
17:44073777:A:C,P10636,K507T,0.308,Loss of methylation at K507 (P = 0.0021); Gain of phosphorylation at K507 (P = 0.0025); Loss of ubiquitination at K507 (P = 0.0037); Gain of glycosylation at K507 (P = 0.0547); Loss of solvent accessibility (P = 0.1922)
17:44073777:A:G,P10636,K507R,0.258,Loss of ubiquitination at K507 (P = 0.0037); Loss of methylation at K507 (P = 0.0089); Loss of glycosylation at K507 (P = 0.0457); Gain of MoRF binding (P = 0.2689); Loss of catalytic residue at K507 (P = 0.4514)
17:44073777:A:T,P10636,K507I,0.305,Loss of methylation at K507 (P = 0.0021); Loss of ubiquitination at K507 (P = 0.0037); Loss of solvent accessibility (P = 0.045); Loss of glycosylation at K507 (P = 0.0457); Loss of relative solvent accessibility (P = 0.114)
17:44073778:A:C,P10636,K507N,0.281,Loss of methylation at K507 (P = 0.0021); Loss of ubiquitination at K507 (P = 0.0037); Loss of glycosylation at K507 (P = 0.0457); Gain of relative solvent accessibility (P = 0.1684); Loss of catalytic residue at K507 (P = 0.3149)
17:44073778:A:T,P10636,K507N,0.281,Loss of methylation at K507 (P = 0.0021); Loss of ubiquitination at K507 (P = 0.0037); Loss of glycosylation at K507 (P = 0.0457); Gain of relative solvent accessibility (P = 0.1684); Loss of catalytic residue at K507 (P = 0.3149)
17:44073779:T:A,P10636,S508T,0.228,Loss of glycosylation at S508 (P = 0.0501); Loss of ubiquitination at K507 (P = 0.3494); Gain of MoRF binding (P = 0.3627); Gain of solvent accessibility (P = 0.4496); Gain of methylation at R511 (P = 0.4545)
17:44073779:T:C,P10636,S508P,0.219,Loss of phosphorylation at S508 (P = 8e-04); Loss of glycosylation at S508 (P = 0.0419); Loss of ubiquitination at K507 (P = 0.321); Loss of MoRF binding (P = 0.323); Loss of stability (P = 0.3657)
17:44073779:T:G,P10636,S508A,0.249,Loss of phosphorylation at S508 (P = 8e-04); Loss of glycosylation at S508 (P = 0.0201); Gain of MoRF binding (P = 0.3454); Loss of ubiquitination at K507 (P = 0.3494); Gain of methylation at R511 (P = 0.3549)
17:44073780:C:T,P10636,S508L,0.309,Loss of phosphorylation at S508 (P = 8e-04); Gain of catalytic residue at S508 (P = 0.001); Loss of glycosylation at S508 (P = 0.0201); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0606)
17:44073782:G:A,P10636,G509R,0.198,Loss of glycosylation at S508 (P = 0.0535); Gain of MoRF binding (P = 0.088); Loss of relative solvent accessibility (P = 0.107); Loss of ubiquitination at K507 (P = 0.1099); Gain of solvent accessibility (P = 0.2455)
17:44073782:G:C,P10636,G509R,0.198,Loss of glycosylation at S508 (P = 0.0535); Gain of MoRF binding (P = 0.088); Loss of relative solvent accessibility (P = 0.107); Loss of ubiquitination at K507 (P = 0.1099); Gain of solvent accessibility (P = 0.2455)
17:44073782:G:T,P10636,G509W,0.202,Loss of glycosylation at S508 (P = 0.0247); Loss of relative solvent accessibility (P = 0.0404); Gain of MoRF binding (P = 0.0733); Loss of ubiquitination at K507 (P = 0.207); Loss of catalytic residue at S512 (P = 0.3113)
17:44073783:G:A,P10636,G509E,0.206,Gain of solvent accessibility (P = 0.024); Loss of glycosylation at S508 (P = 0.0357); Gain of loop (P = 0.2754); Loss of MoRF binding (P = 0.2859); Loss of ubiquitination at K507 (P = 0.321)
17:44073783:G:C,P10636,G509A,0.136,Loss of glycosylation at S508 (P = 0.0636); Gain of MoRF binding (P = 0.3152); Loss of stability (P = 0.3231); Gain of solvent accessibility (P = 0.3304); Loss of ubiquitination at K507 (P = 0.3494)
17:44073783:G:T,P10636,G509V,0.18,Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at S508 (P = 0.0501); Loss of solvent accessibility (P = 0.2668); Gain of MoRF binding (P = 0.2935); Loss of ubiquitination at K507 (P = 0.34)
17:44073785:G:A,P10636,D510N,0.175,Gain of MoRF binding (P = 0.0678); Loss of glycosylation at S508 (P = 0.1653); Loss of stability (P = 0.1859); Loss of ubiquitination at K507 (P = 0.2767); Gain of catalytic residue at S512 (P = 0.3336)
17:44073785:G:C,P10636,D510H,0.167,Gain of MoRF binding (P = 0.0742); Loss of glycosylation at S508 (P = 0.1288); Loss of stability (P = 0.1384); Loss of ubiquitination at K507 (P = 0.2351); Gain of catalytic residue at S512 (P = 0.2801)
17:44073785:G:T,P10636,D510Y,0.19,Gain of phosphorylation at D510 (P = 0.0111); Gain of MoRF binding (P = 0.0674); Gain of glycosylation at P505 (P = 0.1013); Gain of catalytic residue at D510 (P = 0.1111); Loss of ubiquitination at K507 (P = 0.2583)
17:44073786:A:C,P10636,D510A,0.171,Gain of MoRF binding (P = 0.0489); Loss of stability (P = 0.0959); Gain of methylation at R511 (P = 0.1199); Gain of glycosylation at S508 (P = 0.1242); Loss of ubiquitination at K507 (P = 0.2351)
17:44073786:A:G,P10636,D510G,0.224,Gain of methylation at R511 (P = 0.0406); Gain of MoRF binding (P = 0.0597); Gain of catalytic residue at D510 (P = 0.0632); Loss of stability (P = 0.0658); Loss of solvent accessibility (P = 0.1813)
17:44073786:A:T,P10636,D510V,0.204,Gain of MoRF binding (P = 0.0369); Gain of glycosylation at S508 (P = 0.103); Loss of solvent accessibility (P = 0.1744); Gain of methylation at R511 (P = 0.2081); Loss of ubiquitination at K507 (P = 0.2351)
17:44073787:T:A,P10636,D510E,0.149,Gain of glycosylation at S512 (P = 0.1522); Gain of MoRF binding (P = 0.3025); Loss of stability (P = 0.3028); Loss of ubiquitination at K507 (P = 0.3078); Gain of solvent accessibility (P = 0.3089)
17:44073787:T:G,P10636,D510E,0.149,Gain of glycosylation at S512 (P = 0.1522); Gain of MoRF binding (P = 0.3025); Loss of stability (P = 0.3028); Loss of ubiquitination at K507 (P = 0.3078); Gain of solvent accessibility (P = 0.3089)
17:44073788:C:A,P10636,R511S,0.292,Gain of phosphorylation at R511 (P = 3e-04); Gain of glycosylation at R511 (P = 0.0621); Loss of MoRF binding (P = 0.181); Loss of ubiquitination at K507 (P = 0.2583); Gain of loop (P = 0.2754)
17:44073788:C:G,P10636,R511G,0.26,Gain of glycosylation at S508 (P = 0.07); Loss of MoRF binding (P = 0.1769); Gain of catalytic residue at G513 (P = 0.2347); Loss of solvent accessibility (P = 0.239); Loss of ubiquitination at K507 (P = 0.2583)
17:44073788:C:T,P10636,R511C,0.311,Gain of glycosylation at S508 (P = 0.0758); Loss of MoRF binding (P = 0.1399); Gain of catalytic residue at G513 (P = 0.1731); Loss of solvent accessibility (P = 0.2668); Loss of ubiquitination at K507 (P = 0.2936)
17:44073789:G:C,P10636,R511P,0.27,Gain of glycosylation at S508 (P = 0.0707); Loss of catalytic residue at S516 (P = 0.1253); Loss of MoRF binding (P = 0.1351); Loss of ubiquitination at K507 (P = 0.207); Gain of loop (P = 0.2754)
17:44073789:G:T,P10636,R511L,0.275,Gain of glycosylation at S515 (P = 0.0941); Loss of MoRF binding (P = 0.1701); Loss of solvent accessibility (P = 0.3103); Gain of ubiquitination at K507 (P = 0.3527); Loss of methylation at K507 (P = 0.4067)
17:44073791:A:C,P10636,S512R,0.254,Loss of phosphorylation at S512 (P = 8e-04); Loss of glycosylation at S512 (P = 0.0181); Gain of MoRF binding (P = 0.0416); Gain of methylation at S512 (P = 0.1997); Loss of relative solvent accessibility (P = 0.3219)
17:44073791:A:G,P10636,S512G,0.244,Loss of phosphorylation at S512 (P = 8e-04); Loss of glycosylation at S512 (P = 0.0181); Loss of stability (P = 0.0958); Gain of methylation at R511 (P = 0.1678); Gain of MoRF binding (P = 0.2922)
17:44073791:A:T,P10636,S512C,0.253,Loss of phosphorylation at S512 (P = 8e-04); Loss of glycosylation at S512 (P = 0.0181); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1986); Loss of MoRF binding (P = 0.2662)
17:44073792:G:A,P10636,S512N,0.244,Loss of phosphorylation at S512 (P = 8e-04); Loss of glycosylation at S512 (P = 0.0181); Loss of MoRF binding (P = 0.3026); Loss of ubiquitination at K507 (P = 0.321); Gain of solvent accessibility (P = 0.3304)
17:44073792:G:C,P10636,S512T,0.25,Loss of glycosylation at S512 (P = 0.0298); Loss of relative solvent accessibility (P = 0.0306); Loss of solvent accessibility (P = 0.0468); Loss of loop (P = 0.1242); Gain of sheet (P = 0.1451)
17:44073792:G:T,P10636,S512I,0.282,Loss of phosphorylation at S512 (P = 8e-04); Loss of glycosylation at S512 (P = 0.0181); Loss of relative solvent accessibility (P = 0.1807); Gain of MoRF binding (P = 0.252); Gain of catalytic residue at R511 (P = 0.2706)
17:44073793:C:A,P10636,S512R,0.254,Loss of phosphorylation at S512 (P = 8e-04); Loss of glycosylation at S512 (P = 0.0181); Gain of MoRF binding (P = 0.0416); Gain of methylation at S512 (P = 0.1997); Loss of relative solvent accessibility (P = 0.3219)
17:44073793:C:G,P10636,S512R,0.254,Loss of phosphorylation at S512 (P = 8e-04); Loss of glycosylation at S512 (P = 0.0181); Gain of MoRF binding (P = 0.0416); Gain of methylation at S512 (P = 0.1997); Loss of relative solvent accessibility (P = 0.3219)
17:44073794:G:A,P10636,G513S,0.199,Gain of phosphorylation at G513 (P = 2e-04); Loss of glycosylation at S512 (P = 0.0347); Gain of relative solvent accessibility (P = 0.1894); Gain of solvent accessibility (P = 0.194); Loss of catalytic residue at S515 (P = 0.2809)
17:44073794:G:C,P10636,G513R,0.226,Gain of MoRF binding (P = 0.036); Loss of glycosylation at S512 (P = 0.0419); Gain of methylation at G513 (P = 0.1686); Gain of solvent accessibility (P = 0.1846); Loss of catalytic residue at S515 (P = 0.2126)
17:44073794:G:T,P10636,G513C,0.221,Loss of glycosylation at S512 (P = 0.0602); Gain of catalytic residue at G513 (P = 0.1765); Loss of MoRF binding (P = 0.2642); Loss of loop (P = 0.4412); Gain of sheet (P = 0.4423)
17:44073795:G:A,P10636,G513D,0.192,Loss of glycosylation at S512 (P = 0.032); Gain of solvent accessibility (P = 0.039); Gain of relative solvent accessibility (P = 0.09); Loss of catalytic residue at S515 (P = 0.1836); Loss of MoRF binding (P = 0.208)
17:44073795:G:C,P10636,G513A,0.157,Loss of glycosylation at S512 (P = 0.0603); Loss of catalytic residue at S515 (P = 0.2056); Gain of MoRF binding (P = 0.2596); Loss of loop (P = 0.4412); Gain of sheet (P = 0.4423)
17:44073795:G:T,P10636,G513V,0.229,Loss of glycosylation at S512 (P = 0.0518); Loss of loop (P = 0.1242); Gain of sheet (P = 0.1451); Loss of catalytic residue at S515 (P = 0.2118); Gain of MoRF binding (P = 0.2321)
17:44073797:T:A,P10636,Y514N,0.248,Loss of phosphorylation at Y514 (P = 0.0016); Loss of catalytic residue at Y514 (P = 0.0588); Loss of glycosylation at S512 (P = 0.0895); Loss of stability (P = 0.2221); Gain of relative solvent accessibility (P = 0.2363)
17:44073797:T:C,P10636,Y514H,0.22,Loss of phosphorylation at Y514 (P = 0.0016); Loss of glycosylation at S512 (P = 0.0845); Loss of stability (P = 0.2951); Loss of MoRF binding (P = 0.3024); Gain of methylation at R511 (P = 0.3859)
17:44073797:T:G,P10636,Y514D,0.26,Loss of phosphorylation at Y514 (P = 0.0016); Gain of relative solvent accessibility (P = 0.0479); Loss of catalytic residue at Y514 (P = 0.0549); Loss of glycosylation at P517 (P = 0.1049); Gain of solvent accessibility (P = 0.1154)
17:44073798:A:C,P10636,Y514S,0.277,Loss of catalytic residue at Y514 (P = 0.0396); Gain of glycosylation at Y514 (P = 0.0941); Loss of stability (P = 0.2562); Gain of MoRF binding (P = 0.2715); Gain of loop (P = 0.4248)
17:44073798:A:G,P10636,Y514C,0.207,Loss of phosphorylation at Y514 (P = 0.0016); Loss of glycosylation at S515 (P = 0.1506); Loss of MoRF binding (P = 0.2677); Loss of solvent accessibility (P = 0.3368); Gain of loop (P = 0.4248)
17:44073798:A:T,P10636,Y514F,0.204,Loss of phosphorylation at Y514 (P = 0.0016); Gain of glycosylation at S515 (P = 0.0826); Loss of MoRF binding (P = 0.3); Gain of loop (P = 0.4248); Gain of methylation at R511 (P = 0.4539)
17:44073800:A:C,P10636,S515R,0.279,Loss of phosphorylation at S515 (P = 0.0017); Gain of MoRF binding (P = 0.0074); Loss of glycosylation at S515 (P = 0.0589); Loss of relative solvent accessibility (P = 0.1807); Loss of catalytic residue at S512 (P = 0.2486)
17:44073800:A:G,P10636,S515G,0.194,Loss of phosphorylation at S515 (P = 0.0017); Loss of glycosylation at S515 (P = 0.0589); Loss of MoRF binding (P = 0.2873); Loss of solvent accessibility (P = 0.4011); Loss of stability (P = 0.4154)
17:44073800:A:T,P10636,S515C,0.329,Loss of phosphorylation at S515 (P = 0.0017); Loss of glycosylation at S515 (P = 0.0589); Gain of catalytic residue at S519 (P = 0.0657); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.086)
17:44073801:G:A,P10636,S515N,0.211,Loss of phosphorylation at S515 (P = 0.0017); Loss of glycosylation at S515 (P = 0.0589); Gain of MoRF binding (P = 0.2537); Gain of catalytic residue at S515 (P = 0.254); Loss of sheet (P = 0.371)
17:44073801:G:C,P10636,S515T,0.244,Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at S512 (P = 0.198); Loss of solvent accessibility (P = 0.2073); Loss of catalytic residue at S515 (P = 0.248); Gain of loop (P = 0.2754)
17:44073801:G:T,P10636,S515I,0.38,Loss of phosphorylation at S515 (P = 0.0017); Gain of sheet (P = 0.0266); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.0533); Loss of glycosylation at S515 (P = 0.0589)
17:44073802:C:A,P10636,S515R,0.279,Loss of phosphorylation at S515 (P = 0.0017); Gain of MoRF binding (P = 0.0074); Loss of glycosylation at S515 (P = 0.0589); Loss of relative solvent accessibility (P = 0.1807); Loss of catalytic residue at S512 (P = 0.2486)
17:44073802:C:G,P10636,S515R,0.279,Loss of phosphorylation at S515 (P = 0.0017); Gain of MoRF binding (P = 0.0074); Loss of glycosylation at S515 (P = 0.0589); Loss of relative solvent accessibility (P = 0.1807); Loss of catalytic residue at S512 (P = 0.2486)
17:44073803:A:C,P10636,S516R,0.308,Loss of phosphorylation at S516 (P = 0.0015); Gain of MoRF binding (P = 0.0224); Gain of methylation at S516 (P = 0.0304); Loss of glycosylation at S512 (P = 0.0756); Gain of solvent accessibility (P = 0.1376)
17:44073803:A:G,P10636,S516G,0.209,Loss of phosphorylation at S516 (P = 0.0015); Gain of glycosylation at S515 (P = 0.0286); Loss of stability (P = 0.0715); Gain of MoRF binding (P = 0.3); Loss of catalytic residue at S516 (P = 0.3028)
17:44073803:A:T,P10636,S516C,0.242,Loss of phosphorylation at S516 (P = 0.0015); Gain of glycosylation at S515 (P = 0.0631); Loss of MoRF binding (P = 0.2622); Gain of relative solvent accessibility (P = 0.2629); Gain of loop (P = 0.2754)
17:44073804:G:A,P10636,S516N,0.246,Loss of phosphorylation at S516 (P = 0.0015); Loss of glycosylation at S516 (P = 0.0907); Loss of catalytic residue at S516 (P = 0.2586); Gain of relative solvent accessibility (P = 0.2629); Gain of loop (P = 0.2754)
17:44073804:G:C,P10636,S516T,0.238,Gain of glycosylation at S515 (P = 0.0491); Gain of MoRF binding (P = 0.2888); Gain of loop (P = 0.4248); Loss of catalytic residue at S516 (P = 0.4359); Loss of sheet (P = 0.437)
17:44073804:G:T,P10636,S516I,0.232,Loss of phosphorylation at S516 (P = 0.0015); Gain of glycosylation at S519 (P = 0.0407); Gain of MoRF binding (P = 0.2317); Gain of catalytic residue at R511 (P = 0.2517); Gain of loop (P = 0.4248)
17:44073805:C:A,P10636,S516R,0.308,Loss of phosphorylation at S516 (P = 0.0015); Gain of MoRF binding (P = 0.0224); Gain of methylation at S516 (P = 0.0304); Loss of glycosylation at S512 (P = 0.0756); Gain of solvent accessibility (P = 0.1376)
17:44073805:C:G,P10636,S516R,0.308,Loss of phosphorylation at S516 (P = 0.0015); Gain of MoRF binding (P = 0.0224); Gain of methylation at S516 (P = 0.0304); Loss of glycosylation at S512 (P = 0.0756); Gain of solvent accessibility (P = 0.1376)
17:44073806:C:A,P10636,P517T,0.235,Gain of phosphorylation at P517 (P = 0.0102); Gain of MoRF binding (P = 0.0665); Gain of glycosylation at S516 (P = 0.0874); Gain of catalytic residue at S519 (P = 0.1621); Loss of stability (P = 0.2157)
17:44073806:C:G,P10636,P517A,0.243,Loss of glycosylation at P517 (P = 0.0286); Gain of relative solvent accessibility (P = 0.0479); Gain of MoRF binding (P = 0.052); Loss of stability (P = 0.1301); Gain of solvent accessibility (P = 0.199)
17:44073806:C:T,P10636,P517S,0.304,Gain of phosphorylation at P517 (P = 7e-04); Gain of relative solvent accessibility (P = 0.0479); Gain of MoRF binding (P = 0.0683); Gain of glycosylation at P517 (P = 0.0758); Gain of solvent accessibility (P = 0.1116)
17:44073807:C:A,P10636,P517H,0.297,Gain of solvent accessibility (P = 0.007); Gain of relative solvent accessibility (P = 0.0166); Loss of glycosylation at P517 (P = 0.0286); Gain of MoRF binding (P = 0.0911); Loss of stability (P = 0.2123)
17:44073807:C:G,P10636,P517R,0.324,Gain of MoRF binding (P = 0.0026); Gain of methylation at P517 (P = 0.0195); Loss of glycosylation at P517 (P = 0.0286); Gain of solvent accessibility (P = 0.0789); Gain of relative solvent accessibility (P = 0.2363)
17:44073807:C:T,P10636,P517L,0.227,Loss of glycosylation at P517 (P = 0.0286); Gain of MoRF binding (P = 0.0573); Gain of catalytic residue at S512 (P = 0.2331); Loss of sheet (P = 0.6423); Loss of phosphorylation at Y514 (P = 0.7698)
17:44073809:G:C,P10636,G518R,0.28,Gain of MoRF binding (P = 0.0059); Gain of solvent accessibility (P = 0.019); Gain of methylation at G518 (P = 0.0343); Gain of glycosylation at P523 (P = 0.1096); Loss of catalytic residue at S515 (P = 0.2225)
17:44073809:G:T,P10636,G518C,0.26,Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at S519 (P = 0.1458); Loss of catalytic residue at S516 (P = 0.208); Loss of solvent accessibility (P = 0.2517); Loss of MoRF binding (P = 0.2611)
17:44073810:G:A,P10636,G518D,0.23,Gain of solvent accessibility (P = 0.0638); Loss of glycosylation at P517 (P = 0.1359); Loss of catalytic residue at S516 (P = 0.1579); Loss of MoRF binding (P = 0.2255); Loss of sheet (P = 0.6423)
17:44073810:G:C,P10636,G518A,0.243,Loss of relative solvent accessibility (P = 0.0186); Gain of glycosylation at S516 (P = 0.13); Loss of solvent accessibility (P = 0.1459); Loss of catalytic residue at G518 (P = 0.2117); Gain of MoRF binding (P = 0.2583)
17:44073810:G:T,P10636,G518V,0.275,Loss of relative solvent accessibility (P = 0.0186); Loss of glycosylation at P517 (P = 0.0802); Loss of solvent accessibility (P = 0.1744); Loss of catalytic residue at S516 (P = 0.2128); Gain of MoRF binding (P = 0.2337)
17:44073812:T:A,P10636,S519T,0.262,Loss of glycosylation at P517 (P = 0.1396); Loss of catalytic residue at S516 (P = 0.2292); Loss of MoRF binding (P = 0.2959); Loss of stability (P = 0.61); Gain of sheet (P = 0.6509)
17:44073812:T:C,P10636,S519P,0.288,Loss of phosphorylation at S519 (P = 9e-04); Gain of glycosylation at P520 (P = 0.0618); Gain of catalytic residue at S519 (P = 0.0982); Loss of MoRF binding (P = 0.2068); Loss of stability (P = 0.2899)
17:44073812:T:G,P10636,S519A,0.278,Loss of phosphorylation at S519 (P = 9e-04); Loss of glycosylation at S519 (P = 0.0449); Loss of catalytic residue at S516 (P = 0.1534); Loss of MoRF binding (P = 0.2946); Loss of sheet (P = 0.6423)
17:44073813:C:G,P10636,S519C,0.31,Loss of phosphorylation at S519 (P = 9e-04); Loss of glycosylation at S519 (P = 0.0449); Gain of catalytic residue at S519 (P = 0.1021); Loss of MoRF binding (P = 0.244); Gain of sheet (P = 0.6509)
17:44073813:C:T,P10636,S519F,0.301,Loss of phosphorylation at S519 (P = 9e-04); Loss of glycosylation at S519 (P = 0.0449); Loss of catalytic residue at S516 (P = 0.1998); Loss of MoRF binding (P = 0.262); Gain of solvent accessibility (P = 0.4067)
17:44073815:C:A,P10636,P520T,0.292,Gain of phosphorylation at P520 (P = 0.0026); Gain of glycosylation at P520 (P = 0.0452); Gain of MoRF binding (P = 0.0673); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.0721)
17:44073815:C:G,P10636,P520A,0.216,Gain of MoRF binding (P = 0.0503); Loss of glycosylation at P520 (P = 0.0575); Loss of solvent accessibility (P = 0.089); Loss of relative solvent accessibility (P = 0.0981); Gain of catalytic residue at S525 (P = 0.2384)
17:44073815:C:T,P10636,P520S,0.3,Gain of phosphorylation at P520 (P = 9e-04); Gain of glycosylation at P520 (P = 0.0289); Gain of MoRF binding (P = 0.0663); Loss of catalytic residue at P520 (P = 0.314); Loss of sheet (P = 0.5184)
17:44073816:C:A,P10636,P520Q,0.251,Gain of solvent accessibility (P = 0.0411); Loss of glycosylation at P520 (P = 0.0575); Gain of MoRF binding (P = 0.0627); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at P520 (P = 0.1925)
17:44073816:C:G,P10636,P520R,0.306,Gain of MoRF binding (P = 0.0015); Gain of methylation at P520 (P = 0.0223); Gain of solvent accessibility (P = 0.0411); Loss of glycosylation at P520 (P = 0.0575); Loss of catalytic residue at P520 (P = 0.1519)
17:44073816:C:T,P10636,P520L,0.264,Gain of MoRF binding (P = 0.0552); Loss of glycosylation at P520 (P = 0.0575); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1362); Gain of catalytic residue at S525 (P = 0.2022)
17:44073818:G:A,P10636,G521S,0.252,Gain of phosphorylation at G521 (P = 4e-04); Gain of glycosylation at G521 (P = 0.0055); Loss of catalytic residue at P517 (P = 0.0852); Loss of methylation at R526 (P = 0.1152); Gain of solvent accessibility (P = 0.1683)
17:44073818:G:C,P10636,G521R,0.331,Gain of solvent accessibility (P = 0.0037); Gain of MoRF binding (P = 0.0136); Gain of methylation at G521 (P = 0.0143); Loss of glycosylation at T522 (P = 0.073); Loss of catalytic residue at P517 (P = 0.0852)
17:44073818:G:T,P10636,G521C,0.307,Loss of relative solvent accessibility (P = 0.0404); Loss of catalytic residue at P517 (P = 0.0852); Loss of methylation at R526 (P = 0.1114); Gain of glycosylation at S519 (P = 0.1329); Loss of solvent accessibility (P = 0.2517)
17:44073819:G:A,P10636,G521D,0.245,Gain of solvent accessibility (P = 0.0638); Loss of methylation at R526 (P = 0.0719); Loss of catalytic residue at P517 (P = 0.0852); Loss of glycosylation at T522 (P = 0.1381); Loss of MoRF binding (P = 0.2074)
17:44073819:G:C,P10636,G521A,0.202,Loss of catalytic residue at P517 (P = 0.0852); Gain of glycosylation at S519 (P = 0.1018); Gain of methylation at R526 (P = 0.1537); Gain of MoRF binding (P = 0.2503); Gain of solvent accessibility (P = 0.3304)
17:44073819:G:T,P10636,G521V,0.229,Gain of glycosylation at S519 (P = 0.0654); Loss of relative solvent accessibility (P = 0.0676); Loss of catalytic residue at P517 (P = 0.0852); Loss of methylation at R526 (P = 0.1173); Gain of MoRF binding (P = 0.2053)
17:44073821:A:C,P10636,T522P,0.335,Loss of phosphorylation at T522 (P = 9e-04); Gain of glycosylation at P523 (P = 0.0547); Gain of methylation at R526 (P = 0.1437); Loss of catalytic residue at S527 (P = 0.1462); Loss of stability (P = 0.1495)
17:44073821:A:G,P10636,T522A,0.311,Loss of phosphorylation at T522 (P = 9e-04); Loss of glycosylation at T522 (P = 0.0224); Gain of methylation at R526 (P = 0.1266); Gain of relative solvent accessibility (P = 0.2363); Gain of MoRF binding (P = 0.2962)
17:44073821:A:T,P10636,T522S,0.32,Gain of glycosylation at P520 (P = 0.1263); Loss of methylation at R526 (P = 0.1359); Gain of catalytic residue at S519 (P = 0.1982); Gain of relative solvent accessibility (P = 0.2363); Gain of MoRF binding (P = 0.2846)
17:44073822:C:A,P10636,T522N,0.339,Loss of phosphorylation at T522 (P = 9e-04); Loss of glycosylation at T522 (P = 0.0224); Gain of relative solvent accessibility (P = 0.1259); Loss of methylation at R526 (P = 0.1271); Gain of solvent accessibility (P = 0.2346)
17:44073822:C:G,P10636,T522S,0.32,Gain of glycosylation at P520 (P = 0.1263); Loss of methylation at R526 (P = 0.1359); Gain of catalytic residue at S519 (P = 0.1982); Gain of relative solvent accessibility (P = 0.2363); Gain of MoRF binding (P = 0.2846)
17:44073822:C:T,P10636,T522I,0.273,Loss of phosphorylation at T522 (P = 9e-04); Loss of glycosylation at T522 (P = 0.0224); Loss of methylation at R526 (P = 0.1092); Loss of MoRF binding (P = 0.2961); Gain of catalytic residue at T522 (P = 0.506)
17:44073824:C:A,P10636,P523T,0.331,Gain of phosphorylation at P523 (P = 0.0019); Gain of relative solvent accessibility (P = 0.0479); Gain of catalytic residue at P523 (P = 0.0609); Gain of MoRF binding (P = 0.0654); Gain of glycosylation at P523 (P = 0.0858)
17:44073824:C:G,P10636,P523A,0.287,Gain of MoRF binding (P = 0.0552); Loss of glycosylation at P523 (P = 0.0693); Gain of methylation at R526 (P = 0.0904); Gain of catalytic residue at P523 (P = 0.0988); Gain of relative solvent accessibility (P = 0.1259)
17:44073824:C:T,P10636,P523S,0.354,Gain of phosphorylation at P523 (P = 4e-04); Gain of glycosylation at P523 (P = 0.0317); Gain of MoRF binding (P = 0.06); Gain of relative solvent accessibility (P = 0.09); Gain of methylation at R526 (P = 0.1379)
17:44073825:C:A,P10636,P523H,0.287,Loss of glycosylation at P523 (P = 0.0693); Gain of MoRF binding (P = 0.0696); Gain of methylation at R526 (P = 0.0807); Gain of catalytic residue at P523 (P = 0.139); Gain of relative solvent accessibility (P = 0.2363)
17:44073825:C:G,P10636,P523R,0.427,Gain of MoRF binding (P = 3e-04); Gain of solvent accessibility (P = 0.0171); Gain of methylation at P523 (P = 0.021); Gain of catalytic residue at P523 (P = 0.0318); Gain of relative solvent accessibility (P = 0.0479)
17:44073825:C:T,P10636,P523L,0.331,Gain of catalytic residue at P523 (P = 0.0143); Gain of MoRF binding (P = 0.0674); Loss of glycosylation at P523 (P = 0.0693); Loss of methylation at R526 (P = 0.1172); Gain of relative solvent accessibility (P = 0.2363)
17:44073827:G:C,P10636,G524R,0.385,Gain of solvent accessibility (P = 1e-04); Gain of relative solvent accessibility (P = 0.0023); Gain of methylation at G524 (P = 0.0135); Gain of MoRF binding (P = 0.0147); Gain of glycosylation at P523 (P = 0.0701)
17:44073827:G:T,P10636,G524C,0.35,Gain of catalytic residue at P523 (P = 0.0116); Loss of glycosylation at T522 (P = 0.0536); Loss of methylation at R526 (P = 0.0848); Loss of MoRF binding (P = 0.2574); Gain of stability (P = 0.4856)
17:44073828:G:A,P10636,G524D,0.279,Gain of relative solvent accessibility (P = 0.0023); Gain of solvent accessibility (P = 0.0039); Loss of methylation at R526 (P = 0.0669); Loss of catalytic residue at P520 (P = 0.0946); Gain of glycosylation at S519 (P = 0.1351)
17:44073828:G:T,P10636,G524V,0.301,Loss of methylation at R526 (P = 0.0687); Loss of catalytic residue at P520 (P = 0.0946); Gain of glycosylation at S519 (P = 0.1309); Gain of stability (P = 0.1364); Gain of MoRF binding (P = 0.2135)
17:44073830:A:C,P10636,S525R,0.328,Loss of phosphorylation at S525 (P = 6e-04); Loss of glycosylation at S525 (P = 0.0112); Gain of methylation at S525 (P = 0.0296); Gain of MoRF binding (P = 0.0302); Gain of catalytic residue at S525 (P = 0.2076)
17:44073830:A:G,P10636,S525G,0.29,Loss of phosphorylation at S525 (P = 6e-04); Loss of glycosylation at S525 (P = 0.0112); Gain of methylation at R526 (P = 0.0425); Loss of solvent accessibility (P = 0.0635); Loss of relative solvent accessibility (P = 0.0676)
17:44073830:A:T,P10636,S525C,0.317,Loss of phosphorylation at S525 (P = 6e-04); Loss of glycosylation at S525 (P = 0.0112); Gain of catalytic residue at S525 (P = 0.0325); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.086)
17:44073831:G:A,P10636,S525N,0.33,Loss of phosphorylation at S525 (P = 6e-04); Loss of glycosylation at S525 (P = 0.0112); Loss of methylation at R528 (P = 0.1282); Gain of MoRF binding (P = 0.2858); Gain of solvent accessibility (P = 0.3304)
17:44073831:G:C,P10636,S525T,0.279,Loss of glycosylation at S525 (P = 0.092); Gain of methylation at R528 (P = 0.1434); Gain of catalytic residue at S525 (P = 0.2261); Loss of MoRF binding (P = 0.2868); Gain of sheet (P = 0.3763)
17:44073831:G:T,P10636,S525I,0.311,Loss of phosphorylation at S525 (P = 6e-04); Loss of glycosylation at S525 (P = 0.0112); Loss of methylation at R526 (P = 0.058); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1115)
17:44073832:C:A,P10636,S525R,0.328,Loss of phosphorylation at S525 (P = 6e-04); Loss of glycosylation at S525 (P = 0.0112); Gain of methylation at S525 (P = 0.0296); Gain of MoRF binding (P = 0.0302); Gain of catalytic residue at S525 (P = 0.2076)
17:44073832:C:G,P10636,S525R,0.328,Loss of phosphorylation at S525 (P = 6e-04); Loss of glycosylation at S525 (P = 0.0112); Gain of methylation at S525 (P = 0.0296); Gain of MoRF binding (P = 0.0302); Gain of catalytic residue at S525 (P = 0.2076)
17:44073833:C:A,P10636,R526S,0.327,Gain of phosphorylation at R526 (P = 9e-04); Gain of glycosylation at R526 (P = 0.0154); Loss of methylation at R526 (P = 0.0204); Loss of MoRF binding (P = 0.134); Loss of catalytic residue at R526 (P = 0.1512)
17:44073833:C:G,P10636,R526G,0.261,Loss of methylation at R526 (P = 0.0204); Gain of glycosylation at S525 (P = 0.0976); Loss of catalytic residue at R526 (P = 0.1113); Loss of MoRF binding (P = 0.1363); Loss of solvent accessibility (P = 0.239)
17:44073834:G:C,P10636,R526P,0.263,Gain of glycosylation at R526 (P = 0.0197); Loss of methylation at R526 (P = 0.0204); Loss of catalytic residue at R526 (P = 0.0253); Loss of MoRF binding (P = 0.0963); Loss of solvent accessibility (P = 0.3854)
17:44073834:G:T,P10636,R526L,0.334,Loss of methylation at R526 (P = 0.0204); Loss of MoRF binding (P = 0.1263); Gain of glycosylation at T522 (P = 0.1592); Loss of solvent accessibility (P = 0.1922); Loss of catalytic residue at R526 (P = 0.2023)
17:44073836:T:A,P10636,S527T,0.275,Loss of glycosylation at S527 (P = 0.0436); Loss of methylation at R526 (P = 0.1458); Loss of catalytic residue at S527 (P = 0.2176); Loss of MoRF binding (P = 0.2519); Gain of solvent accessibility (P = 0.4656)
17:44073836:T:C,P10636,S527P,0.225,Loss of phosphorylation at S527 (P = 0.0013); Loss of glycosylation at S527 (P = 0.0661); Loss of catalytic residue at S527 (P = 0.0706); Gain of methylation at R526 (P = 0.1473); Loss of MoRF binding (P = 0.1639)
17:44073836:T:G,P10636,S527A,0.243,Loss of phosphorylation at S527 (P = 0.0013); Loss of glycosylation at S527 (P = 0.0052); Loss of catalytic residue at S527 (P = 0.0603); Gain of methylation at R526 (P = 0.0653); Gain of MoRF binding (P = 0.1847)
17:44073837:C:A,P10636,S527Y,0.299,Loss of glycosylation at S527 (P = 0.0052); Gain of solvent accessibility (P = 0.0155); Loss of methylation at R526 (P = 0.1453); Gain of relative solvent accessibility (P = 0.1571); Gain of MoRF binding (P = 0.2495)
17:44073837:C:G,P10636,S527C,0.261,Loss of phosphorylation at S527 (P = 0.0013); Loss of glycosylation at S527 (P = 0.0052); Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.1322); Gain of methylation at R526 (P = 0.1441)
17:44073837:C:T,P10636,S527F,0.236,Loss of phosphorylation at S527 (P = 0.0013); Loss of glycosylation at S527 (P = 0.0052); Gain of methylation at R526 (P = 0.0801); Loss of relative solvent accessibility (P = 0.0981); Loss of catalytic residue at S527 (P = 0.1534)
17:44073839:C:A,P10636,R528S,0.277,Gain of phosphorylation at R528 (P = 7e-04); Gain of glycosylation at R528 (P = 0.0052); Loss of methylation at R528 (P = 0.0265); Loss of MoRF binding (P = 0.1064); Loss of catalytic residue at R528 (P = 0.2091)
17:44073839:C:G,P10636,R528G,0.25,Loss of methylation at R528 (P = 0.0265); Gain of relative solvent accessibility (P = 0.0479); Loss of stability (P = 0.076); Gain of glycosylation at T529 (P = 0.0761); Loss of catalytic residue at R528 (P = 0.0971)
17:44073839:C:T,P10636,R528C,0.287,Loss of methylation at R528 (P = 0.0265); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0829); Gain of glycosylation at P523 (P = 0.1117); Loss of catalytic residue at S527 (P = 0.2345)
17:44073840:G:A,P10636,R528H,0.256,Loss of methylation at R528 (P = 0.0265); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0967); Gain of solvent accessibility (P = 0.0971); Gain of glycosylation at S531 (P = 0.1424)
17:44073840:G:C,P10636,R528P,0.259,Gain of relative solvent accessibility (P = 0.0166); Gain of glycosylation at R528 (P = 0.02); Loss of methylation at R528 (P = 0.0265); Loss of MoRF binding (P = 0.0773); Loss of catalytic residue at R528 (P = 0.094)
17:44073840:G:T,P10636,R528L,0.304,Loss of methylation at R528 (P = 0.0265); Loss of MoRF binding (P = 0.1044); Gain of glycosylation at P523 (P = 0.1305); Loss of catalytic residue at S527 (P = 0.1984); Loss of solvent accessibility (P = 0.3103)
17:44073842:A:C,P10636,T529P,0.305,Loss of phosphorylation at T529 (P = 7e-04); Gain of glycosylation at T529 (P = 0.0432); Gain of catalytic residue at T529 (P = 0.1044); Loss of MoRF binding (P = 0.1295); Loss of methylation at R526 (P = 0.1433)
17:44073842:A:G,P10636,T529A,0.275,Loss of phosphorylation at T529 (P = 7e-04); Gain of methylation at R526 (P = 0.0656); Loss of glycosylation at S525 (P = 0.1546); Gain of MoRF binding (P = 0.1831); Loss of catalytic residue at T529 (P = 0.315)
17:44073842:A:T,P10636,T529S,0.219,Gain of glycosylation at P530 (P = 0.0933); Gain of methylation at R526 (P = 0.1503); Gain of MoRF binding (P = 0.2196); Loss of stability (P = 0.3947); Loss of catalytic residue at T529 (P = 0.5586)
17:44073843:C:A,P10636,T529N,0.278,Loss of phosphorylation at T529 (P = 7e-04); Loss of glycosylation at S527 (P = 0.1013); Loss of methylation at R526 (P = 0.1429); Gain of MoRF binding (P = 0.2209); Loss of stability (P = 0.3382)
17:44073843:C:G,P10636,T529S,0.219,Gain of glycosylation at P530 (P = 0.0933); Gain of methylation at R526 (P = 0.1503); Gain of MoRF binding (P = 0.2196); Loss of stability (P = 0.3947); Loss of catalytic residue at T529 (P = 0.5586)
17:44073843:C:T,P10636,T529I,0.293,Loss of phosphorylation at T529 (P = 7e-04); Loss of glycosylation at S525 (P = 0.0513); Loss of methylation at R528 (P = 0.0679); Gain of MoRF binding (P = 0.1772); Gain of catalytic residue at S531 (P = 0.3077)
17:44073845:C:A,P10636,P530T,0.225,Gain of phosphorylation at P530 (P = 9e-04); Gain of glycosylation at P530 (P = 0.0368); Gain of MoRF binding (P = 0.0564); Gain of methylation at R528 (P = 0.1159); Loss of stability (P = 0.2674)
17:44073845:C:G,P10636,P530A,0.144,Loss of glycosylation at P530 (P = 0.0355); Gain of MoRF binding (P = 0.048); Gain of methylation at R528 (P = 0.0822); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807)
17:44073845:C:T,P10636,P530S,0.195,Gain of phosphorylation at P530 (P = 0.0019); Gain of MoRF binding (P = 0.0506); Gain of methylation at R528 (P = 0.1063); Gain of glycosylation at P530 (P = 0.1102); Loss of solvent accessibility (P = 0.1744)
17:44073846:C:A,P10636,P530Q,0.166,Gain of MoRF binding (P = 0.0353); Loss of glycosylation at P530 (P = 0.0355); Loss of methylation at R528 (P = 0.1026); Gain of solvent accessibility (P = 0.1505); Loss of sheet (P = 0.371)
17:44073846:C:G,P10636,P530R,0.27,Gain of MoRF binding (P = 3e-04); Loss of glycosylation at P530 (P = 0.0355); Gain of methylation at R528 (P = 0.0607); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at P530 (P = 0.2403)
17:44073846:C:T,P10636,P530L,0.175,Loss of glycosylation at P530 (P = 0.0355); Gain of MoRF binding (P = 0.0639); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at R528 (P = 0.1172); Loss of solvent accessibility (P = 0.1362)
17:44073848:T:A,P10636,S531T,0.205,Loss of methylation at R526 (P = 0.1405); Gain of glycosylation at P530 (P = 0.1642); Loss of MoRF binding (P = 0.1677); Gain of solvent accessibility (P = 0.4656); Gain of catalytic residue at P533 (P = 0.6408)
17:44073848:T:C,P10636,S531P,0.231,Loss of phosphorylation at S531 (P = 0.0015); Gain of catalytic residue at P530 (P = 0.0186); Loss of MoRF binding (P = 0.084); Gain of glycosylation at P530 (P = 0.106); Loss of methylation at R528 (P = 0.1323)
17:44073848:T:G,P10636,S531A,0.254,Loss of phosphorylation at S531 (P = 0.0015); Loss of glycosylation at S531 (P = 0.02); Gain of methylation at R528 (P = 0.0941); Gain of relative solvent accessibility (P = 0.1571); Loss of MoRF binding (P = 0.1875)
17:44073849:C:A,P10636,S531Y,0.333,Loss of glycosylation at S531 (P = 0.02); Gain of catalytic residue at S531 (P = 0.0327); Gain of solvent accessibility (P = 0.0739); Loss of methylation at R528 (P = 0.1405); Loss of MoRF binding (P = 0.1559)
17:44073849:C:G,P10636,S531C,0.347,Loss of phosphorylation at S531 (P = 0.0015); Gain of catalytic residue at P530 (P = 0.0116); Loss of glycosylation at S531 (P = 0.02); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.086)
17:44073849:C:T,P10636,S531F,0.291,Loss of phosphorylation at S531 (P = 0.0015); Loss of glycosylation at S531 (P = 0.02); Loss of MoRF binding (P = 0.1165); Gain of solvent accessibility (P = 0.1376); Gain of methylation at R526 (P = 0.1418)
17:44073851:C:A,P10636,L532I,0.184,Gain of MoRF binding (P = 0.1188); Loss of glycosylation at P533 (P = 0.1189); Loss of methylation at R528 (P = 0.129); Loss of catalytic residue at L532 (P = 0.2659); Loss of stability (P = 0.586)
17:44073851:C:G,P10636,L532V,0.172,Gain of MoRF binding (P = 0.088); Loss of glycosylation at P530 (P = 0.112); Loss of catalytic residue at L532 (P = 0.1199); Gain of methylation at R528 (P = 0.1546); Loss of stability (P = 0.2812)
17:44073851:C:T,P10636,L532F,0.196,Loss of glycosylation at S531 (P = 0.097); Gain of catalytic residue at P530 (P = 0.1578); Gain of methylation at R528 (P = 0.1581); Loss of MoRF binding (P = 0.1581); Loss of stability (P = 0.2893)
17:44073852:T:A,P10636,L532H,0.236,Loss of stability (P = 0.0518); Loss of glycosylation at S531 (P = 0.0897); Gain of methylation at R528 (P = 0.1506); Gain of MoRF binding (P = 0.1728); Loss of catalytic residue at R528 (P = 0.2408)
17:44073852:T:G,P10636,L532R,0.267,Gain of MoRF binding (P = 0.0105); Gain of methylation at L532 (P = 0.0391); Loss of stability (P = 0.077); Loss of catalytic residue at L532 (P = 0.1079); Loss of glycosylation at T534 (P = 0.1165)
17:44073854:C:A,P10636,P533T,0.238,Gain of phosphorylation at P533 (P = 0.0075); Gain of MoRF binding (P = 0.0481); Gain of glycosylation at P533 (P = 0.0603); Gain of methylation at R528 (P = 0.1415); Loss of catalytic residue at L532 (P = 0.3528)
17:44073854:C:G,P10636,P533A,0.18,Loss of glycosylation at P533 (P = 0.021); Gain of MoRF binding (P = 0.0343); Gain of methylation at R528 (P = 0.1009); Loss of catalytic residue at L532 (P = 0.2416); Loss of solvent accessibility (P = 0.4838)
17:44073854:C:T,P10636,P533S,0.228,Gain of phosphorylation at P533 (P = 0.0027); Gain of MoRF binding (P = 0.0377); Loss of glycosylation at S531 (P = 0.1218); Gain of methylation at R528 (P = 0.139); Loss of catalytic residue at P533 (P = 0.3186)
17:44073855:C:A,P10636,P533Q,0.188,Loss of glycosylation at P533 (P = 0.021); Gain of MoRF binding (P = 0.0316); Gain of solvent accessibility (P = 0.1045); Loss of methylation at R528 (P = 0.1289); Loss of catalytic residue at L532 (P = 0.352)
17:44073855:C:G,P10636,P533R,0.303,Gain of MoRF binding (P = 6e-04); Loss of glycosylation at P533 (P = 0.021); Gain of methylation at R528 (P = 0.0913); Gain of solvent accessibility (P = 0.1045); Gain of catalytic residue at P533 (P = 0.1686)
17:44073855:C:T,P10636,P533L,0.217,Loss of glycosylation at P533 (P = 0.021); Gain of MoRF binding (P = 0.0508); Gain of methylation at R528 (P = 0.16); Loss of catalytic residue at L532 (P = 0.3151); Loss of phosphorylation at T534 (P = 0.4003)
17:44073857:A:C,P10636,T534P,0.249,Loss of phosphorylation at T534 (P = 0.0083); Gain of catalytic residue at T534 (P = 0.0688); Loss of MoRF binding (P = 0.0713); Gain of glycosylation at P533 (P = 0.0877); Gain of methylation at R538 (P = 0.4484)
17:44073857:A:G,P10636,T534A,0.168,Loss of glycosylation at T534 (P = 0.0065); Loss of phosphorylation at T534 (P = 0.0083); Gain of MoRF binding (P = 0.1286); Gain of methylation at R538 (P = 0.4372); Gain of catalytic residue at T529 (P = 0.5017)
17:44073857:A:T,P10636,T534S,0.172,Gain of MoRF binding (P = 0.1089); Loss of glycosylation at T534 (P = 0.1177); Gain of methylation at R538 (P = 0.4664); Gain of catalytic residue at P533 (P = 0.6408); Gain of phosphorylation at T534 (P = 0.6655)
17:44073858:C:G,P10636,T534S,0.172,Gain of MoRF binding (P = 0.1089); Loss of glycosylation at T534 (P = 0.1177); Gain of methylation at R538 (P = 0.4664); Gain of catalytic residue at P533 (P = 0.6408); Gain of phosphorylation at T534 (P = 0.6655)
17:44073858:C:T,P10636,T534I,0.188,Loss of glycosylation at T534 (P = 0.0065); Loss of phosphorylation at T534 (P = 0.0083); Gain of catalytic residue at P536 (P = 0.064); Loss of MoRF binding (P = 0.1365); Loss of methylation at R538 (P = 0.4691)
17:44073860:C:A,P10636,P535T,0.275,Gain of phosphorylation at P535 (P = 0.0023); Loss of catalytic residue at P535 (P = 0.0302); Gain of MoRF binding (P = 0.0406); Loss of glycosylation at P535 (P = 0.1132); Loss of relative solvent accessibility (P = 0.1807)
17:44073860:C:G,P10636,P535A,0.275,Loss of catalytic residue at P535 (P = 0.0052); Loss of glycosylation at P535 (P = 0.0059); Gain of MoRF binding (P = 0.0331); Loss of solvent accessibility (P = 0.0606); Loss of relative solvent accessibility (P = 0.0676)
17:44073860:C:T,P10636,P535S,0.295,Loss of catalytic residue at P535 (P = 0.0011); Gain of phosphorylation at P535 (P = 0.0031); Gain of MoRF binding (P = 0.0287); Loss of solvent accessibility (P = 0.0674); Loss of relative solvent accessibility (P = 0.0676)
17:44073861:C:A,P10636,P535Q,0.293,Loss of catalytic residue at P535 (P = 0.0051); Loss of glycosylation at P535 (P = 0.0059); Gain of MoRF binding (P = 0.0224); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at T534 (P = 0.2263)
17:44073861:C:G,P10636,P535R,0.309,Gain of MoRF binding (P = 2e-04); Loss of glycosylation at P535 (P = 0.0059); Gain of methylation at P535 (P = 0.0425); Loss of catalytic residue at P535 (P = 0.0848); Loss of relative solvent accessibility (P = 0.1807)
17:44073861:C:T,P10636,P535L,0.227,Loss of glycosylation at P535 (P = 0.0059); Gain of MoRF binding (P = 0.051); Loss of relative solvent accessibility (P = 0.0981); Loss of phosphorylation at T534 (P = 0.1085); Loss of solvent accessibility (P = 0.1362)
17:44073863:C:A,P10636,P536T,0.186,Gain of phosphorylation at P536 (P = 0.0208); Loss of catalytic residue at P535 (P = 0.0223); Gain of MoRF binding (P = 0.0413); Loss of ubiquitination at K541 (P = 0.1202); Loss of glycosylation at P533 (P = 0.1531)
17:44073863:C:G,P10636,P536A,0.236,Loss of glycosylation at P536 (P = 0.0076); Loss of catalytic residue at P535 (P = 0.0165); Gain of MoRF binding (P = 0.0245); Loss of ubiquitination at K541 (P = 0.1498); Loss of methylation at K541 (P = 0.2926)
17:44073863:C:T,P10636,P536S,0.231,Gain of phosphorylation at P536 (P = 0.0028); Loss of catalytic residue at P535 (P = 0.0165); Gain of MoRF binding (P = 0.0311); Loss of glycosylation at P536 (P = 0.0364); Loss of ubiquitination at K541 (P = 0.1498)
17:44073864:C:A,P10636,P536H,0.201,Loss of glycosylation at P536 (P = 0.0076); Loss of catalytic residue at P535 (P = 0.0165); Gain of MoRF binding (P = 0.05); Loss of ubiquitination at K541 (P = 0.1202); Gain of solvent accessibility (P = 0.2601)
17:44073864:C:G,P10636,P536R,0.297,Gain of MoRF binding (P = 0.0045); Loss of glycosylation at P536 (P = 0.0076); Loss of catalytic residue at P535 (P = 0.0283); Gain of methylation at P536 (P = 0.0817); Loss of ubiquitination at K541 (P = 0.1202)
17:44073864:C:T,P10636,P536L,0.228,Loss of glycosylation at P536 (P = 0.0076); Loss of catalytic residue at P535 (P = 0.0283); Gain of MoRF binding (P = 0.0306); Gain of stability (P = 0.1447); Loss of ubiquitination at K541 (P = 0.1498)
17:44073866:A:C,P10636,T537P,0.202,Loss of phosphorylation at T537 (P = 0.003); Loss of MoRF binding (P = 0.0626); Gain of catalytic residue at P536 (P = 0.0641); Gain of glycosylation at P540 (P = 0.127); Loss of ubiquitination at K541 (P = 0.1498)
17:44073866:A:G,P10636,T537A,0.157,Loss of phosphorylation at T537 (P = 0.003); Loss of glycosylation at T537 (P = 0.0037); Gain of MoRF binding (P = 0.1061); Loss of ubiquitination at K541 (P = 0.1351); Loss of methylation at K541 (P = 0.2891)
17:44073866:A:T,P10636,T537S,0.194,Loss of glycosylation at T537 (P = 0.0806); Gain of MoRF binding (P = 0.1098); Gain of ubiquitination at K541 (P = 0.1103); Loss of methylation at K541 (P = 0.4519); Loss of sheet (P = 0.5184)
17:44073867:C:A,P10636,T537N,0.155,Loss of phosphorylation at T537 (P = 0.003); Loss of glycosylation at T537 (P = 0.0037); Gain of MoRF binding (P = 0.1382); Loss of ubiquitination at K541 (P = 0.1498); Loss of methylation at K541 (P = 0.3857)
17:44073867:C:G,P10636,T537S,0.194,Loss of glycosylation at T537 (P = 0.0806); Gain of MoRF binding (P = 0.1098); Gain of ubiquitination at K541 (P = 0.1103); Loss of methylation at K541 (P = 0.4519); Loss of sheet (P = 0.5184)
17:44073867:C:T,P10636,T537I,0.185,Loss of phosphorylation at T537 (P = 0.003); Loss of glycosylation at T537 (P = 0.0037); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.086); Gain of MoRF binding (P = 0.0917)
17:44073869:C:G,P10636,R538G,0.255,Loss of MoRF binding (P = 0.0116); Gain of relative solvent accessibility (P = 0.0166); Gain of ubiquitination at K541 (P = 0.0685); Loss of glycosylation at P535 (P = 0.0994); Gain of catalytic residue at K541 (P = 0.222)
17:44073870:G:A,P10636,R538Q,0.28,Gain of relative solvent accessibility (P = 0.0166); Gain of solvent accessibility (P = 0.0171); Loss of MoRF binding (P = 0.0174); Gain of glycosylation at K541 (P = 0.1149); Gain of ubiquitination at K542 (P = 0.1317)
17:44073870:G:C,P10636,R538P,0.291,Loss of MoRF binding (P = 0.0028); Gain of glycosylation at R538 (P = 0.0036); Gain of relative solvent accessibility (P = 0.0479); Gain of ubiquitination at K542 (P = 0.1111); Gain of solvent accessibility (P = 0.2987)
17:44073870:G:T,P10636,R538L,0.287,Loss of MoRF binding (P = 0.0089); Gain of catalytic residue at R538 (P = 0.0591); Loss of glycosylation at P533 (P = 0.12); Gain of ubiquitination at K542 (P = 0.1317); Loss of solvent accessibility (P = 0.3103)
17:44073872:G:A,P10636,E539K,0.294,Gain of sheet (P = 0.0028); Gain of methylation at E539 (P = 0.0039); Gain of MoRF binding (P = 0.0045); Loss of loop (P = 0.0112); Gain of ubiquitination at E539 (P = 0.0337)
17:44073872:G:C,P10636,E539Q,0.168,Gain of MoRF binding (P = 0.0205); Loss of ubiquitination at K541 (P = 0.1202); Loss of glycosylation at P540 (P = 0.157); Loss of solvent accessibility (P = 0.1868); Loss of relative solvent accessibility (P = 0.3219)
17:44073873:A:C,P10636,E539A,0.21,Gain of MoRF binding (P = 0.0137); Loss of solvent accessibility (P = 0.0159); Gain of ubiquitination at K542 (P = 0.0822); Loss of relative solvent accessibility (P = 0.0981); Gain of methylation at R538 (P = 0.1256)
17:44073873:A:G,P10636,E539G,0.21,Gain of MoRF binding (P = 0.0155); Loss of stability (P = 0.0456); Gain of methylation at R538 (P = 0.0539); Loss of solvent accessibility (P = 0.0769); Gain of ubiquitination at K542 (P = 0.095)
17:44073873:A:T,P10636,E539V,0.211,Gain of MoRF binding (P = 0.0092); Loss of solvent accessibility (P = 0.0199); Loss of glycosylation at P540 (P = 0.0891); Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K541 (P = 0.1498)
17:44073874:G:C,P10636,E539D,0.152,Gain of MoRF binding (P = 0.1079); Gain of ubiquitination at K541 (P = 0.1103); Loss of glycosylation at P540 (P = 0.1747); Loss of methylation at K541 (P = 0.397); Loss of stability (P = 0.4765)
17:44073874:G:T,P10636,E539D,0.152,Gain of MoRF binding (P = 0.1079); Gain of ubiquitination at K541 (P = 0.1103); Loss of glycosylation at P540 (P = 0.1747); Loss of methylation at K541 (P = 0.397); Loss of stability (P = 0.4765)
17:44073875:C:A,P10636,P540T,0.204,Gain of phosphorylation at P540 (P = 0.0048); Gain of MoRF binding (P = 0.0416); Loss of glycosylation at P540 (P = 0.0793); Loss of ubiquitination at K541 (P = 0.1202); Gain of sheet (P = 0.1208)
17:44073875:C:G,P10636,P540A,0.212,Loss of glycosylation at P540 (P = 0.0344); Gain of MoRF binding (P = 0.0348); Loss of sheet (P = 0.0457); Gain of loop (P = 0.0502); Loss of stability (P = 0.0582)
17:44073875:C:T,P10636,P540S,0.227,Gain of phosphorylation at P540 (P = 0.0051); Gain of MoRF binding (P = 0.0307); Loss of glycosylation at T537 (P = 0.1051); Gain of sheet (P = 0.1208); Loss of ubiquitination at K541 (P = 0.1351)
17:44073876:C:A,P10636,P540H,0.222,Loss of glycosylation at P540 (P = 0.0344); Loss of sheet (P = 0.0457); Gain of MoRF binding (P = 0.0491); Gain of loop (P = 0.0851); Loss of ubiquitination at K541 (P = 0.1202)
17:44073876:C:G,P10636,P540R,0.246,Gain of MoRF binding (P = 0.0043); Loss of glycosylation at P540 (P = 0.0344); Gain of solvent accessibility (P = 0.1045); Gain of methylation at P540 (P = 0.1055); Loss of ubiquitination at K541 (P = 0.1202)
17:44073876:C:T,P10636,P540L,0.202,Loss of glycosylation at P540 (P = 0.0344); Gain of MoRF binding (P = 0.0416); Loss of ubiquitination at K541 (P = 0.1055); Gain of loop (P = 0.1069); Loss of sheet (P = 0.1158)
17:44073878:A:C,P10636,K541Q,0.28,Loss of methylation at K541 (P = 0.0032); Loss of ubiquitination at K541 (P = 0.0233); Loss of MoRF binding (P = 0.0515); Loss of glycosylation at K541 (P = 0.0543); Loss of sheet (P = 0.302)
17:44073878:A:G,P10636,K541E,0.304,Loss of methylation at K541 (P = 0.0032); Loss of MoRF binding (P = 0.0047); Loss of ubiquitination at K541 (P = 0.0233); Loss of glycosylation at K541 (P = 0.0543); Loss of sheet (P = 0.302)
17:44073879:A:C,P10636,K541T,0.304,Loss of methylation at K541 (P = 0.0032); Gain of phosphorylation at K541 (P = 0.0051); Loss of ubiquitination at K541 (P = 0.0233); Gain of sheet (P = 0.039); Loss of MoRF binding (P = 0.0464)
17:44073879:A:G,P10636,K541R,0.23,Loss of methylation at K541 (P = 0.0129); Loss of ubiquitination at K541 (P = 0.0233); Gain of sheet (P = 0.039); Loss of glycosylation at K541 (P = 0.0543); Gain of MoRF binding (P = 0.079)
17:44073879:A:T,P10636,K541M,0.257,Loss of methylation at K541 (P = 0.0032); Loss of solvent accessibility (P = 0.0045); Loss of ubiquitination at K541 (P = 0.0233); Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at K541 (P = 0.0543)
17:44073880:G:C,P10636,K541N,0.265,Loss of methylation at K541 (P = 0.0032); Loss of ubiquitination at K541 (P = 0.0233); Loss of MoRF binding (P = 0.0469); Loss of glycosylation at K541 (P = 0.0543); Loss of sheet (P = 0.1158)
17:44073880:G:T,P10636,K541N,0.265,Loss of methylation at K541 (P = 0.0032); Loss of ubiquitination at K541 (P = 0.0233); Loss of MoRF binding (P = 0.0469); Loss of glycosylation at K541 (P = 0.0543); Loss of sheet (P = 0.1158)
17:44073881:A:C,P10636,K542Q,0.245,Loss of methylation at K542 (P = 0.0018); Loss of ubiquitination at K542 (P = 0.0283); Loss of MoRF binding (P = 0.0491); Gain of sheet (P = 0.1208); Loss of glycosylation at K542 (P = 0.1961)
17:44073881:A:G,P10636,K542E,0.273,Loss of methylation at K542 (P = 0.0018); Loss of MoRF binding (P = 0.0033); Loss of ubiquitination at K542 (P = 0.0283); Loss of glycosylation at P540 (P = 0.1684); Loss of sheet (P = 0.3635)
17:44073882:A:C,P10636,K542T,0.294,Loss of methylation at K542 (P = 0.0018); Gain of phosphorylation at K542 (P = 0.0081); Loss of ubiquitination at K542 (P = 0.0283); Loss of MoRF binding (P = 0.0411); Loss of sheet (P = 0.1907)
17:44073882:A:G,P10636,K542R,0.221,Loss of methylation at K542 (P = 0.0156); Loss of ubiquitination at K542 (P = 0.0283); Gain of sheet (P = 0.0344); Gain of MoRF binding (P = 0.0713); Loss of loop (P = 0.0804)
17:44073882:A:T,P10636,K542M,0.255,Loss of methylation at K542 (P = 0.0018); Loss of ubiquitination at K542 (P = 0.0283); Loss of MoRF binding (P = 0.0685); Loss of solvent accessibility (P = 0.1235); Loss of glycosylation at P540 (P = 0.1757)
17:44073883:G:C,P10636,K542N,0.256,Loss of methylation at K542 (P = 0.0018); Gain of sheet (P = 0.0149); Loss of ubiquitination at K542 (P = 0.0283); Loss of MoRF binding (P = 0.0443); Loss of loop (P = 0.0512)
17:44073883:G:T,P10636,K542N,0.256,Loss of methylation at K542 (P = 0.0018); Gain of sheet (P = 0.0149); Loss of ubiquitination at K542 (P = 0.0283); Loss of MoRF binding (P = 0.0443); Loss of loop (P = 0.0512)
17:44073884:G:A,P10636,V543M,0.135,Loss of methylation at K542 (P = 0.0237); Loss of sheet (P = 0.0817); Gain of MoRF binding (P = 0.0951); Gain of glycosylation at P540 (P = 0.1179); Gain of ubiquitination at K541 (P = 0.1295)
17:44073884:G:C,P10636,V543L,0.156,Gain of sheet (P = 0.0827); Loss of MoRF binding (P = 0.1075); Gain of ubiquitination at K541 (P = 0.1103); Gain of glycosylation at P540 (P = 0.1148); Gain of catalytic residue at V543 (P = 0.1879)
17:44073884:G:T,P10636,V543L,0.156,Gain of sheet (P = 0.0827); Loss of MoRF binding (P = 0.1075); Gain of ubiquitination at K541 (P = 0.1103); Gain of glycosylation at P540 (P = 0.1148); Gain of catalytic residue at V543 (P = 0.1879)
17:44073885:T:A,P10636,V543E,0.216,Gain of solvent accessibility (P = 0.0256); Loss of MoRF binding (P = 0.0269); Loss of sheet (P = 0.0315); Gain of relative solvent accessibility (P = 0.0479); Gain of glycosylation at P540 (P = 0.1014)
17:44073885:T:C,P10636,V543A,0.157,Loss of stability (P = 0.0512); Loss of sheet (P = 0.0817); Gain of ubiquitination at K542 (P = 0.0822); Loss of MoRF binding (P = 0.1162); Gain of glycosylation at P540 (P = 0.1168)
17:44073885:T:G,P10636,V543G,0.211,Loss of stability (P = 0.0081); Loss of sheet (P = 0.0315); Gain of loop (P = 0.0502); Gain of ubiquitination at K542 (P = 0.0822); Gain of glycosylation at K542 (P = 0.0985)
17:44073887:G:A,P10636,A544T,0.2,Gain of phosphorylation at A544 (P = 0.0021); Gain of sheet (P = 0.0827); Gain of ubiquitination at K541 (P = 0.1103); Loss of MoRF binding (P = 0.1365); Gain of glycosylation at A544 (P = 0.1819)
17:44073887:G:C,P10636,A544P,0.2,Gain of sheet (P = 0.039); Loss of MoRF binding (P = 0.0465); Gain of ubiquitination at K541 (P = 0.1103); Loss of loop (P = 0.1242); Loss of methylation at R547 (P = 0.182)
17:44073887:G:T,P10636,A544S,0.215,Gain of phosphorylation at A544 (P = 0.0046); Gain of sheet (P = 0.0221); Loss of loop (P = 0.0804); Gain of glycosylation at A544 (P = 0.0871); Gain of ubiquitination at K541 (P = 0.1103)
17:44073888:C:A,P10636,A544E,0.202,Loss of MoRF binding (P = 0.0377); Gain of ubiquitination at K542 (P = 0.0822); Gain of sheet (P = 0.0827); Loss of loop (P = 0.1242); Gain of solvent accessibility (P = 0.1319)
17:44073888:C:G,P10636,A544G,0.188,Loss of sheet (P = 0.0817); Gain of catalytic residue at P540 (P = 0.0924); Gain of ubiquitination at K541 (P = 0.1103); Loss of MoRF binding (P = 0.1301); Loss of stability (P = 0.1515)
17:44073888:C:T,P10636,A544V,0.298,Gain of sheet (P = 0.0043); Loss of loop (P = 0.0112); Loss of relative solvent accessibility (P = 0.0793); Gain of ubiquitination at K541 (P = 0.1295); Loss of MoRF binding (P = 0.1426)
17:44073890:G:A,P10636,V545M,0.266,Gain of MoRF binding (P = 0.0809); Gain of sheet (P = 0.0827); Gain of ubiquitination at K541 (P = 0.1103); Gain of methylation at R547 (P = 0.185); Gain of glycosylation at P540 (P = 0.1964)
17:44073890:G:C,P10636,V545L,0.257,Loss of sheet (P = 0.0457); Gain of loop (P = 0.0851); Gain of ubiquitination at K541 (P = 0.1103); Loss of MoRF binding (P = 0.1109); Gain of glycosylation at P540 (P = 0.1454)
17:44073890:G:T,P10636,V545L,0.257,Loss of sheet (P = 0.0457); Gain of loop (P = 0.0851); Gain of ubiquitination at K541 (P = 0.1103); Loss of MoRF binding (P = 0.1109); Gain of glycosylation at P540 (P = 0.1454)
17:44073891:T:A,P10636,V545E,0.254,Loss of sheet (P = 0.0315); Loss of MoRF binding (P = 0.0436); Gain of loop (P = 0.069); Gain of ubiquitination at K542 (P = 0.095); Gain of methylation at R547 (P = 0.1221)
17:44073891:T:C,P10636,V545A,0.216,Loss of sheet (P = 0.0126); Gain of loop (P = 0.069); Gain of ubiquitination at K542 (P = 0.0822); Gain of methylation at R547 (P = 0.0989); Gain of MoRF binding (P = 0.1395)
17:44073891:T:G,P10636,V545G,0.264,Loss of stability (P = 0.0074); Loss of sheet (P = 0.0126); Gain of loop (P = 0.0312); Gain of methylation at R547 (P = 0.07); Gain of ubiquitination at K542 (P = 0.0822)
17:44073893:G:A,P10636,V546I,0.239,Loss of sheet (P = 0.0817); Loss of methylation at R547 (P = 0.1156); Loss of MoRF binding (P = 0.1373); Gain of ubiquitination at K551 (P = 0.1446); Gain of glycosylation at K541 (P = 0.2046)
17:44073893:G:C,P10636,V546L,0.226,Loss of sheet (P = 0.0817); Loss of methylation at K551 (P = 0.0821); Gain of loop (P = 0.0851); Loss of MoRF binding (P = 0.1098); Gain of ubiquitination at K541 (P = 0.1103)
17:44073893:G:T,P10636,V546F,0.262,Loss of sheet (P = 0.0817); Loss of MoRF binding (P = 0.0939); Loss of methylation at K551 (P = 0.1333); Loss of ubiquitination at K541 (P = 0.1498); Gain of glycosylation at P549 (P = 0.1923)
17:44073894:T:A,P10636,V546D,0.268,Loss of MoRF binding (P = 0.0315); Gain of loop (P = 0.0435); Loss of sheet (P = 0.0457); Gain of ubiquitination at K551 (P = 0.0762); Gain of methylation at K551 (P = 0.122)
17:44073894:T:C,P10636,V546A,0.221,Loss of sheet (P = 0.0315); Gain of relative solvent accessibility (P = 0.0507); Gain of loop (P = 0.0851); Loss of methylation at K551 (P = 0.1114); Loss of MoRF binding (P = 0.1222)
17:44073894:T:G,P10636,V546G,0.267,Loss of sheet (P = 0.0181); Gain of relative solvent accessibility (P = 0.0249); Loss of stability (P = 0.0268); Gain of methylation at R547 (P = 0.0426); Gain of loop (P = 0.0435)
17:44073896:C:A,P10636,R547S,0.386,Gain of glycosylation at R547 (P = 0.0031); Gain of sheet (P = 0.0049); Gain of phosphorylation at R547 (P = 0.0073); Loss of MoRF binding (P = 0.0185); Loss of loop (P = 0.0288)
17:44073896:C:G,P10636,R547G,0.325,Loss of MoRF binding (P = 0.0135); Gain of sheet (P = 0.0149); Loss of methylation at R547 (P = 0.046); Loss of loop (P = 0.0603); Gain of ubiquitination at K551 (P = 0.07)
17:44073896:C:T,P10636,R547C,0.377,Loss of MoRF binding (P = 0.0025); Loss of methylation at R547 (P = 0.046); Loss of solvent accessibility (P = 0.0561); Gain of sheet (P = 0.0827); Gain of ubiquitination at K542 (P = 0.095)
17:44073897:G:A,P10636,R547H,0.279,Loss of MoRF binding (P = 0.0096); Loss of methylation at R547 (P = 0.046); Gain of ubiquitination at K542 (P = 0.0666); Gain of glycosylation at K542 (P = 0.1938); Loss of catalytic residue at R547 (P = 0.1952)
17:44073897:G:C,P10636,R547P,0.34,Loss of MoRF binding (P = 5e-04); Gain of sheet (P = 0.0085); Loss of loop (P = 0.0288); Loss of methylation at R547 (P = 0.046); Gain of glycosylation at T548 (P = 0.0563)
17:44073897:G:T,P10636,R547L,0.317,Loss of MoRF binding (P = 0.0102); Loss of sheet (P = 0.0457); Loss of methylation at R547 (P = 0.046); Gain of ubiquitination at K551 (P = 0.0762); Gain of loop (P = 0.0851)
17:44073899:A:C,P10636,T548P,0.322,Gain of sheet (P = 0.0016); Loss of loop (P = 0.0022); Loss of phosphorylation at T548 (P = 0.0042); Gain of catalytic residue at T548 (P = 0.0127); Gain of glycosylation at T548 (P = 0.0302)
17:44073899:A:G,P10636,T548A,0.24,Gain of sheet (P = 0.0016); Loss of loop (P = 0.0022); Loss of phosphorylation at T548 (P = 0.0042); Loss of methylation at K551 (P = 0.0938); Loss of stability (P = 0.1096)
17:44073899:A:T,P10636,T548S,0.249,Gain of sheet (P = 0.0016); Loss of loop (P = 0.0022); Loss of methylation at K551 (P = 0.1449); Gain of MoRF binding (P = 0.1452); Gain of relative solvent accessibility (P = 0.1571)
17:44073900:C:A,P10636,T548N,0.226,Loss of phosphorylation at T548 (P = 0.0042); Gain of sheet (P = 0.0043); Loss of loop (P = 0.0112); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1376)
17:44073900:C:G,P10636,T548S,0.249,Gain of sheet (P = 0.0016); Loss of loop (P = 0.0022); Loss of methylation at K551 (P = 0.1449); Gain of MoRF binding (P = 0.1452); Gain of relative solvent accessibility (P = 0.1571)
17:44073900:C:T,P10636,T548I,0.253,Loss of phosphorylation at T548 (P = 0.0042); Gain of catalytic residue at P550 (P = 0.0546); Loss of glycosylation at P549 (P = 0.1093); Loss of methylation at R547 (P = 0.1214); Gain of MoRF binding (P = 0.1568)
17:44073902:C:A,P10636,P549T,0.223,Loss of sheet (P = 0.0054); Gain of phosphorylation at P549 (P = 0.0068); Gain of loop (P = 0.0166); Loss of catalytic residue at P549 (P = 0.0545); Gain of MoRF binding (P = 0.0814)
17:44073902:C:G,P10636,P549A,0.266,Loss of glycosylation at P549 (P = 0.0148); Loss of catalytic residue at P549 (P = 0.0155); Loss of sheet (P = 0.0315); Loss of stability (P = 0.0618); Loss of methylation at K551 (P = 0.072)
17:44073902:C:T,P10636,P549S,0.253,Gain of phosphorylation at P549 (P = 0.002); Loss of catalytic residue at P549 (P = 0.0322); Loss of sheet (P = 0.0357); Gain of MoRF binding (P = 0.0748); Loss of methylation at K551 (P = 0.0866)
17:44073903:C:A,P10636,P549Q,0.253,Loss of glycosylation at P549 (P = 0.0148); Loss of catalytic residue at P549 (P = 0.0264); Gain of MoRF binding (P = 0.0773); Gain of sheet (P = 0.0827); Loss of loop (P = 0.1242)
17:44073903:C:G,P10636,P549R,0.279,Loss of glycosylation at P549 (P = 0.0148); Loss of sheet (P = 0.0315); Gain of methylation at P549 (P = 0.0323); Gain of MoRF binding (P = 0.0391); Gain of solvent accessibility (P = 0.0789)
17:44073903:C:T,P10636,P549L,0.216,Loss of glycosylation at P549 (P = 0.0148); Loss of sheet (P = 0.0315); Loss of methylation at K551 (P = 0.0687); Gain of MoRF binding (P = 0.0799); Loss of catalytic residue at P549 (P = 0.1199)
17:44073905:C:A,P10636,P550T,0.27,Gain of phosphorylation at P550 (P = 0.0034); Loss of catalytic residue at P549 (P = 0.0175); Gain of MoRF binding (P = 0.0939); Gain of relative solvent accessibility (P = 0.0999); Loss of methylation at K551 (P = 0.1276)
17:44073905:C:G,P10636,P550A,0.247,Loss of glycosylation at P550 (P = 0.003); Loss of catalytic residue at P549 (P = 0.016); Gain of relative solvent accessibility (P = 0.0166); Loss of methylation at K551 (P = 0.0755); Gain of MoRF binding (P = 0.0865)
17:44073905:C:T,P10636,P550S,0.319,Gain of phosphorylation at P550 (P = 0.0024); Loss of catalytic residue at P549 (P = 0.0191); Loss of glycosylation at P550 (P = 0.0267); Loss of helix (P = 0.0376); Gain of relative solvent accessibility (P = 0.0479)
17:44073906:C:A,P10636,P550H,0.219,Loss of glycosylation at P550 (P = 0.003); Loss of catalytic residue at P549 (P = 0.016); Loss of helix (P = 0.0376); Gain of loop (P = 0.0851); Gain of MoRF binding (P = 0.1013)
17:44073906:C:G,P10636,P550R,0.291,Loss of glycosylation at P550 (P = 0.003); Loss of catalytic residue at P549 (P = 0.0191); Gain of solvent accessibility (P = 0.0246); Loss of helix (P = 0.0376); Gain of MoRF binding (P = 0.0428)
17:44073906:C:T,P10636,P550L,0.277,Loss of glycosylation at P550 (P = 0.003); Loss of catalytic residue at P549 (P = 0.016); Loss of helix (P = 0.0376); Loss of methylation at K551 (P = 0.0673); Gain of loop (P = 0.0851)
17:44073908:A:C,P10636,K551Q,0.279,Loss of methylation at K551 (P = 0.0141); Loss of ubiquitination at K551 (P = 0.0255); Loss of MoRF binding (P = 0.0471); Loss of catalytic residue at K551 (P = 0.061); Loss of glycosylation at P550 (P = 0.0824)
17:44073908:A:G,P10636,K551E,0.352,Loss of MoRF binding (P = 7e-04); Loss of methylation at K551 (P = 0.0141); Loss of ubiquitination at K551 (P = 0.0255); Loss of catalytic residue at K551 (P = 0.0322); Gain of glycosylation at S554 (P = 0.1123)
17:44073909:A:C,P10636,K551T,0.322,Loss of methylation at K551 (P = 0.0141); Gain of phosphorylation at K551 (P = 0.0187); Loss of ubiquitination at K551 (P = 0.0255); Loss of MoRF binding (P = 0.0276); Gain of glycosylation at K551 (P = 0.0306)
17:44073909:A:G,P10636,K551R,0.226,Loss of ubiquitination at K551 (P = 0.0255); Loss of methylation at K551 (P = 0.0401); Gain of MoRF binding (P = 0.0981); Loss of glycosylation at S555 (P = 0.209); Loss of sheet (P = 0.3635)
17:44073909:A:T,P10636,K551M,0.284,Loss of methylation at K551 (P = 0.0141); Loss of ubiquitination at K551 (P = 0.0255); Loss of catalytic residue at K551 (P = 0.0325); Loss of MoRF binding (P = 0.0478); Gain of stability (P = 0.0697)
17:44073910:G:C,P10636,K551N,0.291,Loss of methylation at K551 (P = 0.0141); Loss of ubiquitination at K551 (P = 0.0255); Loss of MoRF binding (P = 0.04); Gain of glycosylation at T548 (P = 0.0887); Loss of loop (P = 0.2237)
17:44073910:G:T,P10636,K551N,0.291,Loss of methylation at K551 (P = 0.0141); Loss of ubiquitination at K551 (P = 0.0255); Loss of MoRF binding (P = 0.04); Gain of glycosylation at T548 (P = 0.0887); Loss of loop (P = 0.2237)
17:44073911:T:A,P10636,S552T,0.203,Gain of glycosylation at S552 (P = 0.0984); Gain of relative solvent accessibility (P = 0.0999); Gain of methylation at K551 (P = 0.1167); Loss of ubiquitination at K557 (P = 0.1231); Loss of helix (P = 0.1299)
17:44073911:T:C,P10636,S552P,0.298,Gain of catalytic residue at S552 (P = 0.0024); Loss of phosphorylation at S552 (P = 0.0061); Gain of glycosylation at S552 (P = 0.0188); Loss of MoRF binding (P = 0.0594); Gain of methylation at K551 (P = 0.0951)
17:44073911:T:G,P10636,S552A,0.206,Loss of phosphorylation at S552 (P = 0.0061); Loss of methylation at K557 (P = 0.0707); Loss of helix (P = 0.1299); Gain of MoRF binding (P = 0.1315); Loss of ubiquitination at K557 (P = 0.1435)
17:44073912:C:G,P10636,S552W,0.259,Loss of phosphorylation at S552 (P = 0.0061); Gain of MoRF binding (P = 0.0548); Gain of methylation at K551 (P = 0.0659); Loss of ubiquitination at K557 (P = 0.0768); Loss of glycosylation at P549 (P = 0.0919)
17:44073912:C:T,P10636,S552L,0.198,Loss of phosphorylation at S552 (P = 0.0061); Loss of methylation at K557 (P = 0.0607); Loss of glycosylation at P549 (P = 0.0924); Loss of ubiquitination at K557 (P = 0.1079); Loss of helix (P = 0.1299)
17:44073914:C:A,P10636,P553T,0.242,Gain of phosphorylation at P553 (P = 0.0146); Gain of MoRF binding (P = 0.0635); Loss of glycosylation at P553 (P = 0.0639); Loss of ubiquitination at K557 (P = 0.1079); Loss of helix (P = 0.1299)
17:44073914:C:G,P10636,P553A,0.22,Loss of glycosylation at P553 (P = 0.0047); Gain of MoRF binding (P = 0.0564); Loss of methylation at K557 (P = 0.0652); Gain of ubiquitination at K551 (P = 0.1025); Loss of helix (P = 0.1299)
17:44073914:C:T,P10636,P553S,0.315,Gain of phosphorylation at P553 (P = 0.0081); Loss of glycosylation at P553 (P = 0.0276); Gain of MoRF binding (P = 0.0643); Loss of methylation at K551 (P = 0.073); Loss of ubiquitination at K557 (P = 0.1079)
17:44073915:C:A,P10636,P553Q,0.24,Loss of glycosylation at P553 (P = 0.0047); Gain of MoRF binding (P = 0.064); Gain of solvent accessibility (P = 0.1045); Loss of ubiquitination at K557 (P = 0.1231); Loss of helix (P = 0.1299)
17:44073915:C:G,P10636,P553R,0.322,Loss of glycosylation at P553 (P = 0.0047); Gain of solvent accessibility (P = 0.0216); Gain of MoRF binding (P = 0.023); Gain of methylation at P553 (P = 0.0291); Gain of catalytic residue at P553 (P = 0.0697)
17:44073915:C:T,P10636,P553L,0.248,Loss of glycosylation at P553 (P = 0.0047); Loss of methylation at K551 (P = 0.0564); Gain of MoRF binding (P = 0.0613); Loss of ubiquitination at K557 (P = 0.0768); Loss of helix (P = 0.1299)
17:44073917:T:A,P10636,S554T,0.124,Gain of glycosylation at S554 (P = 0.0346); Gain of methylation at K551 (P = 0.1096); Loss of MoRF binding (P = 0.1421); Loss of ubiquitination at K557 (P = 0.1435); Gain of helix (P = 0.1736)
17:44073917:T:C,P10636,S554P,0.182,Loss of phosphorylation at S554 (P = 0.0064); Gain of glycosylation at S554 (P = 0.0089); Gain of catalytic residue at P553 (P = 0.0211); Loss of MoRF binding (P = 0.0522); Gain of methylation at K557 (P = 0.0629)
17:44073917:T:G,P10636,S554A,0.126,Loss of phosphorylation at S554 (P = 0.0064); Gain of helix (P = 0.0225); Loss of loop (P = 0.0374); Gain of glycosylation at S552 (P = 0.1018); Loss of MoRF binding (P = 0.1299)
17:44073918:C:A,P10636,S554Y,0.264,Gain of catalytic residue at S554 (P = 0.0026); Gain of solvent accessibility (P = 0.039); Loss of ubiquitination at K557 (P = 0.0557); Gain of helix (P = 0.0854); Loss of methylation at K557 (P = 0.0919)
17:44073918:C:G,P10636,S554C,0.189,Loss of phosphorylation at S554 (P = 0.0064); Gain of catalytic residue at P553 (P = 0.0104); Loss of MoRF binding (P = 0.0735); Loss of ubiquitination at K557 (P = 0.0834); Loss of glycosylation at S555 (P = 0.0888)
17:44073918:C:T,P10636,S554F,0.216,Loss of phosphorylation at S554 (P = 0.0064); Loss of ubiquitination at K557 (P = 0.0524); Loss of MoRF binding (P = 0.0841); Gain of helix (P = 0.0854); Gain of solvent accessibility (P = 0.0854)
17:44073920:T:A,P10636,S555T,0.081,Gain of glycosylation at S554 (P = 0.0687); Gain of methylation at K557 (P = 0.0988); Loss of ubiquitination at K557 (P = 0.1231); Loss of MoRF binding (P = 0.1405); Loss of helix (P = 0.1706)
17:44073920:T:C,P10636,S555P,0.138,Loss of phosphorylation at S555 (P = 0.014); Loss of MoRF binding (P = 0.05); Loss of helix (P = 0.0558); Gain of methylation at K557 (P = 0.0684); Gain of loop (P = 0.0851)
17:44073920:T:G,P10636,S555A,0.132,Loss of phosphorylation at S555 (P = 0.014); Loss of glycosylation at S555 (P = 0.0224); Loss of stability (P = 0.0921); Loss of methylation at K551 (P = 0.1125); Loss of MoRF binding (P = 0.1226)
17:44073921:C:A,P10636,S555Y,0.237,Gain of catalytic residue at S555 (P = 0.0141); Loss of glycosylation at S555 (P = 0.0224); Loss of ubiquitination at K557 (P = 0.0524); Gain of methylation at K551 (P = 0.0599); Loss of MoRF binding (P = 0.1057)
17:44073921:C:G,P10636,S555C,0.196,Loss of phosphorylation at S555 (P = 0.014); Loss of glycosylation at S555 (P = 0.0224); Gain of catalytic residue at S555 (P = 0.0463); Loss of MoRF binding (P = 0.0726); Loss of ubiquitination at K557 (P = 0.0834)
17:44073921:C:T,P10636,S555F,0.174,Loss of phosphorylation at S555 (P = 0.014); Loss of glycosylation at S555 (P = 0.0224); Loss of helix (P = 0.0376); Loss of ubiquitination at K557 (P = 0.0524); Loss of MoRF binding (P = 0.0817)
17:44073923:G:C,P10636,A556P,0.19,Gain of glycosylation at A556 (P = 0.0016); Loss of helix (P = 0.0138); Gain of loop (P = 0.024); Loss of MoRF binding (P = 0.0429); Gain of methylation at K557 (P = 0.0546)
17:44073923:G:T,P10636,A556S,0.201,Gain of phosphorylation at A556 (P = 0.0067); Loss of helix (P = 0.0376); Gain of glycosylation at A556 (P = 0.0492); Gain of loop (P = 0.0851); Gain of methylation at K551 (P = 0.0891)
17:44073924:C:A,P10636,A556D,0.213,Loss of MoRF binding (P = 0.0265); Loss of helix (P = 0.0376); Gain of loop (P = 0.0435); Gain of ubiquitination at K557 (P = 0.0671); Loss of glycosylation at S555 (P = 0.0677)
17:44073924:C:G,P10636,A556G,0.156,Loss of helix (P = 0.0237); Gain of loop (P = 0.0435); Gain of glycosylation at S555 (P = 0.0703); Loss of stability (P = 0.0998); Loss of ubiquitination at K557 (P = 0.1231)
17:44073926:A:C,P10636,K557Q,0.199,Loss of ubiquitination at K557 (P = 0.0218); Loss of methylation at K557 (P = 0.0264); Loss of MoRF binding (P = 0.048); Loss of glycosylation at S555 (P = 0.093); Gain of helix (P = 0.1736)
17:44073926:A:G,P10636,K557E,0.227,Loss of MoRF binding (P = 0.0038); Loss of ubiquitination at K557 (P = 0.0218); Loss of methylation at K557 (P = 0.0264); Loss of glycosylation at S555 (P = 0.1079); Loss of helix (P = 0.1299)
17:44073927:A:C,P10636,K557T,0.27,Gain of glycosylation at K557 (P = 0.0165); Loss of ubiquitination at K557 (P = 0.0218); Gain of phosphorylation at K557 (P = 0.0218); Loss of methylation at K557 (P = 0.0264); Loss of MoRF binding (P = 0.0481)
17:44073927:A:G,P10636,K557R,0.17,Loss of ubiquitination at K557 (P = 0.0218); Gain of methylation at K557 (P = 0.0425); Gain of glycosylation at S558 (P = 0.0899); Gain of MoRF binding (P = 0.0916); Gain of helix (P = 0.1736)
17:44073927:A:T,P10636,K557M,0.176,Loss of ubiquitination at K557 (P = 0.0218); Loss of methylation at K557 (P = 0.0264); Loss of MoRF binding (P = 0.0746); Loss of glycosylation at S555 (P = 0.1385); Gain of helix (P = 0.1736)
17:44073928:G:C,P10636,K557N,0.208,Loss of ubiquitination at K557 (P = 0.0218); Loss of methylation at K557 (P = 0.0264); Loss of MoRF binding (P = 0.0473); Loss of helix (P = 0.0558); Loss of glycosylation at S555 (P = 0.09)
17:44073928:G:T,P10636,K557N,0.208,Loss of ubiquitination at K557 (P = 0.0218); Loss of methylation at K557 (P = 0.0264); Loss of MoRF binding (P = 0.0473); Loss of helix (P = 0.0558); Loss of glycosylation at S555 (P = 0.09)
17:44073929:A:C,P10636,S558R,0.32,Loss of phosphorylation at S558 (P = 0.0113); Gain of MoRF binding (P = 0.0186); Gain of helix (P = 0.0199); Loss of loop (P = 0.0288); Gain of solvent accessibility (P = 0.0367)
17:44073929:A:G,P10636,S558G,0.238,Loss of phosphorylation at S558 (P = 0.0113); Gain of relative solvent accessibility (P = 0.0275); Gain of methylation at R559 (P = 0.0415); Loss of glycosylation at S558 (P = 0.0419); Gain of helix (P = 0.0854)
17:44073929:A:T,P10636,S558C,0.34,Loss of phosphorylation at S558 (P = 0.0113); Gain of methylation at K557 (P = 0.0202); Loss of glycosylation at S558 (P = 0.0419); Loss of MoRF binding (P = 0.0712); Loss of loop (P = 0.0804)
17:44073930:G:A,P10636,S558N,0.229,Loss of phosphorylation at S558 (P = 0.0113); Loss of glycosylation at S558 (P = 0.0419); Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Gain of methylation at K557 (P = 0.0871)
17:44073930:G:C,P10636,S558T,0.214,Gain of methylation at K557 (P = 0.0829); Loss of ubiquitination at K557 (P = 0.1079); Loss of MoRF binding (P = 0.1305); Gain of helix (P = 0.132); Gain of glycosylation at S555 (P = 0.1746)
17:44073930:G:T,P10636,S558I,0.363,Loss of phosphorylation at S558 (P = 0.0113); Loss of glycosylation at S558 (P = 0.0419); Gain of sheet (P = 0.0507); Loss of helix (P = 0.0558); Loss of ubiquitination at K557 (P = 0.064)
17:44073931:C:A,P10636,S558R,0.32,Loss of phosphorylation at S558 (P = 0.0113); Gain of MoRF binding (P = 0.0186); Gain of helix (P = 0.0199); Loss of loop (P = 0.0288); Gain of solvent accessibility (P = 0.0367)
17:44073931:C:G,P10636,S558R,0.32,Loss of phosphorylation at S558 (P = 0.0113); Gain of MoRF binding (P = 0.0186); Gain of helix (P = 0.0199); Loss of loop (P = 0.0288); Gain of solvent accessibility (P = 0.0367)
17:44073932:C:A,P10636,R559S,0.283,Gain of phosphorylation at R559 (P = 0.0147); Loss of MoRF binding (P = 0.0227); Gain of glycosylation at R559 (P = 0.03); Loss of methylation at R559 (P = 0.0431); Gain of ubiquitination at K557 (P = 0.0671)
17:44073932:C:G,P10636,R559G,0.233,Loss of MoRF binding (P = 0.0235); Loss of methylation at R559 (P = 0.0431); Gain of glycosylation at S558 (P = 0.0437); Loss of helix (P = 0.0558); Gain of ubiquitination at K557 (P = 0.0619)
17:44073932:C:T,P10636,R559C,0.256,Loss of MoRF binding (P = 0.0072); Gain of catalytic residue at L560 (P = 0.0178); Loss of helix (P = 0.0376); Loss of methylation at R559 (P = 0.0431); Gain of ubiquitination at K557 (P = 0.0804)
17:44073933:G:A,P10636,R559H,0.218,Loss of MoRF binding (P = 0.0173); Loss of methylation at R559 (P = 0.0431); Gain of ubiquitination at K557 (P = 0.0671); Loss of phosphorylation at T562 (P = 0.0934); Loss of helix (P = 0.1299)
17:44073933:G:C,P10636,R559P,0.283,Loss of MoRF binding (P = 0.0036); Gain of glycosylation at R559 (P = 0.018); Loss of methylation at R559 (P = 0.0431); Loss of helix (P = 0.0444); Gain of ubiquitination at K557 (P = 0.0671)
17:44073933:G:T,P10636,R559L,0.294,Loss of MoRF binding (P = 0.0181); Loss of methylation at R559 (P = 0.0431); Loss of phosphorylation at T562 (P = 0.0566); Gain of ubiquitination at K557 (P = 0.0577); Loss of glycosylation at S555 (P = 0.1185)
17:44073935:C:A,P10636,L560M,0.441,Gain of methylation at K557 (P = 0.0722); Gain of MoRF binding (P = 0.0765); Loss of ubiquitination at K557 (P = 0.0834); Loss of phosphorylation at T562 (P = 0.1107); Gain of glycosylation at S558 (P = 0.1857)
17:44073935:C:G,P10636,L560V,0.441,Gain of methylation at K557 (P = 0.062); Gain of MoRF binding (P = 0.0851); Loss of loop (P = 0.0986); Loss of ubiquitination at K557 (P = 0.1231); Loss of helix (P = 0.1299)
17:44073936:T:A,P10636,L560Q,0.562,Gain of solvent accessibility (P = 0.0137); Gain of relative solvent accessibility (P = 0.0215); Loss of stability (P = 0.0536); Gain of methylation at K557 (P = 0.059); Loss of MoRF binding (P = 0.0925)
17:44073936:T:C,P10636,L560P,0.582,Loss of stability (P = 0.0213); Gain of relative solvent accessibility (P = 0.0215); Loss of MoRF binding (P = 0.0452); Gain of solvent accessibility (P = 0.0503); Gain of glycosylation at L560 (P = 0.051)
17:44073936:T:G,P10636,L560R,0.637,Gain of solvent accessibility (P = 0.0055); Gain of relative solvent accessibility (P = 0.0215); Gain of MoRF binding (P = 0.0285); Gain of methylation at K557 (P = 0.044); Gain of catalytic residue at L560 (P = 0.05)
17:44073938:C:A,P10636,Q561K,0.478,Gain of relative solvent accessibility (P = 0.0289); Gain of MoRF binding (P = 0.03); Gain of solvent accessibility (P = 0.0306); Gain of ubiquitination at Q561 (P = 0.0325); Gain of methylation at R559 (P = 0.0732)
17:44073938:C:G,P10636,Q561E,0.473,Gain of relative solvent accessibility (P = 0.0289); Gain of solvent accessibility (P = 0.0365); Loss of MoRF binding (P = 0.0393); Gain of ubiquitination at K557 (P = 0.0804); Gain of methylation at R559 (P = 0.0918)
17:44073939:A:C,P10636,Q561P,0.42,Gain of relative solvent accessibility (P = 0.0289); Gain of glycosylation at Q561 (P = 0.0318); Loss of MoRF binding (P = 0.0488); Gain of methylation at K557 (P = 0.0993); Gain of solvent accessibility (P = 0.1116)
17:44073939:A:G,P10636,Q561R,0.481,Gain of MoRF binding (P = 0.0151); Gain of methylation at Q561 (P = 0.0182); Gain of solvent accessibility (P = 0.0411); Gain of relative solvent accessibility (P = 0.09); Loss of ubiquitination at K557 (P = 0.1079)
17:44073939:A:T,P10636,Q561L,0.417,Loss of MoRF binding (P = 0.0982); Loss of ubiquitination at K557 (P = 0.1231); Loss of methylation at K557 (P = 0.136); Gain of sheet (P = 0.1451); Loss of helix (P = 0.1706)
17:44073940:G:C,P10636,Q561H,0.39,Gain of methylation at R559 (P = 0.0562); Loss of MoRF binding (P = 0.0994); Loss of ubiquitination at K557 (P = 0.1231); Gain of glycosylation at S558 (P = 0.1363); Gain of relative solvent accessibility (P = 0.1571)
17:44073940:G:T,P10636,Q561H,0.39,Gain of methylation at R559 (P = 0.0562); Loss of MoRF binding (P = 0.0994); Loss of ubiquitination at K557 (P = 0.1231); Gain of glycosylation at S558 (P = 0.1363); Gain of relative solvent accessibility (P = 0.1571)
17:44073941:A:C,P10636,T562P,0.322,Loss of phosphorylation at T562 (P = 0.0238); Loss of MoRF binding (P = 0.0535); Loss of methylation at K557 (P = 0.1042); Loss of ubiquitination at K557 (P = 0.1079); Gain of relative solvent accessibility (P = 0.1571)
17:44073941:A:G,P10636,T562A,0.206,Loss of phosphorylation at T562 (P = 0.0238); Loss of methylation at K557 (P = 0.0598); Gain of helix (P = 0.062); Loss of glycosylation at T562 (P = 0.062); Loss of MoRF binding (P = 0.1151)
17:44073941:A:T,P10636,T562S,0.249,Loss of methylation at K557 (P = 0.1078); Loss of ubiquitination at K557 (P = 0.1231); Gain of MoRF binding (P = 0.1268); Gain of glycosylation at T562 (P = 0.1721); Gain of helix (P = 0.1736)
17:44073942:C:A,P10636,T562K,0.381,Gain of MoRF binding (P = 0.018); Loss of phosphorylation at T562 (P = 0.0238); Gain of ubiquitination at T562 (P = 0.0408); Gain of methylation at T562 (P = 0.0458); Gain of helix (P = 0.062)
17:44073942:C:G,P10636,T562R,0.361,Gain of MoRF binding (P = 0.0074); Loss of phosphorylation at T562 (P = 0.0238); Gain of methylation at T562 (P = 0.0346); Gain of helix (P = 0.0496); Loss of glycosylation at T562 (P = 0.062)
17:44073942:C:T,P10636,T562I,0.304,Loss of phosphorylation at T562 (P = 0.0238); Gain of catalytic residue at P564 (P = 0.0309); Gain of sheet (P = 0.0477); Loss of glycosylation at T562 (P = 0.062); Loss of loop (P = 0.0986)
17:44073944:G:A,P10636,A563T,0.313,Gain of glycosylation at A563 (P = 0.0023); Gain of phosphorylation at A563 (P = 0.0254); Loss of MoRF binding (P = 0.1123); Loss of stability (P = 0.119); Loss of methylation at R559 (P = 0.2173)
17:44073944:G:C,P10636,A563P,0.482,Gain of catalytic residue at A563 (P = 0.0082); Loss of MoRF binding (P = 0.0534); Gain of glycosylation at A563 (P = 0.0537); Gain of relative solvent accessibility (P = 0.0905); Loss of stability (P = 0.1314)
17:44073944:G:T,P10636,A563S,0.398,Gain of phosphorylation at A563 (P = 0.0143); Gain of glycosylation at A563 (P = 0.0232); Loss of stability (P = 0.0895); Loss of MoRF binding (P = 0.1363); Gain of methylation at R559 (P = 0.2106)
17:44073945:C:A,P10636,A563D,0.432,Gain of relative solvent accessibility (P = 0.0098); Gain of solvent accessibility (P = 0.0109); Loss of MoRF binding (P = 0.0441); Loss of stability (P = 0.1648); Loss of methylation at R559 (P = 0.1686)
17:44073945:C:G,P10636,A563G,0.427,Loss of stability (P = 0.0098); Loss of MoRF binding (P = 0.1295); Loss of glycosylation at S558 (P = 0.1699); Gain of methylation at R559 (P = 0.1871); Gain of catalytic residue at A563 (P = 0.2262)
17:44073945:C:T,P10636,A563V,0.341,Gain of catalytic residue at A563 (P = 0.009); Gain of MoRF binding (P = 0.1008); Loss of glycosylation at S558 (P = 0.1864); Gain of sheet (P = 0.1945); Loss of methylation at R559 (P = 0.2083)
17:44073947:C:A,P10636,P564T,0.266,Gain of MoRF binding (P = 0.0377); Gain of glycosylation at P564 (P = 0.0449); Loss of helix (P = 0.0821); Gain of loop (P = 0.1073); Loss of methylation at R559 (P = 0.2057)
17:44073947:C:G,P10636,P564A,0.324,Gain of MoRF binding (P = 0.0354); Loss of helix (P = 0.0821); Gain of relative solvent accessibility (P = 0.1571); Loss of methylation at R559 (P = 0.2129); Loss of phosphorylation at T562 (P = 0.2264)
17:44073947:C:T,P10636,P564S,0.292,Gain of MoRF binding (P = 0.0289); Gain of phosphorylation at P564 (P = 0.0382); Loss of helix (P = 0.0821); Gain of methylation at R559 (P = 0.2188); Gain of loop (P = 0.2754)
17:44073948:C:A,P10636,P564H,0.279,Gain of MoRF binding (P = 0.0445); Loss of helix (P = 0.0821); Gain of glycosylation at T562 (P = 0.1348); Loss of phosphorylation at T562 (P = 0.1803); Gain of solvent accessibility (P = 0.204)
17:44073948:C:G,P10636,P564R,0.372,Gain of MoRF binding (P = 6e-04); Gain of solvent accessibility (P = 0.0411); Gain of catalytic residue at P564 (P = 0.0704); Loss of helix (P = 0.0821); Gain of methylation at R559 (P = 0.1586)
17:44073948:C:T,P10636,P564L,0.364,Gain of MoRF binding (P = 0.0465); Loss of helix (P = 0.0821); Loss of phosphorylation at T562 (P = 0.1034); Loss of methylation at R559 (P = 0.1735); Loss of glycosylation at T562 (P = 0.2297)
17:44073950:G:C,P10636,V565L,0.367,Loss of MoRF binding (P = 0.0915); Gain of glycosylation at P566 (P = 0.1073); Gain of catalytic residue at V565 (P = 0.1945); Loss of phosphorylation at T562 (P = 0.3858); Loss of helix (P = 0.3949)
17:44073950:G:T,P10636,V565L,0.367,Loss of MoRF binding (P = 0.0915); Gain of glycosylation at P566 (P = 0.1073); Gain of catalytic residue at V565 (P = 0.1945); Loss of phosphorylation at T562 (P = 0.3858); Loss of helix (P = 0.3949)
17:44073951:T:A,P10636,V565E,0.368,Gain of solvent accessibility (P = 0.0078); Gain of relative solvent accessibility (P = 0.0166); Loss of MoRF binding (P = 0.0564); Gain of glycosylation at P564 (P = 0.1334); Loss of loop (P = 0.2237)
17:44073951:T:C,P10636,V565A,0.298,Gain of glycosylation at P564 (P = 0.0559); Loss of MoRF binding (P = 0.1216); Loss of loop (P = 0.2237); Gain of relative solvent accessibility (P = 0.2751); Gain of phosphorylation at T562 (P = 0.3441)
17:44073951:T:G,P10636,V565G,0.334,Gain of glycosylation at P566 (P = 0.1115); Loss of MoRF binding (P = 0.1203); Loss of stability (P = 0.1283); Gain of catalytic residue at V565 (P = 0.1459); Gain of relative solvent accessibility (P = 0.1571)
17:44073953:C:A,P10636,P566T,0.323,Gain of MoRF binding (P = 0.037); Gain of phosphorylation at P566 (P = 0.0534); Gain of relative solvent accessibility (P = 0.0999); Loss of methylation at K571 (P = 0.1398); Gain of solvent accessibility (P = 0.1846)
17:44073953:C:G,P10636,P566A,0.32,Gain of MoRF binding (P = 0.0341); Loss of methylation at K571 (P = 0.0729); Loss of glycosylation at P566 (P = 0.0731); Gain of relative solvent accessibility (P = 0.0999); Loss of ubiquitination at K571 (P = 0.2372)
17:44073953:C:T,P10636,P566S,0.295,Gain of phosphorylation at P566 (P = 0.0248); Gain of MoRF binding (P = 0.0282); Gain of relative solvent accessibility (P = 0.0999); Loss of methylation at K571 (P = 0.1308); Loss of glycosylation at P566 (P = 0.1441)
17:44073954:C:A,P10636,P566H,0.34,Gain of MoRF binding (P = 0.0457); Loss of glycosylation at P566 (P = 0.0731); Loss of methylation at K571 (P = 0.0757); Gain of solvent accessibility (P = 0.08); Gain of relative solvent accessibility (P = 0.0999)
17:44073954:C:G,P10636,P566R,0.392,Gain of MoRF binding (P = 6e-04); Gain of methylation at P566 (P = 0.0227); Gain of solvent accessibility (P = 0.0246); Loss of glycosylation at P566 (P = 0.0731); Gain of relative solvent accessibility (P = 0.0999)
17:44073954:C:T,P10636,P566L,0.382,Gain of MoRF binding (P = 0.0461); Loss of methylation at K571 (P = 0.0678); Loss of glycosylation at P566 (P = 0.0731); Loss of ubiquitination at K571 (P = 0.0828); Gain of relative solvent accessibility (P = 0.2363)
17:44073956:A:C,P10636,M567L,0.392,Loss of methylation at K571 (P = 0.0655); Loss of MoRF binding (P = 0.0858); Loss of helix (P = 0.1706); Loss of ubiquitination at K571 (P = 0.212); Gain of glycosylation at T562 (P = 0.2587)
17:44073956:A:G,P10636,M567V,0.435,Loss of MoRF binding (P = 0.1145); Loss of methylation at K571 (P = 0.1266); Gain of relative solvent accessibility (P = 0.1894); Gain of glycosylation at T562 (P = 0.2253); Loss of ubiquitination at K571 (P = 0.2372)
17:44073956:A:T,P10636,M567L,0.392,Loss of methylation at K571 (P = 0.0655); Loss of MoRF binding (P = 0.0858); Loss of helix (P = 0.1706); Loss of ubiquitination at K571 (P = 0.212); Gain of glycosylation at T562 (P = 0.2587)
17:44073957:T:A,P10636,M567K,0.52,Gain of ubiquitination at M567 (P = 0.0325); Gain of MoRF binding (P = 0.0472); Gain of glycosylation at P566 (P = 0.0564); Gain of relative solvent accessibility (P = 0.1012); Gain of solvent accessibility (P = 0.1185)
17:44073957:T:C,P10636,M567T,0.464,Gain of glycosylation at M567 (P = 0.0069); Gain of phosphorylation at M567 (P = 0.0148); Loss of MoRF binding (P = 0.0913); Gain of methylation at K571 (P = 0.1009); Gain of relative solvent accessibility (P = 0.1012)
17:44073957:T:G,P10636,M567R,0.539,Gain of MoRF binding (P = 0.0198); Gain of methylation at M567 (P = 0.0294); Loss of ubiquitination at K571 (P = 0.0563); Gain of solvent accessibility (P = 0.08); Gain of relative solvent accessibility (P = 0.1012)
17:44073958:G:A,P10636,M567I,0.364,Loss of MoRF binding (P = 0.1053); Loss of glycosylation at P566 (P = 0.1414); Loss of methylation at K571 (P = 0.1464); Gain of relative solvent accessibility (P = 0.1894); Loss of ubiquitination at K571 (P = 0.212)
17:44073958:G:C,P10636,M567I,0.364,Loss of MoRF binding (P = 0.1053); Loss of glycosylation at P566 (P = 0.1414); Loss of methylation at K571 (P = 0.1464); Gain of relative solvent accessibility (P = 0.1894); Loss of ubiquitination at K571 (P = 0.212)
17:44073958:G:T,P10636,M567I,0.364,Loss of MoRF binding (P = 0.1053); Loss of glycosylation at P566 (P = 0.1414); Loss of methylation at K571 (P = 0.1464); Gain of relative solvent accessibility (P = 0.1894); Loss of ubiquitination at K571 (P = 0.212)
17:44073959:C:A,P10636,P568T,0.452,Gain of phosphorylation at P568 (P = 0.0305); Gain of MoRF binding (P = 0.036); Loss of methylation at K571 (P = 0.1025); Loss of stability (P = 0.1146); Gain of helix (P = 0.1736)
17:44073959:C:G,P10636,P568A,0.466,Gain of MoRF binding (P = 0.0381); Gain of helix (P = 0.0425); Loss of loop (P = 0.0512); Loss of methylation at K571 (P = 0.0693); Loss of glycosylation at P568 (P = 0.1265)
17:44073959:C:T,P10636,P568S,0.439,Gain of MoRF binding (P = 0.0284); Gain of phosphorylation at P568 (P = 0.0449); Gain of helix (P = 0.062); Loss of methylation at K571 (P = 0.0818); Loss of loop (P = 0.0986)
17:44073960:C:A,P10636,P568Q,0.47,Gain of MoRF binding (P = 0.0243); Gain of helix (P = 0.0325); Loss of loop (P = 0.0374); Loss of glycosylation at P568 (P = 0.1265); Loss of methylation at K571 (P = 0.1426)
17:44073960:C:G,P10636,P568R,0.476,Gain of MoRF binding (P = 4e-04); Loss of loop (P = 0.0374); Gain of solvent accessibility (P = 0.0411); Gain of helix (P = 0.0425); Gain of methylation at P568 (P = 0.0457)
17:44073960:C:T,P10636,P568L,0.483,Gain of MoRF binding (P = 0.0558); Loss of methylation at K571 (P = 0.0592); Gain of helix (P = 0.0854); Loss of ubiquitination at K571 (P = 0.1022); Gain of catalytic residue at P568 (P = 0.1028)
17:44073962:G:A,P10636,D569N,0.482,Gain of MoRF binding (P = 0.0284); Loss of ubiquitination at K574 (P = 0.0286); Gain of methylation at K571 (P = 0.063); Loss of helix (P = 0.079); Gain of relative solvent accessibility (P = 0.1571)
17:44073962:G:C,P10636,D569H,0.516,Loss of ubiquitination at K574 (P = 0.0297); Gain of MoRF binding (P = 0.0357); Gain of methylation at K571 (P = 0.0503); Loss of helix (P = 0.079); Loss of relative solvent accessibility (P = 0.3219)
17:44073962:G:T,P10636,D569Y,0.513,Loss of ubiquitination at K574 (P = 0.0304); Gain of MoRF binding (P = 0.0379); Gain of methylation at K571 (P = 0.0739); Loss of helix (P = 0.079); Gain of phosphorylation at D569 (P = 0.1315)
17:44073963:A:C,P10636,D569A,0.481,Gain of MoRF binding (P = 0.0244); Loss of ubiquitination at K574 (P = 0.0286); Gain of methylation at K571 (P = 0.0499); Gain of helix (P = 0.062); Loss of loop (P = 0.0986)
17:44073963:A:G,P10636,D569G,0.505,Gain of MoRF binding (P = 0.0273); Loss of ubiquitination at K574 (P = 0.0304); Loss of helix (P = 0.0444); Gain of methylation at K571 (P = 0.0505); Gain of loop (P = 0.1069)
17:44073963:A:T,P10636,D569V,0.532,Gain of MoRF binding (P = 0.0213); Loss of ubiquitination at K574 (P = 0.0304); Gain of methylation at K571 (P = 0.0377); Loss of helix (P = 0.079); Loss of solvent accessibility (P = 0.1744)
17:44073964:C:A,P10636,D569E,0.507,Gain of methylation at K571 (P = 0.074); Loss of helix (P = 0.079); Gain of solvent accessibility (P = 0.1014); Gain of relative solvent accessibility (P = 0.1571); Loss of MoRF binding (P = 0.1594)
17:44073964:C:G,P10636,D569E,0.507,Gain of methylation at K571 (P = 0.074); Loss of helix (P = 0.079); Gain of solvent accessibility (P = 0.1014); Gain of relative solvent accessibility (P = 0.1571); Loss of MoRF binding (P = 0.1594)
17:44073965:C:A,P10636,L570M,0.603,Loss of methylation at K571 (P = 0.0388); Gain of MoRF binding (P = 0.0809); Loss of ubiquitination at K574 (P = 0.1403); Loss of helix (P = 0.1706); Loss of stability (P = 0.1935)
17:44073965:C:G,P10636,L570V,0.575,Gain of methylation at K571 (P = 0.0362); Loss of helix (P = 0.079); Gain of MoRF binding (P = 0.104); Loss of stability (P = 0.1495); Loss of ubiquitination at K574 (P = 0.1664)
17:44073966:T:A,P10636,L570Q,0.542,Loss of stability (P = 0.0351); Gain of methylation at K571 (P = 0.0446); Gain of relative solvent accessibility (P = 0.0507); Gain of solvent accessibility (P = 0.0584); Loss of helix (P = 0.079)
17:44073966:T:C,P10636,L570P,0.578,Loss of stability (P = 0.0199); Gain of relative solvent accessibility (P = 0.0507); Gain of methylation at K571 (P = 0.0528); Gain of glycosylation at L570 (P = 0.0626); Loss of MoRF binding (P = 0.0662)
17:44073966:T:G,P10636,L570R,0.612,Loss of stability (P = 0.023); Gain of solvent accessibility (P = 0.0261); Gain of MoRF binding (P = 0.0278); Loss of ubiquitination at K574 (P = 0.0286); Gain of methylation at K571 (P = 0.0386)
17:44073968:A:C,P10636,K571Q,0.443,Loss of ubiquitination at K571 (P = 0.0071); Loss of methylation at K571 (P = 0.0216); Loss of MoRF binding (P = 0.0682); Gain of helix (P = 0.132); Loss of loop (P = 0.2237)
17:44073968:A:G,P10636,K571E,0.46,Loss of ubiquitination at K571 (P = 0.0071); Loss of methylation at K571 (P = 0.0216); Loss of MoRF binding (P = 0.0246); Gain of helix (P = 0.062); Loss of loop (P = 0.0804)
17:44073969:A:C,P10636,K571T,0.444,Loss of ubiquitination at K571 (P = 0.0071); Loss of methylation at K571 (P = 0.0216); Loss of MoRF binding (P = 0.0596); Gain of phosphorylation at K571 (P = 0.0899); Gain of glycosylation at K571 (P = 0.095)
17:44073969:A:G,P10636,K571R,0.384,Loss of ubiquitination at K571 (P = 0.0071); Loss of methylation at K571 (P = 0.0301); Gain of MoRF binding (P = 0.0652); Gain of helix (P = 0.132); Loss of loop (P = 0.2237)
17:44073969:A:T,P10636,K571M,0.449,Loss of ubiquitination at K571 (P = 0.0071); Loss of methylation at K571 (P = 0.0216); Loss of MoRF binding (P = 0.0719); Gain of catalytic residue at K571 (P = 0.081); Gain of helix (P = 0.132)
17:44073970:G:C,P10636,K571N,0.453,Loss of ubiquitination at K571 (P = 0.0071); Loss of methylation at K571 (P = 0.0216); Loss of MoRF binding (P = 0.0613); Loss of solvent accessibility (P = 0.1177); Gain of glycosylation at S575 (P = 0.1488)
17:44073970:G:T,P10636,K571N,0.453,Loss of ubiquitination at K571 (P = 0.0071); Loss of methylation at K571 (P = 0.0216); Loss of MoRF binding (P = 0.0613); Loss of solvent accessibility (P = 0.1177); Gain of glycosylation at S575 (P = 0.1488)
17:44073971:A:C,P10636,N572H,0.397,Loss of ubiquitination at K574 (P = 0.0818); Gain of methylation at K571 (P = 0.1); Loss of catalytic residue at N572 (P = 0.1218); Loss of MoRF binding (P = 0.1286); Gain of helix (P = 0.1736)
17:44073971:A:G,P10636,N572D,0.436,Loss of MoRF binding (P = 0.0613); Loss of methylation at K571 (P = 0.0666); Gain of ubiquitination at K576 (P = 0.0747); Loss of catalytic residue at N572 (P = 0.0994); Gain of phosphorylation at S575 (P = 0.1107)
17:44073971:A:T,P10636,N572Y,0.422,Gain of phosphorylation at N572 (P = 0.0186); Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Loss of ubiquitination at K576 (P = 0.092); Loss of MoRF binding (P = 0.109)
17:44073972:A:C,P10636,N572T,0.409,Gain of glycosylation at N572 (P = 0.0217); Gain of phosphorylation at N572 (P = 0.0273); Gain of methylation at K571 (P = 0.0932); Loss of ubiquitination at K574 (P = 0.1403); Loss of MoRF binding (P = 0.1435)
17:44073972:A:G,P10636,N572S,0.264,Gain of phosphorylation at N572 (P = 0.0505); Gain of methylation at K571 (P = 0.0985); Loss of catalytic residue at N572 (P = 0.1058); Gain of glycosylation at N572 (P = 0.112); Loss of ubiquitination at K574 (P = 0.1403)
17:44073972:A:T,P10636,N572I,0.431,Gain of methylation at K571 (P = 0.0439); Loss of ubiquitination at K574 (P = 0.0724); Loss of loop (P = 0.0804); Loss of MoRF binding (P = 0.1235); Gain of catalytic residue at V573 (P = 0.1294)
17:44073973:T:A,P10636,N572K,0.379,Gain of ubiquitination at N572 (P = 0.0192); Gain of methylation at N572 (P = 0.0249); Gain of MoRF binding (P = 0.0285); Gain of solvent accessibility (P = 0.0854); Gain of phosphorylation at S575 (P = 0.0929)
17:44073973:T:G,P10636,N572K,0.379,Gain of ubiquitination at N572 (P = 0.0192); Gain of methylation at N572 (P = 0.0249); Gain of MoRF binding (P = 0.0285); Gain of solvent accessibility (P = 0.0854); Gain of phosphorylation at S575 (P = 0.0929)
17:44073974:G:A,P10636,V573I,0.7,Loss of methylation at K574 (P = 0.0641); Loss of ubiquitination at K574 (P = 0.0724); Loss of MoRF binding (P = 0.1415); Loss of glycosylation at S575 (P = 0.1441); Gain of helix (P = 0.1736)
17:44073974:G:C,P10636,V573L,0.731,Loss of methylation at K574 (P = 0.035); Loss of ubiquitination at K574 (P = 0.0954); Loss of MoRF binding (P = 0.1063); Loss of catalytic residue at K576 (P = 0.1805); Loss of glycosylation at S575 (P = 0.1887)
17:44073974:G:T,P10636,V573F,0.732,Loss of ubiquitination at K574 (P = 0.0642); Loss of MoRF binding (P = 0.0976); Gain of methylation at K571 (P = 0.1165); Loss of helix (P = 0.1706); Loss of glycosylation at S575 (P = 0.2023)
17:44073975:T:A,P10636,V573D,0.712,Loss of helix (P = 0.0304); Gain of loop (P = 0.0321); Loss of methylation at K574 (P = 0.0334); Loss of MoRF binding (P = 0.04); Loss of stability (P = 0.0594)
17:44073975:T:C,P10636,V573A,0.699,Loss of stability (P = 0.0055); Loss of helix (P = 0.0304); Gain of loop (P = 0.0321); Loss of methylation at K574 (P = 0.0407); Gain of ubiquitination at K576 (P = 0.1093)
17:44073975:T:G,P10636,V573G,0.687,Loss of stability (P = 0.0016); Loss of helix (P = 0.0304); Gain of loop (P = 0.0321); Loss of methylation at K574 (P = 0.0436); Loss of ubiquitination at K574 (P = 0.0818)
17:44073977:A:C,P10636,K574Q,0.395,Loss of methylation at K574 (P = 0.0097); Loss of ubiquitination at K574 (P = 0.0107); Loss of MoRF binding (P = 0.0707); Gain of glycosylation at S575 (P = 0.1448); Loss of catalytic residue at K574 (P = 0.2028)
17:44073977:A:G,P10636,K574E,0.41,Loss of methylation at K574 (P = 0.0097); Loss of ubiquitination at K574 (P = 0.0107); Loss of MoRF binding (P = 0.0219); Loss of helix (P = 0.079); Loss of catalytic residue at K574 (P = 0.1326)
17:44073978:A:C,P10636,K574T,0.601,Loss of methylation at K574 (P = 0.0097); Loss of ubiquitination at K574 (P = 0.0107); Gain of glycosylation at K574 (P = 0.0461); Loss of MoRF binding (P = 0.0659); Loss of helix (P = 0.079)
17:44073978:A:G,P10636,K574R,0.385,Loss of ubiquitination at K574 (P = 0.0107); Loss of methylation at K574 (P = 0.0149); Gain of MoRF binding (P = 0.0706); Gain of phosphorylation at S575 (P = 0.1461); Loss of glycosylation at S575 (P = 0.2151)
17:44073978:A:T,P10636,K574M,0.531,Loss of methylation at K574 (P = 0.0097); Loss of ubiquitination at K574 (P = 0.0107); Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Loss of MoRF binding (P = 0.0883)
17:44073979:G:C,P10636,K574N,0.46,Loss of methylation at K574 (P = 0.0097); Loss of ubiquitination at K574 (P = 0.0107); Loss of MoRF binding (P = 0.0636); Loss of helix (P = 0.1706); Gain of relative solvent accessibility (P = 0.1894)
17:44073979:G:T,P10636,K574N,0.46,Loss of methylation at K574 (P = 0.0097); Loss of ubiquitination at K574 (P = 0.0107); Loss of MoRF binding (P = 0.0636); Loss of helix (P = 0.1706); Gain of relative solvent accessibility (P = 0.1894)
17:44073980:T:A,P10636,S575T,0.449,Loss of glycosylation at S575 (P = 0.0452); Loss of stability (P = 0.0592); Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Gain of methylation at K571 (P = 0.0897)
17:44073980:T:C,P10636,S575P,0.468,Loss of glycosylation at S575 (P = 0.035); Loss of stability (P = 0.0402); Loss of MoRF binding (P = 0.0672); Loss of ubiquitination at K574 (P = 0.0724); Gain of methylation at K571 (P = 0.0874)
17:44073980:T:G,P10636,S575A,0.464,Loss of glycosylation at S575 (P = 0.0239); Gain of helix (P = 0.0325); Loss of loop (P = 0.0374); Loss of stability (P = 0.0394); Loss of ubiquitination at K574 (P = 0.0642)
17:44073981:C:A,P10636,S575Y,0.502,Loss of glycosylation at S575 (P = 0.0239); Gain of methylation at K571 (P = 0.04); Loss of ubiquitination at K576 (P = 0.0422); Gain of catalytic residue at L570 (P = 0.0495); Gain of helix (P = 0.062)
17:44073981:C:G,P10636,S575C,0.562,Loss of glycosylation at S575 (P = 0.0239); Loss of relative solvent accessibility (P = 0.0306); Gain of methylation at K576 (P = 0.0437); Loss of solvent accessibility (P = 0.0468); Loss of ubiquitination at K574 (P = 0.0468)
17:44073981:C:T,P10636,S575F,0.52,Loss of glycosylation at S575 (P = 0.0239); Loss of loop (P = 0.0512); Gain of helix (P = 0.062); Gain of methylation at K576 (P = 0.0638); Loss of ubiquitination at K574 (P = 0.0818)
17:44073983:A:C,P10636,K576Q,0.6,Loss of methylation at K576 (P = 0.0109); Loss of ubiquitination at K576 (P = 0.011); Loss of MoRF binding (P = 0.0689); Loss of glycosylation at S575 (P = 0.0693); Loss of catalytic residue at K576 (P = 0.1154)
17:44073983:A:G,P10636,K576E,0.614,Loss of methylation at K576 (P = 0.0109); Loss of ubiquitination at K576 (P = 0.011); Loss of MoRF binding (P = 0.0195); Loss of glycosylation at S575 (P = 0.0877); Loss of catalytic residue at K576 (P = 0.0971)
17:44073984:A:C,P10636,K576T,0.581,Loss of methylation at K576 (P = 0.0109); Loss of ubiquitination at K576 (P = 0.011); Loss of catalytic residue at K576 (P = 0.0419); Gain of loop (P = 0.0435); Loss of helix (P = 0.0444)
17:44073984:A:G,P10636,K576R,0.617,Loss of ubiquitination at K576 (P = 0.011); Loss of methylation at K576 (P = 0.0139); Gain of MoRF binding (P = 0.066); Gain of phosphorylation at S579 (P = 0.0801); Gain of glycosylation at S575 (P = 0.1369)
17:44073984:A:T,P10636,K576M,0.603,Loss of methylation at K576 (P = 0.0109); Loss of ubiquitination at K576 (P = 0.011); Loss of glycosylation at S575 (P = 0.0382); Loss of helix (P = 0.0444); Loss of MoRF binding (P = 0.084)
17:44073985:G:C,P10636,K576N,0.598,Loss of methylation at K576 (P = 0.0109); Loss of ubiquitination at K576 (P = 0.011); Gain of loop (P = 0.024); Loss of helix (P = 0.0444); Loss of MoRF binding (P = 0.0618)
17:44073985:G:T,P10636,K576N,0.598,Loss of methylation at K576 (P = 0.0109); Loss of ubiquitination at K576 (P = 0.011); Gain of loop (P = 0.024); Loss of helix (P = 0.0444); Loss of MoRF binding (P = 0.0618)
17:44073986:A:C,P10636,I577L,0.598,Loss of catalytic residue at I577 (P = 0.0599); Loss of methylation at K574 (P = 0.0643); Loss of ubiquitination at K574 (P = 0.1172); Loss of MoRF binding (P = 0.1197); Loss of glycosylation at S575 (P = 0.1238)
17:44073986:A:G,P10636,I577V,0.693,Loss of ubiquitination at K574 (P = 0.0954); Gain of methylation at K576 (P = 0.119); Gain of MoRF binding (P = 0.146); Loss of catalytic residue at I577 (P = 0.1702); Gain of phosphorylation at T580 (P = 0.1761)
17:44073986:A:T,P10636,I577F,0.635,Loss of ubiquitination at K574 (P = 0.0642); Loss of catalytic residue at I577 (P = 0.0829); Gain of methylation at K576 (P = 0.09); Loss of MoRF binding (P = 0.1067); Loss of glycosylation at S575 (P = 0.1531)
17:44073987:T:A,P10636,I577N,0.573,Gain of relative solvent accessibility (P = 0.005); Gain of solvent accessibility (P = 0.008); Loss of stability (P = 0.0279); Loss of catalytic residue at I577 (P = 0.0315); Gain of loop (P = 0.0435)
17:44073987:T:C,P10636,I577T,0.601,Loss of stability (P = 0.0133); Gain of relative solvent accessibility (P = 0.0166); Gain of solvent accessibility (P = 0.039); Gain of loop (P = 0.0435); Loss of ubiquitination at K574 (P = 0.058)
17:44073987:T:G,P10636,I577S,0.555,Gain of relative solvent accessibility (P = 0.0166); Loss of stability (P = 0.0305); Loss of catalytic residue at I577 (P = 0.0389); Gain of loop (P = 0.0435); Gain of phosphorylation at I577 (P = 0.0514)
17:44073988:C:G,P10636,I577M,0.603,Loss of methylation at K576 (P = 0.0244); Loss of ubiquitination at K574 (P = 0.058); Gain of catalytic residue at V573 (P = 0.089); Gain of MoRF binding (P = 0.0945); Gain of loop (P = 0.1069)
17:44073989:G:A,P10636,G578S,0.603,Gain of phosphorylation at G578 (P = 0.0528); Loss of glycosylation at S575 (P = 0.0935); Loss of methylation at K576 (P = 0.1235); Gain of MoRF binding (P = 0.1244); Loss of catalytic residue at I577 (P = 0.1433)
17:44073989:G:C,P10636,G578R,0.716,Gain of MoRF binding (P = 0.0037); Loss of ubiquitination at K576 (P = 0.0304); Gain of solvent accessibility (P = 0.0674); Gain of phosphorylation at T580 (P = 0.0823); Loss of catalytic residue at I577 (P = 0.1117)
17:44073989:G:T,P10636,G578C,0.649,Gain of sheet (P = 0.0266); Loss of loop (P = 0.0512); Loss of catalytic residue at I577 (P = 0.0843); Loss of glycosylation at S575 (P = 0.0888); Loss of MoRF binding (P = 0.09)
17:44073990:G:A,P10636,G578D,0.695,Loss of methylation at K576 (P = 0.0645); Loss of MoRF binding (P = 0.0748); Loss of glycosylation at S575 (P = 0.0749); Gain of ubiquitination at K576 (P = 0.0805); Gain of solvent accessibility (P = 0.1045)
17:44073990:G:C,P10636,G578A,0.663,Gain of ubiquitination at K576 (P = 0.0964); Loss of catalytic residue at I577 (P = 0.1114); Loss of loop (P = 0.1242); Loss of glycosylation at S575 (P = 0.1322); Gain of MoRF binding (P = 0.1471)
17:44073990:G:T,P10636,G578V,0.599,Gain of sheet (P = 0.0125); Loss of loop (P = 0.0203); Loss of catalytic residue at I577 (P = 0.0741); Loss of glycosylation at S575 (P = 0.1127); Gain of MoRF binding (P = 0.1294)
17:44073992:T:A,P10636,S579T,0.63,Gain of relative solvent accessibility (P = 0.0479); Loss of ubiquitination at K574 (P = 0.0818); Gain of solvent accessibility (P = 0.0917); Gain of glycosylation at S579 (P = 0.1118); Loss of MoRF binding (P = 0.1408)
17:44073992:T:C,P10636,S579P,0.67,Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0256); Gain of loop (P = 0.0435); Loss of MoRF binding (P = 0.0673); Loss of ubiquitination at K574 (P = 0.0724)
17:44073992:T:G,P10636,S579A,0.636,Gain of relative solvent accessibility (P = 0.0479); Loss of ubiquitination at K574 (P = 0.0642); Loss of methylation at K584 (P = 0.0716); Loss of phosphorylation at S579 (P = 0.1109); Gain of solvent accessibility (P = 0.154)
17:44073993:C:A,P10636,S579Y,0.657,Loss of ubiquitination at K576 (P = 0.0566); Gain of phosphorylation at S579 (P = 0.0669); Gain of solvent accessibility (P = 0.0739); Gain of relative solvent accessibility (P = 0.09); Loss of MoRF binding (P = 0.1187)
17:44073993:C:G,P10636,S579C,0.753,Loss of ubiquitination at K574 (P = 0.058); Loss of MoRF binding (P = 0.0833); Loss of methylation at K584 (P = 0.1014); Loss of phosphorylation at S579 (P = 0.1109); Loss of glycosylation at S575 (P = 0.2344)
17:44073993:C:T,P10636,S579F,0.702,Gain of loop (P = 0.0435); Loss of ubiquitination at K576 (P = 0.0705); Gain of catalytic residue at S579 (P = 0.0865); Loss of glycosylation at S575 (P = 0.0907); Loss of methylation at K584 (P = 0.0977)
17:44073995:A:C,P10636,T580P,0.361,Gain of relative solvent accessibility (P = 0.0166); Gain of solvent accessibility (P = 0.0421); Gain of loop (P = 0.0435); Loss of phosphorylation at T580 (P = 0.0702); Loss of MoRF binding (P = 0.0728)
17:44073995:A:G,P10636,T580A,0.29,Gain of loop (P = 0.0435); Gain of relative solvent accessibility (P = 0.0479); Loss of methylation at K584 (P = 0.0665); Loss of phosphorylation at T580 (P = 0.0702); Gain of MoRF binding (P = 0.1096)
17:44073995:A:T,P10636,T580S,0.251,Gain of relative solvent accessibility (P = 0.0479); Loss of ubiquitination at K584 (P = 0.1079); Gain of phosphorylation at S575 (P = 0.1144); Gain of solvent accessibility (P = 0.1154); Loss of methylation at K576 (P = 0.1186)
17:44073996:C:A,P10636,T580N,0.275,Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0638); Loss of phosphorylation at T580 (P = 0.0702); Loss of ubiquitination at K584 (P = 0.0949); Loss of methylation at K584 (P = 0.109)
17:44073996:C:G,P10636,T580S,0.251,Gain of relative solvent accessibility (P = 0.0479); Loss of ubiquitination at K584 (P = 0.1079); Gain of phosphorylation at S575 (P = 0.1144); Gain of solvent accessibility (P = 0.1154); Loss of methylation at K576 (P = 0.1186)
17:44073996:C:T,P10636,T580I,0.342,Gain of loop (P = 0.0435); Loss of phosphorylation at T580 (P = 0.0702); Gain of MoRF binding (P = 0.0935); Loss of methylation at K584 (P = 0.1307); Loss of ubiquitination at K584 (P = 0.1435)
17:44073998:G:A,P10636,E581K,0.421,Gain of MoRF binding (P = 0.0013); Gain of methylation at E581 (P = 0.0101); Loss of ubiquitination at K576 (P = 0.0261); Gain of glycosylation at E581 (P = 0.0859); Gain of phosphorylation at S579 (P = 0.1134)
17:44073998:G:C,P10636,E581Q,0.37,Gain of MoRF binding (P = 0.0166); Loss of ubiquitination at K576 (P = 0.0286); Gain of methylation at K584 (P = 0.072); Gain of catalytic residue at S579 (P = 0.1648); Gain of helix (P = 0.1736)
17:44073999:A:C,P10636,E581A,0.411,Gain of MoRF binding (P = 0.0158); Loss of ubiquitination at K576 (P = 0.0286); Gain of glycosylation at T580 (P = 0.0735); Loss of methylation at K584 (P = 0.0954); Gain of catalytic residue at S579 (P = 0.1179)
17:44073999:A:G,P10636,E581G,0.401,Gain of MoRF binding (P = 0.0206); Loss of ubiquitination at K576 (P = 0.0286); Gain of catalytic residue at S579 (P = 0.0565); Loss of solvent accessibility (P = 0.0769); Loss of stability (P = 0.1149)
17:44073999:A:T,P10636,E581V,0.439,Gain of MoRF binding (P = 0.0103); Gain of sheet (P = 0.0266); Loss of ubiquitination at K576 (P = 0.0297); Loss of loop (P = 0.0374); Gain of glycosylation at T580 (P = 0.0662)
17:44074000:G:C,P10636,E581D,0.264,Gain of MoRF binding (P = 0.1029); Loss of methylation at K584 (P = 0.1033); Gain of ubiquitination at K584 (P = 0.123); Gain of phosphorylation at T580 (P = 0.172); Gain of helix (P = 0.1736)
17:44074000:G:T,P10636,E581D,0.264,Gain of MoRF binding (P = 0.1029); Loss of methylation at K584 (P = 0.1033); Gain of ubiquitination at K584 (P = 0.123); Gain of phosphorylation at T580 (P = 0.172); Gain of helix (P = 0.1736)
17:44074001:A:C,P10636,N582H,0.657,Loss of ubiquitination at K584 (P = 0.0834); Loss of stability (P = 0.1163); Loss of MoRF binding (P = 0.1256); Gain of methylation at K584 (P = 0.1468); Gain of glycosylation at K584 (P = 0.2275)
17:44074001:A:G,P10636,N582D,0.682,Gain of ubiquitination at K584 (P = 0.0268); Loss of MoRF binding (P = 0.0634); Loss of methylation at K584 (P = 0.0709); Gain of phosphorylation at T580 (P = 0.0929); Gain of catalytic residue at N582 (P = 0.1694)
17:44074001:A:T,P10636,N582Y,0.66,Gain of phosphorylation at N582 (P = 0.0187); Gain of sheet (P = 0.0477); Loss of loop (P = 0.0986); Loss of methylation at K584 (P = 0.1099); Gain of ubiquitination at K584 (P = 0.123)
17:44074002:A:C,P10636,N582T,0.648,Loss of ubiquitination at K584 (P = 0.0834); Gain of methylation at K584 (P = 0.137); Gain of phosphorylation at N582 (P = 0.1394); Loss of MoRF binding (P = 0.1396); Gain of sheet (P = 0.1451)
17:44074002:A:G,P10636,N582S,0.632,Gain of phosphorylation at N582 (P = 0.0499); Loss of ubiquitination at K584 (P = 0.1231); Gain of methylation at K584 (P = 0.1524); Loss of MoRF binding (P = 0.1633); Loss of stability (P = 0.1842)
17:44074002:A:T,P10636,N582I,0.691,Gain of sheet (P = 0.0266); Loss of loop (P = 0.0374); Gain of methylation at K584 (P = 0.0487); Loss of ubiquitination at K584 (P = 0.1435); Gain of MoRF binding (P = 0.1475)
17:44074003:C:A,P10636,N582K,0.699,Gain of methylation at N582 (P = 0.0149); Gain of MoRF binding (P = 0.0297); Gain of ubiquitination at N582 (P = 0.0311); Gain of phosphorylation at S579 (P = 0.0987); Gain of solvent accessibility (P = 0.1319)
17:44074003:C:G,P10636,N582K,0.699,Gain of methylation at N582 (P = 0.0149); Gain of MoRF binding (P = 0.0297); Gain of ubiquitination at N582 (P = 0.0311); Gain of phosphorylation at S579 (P = 0.0987); Gain of solvent accessibility (P = 0.1319)
17:44074004:C:A,P10636,L583M,0.648,Loss of methylation at K584 (P = 0.0355); Gain of MoRF binding (P = 0.072); Loss of ubiquitination at K584 (P = 0.0949); Loss of catalytic residue at L583 (P = 0.1487); Loss of stability (P = 0.2131)
17:44074004:C:G,P10636,L583V,0.635,Gain of methylation at K584 (P = 0.0382); Gain of MoRF binding (P = 0.0901); Loss of stability (P = 0.104); Gain of ubiquitination at K584 (P = 0.123); Loss of catalytic residue at L583 (P = 0.1757)
17:44074005:T:A,P10636,L583Q,0.638,Loss of stability (P = 0.0289); Gain of methylation at K584 (P = 0.0559); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917); Loss of ubiquitination at K584 (P = 0.0949)
17:44074005:T:C,P10636,L583P,0.657,Loss of stability (P = 0.0123); Gain of glycosylation at T580 (P = 0.043); Gain of methylation at K584 (P = 0.0567); Loss of MoRF binding (P = 0.0796); Gain of phosphorylation at T580 (P = 0.0893)
17:44074005:T:G,P10636,L583R,0.723,Gain of MoRF binding (P = 0.0065); Loss of stability (P = 0.0204); Gain of methylation at K584 (P = 0.0442); Loss of ubiquitination at K584 (P = 0.0702); Gain of phosphorylation at T580 (P = 0.0732)
17:44074007:A:C,P10636,K584Q,0.46,Loss of methylation at K584 (P = 0.0181); Loss of ubiquitination at K584 (P = 0.0218); Loss of MoRF binding (P = 0.0703); Loss of catalytic residue at K584 (P = 0.0777); Loss of glycosylation at K584 (P = 0.1923)
17:44074007:A:G,P10636,K584E,0.479,Loss of methylation at K584 (P = 0.0181); Loss of ubiquitination at K584 (P = 0.0218); Loss of MoRF binding (P = 0.0298); Loss of catalytic residue at K584 (P = 0.1057); Loss of glycosylation at K584 (P = 0.1923)
17:44074008:A:C,P10636,K584T,0.523,Loss of methylation at K584 (P = 0.0181); Loss of ubiquitination at K584 (P = 0.0218); Loss of MoRF binding (P = 0.0655); Gain of phosphorylation at T580 (P = 0.1136); Loss of stability (P = 0.1861)
17:44074008:A:G,P10636,K584R,0.429,Loss of ubiquitination at K584 (P = 0.0218); Loss of methylation at K584 (P = 0.0268); Gain of MoRF binding (P = 0.0724); Loss of glycosylation at K584 (P = 0.1923); Loss of catalytic residue at K584 (P = 0.2136)
17:44074008:A:T,P10636,K584M,0.498,Loss of methylation at K584 (P = 0.0181); Loss of ubiquitination at K584 (P = 0.0218); Loss of catalytic residue at K584 (P = 0.0756); Loss of MoRF binding (P = 0.0851); Loss of glycosylation at K584 (P = 0.1923)
17:44074009:G:C,P10636,K584N,0.467,Loss of methylation at K584 (P = 0.0181); Loss of ubiquitination at K584 (P = 0.0218); Loss of MoRF binding (P = 0.0663); Loss of catalytic residue at K584 (P = 0.0917); Loss of glycosylation at K584 (P = 0.1923)
17:44074009:G:T,P10636,K584N,0.467,Loss of methylation at K584 (P = 0.0181); Loss of ubiquitination at K584 (P = 0.0218); Loss of MoRF binding (P = 0.0663); Loss of catalytic residue at K584 (P = 0.0917); Loss of glycosylation at K584 (P = 0.1923)
17:44074010:C:A,P10636,H585N,0.616,Gain of relative solvent accessibility (P = 0.0289); Gain of solvent accessibility (P = 0.0766); Gain of ubiquitination at K584 (P = 0.0913); Loss of methylation at K584 (P = 0.1276); Gain of MoRF binding (P = 0.1398)
17:44074010:C:G,P10636,H585D,0.63,Gain of relative solvent accessibility (P = 0.0166); Gain of ubiquitination at K584 (P = 0.0251); Gain of solvent accessibility (P = 0.0261); Loss of methylation at K584 (P = 0.0623); Loss of MoRF binding (P = 0.0774)
17:44074010:C:T,P10636,H585Y,0.617,Gain of solvent accessibility (P = 0.0638); Gain of phosphorylation at H585 (P = 0.0805); Loss of ubiquitination at K584 (P = 0.0834); Loss of methylation at K584 (P = 0.0853); Gain of relative solvent accessibility (P = 0.09)
17:44074011:A:C,P10636,H585P,0.646,Gain of relative solvent accessibility (P = 0.005); Gain of solvent accessibility (P = 0.0221); Loss of MoRF binding (P = 0.0973); Loss of ubiquitination at K584 (P = 0.1079); Gain of phosphorylation at T580 (P = 0.109)
17:44074011:A:G,P10636,H585R,0.638,Gain of MoRF binding (P = 0.0084); Gain of solvent accessibility (P = 0.0105); Gain of relative solvent accessibility (P = 0.0289); Gain of helix (P = 0.0496); Gain of methylation at K584 (P = 0.0775)
17:44074011:A:T,P10636,H585L,0.608,Loss of methylation at K584 (P = 0.077); Loss of ubiquitination at K584 (P = 0.1231); Gain of MoRF binding (P = 0.148); Gain of relative solvent accessibility (P = 0.1571); Gain of sheet (P = 0.1945)
17:44074012:C:A,P10636,H585Q,0.598,Gain of solvent accessibility (P = 0.0081); Gain of relative solvent accessibility (P = 0.0166); Gain of ubiquitination at K584 (P = 0.1062); Gain of MoRF binding (P = 0.1157); Gain of methylation at K584 (P = 0.1338)
17:44074012:C:G,P10636,H585Q,0.598,Gain of solvent accessibility (P = 0.0081); Gain of relative solvent accessibility (P = 0.0166); Gain of ubiquitination at K584 (P = 0.1062); Gain of MoRF binding (P = 0.1157); Gain of methylation at K584 (P = 0.1338)
17:44074013:C:A,P10636,Q586K,0.577,Loss of ubiquitination at K591 (P = 0.02); Gain of methylation at Q586 (P = 0.0304); Gain of MoRF binding (P = 0.0408); Gain of solvent accessibility (P = 0.08); Gain of relative solvent accessibility (P = 0.09)
17:44074013:C:G,P10636,Q586E,0.54,Gain of ubiquitination at K584 (P = 0.026); Loss of MoRF binding (P = 0.0725); Loss of methylation at K584 (P = 0.085); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0971)
17:44074014:A:C,P10636,Q586P,0.582,Loss of MoRF binding (P = 0.0839); Gain of catalytic residue at Q586 (P = 0.0858); Gain of methylation at K584 (P = 0.097); Gain of ubiquitination at K584 (P = 0.1062); Gain of relative solvent accessibility (P = 0.1571)
17:44074014:A:G,P10636,Q586R,0.579,Gain of MoRF binding (P = 0.0153); Loss of ubiquitination at K591 (P = 0.0234); Gain of methylation at Q586 (P = 0.0434); Gain of solvent accessibility (P = 0.1154); Gain of relative solvent accessibility (P = 0.1571)
17:44074014:A:T,P10636,Q586L,0.482,Loss of ubiquitination at K591 (P = 0.0779); Gain of catalytic residue at Q586 (P = 0.1157); Loss of methylation at K591 (P = 0.1207); Loss of MoRF binding (P = 0.1492); Gain of relative solvent accessibility (P = 0.2751)
17:44074015:G:C,P10636,Q586H,0.515,Gain of ubiquitination at K584 (P = 0.123); Loss of MoRF binding (P = 0.1388); Gain of methylation at K584 (P = 0.1511); Loss of stability (P = 0.2355); Gain of relative solvent accessibility (P = 0.2751)
17:44074015:G:T,P10636,Q586H,0.515,Gain of ubiquitination at K584 (P = 0.123); Loss of MoRF binding (P = 0.1388); Gain of methylation at K584 (P = 0.1511); Loss of stability (P = 0.2355); Gain of relative solvent accessibility (P = 0.2751)
17:44074016:C:A,P10636,P587T,0.757,Gain of MoRF binding (P = 0.0504); Gain of catalytic residue at P587 (P = 0.0626); Loss of methylation at K584 (P = 0.0995); Gain of ubiquitination at K584 (P = 0.1062); Gain of relative solvent accessibility (P = 0.1571)
17:44074016:C:G,P10636,P587A,0.732,Gain of MoRF binding (P = 0.0416); Gain of catalytic residue at P587 (P = 0.0645); Loss of methylation at K584 (P = 0.0654); Loss of ubiquitination at K591 (P = 0.0675); Loss of sheet (P = 0.1398)
17:44074016:C:T,P10636,P587S,0.737,Gain of MoRF binding (P = 0.0405); Loss of methylation at K584 (P = 0.0599); Gain of glycosylation at P587 (P = 0.0977); Gain of ubiquitination at K584 (P = 0.1062); Gain of relative solvent accessibility (P = 0.1571)
17:44074017:C:A,P10636,P587Q,0.768,Gain of MoRF binding (P = 0.0479); Gain of ubiquitination at K584 (P = 0.123); Gain of methylation at K584 (P = 0.1401); Gain of solvent accessibility (P = 0.1505); Loss of sheet (P = 0.3635)
17:44074017:C:G,P10636,P587R,0.739,Gain of MoRF binding (P = 6e-04); Gain of methylation at P587 (P = 0.0172); Loss of ubiquitination at K591 (P = 0.0226); Gain of solvent accessibility (P = 0.0411); Gain of glycosylation at K584 (P = 0.1317)
17:44074017:C:T,P10636,P587L,0.746,Loss of ubiquitination at K591 (P = 0.0471); Loss of methylation at K584 (P = 0.049); Gain of MoRF binding (P = 0.0503); Gain of catalytic residue at P587 (P = 0.0632); Gain of solvent accessibility (P = 0.1185)
17:44074019:G:A,P10636,G588R,0.632,Gain of solvent accessibility (P = 0.0037); Gain of MoRF binding (P = 0.0064); Gain of methylation at G588 (P = 0.0191); Loss of ubiquitination at K591 (P = 0.0219); Loss of sheet (P = 0.1398)
17:44074019:G:C,P10636,G588R,0.632,Gain of solvent accessibility (P = 0.0037); Gain of MoRF binding (P = 0.0064); Gain of methylation at G588 (P = 0.0191); Loss of ubiquitination at K591 (P = 0.0219); Loss of sheet (P = 0.1398)
17:44074020:G:A,P10636,G588E,0.631,Gain of solvent accessibility (P = 0.024); Gain of ubiquitination at K584 (P = 0.0268); Loss of MoRF binding (P = 0.0659); Gain of methylation at K584 (P = 0.1345); Loss of sheet (P = 0.1398)
17:44074020:G:C,P10636,G588A,0.646,Gain of MoRF binding (P = 0.1157); Loss of ubiquitination at K584 (P = 0.1435); Loss of methylation at K584 (P = 0.148); Loss of catalytic residue at G589 (P = 0.2576); Gain of solvent accessibility (P = 0.3304)
17:44074020:G:T,P10636,G588V,0.651,Loss of ubiquitination at K591 (P = 0.0931); Gain of methylation at K584 (P = 0.0969); Gain of MoRF binding (P = 0.098); Gain of solvent accessibility (P = 0.1133); Loss of catalytic residue at G588 (P = 0.2201)
17:44074022:G:A,P10636,G589S,0.675,Gain of glycosylation at G589 (P = 0.0158); Gain of MoRF binding (P = 0.0888); Gain of solvent accessibility (P = 0.1014); Loss of methylation at K584 (P = 0.1133); Gain of ubiquitination at K584 (P = 0.123)
17:44074022:G:C,P10636,G589R,0.706,Gain of MoRF binding (P = 0.0039); Gain of solvent accessibility (P = 0.0097); Gain of methylation at G589 (P = 0.0108); Loss of ubiquitination at K591 (P = 0.0234); Loss of catalytic residue at G588 (P = 0.1563)
17:44074022:G:T,P10636,G589C,0.705,Loss of ubiquitination at K591 (P = 0.0779); Loss of MoRF binding (P = 0.0851); Gain of methylation at K584 (P = 0.1466); Loss of glycosylation at K591 (P = 0.2726); Loss of relative solvent accessibility (P = 0.3219)
17:44074023:G:A,P10636,G589D,0.673,Gain of ubiquitination at K584 (P = 0.0268); Gain of solvent accessibility (P = 0.0354); Loss of MoRF binding (P = 0.0666); Loss of methylation at K584 (P = 0.0853); Loss of catalytic residue at G589 (P = 0.1286)
17:44074023:G:C,P10636,G589A,0.704,Gain of MoRF binding (P = 0.1137); Gain of ubiquitination at K584 (P = 0.123); Loss of methylation at K584 (P = 0.1417); Loss of stability (P = 0.2516); Loss of glycosylation at K591 (P = 0.3032)
17:44074023:G:T,P10636,G589V,0.764,Loss of ubiquitination at K591 (P = 0.0598); Gain of MoRF binding (P = 0.1002); Gain of methylation at K584 (P = 0.1046); Loss of glycosylation at K591 (P = 0.2578); Loss of catalytic residue at G588 (P = 0.2808)
17:44074025:G:A,P10636,G590R,0.82,Gain of MoRF binding (P = 0.0099); Gain of solvent accessibility (P = 0.0171); Loss of ubiquitination at K591 (P = 0.022); Gain of methylation at G590 (P = 0.0346); Gain of relative solvent accessibility (P = 0.0479)
17:44074025:G:C,P10636,G590R,0.82,Gain of MoRF binding (P = 0.0099); Gain of solvent accessibility (P = 0.0171); Loss of ubiquitination at K591 (P = 0.022); Gain of methylation at G590 (P = 0.0346); Gain of relative solvent accessibility (P = 0.0479)
17:44074025:G:T,P10636,G590W,0.802,Gain of MoRF binding (P = 0.0232); Loss of disorder (P = 0.0266); Loss of ubiquitination at K591 (P = 0.0314); Gain of relative solvent accessibility (P = 0.1259); Gain of solvent accessibility (P = 0.1505)
17:44074026:G:A,P10636,G590E,0.775,Gain of solvent accessibility (P = 0.0145); Gain of relative solvent accessibility (P = 0.0215); Loss of MoRF binding (P = 0.0574); Gain of ubiquitination at K591 (P = 0.0646); Loss of catalytic residue at G588 (P = 0.2332)
17:44074026:G:C,P10636,G590A,0.857,Gain of MoRF binding (P = 0.1124); Gain of catalytic residue at G590 (P = 0.1438); Gain of ubiquitination at K591 (P = 0.2392); Gain of relative solvent accessibility (P = 0.281); Loss of disorder (P = 0.2859)
17:44074026:G:T,P10636,G590V,0.821,Gain of MoRF binding (P = 0.0968); Gain of relative solvent accessibility (P = 0.1259); Loss of ubiquitination at K591 (P = 0.1668); Loss of glycosylation at K591 (P = 0.2331); Gain of catalytic residue at G590 (P = 0.2365)
17:44074028:A:C,P10636,K591Q,0.494,Loss of methylation at K591 (P = 0.0043); Loss of ubiquitination at K591 (P = 0.0074); Loss of MoRF binding (P = 0.0497); Loss of glycosylation at K591 (P = 0.0853); Gain of catalytic residue at G589 (P = 0.3167)
17:44074028:A:G,P10636,K591E,0.512,Loss of methylation at K591 (P = 0.0043); Loss of ubiquitination at K591 (P = 0.0074); Loss of MoRF binding (P = 0.0088); Loss of glycosylation at K591 (P = 0.0853); Gain of sheet (P = 0.1539)
17:44074029:A:C,P10636,K591T,0.511,Loss of methylation at K591 (P = 0.0043); Loss of ubiquitination at K591 (P = 0.0074); Loss of MoRF binding (P = 0.0452); Gain of sheet (P = 0.1539); Loss of glycosylation at K591 (P = 0.1621)
17:44074029:A:G,P10636,K591R,0.486,Loss of ubiquitination at K591 (P = 0.0074); Loss of methylation at K591 (P = 0.0211); Gain of MoRF binding (P = 0.077); Loss of glycosylation at K591 (P = 0.0853); Gain of catalytic residue at K591 (P = 0.2338)
17:44074029:A:T,P10636,K591M,0.543,Loss of methylation at K591 (P = 0.0043); Loss of ubiquitination at K591 (P = 0.0074); Loss of MoRF binding (P = 0.0673); Loss of glycosylation at K591 (P = 0.0853); Gain of sheet (P = 0.1539)
17:44074030:G:C,P10636,K591N,0.484,Loss of methylation at K591 (P = 0.0043); Loss of ubiquitination at K591 (P = 0.0074); Loss of MoRF binding (P = 0.0479); Loss of glycosylation at K591 (P = 0.0853); Loss of sheet (P = 0.1398)
17:44074030:G:T,P10636,K591N,0.484,Loss of methylation at K591 (P = 0.0043); Loss of ubiquitination at K591 (P = 0.0074); Loss of MoRF binding (P = 0.0479); Loss of glycosylation at K591 (P = 0.0853); Loss of sheet (P = 0.1398)
17:44087676:G:A,P10636,V592M,0.695,Loss of methylation at K591 (P = 0.0176); Gain of MoRF binding (P = 0.1133); Loss of sheet (P = 0.1398); Gain of glycosylation at K591 (P = 0.1733); Loss of ubiquitination at K591 (P = 0.264)
17:44087676:G:C,P10636,V592L,0.692,Loss of methylation at K591 (P = 0.0491); Loss of MoRF binding (P = 0.0926); Gain of catalytic residue at V592 (P = 0.2142); Loss of ubiquitination at K591 (P = 0.2457); Gain of glycosylation at K591 (P = 0.2759)
17:44087676:G:T,P10636,V592L,0.692,Loss of methylation at K591 (P = 0.0491); Loss of MoRF binding (P = 0.0926); Gain of catalytic residue at V592 (P = 0.2142); Loss of ubiquitination at K591 (P = 0.2457); Gain of glycosylation at K591 (P = 0.2759)
17:44087677:T:A,P10636,V592E,0.755,Gain of ubiquitination at K597 (P = 0.0193); Loss of MoRF binding (P = 0.0219); Loss of sheet (P = 0.0357); Gain of solvent accessibility (P = 0.0411); Gain of relative solvent accessibility (P = 0.0479)
17:44087677:T:C,P10636,V592A,0.753,Loss of methylation at K591 (P = 0.0669); Loss of sheet (P = 0.0817); Loss of MoRF binding (P = 0.1012); Gain of glycosylation at K591 (P = 0.1834); Gain of catalytic residue at V592 (P = 0.2511)
17:44087677:T:G,P10636,V592G,0.748,Loss of sheet (P = 0.0228); Gain of glycosylation at K591 (P = 0.0668); Loss of methylation at K591 (P = 0.0677); Gain of loop (P = 0.069); Loss of MoRF binding (P = 0.088)
17:44087679:C:A,P10636,Q593K,0.572,Gain of methylation at Q593 (P = 0.0174); Loss of ubiquitination at K591 (P = 0.0219); Gain of MoRF binding (P = 0.0304); Gain of relative solvent accessibility (P = 0.2629); Gain of catalytic residue at Q593 (P = 0.278)
17:44087679:C:G,P10636,Q593E,0.57,Gain of ubiquitination at K597 (P = 0.0219); Loss of MoRF binding (P = 0.0334); Gain of catalytic residue at Q593 (P = 0.1066); Gain of glycosylation at K591 (P = 0.2163); Gain of relative solvent accessibility (P = 0.2629)
17:44087680:A:C,P10636,Q593P,0.628,Loss of MoRF binding (P = 0.0401); Loss of sheet (P = 0.1398); Gain of glycosylation at K591 (P = 0.2102); Loss of ubiquitination at K591 (P = 0.225); Gain of methylation at K598 (P = 0.2449)
17:44087680:A:G,P10636,Q593R,0.565,Gain of MoRF binding (P = 0.0109); Loss of ubiquitination at K591 (P = 0.0237); Gain of methylation at Q593 (P = 0.1564); Gain of catalytic residue at Q593 (P = 0.1906); Loss of sheet (P = 0.302)
17:44087680:A:T,P10636,Q593L,0.532,Gain of catalytic residue at Q593 (P = 0.0567); Loss of ubiquitination at K591 (P = 0.0598); Loss of MoRF binding (P = 0.066); Gain of stability (P = 0.0682); Loss of disorder (P = 0.1188)
17:44087681:G:C,P10636,Q593H,0.518,Loss of MoRF binding (P = 0.0899); Gain of catalytic residue at K591 (P = 0.139); Loss of ubiquitination at K591 (P = 0.2457); Gain of glycosylation at K591 (P = 0.2459); Loss of sheet (P = 0.302)
17:44087681:G:T,P10636,Q593H,0.518,Loss of MoRF binding (P = 0.0899); Gain of catalytic residue at K591 (P = 0.139); Loss of ubiquitination at K591 (P = 0.2457); Gain of glycosylation at K591 (P = 0.2459); Loss of sheet (P = 0.302)
17:44087682:A:C,P10636,I594L,0.586,Loss of catalytic residue at L599 (P = 0.0269); Loss of MoRF binding (P = 0.1206); Gain of relative solvent accessibility (P = 0.1259); Loss of methylation at K591 (P = 0.1453); Gain of loop (P = 0.2045)
17:44087682:A:G,P10636,I594V,0.574,Loss of catalytic residue at L599 (P = 0.0269); Gain of MoRF binding (P = 0.1005); Gain of ubiquitination at K591 (P = 0.2575); Loss of loop (P = 0.2897); Loss of sheet (P = 0.302)
17:44087682:A:T,P10636,I594L,0.586,Loss of catalytic residue at L599 (P = 0.0269); Loss of MoRF binding (P = 0.1206); Gain of relative solvent accessibility (P = 0.1259); Loss of methylation at K591 (P = 0.1453); Gain of loop (P = 0.2045)
17:44087683:T:A,P10636,I594K,0.694,Gain of MoRF binding (P = 0.0191); Loss of ubiquitination at K591 (P = 0.0219); Loss of catalytic residue at L599 (P = 0.0246); Loss of stability (P = 0.0351); Gain of solvent accessibility (P = 0.0354)
17:44087683:T:C,P10636,I594T,0.616,Loss of stability (P = 0.0223); Loss of catalytic residue at L599 (P = 0.0257); Gain of phosphorylation at I594 (P = 0.0805); Gain of relative solvent accessibility (P = 0.09); Gain of MoRF binding (P = 0.1119)
17:44087683:T:G,P10636,I594R,0.721,Gain of MoRF binding (P = 0.0072); Loss of ubiquitination at K591 (P = 0.0234); Loss of catalytic residue at L599 (P = 0.0248); Gain of solvent accessibility (P = 0.0584); Gain of glycosylation at K591 (P = 0.0683)
17:44087684:A:G,P10636,I594M,0.635,Loss of catalytic residue at L599 (P = 0.0265); Gain of MoRF binding (P = 0.0691); Gain of relative solvent accessibility (P = 0.1259); Gain of solvent accessibility (P = 0.194); Gain of ubiquitination at K591 (P = 0.2575)
17:44087685:A:C,P10636,I595L,0.533,Loss of MoRF binding (P = 0.1061); Loss of methylation at K591 (P = 0.1351); Gain of relative solvent accessibility (P = 0.2363); Loss of ubiquitination at K591 (P = 0.2457); Gain of catalytic residue at I595 (P = 0.2603)
17:44087685:A:G,P10636,I595V,0.454,Gain of sheet (P = 0.0827); Gain of MoRF binding (P = 0.109); Loss of ubiquitination at K591 (P = 0.2457); Loss of methylation at K598 (P = 0.2954); Loss of stability (P = 0.3411)
17:44087685:A:T,P10636,I595F,0.535,Gain of sheet (P = 0.0827); Loss of MoRF binding (P = 0.0953); Gain of relative solvent accessibility (P = 0.2363); Loss of ubiquitination at K591 (P = 0.264); Loss of methylation at K598 (P = 0.284)
17:44087686:T:A,P10636,I595N,0.569,Loss of sheet (P = 0.0457); Loss of stability (P = 0.0588); Gain of relative solvent accessibility (P = 0.09); Loss of methylation at K591 (P = 0.0933); Loss of MoRF binding (P = 0.0975)
17:44087686:T:C,P10636,I595T,0.561,Loss of stability (P = 0.0286); Gain of relative solvent accessibility (P = 0.09); Loss of MoRF binding (P = 0.1062); Loss of sheet (P = 0.1501); Gain of solvent accessibility (P = 0.1683)
17:44087686:T:G,P10636,I595S,0.559,Loss of stability (P = 0.0302); Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.09); Loss of methylation at K591 (P = 0.1233); Loss of MoRF binding (P = 0.1252)
17:44087687:T:G,P10636,I595M,0.543,Gain of MoRF binding (P = 0.082); Gain of relative solvent accessibility (P = 0.1259); Gain of solvent accessibility (P = 0.194); Gain of sheet (P = 0.1945); Loss of ubiquitination at K591 (P = 0.225)
17:44087688:A:C,P10636,N596H,0.619,Gain of catalytic residue at K597 (P = 0.053); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1071); Loss of MoRF binding (P = 0.1089); Loss of stability (P = 0.1254)
17:44087688:A:G,P10636,N596D,0.642,Gain of ubiquitination at K597 (P = 0.0199); Loss of MoRF binding (P = 0.0378); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0704); Gain of loop (P = 0.2045)
17:44087688:A:T,P10636,N596Y,0.555,Loss of disorder (P = 0.0273); Gain of solvent accessibility (P = 0.0739); Gain of sheet (P = 0.0827); Gain of relative solvent accessibility (P = 0.09); Loss of ubiquitination at K591 (P = 0.0931)
17:44087689:A:C,P10636,N596T,0.58,Gain of relative solvent accessibility (P = 0.0479); Gain of sheet (P = 0.0827); Gain of solvent accessibility (P = 0.0917); Loss of stability (P = 0.106); Loss of MoRF binding (P = 0.1303)
17:44087689:A:G,P10636,N596S,0.594,Gain of catalytic residue at K597 (P = 0.0359); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.11); Gain of MoRF binding (P = 0.1264); Loss of stability (P = 0.1638)
17:44087689:A:T,P10636,N596I,0.557,Gain of catalytic residue at L601 (P = 0.0446); Gain of sheet (P = 0.0477); Loss of ubiquitination at K591 (P = 0.0598); Loss of disorder (P = 0.0666); Loss of loop (P = 0.1242)
17:44087690:T:A,P10636,N596K,0.766,Gain of catalytic residue at N596 (P = 0.0171); Loss of ubiquitination at K591 (P = 0.0211); Gain of MoRF binding (P = 0.034); Gain of solvent accessibility (P = 0.0354); Gain of relative solvent accessibility (P = 0.0479)
17:44087690:T:G,P10636,N596K,0.766,Gain of catalytic residue at N596 (P = 0.0171); Loss of ubiquitination at K591 (P = 0.0211); Gain of MoRF binding (P = 0.034); Gain of solvent accessibility (P = 0.0354); Gain of relative solvent accessibility (P = 0.0479)
17:44087691:A:C,P10636,K597Q,0.568,Gain of ubiquitination at K598 (P = 0.0276); Loss of MoRF binding (P = 0.0444); Loss of methylation at K597 (P = 0.1406); Gain of sheet (P = 0.1945); Loss of stability (P = 0.2483)
17:44087691:A:G,P10636,K597E,0.549,Loss of MoRF binding (P = 0.0038); Gain of ubiquitination at K598 (P = 0.0138); Loss of sheet (P = 0.0817); Gain of catalytic residue at K597 (P = 0.0977); Loss of methylation at K597 (P = 0.1406)
17:44087692:A:C,P10636,K597T,0.65,Gain of ubiquitination at K598 (P = 0.0276); Loss of MoRF binding (P = 0.0383); Loss of disorder (P = 0.0805); Loss of stability (P = 0.1348); Loss of methylation at K597 (P = 0.1406)
17:44087692:A:G,P10636,K597R,0.551,Gain of MoRF binding (P = 0.0704); Loss of ubiquitination at K597 (P = 0.0982); Loss of disorder (P = 0.1073); Gain of methylation at K598 (P = 0.2086); Loss of sheet (P = 0.302)
17:44087692:A:T,P10636,K597M,0.632,Gain of ubiquitination at K598 (P = 0.0301); Loss of MoRF binding (P = 0.0618); Loss of disorder (P = 0.064); Gain of sheet (P = 0.0827); Loss of methylation at K597 (P = 0.1406)
17:44087693:G:C,P10636,K597N,0.561,Gain of ubiquitination at K598 (P = 0.0251); Loss of MoRF binding (P = 0.0379); Loss of sheet (P = 0.0817); Loss of methylation at K597 (P = 0.1406); Loss of stability (P = 0.1673)
17:44087694:A:C,P10636,K598Q,0.572,Gain of ubiquitination at K597 (P = 0.0267); Loss of MoRF binding (P = 0.0471); Gain of sheet (P = 0.0827); Loss of methylation at K598 (P = 0.1072); Loss of phosphorylation at S602 (P = 0.2206)
17:44087694:A:G,P10636,K598E,0.593,Loss of MoRF binding (P = 0.0045); Gain of ubiquitination at K597 (P = 0.0155); Gain of sheet (P = 0.0827); Loss of methylation at K598 (P = 0.1072); Gain of relative solvent accessibility (P = 0.1894)
17:44087695:A:C,P10636,K598T,0.581,Gain of ubiquitination at K597 (P = 0.0317); Loss of MoRF binding (P = 0.0448); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.085); Loss of methylation at K598 (P = 0.1072)
17:44087695:A:G,P10636,K598R,0.589,Gain of MoRF binding (P = 0.0761); Loss of disorder (P = 0.1153); Gain of catalytic residue at K598 (P = 0.1562); Loss of methylation at K598 (P = 0.1655); Gain of sheet (P = 0.1945)
17:44087695:A:T,P10636,K598M,0.616,Gain of ubiquitination at K597 (P = 0.0358); Loss of disorder (P = 0.066); Loss of MoRF binding (P = 0.0708); Loss of methylation at K598 (P = 0.1072); Gain of sheet (P = 0.1945)
17:44087696:G:C,P10636,K598N,0.53,Gain of ubiquitination at K597 (P = 0.0247); Loss of MoRF binding (P = 0.0408); Loss of methylation at K598 (P = 0.1072); Gain of relative solvent accessibility (P = 0.1894); Gain of loop (P = 0.2045)
17:44087696:G:T,P10636,K598N,0.53,Gain of ubiquitination at K597 (P = 0.0247); Loss of MoRF binding (P = 0.0408); Loss of methylation at K598 (P = 0.1072); Gain of relative solvent accessibility (P = 0.1894); Gain of loop (P = 0.2045)
17:44087697:C:A,P10636,L599M,0.572,Loss of catalytic residue at L599 (P = 0.0106); Gain of MoRF binding (P = 0.0657); Gain of methylation at K597 (P = 0.1327); Gain of relative solvent accessibility (P = 0.2363); Gain of phosphorylation at S602 (P = 0.2432)
17:44087697:C:G,P10636,L599V,0.614,Loss of catalytic residue at L599 (P = 0.02); Gain of methylation at K598 (P = 0.0343); Gain of MoRF binding (P = 0.0786); Loss of stability (P = 0.0815); Gain of sheet (P = 0.0827)
17:44087698:T:A,P10636,L599Q,0.615,Loss of stability (P = 0.026); Loss of catalytic residue at L599 (P = 0.0376); Gain of methylation at K597 (P = 0.0749); Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.09)
17:44087698:T:C,P10636,L599P,0.683,Loss of stability (P = 0.0047); Loss of catalytic residue at L599 (P = 0.0405); Gain of loop (P = 0.0435); Loss of sheet (P = 0.0457); Loss of MoRF binding (P = 0.0572)
17:44087698:T:G,P10636,L599R,0.697,Loss of stability (P = 0.0106); Gain of MoRF binding (P = 0.0183); Loss of catalytic residue at L599 (P = 0.0219); Gain of methylation at K598 (P = 0.0439); Gain of phosphorylation at S602 (P = 0.0563)
17:44087700:G:A,P10636,D600N,0.684,Gain of MoRF binding (P = 0.0352); Gain of methylation at K598 (P = 0.1195); Loss of ubiquitination at K597 (P = 0.2593); Gain of catalytic residue at K598 (P = 0.2603); Loss of phosphorylation at S602 (P = 0.262)
17:44087700:G:C,P10636,D600H,0.716,Gain of MoRF binding (P = 0.0435); Gain of methylation at K598 (P = 0.0694); Loss of sheet (P = 0.0817); Loss of loop (P = 0.1242); Gain of catalytic residue at K598 (P = 0.2054)
17:44087700:G:T,P10636,D600Y,0.694,Gain of sheet (P = 0.0221); Loss of disorder (P = 0.0325); Loss of loop (P = 0.0512); Gain of MoRF binding (P = 0.0528); Gain of catalytic residue at S602 (P = 0.0811)
17:44087701:A:C,P10636,D600A,0.72,Gain of MoRF binding (P = 0.0429); Gain of methylation at K598 (P = 0.0787); Loss of sheet (P = 0.0817); Loss of disorder (P = 0.1105); Gain of catalytic residue at S602 (P = 0.1124)
17:44087701:A:G,P10636,D600G,0.688,Gain of catalytic residue at S602 (P = 0.0222); Gain of MoRF binding (P = 0.0416); Gain of methylation at K598 (P = 0.0635); Loss of stability (P = 0.1285); Gain of relative solvent accessibility (P = 0.1894)
17:44087701:A:T,P10636,D600V,0.67,Gain of sheet (P = 0.0125); Loss of loop (P = 0.0203); Gain of methylation at K598 (P = 0.0356); Gain of MoRF binding (P = 0.0379); Gain of catalytic residue at S602 (P = 0.0628)
17:44087702:T:A,P10636,D600E,0.706,Gain of sheet (P = 0.0477); Loss of MoRF binding (P = 0.1031); Loss of loop (P = 0.1242); Gain of methylation at K598 (P = 0.1954); Gain of ubiquitination at K598 (P = 0.2923)
17:44087702:T:G,P10636,D600E,0.706,Gain of sheet (P = 0.0477); Loss of MoRF binding (P = 0.1031); Loss of loop (P = 0.1242); Gain of methylation at K598 (P = 0.1954); Gain of ubiquitination at K598 (P = 0.2923)
17:44087703:C:A,P10636,L601I,0.582,Loss of sheet (P = 0.0817); Gain of MoRF binding (P = 0.0878); Gain of methylation at K598 (P = 0.0975); Gain of ubiquitination at K597 (P = 0.2995); Loss of phosphorylation at S602 (P = 0.3209)
17:44087703:C:G,P10636,L601V,0.594,Gain of MoRF binding (P = 0.0793); Gain of relative solvent accessibility (P = 0.1259); Gain of methylation at K598 (P = 0.1322); Gain of solvent accessibility (P = 0.2601); Loss of sheet (P = 0.302)
17:44087703:C:T,P10636,L601F,0.587,Gain of catalytic residue at L601 (P = 0.0098); Loss of MoRF binding (P = 0.1252); Gain of methylation at K597 (P = 0.213); Loss of phosphorylation at S602 (P = 0.262); Loss of disorder (P = 0.2919)
17:44087704:T:A,P10636,L601H,0.615,Loss of stability (P = 0.0586); Gain of relative solvent accessibility (P = 0.09); Gain of MoRF binding (P = 0.1067); Gain of solvent accessibility (P = 0.1071); Gain of methylation at K598 (P = 0.1179)
17:44087704:T:C,P10636,L601P,0.69,Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at K598 (P = 0.0594); Loss of MoRF binding (P = 0.0648); Loss of stability (P = 0.0697); Gain of solvent accessibility (P = 0.1014)
17:44087704:T:G,P10636,L601R,0.781,Gain of MoRF binding (P = 0.0115); Gain of solvent accessibility (P = 0.0171); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at K598 (P = 0.0562); Gain of phosphorylation at S602 (P = 0.0709)
17:44087706:A:C,P10636,S602R,0.413,Gain of solvent accessibility (P = 0.0071); Gain of MoRF binding (P = 0.0168); Gain of helix (P = 0.0854); Gain of relative solvent accessibility (P = 0.09); Loss of phosphorylation at S602 (P = 0.1087)
17:44087706:A:G,P10636,S602G,0.392,Loss of stability (P = 0.0305); Gain of sheet (P = 0.0827); Gain of relative solvent accessibility (P = 0.09); Loss of phosphorylation at S602 (P = 0.1087); Gain of MoRF binding (P = 0.1292)
17:44087706:A:T,P10636,S602C,0.55,Loss of disorder (P = 0.0448); Loss of MoRF binding (P = 0.0733); Loss of sheet (P = 0.0817); Gain of catalytic residue at V604 (P = 0.0987); Loss of phosphorylation at S602 (P = 0.1087)
17:44087707:G:A,P10636,S602N,0.309,Gain of sheet (P = 0.0827); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917); Loss of phosphorylation at S602 (P = 0.1087); Loss of MoRF binding (P = 0.1139)
17:44087707:G:C,P10636,S602T,0.452,Gain of relative solvent accessibility (P = 0.09); Loss of disorder (P = 0.1034); Loss of phosphorylation at S602 (P = 0.1161); Loss of MoRF binding (P = 0.1269); Gain of solvent accessibility (P = 0.1376)
17:44087707:G:T,P10636,S602I,0.525,Loss of disorder (P = 0.0189); Loss of sheet (P = 0.0817); Gain of MoRF binding (P = 0.089); Loss of phosphorylation at S602 (P = 0.1087); Loss of loop (P = 0.1242)
17:44087708:C:A,P10636,S602R,0.413,Gain of solvent accessibility (P = 0.0071); Gain of MoRF binding (P = 0.0168); Gain of helix (P = 0.0854); Gain of relative solvent accessibility (P = 0.09); Loss of phosphorylation at S602 (P = 0.1087)
17:44087708:C:G,P10636,S602R,0.413,Gain of solvent accessibility (P = 0.0071); Gain of MoRF binding (P = 0.0168); Gain of helix (P = 0.0854); Gain of relative solvent accessibility (P = 0.09); Loss of phosphorylation at S602 (P = 0.1087)
17:44087709:A:C,P10636,N603H,0.436,Loss of MoRF binding (P = 0.1058); Gain of loop (P = 0.2045); Loss of ubiquitination at K607 (P = 0.2505); Gain of phosphorylation at S602 (P = 0.2569); Loss of sheet (P = 0.302)
17:44087709:A:G,P10636,N603D,0.532,Gain of ubiquitination at K598 (P = 0.0221); Loss of MoRF binding (P = 0.04); Gain of phosphorylation at S602 (P = 0.1133); Gain of helix (P = 0.1736); Gain of relative solvent accessibility (P = 0.1894)
17:44087709:A:T,P10636,N603Y,0.528,Loss of disorder (P = 0.0311); Gain of phosphorylation at N603 (P = 0.0851); Loss of MoRF binding (P = 0.0929); Loss of loop (P = 0.0986); Gain of sheet (P = 0.1945)
17:44087710:A:C,P10636,N603T,0.431,Loss of MoRF binding (P = 0.1198); Gain of sheet (P = 0.1945); Gain of catalytic residue at S602 (P = 0.2106); Loss of loop (P = 0.2237); Gain of phosphorylation at S602 (P = 0.2379)
17:44087710:A:G,P10636,N603S,0.33,Gain of phosphorylation at S602 (P = 0.0969); Loss of MoRF binding (P = 0.1237); Gain of relative solvent accessibility (P = 0.1894); Gain of methylation at K598 (P = 0.2134); Loss of ubiquitination at K607 (P = 0.2665)
17:44087710:A:T,P10636,N603I,0.523,Gain of sheet (P = 0.0266); Loss of disorder (P = 0.06); Loss of loop (P = 0.0804); Gain of catalytic residue at V604 (P = 0.0972); Loss of MoRF binding (P = 0.1384)
17:44087711:C:A,P10636,N603K,0.417,Gain of MoRF binding (P = 0.026); Gain of phosphorylation at S602 (P = 0.1115); Gain of solvent accessibility (P = 0.1319); Loss of ubiquitination at K607 (P = 0.1741); Gain of relative solvent accessibility (P = 0.1894)
17:44087711:C:G,P10636,N603K,0.417,Gain of MoRF binding (P = 0.026); Gain of phosphorylation at S602 (P = 0.1115); Gain of solvent accessibility (P = 0.1319); Loss of ubiquitination at K607 (P = 0.1741); Gain of relative solvent accessibility (P = 0.1894)
17:44087712:G:C,P10636,V604L,0.76,Loss of MoRF binding (P = 0.0847); Loss of catalytic residue at K607 (P = 0.2238); Gain of relative solvent accessibility (P = 0.2363); Loss of ubiquitination at K607 (P = 0.2592); Gain of phosphorylation at S602 (P = 0.2786)
17:44087712:G:T,P10636,V604F,0.73,Loss of MoRF binding (P = 0.0791); Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at K607 (P = 0.2517); Gain of ubiquitination at K607 (P = 0.2584); Loss of disorder (P = 0.2957)
17:44087713:T:A,P10636,V604D,0.749,Gain of relative solvent accessibility (P = 0.0215); Gain of solvent accessibility (P = 0.0306); Gain of ubiquitination at K607 (P = 0.0357); Loss of MoRF binding (P = 0.0449); Gain of phosphorylation at S602 (P = 0.1369)
17:44087713:T:C,P10636,V604A,0.726,Loss of stability (P = 0.0345); Gain of relative solvent accessibility (P = 0.09); Loss of MoRF binding (P = 0.1134); Loss of catalytic residue at K607 (P = 0.2076); Gain of solvent accessibility (P = 0.2346)
17:44087713:T:G,P10636,V604G,0.737,Loss of stability (P = 0.0075); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.1094); Gain of phosphorylation at S602 (P = 0.1796); Gain of catalytic residue at V604 (P = 0.188)
17:44087715:C:A,P10636,Q605K,0.621,Gain of MoRF binding (P = 0.0377); Gain of phosphorylation at S602 (P = 0.0908); Gain of relative solvent accessibility (P = 0.0999); Gain of solvent accessibility (P = 0.1071); Gain of catalytic residue at Q605 (P = 0.1327)
17:44087715:C:G,P10636,Q605E,0.547,Gain of ubiquitination at K607 (P = 0.0268); Loss of MoRF binding (P = 0.0363); Gain of relative solvent accessibility (P = 0.0999); Gain of solvent accessibility (P = 0.1319); Gain of phosphorylation at S602 (P = 0.1369)
17:44087716:A:C,P10636,Q605P,0.608,Loss of MoRF binding (P = 0.0601); Gain of catalytic residue at Q605 (P = 0.1018); Gain of loop (P = 0.1069); Gain of phosphorylation at S602 (P = 0.1328); Gain of relative solvent accessibility (P = 0.2363)
17:44087716:A:G,P10636,Q605R,0.588,Gain of MoRF binding (P = 0.0194); Gain of phosphorylation at S602 (P = 0.0686); Gain of catalytic residue at Q605 (P = 0.0846); Gain of solvent accessibility (P = 0.1505); Gain of relative solvent accessibility (P = 0.2363)
17:44087716:A:T,P10636,Q605L,0.523,Loss of disorder (P = 0.0988); Loss of MoRF binding (P = 0.1172); Gain of helix (P = 0.1736); Loss of loop (P = 0.2237); Loss of ubiquitination at K607 (P = 0.2413)
17:44087717:G:C,P10636,Q605H,0.555,Loss of MoRF binding (P = 0.1052); Gain of ubiquitination at K607 (P = 0.2584); Gain of phosphorylation at S602 (P = 0.3184); Loss of disorder (P = 0.4029); Loss of glycosylation at S606 (P = 0.4123)
17:44087717:G:T,P10636,Q605H,0.555,Loss of MoRF binding (P = 0.1052); Gain of ubiquitination at K607 (P = 0.2584); Gain of phosphorylation at S602 (P = 0.3184); Loss of disorder (P = 0.4029); Loss of glycosylation at S606 (P = 0.4123)
17:44087718:T:A,P10636,S606T,0.63,Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0202); Loss of ubiquitination at K611 (P = 0.1037); Loss of disorder (P = 0.1298); Loss of MoRF binding (P = 0.1389)
17:44087718:T:C,P10636,S606P,0.658,Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0256); Loss of MoRF binding (P = 0.0659); Loss of stability (P = 0.1015); Gain of loop (P = 0.1069)
17:44087718:T:G,P10636,S606A,0.635,Gain of relative solvent accessibility (P = 0.0215); Loss of disorder (P = 0.0502); Gain of helix (P = 0.0854); Loss of ubiquitination at K611 (P = 0.0907); Gain of solvent accessibility (P = 0.0917)
17:44087719:C:A,P10636,S606Y,0.674,Loss of disorder (P = 0.0087); Gain of solvent accessibility (P = 0.0273); Gain of relative solvent accessibility (P = 0.0479); Loss of ubiquitination at K611 (P = 0.0603); Loss of loop (P = 0.0804)
17:44087719:C:G,P10636,S606C,0.79,Loss of disorder (P = 0.0444); Gain of catalytic residue at S610 (P = 0.0703); Loss of MoRF binding (P = 0.0763); Loss of ubiquitination at K611 (P = 0.0801); Loss of glycosylation at S606 (P = 0.1107)
17:44087719:C:T,P10636,S606F,0.683,Loss of disorder (P = 0.0039); Loss of ubiquitination at K611 (P = 0.0566); Loss of loop (P = 0.0804); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917)
17:44087721:A:C,P10636,K607Q,0.718,Loss of methylation at K607 (P = 0.0013); Gain of ubiquitination at K611 (P = 0.0276); Loss of MoRF binding (P = 0.0488); Loss of catalytic residue at K607 (P = 0.1896); Loss of loop (P = 0.2237)
17:44087721:A:G,P10636,K607E,0.734,Loss of methylation at K607 (P = 0.0013); Loss of MoRF binding (P = 0.0099); Gain of ubiquitination at K611 (P = 0.0279); Loss of loop (P = 0.2237); Loss of glycosylation at S606 (P = 0.2499)
17:44087722:A:C,P10636,K607T,0.761,Loss of methylation at K607 (P = 0.0013); Gain of ubiquitination at K611 (P = 0.0289); Loss of MoRF binding (P = 0.0405); Gain of glycosylation at K607 (P = 0.0466); Loss of disorder (P = 0.1185)
17:44087722:A:G,P10636,K607R,0.706,Loss of methylation at K607 (P = 0.004); Loss of ubiquitination at K607 (P = 0.0496); Gain of MoRF binding (P = 0.0658); Gain of phosphorylation at S610 (P = 0.1161); Loss of disorder (P = 0.1784)
17:44087722:A:T,P10636,K607M,0.719,Loss of methylation at K607 (P = 0.0013); Gain of ubiquitination at K611 (P = 0.0312); Loss of MoRF binding (P = 0.0594); Loss of disorder (P = 0.0631); Loss of glycosylation at S606 (P = 0.1366)
17:44087723:G:C,P10636,K607N,0.739,Loss of methylation at K607 (P = 0.0013); Gain of ubiquitination at K611 (P = 0.0279); Loss of MoRF binding (P = 0.0444); Loss of phosphorylation at S602 (P = 0.2371); Loss of catalytic residue at K607 (P = 0.2653)
17:44087723:G:T,P10636,K607N,0.739,Loss of methylation at K607 (P = 0.0013); Gain of ubiquitination at K611 (P = 0.0279); Loss of MoRF binding (P = 0.0444); Loss of phosphorylation at S602 (P = 0.2371); Loss of catalytic residue at K607 (P = 0.2653)
17:44087724:T:A,P10636,C608S,0.6,Gain of relative solvent accessibility (P = 0.005); Loss of methylation at K607 (P = 0.021); Gain of solvent accessibility (P = 0.0216); Gain of ubiquitination at K611 (P = 0.0462); Gain of MoRF binding (P = 0.0654)
17:44087724:T:C,P10636,C608R,0.674,Gain of solvent accessibility (P = 0.0016); Gain of MoRF binding (P = 0.0028); Gain of relative solvent accessibility (P = 0.0166); Loss of ubiquitination at K611 (P = 0.0318); Loss of methylation at K607 (P = 0.0334)
17:44087724:T:G,P10636,C608G,0.647,Gain of relative solvent accessibility (P = 0.005); Loss of methylation at K607 (P = 0.0211); Gain of ubiquitination at K611 (P = 0.0462); Loss of stability (P = 0.0505); Gain of MoRF binding (P = 0.0643)
17:44087725:G:A,P10636,C608Y,0.535,Loss of methylation at K607 (P = 0.0179); Gain of MoRF binding (P = 0.0734); Gain of phosphorylation at C608 (P = 0.111); Gain of ubiquitination at K611 (P = 0.1181); Loss of catalytic residue at K611 (P = 0.3139)
17:44087725:G:C,P10636,C608S,0.6,Gain of relative solvent accessibility (P = 0.005); Loss of methylation at K607 (P = 0.021); Gain of solvent accessibility (P = 0.0216); Gain of ubiquitination at K611 (P = 0.0462); Gain of MoRF binding (P = 0.0654)
17:44087725:G:T,P10636,C608F,0.469,Loss of methylation at K607 (P = 0.0749); Gain of MoRF binding (P = 0.0752); Loss of ubiquitination at K611 (P = 0.0801); Gain of glycosylation at S606 (P = 0.3178); Loss of catalytic residue at K607 (P = 0.3564)
17:44087726:T:G,P10636,C608W,0.692,Gain of MoRF binding (P = 0.0084); Loss of methylation at K607 (P = 0.0264); Loss of ubiquitination at K611 (P = 0.0391); Gain of solvent accessibility (P = 0.1133); Loss of disorder (P = 0.1542)
17:44087727:G:A,P10636,G609S,0.734,Loss of ubiquitination at K611 (P = 0.1191); Loss of methylation at K611 (P = 0.1401); Loss of MoRF binding (P = 0.1512); Gain of relative solvent accessibility (P = 0.2363); Loss of stability (P = 0.2421)
17:44087727:G:C,P10636,G609R,0.734,Gain of MoRF binding (P = 0.0105); Gain of solvent accessibility (P = 0.0128); Loss of ubiquitination at K611 (P = 0.0246); Gain of relative solvent accessibility (P = 0.0999); Gain of catalytic residue at G609 (P = 0.1121)
17:44087727:G:T,P10636,G609C,0.771,Loss of MoRF binding (P = 0.0786); Loss of ubiquitination at K611 (P = 0.0907); Gain of methylation at K611 (P = 0.1965); Loss of disorder (P = 0.2312); Loss of loop (P = 0.2897)
17:44087728:G:A,P10636,G609D,0.75,Gain of solvent accessibility (P = 0.0281); Gain of ubiquitination at K607 (P = 0.0357); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0606); Loss of sheet (P = 0.0817)
17:44087728:G:C,P10636,G609A,0.745,Loss of sheet (P = 0.0817); Loss of ubiquitination at K611 (P = 0.0907); Loss of methylation at K611 (P = 0.1458); Gain of MoRF binding (P = 0.1486); Loss of stability (P = 0.1862)
17:44087728:G:T,P10636,G609V,0.755,Loss of ubiquitination at K611 (P = 0.0907); Gain of methylation at K611 (P = 0.1); Gain of MoRF binding (P = 0.1171); Loss of disorder (P = 0.2059); Loss of loop (P = 0.2237)
17:44087730:T:A,P10636,S610T,0.685,Gain of phosphorylation at S610 (P = 0.0621); Loss of ubiquitination at K611 (P = 0.0801); Gain of catalytic residue at S610 (P = 0.1413); Loss of disorder (P = 0.1418); Loss of MoRF binding (P = 0.1504)
17:44087730:T:C,P10636,S610P,0.734,Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0773); Gain of methylation at K611 (P = 0.0934); Gain of solvent accessibility (P = 0.0971); Loss of ubiquitination at K611 (P = 0.1372)
17:44087730:T:G,P10636,S610A,0.752,Loss of disorder (P = 0.0655); Loss of ubiquitination at K611 (P = 0.0907); Loss of methylation at K615 (P = 0.1042); Gain of MoRF binding (P = 0.144); Gain of catalytic residue at S610 (P = 0.1948)
17:44087731:C:T,P10636,S610L,0.752,Loss of disorder (P = 0.0572); Loss of ubiquitination at K611 (P = 0.0603); Loss of methylation at K615 (P = 0.0778); Loss of MoRF binding (P = 0.1503); Loss of phosphorylation at S610 (P = 0.285)
17:44087733:A:C,P10636,K611Q,0.509,Loss of ubiquitination at K611 (P = 0.0199); Loss of methylation at K611 (P = 0.0353); Loss of MoRF binding (P = 0.073); Gain of sheet (P = 0.1451); Loss of catalytic residue at K611 (P = 0.1528)
17:44087733:A:G,P10636,K611E,0.526,Loss of ubiquitination at K611 (P = 0.0199); Loss of methylation at K611 (P = 0.0353); Loss of MoRF binding (P = 0.0362); Loss of catalytic residue at K611 (P = 0.0383); Gain of sheet (P = 0.1451)
17:44087734:A:C,P10636,K611T,0.525,Loss of ubiquitination at K611 (P = 0.0199); Loss of methylation at K611 (P = 0.0353); Loss of catalytic residue at K611 (P = 0.0595); Loss of MoRF binding (P = 0.068); Loss of disorder (P = 0.1398)
17:44087734:A:G,P10636,K611R,0.508,Loss of ubiquitination at K611 (P = 0.0199); Loss of methylation at K611 (P = 0.0504); Gain of catalytic residue at S610 (P = 0.0742); Gain of MoRF binding (P = 0.0744); Loss of sheet (P = 0.0817)
17:44087734:A:T,P10636,K611M,0.533,Loss of ubiquitination at K611 (P = 0.0199); Loss of methylation at K611 (P = 0.0353); Gain of catalytic residue at S610 (P = 0.0735); Loss of sheet (P = 0.0817); Loss of MoRF binding (P = 0.0845)
17:44087735:G:C,P10636,K611N,0.497,Loss of catalytic residue at K611 (P = 0.0097); Loss of ubiquitination at K611 (P = 0.0199); Loss of methylation at K611 (P = 0.0353); Loss of MoRF binding (P = 0.0692); Gain of sheet (P = 0.1451)
17:44087735:G:T,P10636,K611N,0.497,Loss of catalytic residue at K611 (P = 0.0097); Loss of ubiquitination at K611 (P = 0.0199); Loss of methylation at K611 (P = 0.0353); Loss of MoRF binding (P = 0.0692); Gain of sheet (P = 0.1451)
17:44087736:G:A,P10636,D612N,0.476,Loss of ubiquitination at K615 (P = 0.022); Gain of MoRF binding (P = 0.0377); Gain of methylation at K611 (P = 0.0718); Gain of sheet (P = 0.1451); Loss of helix (P = 0.2662)
17:44087736:G:C,P10636,D612H,0.506,Loss of ubiquitination at K615 (P = 0.0224); Gain of catalytic residue at N613 (P = 0.0371); Gain of MoRF binding (P = 0.0461); Gain of methylation at K611 (P = 0.0528); Loss of sheet (P = 0.0817)
17:44087736:G:T,P10636,D612Y,0.599,Loss of ubiquitination at K615 (P = 0.0224); Gain of MoRF binding (P = 0.046); Loss of disorder (P = 0.0582); Gain of methylation at K611 (P = 0.1151); Gain of sheet (P = 0.1451)
17:44087737:A:C,P10636,D612A,0.563,Loss of ubiquitination at K615 (P = 0.0219); Gain of MoRF binding (P = 0.0314); Gain of methylation at K611 (P = 0.0879); Loss of disorder (P = 0.1166); Gain of sheet (P = 0.1451)
17:44087737:A:G,P10636,D612G,0.522,Loss of ubiquitination at K615 (P = 0.0219); Gain of MoRF binding (P = 0.0366); Gain of sheet (P = 0.0477); Gain of methylation at K611 (P = 0.0701); Loss of stability (P = 0.143)
17:44087737:A:T,P10636,D612V,0.589,Loss of ubiquitination at K615 (P = 0.0219); Gain of MoRF binding (P = 0.0231); Gain of methylation at K611 (P = 0.0285); Gain of sheet (P = 0.0477); Loss of disorder (P = 0.1315)
17:44087738:T:A,P10636,D612E,0.511,Loss of sheet (P = 0.0817); Gain of methylation at K611 (P = 0.0875); Gain of ubiquitination at K611 (P = 0.102); Gain of catalytic residue at D612 (P = 0.1308); Loss of MoRF binding (P = 0.1921)
17:44087738:T:G,P10636,D612E,0.511,Loss of sheet (P = 0.0817); Gain of methylation at K611 (P = 0.0875); Gain of ubiquitination at K611 (P = 0.102); Gain of catalytic residue at D612 (P = 0.1308); Loss of MoRF binding (P = 0.1921)
17:44087739:A:C,P10636,N613H,0.839,Loss of stability (P = 0.0692); Gain of ubiquitination at K611 (P = 0.1181); Gain of sheet (P = 0.1451); Gain of methylation at K611 (P = 0.1451); Loss of MoRF binding (P = 0.2059)
17:44087739:A:G,P10636,N613D,0.781,Gain of ubiquitination at K615 (P = 0.038); Loss of sheet (P = 0.0817); Loss of MoRF binding (P = 0.0865); Loss of methylation at K611 (P = 0.0963); Gain of relative solvent accessibility (P = 0.0999)
17:44087739:A:T,P10636,N613Y,0.767,Gain of phosphorylation at N613 (P = 0.0493); Loss of disorder (P = 0.0637); Loss of ubiquitination at K611 (P = 0.0727); Loss of loop (P = 0.1242); Gain of sheet (P = 0.1451)
17:44087740:A:C,P10636,N613T,0.796,Gain of sheet (P = 0.0477); Loss of stability (P = 0.0952); Gain of phosphorylation at N613 (P = 0.0972); Loss of ubiquitination at K615 (P = 0.1066); Loss of loop (P = 0.1242)
17:44087740:A:G,P10636,N613S,0.761,Gain of phosphorylation at N613 (P = 0.0488); Loss of stability (P = 0.0732); Gain of ubiquitination at K611 (P = 0.078); Gain of sheet (P = 0.1451); Loss of methylation at K611 (P = 0.1827)
17:44087740:A:T,P10636,N613I,0.76,Gain of sheet (P = 0.0266); Gain of methylation at K611 (P = 0.0403); Loss of ubiquitination at K615 (P = 0.0505); Loss of loop (P = 0.0512); Loss of disorder (P = 0.0837)
17:44087741:T:A,P10636,N613K,0.772,Loss of ubiquitination at K615 (P = 0.0184); Gain of methylation at N613 (P = 0.0283); Gain of sheet (P = 0.0477); Gain of MoRF binding (P = 0.0503); Loss of stability (P = 0.063)
17:44087741:T:G,P10636,N613K,0.772,Loss of ubiquitination at K615 (P = 0.0184); Gain of methylation at N613 (P = 0.0283); Gain of sheet (P = 0.0477); Gain of MoRF binding (P = 0.0503); Loss of stability (P = 0.063)
17:44087742:A:C,P10636,I614L,0.725,Loss of sheet (P = 0.0315); Gain of ubiquitination at K615 (P = 0.0822); Loss of methylation at K611 (P = 0.0906); Gain of loop (P = 0.1069); Loss of MoRF binding (P = 0.2196)
17:44087742:A:G,P10636,I614V,0.668,Loss of sheet (P = 0.0817); Gain of ubiquitination at K611 (P = 0.0882); Loss of methylation at K611 (P = 0.1508); Loss of catalytic residue at I614 (P = 0.1779); Gain of MoRF binding (P = 0.2151)
17:44087742:A:T,P10636,I614F,0.738,Loss of sheet (P = 0.0817); Gain of ubiquitination at K615 (P = 0.0918); Loss of methylation at K611 (P = 0.1297); Loss of stability (P = 0.154); Gain of catalytic residue at I614 (P = 0.1939)
17:44087743:T:A,P10636,I614N,0.707,Loss of sheet (P = 0.0084); Gain of loop (P = 0.0195); Loss of stability (P = 0.0275); Gain of ubiquitination at K615 (P = 0.0562); Gain of disorder (P = 0.1151)
17:44087743:T:C,P10636,I614T,0.691,Loss of stability (P = 0.0126); Loss of sheet (P = 0.0181); Gain of ubiquitination at K615 (P = 0.0654); Gain of loop (P = 0.069); Gain of glycosylation at I614 (P = 0.0801)
17:44087743:T:G,P10636,I614S,0.679,Loss of sheet (P = 0.0104); Loss of stability (P = 0.0227); Gain of loop (P = 0.0435); Gain of ubiquitination at K615 (P = 0.0446); Gain of disorder (P = 0.0599)
17:44087744:C:G,P10636,I614M,0.687,Loss of sheet (P = 0.0181); Loss of methylation at K615 (P = 0.0249); Gain of ubiquitination at K615 (P = 0.0654); Gain of loop (P = 0.1069); Loss of stability (P = 0.1587)
17:44087745:A:C,P10636,K615Q,0.56,Loss of methylation at K615 (P = 0.0041); Loss of ubiquitination at K615 (P = 0.0134); Loss of catalytic residue at K615 (P = 0.0815); Loss of MoRF binding (P = 0.1231); Gain of sheet (P = 0.1451)
17:44087745:A:G,P10636,K615E,0.573,Loss of methylation at K615 (P = 0.0041); Loss of ubiquitination at K615 (P = 0.0134); Loss of MoRF binding (P = 0.0748); Loss of disorder (P = 0.1193); Gain of sheet (P = 0.1451)
17:44087746:A:C,P10636,K615T,0.58,Loss of methylation at K615 (P = 0.0041); Loss of ubiquitination at K615 (P = 0.0134); Gain of glycosylation at K615 (P = 0.0214); Gain of sheet (P = 0.0477); Loss of disorder (P = 0.0792)
17:44087746:A:G,P10636,K615R,0.508,Loss of methylation at K615 (P = 0.0051); Loss of ubiquitination at K615 (P = 0.0134); Gain of MoRF binding (P = 0.0948); Loss of disorder (P = 0.1041); Gain of sheet (P = 0.1451)
17:44087746:A:T,P10636,K615I,0.571,Loss of methylation at K615 (P = 0.0041); Loss of disorder (P = 0.0129); Loss of ubiquitination at K615 (P = 0.0134); Gain of sheet (P = 0.0266); Loss of catalytic residue at K615 (P = 0.0367)
17:44087747:A:C,P10636,K615N,0.551,Loss of methylation at K615 (P = 0.0041); Loss of ubiquitination at K615 (P = 0.0134); Loss of sheet (P = 0.0357); Loss of catalytic residue at K615 (P = 0.0631); Gain of loop (P = 0.1069)
17:44087747:A:T,P10636,K615N,0.551,Loss of methylation at K615 (P = 0.0041); Loss of ubiquitination at K615 (P = 0.0134); Loss of sheet (P = 0.0357); Loss of catalytic residue at K615 (P = 0.0631); Gain of loop (P = 0.1069)
17:44087748:C:A,P10636,H616N,0.762,Loss of sheet (P = 0.0315); Gain of relative solvent accessibility (P = 0.0507); Gain of ubiquitination at K615 (P = 0.0751); Gain of loop (P = 0.1069); Gain of catalytic residue at H616 (P = 0.1072)
17:44087748:C:G,P10636,H616D,0.781,Loss of sheet (P = 0.0315); Gain of ubiquitination at K615 (P = 0.0359); Gain of relative solvent accessibility (P = 0.0507); Gain of solvent accessibility (P = 0.1071); Loss of MoRF binding (P = 0.154)
17:44087748:C:T,P10636,H616Y,0.772,Gain of methylation at K611 (P = 0.0602); Loss of disorder (P = 0.0674); Loss of ubiquitination at K615 (P = 0.0787); Gain of sheet (P = 0.1451); Loss of catalytic residue at I614 (P = 0.16)
17:44087749:A:C,P10636,H616P,0.766,Loss of sheet (P = 0.0315); Gain of catalytic residue at H616 (P = 0.0339); Gain of relative solvent accessibility (P = 0.0507); Gain of ubiquitination at K611 (P = 0.0882); Gain of loop (P = 0.1069)
17:44087749:A:G,P10636,H616R,0.75,Gain of MoRF binding (P = 0.0182); Loss of ubiquitination at K615 (P = 0.0246); Gain of solvent accessibility (P = 0.0704); Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.1066)
17:44087749:A:T,P10636,H616L,0.782,Gain of sheet (P = 0.0477); Loss of methylation at K611 (P = 0.1118); Gain of ubiquitination at K611 (P = 0.1181); Loss of disorder (P = 0.1274); Loss of catalytic residue at I614 (P = 0.1625)
17:44087750:C:A,P10636,H616Q,0.778,Loss of sheet (P = 0.0817); Gain of ubiquitination at K615 (P = 0.1028); Gain of relative solvent accessibility (P = 0.1066); Gain of solvent accessibility (P = 0.1422); Loss of catalytic residue at I614 (P = 0.1646)
17:44087750:C:G,P10636,H616Q,0.778,Loss of sheet (P = 0.0817); Gain of ubiquitination at K615 (P = 0.1028); Gain of relative solvent accessibility (P = 0.1066); Gain of solvent accessibility (P = 0.1422); Loss of catalytic residue at I614 (P = 0.1646)
17:44087751:G:C,P10636,V617L,0.496,Loss of sheet (P = 0.0817); Gain of catalytic residue at V617 (P = 0.0902); Gain of ubiquitination at K615 (P = 0.1132); Loss of disorder (P = 0.2604); Loss of MoRF binding (P = 0.2659)
17:44087751:G:T,P10636,V617F,0.57,Gain of catalytic residue at V617 (P = 0.0415); Loss of sheet (P = 0.0817); Loss of disorder (P = 0.0878); Loss of ubiquitination at K615 (P = 0.1459); Gain of relative solvent accessibility (P = 0.2363)
17:44087752:T:A,P10636,V617D,0.586,Gain of catalytic residue at V617 (P = 0.0086); Gain of ubiquitination at K615 (P = 0.0337); Gain of disorder (P = 0.074); Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.09)
17:44087752:T:C,P10636,V617A,0.48,Loss of sheet (P = 0.0817); Gain of ubiquitination at K615 (P = 0.0918); Gain of catalytic residue at V617 (P = 0.1044); Gain of relative solvent accessibility (P = 0.1259); Loss of stability (P = 0.1411)
17:44087752:T:G,P10636,V617G,0.524,Loss of stability (P = 0.0151); Gain of catalytic residue at V617 (P = 0.0182); Gain of ubiquitination at K615 (P = 0.0513); Gain of disorder (P = 0.0724); Loss of sheet (P = 0.0817)
17:44087754:C:A,P10636,P618T,0.897,Loss of disorder (P = 0.0852); Gain of catalytic residue at P618 (P = 0.0874); Gain of relative solvent accessibility (P = 0.09); Loss of ubiquitination at K615 (P = 0.0907); Gain of MoRF binding (P = 0.1322)
17:44087754:C:G,P10636,P618A,0.876,Gain of catalytic residue at P618 (P = 0.0229); Loss of disorder (P = 0.0375); Gain of relative solvent accessibility (P = 0.09); Loss of ubiquitination at K615 (P = 0.0907); Gain of MoRF binding (P = 0.1171)
17:44087754:C:T,P10636,P618S,0.855,Gain of catalytic residue at P618 (P = 0.0465); Gain of sheet (P = 0.0477); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K615 (P = 0.0918); Gain of MoRF binding (P = 0.1007)
17:44087755:C:A,P10636,P618Q,0.879,Gain of solvent accessibility (P = 0.0365); Gain of MoRF binding (P = 0.0818); Gain of relative solvent accessibility (P = 0.09); Gain of sheet (P = 0.1451); Loss of ubiquitination at K615 (P = 0.1459)
17:44087755:C:G,P10636,P618R,0.858,Gain of MoRF binding (P = 0.0025); Loss of ubiquitination at K615 (P = 0.0224); Gain of solvent accessibility (P = 0.0411); Loss of sheet (P = 0.0817); Loss of disorder (P = 0.1052)
17:44087755:C:T,P10636,P618L,0.892,Gain of catalytic residue at P618 (P = 0.024); Loss of disorder (P = 0.0325); Loss of ubiquitination at K615 (P = 0.0709); Gain of sheet (P = 0.1208); Gain of MoRF binding (P = 0.1587)
17:44087757:G:A,P10636,G619R,0.707,Gain of solvent accessibility (P = 0.0014); Gain of MoRF binding (P = 0.0166); Loss of ubiquitination at K615 (P = 0.02); Gain of methylation at G619 (P = 0.0589); Loss of sheet (P = 0.0817)
17:44087757:G:C,P10636,G619R,0.707,Gain of solvent accessibility (P = 0.0014); Gain of MoRF binding (P = 0.0166); Loss of ubiquitination at K615 (P = 0.02); Gain of methylation at G619 (P = 0.0589); Loss of sheet (P = 0.0817)
17:44087758:G:A,P10636,G619E,0.738,Gain of solvent accessibility (P = 0.012); Gain of ubiquitination at K615 (P = 0.0416); Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.1571); Loss of disorder (P = 0.1807)
17:44087758:G:C,P10636,G619A,0.76,Loss of disorder (P = 0.0529); Loss of sheet (P = 0.0817); Loss of ubiquitination at K615 (P = 0.0907); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.204)
17:44087758:G:T,P10636,G619V,0.778,Loss of disorder (P = 0.0651); Loss of ubiquitination at K615 (P = 0.0787); Gain of sheet (P = 0.1208); Gain of solvent accessibility (P = 0.1683); Gain of MoRF binding (P = 0.3231)
17:44087760:G:A,P10636,G620S,0.793,Gain of glycosylation at G620 (P = 0.0252); Gain of ubiquitination at K615 (P = 0.0822); Gain of disorder (P = 0.0953); Gain of sheet (P = 0.1451); Gain of catalytic residue at Q624 (P = 0.1686)
17:44087760:G:C,P10636,G620R,0.78,Gain of solvent accessibility (P = 0.0097); Gain of MoRF binding (P = 0.0127); Gain of methylation at G620 (P = 0.0199); Loss of ubiquitination at K615 (P = 0.0219); Loss of catalytic residue at G621 (P = 0.1146)
17:44087760:G:T,P10636,G620C,0.826,Loss of disorder (P = 0.0702); Loss of ubiquitination at K615 (P = 0.0709); Loss of relative solvent accessibility (P = 0.1807); Loss of sheet (P = 0.302); Loss of MoRF binding (P = 0.3514)
17:44087761:G:A,P10636,G620D,0.799,Gain of solvent accessibility (P = 0.0354); Gain of ubiquitination at K615 (P = 0.0359); Gain of sheet (P = 0.1451); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at S622 (P = 0.2051)
17:44087761:G:C,P10636,G620A,0.859,Loss of disorder (P = 0.0503); Loss of ubiquitination at K615 (P = 0.0787); Loss of sheet (P = 0.1398); Gain of MoRF binding (P = 0.3491); Gain of solvent accessibility (P = 0.367)
17:44087761:G:T,P10636,G620V,0.853,Loss of ubiquitination at K615 (P = 0.0505); Loss of disorder (P = 0.0584); Gain of sheet (P = 0.1208); Loss of relative solvent accessibility (P = 0.3219); Gain of MoRF binding (P = 0.3398)
17:44087763:G:A,P10636,G621S,0.875,Gain of relative solvent accessibility (P = 0.0479); Gain of phosphorylation at G621 (P = 0.0762); Gain of disorder (P = 0.0936); Gain of solvent accessibility (P = 0.11); Loss of sheet (P = 0.1398)
17:44087763:G:C,P10636,G621R,0.881,Gain of solvent accessibility (P = 0.0171); Gain of MoRF binding (P = 0.0415); Gain of relative solvent accessibility (P = 0.0479); Loss of disorder (P = 0.1423); Gain of methylation at G621 (P = 0.1424)
17:44087763:G:T,P10636,G621C,0.92,Loss of disorder (P = 0.0649); Gain of catalytic residue at V623 (P = 0.1451); Gain of relative solvent accessibility (P = 0.281); Loss of sheet (P = 0.302); Loss of MoRF binding (P = 0.3317)
17:44087764:G:A,P10636,G621D,0.885,Gain of relative solvent accessibility (P = 0.0215); Gain of solvent accessibility (P = 0.0306); Loss of catalytic residue at G619 (P = 0.0551); Loss of sheet (P = 0.1398); Gain of disorder (P = 0.2129)
17:44087764:G:C,P10636,G621A,0.946,Loss of disorder (P = 0.0488); Loss of sheet (P = 0.302); Loss of catalytic residue at S622 (P = 0.3254); Gain of MoRF binding (P = 0.3402); Loss of loop (P = 0.3664)
17:44087764:G:T,P10636,G621V,0.927,Loss of disorder (P = 0.054); Gain of sheet (P = 0.1208); Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at G619 (P = 0.2718); Gain of MoRF binding (P = 0.3244)
17:44087766:A:C,P10636,S622R,0.593,Gain of methylation at S622 (P = 0.0469); Gain of MoRF binding (P = 0.0492); Gain of solvent accessibility (P = 0.0584); Loss of disorder (P = 0.0644); Gain of relative solvent accessibility (P = 0.09)
17:44087766:A:G,P10636,S622G,0.583,Gain of catalytic residue at P618 (P = 0.0761); Gain of relative solvent accessibility (P = 0.09); Loss of disorder (P = 0.1333); Loss of sheet (P = 0.1907); Gain of solvent accessibility (P = 0.2863)
17:44087766:A:T,P10636,S622C,0.635,Loss of disorder (P = 0.0266); Loss of phosphorylation at Y627 (P = 0.1288); Gain of sheet (P = 0.1539); Gain of catalytic residue at S622 (P = 0.225); Loss of MoRF binding (P = 0.3008)
17:44087767:G:A,P10636,S622N,0.67,Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0766); Loss of disorder (P = 0.1047); Gain of catalytic residue at S622 (P = 0.189); Loss of sheet (P = 0.1907)
17:44087767:G:C,P10636,S622T,0.574,Loss of disorder (P = 0.0532); Gain of relative solvent accessibility (P = 0.09); Gain of sheet (P = 0.1539); Gain of solvent accessibility (P = 0.1683); Loss of phosphorylation at Y627 (P = 0.2962)
17:44087767:G:T,P10636,S622I,0.561,Loss of disorder (P = 0.0084); Gain of relative solvent accessibility (P = 0.1259); Loss of phosphorylation at Y627 (P = 0.1468); Gain of sheet (P = 0.1539); Gain of solvent accessibility (P = 0.2192)
17:44087768:T:A,P10636,S622R,0.593,Gain of methylation at S622 (P = 0.0469); Gain of MoRF binding (P = 0.0492); Gain of solvent accessibility (P = 0.0584); Loss of disorder (P = 0.0644); Gain of relative solvent accessibility (P = 0.09)
17:44087768:T:G,P10636,S622R,0.593,Gain of methylation at S622 (P = 0.0469); Gain of MoRF binding (P = 0.0492); Gain of solvent accessibility (P = 0.0584); Loss of disorder (P = 0.0644); Gain of relative solvent accessibility (P = 0.09)
17:44091609:G:A,P10636,V623M,0.731,Gain of ubiquitination at K628 (P = 0.0972); Loss of sheet (P = 0.1398); Gain of disorder (P = 0.1719); Loss of methylation at K628 (P = 0.1725); Gain of phosphorylation at Y627 (P = 0.2292)
17:44091609:G:C,P10636,V623L,0.682,Loss of methylation at K628 (P = 0.1013); Gain of catalytic residue at Q624 (P = 0.1599); Loss of ubiquitination at K628 (P = 0.1601); Loss of phosphorylation at Y627 (P = 0.2399); Loss of disorder (P = 0.2444)
17:44091609:G:T,P10636,V623L,0.682,Loss of methylation at K628 (P = 0.1013); Gain of catalytic residue at Q624 (P = 0.1599); Loss of ubiquitination at K628 (P = 0.1601); Loss of phosphorylation at Y627 (P = 0.2399); Loss of disorder (P = 0.2444)
17:44091610:T:A,P10636,V623E,0.818,Loss of sheet (P = 0.0357); Gain of solvent accessibility (P = 0.0411); Gain of ubiquitination at K628 (P = 0.0421); Gain of relative solvent accessibility (P = 0.0479); Gain of disorder (P = 0.0486)
17:44091610:T:C,P10636,V623A,0.733,Gain of ubiquitination at K628 (P = 0.0972); Gain of loop (P = 0.1069); Loss of methylation at K628 (P = 0.1221); Loss of sheet (P = 0.1398); Gain of catalytic residue at V623 (P = 0.1568)
17:44091610:T:G,P10636,V623G,0.818,Gain of glycosylation at S622 (P = 0.0174); Loss of sheet (P = 0.0357); Gain of disorder (P = 0.0368); Gain of ubiquitination at K628 (P = 0.0522); Loss of stability (P = 0.0856)
17:44091612:C:A,P10636,Q624K,0.711,Gain of methylation at Q624 (P = 0.0109); Loss of ubiquitination at K628 (P = 0.0428); Gain of MoRF binding (P = 0.0563); Gain of disorder (P = 0.0755); Loss of phosphorylation at Y627 (P = 0.2017)
17:44091612:C:G,P10636,Q624E,0.686,Gain of ubiquitination at K628 (P = 0.0585); Gain of catalytic residue at Q624 (P = 0.1215); Loss of methylation at K628 (P = 0.1541); Gain of phosphorylation at Y627 (P = 0.1817); Loss of MoRF binding (P = 0.2054)
17:44091613:A:C,P10636,Q624P,0.723,Gain of disorder (P = 0.1067); Gain of methylation at K628 (P = 0.1109); Gain of ubiquitination at K628 (P = 0.1375); Gain of glycosylation at S622 (P = 0.1564); Loss of MoRF binding (P = 0.2097)
17:44091613:A:G,P10636,Q624R,0.678,Gain of MoRF binding (P = 0.021); Loss of ubiquitination at K628 (P = 0.0385); Gain of phosphorylation at S622 (P = 0.1189); Gain of catalytic residue at Q624 (P = 0.1193); Loss of methylation at K628 (P = 0.1342)
17:44091613:A:T,P10636,Q624L,0.643,Loss of disorder (P = 0.0418); Loss of methylation at K628 (P = 0.1256); Loss of phosphorylation at Y627 (P = 0.1261); Gain of ubiquitination at K628 (P = 0.1375); Loss of MoRF binding (P = 0.2375)
17:44091614:A:C,P10636,Q624H,0.684,Gain of methylation at K628 (P = 0.1469); Loss of ubiquitination at K628 (P = 0.1601); Loss of disorder (P = 0.1713); Gain of catalytic residue at Q624 (P = 0.273); Loss of MoRF binding (P = 0.2749)
17:44091614:A:T,P10636,Q624H,0.684,Gain of methylation at K628 (P = 0.1469); Loss of ubiquitination at K628 (P = 0.1601); Loss of disorder (P = 0.1713); Gain of catalytic residue at Q624 (P = 0.273); Loss of MoRF binding (P = 0.2749)
17:44091615:A:C,P10636,I625L,0.642,Loss of methylation at K628 (P = 0.0809); Gain of ubiquitination at K628 (P = 0.0972); Gain of disorder (P = 0.1322); Gain of phosphorylation at Y627 (P = 0.2122); Loss of catalytic residue at V626 (P = 0.2361)
17:44091615:A:G,P10636,I625V,0.615,Gain of catalytic residue at I625 (P = 0.0772); Gain of ubiquitination at K628 (P = 0.0837); Gain of disorder (P = 0.0959); Loss of methylation at K628 (P = 0.1327); Gain of phosphorylation at Y627 (P = 0.1874)
17:44091615:A:T,P10636,I625L,0.642,Loss of methylation at K628 (P = 0.0809); Gain of ubiquitination at K628 (P = 0.0972); Gain of disorder (P = 0.1322); Gain of phosphorylation at Y627 (P = 0.2122); Loss of catalytic residue at V626 (P = 0.2361)
17:44091616:T:A,P10636,I625K,0.776,Gain of disorder (P = 0.0079); Loss of ubiquitination at K628 (P = 0.0367); Gain of methylation at I625 (P = 0.0462); Gain of MoRF binding (P = 0.0528); Loss of stability (P = 0.0662)
17:44091616:T:C,P10636,I625T,0.741,Gain of disorder (P = 0.0407); Loss of stability (P = 0.0492); Gain of ubiquitination at K628 (P = 0.056); Gain of phosphorylation at I625 (P = 0.0797); Gain of relative solvent accessibility (P = 0.1259)
17:44091616:T:G,P10636,I625R,0.801,Gain of MoRF binding (P = 0.0221); Gain of disorder (P = 0.0346); Loss of ubiquitination at K628 (P = 0.0367); Gain of phosphorylation at S622 (P = 0.1189); Gain of relative solvent accessibility (P = 0.1259)
17:44091617:A:G,P10636,I625M,0.698,Gain of ubiquitination at K628 (P = 0.0693); Gain of disorder (P = 0.0707); Gain of sheet (P = 0.1451); Loss of methylation at K628 (P = 0.1531); Loss of phosphorylation at Y627 (P = 0.1583)
17:44091618:G:A,P10636,V626I,0.548,Gain of methylation at K628 (P = 0.0841); Gain of ubiquitination at K628 (P = 0.1128); Loss of phosphorylation at Y627 (P = 0.1423); Loss of disorder (P = 0.1518); Loss of sheet (P = 0.1907)
17:44091618:G:C,P10636,V626L,0.598,Loss of methylation at K628 (P = 0.0985); Gain of ubiquitination at K628 (P = 0.1375); Gain of catalytic residue at Q624 (P = 0.1596); Loss of phosphorylation at Y627 (P = 0.1636); Loss of disorder (P = 0.2434)
17:44091618:G:T,P10636,V626F,0.584,Loss of disorder (P = 0.0736); Gain of ubiquitination at K628 (P = 0.0972); Gain of relative solvent accessibility (P = 0.1259); Loss of phosphorylation at Y627 (P = 0.1381); Loss of methylation at K628 (P = 0.178)
17:44091619:T:A,P10636,V626D,0.705,Gain of disorder (P = 0.0324); Gain of ubiquitination at K628 (P = 0.0398); Loss of methylation at K628 (P = 0.0475); Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.1046)
17:44091619:T:C,P10636,V626A,0.61,Loss of stability (P = 0.0581); Gain of ubiquitination at K628 (P = 0.0585); Loss of methylation at K628 (P = 0.0901); Gain of sheet (P = 0.1945); Loss of disorder (P = 0.2284)
17:44091619:T:G,P10636,V626G,0.685,Loss of stability (P = 0.0023); Gain of disorder (P = 0.0362); Gain of ubiquitination at K628 (P = 0.0635); Loss of methylation at K628 (P = 0.0949); Loss of loop (P = 0.0986)
17:44091621:T:A,P10636,Y627N,0.545,Gain of disorder (P = 0.0128); Loss of phosphorylation at Y627 (P = 0.0307); Gain of ubiquitination at K628 (P = 0.0458); Gain of loop (P = 0.069); Gain of catalytic residue at Y627 (P = 0.07)
17:44091621:T:C,P10636,Y627H,0.529,Gain of disorder (P = 0.0175); Loss of phosphorylation at Y627 (P = 0.0307); Gain of ubiquitination at K628 (P = 0.0522); Gain of methylation at K628 (P = 0.0745); Loss of sheet (P = 0.0817)
17:44091621:T:G,P10636,Y627D,0.534,Gain of disorder (P = 0.0093); Gain of ubiquitination at K628 (P = 0.029); Loss of phosphorylation at Y627 (P = 0.0307); Loss of sheet (P = 0.0315); Gain of loop (P = 0.069)
17:44091622:A:C,P10636,Y627S,0.53,Gain of disorder (P = 0.0052); Gain of ubiquitination at K628 (P = 0.0475); Loss of phosphorylation at Y627 (P = 0.0533); Gain of glycosylation at Y627 (P = 0.0799); Loss of sheet (P = 0.0817)
17:44091622:A:G,P10636,Y627C,0.662,Gain of methylation at K628 (P = 0.0184); Loss of phosphorylation at Y627 (P = 0.0307); Gain of disorder (P = 0.035); Gain of ubiquitination at K628 (P = 0.0972); Gain of catalytic residue at I625 (P = 0.1983)
17:44091622:A:T,P10636,Y627F,0.615,Loss of phosphorylation at Y627 (P = 0.0307); Gain of methylation at K628 (P = 0.0308); Gain of catalytic residue at Y627 (P = 0.1093); Loss of ubiquitination at K628 (P = 0.1601); Gain of disorder (P = 0.1969)
17:44091624:A:C,P10636,K628Q,0.699,Loss of ubiquitination at K628 (P = 0.0244); Loss of methylation at K628 (P = 0.0316); Loss of MoRF binding (P = 0.1261); Loss of disorder (P = 0.143); Gain of sheet (P = 0.1451)
17:44091624:A:G,P10636,K628E,0.696,Loss of ubiquitination at K628 (P = 0.0244); Loss of methylation at K628 (P = 0.0316); Loss of MoRF binding (P = 0.0755); Loss of disorder (P = 0.0924); Gain of sheet (P = 0.1451)
17:44091625:A:C,P10636,K628T,0.676,Loss of ubiquitination at K628 (P = 0.0244); Loss of methylation at K628 (P = 0.0316); Loss of disorder (P = 0.0519); Loss of catalytic residue at K628 (P = 0.0632); Loss of MoRF binding (P = 0.1118)
17:44091625:A:G,P10636,K628R,0.678,Loss of ubiquitination at K628 (P = 0.0244); Loss of methylation at K628 (P = 0.0422); Loss of disorder (P = 0.057); Gain of sheet (P = 0.1451); Gain of MoRF binding (P = 0.1511)
17:44091625:A:T,P10636,K628I,0.652,Loss of catalytic residue at K628 (P = 0.0069); Loss of disorder (P = 0.0079); Loss of ubiquitination at K628 (P = 0.0244); Loss of methylation at K628 (P = 0.0316); Gain of sheet (P = 0.0477)
17:44091626:A:C,P10636,K628N,0.684,Loss of ubiquitination at K628 (P = 0.0244); Loss of catalytic residue at K628 (P = 0.0291); Loss of methylation at K628 (P = 0.0316); Loss of sheet (P = 0.0817); Loss of disorder (P = 0.0922)
17:44091626:A:T,P10636,K628N,0.684,Loss of ubiquitination at K628 (P = 0.0244); Loss of catalytic residue at K628 (P = 0.0291); Loss of methylation at K628 (P = 0.0316); Loss of sheet (P = 0.0817); Loss of disorder (P = 0.0922)
17:44091627:C:A,P10636,P629T,0.585,Gain of sheet (P = 0.0477); Gain of MoRF binding (P = 0.0654); Gain of ubiquitination at K628 (P = 0.0754); Loss of disorder (P = 0.0786); Loss of loop (P = 0.0986)
17:44091627:C:G,P10636,P629A,0.591,Loss of disorder (P = 0.0292); Gain of sheet (P = 0.0344); Gain of ubiquitination at K628 (P = 0.056); Gain of MoRF binding (P = 0.0564); Loss of loop (P = 0.0986)
17:44091627:C:T,P10636,P629S,0.545,Gain of MoRF binding (P = 0.0597); Loss of methylation at K628 (P = 0.0898); Gain of ubiquitination at K628 (P = 0.0972); Gain of sheet (P = 0.1208); Gain of disorder (P = 0.157)
17:44091628:C:A,P10636,P629Q,0.572,Gain of catalytic residue at P629 (P = 0.0213); Gain of sheet (P = 0.0477); Gain of MoRF binding (P = 0.0612); Loss of loop (P = 0.0986); Gain of ubiquitination at K628 (P = 0.1128)
17:44091628:C:G,P10636,P629R,0.597,Gain of MoRF binding (P = 0.0039); Loss of ubiquitination at K634 (P = 0.0245); Loss of disorder (P = 0.086); Loss of methylation at K628 (P = 0.096); Loss of loop (P = 0.0986)
17:44091628:C:T,P10636,P629L,0.701,Loss of disorder (P = 0.0278); Gain of sheet (P = 0.0344); Loss of loop (P = 0.0374); Loss of ubiquitination at K634 (P = 0.0505); Gain of MoRF binding (P = 0.0672)
17:44091630:G:A,P10636,V630I,0.381,Gain of ubiquitination at K628 (P = 0.1128); Gain of methylation at K628 (P = 0.1205); Loss of disorder (P = 0.1538); Loss of MoRF binding (P = 0.2298); Loss of phosphorylation at Y627 (P = 0.2333)
17:44091630:G:C,P10636,V630L,0.462,Gain of catalytic residue at V630 (P = 0.0186); Loss of sheet (P = 0.0817); Loss of methylation at K628 (P = 0.0838); Gain of ubiquitination at K628 (P = 0.0972); Loss of phosphorylation at Y627 (P = 0.1252)
17:44091630:G:T,P10636,V630F,0.64,Loss of disorder (P = 0.0773); Loss of sheet (P = 0.0817); Gain of ubiquitination at K628 (P = 0.0972); Loss of phosphorylation at Y627 (P = 0.1076); Loss of methylation at K628 (P = 0.1228)
17:44091631:T:A,P10636,V630D,0.675,Gain of relative solvent accessibility (P = 0.0023); Gain of solvent accessibility (P = 0.0039); Loss of sheet (P = 0.0181); Gain of loop (P = 0.0312); Gain of ubiquitination at K628 (P = 0.0329)
17:44091631:T:C,P10636,V630A,0.567,Gain of relative solvent accessibility (P = 0.0082); Loss of sheet (P = 0.0315); Gain of solvent accessibility (P = 0.0503); Loss of stability (P = 0.0652); Gain of loop (P = 0.069)
17:44091631:T:G,P10636,V630G,0.63,Gain of relative solvent accessibility (P = 0.0023); Loss of stability (P = 0.0062); Loss of sheet (P = 0.0181); Gain of catalytic residue at V630 (P = 0.025); Gain of loop (P = 0.0312)
17:44091633:G:A,P10636,D631N,0.706,Loss of ubiquitination at K634 (P = 0.0245); Gain of MoRF binding (P = 0.0346); Gain of methylation at K628 (P = 0.078); Loss of phosphorylation at Y627 (P = 0.1162); Gain of sheet (P = 0.1208)
17:44091633:G:C,P10636,D631H,0.702,Loss of ubiquitination at K634 (P = 0.022); Gain of sheet (P = 0.0266); Gain of methylation at K634 (P = 0.0472); Gain of MoRF binding (P = 0.0532); Loss of loop (P = 0.0986)
17:44091633:G:T,P10636,D631Y,0.69,Gain of sheet (P = 0.0101); Loss of ubiquitination at K634 (P = 0.0211); Loss of disorder (P = 0.0279); Loss of loop (P = 0.0374); Gain of methylation at K634 (P = 0.0624)
17:44091634:A:C,P10636,D631A,0.756,Gain of sheet (P = 0.0266); Loss of ubiquitination at K634 (P = 0.0271); Gain of methylation at K634 (P = 0.0493); Loss of disorder (P = 0.0544); Gain of MoRF binding (P = 0.0625)
17:44091634:A:G,P10636,D631G,0.744,Loss of ubiquitination at K634 (P = 0.0271); Gain of sheet (P = 0.0344); Gain of methylation at K628 (P = 0.0448); Gain of catalytic residue at D631 (P = 0.0468); Gain of MoRF binding (P = 0.0586)
17:44091634:A:T,P10636,D631V,0.686,Gain of sheet (P = 0.0061); Loss of loop (P = 0.0235); Loss of ubiquitination at K634 (P = 0.0271); Gain of methylation at K634 (P = 0.0351); Gain of catalytic residue at D631 (P = 0.0448)
17:44091635:C:A,P10636,D631E,0.726,Gain of sheet (P = 0.0221); Loss of loop (P = 0.0374); Loss of ubiquitination at K634 (P = 0.0609); Gain of methylation at K628 (P = 0.0751); Loss of phosphorylation at Y627 (P = 0.1811)
17:44091635:C:G,P10636,D631E,0.726,Gain of sheet (P = 0.0221); Loss of loop (P = 0.0374); Loss of ubiquitination at K634 (P = 0.0609); Gain of methylation at K628 (P = 0.0751); Loss of phosphorylation at Y627 (P = 0.1811)
17:44091636:C:A,P10636,L632M,0.634,Gain of methylation at K628 (P = 0.0517); Gain of MoRF binding (P = 0.1034); Gain of disorder (P = 0.1315); Loss of ubiquitination at K634 (P = 0.1372); Gain of sheet (P = 0.1945)
17:44091636:C:G,P10636,L632V,0.612,Gain of sheet (P = 0.0477); Gain of methylation at K628 (P = 0.0746); Gain of ubiquitination at K628 (P = 0.0972); Gain of MoRF binding (P = 0.1642); Gain of disorder (P = 0.1642)
17:44091637:T:A,P10636,L632Q,0.681,Gain of disorder (P = 0.0334); Gain of sheet (P = 0.0344); Gain of methylation at K628 (P = 0.0357); Gain of solvent accessibility (P = 0.0374); Gain of relative solvent accessibility (P = 0.0479)
17:44091637:T:C,P10636,L632P,0.745,Gain of disorder (P = 0.0233); Gain of methylation at K628 (P = 0.0385); Gain of sheet (P = 0.0477); Gain of relative solvent accessibility (P = 0.0479); Gain of ubiquitination at K628 (P = 0.0635)
17:44091637:T:G,P10636,L632R,0.737,Gain of solvent accessibility (P = 0.0171); Gain of MoRF binding (P = 0.0193); Loss of ubiquitination at K634 (P = 0.0235); Gain of sheet (P = 0.0344); Gain of methylation at K628 (P = 0.039)
17:44091639:A:C,P10636,S633R,0.501,Loss of ubiquitination at K634 (P = 0.0211); Gain of MoRF binding (P = 0.0244); Gain of solvent accessibility (P = 0.0367); Loss of disorder (P = 0.0663); Loss of methylation at K628 (P = 0.1029)
17:44091639:A:G,P10636,S633G,0.494,Loss of stability (P = 0.0175); Gain of loop (P = 0.0502); Gain of catalytic residue at P629 (P = 0.0721); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K634 (P = 0.0931)
17:44091639:A:T,P10636,S633C,0.609,Gain of methylation at K634 (P = 0.0127); Loss of disorder (P = 0.0268); Gain of sheet (P = 0.0477); Loss of ubiquitination at K634 (P = 0.0478); Gain of catalytic residue at S637 (P = 0.0886)
17:44091640:G:A,P10636,S633N,0.426,Loss of ubiquitination at K634 (P = 0.0863); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917); Loss of disorder (P = 0.0974); Loss of stability (P = 0.1246)
17:44091640:G:C,P10636,S633T,0.546,Loss of ubiquitination at K634 (P = 0.057); Loss of disorder (P = 0.0622); Loss of stability (P = 0.0765); Gain of relative solvent accessibility (P = 0.09); Gain of sheet (P = 0.1208)
17:44091640:G:T,P10636,S633I,0.606,Gain of sheet (P = 0.0061); Loss of disorder (P = 0.0063); Loss of ubiquitination at K634 (P = 0.0304); Gain of methylation at K634 (P = 0.0424); Loss of loop (P = 0.0512)
17:44091641:C:A,P10636,S633R,0.501,Loss of ubiquitination at K634 (P = 0.0211); Gain of MoRF binding (P = 0.0244); Gain of solvent accessibility (P = 0.0367); Loss of disorder (P = 0.0663); Loss of methylation at K628 (P = 0.1029)
17:44091641:C:G,P10636,S633R,0.501,Loss of ubiquitination at K634 (P = 0.0211); Gain of MoRF binding (P = 0.0244); Gain of solvent accessibility (P = 0.0367); Loss of disorder (P = 0.0663); Loss of methylation at K628 (P = 0.1029)
17:44091642:A:C,P10636,K634Q,0.559,Loss of ubiquitination at K634 (P = 0.0155); Gain of glycosylation at S637 (P = 0.0651); Gain of helix (P = 0.0854); Loss of MoRF binding (P = 0.0946); Loss of methylation at K634 (P = 0.1041)
17:44091642:A:G,P10636,K634E,0.585,Loss of ubiquitination at K634 (P = 0.0155); Loss of MoRF binding (P = 0.0555); Loss of sheet (P = 0.0817); Gain of helix (P = 0.0854); Loss of methylation at K634 (P = 0.1041)
17:44091643:A:C,P10636,K634T,0.637,Loss of ubiquitination at K634 (P = 0.0155); Gain of catalytic residue at S633 (P = 0.0533); Loss of disorder (P = 0.0589); Gain of glycosylation at S637 (P = 0.0609); Loss of MoRF binding (P = 0.0792)
17:44091643:A:G,P10636,K634R,0.545,Loss of ubiquitination at K634 (P = 0.0155); Loss of disorder (P = 0.0629); Gain of MoRF binding (P = 0.0803); Gain of glycosylation at S637 (P = 0.1349); Loss of methylation at K634 (P = 0.1554)
17:44091643:A:T,P10636,K634M,0.75,Gain of catalytic residue at V630 (P = 0.0127); Loss of ubiquitination at K634 (P = 0.0155); Loss of disorder (P = 0.0289); Gain of glycosylation at S637 (P = 0.086); Loss of MoRF binding (P = 0.0944)
17:44091644:G:C,P10636,K634N,0.578,Loss of ubiquitination at K634 (P = 0.0155); Gain of glycosylation at S637 (P = 0.0635); Gain of loop (P = 0.0851); Loss of MoRF binding (P = 0.0898); Loss of disorder (P = 0.0903)
17:44091644:G:T,P10636,K634N,0.578,Loss of ubiquitination at K634 (P = 0.0155); Gain of glycosylation at S637 (P = 0.0635); Gain of loop (P = 0.0851); Loss of MoRF binding (P = 0.0898); Loss of disorder (P = 0.0903)
17:44091645:G:A,P10636,V635M,0.734,Loss of ubiquitination at K634 (P = 0.1166); Loss of methylation at K634 (P = 0.13); Loss of sheet (P = 0.1398); Gain of MoRF binding (P = 0.1806); Gain of disorder (P = 0.2025)
17:44091645:G:C,P10636,V635L,0.744,Loss of ubiquitination at K634 (P = 0.0609); Loss of methylation at K638 (P = 0.1684); Loss of MoRF binding (P = 0.1813); Loss of sheet (P = 0.1907); Gain of loop (P = 0.2045)
17:44091645:G:T,P10636,V635L,0.744,Loss of ubiquitination at K634 (P = 0.0609); Loss of methylation at K638 (P = 0.1684); Loss of MoRF binding (P = 0.1813); Loss of sheet (P = 0.1907); Gain of loop (P = 0.2045)
17:44091646:T:A,P10636,V635E,0.809,Gain of solvent accessibility (P = 0.0145); Gain of relative solvent accessibility (P = 0.0215); Gain of ubiquitination at K638 (P = 0.0258); Gain of disorder (P = 0.0626); Loss of MoRF binding (P = 0.0791)
17:44091646:T:C,P10636,V635A,0.718,Loss of stability (P = 0.0354); Gain of ubiquitination at K634 (P = 0.1204); Loss of sheet (P = 0.1398); Loss of methylation at K638 (P = 0.2004); Gain of loop (P = 0.2045)
17:44091646:T:G,P10636,V635G,0.755,Loss of stability (P = 0.0047); Gain of loop (P = 0.024); Gain of relative solvent accessibility (P = 0.0479); Loss of sheet (P = 0.0483); Gain of disorder (P = 0.0609)
17:44091648:A:C,P10636,T636P,0.521,Gain of loop (P = 0.0435); Gain of disorder (P = 0.046); Gain of catalytic residue at T636 (P = 0.0524); Loss of ubiquitination at K634 (P = 0.0755); Loss of MoRF binding (P = 0.1069)
17:44091648:A:G,P10636,T636A,0.391,Gain of helix (P = 0.0854); Loss of ubiquitination at K634 (P = 0.0992); Gain of MoRF binding (P = 0.19); Loss of sheet (P = 0.1907); Loss of disorder (P = 0.2035)
17:44091648:A:T,P10636,T636S,0.332,Gain of disorder (P = 0.0379); Gain of sheet (P = 0.1208); Loss of ubiquitination at K634 (P = 0.1372); Gain of phosphorylation at S641 (P = 0.1819); Gain of loop (P = 0.2045)
17:44091649:C:A,P10636,T636N,0.41,Gain of catalytic residue at T636 (P = 0.0265); Loss of ubiquitination at K634 (P = 0.0755); Gain of disorder (P = 0.1101); Gain of relative solvent accessibility (P = 0.1894); Loss of sheet (P = 0.1907)
17:44091649:C:G,P10636,T636S,0.332,Gain of disorder (P = 0.0379); Gain of sheet (P = 0.1208); Loss of ubiquitination at K634 (P = 0.1372); Gain of phosphorylation at S641 (P = 0.1819); Gain of loop (P = 0.2045)
17:44091649:C:T,P10636,T636I,0.454,Loss of ubiquitination at K634 (P = 0.0342); Gain of sheet (P = 0.0344); Gain of methylation at K634 (P = 0.0557); Loss of loop (P = 0.0804); Loss of disorder (P = 0.1035)
17:44091651:T:A,P10636,S637T,0.736,Gain of relative solvent accessibility (P = 0.0215); Gain of solvent accessibility (P = 0.0456); Loss of disorder (P = 0.066); Loss of stability (P = 0.085); Loss of ubiquitination at K634 (P = 0.0863)
17:44091651:T:C,P10636,S637P,0.737,Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0256); Gain of loop (P = 0.0435); Loss of ubiquitination at K634 (P = 0.0863); Loss of MoRF binding (P = 0.1007)
17:44091651:T:G,P10636,S637A,0.736,Gain of relative solvent accessibility (P = 0.0082); Loss of disorder (P = 0.0217); Gain of solvent accessibility (P = 0.0503); Loss of stability (P = 0.0618); Loss of glycosylation at S637 (P = 0.08)
17:44091652:C:A,P10636,S637Y,0.754,Loss of disorder (P = 0.004); Loss of ubiquitination at K634 (P = 0.0363); Gain of catalytic residue at L632 (P = 0.0705); Gain of solvent accessibility (P = 0.0739); Loss of glycosylation at S637 (P = 0.08)
17:44091652:C:G,P10636,S637C,0.789,Loss of disorder (P = 0.0244); Gain of sheet (P = 0.0477); Loss of ubiquitination at K634 (P = 0.0609); Loss of glycosylation at S637 (P = 0.08); Loss of loop (P = 0.0804)
17:44091652:C:T,P10636,S637F,0.788,Loss of disorder (P = 0.0034); Loss of ubiquitination at K634 (P = 0.0369); Gain of sheet (P = 0.0477); Loss of glycosylation at S637 (P = 0.08); Loss of loop (P = 0.0804)
17:44091654:A:C,P10636,K638Q,0.733,Loss of methylation at K638 (P = 0.0068); Loss of MoRF binding (P = 0.0946); Gain of ubiquitination at K634 (P = 0.1204); Loss of disorder (P = 0.1539); Loss of catalytic residue at K638 (P = 0.1743)
17:44091654:A:G,P10636,K638E,0.736,Loss of methylation at K638 (P = 0.0068); Loss of MoRF binding (P = 0.0548); Gain of ubiquitination at K634 (P = 0.0931); Loss of disorder (P = 0.1417); Loss of glycosylation at S637 (P = 0.1856)
17:44091655:A:C,P10636,K638T,0.725,Loss of methylation at K638 (P = 0.0068); Gain of glycosylation at K638 (P = 0.0572); Loss of disorder (P = 0.0677); Loss of MoRF binding (P = 0.082); Loss of catalytic residue at K638 (P = 0.0868)
17:44091655:A:G,P10636,K638R,0.742,Loss of methylation at K638 (P = 0.0141); Loss of disorder (P = 0.0828); Gain of MoRF binding (P = 0.0942); Loss of ubiquitination at K634 (P = 0.0992); Gain of sheet (P = 0.1208)
17:44091655:A:T,P10636,K638M,0.746,Loss of methylation at K638 (P = 0.0068); Loss of catalytic residue at K638 (P = 0.0215); Loss of disorder (P = 0.0304); Loss of glycosylation at S637 (P = 0.0985); Loss of MoRF binding (P = 0.1059)
17:44091656:G:C,P10636,K638N,0.706,Loss of methylation at K638 (P = 0.0068); Gain of loop (P = 0.0851); Loss of MoRF binding (P = 0.0884); Loss of disorder (P = 0.1072); Gain of ubiquitination at K634 (P = 0.1204)
17:44091656:G:T,P10636,K638N,0.706,Loss of methylation at K638 (P = 0.0068); Gain of loop (P = 0.0851); Loss of MoRF binding (P = 0.0884); Loss of disorder (P = 0.1072); Gain of ubiquitination at K634 (P = 0.1204)
17:44091657:T:A,P10636,C639S,0.706,Loss of methylation at K638 (P = 0.0136); Gain of disorder (P = 0.0326); Gain of sheet (P = 0.0344); Gain of ubiquitination at K634 (P = 0.0609); Gain of glycosylation at C639 (P = 0.0635)
17:44091657:T:C,P10636,C639R,0.729,Gain of MoRF binding (P = 0.0101); Loss of methylation at K638 (P = 0.0172); Loss of ubiquitination at K634 (P = 0.0235); Gain of phosphorylation at S641 (P = 0.0568); Gain of solvent accessibility (P = 0.0584)
17:44091657:T:G,P10636,C639G,0.695,Loss of methylation at K638 (P = 0.0152); Gain of loop (P = 0.024); Gain of sheet (P = 0.0344); Gain of disorder (P = 0.0545); Loss of stability (P = 0.071)
17:44091658:G:A,P10636,C639Y,0.528,Loss of methylation at K638 (P = 0.0145); Gain of phosphorylation at C639 (P = 0.043); Loss of ubiquitination at K634 (P = 0.0992); Gain of MoRF binding (P = 0.105); Gain of sheet (P = 0.1208)
17:44091658:G:C,P10636,C639S,0.706,Loss of methylation at K638 (P = 0.0136); Gain of disorder (P = 0.0326); Gain of sheet (P = 0.0344); Gain of ubiquitination at K634 (P = 0.0609); Gain of glycosylation at C639 (P = 0.0635)
17:44091658:G:T,P10636,C639F,0.557,Loss of methylation at K638 (P = 0.0362); Gain of MoRF binding (P = 0.0854); Loss of ubiquitination at K634 (P = 0.0863); Gain of sheet (P = 0.1208); Loss of disorder (P = 0.1505)
17:44091659:T:G,P10636,C639W,0.738,Gain of MoRF binding (P = 0.0074); Loss of methylation at K638 (P = 0.0188); Loss of disorder (P = 0.0523); Loss of ubiquitination at K634 (P = 0.0992); Gain of sheet (P = 0.1208)
17:44091660:G:A,P10636,G640S,0.826,Loss of catalytic residue at G640 (P = 0.0432); Gain of relative solvent accessibility (P = 0.09); Gain of disorder (P = 0.1504); Gain of solvent accessibility (P = 0.1846); Loss of glycosylation at S637 (P = 0.1851)
17:44091660:G:C,P10636,G640R,0.854,Gain of MoRF binding (P = 0.0079); Gain of solvent accessibility (P = 0.0584); Gain of helix (P = 0.0854); Gain of relative solvent accessibility (P = 0.09); Loss of glycosylation at S637 (P = 0.1152)
17:44091660:G:T,P10636,G640C,0.86,Loss of disorder (P = 0.0496); Gain of relative solvent accessibility (P = 0.1259); Loss of MoRF binding (P = 0.1465); Loss of glycosylation at S637 (P = 0.1867); Loss of catalytic residue at G640 (P = 0.2261)
17:44091661:G:A,P10636,G640D,0.87,Gain of ubiquitination at K638 (P = 0.0329); Gain of relative solvent accessibility (P = 0.09); Loss of MoRF binding (P = 0.1022); Gain of solvent accessibility (P = 0.1376); Loss of glycosylation at S637 (P = 0.1379)
17:44091661:G:C,P10636,G640A,0.879,Loss of disorder (P = 0.0612); Gain of helix (P = 0.2059); Gain of MoRF binding (P = 0.2183); Loss of glycosylation at S637 (P = 0.2285); Loss of methylation at K638 (P = 0.2827)
17:44091661:G:T,P10636,G640V,0.868,Loss of disorder (P = 0.0501); Loss of catalytic residue at G640 (P = 0.0838); Loss of loop (P = 0.0986); Gain of sheet (P = 0.1208); Gain of relative solvent accessibility (P = 0.1259)
17:44091663:T:A,P10636,S641T,0.694,Gain of relative solvent accessibility (P = 0.0479); Loss of disorder (P = 0.0704); Gain of sheet (P = 0.0827); Gain of solvent accessibility (P = 0.0917); Gain of phosphorylation at S641 (P = 0.18)
17:44091663:T:C,P10636,S641P,0.708,Gain of relative solvent accessibility (P = 0.0023); Gain of solvent accessibility (P = 0.0078); Gain of sheet (P = 0.0827); Loss of MoRF binding (P = 0.1068); Gain of loop (P = 0.1069)
17:44091663:T:G,P10636,S641A,0.791,Loss of disorder (P = 0.0231); Gain of helix (P = 0.0854); Loss of sheet (P = 0.1907); Gain of loop (P = 0.2045); Loss of MoRF binding (P = 0.2131)
17:44091664:C:T,P10636,S641L,0.749,Loss of disorder (P = 0.0129); Gain of sheet (P = 0.0827); Gain of relative solvent accessibility (P = 0.1259); Loss of MoRF binding (P = 0.1645); Gain of loop (P = 0.2045)
17:44091666:T:A,P10636,L642I,0.583,Gain of sheet (P = 0.0827); Gain of MoRF binding (P = 0.1875); Gain of loop (P = 0.2045); Gain of methylation at K638 (P = 0.2565); Loss of disorder (P = 0.2671)
17:44091666:T:G,P10636,L642V,0.48,Gain of sheet (P = 0.0827); Loss of catalytic residue at L642 (P = 0.1179); Gain of MoRF binding (P = 0.1386); Gain of loop (P = 0.2045); Gain of disorder (P = 0.2269)
17:44091667:T:C,P10636,L642S,0.46,Gain of relative solvent accessibility (P = 0.0023); Gain of solvent accessibility (P = 0.0104); Gain of glycosylation at L642 (P = 0.0278); Gain of disorder (P = 0.0373); Gain of sheet (P = 0.039)
17:44091668:A:C,P10636,L642F,0.621,Gain of sheet (P = 0.0827); Loss of disorder (P = 0.2013); Gain of loop (P = 0.2045); Loss of MoRF binding (P = 0.2235); Loss of glycosylation at S637 (P = 0.2394)
17:44091668:A:T,P10636,L642F,0.621,Gain of sheet (P = 0.0827); Loss of disorder (P = 0.2013); Gain of loop (P = 0.2045); Loss of MoRF binding (P = 0.2235); Loss of glycosylation at S637 (P = 0.2394)
17:44091669:G:A,P10636,G643S,0.425,Gain of catalytic residue at G643 (P = 0.0107); Loss of sheet (P = 0.1158); Gain of relative solvent accessibility (P = 0.1259); Gain of disorder (P = 0.1585); Gain of loop (P = 0.2045)
17:44091669:G:C,P10636,G643R,0.603,Gain of MoRF binding (P = 0.0169); Loss of ubiquitination at K648 (P = 0.0184); Gain of catalytic residue at G643 (P = 0.0558); Gain of solvent accessibility (P = 0.0584); Gain of methylation at G643 (P = 0.0602)
17:44091669:G:T,P10636,G643C,0.579,Loss of disorder (P = 0.0363); Loss of ubiquitination at K648 (P = 0.1039); Loss of sheet (P = 0.1158); Loss of MoRF binding (P = 0.1595); Loss of loop (P = 0.2237)
17:44091670:G:A,P10636,G643D,0.52,Gain of catalytic residue at G643 (P = 0.0159); Gain of ubiquitination at K638 (P = 0.0325); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0704); Loss of MoRF binding (P = 0.1038)
17:44091670:G:C,P10636,G643A,0.526,Loss of disorder (P = 0.0587); Gain of catalytic residue at G643 (P = 0.1418); Loss of ubiquitination at K648 (P = 0.2094); Gain of MoRF binding (P = 0.2156); Loss of methylation at K638 (P = 0.2547)
17:44091670:G:T,P10636,G643V,0.549,Gain of sheet (P = 0.0266); Loss of disorder (P = 0.0366); Gain of catalytic residue at G643 (P = 0.0546); Loss of ubiquitination at K648 (P = 0.0642); Loss of loop (P = 0.0986)
17:44091672:A:C,P10636,N644H,0.801,Gain of sheet (P = 0.0827); Loss of ubiquitination at K648 (P = 0.152); Gain of disorder (P = 0.2103); Loss of loop (P = 0.2237); Loss of stability (P = 0.2252)
17:44091672:A:G,P10636,N644D,0.84,Gain of relative solvent accessibility (P = 0.09); Loss of sheet (P = 0.1158); Gain of ubiquitination at K648 (P = 0.1236); Loss of MoRF binding (P = 0.1277); Gain of solvent accessibility (P = 0.1376)
17:44091672:A:T,P10636,N644Y,0.764,Gain of sheet (P = 0.0221); Loss of disorder (P = 0.0393); Loss of ubiquitination at K648 (P = 0.0432); Gain of phosphorylation at N644 (P = 0.0454); Loss of loop (P = 0.0804)
17:44091673:A:C,P10636,N644T,0.737,Gain of glycosylation at N644 (P = 0.0312); Gain of sheet (P = 0.039); Gain of phosphorylation at N644 (P = 0.0723); Loss of ubiquitination at K648 (P = 0.0731); Loss of loop (P = 0.1242)
17:44091673:A:G,P10636,N644S,0.8,Gain of phosphorylation at N644 (P = 0.0563); Gain of sheet (P = 0.0827); Gain of disorder (P = 0.094); Loss of stability (P = 0.2062); Loss of loop (P = 0.2237)
17:44091673:A:T,P10636,N644I,0.746,Gain of sheet (P = 0.0125); Loss of ubiquitination at K648 (P = 0.0345); Loss of loop (P = 0.0374); Loss of disorder (P = 0.0477); Gain of methylation at K648 (P = 0.1982)
17:44091674:C:A,P10636,N644K,0.802,Loss of ubiquitination at K648 (P = 0.0183); Gain of methylation at N644 (P = 0.0287); Gain of solvent accessibility (P = 0.0354); Gain of MoRF binding (P = 0.0367); Gain of relative solvent accessibility (P = 0.0479)
17:44091674:C:G,P10636,N644K,0.802,Loss of ubiquitination at K648 (P = 0.0183); Gain of methylation at N644 (P = 0.0287); Gain of solvent accessibility (P = 0.0354); Gain of MoRF binding (P = 0.0367); Gain of relative solvent accessibility (P = 0.0479)
17:44091675:A:C,P10636,I645L,0.772,Loss of sheet (P = 0.0457); Loss of methylation at K648 (P = 0.0677); Gain of disorder (P = 0.1977); Gain of loop (P = 0.2045); Gain of ubiquitination at K648 (P = 0.2467)
17:44091675:A:G,P10636,I645V,0.764,Loss of catalytic residue at I645 (P = 0.029); Gain of disorder (P = 0.1793); Loss of methylation at K648 (P = 0.2062); Gain of MoRF binding (P = 0.2271); Loss of ubiquitination at K648 (P = 0.2547)
17:44091675:A:T,P10636,I645F,0.784,Loss of sheet (P = 0.1158); Loss of methylation at K648 (P = 0.1879); Gain of loop (P = 0.2045); Loss of ubiquitination at K648 (P = 0.2094); Gain of relative solvent accessibility (P = 0.2363)
17:44091676:T:A,P10636,I645N,0.759,Loss of sheet (P = 0.0228); Loss of stability (P = 0.039); Gain of loop (P = 0.0435); Gain of disorder (P = 0.056); Loss of catalytic residue at I645 (P = 0.0599)
17:44091676:T:C,P10636,I645T,0.756,Loss of stability (P = 0.0184); Gain of glycosylation at I645 (P = 0.0403); Loss of sheet (P = 0.0457); Gain of disorder (P = 0.0794); Gain of loop (P = 0.0851)
17:44091676:T:G,P10636,I645S,0.731,Loss of sheet (P = 0.0228); Loss of stability (P = 0.0251); Gain of disorder (P = 0.0304); Loss of methylation at K648 (P = 0.0632); Loss of catalytic residue at I645 (P = 0.0679)
17:44091677:C:G,P10636,I645M,0.763,Loss of catalytic residue at I645 (P = 0.0146); Loss of sheet (P = 0.0457); Gain of disorder (P = 0.134); Loss of methylation at K648 (P = 0.1841); Gain of MoRF binding (P = 0.1843)
17:44091678:C:A,P10636,H646N,0.413,Gain of relative solvent accessibility (P = 0.09); Loss of sheet (P = 0.1158); Gain of solvent accessibility (P = 0.1583); Loss of stability (P = 0.197); Gain of loop (P = 0.2045)
17:44091678:C:G,P10636,H646D,0.495,Gain of relative solvent accessibility (P = 0.0289); Gain of solvent accessibility (P = 0.0674); Loss of methylation at K648 (P = 0.0751); Loss of sheet (P = 0.1158); Gain of ubiquitination at K648 (P = 0.1484)
17:44091678:C:T,P10636,H646Y,0.51,Loss of disorder (P = 0.0342); Gain of sheet (P = 0.039); Gain of phosphorylation at H646 (P = 0.0584); Loss of loop (P = 0.0804); Loss of methylation at K648 (P = 0.1783)
17:44091679:A:C,P10636,H646P,0.528,Gain of relative solvent accessibility (P = 0.0289); Loss of sheet (P = 0.0457); Gain of loop (P = 0.0851); Gain of solvent accessibility (P = 0.11); Gain of disorder (P = 0.1779)
17:44091679:A:G,P10636,H646R,0.452,Loss of ubiquitination at K648 (P = 0.0218); Gain of MoRF binding (P = 0.0269); Gain of sheet (P = 0.0827); Gain of solvent accessibility (P = 0.1133); Gain of relative solvent accessibility (P = 0.1571)
17:44091679:A:T,P10636,H646L,0.506,Gain of sheet (P = 0.039); Loss of disorder (P = 0.0688); Loss of loop (P = 0.0804); Loss of methylation at K648 (P = 0.1985); Gain of catalytic residue at H646 (P = 0.2002)
17:44091680:T:A,P10636,H646Q,0.396,Gain of sheet (P = 0.0827); Gain of solvent accessibility (P = 0.0837); Gain of relative solvent accessibility (P = 0.09); Loss of ubiquitination at K648 (P = 0.152); Loss of stability (P = 0.1955)
17:44091680:T:G,P10636,H646Q,0.396,Gain of sheet (P = 0.0827); Gain of solvent accessibility (P = 0.0837); Gain of relative solvent accessibility (P = 0.09); Loss of ubiquitination at K648 (P = 0.152); Loss of stability (P = 0.1955)
17:44091681:C:A,P10636,H647N,0.774,Gain of catalytic residue at H647 (P = 0.0283); Loss of sheet (P = 0.0457); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1422); Gain of loop (P = 0.2045)
17:44091681:C:G,P10636,H647D,0.77,Loss of sheet (P = 0.0457); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0704); Loss of methylation at K648 (P = 0.072); Gain of catalytic residue at H647 (P = 0.0727)
17:44091681:C:T,P10636,H647Y,0.822,Loss of disorder (P = 0.0355); Loss of ubiquitination at K648 (P = 0.0432); Loss of loop (P = 0.0804); Gain of sheet (P = 0.0827); Gain of phosphorylation at H647 (P = 0.1068)
17:44091682:A:C,P10636,H647P,0.762,Loss of sheet (P = 0.0457); Gain of relative solvent accessibility (P = 0.0479); Gain of catalytic residue at H647 (P = 0.0519); Gain of loop (P = 0.0851); Gain of solvent accessibility (P = 0.1014)
17:44091682:A:G,P10636,H647R,0.806,Loss of ubiquitination at K648 (P = 0.0193); Gain of MoRF binding (P = 0.0301); Gain of solvent accessibility (P = 0.0584); Gain of relative solvent accessibility (P = 0.09); Loss of sheet (P = 0.1158)
17:44091682:A:T,P10636,H647L,0.793,Gain of sheet (P = 0.039); Loss of ubiquitination at K648 (P = 0.0642); Loss of disorder (P = 0.0706); Loss of loop (P = 0.0804); Loss of methylation at K648 (P = 0.1243)
17:44091683:T:A,P10636,H647Q,0.796,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917); Loss of sheet (P = 0.1158); Gain of loop (P = 0.2045); Loss of ubiquitination at K648 (P = 0.2335)
17:44091683:T:G,P10636,H647Q,0.796,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917); Loss of sheet (P = 0.1158); Gain of loop (P = 0.2045); Loss of ubiquitination at K648 (P = 0.2335)
17:44091684:A:C,P10636,K648Q,0.517,Loss of methylation at K648 (P = 0.0075); Loss of ubiquitination at K648 (P = 0.0077); Loss of catalytic residue at K648 (P = 0.0226); Loss of sheet (P = 0.1158); Loss of glycosylation at K648 (P = 0.1795)
17:44091684:A:G,P10636,K648E,0.514,Loss of methylation at K648 (P = 0.0075); Loss of ubiquitination at K648 (P = 0.0077); Gain of relative solvent accessibility (P = 0.1066); Gain of solvent accessibility (P = 0.1751); Loss of glycosylation at K648 (P = 0.1795)
17:44091685:A:C,P10636,K648T,0.596,Loss of methylation at K648 (P = 0.0075); Loss of ubiquitination at K648 (P = 0.0077); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.0893); Gain of phosphorylation at K648 (P = 0.1238)
17:44091685:A:G,P10636,K648R,0.496,Loss of ubiquitination at K648 (P = 0.0077); Loss of methylation at K648 (P = 0.018); Loss of disorder (P = 0.143); Loss of glycosylation at K648 (P = 0.1795); Gain of catalytic residue at H647 (P = 0.2335)
17:44091685:A:T,P10636,K648I,0.605,Loss of disorder (P = 0.0073); Loss of methylation at K648 (P = 0.0075); Loss of ubiquitination at K648 (P = 0.0077); Loss of loop (P = 0.0804); Gain of sheet (P = 0.0827)
17:44091686:A:C,P10636,K648N,0.599,Loss of methylation at K648 (P = 0.0075); Loss of ubiquitination at K648 (P = 0.0077); Loss of disorder (P = 0.165); Loss of glycosylation at K648 (P = 0.1795); Gain of relative solvent accessibility (P = 0.2629)
17:44091686:A:T,P10636,K648N,0.599,Loss of methylation at K648 (P = 0.0075); Loss of ubiquitination at K648 (P = 0.0077); Loss of disorder (P = 0.165); Loss of glycosylation at K648 (P = 0.1795); Gain of relative solvent accessibility (P = 0.2629)
17:44091687:C:A,P10636,P649T,0.762,Loss of ubiquitination at K648 (P = 0.1039); Gain of catalytic residue at P649 (P = 0.1458); Loss of methylation at K648 (P = 0.171); Gain of phosphorylation at P649 (P = 0.1781); Loss of disorder (P = 0.1884)
17:44091687:C:G,P10636,P649A,0.78,Gain of catalytic residue at P649 (P = 0.0366); Loss of disorder (P = 0.0753); Loss of methylation at K648 (P = 0.1012); Loss of ubiquitination at K648 (P = 0.152); Loss of stability (P = 0.1843)
17:44091687:C:T,P10636,P649S,0.74,Gain of sheet (P = 0.0827); Gain of phosphorylation at P649 (P = 0.1248); Loss of methylation at K648 (P = 0.1314); Gain of disorder (P = 0.2136); Gain of MoRF binding (P = 0.2197)
17:44091688:C:A,P10636,P649Q,0.791,Loss of ubiquitination at K648 (P = 0.0578); Gain of solvent accessibility (P = 0.1045); Gain of MoRF binding (P = 0.2302); Gain of methylation at K648 (P = 0.2841); Loss of loop (P = 0.2897)
17:44091688:C:G,P10636,P649R,0.791,Loss of ubiquitination at K648 (P = 0.0162); Gain of methylation at P649 (P = 0.0179); Gain of solvent accessibility (P = 0.0216); Gain of MoRF binding (P = 0.0256); Loss of loop (P = 0.2237)
17:44091688:C:T,P10636,P649L,0.746,Loss of disorder (P = 0.0461); Loss of ubiquitination at K648 (P = 0.0525); Gain of catalytic residue at P649 (P = 0.0556); Loss of relative solvent accessibility (P = 0.0676); Loss of methylation at K648 (P = 0.0778)
17:44091690:G:A,P10636,G650R,0.809,Gain of solvent accessibility (P = 0.0037); Loss of ubiquitination at K648 (P = 0.0167); Gain of methylation at G650 (P = 0.0271); Gain of MoRF binding (P = 0.0578); Loss of sheet (P = 0.1158)
17:44091690:G:C,P10636,G650R,0.809,Gain of solvent accessibility (P = 0.0037); Loss of ubiquitination at K648 (P = 0.0167); Gain of methylation at G650 (P = 0.0271); Gain of MoRF binding (P = 0.0578); Loss of sheet (P = 0.1158)
17:44095984:G:A,P10636,G650E,0.809,Gain of solvent accessibility (P = 0.024); Gain of ubiquitination at K648 (P = 0.0941); Loss of sheet (P = 0.1158); Gain of glycosylation at K648 (P = 0.2089); Loss of methylation at K648 (P = 0.2431)
17:44095984:G:C,P10636,G650A,0.871,Loss of disorder (P = 0.084); Loss of sheet (P = 0.1158); Loss of ubiquitination at K648 (P = 0.1268); Gain of catalytic residue at G650 (P = 0.1576); Loss of methylation at K648 (P = 0.2183)
17:44095984:G:T,P10636,G650V,0.866,Loss of ubiquitination at K648 (P = 0.0331); Loss of disorder (P = 0.0621); Gain of solvent accessibility (P = 0.1133); Gain of methylation at K648 (P = 0.2781); Loss of loop (P = 0.2897)
17:44095986:G:A,P10636,G651S,0.791,Gain of glycosylation at G651 (P = 0.0373); Gain of phosphorylation at G651 (P = 0.0964); Loss of catalytic residue at G651 (P = 0.1399); Loss of sheet (P = 0.1501); Gain of solvent accessibility (P = 0.1683)
17:44095986:G:C,P10636,G651R,0.784,Gain of solvent accessibility (P = 0.0037); Loss of ubiquitination at K648 (P = 0.0162); Gain of methylation at G651 (P = 0.0185); Gain of MoRF binding (P = 0.0494); Loss of catalytic residue at G652 (P = 0.1106)
17:44095986:G:T,P10636,G651C,0.798,Loss of ubiquitination at K648 (P = 0.0413); Loss of disorder (P = 0.0461); Loss of relative solvent accessibility (P = 0.107); Loss of sheet (P = 0.1501); Gain of loop (P = 0.2045)
17:44095987:G:A,P10636,G651D,0.798,Gain of solvent accessibility (P = 0.0638); Loss of methylation at K648 (P = 0.1014); Loss of catalytic residue at G652 (P = 0.1221); Gain of ubiquitination at K648 (P = 0.1367); Loss of sheet (P = 0.302)
17:44095987:G:C,P10636,G651A,0.83,Loss of disorder (P = 0.0905); Loss of sheet (P = 0.1158); Loss of ubiquitination at K648 (P = 0.1808); Loss of methylation at K648 (P = 0.1877); Gain of loop (P = 0.2045)
17:44095987:G:T,P10636,G651V,0.823,Loss of ubiquitination at K648 (P = 0.0301); Loss of disorder (P = 0.0722); Loss of sheet (P = 0.1158); Loss of catalytic residue at G652 (P = 0.1475); Gain of loop (P = 0.2045)
17:44095989:G:A,P10636,G652S,0.876,Gain of phosphorylation at G652 (P = 0.0374); Gain of ubiquitination at K657 (P = 0.1827); Loss of catalytic residue at G652 (P = 0.1933); Gain of methylation at K648 (P = 0.2263); Gain of relative solvent accessibility (P = 0.2629)
17:44095989:G:C,P10636,G652R,0.857,Loss of ubiquitination at K648 (P = 0.02); Gain of solvent accessibility (P = 0.0328); Gain of MoRF binding (P = 0.0822); Gain of relative solvent accessibility (P = 0.1066); Gain of methylation at G652 (P = 0.1088)
17:44095989:G:T,P10636,G652C,0.91,Loss of disorder (P = 0.0547); Gain of catalytic residue at V654 (P = 0.0983); Loss of ubiquitination at K648 (P = 0.1039); Gain of sheet (P = 0.1945); Gain of loop (P = 0.2045)
17:44095990:G:A,P10636,G652D,0.863,Loss of ubiquitination at K657 (P = 0.0821); Loss of catalytic residue at G652 (P = 0.0894); Gain of relative solvent accessibility (P = 0.1066); Gain of solvent accessibility (P = 0.1133); Gain of methylation at K648 (P = 0.2566)
17:44095990:G:C,P10636,G652A,0.925,Loss of disorder (P = 0.0964); Loss of methylation at K648 (P = 0.1403); Gain of ubiquitination at K657 (P = 0.1686); Gain of sheet (P = 0.1945); Gain of loop (P = 0.2045)
17:44095990:G:T,P10636,G652V,0.935,Gain of sheet (P = 0.0477); Loss of disorder (P = 0.0822); Loss of ubiquitination at K648 (P = 0.0839); Loss of loop (P = 0.1242); Loss of methylation at K648 (P = 0.235)
17:44095992:C:A,P10636,Q653K,0.487,Gain of ubiquitination at Q653 (P = 0.0177); Gain of methylation at Q653 (P = 0.0215); Gain of phosphorylation at S658 (P = 0.1371); Gain of glycosylation at Q653 (P = 0.1666); Loss of catalytic residue at G652 (P = 0.1785)
17:44095992:C:G,P10636,Q653E,0.467,Gain of ubiquitination at K648 (P = 0.1115); Gain of phosphorylation at S658 (P = 0.1459); Gain of relative solvent accessibility (P = 0.1894); Gain of solvent accessibility (P = 0.2863); Gain of methylation at K648 (P = 0.2957)
17:44095993:A:C,P10636,Q653P,0.56,Gain of ubiquitination at K657 (P = 0.1051); Loss of sheet (P = 0.1501); Gain of phosphorylation at S658 (P = 0.1703); Gain of relative solvent accessibility (P = 0.1894); Gain of loop (P = 0.2045)
17:44095993:A:G,P10636,Q653R,0.549,Loss of ubiquitination at K648 (P = 0.0199); Gain of methylation at Q653 (P = 0.0329); Gain of MoRF binding (P = 0.0785); Gain of phosphorylation at S658 (P = 0.136); Loss of sheet (P = 0.302)
17:44095993:A:T,P10636,Q653L,0.504,Gain of stability (P = 0.0205); Loss of methylation at K648 (P = 0.0986); Loss of ubiquitination at K648 (P = 0.1039); Loss of disorder (P = 0.112); Gain of loop (P = 0.2045)
17:44095994:G:C,P10636,Q653H,0.445,Loss of ubiquitination at K648 (P = 0.1808); Loss of phosphorylation at S658 (P = 0.2268); Loss of methylation at K648 (P = 0.2272); Gain of catalytic residue at E655 (P = 0.2646); Loss of sheet (P = 0.302)
17:44095994:G:T,P10636,Q653H,0.445,Loss of ubiquitination at K648 (P = 0.1808); Loss of phosphorylation at S658 (P = 0.2268); Loss of methylation at K648 (P = 0.2272); Gain of catalytic residue at E655 (P = 0.2646); Loss of sheet (P = 0.302)
17:44095995:G:A,P10636,V654M,0.81,Gain of ubiquitination at K657 (P = 0.14); Loss of sheet (P = 0.1501); Gain of phosphorylation at S658 (P = 0.2252); Gain of relative solvent accessibility (P = 0.281); Gain of catalytic residue at V654 (P = 0.3517)
17:44095995:G:C,P10636,V654L,0.743,Gain of sheet (P = 0.0827); Gain of catalytic residue at V654 (P = 0.1361); Loss of ubiquitination at K657 (P = 0.2014); Gain of phosphorylation at S658 (P = 0.2346); Loss of MoRF binding (P = 0.4024)
17:44095995:G:T,P10636,V654L,0.743,Gain of sheet (P = 0.0827); Gain of catalytic residue at V654 (P = 0.1361); Loss of ubiquitination at K657 (P = 0.2014); Gain of phosphorylation at S658 (P = 0.2346); Loss of MoRF binding (P = 0.4024)
17:44095996:T:A,P10636,V654E,0.795,Gain of solvent accessibility (P = 0.0411); Loss of sheet (P = 0.0457); Gain of relative solvent accessibility (P = 0.0479); Gain of ubiquitination at K657 (P = 0.0707); Gain of loop (P = 0.1069)
17:44095996:T:C,P10636,V654A,0.754,Gain of ubiquitination at K657 (P = 0.1117); Loss of sheet (P = 0.1501); Gain of relative solvent accessibility (P = 0.2363); Gain of phosphorylation at S658 (P = 0.2406); Loss of catalytic residue at K657 (P = 0.346)
17:44095996:T:G,P10636,V654G,0.759,Loss of sheet (P = 0.0181); Gain of loop (P = 0.0435); Gain of ubiquitination at K657 (P = 0.1117); Gain of relative solvent accessibility (P = 0.1259); Loss of stability (P = 0.1281)
17:44095998:G:A,P10636,E655K,0.627,Gain of methylation at E655 (P = 0.0118); Loss of ubiquitination at K657 (P = 0.0134); Gain of MoRF binding (P = 0.0149); Gain of sheet (P = 0.0827); Gain of phosphorylation at S658 (P = 0.2395)
17:44095998:G:C,P10636,E655Q,0.493,Loss of ubiquitination at K657 (P = 0.039); Gain of sheet (P = 0.0827); Gain of MoRF binding (P = 0.0846); Loss of phosphorylation at S658 (P = 0.1135); Loss of catalytic residue at E655 (P = 0.1872)
17:44095999:A:C,P10636,E655A,0.642,Loss of ubiquitination at K657 (P = 0.0574); Loss of disorder (P = 0.0719); Gain of sheet (P = 0.0827); Gain of MoRF binding (P = 0.09); Loss of phosphorylation at S658 (P = 0.1346)
17:44095999:A:G,P10636,E655G,0.617,Loss of ubiquitination at K660 (P = 0.0531); Loss of stability (P = 0.0777); Gain of sheet (P = 0.0827); Gain of MoRF binding (P = 0.0975); Loss of phosphorylation at S658 (P = 0.1724)
17:44095999:A:T,P10636,E655V,0.637,Loss of ubiquitination at K657 (P = 0.0419); Loss of disorder (P = 0.045); Gain of MoRF binding (P = 0.0796); Gain of sheet (P = 0.0827); Loss of phosphorylation at S658 (P = 0.1107)
17:44096000:A:C,P10636,E655D,0.576,Gain of ubiquitination at K660 (P = 0.0756); Loss of sheet (P = 0.1501); Gain of phosphorylation at S658 (P = 0.237); Gain of MoRF binding (P = 0.3467); Gain of disorder (P = 0.4533)
17:44096000:A:T,P10636,E655D,0.576,Gain of ubiquitination at K660 (P = 0.0756); Loss of sheet (P = 0.1501); Gain of phosphorylation at S658 (P = 0.237); Gain of MoRF binding (P = 0.3467); Gain of disorder (P = 0.4533)
17:44096001:G:A,P10636,V656I,0.485,Gain of catalytic residue at L661 (P = 0.0375); Loss of sheet (P = 0.1158); Loss of ubiquitination at K660 (P = 0.1166); Gain of loop (P = 0.2045); Loss of phosphorylation at S658 (P = 0.2465)
17:44096001:G:C,P10636,V656L,0.645,Gain of sheet (P = 0.0827); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1319); Loss of ubiquitination at K660 (P = 0.1372); Gain of loop (P = 0.2045)
17:44096001:G:T,P10636,V656L,0.645,Gain of sheet (P = 0.0827); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1319); Loss of ubiquitination at K660 (P = 0.1372); Gain of loop (P = 0.2045)
17:44096002:T:A,P10636,V656E,0.746,Gain of solvent accessibility (P = 0.0411); Gain of ubiquitination at K660 (P = 0.0441); Gain of relative solvent accessibility (P = 0.0479); Loss of catalytic residue at E659 (P = 0.1106); Loss of sheet (P = 0.1158)
17:44096002:T:C,P10636,V656A,0.627,Loss of stability (P = 0.042); Gain of sheet (P = 0.0827); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K660 (P = 0.0931); Gain of phosphorylation at S658 (P = 0.1957)
17:44096002:T:G,P10636,V656G,0.737,Loss of stability (P = 0.0077); Gain of relative solvent accessibility (P = 0.0479); Gain of ubiquitination at K660 (P = 0.0579); Loss of sheet (P = 0.1501); Gain of phosphorylation at S658 (P = 0.151)
17:44096004:A:C,P10636,K657Q,0.446,Loss of ubiquitination at K657 (P = 0.0092); Gain of sheet (P = 0.0827); Loss of catalytic residue at K657 (P = 0.122); Loss of phosphorylation at S658 (P = 0.1503); Loss of MoRF binding (P = 0.1917)
17:44096004:A:G,P10636,K657E,0.441,Loss of ubiquitination at K657 (P = 0.0092); Gain of sheet (P = 0.039); Loss of MoRF binding (P = 0.1033); Gain of phosphorylation at S658 (P = 0.2025); Gain of loop (P = 0.2045)
17:44096005:A:C,P10636,K657T,0.482,Loss of ubiquitination at K657 (P = 0.0092); Gain of phosphorylation at K657 (P = 0.0455); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.1272); Loss of MoRF binding (P = 0.1793)
17:44096005:A:G,P10636,K657R,0.518,Loss of ubiquitination at K657 (P = 0.0092); Gain of sheet (P = 0.0827); Gain of phosphorylation at S658 (P = 0.1371); Gain of MoRF binding (P = 0.1401); Loss of disorder (P = 0.2365)
17:44096005:A:T,P10636,K657I,0.5,Loss of ubiquitination at K657 (P = 0.0092); Loss of disorder (P = 0.012); Gain of sheet (P = 0.039); Loss of catalytic residue at K657 (P = 0.1048); Loss of phosphorylation at S658 (P = 0.1056)
17:44096006:A:C,P10636,K657N,0.536,Loss of ubiquitination at K657 (P = 0.0092); Loss of phosphorylation at S658 (P = 0.12); Loss of catalytic residue at K657 (P = 0.1226); Loss of sheet (P = 0.1501); Loss of MoRF binding (P = 0.1835)
17:44096006:A:T,P10636,K657N,0.536,Loss of ubiquitination at K657 (P = 0.0092); Loss of phosphorylation at S658 (P = 0.12); Loss of catalytic residue at K657 (P = 0.1226); Loss of sheet (P = 0.1501); Loss of MoRF binding (P = 0.1835)
17:44096007:T:A,P10636,S658T,0.556,Loss of phosphorylation at S658 (P = 0.1102); Loss of sheet (P = 0.1158); Loss of ubiquitination at K660 (P = 0.1372); Loss of disorder (P = 0.1699); Gain of loop (P = 0.2045)
17:44096007:T:C,P10636,S658P,0.601,Loss of phosphorylation at S658 (P = 0.0428); Loss of sheet (P = 0.0457); Gain of loop (P = 0.0851); Gain of relative solvent accessibility (P = 0.0999); Loss of ubiquitination at K660 (P = 0.1372)
17:44096007:T:G,P10636,S658A,0.548,Gain of sheet (P = 0.039); Loss of phosphorylation at S658 (P = 0.0428); Loss of disorder (P = 0.0563); Gain of ubiquitination at K660 (P = 0.1204); Gain of relative solvent accessibility (P = 0.2363)
17:44096008:C:A,P10636,S658Y,0.567,Loss of disorder (P = 0.0112); Gain of sheet (P = 0.039); Loss of ubiquitination at K660 (P = 0.0683); Loss of loop (P = 0.1242); Gain of phosphorylation at S658 (P = 0.1475)
17:44096008:C:G,P10636,S658C,0.603,Gain of methylation at K657 (P = 0.0209); Loss of disorder (P = 0.0355); Gain of sheet (P = 0.039); Loss of phosphorylation at S658 (P = 0.0428); Loss of ubiquitination at K660 (P = 0.057)
17:44096008:C:T,P10636,S658F,0.591,Loss of disorder (P = 0.0247); Gain of sheet (P = 0.039); Loss of phosphorylation at S658 (P = 0.0428); Loss of ubiquitination at K660 (P = 0.0755); Loss of loop (P = 0.1242)
17:44096010:G:A,P10636,E659K,0.497,Gain of MoRF binding (P = 0.0052); Loss of ubiquitination at K657 (P = 0.0148); Loss of stability (P = 0.0383); Loss of sheet (P = 0.1158); Gain of methylation at K664 (P = 0.1501)
17:44096010:G:C,P10636,E659Q,0.477,Loss of ubiquitination at K664 (P = 0.0297); Gain of MoRF binding (P = 0.04); Gain of sheet (P = 0.0827); Loss of stability (P = 0.1317); Loss of phosphorylation at S658 (P = 0.1329)
17:44096011:A:C,P10636,E659A,0.627,Loss of stability (P = 0.0273); Gain of MoRF binding (P = 0.0353); Loss of ubiquitination at K664 (P = 0.0368); Loss of methylation at K664 (P = 0.052); Loss of catalytic residue at E659 (P = 0.0555)
17:44096011:A:G,P10636,E659G,0.566,Loss of stability (P = 0.017); Loss of ubiquitination at K664 (P = 0.0347); Gain of MoRF binding (P = 0.0364); Loss of catalytic residue at E659 (P = 0.0719); Gain of loop (P = 0.0851)
17:44096011:A:T,P10636,E659V,0.758,Gain of MoRF binding (P = 0.0249); Loss of ubiquitination at K664 (P = 0.0334); Gain of sheet (P = 0.039); Loss of disorder (P = 0.0612); Loss of catalytic residue at E659 (P = 0.0612)
17:44096012:G:C,P10636,E659D,0.523,Loss of sheet (P = 0.0457); Loss of catalytic residue at E659 (P = 0.0475); Gain of ubiquitination at K660 (P = 0.0831); Gain of loop (P = 0.0851); Loss of methylation at K664 (P = 0.125)
17:44096012:G:T,P10636,E659D,0.523,Loss of sheet (P = 0.0457); Loss of catalytic residue at E659 (P = 0.0475); Gain of ubiquitination at K660 (P = 0.0831); Gain of loop (P = 0.0851); Loss of methylation at K664 (P = 0.125)
17:44096013:A:C,P10636,K660Q,0.663,Loss of ubiquitination at K660 (P = 0.0155); Gain of catalytic residue at K660 (P = 0.0283); Loss of MoRF binding (P = 0.1091); Gain of methylation at K664 (P = 0.1187); Loss of phosphorylation at S658 (P = 0.1252)
17:44096013:A:G,P10636,K660E,0.695,Loss of ubiquitination at K660 (P = 0.0155); Loss of MoRF binding (P = 0.0677); Gain of loop (P = 0.0851); Loss of sheet (P = 0.1158); Gain of methylation at K664 (P = 0.1205)
17:44096014:A:C,P10636,K660T,0.686,Loss of ubiquitination at K660 (P = 0.0155); Loss of MoRF binding (P = 0.107); Loss of disorder (P = 0.1216); Loss of phosphorylation at S658 (P = 0.1342); Loss of methylation at K664 (P = 0.1351)
17:44096014:A:G,P10636,K660R,0.677,Loss of ubiquitination at K660 (P = 0.0155); Gain of catalytic residue at K660 (P = 0.0375); Loss of methylation at K664 (P = 0.0929); Gain of phosphorylation at S658 (P = 0.1365); Gain of MoRF binding (P = 0.1406)
17:44096014:A:T,P10636,K660M,0.683,Loss of ubiquitination at K660 (P = 0.0155); Loss of disorder (P = 0.0574); Gain of sheet (P = 0.0827); Gain of catalytic residue at V656 (P = 0.1019); Loss of methylation at K664 (P = 0.1058)
17:44096015:G:C,P10636,K660N,0.699,Loss of ubiquitination at K660 (P = 0.0155); Loss of methylation at K664 (P = 0.0871); Loss of MoRF binding (P = 0.1041); Loss of phosphorylation at S658 (P = 0.1059); Loss of sheet (P = 0.1158)
17:44096015:G:T,P10636,K660N,0.699,Loss of ubiquitination at K660 (P = 0.0155); Loss of methylation at K664 (P = 0.0871); Loss of MoRF binding (P = 0.1041); Loss of phosphorylation at S658 (P = 0.1059); Loss of sheet (P = 0.1158)
17:44096016:C:A,P10636,L661I,0.604,Gain of methylation at K664 (P = 0.0575); Loss of ubiquitination at K664 (P = 0.0699); Gain of MoRF binding (P = 0.1653); Gain of sheet (P = 0.1945); Gain of phosphorylation at S658 (P = 0.2395)
17:44096016:C:G,P10636,L661V,0.618,Gain of methylation at K664 (P = 0.0671); Loss of ubiquitination at K664 (P = 0.0896); Loss of stability (P = 0.1248); Gain of MoRF binding (P = 0.1399); Gain of phosphorylation at S658 (P = 0.1857)
17:44096016:C:T,P10636,L661F,0.63,Gain of catalytic residue at L661 (P = 0.0404); Gain of ubiquitination at K660 (P = 0.1062); Gain of methylation at K664 (P = 0.1071); Loss of sheet (P = 0.1158); Loss of stability (P = 0.1403)
17:44096017:T:A,P10636,L661H,0.632,Loss of stability (P = 0.0123); Gain of methylation at K664 (P = 0.0418); Loss of sheet (P = 0.0457); Gain of ubiquitination at K664 (P = 0.0469); Gain of loop (P = 0.0851)
17:44096017:T:C,P10636,L661P,0.658,Loss of stability (P = 0.0074); Loss of sheet (P = 0.0142); Gain of relative solvent accessibility (P = 0.0166); Gain of loop (P = 0.024); Gain of methylation at K664 (P = 0.0394)
17:44096017:T:G,P10636,L661R,0.746,Gain of MoRF binding (P = 0.0084); Loss of sheet (P = 0.0228); Loss of stability (P = 0.0247); Gain of methylation at K664 (P = 0.0405); Gain of helix (P = 0.0425)
17:44096019:G:A,P10636,D662N,0.653,Loss of ubiquitination at K664 (P = 0.0311); Gain of MoRF binding (P = 0.0341); Gain of sheet (P = 0.0827); Gain of methylation at K664 (P = 0.0952); Loss of helix (P = 0.1299)
17:44096019:G:C,P10636,D662H,0.648,Loss of ubiquitination at K664 (P = 0.0347); Gain of MoRF binding (P = 0.049); Loss of helix (P = 0.0558); Gain of methylation at K664 (P = 0.0668); Gain of sheet (P = 0.0827)
17:44096019:G:T,P10636,D662Y,0.677,Loss of disorder (P = 0.015); Gain of sheet (P = 0.0266); Loss of ubiquitination at K664 (P = 0.0356); Loss of loop (P = 0.0512); Loss of helix (P = 0.0558)
17:44096020:A:C,P10636,D662A,0.651,Loss of ubiquitination at K664 (P = 0.0391); Gain of MoRF binding (P = 0.051); Gain of methylation at K664 (P = 0.0602); Loss of disorder (P = 0.0662); Loss of helix (P = 0.1299)
17:44096020:A:G,P10636,D662G,0.629,Loss of stability (P = 0.0187); Loss of ubiquitination at K664 (P = 0.0328); Gain of methylation at K664 (P = 0.0417); Gain of MoRF binding (P = 0.0497); Loss of helix (P = 0.0558)
17:44096020:A:T,P10636,D662V,0.642,Gain of sheet (P = 0.0125); Loss of loop (P = 0.0203); Loss of ubiquitination at K657 (P = 0.0365); Loss of helix (P = 0.0376); Gain of methylation at K664 (P = 0.0391)
17:44096021:C:A,P10636,D662E,0.639,Gain of sheet (P = 0.0477); Loss of loop (P = 0.0512); Gain of methylation at K664 (P = 0.07); Gain of ubiquitination at K660 (P = 0.1204); Loss of helix (P = 0.1299)
17:44096021:C:G,P10636,D662E,0.639,Gain of sheet (P = 0.0477); Loss of loop (P = 0.0512); Gain of methylation at K664 (P = 0.07); Gain of ubiquitination at K660 (P = 0.1204); Loss of helix (P = 0.1299)
17:44096022:T:A,P10636,F663I,0.625,Loss of methylation at K664 (P = 0.0486); Gain of ubiquitination at K660 (P = 0.0931); Gain of MoRF binding (P = 0.1086); Loss of helix (P = 0.1299); Loss of catalytic residue at F663 (P = 0.1634)
17:44096022:T:C,P10636,F663L,0.588,Loss of methylation at K664 (P = 0.0339); Loss of helix (P = 0.0558); Gain of ubiquitination at K660 (P = 0.0651); Gain of sheet (P = 0.0827); Loss of catalytic residue at F663 (P = 0.108)
17:44096022:T:G,P10636,F663V,0.59,Loss of helix (P = 0.0376); Gain of loop (P = 0.069); Gain of ubiquitination at K660 (P = 0.0701); Gain of sheet (P = 0.0827); Loss of methylation at K664 (P = 0.096)
17:44096023:T:A,P10636,F663Y,0.684,Gain of phosphorylation at F663 (P = 0.0327); Loss of methylation at K664 (P = 0.0347); Loss of catalytic residue at F663 (P = 0.074); Gain of ubiquitination at K660 (P = 0.0756); Loss of helix (P = 0.1299)
17:44096023:T:C,P10636,F663S,0.65,Gain of relative solvent accessibility (P = 0.0027); Gain of solvent accessibility (P = 0.0155); Gain of phosphorylation at F663 (P = 0.0276); Gain of loop (P = 0.0312); Gain of disorder (P = 0.0335)
17:44096023:T:G,P10636,F663C,0.723,Gain of loop (P = 0.0312); Gain of methylation at K664 (P = 0.032); Loss of helix (P = 0.0376); Loss of ubiquitination at K664 (P = 0.0699); Loss of catalytic residue at F663 (P = 0.0777)
17:44096024:C:A,P10636,F663L,0.588,Loss of methylation at K664 (P = 0.0339); Loss of helix (P = 0.0558); Gain of ubiquitination at K660 (P = 0.0651); Gain of sheet (P = 0.0827); Loss of catalytic residue at F663 (P = 0.108)
17:44096024:C:G,P10636,F663L,0.588,Loss of methylation at K664 (P = 0.0339); Loss of helix (P = 0.0558); Gain of ubiquitination at K660 (P = 0.0651); Gain of sheet (P = 0.0827); Loss of catalytic residue at F663 (P = 0.108)
17:44096025:A:C,P10636,K664Q,0.48,Loss of ubiquitination at K664 (P = 0.0141); Loss of methylation at K664 (P = 0.0196); Loss of MoRF binding (P = 0.086); Loss of glycosylation at S669 (P = 0.1055); Loss of helix (P = 0.1299)
17:44096025:A:G,P10636,K664E,0.518,Loss of ubiquitination at K664 (P = 0.0141); Loss of methylation at K664 (P = 0.0196); Loss of MoRF binding (P = 0.0495); Loss of helix (P = 0.1299); Gain of relative solvent accessibility (P = 0.1684)
17:44096026:A:C,P10636,K664T,0.52,Loss of ubiquitination at K664 (P = 0.0141); Loss of methylation at K664 (P = 0.0196); Loss of helix (P = 0.0558); Loss of disorder (P = 0.0739); Gain of sheet (P = 0.0827)
17:44096026:A:G,P10636,K664R,0.459,Loss of ubiquitination at K664 (P = 0.0141); Loss of methylation at K664 (P = 0.0272); Gain of MoRF binding (P = 0.1385); Loss of disorder (P = 0.1482); Loss of glycosylation at S669 (P = 0.1645)
17:44096026:A:T,P10636,K664M,0.542,Loss of ubiquitination at K664 (P = 0.0141); Loss of methylation at K664 (P = 0.0196); Loss of disorder (P = 0.0305); Loss of glycosylation at S669 (P = 0.0686); Loss of sheet (P = 0.1158)
17:44096027:G:C,P10636,K664N,0.502,Loss of ubiquitination at K664 (P = 0.0141); Loss of methylation at K664 (P = 0.0196); Loss of helix (P = 0.0558); Gain of loop (P = 0.069); Gain of sheet (P = 0.0827)
17:44096027:G:T,P10636,K664N,0.502,Loss of ubiquitination at K664 (P = 0.0141); Loss of methylation at K664 (P = 0.0196); Loss of helix (P = 0.0558); Gain of loop (P = 0.069); Gain of sheet (P = 0.0827)
17:44096028:G:A,P10636,D665N,0.37,Gain of MoRF binding (P = 0.0292); Loss of ubiquitination at K664 (P = 0.0311); Loss of glycosylation at S669 (P = 0.0955); Gain of methylation at K664 (P = 0.0968); Gain of helix (P = 0.132)
17:44096028:G:C,P10636,D665H,0.38,Loss of ubiquitination at K664 (P = 0.0347); Gain of MoRF binding (P = 0.0404); Gain of methylation at K664 (P = 0.0687); Loss of glycosylation at S669 (P = 0.0962); Loss of phosphorylation at S669 (P = 0.107)
17:44096028:G:T,P10636,D665Y,0.498,Loss of disorder (P = 0.0067); Loss of ubiquitination at K664 (P = 0.0334); Gain of MoRF binding (P = 0.0461); Gain of phosphorylation at D665 (P = 0.0519); Loss of glycosylation at S669 (P = 0.0536)
17:44096029:A:C,P10636,D665A,0.438,Gain of MoRF binding (P = 0.0276); Gain of helix (P = 0.0325); Loss of ubiquitination at K664 (P = 0.0368); Loss of disorder (P = 0.0516); Loss of glycosylation at S669 (P = 0.0607)
17:44096029:A:G,P10636,D665G,0.417,Gain of MoRF binding (P = 0.0296); Gain of loop (P = 0.0312); Loss of ubiquitination at K664 (P = 0.0334); Loss of helix (P = 0.0376); Loss of glycosylation at S669 (P = 0.0676)
17:44096029:A:T,P10636,D665V,0.476,Gain of MoRF binding (P = 0.0211); Loss of ubiquitination at K664 (P = 0.0334); Loss of disorder (P = 0.0339); Gain of methylation at K664 (P = 0.0371); Loss of glycosylation at S669 (P = 0.0472)
17:44096030:C:A,P10636,D665E,0.309,Gain of helix (P = 0.0325); Loss of loop (P = 0.0512); Gain of methylation at K664 (P = 0.0798); Gain of ubiquitination at K660 (P = 0.1062); Loss of sheet (P = 0.1158)
17:44096030:C:G,P10636,D665E,0.309,Gain of helix (P = 0.0325); Loss of loop (P = 0.0512); Gain of methylation at K664 (P = 0.0798); Gain of ubiquitination at K660 (P = 0.1062); Loss of sheet (P = 0.1158)
17:44096031:A:G,P10636,R666G,0.596,Gain of loop (P = 0.0166); Loss of helix (P = 0.0376); Loss of MoRF binding (P = 0.0566); Loss of phosphorylation at S669 (P = 0.0714); Gain of ubiquitination at K670 (P = 0.0804)
17:44096032:G:A,P10636,R666K,0.406,Gain of ubiquitination at R666 (P = 0.0289); Gain of methylation at R666 (P = 0.0336); Loss of glycosylation at S669 (P = 0.0567); Loss of phosphorylation at S669 (P = 0.0803); Gain of disorder (P = 0.0902)
17:44096032:G:C,P10636,R666T,0.617,Loss of helix (P = 0.0558); Loss of MoRF binding (P = 0.0575); Loss of phosphorylation at S669 (P = 0.0624); Gain of methylation at K670 (P = 0.0664); Gain of ubiquitination at K664 (P = 0.0798)
17:44096032:G:T,P10636,R666I,0.612,Gain of methylation at K670 (P = 0.045); Loss of ubiquitination at K664 (P = 0.045); Loss of disorder (P = 0.0481); Loss of phosphorylation at S669 (P = 0.0561); Loss of MoRF binding (P = 0.0576)
17:44096033:A:C,P10636,R666S,0.619,Gain of ubiquitination at K670 (P = 0.0495); Loss of helix (P = 0.0558); Loss of MoRF binding (P = 0.0577); Gain of methylation at K670 (P = 0.0672); Gain of loop (P = 0.069)
17:44096033:A:T,P10636,R666S,0.619,Gain of ubiquitination at K670 (P = 0.0495); Loss of helix (P = 0.0558); Loss of MoRF binding (P = 0.0577); Gain of methylation at K670 (P = 0.0672); Gain of loop (P = 0.069)
17:44096034:G:A,P10636,V667I,0.649,Loss of ubiquitination at K664 (P = 0.0699); Gain of methylation at K664 (P = 0.1179); Gain of helix (P = 0.132); Loss of glycosylation at S669 (P = 0.1441); Loss of MoRF binding (P = 0.1986)
17:44096034:G:C,P10636,V667L,0.736,Loss of methylation at K664 (P = 0.0693); Loss of ubiquitination at K664 (P = 0.1223); Gain of helix (P = 0.132); Loss of MoRF binding (P = 0.1472); Loss of glycosylation at S669 (P = 0.1972)
17:44096034:G:T,P10636,V667F,0.754,Gain of ubiquitination at K664 (P = 0.1106); Loss of methylation at K664 (P = 0.111); Loss of MoRF binding (P = 0.1297); Loss of helix (P = 0.1299); Loss of glycosylation at S669 (P = 0.1567)
17:44096035:T:A,P10636,V667D,0.778,Gain of loop (P = 0.0166); Gain of relative solvent accessibility (P = 0.0215); Loss of helix (P = 0.0237); Gain of solvent accessibility (P = 0.0306); Gain of disorder (P = 0.0307)
17:44096035:T:C,P10636,V667A,0.795,Loss of stability (P = 0.0639); Gain of ubiquitination at K664 (P = 0.0689); Loss of methylation at K664 (P = 0.0798); Gain of helix (P = 0.132); Gain of disorder (P = 0.1556)
17:44096035:T:G,P10636,V667G,0.736,Loss of stability (P = 0.0055); Gain of loop (P = 0.0097); Loss of helix (P = 0.0237); Gain of disorder (P = 0.0391); Gain of ubiquitination at K670 (P = 0.0432)
17:44096037:C:A,P10636,Q668K,0.551,Loss of ubiquitination at K664 (P = 0.0236); Gain of methylation at Q668 (P = 0.025); Gain of MoRF binding (P = 0.04); Gain of disorder (P = 0.0883); Gain of phosphorylation at S669 (P = 0.1213)
17:44096037:C:G,P10636,Q668E,0.543,Loss of MoRF binding (P = 0.0728); Gain of ubiquitination at K670 (P = 0.0737); Loss of methylation at K670 (P = 0.1092); Gain of phosphorylation at S669 (P = 0.128); Loss of helix (P = 0.1299)
17:44096038:A:C,P10636,Q668P,0.637,Gain of loop (P = 0.0166); Loss of helix (P = 0.0237); Gain of catalytic residue at Q668 (P = 0.0634); Loss of MoRF binding (P = 0.0834); Loss of ubiquitination at K664 (P = 0.1037)
17:44096038:A:G,P10636,Q668R,0.548,Gain of MoRF binding (P = 0.0199); Loss of ubiquitination at K664 (P = 0.0328); Loss of methylation at K664 (P = 0.0865); Gain of phosphorylation at S669 (P = 0.0962); Gain of helix (P = 0.132)
17:44096038:A:T,P10636,Q668L,0.555,Loss of ubiquitination at K664 (P = 0.0472); Loss of disorder (P = 0.0473); Loss of glycosylation at S669 (P = 0.0546); Loss of methylation at K664 (P = 0.1074); Loss of loop (P = 0.1242)
17:44096039:G:C,P10636,Q668H,0.542,Gain of catalytic residue at R666 (P = 0.0486); Loss of helix (P = 0.0558); Loss of ubiquitination at K670 (P = 0.0618); Loss of methylation at K670 (P = 0.1425); Loss of MoRF binding (P = 0.1798)
17:44096039:G:T,P10636,Q668H,0.542,Gain of catalytic residue at R666 (P = 0.0486); Loss of helix (P = 0.0558); Loss of ubiquitination at K670 (P = 0.0618); Loss of methylation at K670 (P = 0.1425); Loss of MoRF binding (P = 0.1798)
17:44096040:T:A,P10636,S669T,0.67,Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0202); Loss of glycosylation at S669 (P = 0.0248); Gain of helix (P = 0.0696); Loss of disorder (P = 0.0749)
17:44096040:T:C,P10636,S669P,0.681,Gain of relative solvent accessibility (P = 0.0082); Loss of glycosylation at S669 (P = 0.0242); Gain of solvent accessibility (P = 0.0256); Loss of phosphorylation at S669 (P = 0.0387); Loss of stability (P = 0.0797)
17:44096040:T:G,P10636,S669A,0.667,Loss of glycosylation at S669 (P = 0.0194); Gain of relative solvent accessibility (P = 0.0215); Loss of disorder (P = 0.0295); Gain of helix (P = 0.0325); Loss of phosphorylation at S669 (P = 0.0387)
17:44096041:C:G,P10636,S669W,0.689,Loss of disorder (P = 0); Loss of glycosylation at S669 (P = 0.0194); Loss of phosphorylation at S669 (P = 0.0387); Gain of MoRF binding (P = 0.0476); Loss of ubiquitination at K664 (P = 0.0618)
17:44096041:C:T,P10636,S669L,0.733,Loss of disorder (P = 0.0143); Loss of glycosylation at S669 (P = 0.0194); Loss of phosphorylation at S669 (P = 0.0387); Gain of relative solvent accessibility (P = 0.0479); Gain of catalytic residue at S669 (P = 0.06)
17:44096043:A:C,P10636,K670Q,0.791,Loss of ubiquitination at K670 (P = 0.0167); Loss of methylation at K670 (P = 0.0305); Loss of MoRF binding (P = 0.0797); Loss of glycosylation at S669 (P = 0.1144); Loss of helix (P = 0.1299)
17:44096043:A:G,P10636,K670E,0.771,Loss of ubiquitination at K670 (P = 0.0167); Loss of methylation at K670 (P = 0.0305); Loss of MoRF binding (P = 0.0472); Gain of relative solvent accessibility (P = 0.0999); Loss of glycosylation at S669 (P = 0.1278)
17:44096044:A:C,P10636,K670T,0.774,Loss of ubiquitination at K670 (P = 0.0167); Loss of methylation at K670 (P = 0.0305); Loss of helix (P = 0.0558); Loss of disorder (P = 0.0628); Loss of MoRF binding (P = 0.0791)
17:44096044:A:G,P10636,K670R,0.822,Loss of ubiquitination at K670 (P = 0.0167); Loss of methylation at K670 (P = 0.033); Gain of phosphorylation at S673 (P = 0.0887); Loss of disorder (P = 0.1146); Gain of MoRF binding (P = 0.1164)
17:44096044:A:T,P10636,K670M,0.772,Loss of ubiquitination at K670 (P = 0.0167); Loss of disorder (P = 0.0253); Loss of methylation at K670 (P = 0.0305); Loss of glycosylation at S669 (P = 0.0317); Gain of helix (P = 0.0696)
17:44096045:G:C,P10636,K670N,0.754,Loss of ubiquitination at K670 (P = 0.0167); Loss of methylation at K670 (P = 0.0305); Loss of helix (P = 0.0558); Gain of loop (P = 0.069); Loss of MoRF binding (P = 0.0795)
17:44096045:G:T,P10636,K670N,0.754,Loss of ubiquitination at K670 (P = 0.0167); Loss of methylation at K670 (P = 0.0305); Loss of helix (P = 0.0558); Gain of loop (P = 0.069); Loss of MoRF binding (P = 0.0795)
17:44096046:A:C,P10636,I671L,0.67,Loss of catalytic residue at I671 (P = 0.0035); Loss of methylation at K670 (P = 0.0722); Gain of ubiquitination at K670 (P = 0.102); Gain of helix (P = 0.132); Gain of disorder (P = 0.1589)
17:44096046:A:G,P10636,I671V,0.655,Loss of catalytic residue at I671 (P = 0.0069); Gain of methylation at K670 (P = 0.0528); Loss of helix (P = 0.0558); Gain of ubiquitination at K670 (P = 0.1162); Gain of disorder (P = 0.1697)
17:44096046:A:T,P10636,I671F,0.72,Loss of catalytic residue at I671 (P = 0.0332); Gain of methylation at K670 (P = 0.0384); Loss of ubiquitination at K670 (P = 0.1139); Loss of helix (P = 0.1299); Loss of glycosylation at S669 (P = 0.1522)
17:44096047:T:A,P10636,I671N,0.742,Loss of catalytic residue at I671 (P = 9e-04); Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0128); Gain of loop (P = 0.0312); Gain of disorder (P = 0.032)
17:44096047:T:C,P10636,I671T,0.783,Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0202); Loss of stability (P = 0.0218); Loss of helix (P = 0.0376); Gain of disorder (P = 0.0436)
17:44096047:T:G,P10636,I671S,0.711,Loss of catalytic residue at I671 (P = 8e-04); Gain of relative solvent accessibility (P = 0.0082); Gain of disorder (P = 0.0178); Gain of sheet (P = 0.0266); Gain of solvent accessibility (P = 0.0273)
17:44096048:T:G,P10636,I671M,0.71,Loss of catalytic residue at I671 (P = 0.0039); Loss of methylation at K670 (P = 0.0401); Gain of ubiquitination at K670 (P = 0.0686); Gain of disorder (P = 0.0962); Loss of helix (P = 0.1299)
17:44096049:G:A,P10636,G672R,0.842,Gain of MoRF binding (P = 0.0051); Gain of helix (P = 0.0325); Loss of ubiquitination at K670 (P = 0.0346); Loss of loop (P = 0.0374); Gain of solvent accessibility (P = 0.0456)
17:44096049:G:C,P10636,G672R,0.842,Gain of MoRF binding (P = 0.0051); Gain of helix (P = 0.0325); Loss of ubiquitination at K670 (P = 0.0346); Loss of loop (P = 0.0374); Gain of solvent accessibility (P = 0.0456)
17:44096049:G:T,P10636,G672W,0.819,Loss of disorder (P = 0.0017); Gain of helix (P = 0.0325); Loss of loop (P = 0.0374); Loss of glycosylation at S669 (P = 0.0407); Gain of MoRF binding (P = 0.0433)
17:44096050:G:A,P10636,G672E,0.864,Gain of helix (P = 0.0325); Loss of glycosylation at S669 (P = 0.0663); Loss of MoRF binding (P = 0.0945); Loss of loop (P = 0.0986); Gain of solvent accessibility (P = 0.1045)
17:44096050:G:C,P10636,G672A,0.884,Gain of helix (P = 0.062); Loss of ubiquitination at K670 (P = 0.0755); Loss of disorder (P = 0.076); Loss of loop (P = 0.0986); Loss of glycosylation at S669 (P = 0.109)
17:44096050:G:T,P10636,G672V,0.931,Gain of sheet (P = 0.0266); Loss of helix (P = 0.0376); Loss of disorder (P = 0.0443); Loss of ubiquitination at K670 (P = 0.0618); Gain of methylation at K670 (P = 0.0643)
17:44096052:T:A,P10636,S673T,0.859,Gain of relative solvent accessibility (P = 0.0479); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.0901); Gain of solvent accessibility (P = 0.0917); Loss of ubiquitination at K670 (P = 0.0962)
17:44096052:T:C,P10636,S673P,0.881,Gain of sheet (P = 0.0344); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at K670 (P = 0.0575); Gain of loop (P = 0.0851); Loss of stability (P = 0.0921)
17:44096052:T:G,P10636,S673A,0.866,Loss of disorder (P = 0.0373); Gain of relative solvent accessibility (P = 0.0479); Loss of ubiquitination at K670 (P = 0.069); Gain of sheet (P = 0.0827); Gain of helix (P = 0.132)
17:44096053:C:A,P10636,S673Y,0.795,Loss of disorder (P = 0.0031); Gain of solvent accessibility (P = 0.0273); Gain of sheet (P = 0.0344); Gain of relative solvent accessibility (P = 0.0479); Loss of ubiquitination at K670 (P = 0.069)
17:44096053:C:G,P10636,S673C,0.869,Loss of disorder (P = 0.012); Gain of catalytic residue at L674 (P = 0.0433); Loss of ubiquitination at K670 (P = 0.0578); Gain of sheet (P = 0.0827); Gain of methylation at K670 (P = 0.0834)
17:44096053:C:T,P10636,S673F,0.849,Loss of disorder (P = 0.0104); Loss of ubiquitination at K670 (P = 0.0578); Loss of glycosylation at S669 (P = 0.0598); Gain of methylation at K670 (P = 0.0728); Gain of sheet (P = 0.0827)
17:44096055:C:A,P10636,L674M,0.476,Gain of methylation at K670 (P = 0.0634); Gain of sheet (P = 0.0827); Gain of MoRF binding (P = 0.0988); Gain of disorder (P = 0.1003); Gain of ubiquitination at K670 (P = 0.1162)
17:44096055:C:G,P10636,L674V,0.477,Gain of sheet (P = 0.0344); Loss of helix (P = 0.0558); Gain of methylation at K670 (P = 0.0663); Loss of ubiquitination at K670 (P = 0.1139); Gain of relative solvent accessibility (P = 0.1259)
17:44096056:T:A,P10636,L674Q,0.54,Gain of disorder (P = 0.033); Gain of sheet (P = 0.0344); Gain of solvent accessibility (P = 0.0374); Gain of methylation at K670 (P = 0.0393); Gain of relative solvent accessibility (P = 0.0479)
17:44096056:T:C,P10636,L674P,0.547,Gain of relative solvent accessibility (P = 0.0023); Gain of solvent accessibility (P = 0.0078); Gain of disorder (P = 0.0216); Loss of stability (P = 0.0294); Gain of sheet (P = 0.0344)
17:44096056:T:G,P10636,L674R,0.587,Gain of MoRF binding (P = 0.0178); Gain of disorder (P = 0.03); Gain of sheet (P = 0.0344); Gain of methylation at K670 (P = 0.0367); Loss of stability (P = 0.0475)
17:44096058:G:A,P10636,D675N,0.808,Gain of MoRF binding (P = 0.0452); Gain of sheet (P = 0.0827); Loss of ubiquitination at K670 (P = 0.1139); Loss of helix (P = 0.1299); Gain of glycosylation at T678 (P = 0.1367)
17:44096058:G:C,P10636,D675H,0.765,Loss of catalytic residue at D675 (P = 0.0355); Gain of MoRF binding (P = 0.0529); Loss of ubiquitination at K670 (P = 0.1139); Gain of sheet (P = 0.1208); Loss of helix (P = 0.1299)
17:44096058:G:T,P10636,D675Y,0.741,Loss of disorder (P = 0.0069); Gain of methylation at K670 (P = 0.0449); Gain of MoRF binding (P = 0.056); Gain of sheet (P = 0.0827); Loss of ubiquitination at K670 (P = 0.0853)
17:44096059:A:C,P10636,D675A,0.796,Gain of MoRF binding (P = 0.0394); Loss of disorder (P = 0.0575); Gain of sheet (P = 0.0827); Loss of ubiquitination at K670 (P = 0.1139); Loss of helix (P = 0.1299)
17:44096059:A:G,P10636,D675G,0.74,Loss of catalytic residue at D675 (P = 0.0051); Gain of MoRF binding (P = 0.0462); Gain of sheet (P = 0.0827); Loss of stability (P = 0.1052); Loss of ubiquitination at K670 (P = 0.1139)
17:44096059:A:T,P10636,D675V,0.766,Gain of sheet (P = 0.0266); Gain of MoRF binding (P = 0.0312); Loss of disorder (P = 0.0332); Loss of loop (P = 0.0512); Loss of helix (P = 0.0558)
17:44096060:C:A,P10636,D675E,0.772,Gain of sheet (P = 0.0827); Loss of ubiquitination at K670 (P = 0.1139); Loss of helix (P = 0.1299); Gain of methylation at K670 (P = 0.1461); Gain of disorder (P = 0.1511)
17:44096060:C:G,P10636,D675E,0.772,Gain of sheet (P = 0.0827); Loss of ubiquitination at K670 (P = 0.1139); Loss of helix (P = 0.1299); Gain of methylation at K670 (P = 0.1461); Gain of disorder (P = 0.1511)
17:44096061:A:C,P10636,N676H,0.891,Gain of sheet (P = 0.0344); Loss of stability (P = 0.1353); Gain of disorder (P = 0.147); Gain of phosphorylation at T678 (P = 0.2003); Gain of loop (P = 0.2045)
17:44096061:A:G,P10636,N676D,0.92,Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.09); Gain of phosphorylation at T678 (P = 0.0966); Loss of MoRF binding (P = 0.1014); Gain of disorder (P = 0.1364)
17:44096061:A:T,P10636,N676Y,0.835,Gain of sheet (P = 0.0149); Loss of disorder (P = 0.0152); Gain of phosphorylation at N676 (P = 0.0178); Loss of loop (P = 0.0986); Loss of MoRF binding (P = 0.2033)
17:44096062:A:C,P10636,N676T,0.854,Gain of sheet (P = 0.0149); Gain of relative solvent accessibility (P = 0.09); Gain of phosphorylation at N676 (P = 0.1001); Loss of stability (P = 0.1583); Gain of solvent accessibility (P = 0.1683)
17:44096062:A:G,P10636,N676S,0.867,Gain of sheet (P = 0.0827); Gain of disorder (P = 0.0874); Gain of phosphorylation at N676 (P = 0.0879); Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.1227)
17:44096062:A:T,P10636,N676I,0.856,Gain of sheet (P = 0.0085); Loss of loop (P = 0.0374); Loss of disorder (P = 0.0399); Loss of MoRF binding (P = 0.2159); Gain of glycosylation at T678 (P = 0.2165)
17:44096063:T:A,P10636,N676K,0.87,Gain of methylation at N676 (P = 0.0103); Gain of sheet (P = 0.0344); Gain of solvent accessibility (P = 0.0354); Gain of MoRF binding (P = 0.0365); Gain of relative solvent accessibility (P = 0.0479)
17:44096063:T:G,P10636,N676K,0.87,Gain of methylation at N676 (P = 0.0103); Gain of sheet (P = 0.0344); Gain of solvent accessibility (P = 0.0354); Gain of MoRF binding (P = 0.0365); Gain of relative solvent accessibility (P = 0.0479)
17:44096064:A:C,P10636,I677L,0.717,Loss of sheet (P = 0.1158); Gain of disorder (P = 0.1318); Gain of phosphorylation at T678 (P = 0.1975); Gain of loop (P = 0.2045); Loss of MoRF binding (P = 0.2333)
17:44096064:A:G,P10636,I677V,0.637,Loss of catalytic residue at I677 (P = 0.0978); Gain of disorder (P = 0.1404); Gain of phosphorylation at T678 (P = 0.2131); Gain of MoRF binding (P = 0.2135); Gain of glycosylation at T678 (P = 0.2645)
17:44096064:A:T,P10636,I677F,0.724,Loss of sheet (P = 0.1158); Loss of stability (P = 0.1201); Gain of phosphorylation at T678 (P = 0.2069); Gain of disorder (P = 0.2128); Loss of MoRF binding (P = 0.226)
17:44096065:T:A,P10636,I677N,0.814,Loss of stability (P = 0.0104); Gain of disorder (P = 0.0183); Loss of sheet (P = 0.0457); Gain of loop (P = 0.0851); Gain of relative solvent accessibility (P = 0.1259)
17:44096065:T:C,P10636,I677T,0.799,Loss of stability (P = 0.0027); Gain of disorder (P = 0.0251); Gain of glycosylation at T678 (P = 0.0719); Loss of sheet (P = 0.1158); Gain of phosphorylation at T678 (P = 0.1499)
17:44096065:T:G,P10636,I677S,0.766,Loss of stability (P = 0.0078); Gain of disorder (P = 0.0098); Loss of sheet (P = 0.0457); Gain of phosphorylation at I677 (P = 0.0845); Gain of loop (P = 0.0851)
17:44096066:C:G,P10636,I677M,0.74,Gain of disorder (P = 0.0672); Loss of catalytic residue at I677 (P = 0.082); Loss of sheet (P = 0.1158); Loss of stability (P = 0.1353); Gain of MoRF binding (P = 0.1511)
17:44096067:A:C,P10636,T678P,0.529,Loss of sheet (P = 0.0228); Gain of loop (P = 0.0435); Gain of relative solvent accessibility (P = 0.0479); Gain of disorder (P = 0.0658); Loss of phosphorylation at T678 (P = 0.079)
17:44096067:A:G,P10636,T678A,0.491,Loss of phosphorylation at T678 (P = 0.079); Loss of glycosylation at T678 (P = 0.1175); Loss of disorder (P = 0.1451); Loss of stability (P = 0.1539); Gain of MoRF binding (P = 0.2442)
17:44096067:A:T,P10636,T678S,0.446,Gain of relative solvent accessibility (P = 0.0479); Gain of disorder (P = 0.0523); Gain of solvent accessibility (P = 0.11); Loss of sheet (P = 0.1158); Gain of phosphorylation at S673 (P = 0.1367)
17:44096068:C:A,P10636,T678N,0.451,Loss of sheet (P = 0.0457); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0766); Loss of phosphorylation at T678 (P = 0.079); Gain of disorder (P = 0.1137)
17:44096068:C:G,P10636,T678S,0.446,Gain of relative solvent accessibility (P = 0.0479); Gain of disorder (P = 0.0523); Gain of solvent accessibility (P = 0.11); Loss of sheet (P = 0.1158); Gain of phosphorylation at S673 (P = 0.1367)
17:44096068:C:T,P10636,T678I,0.579,Gain of sheet (P = 0.0149); Loss of disorder (P = 0.0562); Loss of loop (P = 0.0603); Loss of phosphorylation at T678 (P = 0.079); Loss of glycosylation at T678 (P = 0.1175)
17:44096070:C:A,P10636,H679N,0.916,Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0766); Gain of disorder (P = 0.1092); Loss of sheet (P = 0.1158); Loss of catalytic residue at I677 (P = 0.1443)
17:44096070:C:G,P10636,H679D,0.898,Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0704); Gain of disorder (P = 0.0719); Loss of sheet (P = 0.1158); Gain of phosphorylation at T678 (P = 0.1239)
17:44096070:C:T,P10636,H679Y,0.893,Loss of disorder (P = 0.0258); Gain of sheet (P = 0.0344); Gain of catalytic residue at L674 (P = 0.0799); Gain of phosphorylation at H679 (P = 0.0814); Loss of loop (P = 0.1242)
17:44096071:A:C,P10636,H679P,0.888,Loss of sheet (P = 0.0457); Gain of relative solvent accessibility (P = 0.0479); Gain of disorder (P = 0.0621); Gain of phosphorylation at T678 (P = 0.0709); Gain of loop (P = 0.0851)
17:44096071:A:G,P10636,H679R,0.904,Gain of MoRF binding (P = 0.0109); Gain of solvent accessibility (P = 0.0584); Gain of sheet (P = 0.0827); Gain of relative solvent accessibility (P = 0.09); Gain of phosphorylation at T678 (P = 0.1027)
17:44096071:A:T,P10636,H679L,0.9,Gain of sheet (P = 0.0344); Loss of disorder (P = 0.0576); Loss of loop (P = 0.1242); Loss of catalytic residue at I677 (P = 0.1299); Loss of phosphorylation at T678 (P = 0.2601)
17:44096072:C:A,P10636,H679Q,0.909,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917); Gain of disorder (P = 0.1204); Loss of catalytic residue at I677 (P = 0.1382); Loss of sheet (P = 0.1907)
17:44096072:C:G,P10636,H679Q,0.909,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917); Gain of disorder (P = 0.1204); Loss of catalytic residue at I677 (P = 0.1382); Loss of sheet (P = 0.1907)
17:44096073:G:A,P10636,V680I,0.667,Gain of catalytic residue at V680 (P = 0.1713); Gain of disorder (P = 0.2354); Loss of phosphorylation at T678 (P = 0.2621); Loss of sheet (P = 0.302); Loss of glycosylation at T678 (P = 0.3298)
17:44096073:G:C,P10636,V680L,0.504,Gain of catalytic residue at V680 (P = 0.0843); Gain of disorder (P = 0.1654); Loss of sheet (P = 0.1907); Loss of phosphorylation at T678 (P = 0.2601); Loss of MoRF binding (P = 0.3254)
17:44096073:G:T,P10636,V680F,0.645,Gain of catalytic residue at V680 (P = 0.0255); Loss of sheet (P = 0.1907); Loss of disorder (P = 0.2232); Gain of phosphorylation at T678 (P = 0.2786); Loss of MoRF binding (P = 0.3195)
17:44096074:T:A,P10636,V680D,0.624,Gain of catalytic residue at V680 (P = 0.0054); Gain of disorder (P = 0.0134); Gain of relative solvent accessibility (P = 0.09); Gain of phosphorylation at T678 (P = 0.0912); Loss of sheet (P = 0.1158)
17:44096074:T:C,P10636,V680A,0.499,Gain of disorder (P = 0.0638); Loss of sheet (P = 0.1158); Gain of catalytic residue at V680 (P = 0.191); Gain of phosphorylation at T678 (P = 0.1988); Gain of loop (P = 0.2045)
17:44096074:T:G,P10636,V680G,0.586,Gain of disorder (P = 0.0177); Gain of catalytic residue at V680 (P = 0.0194); Loss of stability (P = 0.027); Loss of sheet (P = 0.0457); Gain of loop (P = 0.0851)
17:44096076:C:A,P10636,P681T,0.881,Gain of sheet (P = 0.039); Gain of catalytic residue at P681 (P = 0.071); Gain of relative solvent accessibility (P = 0.1066); Loss of phosphorylation at T678 (P = 0.126); Gain of MoRF binding (P = 0.1422)
17:44096076:C:G,P10636,P681A,0.896,Gain of catalytic residue at P681 (P = 0.0381); Gain of sheet (P = 0.039); Loss of methylation at K686 (P = 0.0778); Loss of disorder (P = 0.08); Gain of MoRF binding (P = 0.0883)
17:44096076:C:T,P10636,P681S,0.822,Gain of glycosylation at P681 (P = 0.0234); Gain of catalytic residue at P681 (P = 0.0275); Gain of sheet (P = 0.039); Gain of disorder (P = 0.0995); Gain of relative solvent accessibility (P = 0.1066)
17:44096077:C:A,P10636,P681H,0.897,Gain of sheet (P = 0.039); Gain of catalytic residue at P681 (P = 0.1644); Loss of methylation at K686 (P = 0.1651); Gain of MoRF binding (P = 0.1813); Loss of disorder (P = 0.2121)
17:44096077:C:G,P10636,P681R,0.86,Gain of MoRF binding (P = 0.0105); Gain of methylation at P681 (P = 0.0382); Gain of sheet (P = 0.039); Gain of solvent accessibility (P = 0.0488); Gain of catalytic residue at P681 (P = 0.0516)
17:44096077:C:T,P10636,P681L,0.883,Loss of disorder (P = 0.0341); Gain of sheet (P = 0.039); Gain of catalytic residue at P681 (P = 0.0676); Loss of methylation at K686 (P = 0.0715); Gain of MoRF binding (P = 0.112)
17:44096079:G:A,P10636,G682S,0.823,Gain of glycosylation at G682 (P = 0.0197); Gain of sheet (P = 0.0827); Gain of disorder (P = 0.1074); Gain of methylation at K687 (P = 0.1424); Gain of solvent accessibility (P = 0.1683)
17:44096079:G:C,P10636,G682R,0.828,Gain of MoRF binding (P = 0.0054); Gain of solvent accessibility (P = 0.019); Gain of methylation at G682 (P = 0.0293); Gain of disorder (P = 0.2165); Loss of glycosylation at K686 (P = 0.2312)
17:44096079:G:T,P10636,G682C,0.831,Loss of disorder (P = 0.0176); Gain of catalytic residue at P681 (P = 0.037); Loss of relative solvent accessibility (P = 0.0676); Gain of sheet (P = 0.0827); Loss of methylation at K687 (P = 0.1214)
17:44096080:G:A,P10636,G682D,0.836,Gain of ubiquitination at K686 (P = 0.0289); Gain of solvent accessibility (P = 0.0638); Gain of sheet (P = 0.0827); Loss of methylation at K687 (P = 0.113); Gain of disorder (P = 0.1584)
17:44096080:G:C,P10636,G682A,0.87,Loss of disorder (P = 0.0795); Gain of sheet (P = 0.0827); Loss of methylation at K687 (P = 0.0841); Gain of MoRF binding (P = 0.2519); Gain of ubiquitination at K686 (P = 0.2682)
17:44096080:G:T,P10636,G682V,0.868,Loss of disorder (P = 0.0347); Loss of relative solvent accessibility (P = 0.0676); Gain of sheet (P = 0.0827); Gain of methylation at K686 (P = 0.1123); Loss of catalytic residue at G682 (P = 0.222)
17:44096082:G:A,P10636,G683R,0.857,Gain of solvent accessibility (P = 0.0037); Gain of MoRF binding (P = 0.0067); Gain of methylation at G683 (P = 0.0262); Gain of glycosylation at T678 (P = 0.0629); Gain of sheet (P = 0.1451)
17:44096082:G:C,P10636,G683R,0.857,Gain of solvent accessibility (P = 0.0037); Gain of MoRF binding (P = 0.0067); Gain of methylation at G683 (P = 0.0262); Gain of glycosylation at T678 (P = 0.0629); Gain of sheet (P = 0.1451)
17:44096083:G:A,P10636,G683E,0.858,Gain of solvent accessibility (P = 0.024); Gain of ubiquitination at K687 (P = 0.0338); Gain of sheet (P = 0.0827); Gain of glycosylation at T678 (P = 0.1033); Gain of disorder (P = 0.1207)
17:44096083:G:C,P10636,G683A,0.886,Loss of disorder (P = 0.0827); Loss of methylation at K687 (P = 0.089); Gain of phosphorylation at T678 (P = 0.2082); Loss of catalytic residue at G684 (P = 0.221); Gain of MoRF binding (P = 0.2219)
17:44096083:G:T,P10636,G683V,0.895,Loss of disorder (P = 0.0384); Gain of sheet (P = 0.0827); Gain of methylation at K686 (P = 0.1137); Loss of catalytic residue at G684 (P = 0.1972); Gain of MoRF binding (P = 0.2206)
17:44096085:G:A,P10636,G684R,0.874,Gain of solvent accessibility (P = 0.0037); Gain of MoRF binding (P = 0.0418); Gain of methylation at K686 (P = 0.0752); Gain of sheet (P = 0.0827); Gain of disorder (P = 0.2107)
17:44096085:G:C,P10636,G684R,0.874,Gain of solvent accessibility (P = 0.0037); Gain of MoRF binding (P = 0.0418); Gain of methylation at K686 (P = 0.0752); Gain of sheet (P = 0.0827); Gain of disorder (P = 0.2107)
17:44096086:G:A,P10636,G684E,0.839,Gain of solvent accessibility (P = 0.024); Gain of ubiquitination at K686 (P = 0.0276); Gain of sheet (P = 0.0827); Gain of methylation at K687 (P = 0.0849); Loss of MoRF binding (P = 0.0943)
17:44096086:G:C,P10636,G684A,0.888,Loss of methylation at K687 (P = 0.084); Loss of disorder (P = 0.0896); Gain of MoRF binding (P = 0.1798); Loss of sheet (P = 0.1907); Gain of loop (P = 0.2045)
17:44096086:G:T,P10636,G684V,0.896,Loss of disorder (P = 0.0453); Gain of MoRF binding (P = 0.1249); Loss of methylation at K687 (P = 0.1306); Loss of glycosylation at K686 (P = 0.1743); Loss of sheet (P = 0.1907)
17:44096088:A:C,P10636,N685H,0.494,Gain of glycosylation at K686 (P = 0.1146); Gain of disorder (P = 0.1451); Gain of catalytic residue at K686 (P = 0.1553); Loss of methylation at K687 (P = 0.1564); Loss of MoRF binding (P = 0.1802)
17:44096088:A:G,P10636,N685D,0.529,Gain of ubiquitination at K686 (P = 0.0289); Loss of methylation at K687 (P = 0.0704); Loss of MoRF binding (P = 0.0856); Gain of disorder (P = 0.1496); Gain of relative solvent accessibility (P = 0.1684)
17:44096088:A:T,P10636,N685Y,0.51,Loss of disorder (P = 0.0403); Gain of sheet (P = 0.0477); Gain of phosphorylation at N685 (P = 0.0512); Loss of methylation at K687 (P = 0.0722); Loss of MoRF binding (P = 0.171)
17:44096089:A:C,P10636,N685T,0.452,Gain of phosphorylation at N685 (P = 0.0737); Gain of sheet (P = 0.1451); Loss of methylation at K687 (P = 0.1533); Gain of relative solvent accessibility (P = 0.1684); Gain of glycosylation at K686 (P = 0.1713)
17:44096089:A:G,P10636,N685S,0.453,Gain of glycosylation at N685 (P = 0.0298); Gain of disorder (P = 0.0902); Gain of catalytic residue at K686 (P = 0.1223); Gain of phosphorylation at N685 (P = 0.1256); Gain of sheet (P = 0.1451)
17:44096089:A:T,P10636,N685I,0.514,Loss of disorder (P = 0.0475); Gain of sheet (P = 0.0477); Gain of methylation at K687 (P = 0.0811); Gain of catalytic residue at N685 (P = 0.0852); Gain of glycosylation at K686 (P = 0.1359)
17:44096090:T:A,P10636,N685K,0.568,Gain of methylation at N685 (P = 0.0228); Gain of MoRF binding (P = 0.0407); Gain of glycosylation at N685 (P = 0.0419); Gain of catalytic residue at N685 (P = 0.0537); Gain of sheet (P = 0.0827)
17:44096090:T:G,P10636,N685K,0.568,Gain of methylation at N685 (P = 0.0228); Gain of MoRF binding (P = 0.0407); Gain of glycosylation at N685 (P = 0.0419); Gain of catalytic residue at N685 (P = 0.0537); Gain of sheet (P = 0.0827)
17:44096091:A:C,P10636,K686Q,0.391,Gain of ubiquitination at K687 (P = 0.0289); Loss of methylation at K686 (P = 0.0305); Loss of glycosylation at K686 (P = 0.0671); Loss of MoRF binding (P = 0.0775); Loss of sheet (P = 0.1158)
17:44096091:A:G,P10636,K686E,0.337,Gain of ubiquitination at K687 (P = 0.0212); Loss of methylation at K686 (P = 0.0305); Loss of MoRF binding (P = 0.0447); Loss of glycosylation at K686 (P = 0.0671); Loss of sheet (P = 0.1398)
17:44096092:A:C,P10636,K686T,0.358,Gain of ubiquitination at K687 (P = 0.0239); Loss of methylation at K686 (P = 0.0305); Gain of phosphorylation at K686 (P = 0.0472); Loss of MoRF binding (P = 0.0721); Loss of glycosylation at K686 (P = 0.0836)
17:44096092:A:G,P10636,K686R,0.224,Loss of glycosylation at K686 (P = 0.0671); Gain of MoRF binding (P = 0.0776); Loss of sheet (P = 0.0817); Gain of methylation at K687 (P = 0.1294); Loss of disorder (P = 0.163)
17:44096092:A:T,P10636,K686I,0.685,Loss of disorder (P = 0.0187); Loss of methylation at K686 (P = 0.0305); Gain of ubiquitination at K687 (P = 0.0326); Gain of sheet (P = 0.039); Loss of glycosylation at K686 (P = 0.0671)
17:44096093:A:C,P10636,K686N,0.344,Gain of ubiquitination at K687 (P = 0.025); Loss of methylation at K686 (P = 0.0305); Loss of glycosylation at K686 (P = 0.0671); Loss of MoRF binding (P = 0.0738); Loss of sheet (P = 0.0817)
17:44096093:A:T,P10636,K686N,0.344,Gain of ubiquitination at K687 (P = 0.025); Loss of methylation at K686 (P = 0.0305); Loss of glycosylation at K686 (P = 0.0671); Loss of MoRF binding (P = 0.0738); Loss of sheet (P = 0.0817)
17:44096094:A:C,P10636,K687Q,0.367,Loss of methylation at K687 (P = 0.0171); Gain of ubiquitination at K686 (P = 0.0289); Loss of MoRF binding (P = 0.0755); Loss of glycosylation at K687 (P = 0.1084); Loss of disorder (P = 0.1163)
17:44096094:A:G,P10636,K687E,0.374,Loss of methylation at K687 (P = 0.0171); Gain of ubiquitination at K686 (P = 0.0222); Loss of MoRF binding (P = 0.0378); Loss of glycosylation at K687 (P = 0.1084); Gain of sheet (P = 0.1451)
17:44096095:A:C,P10636,K687T,0.364,Loss of methylation at K687 (P = 0.0171); Gain of ubiquitination at K686 (P = 0.0314); Loss of MoRF binding (P = 0.0719); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.1134)
17:44096095:A:G,P10636,K687R,0.254,Loss of methylation at K687 (P = 0.0284); Gain of MoRF binding (P = 0.0761); Gain of phosphorylation at T690 (P = 0.1028); Loss of glycosylation at K687 (P = 0.1084); Loss of disorder (P = 0.1365)
17:44096095:A:T,P10636,K687M,0.388,Loss of methylation at K687 (P = 0.0171); Gain of ubiquitination at K686 (P = 0.0337); Loss of disorder (P = 0.043); Gain of sheet (P = 0.0827); Loss of MoRF binding (P = 0.0974)
17:44096096:G:C,P10636,K687N,0.337,Loss of methylation at K687 (P = 0.0171); Gain of ubiquitination at K686 (P = 0.0276); Loss of MoRF binding (P = 0.0725); Loss of glycosylation at K687 (P = 0.1084); Loss of sheet (P = 0.1158)
17:44096096:G:T,P10636,K687N,0.337,Loss of methylation at K687 (P = 0.0171); Gain of ubiquitination at K686 (P = 0.0276); Loss of MoRF binding (P = 0.0725); Loss of glycosylation at K687 (P = 0.1084); Loss of sheet (P = 0.1158)
17:44101322:A:C,P10636,I688L,0.221,Loss of methylation at K687 (P = 0.0501); Loss of sheet (P = 0.0817); Gain of disorder (P = 0.123); Loss of MoRF binding (P = 0.1266); Gain of phosphorylation at T690 (P = 0.2202)
17:44101322:A:G,P10636,I688V,0.182,Gain of methylation at K687 (P = 0.0667); Gain of disorder (P = 0.1419); Gain of sheet (P = 0.1451); Gain of MoRF binding (P = 0.1472); Loss of stability (P = 0.1753)
17:44101322:A:T,P10636,I688F,0.24,Gain of methylation at K687 (P = 0.0474); Loss of sheet (P = 0.0817); Loss of MoRF binding (P = 0.1188); Gain of phosphorylation at T690 (P = 0.1503); Gain of disorder (P = 0.1668)
17:44101323:T:A,P10636,I688N,0.388,Loss of sheet (P = 0.0084); Gain of loop (P = 0.0166); Gain of disorder (P = 0.0205); Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0421)
17:44101323:T:C,P10636,I688T,0.369,Loss of sheet (P = 0.0181); Loss of stability (P = 0.0189); Gain of disorder (P = 0.021); Gain of loop (P = 0.0312); Gain of phosphorylation at I688 (P = 0.032)
17:44101323:T:G,P10636,I688S,0.396,Loss of sheet (P = 0.0084); Gain of disorder (P = 0.01); Loss of stability (P = 0.0263); Gain of loop (P = 0.0312); Gain of relative solvent accessibility (P = 0.0507)
17:44101324:T:G,P10636,I688M,0.24,Loss of methylation at K687 (P = 0.0265); Loss of sheet (P = 0.0315); Gain of disorder (P = 0.0584); Gain of loop (P = 0.069); Gain of MoRF binding (P = 0.1215)
17:44101325:G:A,P10636,E689K,0.377,Gain of MoRF binding (P = 0.0016); Gain of catalytic residue at E689 (P = 0.0254); Gain of methylation at E689 (P = 0.1411); Gain of disorder (P = 0.1541); Gain of phosphorylation at T690 (P = 0.1904)
17:44101325:G:C,P10636,E689Q,0.272,Gain of MoRF binding (P = 0.0221); Gain of methylation at K686 (P = 0.0734); Loss of disorder (P = 0.1183); Loss of phosphorylation at T690 (P = 0.2477); Loss of sheet (P = 0.302)
17:44101326:A:C,P10636,E689A,0.31,Gain of MoRF binding (P = 0.0373); Loss of disorder (P = 0.0569); Gain of methylation at K686 (P = 0.0726); Gain of glycosylation at T690 (P = 0.1459); Loss of phosphorylation at T690 (P = 0.257)
17:44101326:A:G,P10636,E689G,0.316,Gain of MoRF binding (P = 0.044); Gain of methylation at K686 (P = 0.0592); Loss of stability (P = 0.0781); Loss of sheet (P = 0.0817); Loss of disorder (P = 0.1445)
17:44101326:A:T,P10636,E689V,0.404,Loss of disorder (P = 0.016); Gain of MoRF binding (P = 0.0325); Gain of methylation at K686 (P = 0.0405); Gain of sheet (P = 0.0477); Loss of solvent accessibility (P = 0.1986)
17:44101327:A:C,P10636,E689D,0.26,Loss of sheet (P = 0.0357); Loss of methylation at K687 (P = 0.0865); Gain of loop (P = 0.1069); Gain of MoRF binding (P = 0.1255); Loss of disorder (P = 0.1822)
17:44101327:A:T,P10636,E689D,0.26,Loss of sheet (P = 0.0357); Loss of methylation at K687 (P = 0.0865); Gain of loop (P = 0.1069); Gain of MoRF binding (P = 0.1255); Loss of disorder (P = 0.1822)
17:44101328:A:C,P10636,T690P,0.309,Loss of sheet (P = 0.0126); Gain of loop (P = 0.069); Loss of phosphorylation at T690 (P = 0.073); Loss of MoRF binding (P = 0.0767); Gain of catalytic residue at T690 (P = 0.0885)
17:44101328:A:G,P10636,T690A,0.234,Loss of methylation at K686 (P = 0.0679); Loss of phosphorylation at T690 (P = 0.073); Loss of sheet (P = 0.0817); Gain of MoRF binding (P = 0.1375); Loss of disorder (P = 0.1507)
17:44101328:A:T,P10636,T690S,0.216,Loss of methylation at K687 (P = 0.0643); Gain of disorder (P = 0.0739); Loss of sheet (P = 0.0817); Gain of MoRF binding (P = 0.1255); Loss of phosphorylation at T690 (P = 0.1859)
17:44101329:C:A,P10636,T690N,0.237,Loss of sheet (P = 0.0357); Loss of phosphorylation at T690 (P = 0.073); Loss of methylation at K686 (P = 0.1031); Gain of loop (P = 0.1069); Gain of MoRF binding (P = 0.1418)
17:44101329:C:G,P10636,T690S,0.216,Loss of methylation at K687 (P = 0.0643); Gain of disorder (P = 0.0739); Loss of sheet (P = 0.0817); Gain of MoRF binding (P = 0.1255); Loss of phosphorylation at T690 (P = 0.1859)
17:44101329:C:T,P10636,T690I,0.324,Loss of disorder (P = 0.0402); Loss of phosphorylation at T690 (P = 0.073); Gain of sheet (P = 0.0827); Gain of methylation at K692 (P = 0.0916); Gain of MoRF binding (P = 0.1519)
17:44101331:C:A,P10636,H691N,0.312,Loss of sheet (P = 0.0357); Gain of loop (P = 0.069); Loss of stability (P = 0.0697); Gain of relative solvent accessibility (P = 0.09); Loss of methylation at K687 (P = 0.119)
17:44101331:C:G,P10636,H691D,0.365,Gain of ubiquitination at K686 (P = 0.0276); Loss of sheet (P = 0.0315); Gain of loop (P = 0.069); Loss of MoRF binding (P = 0.0699); Loss of methylation at K692 (P = 0.0831)
17:44101331:C:T,P10636,H691Y,0.399,Loss of disorder (P = 0.0402); Loss of methylation at K692 (P = 0.0725); Gain of phosphorylation at H691 (P = 0.0889); Gain of sheet (P = 0.1208); Gain of MoRF binding (P = 0.1469)
17:44101332:A:C,P10636,H691P,0.386,Loss of sheet (P = 0.0084); Gain of loop (P = 0.0195); Gain of relative solvent accessibility (P = 0.0289); Gain of phosphorylation at T690 (P = 0.0711); Gain of disorder (P = 0.0813)
17:44101332:A:G,P10636,H691R,0.316,Gain of MoRF binding (P = 0.0218); Gain of phosphorylation at T694 (P = 0.0693); Gain of methylation at K692 (P = 0.0823); Gain of solvent accessibility (P = 0.1133); Gain of disorder (P = 0.1292)
17:44101332:A:T,P10636,H691L,0.378,Loss of methylation at K687 (P = 0.0488); Loss of disorder (P = 0.0587); Gain of MoRF binding (P = 0.0963); Gain of sheet (P = 0.1208); Loss of phosphorylation at T690 (P = 0.22)
17:44101333:C:A,P10636,H691Q,0.273,Gain of methylation at K692 (P = 0.11); Gain of MoRF binding (P = 0.1379); Loss of sheet (P = 0.1398); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1709)
17:44101333:C:G,P10636,H691Q,0.273,Gain of methylation at K692 (P = 0.11); Gain of MoRF binding (P = 0.1379); Loss of sheet (P = 0.1398); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1709)
17:44101334:A:C,P10636,K692Q,0.46,Gain of ubiquitination at K687 (P = 0.0239); Loss of methylation at K692 (P = 0.0291); Loss of MoRF binding (P = 0.068); Loss of disorder (P = 0.0896); Loss of sheet (P = 0.1398)
17:44101334:A:G,P10636,K692E,0.463,Loss of MoRF binding (P = 0.0228); Gain of ubiquitination at K687 (P = 0.0232); Loss of methylation at K692 (P = 0.0291); Loss of sheet (P = 0.1398); Gain of helix (P = 0.1736)
17:44101335:A:C,P10636,K692T,0.443,Gain of ubiquitination at K687 (P = 0.0219); Loss of methylation at K692 (P = 0.0291); Loss of MoRF binding (P = 0.0616); Loss of disorder (P = 0.0853); Gain of catalytic residue at F695 (P = 0.1267)
17:44101335:A:G,P10636,K692R,0.378,Loss of methylation at K692 (P = 0.039); Gain of MoRF binding (P = 0.073); Loss of disorder (P = 0.1087); Gain of phosphorylation at T694 (P = 0.1106); Gain of sheet (P = 0.1451)
17:44101335:A:T,P10636,K692M,0.509,Gain of ubiquitination at K687 (P = 0.0276); Loss of methylation at K692 (P = 0.0291); Loss of disorder (P = 0.0325); Loss of MoRF binding (P = 0.0797); Gain of sheet (P = 0.1451)
17:44101336:G:C,P10636,K692N,0.451,Gain of catalytic residue at K692 (P = 0.0055); Gain of ubiquitination at K687 (P = 0.0232); Loss of methylation at K692 (P = 0.0291); Loss of MoRF binding (P = 0.0654); Loss of sheet (P = 0.0817)
17:44101336:G:T,P10636,K692N,0.451,Gain of catalytic residue at K692 (P = 0.0055); Gain of ubiquitination at K687 (P = 0.0232); Loss of methylation at K692 (P = 0.0291); Loss of MoRF binding (P = 0.0654); Loss of sheet (P = 0.0817)
17:44101337:C:A,P10636,L693M,0.364,Loss of methylation at K692 (P = 0.0449); Gain of MoRF binding (P = 0.0652); Gain of disorder (P = 0.0669); Loss of sheet (P = 0.0817); Gain of helix (P = 0.1736)
17:44101337:C:G,P10636,L693V,0.321,Loss of catalytic residue at L693 (P = 0.0055); Gain of methylation at K692 (P = 0.0325); Gain of MoRF binding (P = 0.0878); Gain of disorder (P = 0.1742); Gain of phosphorylation at T690 (P = 0.2319)
17:44101338:T:A,P10636,L693Q,0.455,Loss of sheet (P = 0.0054); Gain of helix (P = 0.0093); Loss of catalytic residue at L693 (P = 0.0101); Gain of disorder (P = 0.021); Gain of methylation at K692 (P = 0.0632)
17:44101338:T:C,P10636,L693P,0.605,Loss of sheet (P = 0.0054); Gain of disorder (P = 0.0087); Gain of loop (P = 0.0166); Gain of helix (P = 0.0199); Gain of glycosylation at T690 (P = 0.0368)
17:44101338:T:G,P10636,L693R,0.535,Loss of catalytic residue at L693 (P = 0.0016); Gain of MoRF binding (P = 0.0035); Loss of sheet (P = 0.0054); Gain of helix (P = 0.0093); Gain of disorder (P = 0.0134)
17:44101340:A:C,P10636,T694P,0.319,Loss of sheet (P = 0.0315); Gain of loop (P = 0.069); Loss of MoRF binding (P = 0.0762); Gain of methylation at K692 (P = 0.0896); Gain of disorder (P = 0.0915)
17:44101340:A:G,P10636,T694A,0.252,Loss of sheet (P = 0.0817); Loss of phosphorylation at T694 (P = 0.1204); Gain of MoRF binding (P = 0.1367); Loss of disorder (P = 0.1573); Loss of methylation at K692 (P = 0.1634)
17:44101340:A:T,P10636,T694S,0.233,Gain of disorder (P = 0.0678); Loss of methylation at K692 (P = 0.1055); Gain of phosphorylation at T694 (P = 0.1181); Gain of MoRF binding (P = 0.1275); Loss of sheet (P = 0.1398)
17:44101341:C:A,P10636,T694N,0.24,Loss of sheet (P = 0.0817); Loss of phosphorylation at T694 (P = 0.1204); Gain of disorder (P = 0.1517); Loss of methylation at K692 (P = 0.1533); Gain of MoRF binding (P = 0.166)
17:44101341:C:G,P10636,T694S,0.233,Gain of disorder (P = 0.0678); Loss of methylation at K692 (P = 0.1055); Gain of phosphorylation at T694 (P = 0.1181); Gain of MoRF binding (P = 0.1275); Loss of sheet (P = 0.1398)
17:44101341:C:T,P10636,T694I,0.368,Loss of disorder (P = 0.0421); Gain of methylation at K692 (P = 0.0479); Gain of MoRF binding (P = 0.119); Loss of phosphorylation at T694 (P = 0.1204); Gain of sheet (P = 0.1208)
17:44101343:T:A,P10636,F695I,0.352,Gain of MoRF binding (P = 0.086); Gain of methylation at K692 (P = 0.0869); Gain of ubiquitination at K700 (P = 0.1235); Gain of disorder (P = 0.1357); Loss of helix (P = 0.1706)
17:44101343:T:C,P10636,F695L,0.376,Gain of ubiquitination at K700 (P = 0.0628); Loss of sheet (P = 0.0817); Gain of disorder (P = 0.0876); Loss of methylation at K692 (P = 0.0912); Gain of MoRF binding (P = 0.1601)
17:44101343:T:G,P10636,F695V,0.384,Gain of ubiquitination at K700 (P = 0.071); Gain of MoRF binding (P = 0.0744); Gain of disorder (P = 0.0965); Loss of helix (P = 0.1299); Loss of sheet (P = 0.1398)
17:44101344:T:A,P10636,F695Y,0.328,Gain of ubiquitination at K700 (P = 0.0843); Gain of phosphorylation at F695 (P = 0.1101); Loss of methylation at K692 (P = 0.1278); Loss of sheet (P = 0.1398); Loss of MoRF binding (P = 0.1614)
17:44101344:T:C,P10636,F695S,0.554,Gain of disorder (P = 0.005); Loss of sheet (P = 0.0181); Gain of loop (P = 0.0312); Gain of ubiquitination at K700 (P = 0.0435); Gain of helix (P = 0.062)
17:44101344:T:G,P10636,F695C,0.489,Gain of ubiquitination at K700 (P = 0.071); Loss of sheet (P = 0.0817); Gain of catalytic residue at K692 (P = 0.0853); Loss of MoRF binding (P = 0.0999); Loss of helix (P = 0.1299)
17:44101345:C:A,P10636,F695L,0.376,Gain of ubiquitination at K700 (P = 0.0628); Loss of sheet (P = 0.0817); Gain of disorder (P = 0.0876); Loss of methylation at K692 (P = 0.0912); Gain of MoRF binding (P = 0.1601)
17:44101345:C:G,P10636,F695L,0.376,Gain of ubiquitination at K700 (P = 0.0628); Loss of sheet (P = 0.0817); Gain of disorder (P = 0.0876); Loss of methylation at K692 (P = 0.0912); Gain of MoRF binding (P = 0.1601)
17:44101346:C:A,P10636,R696S,0.378,Loss of MoRF binding (P = 0.0397); Gain of ubiquitination at K700 (P = 0.0628); Gain of disorder (P = 0.0725); Gain of methylation at K692 (P = 0.0794); Loss of sheet (P = 0.0817)
17:44101346:C:G,P10636,R696G,0.441,Loss of MoRF binding (P = 0.0352); Gain of methylation at K692 (P = 0.0565); Gain of ubiquitination at K700 (P = 0.071); Loss of sheet (P = 0.0817); Loss of catalytic residue at R696 (P = 0.0895)
17:44101346:C:T,P10636,R696C,0.482,Loss of MoRF binding (P = 0.0209); Loss of disorder (P = 0.0354); Gain of methylation at K692 (P = 0.0439); Loss of catalytic residue at R696 (P = 0.0652); Gain of ubiquitination at K700 (P = 0.1092)
17:44101347:G:A,P10636,R696H,0.405,Loss of MoRF binding (P = 0.0323); Gain of methylation at K692 (P = 0.0516); Gain of disorder (P = 0.1295); Loss of ubiquitination at K700 (P = 0.1388); Loss of sheet (P = 0.1398)
17:44101347:G:C,P10636,R696P,0.445,Loss of MoRF binding (P = 0.0152); Loss of sheet (P = 0.0315); Gain of loop (P = 0.0435); Gain of methylation at K692 (P = 0.046); Gain of ubiquitination at K700 (P = 0.0628)
17:44101347:G:T,P10636,R696L,0.397,Loss of MoRF binding (P = 0.0301); Loss of disorder (P = 0.0579); Gain of helix (P = 0.062); Gain of methylation at K692 (P = 0.0781); Loss of ubiquitination at K700 (P = 0.1388)
17:44101349:G:A,P10636,E697K,0.345,Gain of MoRF binding (P = 0.0031); Loss of ubiquitination at K700 (P = 0.0199); Gain of helix (P = 0.062); Loss of stability (P = 0.0709); Loss of sheet (P = 0.0817)
17:44101349:G:C,P10636,E697Q,0.237,Gain of MoRF binding (P = 0.0221); Loss of ubiquitination at K702 (P = 0.0283); Gain of helix (P = 0.062); Loss of sheet (P = 0.0817); Gain of methylation at K692 (P = 0.1086)
17:44101350:A:C,P10636,E697A,0.297,Gain of MoRF binding (P = 0.0217); Loss of ubiquitination at K702 (P = 0.027); Gain of methylation at R696 (P = 0.0444); Gain of helix (P = 0.062); Loss of disorder (P = 0.0773)
17:44101350:A:G,P10636,E697G,0.334,Loss of stability (P = 0.0021); Gain of MoRF binding (P = 0.021); Loss of ubiquitination at K702 (P = 0.0258); Gain of methylation at R696 (P = 0.031); Gain of loop (P = 0.0312)
17:44101350:A:T,P10636,E697V,0.384,Gain of MoRF binding (P = 0.0134); Loss of disorder (P = 0.0205); Gain of sheet (P = 0.0266); Loss of ubiquitination at K702 (P = 0.0287); Loss of helix (P = 0.0558)
17:44101351:G:C,P10636,E697D,0.189,Loss of ubiquitination at K700 (P = 0.1016); Gain of MoRF binding (P = 0.1319); Loss of methylation at K692 (P = 0.1641); Gain of helix (P = 0.1736); Loss of disorder (P = 0.1943)
17:44101351:G:T,P10636,E697D,0.189,Loss of ubiquitination at K700 (P = 0.1016); Gain of MoRF binding (P = 0.1319); Loss of methylation at K692 (P = 0.1641); Gain of helix (P = 0.1736); Loss of disorder (P = 0.1943)
17:44101352:A:C,P10636,N698H,0.221,Loss of catalytic residue at N698 (P = 0.0481); Loss of sheet (P = 0.0817); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1379); Loss of ubiquitination at K700 (P = 0.1388)
17:44101352:A:G,P10636,N698D,0.276,Loss of MoRF binding (P = 0.0674); Loss of ubiquitination at K702 (P = 0.1016); Gain of sheet (P = 0.1208); Loss of catalytic residue at N698 (P = 0.1297); Loss of helix (P = 0.1299)
17:44101352:A:T,P10636,N698Y,0.304,Loss of sheet (P = 0.0357); Loss of disorder (P = 0.0432); Gain of phosphorylation at N698 (P = 0.0543); Loss of loop (P = 0.0603); Gain of helix (P = 0.062)
17:44101353:A:C,P10636,N698T,0.197,Gain of phosphorylation at N698 (P = 0.0495); Loss of catalytic residue at N698 (P = 0.0589); Loss of ubiquitination at K700 (P = 0.0768); Loss of helix (P = 0.1706); Loss of MoRF binding (P = 0.1766)
17:44101353:A:G,P10636,N698S,0.195,Gain of phosphorylation at N698 (P = 0.04); Gain of glycosylation at N698 (P = 0.0576); Gain of disorder (P = 0.0832); Loss of ubiquitination at K702 (P = 0.1016); Loss of catalytic residue at N698 (P = 0.1095)
17:44101353:A:T,P10636,N698I,0.265,Loss of sheet (P = 0.0315); Gain of helix (P = 0.0325); Loss of disorder (P = 0.0373); Loss of ubiquitination at K700 (P = 0.0393); Loss of catalytic residue at N698 (P = 0.053)
17:44101354:C:A,P10636,N698K,0.296,Loss of ubiquitination at K702 (P = 0.0235); Loss of catalytic residue at N698 (P = 0.0417); Gain of MoRF binding (P = 0.0423); Gain of disorder (P = 0.0663); Gain of solvent accessibility (P = 0.0713)
17:44101354:C:G,P10636,N698K,0.296,Loss of ubiquitination at K702 (P = 0.0235); Loss of catalytic residue at N698 (P = 0.0417); Gain of MoRF binding (P = 0.0423); Gain of disorder (P = 0.0663); Gain of solvent accessibility (P = 0.0713)
17:44101355:G:A,P10636,A699T,0.332,Gain of phosphorylation at A699 (P = 0.0336); Gain of sheet (P = 0.0344); Loss of helix (P = 0.0558); Loss of ubiquitination at K702 (P = 0.0613); Gain of loop (P = 0.0851)
17:44101355:G:C,P10636,A699P,0.499,Loss of helix (P = 0.0138); Gain of glycosylation at A699 (P = 0.0197); Gain of sheet (P = 0.0266); Gain of loop (P = 0.0435); Gain of relative solvent accessibility (P = 0.0479)
17:44101355:G:T,P10636,A699S,0.383,Gain of sheet (P = 0.0344); Loss of helix (P = 0.0376); Gain of disorder (P = 0.0447); Gain of phosphorylation at A699 (P = 0.0461); Gain of relative solvent accessibility (P = 0.0479)
17:44101356:C:A,P10636,A699D,0.437,Gain of sheet (P = 0.0344); Loss of helix (P = 0.0376); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0688); Loss of ubiquitination at K702 (P = 0.069)
17:44101356:C:G,P10636,A699G,0.346,Gain of relative solvent accessibility (P = 0.0215); Gain of sheet (P = 0.0344); Loss of helix (P = 0.0376); Gain of loop (P = 0.0435); Gain of ubiquitination at K700 (P = 0.0961)
17:44101356:C:T,P10636,A699V,0.33,Loss of ubiquitination at K702 (P = 0.0528); Gain of methylation at K700 (P = 0.0872); Loss of disorder (P = 0.0963); Gain of MoRF binding (P = 0.1097); Gain of sheet (P = 0.1208)
17:44101358:A:C,P10636,K700Q,0.345,Loss of ubiquitination at K700 (P = 0.0148); Gain of helix (P = 0.062); Loss of MoRF binding (P = 0.0691); Loss of sheet (P = 0.0817); Loss of disorder (P = 0.1143)
17:44101358:A:G,P10636,K700E,0.375,Loss of ubiquitination at K700 (P = 0.0148); Loss of MoRF binding (P = 0.0302); Gain of helix (P = 0.062); Loss of loop (P = 0.1242); Loss of sheet (P = 0.1907)
17:44101359:A:C,P10636,K700T,0.396,Loss of ubiquitination at K700 (P = 0.0148); Loss of MoRF binding (P = 0.0588); Loss of helix (P = 0.1299); Loss of disorder (P = 0.1403); Gain of sheet (P = 0.1451)
17:44101359:A:G,P10636,K700R,0.309,Loss of ubiquitination at K700 (P = 0.0148); Gain of MoRF binding (P = 0.0658); Gain of helix (P = 0.132); Gain of methylation at K700 (P = 0.1464); Gain of phosphorylation at T703 (P = 0.1753)
17:44101359:A:T,P10636,K700I,0.383,Loss of disorder (P = 0.0138); Loss of ubiquitination at K700 (P = 0.0148); Loss of MoRF binding (P = 0.0568); Gain of helix (P = 0.062); Loss of loop (P = 0.1242)
17:44101360:A:C,P10636,K700N,0.375,Loss of ubiquitination at K700 (P = 0.0148); Loss of MoRF binding (P = 0.0654); Gain of loop (P = 0.0851); Loss of disorder (P = 0.1523); Gain of relative solvent accessibility (P = 0.1684)
17:44101360:A:T,P10636,K700N,0.375,Loss of ubiquitination at K700 (P = 0.0148); Loss of MoRF binding (P = 0.0654); Gain of loop (P = 0.0851); Loss of disorder (P = 0.1523); Gain of relative solvent accessibility (P = 0.1684)
17:44101361:G:A,P10636,A701T,0.183,Loss of ubiquitination at K702 (P = 0.0504); Gain of phosphorylation at A701 (P = 0.0556); Loss of stability (P = 0.1196); Gain of disorder (P = 0.1285); Loss of helix (P = 0.1299)
17:44101361:G:C,P10636,A701P,0.337,Gain of loop (P = 0.024); Loss of stability (P = 0.0351); Loss of helix (P = 0.0376); Loss of ubiquitination at K702 (P = 0.0432); Gain of disorder (P = 0.0652)
17:44101361:G:T,P10636,A701S,0.236,Gain of disorder (P = 0.0492); Gain of ubiquitination at K700 (P = 0.0668); Gain of glycosylation at A701 (P = 0.1151); Gain of MoRF binding (P = 0.1557); Gain of helix (P = 0.1736)
17:44101362:C:A,P10636,A701D,0.265,Gain of helix (P = 0.062); Loss of MoRF binding (P = 0.0716); Loss of ubiquitination at K702 (P = 0.0877); Gain of disorder (P = 0.0954); Gain of solvent accessibility (P = 0.1708)
17:44101362:C:G,P10636,A701G,0.2,Gain of loop (P = 0.0435); Loss of ubiquitination at K702 (P = 0.069); Loss of stability (P = 0.0781); Loss of helix (P = 0.079); Gain of sheet (P = 0.1208)
17:44101362:C:T,P10636,A701V,0.209,Loss of ubiquitination at K702 (P = 0.0451); Gain of methylation at K700 (P = 0.0888); Loss of disorder (P = 0.1123); Gain of MoRF binding (P = 0.1186); Gain of sheet (P = 0.1208)
17:44101364:A:C,P10636,K702Q,0.366,Loss of ubiquitination at K702 (P = 0.0148); Loss of MoRF binding (P = 0.0846); Loss of disorder (P = 0.0997); Loss of phosphorylation at T703 (P = 0.1941); Gain of sheet (P = 0.1945)
17:44101364:A:G,P10636,K702E,0.441,Loss of ubiquitination at K702 (P = 0.0148); Loss of MoRF binding (P = 0.0521); Loss of helix (P = 0.079); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1116)
17:44101365:A:C,P10636,K702T,0.444,Loss of ubiquitination at K702 (P = 0.0148); Loss of helix (P = 0.079); Loss of MoRF binding (P = 0.0822); Gain of phosphorylation at K702 (P = 0.0879); Gain of catalytic residue at T703 (P = 0.0999)
17:44101365:A:G,P10636,K702R,0.347,Loss of ubiquitination at K702 (P = 0.0148); Gain of methylation at K702 (P = 0.0872); Gain of MoRF binding (P = 0.1051); Loss of disorder (P = 0.143); Gain of catalytic residue at K702 (P = 0.1842)
17:44101365:A:T,P10636,K702M,0.392,Loss of ubiquitination at K702 (P = 0.0148); Loss of disorder (P = 0.0484); Gain of helix (P = 0.062); Loss of MoRF binding (P = 0.1218); Loss of phosphorylation at T703 (P = 0.1261)
17:44101366:G:C,P10636,K702N,0.438,Loss of ubiquitination at K702 (P = 0.0148); Gain of loop (P = 0.0166); Loss of helix (P = 0.0237); Gain of sheet (P = 0.0477); Loss of MoRF binding (P = 0.0809)
17:44101366:G:T,P10636,K702N,0.438,Loss of ubiquitination at K702 (P = 0.0148); Gain of loop (P = 0.0166); Loss of helix (P = 0.0237); Gain of sheet (P = 0.0477); Loss of MoRF binding (P = 0.0809)
17:44101367:A:C,P10636,T703P,0.319,Gain of relative solvent accessibility (P = 0.0098); Gain of solvent accessibility (P = 0.0263); Loss of phosphorylation at T703 (P = 0.0283); Loss of stability (P = 0.0651); Gain of ubiquitination at K700 (P = 0.071)
17:44101367:A:G,P10636,T703A,0.259,Gain of relative solvent accessibility (P = 0.0098); Loss of phosphorylation at T703 (P = 0.0283); Gain of helix (P = 0.062); Gain of solvent accessibility (P = 0.0713); Gain of ubiquitination at K700 (P = 0.0961)
17:44101367:A:T,P10636,T703S,0.267,Gain of relative solvent accessibility (P = 0.0098); Gain of solvent accessibility (P = 0.0314); Gain of disorder (P = 0.0565); Loss of phosphorylation at T703 (P = 0.0624); Gain of ubiquitination at K700 (P = 0.071)
17:44101368:C:A,P10636,T703K,0.371,Gain of solvent accessibility (P = 0.0021); Gain of relative solvent accessibility (P = 0.0098); Loss of ubiquitination at K702 (P = 0.0213); Loss of phosphorylation at T703 (P = 0.0283); Gain of MoRF binding (P = 0.0489)
17:44101368:C:G,P10636,T703R,0.349,Gain of solvent accessibility (P = 3e-04); Gain of relative solvent accessibility (P = 0.0098); Gain of MoRF binding (P = 0.0204); Loss of ubiquitination at K702 (P = 0.0228); Loss of phosphorylation at T703 (P = 0.0283)
17:44101368:C:T,P10636,T703I,0.343,Gain of loop (P = 0.0166); Loss of helix (P = 0.0237); Gain of catalytic residue at T703 (P = 0.0244); Gain of sheet (P = 0.0266); Loss of phosphorylation at T703 (P = 0.0283)
17:44101370:G:A,P10636,D704N,0.452,Loss of ubiquitination at K702 (P = 0.0287); Gain of MoRF binding (P = 0.0491); Loss of phosphorylation at T703 (P = 0.1036); Gain of helix (P = 0.132); Gain of catalytic residue at K702 (P = 0.153)
17:44101370:G:C,P10636,D704H,0.456,Loss of ubiquitination at K702 (P = 0.0246); Gain of MoRF binding (P = 0.0607); Gain of catalytic residue at K702 (P = 0.0707); Loss of phosphorylation at T703 (P = 0.1329); Gain of sheet (P = 0.1539)
17:44101370:G:T,P10636,D704Y,0.451,Loss of ubiquitination at K702 (P = 0.0273); Gain of phosphorylation at D704 (P = 0.0279); Loss of disorder (P = 0.0322); Loss of loop (P = 0.0603); Gain of MoRF binding (P = 0.066)
17:44101371:A:C,P10636,D704A,0.444,Loss of ubiquitination at K702 (P = 0.0287); Gain of MoRF binding (P = 0.0609); Loss of loop (P = 0.0986); Gain of helix (P = 0.132); Loss of disorder (P = 0.1342)
17:44101371:A:G,P10636,D704G,0.437,Loss of ubiquitination at K702 (P = 0.0273); Gain of MoRF binding (P = 0.0612); Loss of stability (P = 0.0735); Gain of sheet (P = 0.1539); Gain of relative solvent accessibility (P = 0.1571)
17:44101371:A:T,P10636,D704V,0.485,Loss of ubiquitination at K702 (P = 0.0273); Loss of disorder (P = 0.0433); Gain of MoRF binding (P = 0.0513); Loss of loop (P = 0.0603); Loss of phosphorylation at T703 (P = 0.1229)
17:44101372:C:A,P10636,D704E,0.411,Loss of ubiquitination at K702 (P = 0.0613); Gain of helix (P = 0.062); Loss of loop (P = 0.0986); Gain of solvent accessibility (P = 0.1014); Gain of disorder (P = 0.1146)
17:44101372:C:G,P10636,D704E,0.411,Loss of ubiquitination at K702 (P = 0.0613); Gain of helix (P = 0.062); Loss of loop (P = 0.0986); Gain of solvent accessibility (P = 0.1014); Gain of disorder (P = 0.1146)
17:44101373:C:A,P10636,H705N,0.348,Gain of relative solvent accessibility (P = 0.0166); Gain of solvent accessibility (P = 0.0354); Gain of ubiquitination at K700 (P = 0.0843); Gain of disorder (P = 0.1615); Gain of MoRF binding (P = 0.218)
17:44101373:C:G,P10636,H705D,0.404,Gain of relative solvent accessibility (P = 0.0166); Gain of solvent accessibility (P = 0.0306); Gain of ubiquitination at K702 (P = 0.0564); Gain of disorder (P = 0.0984); Loss of MoRF binding (P = 0.1303)
17:44101373:C:T,P10636,H705Y,0.362,Gain of phosphorylation at H705 (P = 0.0351); Loss of disorder (P = 0.051); Loss of ubiquitination at K702 (P = 0.0613); Gain of solvent accessibility (P = 0.1903); Gain of relative solvent accessibility (P = 0.2363)
17:44101374:A:C,P10636,H705P,0.38,Gain of relative solvent accessibility (P = 0.0166); Gain of ubiquitination at K700 (P = 0.071); Gain of disorder (P = 0.0713); Gain of solvent accessibility (P = 0.0713); Gain of catalytic residue at K702 (P = 0.1707)
17:44101374:A:G,P10636,H705R,0.414,Gain of MoRF binding (P = 0.0137); Loss of ubiquitination at K702 (P = 0.0248); Gain of solvent accessibility (P = 0.0374); Gain of relative solvent accessibility (P = 0.0999); Gain of phosphorylation at T703 (P = 0.1448)
17:44101374:A:T,P10636,H705L,0.371,Loss of disorder (P = 0.0555); Loss of ubiquitination at K702 (P = 0.0613); Loss of catalytic residue at G706 (P = 0.1497); Loss of phosphorylation at T703 (P = 0.1654); Gain of helix (P = 0.1736)
17:44101375:C:A,P10636,H705Q,0.373,Gain of solvent accessibility (P = 0.0338); Gain of relative solvent accessibility (P = 0.0479); Gain of ubiquitination at K700 (P = 0.1092); Gain of helix (P = 0.1736); Loss of catalytic residue at D704 (P = 0.1738)
17:44101375:C:G,P10636,H705Q,0.373,Gain of solvent accessibility (P = 0.0338); Gain of relative solvent accessibility (P = 0.0479); Gain of ubiquitination at K700 (P = 0.1092); Gain of helix (P = 0.1736); Loss of catalytic residue at D704 (P = 0.1738)
17:44101376:G:A,P10636,G706R,0.608,Loss of ubiquitination at K702 (P = 0.0303); Gain of solvent accessibility (P = 0.0306); Gain of MoRF binding (P = 0.0374); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1532)
17:44101376:G:C,P10636,G706R,0.608,Loss of ubiquitination at K702 (P = 0.0303); Gain of solvent accessibility (P = 0.0306); Gain of MoRF binding (P = 0.0374); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1532)
17:44101376:G:T,P10636,G706W,0.47,Loss of disorder (P = 0.0075); Gain of sheet (P = 0.0477); Loss of loop (P = 0.0512); Gain of MoRF binding (P = 0.0607); Loss of ubiquitination at K702 (P = 0.069)
17:44101377:G:A,P10636,G706E,0.37,Gain of sheet (P = 0.0477); Gain of disorder (P = 0.0663); Gain of solvent accessibility (P = 0.0837); Gain of ubiquitination at K702 (P = 0.0961); Loss of loop (P = 0.1242)
17:44101377:G:C,P10636,G706A,0.298,Loss of relative solvent accessibility (P = 0.0793); Loss of ubiquitination at K702 (P = 0.1016); Loss of catalytic residue at G706 (P = 0.1093); Loss of loop (P = 0.1242); Loss of disorder (P = 0.1659)
17:44101377:G:T,P10636,G706V,0.391,Gain of sheet (P = 0.0221); Loss of loop (P = 0.0512); Loss of disorder (P = 0.0563); Loss of ubiquitination at K702 (P = 0.0768); Loss of catalytic residue at G706 (P = 0.087)
17:44101379:G:A,P10636,A707T,0.356,Gain of disorder (P = 0.0973); Loss of ubiquitination at K702 (P = 0.1191); Gain of phosphorylation at A707 (P = 0.1248); Gain of relative solvent accessibility (P = 0.1259); Loss of loop (P = 0.2237)
17:44101379:G:C,P10636,A707P,0.488,Gain of disorder (P = 0.0348); Gain of loop (P = 0.1069); Gain of ubiquitination at K702 (P = 0.1092); Gain of relative solvent accessibility (P = 0.1259); Loss of sheet (P = 0.1398)
17:44101379:G:T,P10636,A707S,0.422,Gain of disorder (P = 0.0272); Loss of sheet (P = 0.0357); Gain of phosphorylation at A707 (P = 0.0845); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K702 (P = 0.0961)
17:44101380:C:A,P10636,A707E,0.515,Gain of disorder (P = 0.0316); Gain of solvent accessibility (P = 0.0411); Gain of relative solvent accessibility (P = 0.0479); Gain of ubiquitination at K702 (P = 0.0628); Gain of loop (P = 0.1069)
17:44101380:C:G,P10636,A707G,0.366,Loss of sheet (P = 0.0357); Gain of disorder (P = 0.0789); Loss of loop (P = 0.0986); Gain of ubiquitination at K702 (P = 0.1235); Gain of relative solvent accessibility (P = 0.1259)
17:44101380:C:T,P10636,A707V,0.373,Loss of ubiquitination at K712 (P = 0.0591); Loss of disorder (P = 0.0978); Loss of loop (P = 0.1242); Gain of sheet (P = 0.1945); Loss of phosphorylation at T703 (P = 0.1953)
17:44101382:G:A,P10636,E708K,0.474,Gain of MoRF binding (P = 0.0078); Gain of methylation at E708 (P = 0.0117); Loss of catalytic residue at E708 (P = 0.0226); Gain of ubiquitination at E708 (P = 0.0369); Loss of stability (P = 0.0565)
17:44101382:G:C,P10636,E708Q,0.395,Gain of MoRF binding (P = 0.0737); Loss of disorder (P = 0.1119); Loss of ubiquitination at K712 (P = 0.1557); Loss of stability (P = 0.1962); Loss of phosphorylation at S713 (P = 0.2286)
17:44101383:A:C,P10636,E708A,0.408,Loss of ubiquitination at K712 (P = 0.0423); Loss of disorder (P = 0.0806); Loss of stability (P = 0.0961); Gain of glycosylation at S713 (P = 0.1536); Loss of phosphorylation at Y711 (P = 0.1688)
17:44101383:A:G,P10636,E708G,0.392,Loss of stability (P = 0.0173); Loss of sheet (P = 0.0357); Loss of ubiquitination at K712 (P = 0.0423); Gain of loop (P = 0.0435); Gain of catalytic residue at A707 (P = 0.0722)
17:44101383:A:T,P10636,E708V,0.497,Loss of disorder (P = 0.0312); Loss of ubiquitination at K712 (P = 0.0423); Loss of phosphorylation at Y711 (P = 0.0755); Gain of sheet (P = 0.1539); Loss of catalytic residue at E708 (P = 0.1656)
17:44101384:G:C,P10636,E708D,0.34,Loss of sheet (P = 0.0126); Gain of loop (P = 0.0435); Loss of catalytic residue at E708 (P = 0.1578); Gain of disorder (P = 0.2026); Gain of ubiquitination at K712 (P = 0.2106)
17:44101384:G:T,P10636,E708D,0.34,Loss of sheet (P = 0.0126); Gain of loop (P = 0.0435); Loss of catalytic residue at E708 (P = 0.1578); Gain of disorder (P = 0.2026); Gain of ubiquitination at K712 (P = 0.2106)
17:44101385:A:C,P10636,I709L,0.33,Gain of catalytic residue at I709 (P = 0.0466); Loss of methylation at K712 (P = 0.0856); Gain of disorder (P = 0.1185); Gain of glycosylation at S713 (P = 0.1538); Gain of phosphorylation at S713 (P = 0.2076)
17:44101385:A:G,P10636,I709V,0.329,Gain of disorder (P = 0.079); Gain of glycosylation at S713 (P = 0.1149); Gain of phosphorylation at S713 (P = 0.166); Loss of catalytic residue at V710 (P = 0.2124); Loss of methylation at K712 (P = 0.2292)
17:44101385:A:T,P10636,I709F,0.339,Gain of catalytic residue at I709 (P = 0.0408); Gain of disorder (P = 0.1903); Loss of methylation at K712 (P = 0.1988); Loss of glycosylation at S713 (P = 0.2224); Gain of ubiquitination at K712 (P = 0.2244)
17:44101386:T:A,P10636,I709N,0.56,Gain of disorder (P = 0.0136); Loss of sheet (P = 0.0357); Gain of loop (P = 0.0435); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K712 (P = 0.115)
17:44101386:T:C,P10636,I709T,0.508,Gain of disorder (P = 0.0153); Gain of phosphorylation at I709 (P = 0.049); Gain of glycosylation at S713 (P = 0.086); Gain of relative solvent accessibility (P = 0.1259); Loss of sheet (P = 0.1398)
17:44101386:T:G,P10636,I709S,0.548,Gain of disorder (P = 0.0049); Gain of phosphorylation at I709 (P = 0.0514); Gain of glycosylation at S713 (P = 0.0792); Gain of ubiquitination at K712 (P = 0.0818); Gain of relative solvent accessibility (P = 0.09)
17:44101387:C:G,P10636,I709M,0.421,Gain of disorder (P = 0.0373); Gain of phosphorylation at S713 (P = 0.1646); Gain of ubiquitination at K712 (P = 0.1691); Gain of glycosylation at S713 (P = 0.1725); Gain of sheet (P = 0.1945)
17:44101388:G:A,P10636,V710M,0.246,Gain of disorder (P = 0.0916); Gain of sheet (P = 0.1539); Loss of catalytic residue at V710 (P = 0.1773); Gain of phosphorylation at S713 (P = 0.1789); Gain of ubiquitination at K712 (P = 0.2244)
17:44101388:G:C,P10636,V710L,0.255,Gain of relative solvent accessibility (P = 0.1259); Loss of methylation at K712 (P = 0.1443); Gain of sheet (P = 0.1539); Loss of catalytic residue at S713 (P = 0.1825); Loss of glycosylation at S713 (P = 0.2058)
17:44101388:G:T,P10636,V710L,0.255,Gain of relative solvent accessibility (P = 0.1259); Loss of methylation at K712 (P = 0.1443); Gain of sheet (P = 0.1539); Loss of catalytic residue at S713 (P = 0.1825); Loss of glycosylation at S713 (P = 0.2058)
17:44101389:T:A,P10636,V710E,0.525,Gain of disorder (P = 0.0142); Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.0936); Gain of solvent accessibility (P = 0.0971); Gain of phosphorylation at S713 (P = 0.1037)
17:44101389:T:C,P10636,V710A,0.361,Loss of stability (P = 0.0272); Gain of disorder (P = 0.0553); Gain of relative solvent accessibility (P = 0.1259); Gain of glycosylation at S713 (P = 0.1422); Gain of sheet (P = 0.1539)
17:44101389:T:G,P10636,V710G,0.452,Loss of stability (P = 0.0012); Gain of disorder (P = 0.0296); Gain of catalytic residue at I709 (P = 0.0722); Gain of relative solvent accessibility (P = 0.09); Gain of phosphorylation at S713 (P = 0.1387)
17:44101391:T:A,P10636,Y711N,0.441,Gain of disorder (P = 0.0101); Loss of phosphorylation at Y711 (P = 0.0169); Loss of sheet (P = 0.0357); Gain of ubiquitination at K712 (P = 0.0719); Gain of relative solvent accessibility (P = 0.09)
17:44101391:T:C,P10636,Y711H,0.45,Gain of disorder (P = 0.0113); Loss of phosphorylation at Y711 (P = 0.0169); Gain of ubiquitination at K712 (P = 0.0758); Gain of relative solvent accessibility (P = 0.1259); Loss of sheet (P = 0.1398)
17:44101391:T:G,P10636,Y711D,0.448,Gain of disorder (P = 0.0064); Loss of sheet (P = 0.0126); Loss of phosphorylation at Y711 (P = 0.0169); Gain of loop (P = 0.0435); Gain of ubiquitination at K712 (P = 0.0561)
17:44101392:A:C,P10636,Y711S,0.454,Gain of disorder (P = 0.0035); Gain of glycosylation at Y711 (P = 0.0437); Gain of ubiquitination at K712 (P = 0.0573); Loss of phosphorylation at Y711 (P = 0.0749); Gain of relative solvent accessibility (P = 0.09)
17:44101392:A:G,P10636,Y711C,0.426,Loss of phosphorylation at Y711 (P = 0.0169); Gain of disorder (P = 0.0831); Loss of glycosylation at S713 (P = 0.1275); Gain of methylation at K712 (P = 0.1497); Gain of sheet (P = 0.1539)
17:44101392:A:T,P10636,Y711F,0.374,Loss of phosphorylation at Y711 (P = 0.0169); Gain of catalytic residue at Y711 (P = 0.0752); Gain of disorder (P = 0.1237); Gain of methylation at K712 (P = 0.1952); Loss of glycosylation at S713 (P = 0.2203)
17:44101394:A:C,P10636,K712Q,0.307,Loss of methylation at K712 (P = 0.0067); Loss of ubiquitination at K712 (P = 0.0087); Loss of disorder (P = 0.0852); Gain of glycosylation at S713 (P = 0.1049); Gain of sheet (P = 0.1451)
17:44101394:A:G,P10636,K712E,0.342,Loss of methylation at K712 (P = 0.0067); Loss of ubiquitination at K712 (P = 0.0087); Gain of sheet (P = 0.1539); Gain of phosphorylation at S713 (P = 0.1767); Gain of glycosylation at S713 (P = 0.2205)
17:44101395:A:C,P10636,K712T,0.38,Loss of methylation at K712 (P = 0.0067); Loss of ubiquitination at K712 (P = 0.0087); Loss of catalytic residue at K712 (P = 0.0107); Gain of phosphorylation at K712 (P = 0.0693); Loss of sheet (P = 0.0817)
17:44101395:A:G,P10636,K712R,0.292,Loss of ubiquitination at K712 (P = 0.0087); Loss of methylation at K712 (P = 0.0109); Gain of phosphorylation at S713 (P = 0.1193); Loss of disorder (P = 0.1387); Gain of sheet (P = 0.1539)
17:44101395:A:T,P10636,K712M,0.426,Loss of methylation at K712 (P = 0.0067); Loss of ubiquitination at K712 (P = 0.0087); Loss of catalytic residue at K712 (P = 0.0226); Loss of disorder (P = 0.0488); Loss of loop (P = 0.1242)
17:44101396:G:C,P10636,K712N,0.321,Loss of methylation at K712 (P = 0.0067); Loss of ubiquitination at K712 (P = 0.0087); Loss of disorder (P = 0.108); Loss of sheet (P = 0.1398); Loss of phosphorylation at S717 (P = 0.1815)
17:44101396:G:T,P10636,K712N,0.321,Loss of methylation at K712 (P = 0.0067); Loss of ubiquitination at K712 (P = 0.0087); Loss of disorder (P = 0.108); Loss of sheet (P = 0.1398); Loss of phosphorylation at S717 (P = 0.1815)
17:44101397:T:A,P10636,S713T,0.421,Loss of disorder (P = 0.0743); Loss of ubiquitination at K712 (P = 0.0896); Gain of sheet (P = 0.1208); Gain of relative solvent accessibility (P = 0.1259); Loss of phosphorylation at S717 (P = 0.1599)
17:44101397:T:C,P10636,S713P,0.379,Loss of glycosylation at S713 (P = 0.0764); Loss of phosphorylation at S713 (P = 0.0787); Loss of sheet (P = 0.0817); Gain of loop (P = 0.1069); Loss of stability (P = 0.1239)
17:44101397:T:G,P10636,S713A,0.449,Loss of disorder (P = 0.046); Loss of glycosylation at S713 (P = 0.0542); Loss of phosphorylation at S713 (P = 0.0787); Loss of ubiquitination at K712 (P = 0.1069); Loss of stability (P = 0.1112)
17:44101398:C:G,P10636,S713W,0.483,Loss of disorder (P = 2e-04); Loss of glycosylation at S717 (P = 0.0535); Loss of phosphorylation at S713 (P = 0.0787); Loss of ubiquitination at K712 (P = 0.0896); Gain of sheet (P = 0.1451)
17:44101398:C:T,P10636,S713L,0.435,Loss of disorder (P = 0.0098); Loss of glycosylation at S713 (P = 0.0542); Loss of phosphorylation at S713 (P = 0.0787); Gain of relative solvent accessibility (P = 0.1259); Gain of sheet (P = 0.1451)
17:44101400:C:A,P10636,P714T,0.399,Gain of sheet (P = 0.0477); Gain of glycosylation at P714 (P = 0.1024); Loss of loop (P = 0.1242); Loss of disorder (P = 0.1256); Loss of ubiquitination at K712 (P = 0.1278)
17:44101400:C:G,P10636,P714A,0.395,Gain of sheet (P = 0.0477); Loss of disorder (P = 0.0698); Loss of loop (P = 0.0986); Loss of stability (P = 0.1272); Loss of phosphorylation at S717 (P = 0.1815)
17:44101400:C:T,P10636,P714S,0.358,Gain of phosphorylation at P714 (P = 0.0524); Gain of disorder (P = 0.1214); Loss of methylation at K712 (P = 0.1326); Gain of sheet (P = 0.1451); Loss of glycosylation at S713 (P = 0.1561)
17:44101401:C:A,P10636,P714Q,0.367,Loss of ubiquitination at K712 (P = 0.0657); Loss of glycosylation at S713 (P = 0.1084); Loss of disorder (P = 0.116); Gain of sheet (P = 0.1208); Loss of phosphorylation at S717 (P = 0.1294)
17:44101401:C:G,P10636,P714R,0.4,Gain of sheet (P = 0.0477); Gain of MoRF binding (P = 0.051); Loss of ubiquitination at K712 (P = 0.0539); Gain of phosphorylation at S717 (P = 0.0929); Loss of disorder (P = 0.1727)
17:44101401:C:T,P10636,P714L,0.446,Loss of disorder (P = 0.0185); Gain of sheet (P = 0.0221); Loss of loop (P = 0.0374); Loss of glycosylation at S713 (P = 0.1105); Loss of phosphorylation at Y711 (P = 0.1381)
17:44101403:G:A,P10636,V715M,0.332,Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.09); Gain of disorder (P = 0.1023); Gain of solvent accessibility (P = 0.1045); Gain of phosphorylation at T720 (P = 0.1113)
17:44101403:G:C,P10636,V715L,0.256,Loss of ubiquitination at K712 (P = 0.1557); Loss of glycosylation at S713 (P = 0.1881); Loss of methylation at K712 (P = 0.1935); Loss of phosphorylation at S717 (P = 0.2); Loss of disorder (P = 0.2208)
17:44101403:G:T,P10636,V715L,0.256,Loss of ubiquitination at K712 (P = 0.1557); Loss of glycosylation at S713 (P = 0.1881); Loss of methylation at K712 (P = 0.1935); Loss of phosphorylation at S717 (P = 0.2); Loss of disorder (P = 0.2208)
17:44101404:T:A,P10636,V715E,0.474,Gain of solvent accessibility (P = 0.0145); Gain of disorder (P = 0.0209); Gain of relative solvent accessibility (P = 0.0215); Gain of ubiquitination at K712 (P = 0.0818); Loss of catalytic residue at K712 (P = 0.0972)
17:44101404:T:C,P10636,V715A,0.281,Gain of disorder (P = 0.0749); Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.09); Gain of glycosylation at S713 (P = 0.1589); Gain of phosphorylation at S717 (P = 0.1749)
17:44101404:T:G,P10636,V715G,0.448,Loss of sheet (P = 0.0181); Gain of relative solvent accessibility (P = 0.0215); Gain of loop (P = 0.0312); Loss of stability (P = 0.0363); Gain of disorder (P = 0.0368)
17:44101406:G:A,P10636,V716M,0.251,Gain of loop (P = 0.069); Loss of sheet (P = 0.0817); Gain of disorder (P = 0.1053); Gain of relative solvent accessibility (P = 0.1259); Gain of ubiquitination at K712 (P = 0.1691)
17:44101406:G:C,P10636,V716L,0.209,Loss of sheet (P = 0.0817); Loss of glycosylation at S713 (P = 0.1264); Loss of ubiquitination at K712 (P = 0.1557); Loss of methylation at K712 (P = 0.1994); Loss of disorder (P = 0.2252)
17:44101406:G:T,P10636,V716L,0.209,Loss of sheet (P = 0.0817); Loss of glycosylation at S713 (P = 0.1264); Loss of ubiquitination at K712 (P = 0.1557); Loss of methylation at K712 (P = 0.1994); Loss of disorder (P = 0.2252)
17:44101407:T:A,P10636,V716E,0.397,Gain of disorder (P = 0.0245); Loss of sheet (P = 0.0315); Gain of solvent accessibility (P = 0.0411); Gain of relative solvent accessibility (P = 0.0479); Gain of loop (P = 0.069)
17:44101407:T:C,P10636,V716A,0.259,Loss of sheet (P = 0.0315); Gain of loop (P = 0.069); Gain of disorder (P = 0.0823); Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.0984)
17:44101407:T:G,P10636,V716G,0.378,Loss of stability (P = 0.0063); Loss of sheet (P = 0.0181); Gain of loop (P = 0.0312); Gain of disorder (P = 0.0415); Gain of glycosylation at S713 (P = 0.0697)
17:44101409:T:A,P10636,S717T,0.182,Gain of relative solvent accessibility (P = 0.0479); Loss of glycosylation at S717 (P = 0.0748); Loss of disorder (P = 0.0811); Gain of solvent accessibility (P = 0.0917); Loss of ubiquitination at K712 (P = 0.1278)
17:44101409:T:C,P10636,S717P,0.206,Gain of relative solvent accessibility (P = 0.0082); Loss of glycosylation at S717 (P = 0.0227); Gain of solvent accessibility (P = 0.0256); Loss of sheet (P = 0.0315); Loss of phosphorylation at S717 (P = 0.0553)
17:44101409:T:G,P10636,S717A,0.217,Loss of glycosylation at S717 (P = 0.0071); Loss of disorder (P = 0.0447); Gain of catalytic residue at S717 (P = 0.0537); Loss of phosphorylation at S717 (P = 0.0553); Gain of relative solvent accessibility (P = 0.09)
17:44101410:C:A,P10636,S717Y,0.337,Loss of disorder (P = 0.0063); Loss of glycosylation at S717 (P = 0.0071); Gain of catalytic residue at S717 (P = 0.0208); Gain of sheet (P = 0.0266); Gain of phosphorylation at S717 (P = 0.0578)
17:44101410:C:G,P10636,S717C,0.3,Loss of disorder (P = 0.003); Loss of glycosylation at S717 (P = 0.0071); Gain of catalytic residue at S721 (P = 0.0374); Loss of ubiquitination at K712 (P = 0.0505); Loss of phosphorylation at S717 (P = 0.0553)
17:44101410:C:T,P10636,S717F,0.314,Loss of disorder (P = 0.002); Loss of glycosylation at S717 (P = 0.0071); Gain of sheet (P = 0.0344); Loss of phosphorylation at S717 (P = 0.0553); Loss of ubiquitination at K712 (P = 0.0657)
17:44101412:G:A,P10636,G718R,0.237,Gain of solvent accessibility (P = 0.0014); Loss of glycosylation at S717 (P = 0.0464); Loss of catalytic residue at P714 (P = 0.0674); Loss of sheet (P = 0.0817); Gain of phosphorylation at T720 (P = 0.0941)
17:44101412:G:C,P10636,G718R,0.237,Gain of solvent accessibility (P = 0.0014); Loss of glycosylation at S717 (P = 0.0464); Loss of catalytic residue at P714 (P = 0.0674); Loss of sheet (P = 0.0817); Gain of phosphorylation at T720 (P = 0.0941)
17:44101412:G:T,P10636,G718W,0.334,Loss of disorder (P = 0.0062); Loss of glycosylation at S717 (P = 0.0115); Gain of solvent accessibility (P = 0.019); Loss of catalytic residue at P714 (P = 0.0674); Loss of phosphorylation at S717 (P = 0.1208)
17:44101413:G:A,P10636,G718E,0.19,Gain of solvent accessibility (P = 0.012); Loss of glycosylation at S717 (P = 0.0372); Loss of catalytic residue at P714 (P = 0.0674); Loss of sheet (P = 0.0817); Gain of disorder (P = 0.1157)
17:44101413:G:C,P10636,G718A,0.115,Loss of glycosylation at S717 (P = 0.0499); Loss of catalytic residue at P714 (P = 0.0674); Loss of stability (P = 0.1409); Gain of sheet (P = 0.1451); Loss of disorder (P = 0.1935)
17:44101413:G:T,P10636,G718V,0.17,Gain of sheet (P = 0.0266); Loss of glycosylation at S717 (P = 0.0348); Loss of loop (P = 0.0512); Loss of catalytic residue at P714 (P = 0.0674); Loss of disorder (P = 0.0741)
17:44101415:G:A,P10636,D719N,0.129,Loss of phosphorylation at S721 (P = 0.1433); Gain of relative solvent accessibility (P = 0.1571); Loss of disorder (P = 0.2229); Gain of solvent accessibility (P = 0.2902); Gain of glycosylation at P722 (P = 0.2958)
17:44101415:G:C,P10636,D719H,0.126,Gain of catalytic residue at D719 (P = 0.1188); Loss of solvent accessibility (P = 0.1473); Loss of phosphorylation at S717 (P = 0.169); Loss of relative solvent accessibility (P = 0.1807); Gain of disorder (P = 0.2407)
17:44101415:G:T,P10636,D719Y,0.227,Loss of disorder (P = 0.0398); Gain of phosphorylation at D719 (P = 0.0449); Gain of sheet (P = 0.1208); Loss of loop (P = 0.1242); Loss of relative solvent accessibility (P = 0.1807)
17:44101416:A:C,P10636,D719A,0.124,Loss of disorder (P = 0.1301); Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at T720 (P = 0.1861); Loss of phosphorylation at S717 (P = 0.21); Gain of catalytic residue at D719 (P = 0.2312)
17:44101416:A:G,P10636,D719G,0.158,Gain of catalytic residue at S721 (P = 0.098); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1617); Loss of phosphorylation at S717 (P = 0.2521); Loss of disorder (P = 0.2578)
17:44101416:A:T,P10636,D719V,0.189,Loss of solvent accessibility (P = 0.0544); Loss of disorder (P = 0.0581); Gain of catalytic residue at D719 (P = 0.0854); Loss of relative solvent accessibility (P = 0.0981); Gain of sheet (P = 0.1208)
17:44101417:C:A,P10636,D719E,0.1,Gain of catalytic residue at D719 (P = 0.099); Gain of disorder (P = 0.1722); Gain of phosphorylation at S717 (P = 0.1811); Gain of glycosylation at S721 (P = 0.2487); Gain of loop (P = 0.2754)
17:44101417:C:G,P10636,D719E,0.1,Gain of catalytic residue at D719 (P = 0.099); Gain of disorder (P = 0.1722); Gain of phosphorylation at S717 (P = 0.1811); Gain of glycosylation at S721 (P = 0.2487); Gain of loop (P = 0.2754)
17:44101418:A:C,P10636,T720P,0.121,Gain of relative solvent accessibility (P = 0.0275); Gain of solvent accessibility (P = 0.08); Gain of phosphorylation at S717 (P = 0.1084); Gain of disorder (P = 0.1112); Gain of glycosylation at P722 (P = 0.1683)
17:44101418:A:G,P10636,T720A,0.066,Loss of glycosylation at T720 (P = 0.1021); Gain of phosphorylation at S717 (P = 0.1757); Gain of relative solvent accessibility (P = 0.1894); Loss of disorder (P = 0.2128); Gain of loop (P = 0.2754)
17:44101418:A:T,P10636,T720S,0.148,Gain of relative solvent accessibility (P = 0.0275); Gain of phosphorylation at T720 (P = 0.0422); Gain of disorder (P = 0.0705); Gain of solvent accessibility (P = 0.0971); Gain of sheet (P = 0.1945)
17:44101419:C:A,P10636,T720K,0.227,Gain of solvent accessibility (P = 0.007); Gain of ubiquitination at T720 (P = 0.0082); Gain of relative solvent accessibility (P = 0.0275); Gain of methylation at T720 (P = 0.068); Gain of sheet (P = 0.1208)
17:44101419:C:G,P10636,T720R,0.153,Gain of methylation at T720 (P = 0.044); Gain of solvent accessibility (P = 0.0456); Gain of phosphorylation at S717 (P = 0.0889); Loss of glycosylation at T720 (P = 0.1021); Gain of MoRF binding (P = 0.1374)
17:44101419:C:T,P10636,T720M,0.117,Loss of glycosylation at T720 (P = 0.1021); Gain of catalytic residue at V716 (P = 0.1179); Gain of solvent accessibility (P = 0.1456); Gain of phosphorylation at S717 (P = 0.1767); Gain of relative solvent accessibility (P = 0.1894)
17:44101421:T:A,P10636,S721T,0.173,Gain of relative solvent accessibility (P = 0.09); Gain of catalytic residue at S721 (P = 0.1012); Loss of disorder (P = 0.1066); Gain of sheet (P = 0.1208); Gain of glycosylation at T720 (P = 0.1478)
17:44101421:T:C,P10636,S721P,0.239,Gain of catalytic residue at S721 (P = 0.0171); Loss of phosphorylation at S721 (P = 0.0222); Gain of relative solvent accessibility (P = 0.09); Gain of glycosylation at P722 (P = 0.1398); Gain of solvent accessibility (P = 0.1751)
17:44101421:T:G,P10636,S721A,0.163,Loss of phosphorylation at S721 (P = 0.0222); Loss of disorder (P = 0.0617); Gain of relative solvent accessibility (P = 0.1259); Gain of sheet (P = 0.1945); Loss of glycosylation at S721 (P = 0.2339)
17:44101422:C:A,P10636,S721Y,0.189,Loss of disorder (P = 0.0208); Loss of phosphorylation at S721 (P = 0.0856); Gain of relative solvent accessibility (P = 0.1259); Gain of catalytic residue at S721 (P = 0.1486); Gain of solvent accessibility (P = 0.154)
17:44101422:C:G,P10636,S721C,0.234,Loss of disorder (P = 0.013); Loss of phosphorylation at S721 (P = 0.0222); Gain of catalytic residue at D719 (P = 0.1311); Loss of glycosylation at S717 (P = 0.1459); Loss of sheet (P = 0.1907)
17:44101422:C:T,P10636,S721F,0.242,Loss of disorder (P = 0.0109); Loss of phosphorylation at S721 (P = 0.0222); Gain of catalytic residue at S721 (P = 0.0318); Loss of glycosylation at S717 (P = 0.0435); Gain of relative solvent accessibility (P = 0.1259)
17:44101424:C:A,P10636,P722T,0.309,Gain of glycosylation at P722 (P = 0.0258); Gain of sheet (P = 0.0477); Gain of catalytic residue at P722 (P = 0.0626); Gain of phosphorylation at P722 (P = 0.0899); Gain of relative solvent accessibility (P = 0.0999)
17:44101424:C:G,P10636,P722A,0.283,Gain of relative solvent accessibility (P = 0.0999); Loss of disorder (P = 0.1364); Loss of phosphorylation at S721 (P = 0.1529); Gain of loop (P = 0.2045); Gain of helix (P = 0.2059)
17:44101424:C:T,P10636,P722S,0.273,Gain of phosphorylation at P722 (P = 0.0266); Gain of sheet (P = 0.1945); Loss of loop (P = 0.2237); Gain of relative solvent accessibility (P = 0.2363); Gain of disorder (P = 0.2544)
17:44101425:C:A,P10636,P722Q,0.292,Gain of solvent accessibility (P = 0.0648); Gain of relative solvent accessibility (P = 0.0999); Gain of sheet (P = 0.1208); Loss of glycosylation at S717 (P = 0.1429); Loss of phosphorylation at S717 (P = 0.1494)
17:44101425:C:G,P10636,P722R,0.354,Gain of catalytic residue at P722 (P = 0.015); Gain of solvent accessibility (P = 0.0246); Gain of MoRF binding (P = 0.0444); Gain of relative solvent accessibility (P = 0.0999); Gain of phosphorylation at T720 (P = 0.1768)
17:44101425:C:T,P10636,P722L,0.323,Loss of disorder (P = 0.0576); Loss of glycosylation at S717 (P = 0.1353); Gain of catalytic residue at S717 (P = 0.1458); Loss of phosphorylation at S717 (P = 0.1478); Gain of sheet (P = 0.1945)
17:44101427:C:G,P10636,R723G,0.231,Loss of stability (P = 0.0398); Gain of glycosylation at T720 (P = 0.0879); Loss of phosphorylation at S726 (P = 0.0887); Gain of relative solvent accessibility (P = 0.1066); Gain of catalytic residue at D719 (P = 0.1145)
17:44101427:C:T,P10636,R723W,0.42,Loss of disorder (P = 0.0292); Loss of phosphorylation at S726 (P = 0.0504); Gain of glycosylation at T720 (P = 0.1114); Gain of sheet (P = 0.1208); Gain of catalytic residue at N727 (P = 0.1329)
17:44101428:G:A,P10636,R723Q,0.198,Loss of phosphorylation at S726 (P = 0.0591); Gain of glycosylation at T720 (P = 0.0671); Gain of relative solvent accessibility (P = 0.1066); Loss of sheet (P = 0.1907); Loss of catalytic residue at R723 (P = 0.1985)
17:44101428:G:C,P10636,R723P,0.237,Gain of catalytic residue at P722 (P = 0.0164); Gain of glycosylation at T720 (P = 0.0219); Gain of relative solvent accessibility (P = 0.1066); Loss of phosphorylation at S726 (P = 0.1193); Loss of stability (P = 0.1292)
17:44101428:G:T,P10636,R723L,0.276,Gain of glycosylation at T720 (P = 0.0649); Loss of phosphorylation at S726 (P = 0.0699); Gain of sheet (P = 0.1208); Gain of catalytic residue at N727 (P = 0.1339); Loss of disorder (P = 0.1593)
17:44101430:C:A,P10636,H724N,0.145,Gain of relative solvent accessibility (P = 0.0507); Gain of solvent accessibility (P = 0.11); Loss of sheet (P = 0.1907); Gain of loop (P = 0.2045); Gain of phosphorylation at S729 (P = 0.2789)
17:44101430:C:G,P10636,H724D,0.153,Gain of relative solvent accessibility (P = 0.025); Gain of solvent accessibility (P = 0.0421); Gain of loop (P = 0.0851); Gain of phosphorylation at S729 (P = 0.1383); Loss of sheet (P = 0.1907)
17:44101430:C:T,P10636,H724Y,0.219,Gain of sheet (P = 0.0344); Gain of phosphorylation at H724 (P = 0.0399); Loss of disorder (P = 0.1236); Gain of relative solvent accessibility (P = 0.1894); Gain of solvent accessibility (P = 0.2192)
17:44101431:A:C,P10636,H724P,0.167,Gain of relative solvent accessibility (P = 0.025); Gain of glycosylation at H724 (P = 0.0607); Gain of solvent accessibility (P = 0.0766); Gain of loop (P = 0.0851); Gain of phosphorylation at S729 (P = 0.1367)
17:44101431:A:G,P10636,H724R,0.213,Gain of solvent accessibility (P = 0.08); Gain of relative solvent accessibility (P = 0.1012); Gain of catalytic residue at H724 (P = 0.1165); Gain of phosphorylation at S729 (P = 0.1423); Gain of MoRF binding (P = 0.1769)
17:44101431:A:T,P10636,H724L,0.233,Gain of sheet (P = 0.0477); Loss of disorder (P = 0.1818); Gain of relative solvent accessibility (P = 0.1894); Gain of phosphorylation at S729 (P = 0.212); Loss of loop (P = 0.2237)
17:44101432:T:A,P10636,H724Q,0.146,Gain of relative solvent accessibility (P = 0.1012); Gain of solvent accessibility (P = 0.1376); Gain of sheet (P = 0.1945); Gain of phosphorylation at S729 (P = 0.2231); Loss of loop (P = 0.2237)
17:44101432:T:G,P10636,H724Q,0.146,Gain of relative solvent accessibility (P = 0.1012); Gain of solvent accessibility (P = 0.1376); Gain of sheet (P = 0.1945); Gain of phosphorylation at S729 (P = 0.2231); Loss of loop (P = 0.2237)
17:44101433:C:A,P10636,L725I,0.123,Gain of sheet (P = 0.1208); Gain of glycosylation at S726 (P = 0.1909); Loss of loop (P = 0.2237); Loss of catalytic residue at L725 (P = 0.2271); Gain of phosphorylation at S730 (P = 0.2387)
17:44101433:C:G,P10636,L725V,0.121,Gain of sheet (P = 0.1208); Gain of glycosylation at S726 (P = 0.1573); Gain of phosphorylation at S730 (P = 0.217); Loss of loop (P = 0.2237); Loss of catalytic residue at L725 (P = 0.2783)
17:44101433:C:T,P10636,L725F,0.124,Gain of sheet (P = 0.1208); Loss of glycosylation at S730 (P = 0.1329); Loss of phosphorylation at S726 (P = 0.1614); Loss of disorder (P = 0.365); Gain of methylation at R723 (P = 0.4901)
17:44101434:T:A,P10636,L725H,0.219,Gain of loop (P = 0.0851); Loss of stability (P = 0.0923); Gain of relative solvent accessibility (P = 0.1259); Loss of sheet (P = 0.1398); Gain of glycosylation at S730 (P = 0.1447)
17:44101434:T:C,P10636,L725P,0.297,Gain of loop (P = 0.0435); Loss of sheet (P = 0.0483); Gain of glycosylation at S726 (P = 0.0704); Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.0967)
17:44101434:T:G,P10636,L725R,0.268,Gain of glycosylation at S730 (P = 0.0507); Gain of loop (P = 0.0851); Gain of catalytic residue at S726 (P = 0.1184); Gain of relative solvent accessibility (P = 0.1259); Loss of stability (P = 0.1301)
17:44101436:A:C,P10636,S726R,0.249,Gain of solvent accessibility (P = 0.0171); Loss of phosphorylation at S726 (P = 0.0239); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at S726 (P = 0.0632); Gain of MoRF binding (P = 0.1202)
17:44101436:A:G,P10636,S726G,0.176,Loss of phosphorylation at S726 (P = 0.0239); Loss of stability (P = 0.0276); Gain of relative solvent accessibility (P = 0.0479); Gain of loop (P = 0.0851); Gain of catalytic residue at P722 (P = 0.1142)
17:44101436:A:T,P10636,S726C,0.272,Loss of disorder (P = 0.0145); Loss of phosphorylation at S726 (P = 0.0239); Loss of glycosylation at T731 (P = 0.1018); Gain of catalytic residue at V728 (P = 0.1091); Gain of sheet (P = 0.1208)
17:44101437:G:A,P10636,S726N,0.122,Gain of relative solvent accessibility (P = 0.0215); Loss of phosphorylation at S726 (P = 0.0239); Gain of solvent accessibility (P = 0.0338); Gain of loop (P = 0.0851); Loss of sheet (P = 0.1398)
17:44101437:G:C,P10636,S726T,0.129,Gain of relative solvent accessibility (P = 0.0479); Loss of phosphorylation at S726 (P = 0.0617); Gain of solvent accessibility (P = 0.0917); Gain of glycosylation at S726 (P = 0.1697); Loss of disorder (P = 0.1913)
17:44101437:G:T,P10636,S726I,0.262,Gain of sheet (P = 0.0149); Loss of disorder (P = 0.0155); Loss of phosphorylation at S726 (P = 0.0239); Loss of glycosylation at T731 (P = 0.0933); Loss of loop (P = 0.1242)
17:44101438:C:A,P10636,S726R,0.249,Gain of solvent accessibility (P = 0.0171); Loss of phosphorylation at S726 (P = 0.0239); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at S726 (P = 0.0632); Gain of MoRF binding (P = 0.1202)
17:44101438:C:G,P10636,S726R,0.249,Gain of solvent accessibility (P = 0.0171); Loss of phosphorylation at S726 (P = 0.0239); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at S726 (P = 0.0632); Gain of MoRF binding (P = 0.1202)
17:44101439:A:C,P10636,N727H,0.152,Gain of sheet (P = 0.1208); Gain of relative solvent accessibility (P = 0.1259); Gain of phosphorylation at S729 (P = 0.1455); Gain of solvent accessibility (P = 0.199); Loss of loop (P = 0.2237)
17:44101439:A:G,P10636,N727D,0.161,Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0704); Gain of phosphorylation at S729 (P = 0.0947); Loss of sheet (P = 0.1907); Loss of catalytic residue at S730 (P = 0.1924)
17:44101439:A:T,P10636,N727Y,0.253,Gain of sheet (P = 0.0344); Gain of phosphorylation at N727 (P = 0.0404); Loss of loop (P = 0.0804); Loss of disorder (P = 0.1073); Gain of relative solvent accessibility (P = 0.1259)
17:44101440:A:C,P10636,N727T,0.19,Gain of glycosylation at N727 (P = 0.0053); Gain of relative solvent accessibility (P = 0.0479); Gain of phosphorylation at N727 (P = 0.0584); Gain of solvent accessibility (P = 0.0917); Gain of sheet (P = 0.1208)
17:44101440:A:G,P10636,N727S,0.166,Gain of relative solvent accessibility (P = 0.0215); Gain of phosphorylation at N727 (P = 0.0403); Gain of solvent accessibility (P = 0.0611); Gain of glycosylation at S729 (P = 0.1331); Loss of sheet (P = 0.1907)
17:44101440:A:T,P10636,N727I,0.236,Gain of sheet (P = 0.0149); Loss of loop (P = 0.0804); Gain of catalytic residue at V728 (P = 0.1107); Loss of disorder (P = 0.1206); Gain of relative solvent accessibility (P = 0.1259)
17:44101441:T:A,P10636,N727K,0.329,Gain of ubiquitination at N727 (P = 0.0085); Gain of methylation at N727 (P = 0.0118); Gain of solvent accessibility (P = 0.012); Gain of relative solvent accessibility (P = 0.0215); Gain of phosphorylation at S729 (P = 0.102)
17:44101441:T:G,P10636,N727K,0.329,Gain of ubiquitination at N727 (P = 0.0085); Gain of methylation at N727 (P = 0.0118); Gain of solvent accessibility (P = 0.012); Gain of relative solvent accessibility (P = 0.0215); Gain of phosphorylation at S729 (P = 0.102)
17:44101442:G:A,P10636,V728I,0.103,Loss of sheet (P = 0.1907); Gain of loop (P = 0.2045); Loss of glycosylation at S730 (P = 0.2319); Gain of phosphorylation at S730 (P = 0.2345); Gain of catalytic residue at L725 (P = 0.3477)
17:44101442:G:C,P10636,V728L,0.147,Loss of sheet (P = 0.1907); Gain of loop (P = 0.2045); Loss of phosphorylation at S730 (P = 0.2259); Loss of glycosylation at T731 (P = 0.2726); Loss of stability (P = 0.3428)
17:44101442:G:T,P10636,V728F,0.164,Gain of loop (P = 0.0851); Loss of glycosylation at T731 (P = 0.1205); Gain of relative solvent accessibility (P = 0.1259); Loss of phosphorylation at S729 (P = 0.1648); Loss of stability (P = 0.1777)
17:44101443:T:A,P10636,V728D,0.238,Gain of relative solvent accessibility (P = 0.0215); Gain of solvent accessibility (P = 0.0306); Gain of loop (P = 0.0435); Loss of stability (P = 0.0469); Gain of phosphorylation at S730 (P = 0.1162)
17:44101443:T:C,P10636,V728A,0.201,Loss of stability (P = 0.0245); Gain of loop (P = 0.0851); Loss of sheet (P = 0.1398); Gain of phosphorylation at S730 (P = 0.168); Gain of relative solvent accessibility (P = 0.2363)
17:44101443:T:G,P10636,V728G,0.256,Loss of stability (P = 0.0021); Gain of loop (P = 0.0435); Gain of relative solvent accessibility (P = 0.09); Loss of glycosylation at T731 (P = 0.1057); Gain of phosphorylation at S729 (P = 0.1204)
17:44101445:T:A,P10636,S729T,0.23,Gain of relative solvent accessibility (P = 0.0215); Gain of glycosylation at S729 (P = 0.0423); Gain of solvent accessibility (P = 0.0456); Gain of sheet (P = 0.1208); Loss of phosphorylation at S729 (P = 0.1269)
17:44101445:T:C,P10636,S729P,0.208,Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0256); Loss of phosphorylation at S729 (P = 0.0716); Gain of loop (P = 0.0851); Loss of stability (P = 0.1248)
17:44101445:T:G,P10636,S729A,0.22,Loss of phosphorylation at S729 (P = 0.0716); Loss of disorder (P = 0.0756); Loss of glycosylation at T731 (P = 0.1183); Loss of stability (P = 0.1516); Loss of sheet (P = 0.1907)
17:44101446:C:A,P10636,S729Y,0.316,Loss of disorder (P = 0.0055); Loss of glycosylation at T731 (P = 0.0573); Gain of phosphorylation at S729 (P = 0.0689); Gain of solvent accessibility (P = 0.0739); Gain of relative solvent accessibility (P = 0.09)
17:44101446:C:G,P10636,S729C,0.358,Loss of disorder (P = 0.0068); Loss of glycosylation at T731 (P = 0.0537); Loss of phosphorylation at S726 (P = 0.0675); Gain of catalytic residue at T731 (P = 0.1476); Loss of sheet (P = 0.1907)
17:44101446:C:T,P10636,S729F,0.343,Loss of disorder (P = 0.0023); Loss of glycosylation at T731 (P = 0.0359); Loss of phosphorylation at S729 (P = 0.0716); Loss of loop (P = 0.0986); Gain of sheet (P = 0.1208)
17:44101448:T:A,P10636,S730T,0.227,Gain of glycosylation at S730 (P = 0.0232); Gain of relative solvent accessibility (P = 0.0479); Loss of phosphorylation at S730 (P = 0.0848); Gain of solvent accessibility (P = 0.0917); Loss of disorder (P = 0.1079)
17:44101448:T:C,P10636,S730P,0.168,Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0256); Loss of phosphorylation at S730 (P = 0.0514); Loss of catalytic residue at S730 (P = 0.0632); Loss of glycosylation at S730 (P = 0.0884)
17:44101448:T:G,P10636,S730A,0.195,Loss of phosphorylation at S730 (P = 0.0514); Loss of glycosylation at S730 (P = 0.0637); Loss of disorder (P = 0.0684); Gain of relative solvent accessibility (P = 0.1259); Loss of stability (P = 0.1301)
17:44101449:C:A,P10636,S730Y,0.279,Loss of disorder (P = 0.0043); Loss of glycosylation at T731 (P = 0.0548); Gain of phosphorylation at S730 (P = 0.0815); Loss of loop (P = 0.1242); Gain of relative solvent accessibility (P = 0.1259)
17:44101449:C:G,P10636,S730C,0.291,Loss of disorder (P = 0.0048); Loss of phosphorylation at S730 (P = 0.0514); Loss of glycosylation at T731 (P = 0.057); Gain of sheet (P = 0.1945); Gain of loop (P = 0.2045)
17:44101449:C:T,P10636,S730F,0.276,Loss of disorder (P = 0.0015); Loss of glycosylation at T731 (P = 0.0404); Loss of phosphorylation at S730 (P = 0.0514); Loss of loop (P = 0.0986); Gain of relative solvent accessibility (P = 0.1259)
17:44101451:A:C,P10636,T731P,0.084,Loss of glycosylation at T731 (P = 0.0335); Loss of stability (P = 0.0933); Gain of phosphorylation at S730 (P = 0.1126); Gain of relative solvent accessibility (P = 0.1571); Loss of sheet (P = 0.1907)
17:44101451:A:G,P10636,T731A,0.122,Loss of glycosylation at T731 (P = 0.016); Loss of sheet (P = 0.1158); Gain of catalytic residue at T731 (P = 0.1283); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1983)
17:44101451:A:T,P10636,T731S,0.124,Gain of phosphorylation at T731 (P = 0.0371); Gain of sheet (P = 0.0827); Gain of disorder (P = 0.1232); Gain of glycosylation at T731 (P = 0.174); Loss of stability (P = 0.3542)
17:44101452:C:A,P10636,T731N,0.114,Loss of glycosylation at T731 (P = 0.016); Gain of sheet (P = 0.0827); Loss of stability (P = 0.1272); Gain of relative solvent accessibility (P = 0.1571); Gain of solvent accessibility (P = 0.1846)
17:44101452:C:G,P10636,T731S,0.124,Gain of phosphorylation at T731 (P = 0.0371); Gain of sheet (P = 0.0827); Gain of disorder (P = 0.1232); Gain of glycosylation at T731 (P = 0.174); Loss of stability (P = 0.3542)
17:44101452:C:T,P10636,T731I,0.142,Loss of glycosylation at T731 (P = 0.016); Loss of disorder (P = 0.0573); Gain of sheet (P = 0.0827); Gain of phosphorylation at S730 (P = 0.2017); Gain of loop (P = 0.2045)
17:44101454:G:A,P10636,G732S,0.453,Gain of phosphorylation at G732 (P = 0.0369); Gain of disorder (P = 0.0682); Loss of sheet (P = 0.0817); Gain of glycosylation at G732 (P = 0.1124); Loss of stability (P = 0.1246)
17:44101454:G:C,P10636,G732R,0.496,Gain of solvent accessibility (P = 0.0789); Loss of sheet (P = 0.1158); Gain of phosphorylation at S729 (P = 0.1164); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at I734 (P = 0.1607)
17:44101454:G:T,P10636,G732C,0.555,Loss of disorder (P = 0.0495); Loss of phosphorylation at S733 (P = 0.0703); Loss of catalytic residue at I734 (P = 0.1545); Loss of glycosylation at S730 (P = 0.1646); Gain of sheet (P = 0.1945)
17:44101455:G:A,P10636,G732D,0.448,Loss of sheet (P = 0.0817); Gain of disorder (P = 0.1423); Loss of catalytic residue at S730 (P = 0.1552); Gain of relative solvent accessibility (P = 0.1571); Gain of phosphorylation at S730 (P = 0.1713)
17:44101455:G:C,P10636,G732A,0.443,Gain of sheet (P = 0.0827); Loss of catalytic residue at I734 (P = 0.1668); Gain of glycosylation at T731 (P = 0.1906); Gain of loop (P = 0.2045); Loss of stability (P = 0.2194)
17:44101455:G:T,P10636,G732V,0.492,Gain of sheet (P = 0.0344); Loss of loop (P = 0.0374); Loss of disorder (P = 0.1066); Loss of catalytic residue at I734 (P = 0.1443); Gain of glycosylation at T731 (P = 0.1689)
17:44101457:A:C,P10636,S733R,0.374,Loss of phosphorylation at S733 (P = 0.0244); Gain of sheet (P = 0.0477); Gain of solvent accessibility (P = 0.0584); Gain of relative solvent accessibility (P = 0.09); Loss of disorder (P = 0.0925)
17:44101457:A:G,P10636,S733G,0.267,Loss of phosphorylation at S733 (P = 0.0244); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.0862); Gain of relative solvent accessibility (P = 0.09); Gain of glycosylation at S730 (P = 0.1311)
17:44101457:A:T,P10636,S733C,0.405,Loss of disorder (P = 0.0011); Loss of phosphorylation at S733 (P = 0.0244); Loss of glycosylation at T731 (P = 0.029); Gain of sheet (P = 0.0827); Gain of loop (P = 0.2045)
17:44101458:G:A,P10636,S733N,0.298,Loss of phosphorylation at S733 (P = 0.0244); Gain of relative solvent accessibility (P = 0.0479); Loss of disorder (P = 0.0637); Gain of solvent accessibility (P = 0.0766); Gain of sheet (P = 0.0827)
17:44101458:G:C,P10636,S733T,0.295,Gain of sheet (P = 0.0344); Gain of glycosylation at S733 (P = 0.072); Loss of disorder (P = 0.072); Loss of phosphorylation at S733 (P = 0.0727); Gain of relative solvent accessibility (P = 0.09)
17:44101458:G:T,P10636,S733I,0.383,Loss of disorder (P = 0.0015); Gain of sheet (P = 0.0149); Loss of phosphorylation at S733 (P = 0.0244); Loss of glycosylation at T731 (P = 0.0478); Loss of loop (P = 0.0512)
17:44101459:C:A,P10636,S733R,0.374,Loss of phosphorylation at S733 (P = 0.0244); Gain of sheet (P = 0.0477); Gain of solvent accessibility (P = 0.0584); Gain of relative solvent accessibility (P = 0.09); Loss of disorder (P = 0.0925)
17:44101459:C:G,P10636,S733R,0.374,Loss of phosphorylation at S733 (P = 0.0244); Gain of sheet (P = 0.0477); Gain of solvent accessibility (P = 0.0584); Gain of relative solvent accessibility (P = 0.09); Loss of disorder (P = 0.0925)
17:44101460:A:C,P10636,I734L,0.196,Loss of sheet (P = 0.0817); Gain of disorder (P = 0.0823); Loss of catalytic residue at I734 (P = 0.1447); Gain of glycosylation at S730 (P = 0.1679); Gain of phosphorylation at S739 (P = 0.1747)
17:44101460:A:G,P10636,I734V,0.184,Gain of disorder (P = 0.095); Gain of glycosylation at S730 (P = 0.1192); Gain of phosphorylation at S729 (P = 0.1856); Loss of sheet (P = 0.302); Loss of catalytic residue at S730 (P = 0.3199)
17:44101460:A:T,P10636,I734F,0.203,Loss of sheet (P = 0.0817); Loss of glycosylation at T731 (P = 0.1436); Loss of phosphorylation at S733 (P = 0.1595); Loss of stability (P = 0.1751); Gain of loop (P = 0.2045)
17:44101461:T:A,P10636,I734N,0.281,Loss of sheet (P = 0.0104); Gain of loop (P = 0.0312); Gain of disorder (P = 0.0382); Loss of stability (P = 0.0443); Gain of glycosylation at S730 (P = 0.0549)
17:44101461:T:C,P10636,I734T,0.301,Loss of sheet (P = 0.0181); Loss of stability (P = 0.0189); Gain of glycosylation at I734 (P = 0.0245); Gain of disorder (P = 0.0305); Gain of phosphorylation at I734 (P = 0.0618)
17:44101461:T:G,P10636,I734S,0.327,Loss of sheet (P = 0.0104); Gain of disorder (P = 0.0118); Gain of phosphorylation at I734 (P = 0.0359); Loss of stability (P = 0.038); Gain of glycosylation at S730 (P = 0.0466)
17:44101462:C:G,P10636,I734M,0.291,Loss of sheet (P = 0.0315); Gain of disorder (P = 0.0355); Gain of glycosylation at S730 (P = 0.1343); Gain of phosphorylation at S729 (P = 0.1413); Gain of loop (P = 0.2045)
17:44101463:G:A,P10636,D735N,0.393,Gain of catalytic residue at D735 (P = 0.0237); Loss of stability (P = 0.069); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.1303); Loss of phosphorylation at S733 (P = 0.1345)
17:44101463:G:C,P10636,D735H,0.396,Gain of sheet (P = 0.0221); Gain of catalytic residue at D735 (P = 0.0274); Loss of stability (P = 0.0529); Loss of loop (P = 0.0986); Loss of disorder (P = 0.0991)
17:44101463:G:T,P10636,D735Y,0.437,Loss of disorder (P = 0.0061); Gain of sheet (P = 0.0125); Gain of catalytic residue at D735 (P = 0.0481); Gain of phosphorylation at D735 (P = 0.0516); Loss of loop (P = 0.0603)
17:44101464:A:C,P10636,D735A,0.397,Gain of sheet (P = 0.0344); Loss of disorder (P = 0.0977); Loss of stability (P = 0.0981); Loss of loop (P = 0.0986); Loss of phosphorylation at S730 (P = 0.1651)
17:44101464:A:G,P10636,D735G,0.413,Loss of stability (P = 0.0227); Gain of catalytic residue at D735 (P = 0.0592); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.1456); Loss of phosphorylation at S730 (P = 0.1928)
17:44101464:A:T,P10636,D735V,0.45,Gain of sheet (P = 0.0125); Gain of catalytic residue at D735 (P = 0.0227); Loss of disorder (P = 0.0245); Loss of loop (P = 0.0374); Loss of phosphorylation at S730 (P = 0.1499)
17:44101465:C:A,P10636,D735E,0.341,Gain of sheet (P = 0.0221); Gain of catalytic residue at D735 (P = 0.0838); Loss of loop (P = 0.0986); Loss of stability (P = 0.1705); Loss of phosphorylation at S730 (P = 0.1982)
17:44101465:C:G,P10636,D735E,0.341,Gain of sheet (P = 0.0221); Gain of catalytic residue at D735 (P = 0.0838); Loss of loop (P = 0.0986); Loss of stability (P = 0.1705); Loss of phosphorylation at S730 (P = 0.1982)
17:44101466:A:C,P10636,M736L,0.134,Gain of sheet (P = 0.0827); Loss of disorder (P = 0.2046); Loss of loop (P = 0.2237); Loss of phosphorylation at S739 (P = 0.236); Gain of glycosylation at T731 (P = 0.2945)
17:44101466:A:G,P10636,M736V,0.21,Gain of catalytic residue at M736 (P = 0.0184); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.1706); Loss of phosphorylation at S739 (P = 0.1899); Gain of glycosylation at S733 (P = 0.2538)
17:44101466:A:T,P10636,M736L,0.134,Gain of sheet (P = 0.0827); Loss of disorder (P = 0.2046); Loss of loop (P = 0.2237); Loss of phosphorylation at S739 (P = 0.236); Gain of glycosylation at T731 (P = 0.2945)
17:44101467:T:A,P10636,M736K,0.457,Gain of ubiquitination at M736 (P = 0.0054); Gain of solvent accessibility (P = 0.012); Loss of stability (P = 0.0154); Gain of relative solvent accessibility (P = 0.0215); Loss of sheet (P = 0.0457)
17:44101467:T:C,P10636,M736T,0.255,Gain of glycosylation at M736 (P = 0.017); Loss of sheet (P = 0.0457); Gain of relative solvent accessibility (P = 0.0479); Gain of phosphorylation at M736 (P = 0.0681); Loss of stability (P = 0.0714)
17:44101467:T:G,P10636,M736R,0.312,Gain of solvent accessibility (P = 0.0171); Loss of sheet (P = 0.0457); Gain of relative solvent accessibility (P = 0.0479); Gain of phosphorylation at S739 (P = 0.079); Gain of disorder (P = 0.1061)
17:44101468:G:A,P10636,M736I,0.151,Loss of disorder (P = 0.0761); Gain of sheet (P = 0.0827); Loss of phosphorylation at S739 (P = 0.1618); Gain of glycosylation at S733 (P = 0.1961); Loss of loop (P = 0.2237)
17:44101468:G:C,P10636,M736I,0.151,Loss of disorder (P = 0.0761); Gain of sheet (P = 0.0827); Loss of phosphorylation at S739 (P = 0.1618); Gain of glycosylation at S733 (P = 0.1961); Loss of loop (P = 0.2237)
17:44101468:G:T,P10636,M736I,0.151,Loss of disorder (P = 0.0761); Gain of sheet (P = 0.0827); Loss of phosphorylation at S739 (P = 0.1618); Gain of glycosylation at S733 (P = 0.1961); Loss of loop (P = 0.2237)
17:44101469:G:A,P10636,V737I,0.113,Gain of catalytic residue at L742 (P = 0.0439); Loss of sheet (P = 0.1158); Loss of disorder (P = 0.1807); Gain of loop (P = 0.2045); Loss of helix (P = 0.2271)
17:44101469:G:C,P10636,V737L,0.177,Loss of sheet (P = 0.0457); Gain of loop (P = 0.0851); Gain of catalytic residue at V737 (P = 0.1153); Loss of helix (P = 0.2022); Gain of disorder (P = 0.2024)
17:44101469:G:T,P10636,V737L,0.177,Loss of sheet (P = 0.0457); Gain of loop (P = 0.0851); Gain of catalytic residue at V737 (P = 0.1153); Loss of helix (P = 0.2022); Gain of disorder (P = 0.2024)
17:44101470:T:A,P10636,V737E,0.269,Gain of solvent accessibility (P = 9e-04); Gain of relative solvent accessibility (P = 0.0023); Loss of sheet (P = 0.0228); Gain of disorder (P = 0.0309); Gain of loop (P = 0.0435)
17:44101470:T:C,P10636,V737A,0.208,Gain of relative solvent accessibility (P = 0.0082); Loss of stability (P = 0.0305); Gain of loop (P = 0.0435); Loss of sheet (P = 0.0457); Gain of solvent accessibility (P = 0.0503)
17:44101470:T:G,P10636,V737G,0.284,Loss of stability (P = 0.002); Gain of relative solvent accessibility (P = 0.0023); Gain of catalytic residue at M736 (P = 0.0116); Loss of sheet (P = 0.0228); Gain of loop (P = 0.0435)
17:44101472:G:A,P10636,D738N,0.265,Loss of sheet (P = 0.1158); Loss of disorder (P = 0.1173); Loss of phosphorylation at S733 (P = 0.1345); Gain of catalytic residue at D738 (P = 0.1453); Loss of helix (P = 0.1706)
17:44101472:G:C,P10636,D738H,0.3,Loss of disorder (P = 0.0824); Gain of loop (P = 0.1069); Loss of sheet (P = 0.1158); Loss of phosphorylation at S739 (P = 0.1454); Loss of helix (P = 0.1706)
17:44101472:G:T,P10636,D738Y,0.375,Loss of disorder (P = 0.0023); Loss of helix (P = 0.0626); Gain of loop (P = 0.1069); Gain of sheet (P = 0.1208); Gain of phosphorylation at D738 (P = 0.1355)
17:44101473:A:C,P10636,D738A,0.314,Loss of helix (P = 0.0626); Loss of disorder (P = 0.0824); Gain of loop (P = 0.1069); Loss of sheet (P = 0.1158); Loss of phosphorylation at S739 (P = 0.1958)
17:44101473:A:G,P10636,D738G,0.236,Loss of sheet (P = 0.1158); Loss of disorder (P = 0.1194); Loss of helix (P = 0.1706); Gain of loop (P = 0.2045); Gain of relative solvent accessibility (P = 0.2363)
17:44101473:A:T,P10636,D738V,0.377,Loss of disorder (P = 0.0185); Gain of sheet (P = 0.0266); Loss of loop (P = 0.0512); Loss of helix (P = 0.0626); Loss of phosphorylation at S739 (P = 0.1572)
17:44101474:C:A,P10636,D738E,0.216,Gain of solvent accessibility (P = 0.0854); Gain of relative solvent accessibility (P = 0.0999); Gain of loop (P = 0.1069); Loss of sheet (P = 0.1158); Loss of helix (P = 0.1706)
17:44101474:C:G,P10636,D738E,0.216,Gain of solvent accessibility (P = 0.0854); Gain of relative solvent accessibility (P = 0.0999); Gain of loop (P = 0.1069); Loss of sheet (P = 0.1158); Loss of helix (P = 0.1706)
17:44101475:T:A,P10636,S739T,0.165,Loss of disorder (P = 0.0576); Loss of sheet (P = 0.1158); Gain of relative solvent accessibility (P = 0.1259); Loss of phosphorylation at S739 (P = 0.1458); Loss of glycosylation at T744 (P = 0.1473)
17:44101475:T:C,P10636,S739P,0.237,Gain of catalytic residue at S739 (P = 0.002); Loss of phosphorylation at S739 (P = 0.0546); Gain of relative solvent accessibility (P = 0.09); Loss of sheet (P = 0.1158); Loss of glycosylation at T744 (P = 0.1595)
17:44101475:T:G,P10636,S739A,0.158,Loss of disorder (P = 0.0351); Loss of phosphorylation at S739 (P = 0.0546); Gain of catalytic residue at S739 (P = 0.1009); Loss of glycosylation at T744 (P = 0.1103); Loss of sheet (P = 0.1158)
17:44101476:C:G,P10636,S739W,0.275,Loss of disorder (P = 0); Loss of glycosylation at T744 (P = 0.0468); Loss of phosphorylation at S739 (P = 0.0546); Loss of sheet (P = 0.1158); Gain of helix (P = 0.132)
17:44101476:C:T,P10636,S739L,0.246,Gain of catalytic residue at S739 (P = 0.0025); Loss of disorder (P = 0.0062); Loss of phosphorylation at S739 (P = 0.0546); Loss of glycosylation at T744 (P = 0.0764); Loss of sheet (P = 0.1158)
17:44101478:C:A,P10636,P740T,0.391,Gain of relative solvent accessibility (P = 0.0215); Gain of solvent accessibility (P = 0.0456); Gain of glycosylation at P740 (P = 0.0883); Gain of phosphorylation at P740 (P = 0.0982); Loss of sheet (P = 0.1158)
17:44101478:C:G,P10636,P740A,0.423,Gain of relative solvent accessibility (P = 0.0215); Gain of helix (P = 0.062); Loss of disorder (P = 0.0736); Loss of loop (P = 0.0804); Gain of solvent accessibility (P = 0.0917)
17:44101478:C:T,P10636,P740S,0.364,Gain of relative solvent accessibility (P = 0.0215); Gain of solvent accessibility (P = 0.0611); Gain of phosphorylation at P740 (P = 0.0629); Gain of sheet (P = 0.0827); Gain of disorder (P = 0.1223)
17:44101479:C:A,P10636,P740H,0.44,Gain of catalytic residue at P740 (P = 0.078); Loss of disorder (P = 0.0806); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1071); Loss of sheet (P = 0.1158)
17:44101479:C:G,P10636,P740R,0.476,Gain of solvent accessibility (P = 0.0171); Gain of relative solvent accessibility (P = 0.0479); Gain of helix (P = 0.062); Loss of glycosylation at T744 (P = 0.0723); Loss of loop (P = 0.0804)
17:44101479:C:T,P10636,P740L,0.449,Loss of disorder (P = 0.0268); Loss of sheet (P = 0.0457); Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Gain of relative solvent accessibility (P = 0.09)
17:44101481:C:A,P10636,Q741K,0.658,Gain of solvent accessibility (P = 0.0071); Gain of ubiquitination at Q741 (P = 0.009); Gain of relative solvent accessibility (P = 0.0166); Gain of glycosylation at Q741 (P = 0.0701); Gain of phosphorylation at S739 (P = 0.1171)
17:44101481:C:G,P10636,Q741E,0.373,Gain of solvent accessibility (P = 0.0105); Gain of relative solvent accessibility (P = 0.0166); Gain of phosphorylation at S739 (P = 0.0941); Loss of sheet (P = 0.1158); Gain of disorder (P = 0.1833)
17:44101482:A:C,P10636,Q741P,0.352,Gain of catalytic residue at P740 (P = 0.0126); Gain of relative solvent accessibility (P = 0.0166); Gain of loop (P = 0.0195); Loss of helix (P = 0.0196); Gain of solvent accessibility (P = 0.0584)
17:44101482:A:G,P10636,Q741R,0.36,Gain of solvent accessibility (P = 0.0411); Gain of phosphorylation at T744 (P = 0.0826); Gain of relative solvent accessibility (P = 0.09); Loss of glycosylation at T744 (P = 0.0907); Loss of sheet (P = 0.1158)
17:44101482:A:T,P10636,Q741L,0.412,Loss of disorder (P = 0.0379); Gain of relative solvent accessibility (P = 0.09); Gain of stability (P = 0.1091); Loss of sheet (P = 0.1158); Loss of catalytic residue at Q741 (P = 0.1179)
17:44101483:G:C,P10636,Q741H,0.391,Gain of loop (P = 0.1069); Loss of disorder (P = 0.1353); Gain of relative solvent accessibility (P = 0.1571); Loss of helix (P = 0.1706); Gain of glycosylation at T744 (P = 0.1961)
17:44101483:G:T,P10636,Q741H,0.391,Gain of loop (P = 0.1069); Loss of disorder (P = 0.1353); Gain of relative solvent accessibility (P = 0.1571); Loss of helix (P = 0.1706); Gain of glycosylation at T744 (P = 0.1961)
17:44101484:C:A,P10636,L742I,0.122,Loss of helix (P = 0.079); Loss of disorder (P = 0.1209); Gain of glycosylation at T744 (P = 0.23); Gain of phosphorylation at S739 (P = 0.2403); Loss of sheet (P = 0.3635)
17:44101484:C:G,P10636,L742V,0.128,Loss of helix (P = 0.079); Gain of catalytic residue at L742 (P = 0.2012); Gain of phosphorylation at S739 (P = 0.205); Loss of glycosylation at T744 (P = 0.2333); Gain of disorder (P = 0.2738)
17:44101484:C:T,P10636,L742F,0.175,Loss of disorder (P = 0.079); Loss of glycosylation at T744 (P = 0.0838); Gain of catalytic residue at L742 (P = 0.1177); Loss of helix (P = 0.1706); Loss of phosphorylation at S739 (P = 0.1849)
17:44101485:T:A,P10636,L742H,0.286,Gain of loop (P = 0.0435); Loss of helix (P = 0.0444); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0488); Loss of stability (P = 0.0659)
17:44101485:T:C,P10636,L742P,0.442,Gain of loop (P = 0.0045); Loss of helix (P = 0.0123); Gain of relative solvent accessibility (P = 0.0215); Gain of disorder (P = 0.0319); Loss of stability (P = 0.0453)
17:44101485:T:G,P10636,L742R,0.36,Gain of solvent accessibility (P = 0.0171); Loss of helix (P = 0.0444); Gain of relative solvent accessibility (P = 0.0479); Gain of disorder (P = 0.0655); Gain of phosphorylation at T744 (P = 0.0686)
17:44101487:G:A,P10636,A743T,0.147,Gain of glycosylation at A743 (P = 0.0054); Gain of relative solvent accessibility (P = 0.09); Gain of loop (P = 0.1069); Gain of solvent accessibility (P = 0.1683); Gain of helix (P = 0.1736)
17:44101487:G:C,P10636,A743P,0.15,Gain of loop (P = 0.0195); Loss of helix (P = 0.0196); Gain of disorder (P = 0.0744); Gain of relative solvent accessibility (P = 0.09); Gain of glycosylation at T744 (P = 0.091)
17:44101487:G:T,P10636,A743S,0.171,Gain of disorder (P = 0.0453); Gain of relative solvent accessibility (P = 0.0479); Gain of phosphorylation at A743 (P = 0.0814); Gain of loop (P = 0.1069); Gain of solvent accessibility (P = 0.11)
17:44101488:C:A,P10636,A743D,0.135,Gain of relative solvent accessibility (P = 0.0215); Gain of solvent accessibility (P = 0.0306); Gain of helix (P = 0.062); Gain of disorder (P = 0.0927); Gain of loop (P = 0.1069)
17:44101488:C:G,P10636,A743G,0.101,Loss of helix (P = 0.028); Gain of loop (P = 0.0435); Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.1197); Loss of glycosylation at T744 (P = 0.1402)
17:44101488:C:T,P10636,A743V,0.112,Loss of loop (P = 0.0804); Loss of disorder (P = 0.0976); Loss of glycosylation at T744 (P = 0.1006); Gain of helix (P = 0.132); Loss of phosphorylation at S739 (P = 0.244)
17:44101490:A:C,P10636,T744P,0.181,Loss of glycosylation at T744 (P = 0.0502); Loss of stability (P = 0.0838); Gain of loop (P = 0.1069); Gain of disorder (P = 0.1149); Gain of phosphorylation at S739 (P = 0.1309)
17:44101490:A:G,P10636,T744A,0.393,Gain of helix (P = 0.0199); Loss of loop (P = 0.0288); Loss of glycosylation at T744 (P = 0.0314); Loss of phosphorylation at T744 (P = 0.1475); Gain of relative solvent accessibility (P = 0.2363)
17:44101490:A:T,P10636,T744S,0.186,Loss of loop (P = 0.0512); Gain of disorder (P = 0.059); Gain of helix (P = 0.062); Gain of phosphorylation at T744 (P = 0.0952); Loss of glycosylation at T744 (P = 0.1207)
17:44101491:C:A,P10636,T744K,0.269,Gain of ubiquitination at T744 (P = 0.0104); Gain of helix (P = 0.0199); Loss of loop (P = 0.0288); Gain of solvent accessibility (P = 0.0611); Loss of glycosylation at T744 (P = 0.0884)
17:44101491:C:G,P10636,T744R,0.31,Gain of helix (P = 0.0199); Loss of loop (P = 0.0288); Loss of glycosylation at T744 (P = 0.0314); Gain of solvent accessibility (P = 0.0808); Loss of phosphorylation at T744 (P = 0.1475)
17:44101491:C:T,P10636,T744M,0.646,Gain of helix (P = 0.0199); Loss of loop (P = 0.0288); Loss of glycosylation at T744 (P = 0.0314); Loss of phosphorylation at T744 (P = 0.1475); Gain of solvent accessibility (P = 0.199)
17:44101493:C:A,P10636,L745I,0.13,Loss of helix (P = 0.079); Loss of disorder (P = 0.1202); Gain of glycosylation at T744 (P = 0.1278); Loss of phosphorylation at S750 (P = 0.192); Gain of catalytic residue at D747 (P = 0.3431)
17:44101493:C:G,P10636,L745V,0.184,Gain of catalytic residue at L745 (P = 0.0067); Loss of helix (P = 0.079); Gain of glycosylation at T744 (P = 0.1014); Gain of phosphorylation at T744 (P = 0.2084); Loss of stability (P = 0.2966)
17:44101494:T:A,P10636,L745Q,0.331,Loss of helix (P = 0.0237); Gain of solvent accessibility (P = 0.0374); Gain of relative solvent accessibility (P = 0.0479); Gain of loop (P = 0.0502); Gain of disorder (P = 0.0638)
17:44101494:T:C,P10636,L745P,0.494,Gain of loop (P = 0.0079); Loss of helix (P = 0.0093); Loss of stability (P = 0.0214); Gain of relative solvent accessibility (P = 0.0479); Gain of disorder (P = 0.051)
17:44101494:T:G,P10636,L745R,0.415,Loss of helix (P = 0.0167); Gain of solvent accessibility (P = 0.0171); Gain of loop (P = 0.024); Gain of relative solvent accessibility (P = 0.0479); Gain of methylation at L745 (P = 0.0669)
17:44101496:G:A,P10636,A746T,0.151,Loss of helix (P = 0.0167); Gain of relative solvent accessibility (P = 0.0215); Gain of loop (P = 0.024); Gain of solvent accessibility (P = 0.0456); Gain of phosphorylation at A746 (P = 0.0884)
17:44101496:G:C,P10636,A746P,0.213,Gain of loop (P = 0.0045); Loss of helix (P = 0.0068); Gain of relative solvent accessibility (P = 0.0215); Gain of solvent accessibility (P = 0.0503); Gain of disorder (P = 0.1149)
17:44101496:G:T,P10636,A746S,0.24,Loss of helix (P = 0.0093); Gain of loop (P = 0.0195); Gain of relative solvent accessibility (P = 0.0215); Gain of phosphorylation at A746 (P = 0.0381); Gain of solvent accessibility (P = 0.0611)
17:44101497:C:A,P10636,A746D,0.197,Loss of helix (P = 0.0093); Gain of loop (P = 0.0111); Gain of relative solvent accessibility (P = 0.0215); Gain of solvent accessibility (P = 0.0306); Gain of phosphorylation at T744 (P = 0.1161)
17:44101497:C:G,P10636,A746G,0.178,Loss of helix (P = 0.0093); Gain of loop (P = 0.0195); Gain of relative solvent accessibility (P = 0.0215); Loss of stability (P = 0.062); Gain of solvent accessibility (P = 0.1422)
17:44101497:C:T,P10636,A746V,0.1,Loss of disorder (P = 0.112); Loss of glycosylation at T744 (P = 0.1347); Loss of helix (P = 0.1706); Loss of phosphorylation at S750 (P = 0.205); Gain of loop (P = 0.4661)
17:44101499:G:A,P10636,D747N,0.169,Loss of loop (P = 0.0512); Gain of helix (P = 0.062); Gain of catalytic residue at D747 (P = 0.0677); Gain of glycosylation at T744 (P = 0.0958); Loss of phosphorylation at S750 (P = 0.1109)
17:44101499:G:C,P10636,D747H,0.177,Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Loss of disorder (P = 0.1101); Gain of glycosylation at T744 (P = 0.1139); Loss of phosphorylation at S750 (P = 0.133)
17:44101499:G:T,P10636,D747Y,0.312,Loss of disorder (P = 0.0011); Gain of phosphorylation at D747 (P = 0.0602); Gain of helix (P = 0.062); Gain of catalytic residue at D747 (P = 0.0655); Loss of loop (P = 0.0804)
17:44101500:A:C,P10636,D747A,0.217,Gain of helix (P = 0.0325); Loss of loop (P = 0.0512); Gain of glycosylation at T744 (P = 0.0645); Loss of disorder (P = 0.1639); Gain of relative solvent accessibility (P = 0.1894)
17:44101500:A:G,P10636,D747G,0.147,Loss of stability (P = 0.0492); Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Gain of catalytic residue at A746 (P = 0.1138); Gain of glycosylation at T744 (P = 0.1576)
17:44101500:A:T,P10636,D747V,0.249,Loss of disorder (P = 0.0213); Gain of helix (P = 0.0325); Loss of loop (P = 0.0512); Loss of phosphorylation at S750 (P = 0.1136); Gain of glycosylation at T744 (P = 0.1656)
17:44101501:C:A,P10636,D747E,0.133,Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Gain of phosphorylation at S752 (P = 0.1609); Gain of solvent accessibility (P = 0.1751); Gain of relative solvent accessibility (P = 0.1894)
17:44101501:C:G,P10636,D747E,0.133,Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Gain of phosphorylation at S752 (P = 0.1609); Gain of solvent accessibility (P = 0.1751); Gain of relative solvent accessibility (P = 0.1894)
17:44101502:G:A,P10636,E748K,0.212,Gain of ubiquitination at E748 (P = 0.0101); Gain of MoRF binding (P = 0.024); Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Gain of relative solvent accessibility (P = 0.0999)
17:44101502:G:C,P10636,E748Q,0.162,Gain of catalytic residue at E748 (P = 0.0797); Loss of loop (P = 0.0804); Gain of helix (P = 0.132); Loss of phosphorylation at S752 (P = 0.1484); Loss of glycosylation at T744 (P = 0.1778)
17:44101503:A:C,P10636,E748A,0.125,Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Loss of phosphorylation at S752 (P = 0.1767); Loss of glycosylation at T744 (P = 0.2319); Gain of relative solvent accessibility (P = 0.2363)
17:44101503:A:G,P10636,E748G,0.144,Loss of helix (P = 0.0237); Gain of loop (P = 0.0502); Gain of catalytic residue at V749 (P = 0.0835); Gain of relative solvent accessibility (P = 0.0999); Loss of stability (P = 0.1154)
17:44101503:A:T,P10636,E748V,0.195,Loss of disorder (P = 0.0449); Loss of phosphorylation at S750 (P = 0.1222); Loss of glycosylation at T744 (P = 0.1623); Gain of helix (P = 0.1736); Loss of loop (P = 0.2237)
17:44101504:G:C,P10636,E748D,0.1,Loss of helix (P = 0.079); Gain of phosphorylation at S750 (P = 0.1932); Gain of disorder (P = 0.213); Loss of glycosylation at T744 (P = 0.217); Gain of relative solvent accessibility (P = 0.2363)
17:44101504:G:T,P10636,E748D,0.1,Loss of helix (P = 0.079); Gain of phosphorylation at S750 (P = 0.1932); Gain of disorder (P = 0.213); Loss of glycosylation at T744 (P = 0.217); Gain of relative solvent accessibility (P = 0.2363)
17:44101505:G:A,P10636,V749M,0.282,Gain of phosphorylation at S752 (P = 0.12); Gain of disorder (P = 0.1221); Loss of helix (P = 0.2271); Loss of glycosylation at T744 (P = 0.2571); Gain of loop (P = 0.3485)
17:44101505:G:C,P10636,V749L,0.196,Gain of phosphorylation at S752 (P = 0.1263); Loss of glycosylation at T744 (P = 0.2386); Gain of disorder (P = 0.271); Loss of helix (P = 0.4763); Gain of catalytic residue at D747 (P = 0.4898)
17:44101505:G:T,P10636,V749L,0.196,Gain of phosphorylation at S752 (P = 0.1263); Loss of glycosylation at T744 (P = 0.2386); Gain of disorder (P = 0.271); Loss of helix (P = 0.4763); Gain of catalytic residue at D747 (P = 0.4898)
17:44101506:T:A,P10636,V749E,0.411,Loss of helix (P = 0.0068); Gain of loop (P = 0.0111); Gain of solvent accessibility (P = 0.0145); Gain of relative solvent accessibility (P = 0.0215); Gain of disorder (P = 0.0644)
17:44101506:T:C,P10636,V749A,0.314,Loss of helix (P = 0.079); Loss of stability (P = 0.0893); Gain of glycosylation at S750 (P = 0.0944); Gain of phosphorylation at S752 (P = 0.0991); Gain of disorder (P = 0.1188)
17:44101506:T:G,P10636,V749G,0.436,Loss of stability (P = 0.002); Loss of helix (P = 0.0068); Gain of loop (P = 0.0111); Gain of relative solvent accessibility (P = 0.0479); Gain of phosphorylation at S752 (P = 0.1037)
17:44101508:T:A,P10636,S750T,0.178,Loss of disorder (P = 0.0744); Gain of relative solvent accessibility (P = 0.09); Loss of phosphorylation at S752 (P = 0.123); Loss of ubiquitination at K755 (P = 0.1264); Gain of solvent accessibility (P = 0.1683)
17:44101508:T:C,P10636,S750P,0.173,Loss of phosphorylation at S750 (P = 0.0468); Gain of relative solvent accessibility (P = 0.0479); Loss of helix (P = 0.079); Gain of solvent accessibility (P = 0.1014); Gain of loop (P = 0.1081)
17:44101508:T:G,P10636,S750A,0.216,Loss of phosphorylation at S750 (P = 0.0468); Loss of disorder (P = 0.0591); Loss of ubiquitination at K755 (P = 0.0718); Loss of glycosylation at S750 (P = 0.0966); Gain of methylation at K755 (P = 0.3304)
17:44101509:C:A,P10636,S750Y,0.355,Loss of disorder (P = 0); Gain of methylation at K755 (P = 0.0391); Loss of ubiquitination at K755 (P = 0.045); Gain of phosphorylation at S750 (P = 0.0728); Gain of solvent accessibility (P = 0.0739)
17:44101509:C:G,P10636,S750C,0.347,Loss of disorder (P = 5e-04); Loss of phosphorylation at S750 (P = 0.0468); Loss of ubiquitination at K755 (P = 0.0483); Gain of catalytic residue at S752 (P = 0.0855); Loss of glycosylation at S750 (P = 0.0966)
17:44101509:C:T,P10636,S750F,0.346,Loss of disorder (P = 0); Loss of ubiquitination at K755 (P = 0.0367); Loss of phosphorylation at S750 (P = 0.0468); Gain of methylation at K755 (P = 0.061); Loss of glycosylation at S750 (P = 0.0966)
17:44101511:G:A,P10636,A751T,0.198,Gain of methylation at K755 (P = 0.1098); Gain of glycosylation at S750 (P = 0.1225); Gain of phosphorylation at A751 (P = 0.134); Gain of catalytic residue at A751 (P = 0.2331); Loss of ubiquitination at K755 (P = 0.2372)
17:44101511:G:C,P10636,A751P,0.181,Gain of glycosylation at A751 (P = 0.0655); Loss of helix (P = 0.0795); Gain of methylation at K755 (P = 0.0814); Gain of loop (P = 0.1081); Gain of phosphorylation at S750 (P = 0.1863)
17:44101511:G:T,P10636,A751S,0.245,Gain of phosphorylation at A751 (P = 0.0532); Gain of glycosylation at A751 (P = 0.1012); Gain of disorder (P = 0.1646); Gain of methylation at K755 (P = 0.1864); Gain of relative solvent accessibility (P = 0.1894)
17:44101512:C:A,P10636,A751D,0.198,Loss of ubiquitination at K755 (P = 0.0563); Gain of methylation at K755 (P = 0.1303); Gain of phosphorylation at S752 (P = 0.1374); Gain of solvent accessibility (P = 0.1422); Gain of relative solvent accessibility (P = 0.1894)
17:44101512:C:G,P10636,A751G,0.151,Gain of glycosylation at S750 (P = 0.0441); Gain of phosphorylation at S752 (P = 0.1425); Gain of relative solvent accessibility (P = 0.1894); Loss of helix (P = 0.2022); Loss of ubiquitination at K755 (P = 0.212)
17:44101512:C:T,P10636,A751V,0.202,Loss of disorder (P = 0.0962); Gain of methylation at K755 (P = 0.1713); Loss of phosphorylation at S750 (P = 0.1718); Loss of glycosylation at S750 (P = 0.2241); Loss of ubiquitination at K755 (P = 0.2561)
17:44101514:T:A,P10636,S752T,0.13,Loss of ubiquitination at K755 (P = 0.0631); Loss of disorder (P = 0.0796); Loss of phosphorylation at S752 (P = 0.1023); Gain of methylation at K755 (P = 0.1543); Gain of helix (P = 0.2294)
17:44101514:T:C,P10636,S752P,0.181,Gain of loop (P = 0.0321); Loss of helix (P = 0.0444); Loss of phosphorylation at S752 (P = 0.051); Gain of methylation at K755 (P = 0.0601); Gain of glycosylation at S750 (P = 0.1014)
17:44101514:T:G,P10636,S752A,0.181,Loss of phosphorylation at S752 (P = 0.051); Loss of disorder (P = 0.0637); Loss of ubiquitination at K755 (P = 0.0828); Gain of glycosylation at S750 (P = 0.1508); Gain of methylation at K755 (P = 0.1565)
17:44101515:C:A,P10636,S752Y,0.275,Loss of disorder (P = 0); Loss of ubiquitination at K755 (P = 0.0367); Gain of methylation at K755 (P = 0.0629); Loss of phosphorylation at S750 (P = 0.1131); Gain of catalytic residue at D747 (P = 0.2146)
17:44101515:C:G,P10636,S752C,0.277,Loss of disorder (P = 0.001); Gain of catalytic residue at L753 (P = 0.0179); Loss of ubiquitination at K755 (P = 0.045); Loss of phosphorylation at S752 (P = 0.051); Gain of methylation at K755 (P = 0.0518)
17:44101515:C:T,P10636,S752F,0.295,Loss of disorder (P = 0); Loss of ubiquitination at K755 (P = 0.0353); Gain of methylation at K755 (P = 0.0373); Loss of phosphorylation at S752 (P = 0.051); Gain of catalytic residue at S752 (P = 0.173)
17:44101517:C:A,P10636,L753M,0.229,Gain of catalytic residue at V749 (P = 0.0276); Gain of methylation at K755 (P = 0.0912); Gain of glycosylation at S750 (P = 0.1388); Gain of phosphorylation at S752 (P = 0.1937); Gain of helix (P = 0.2684)
17:44101517:C:G,P10636,L753V,0.145,Gain of methylation at K755 (P = 0.113); Loss of ubiquitination at K755 (P = 0.1516); Gain of glycosylation at S750 (P = 0.1805); Gain of phosphorylation at S752 (P = 0.2455); Gain of helix (P = 0.2684)
17:44101518:T:A,P10636,L753Q,0.252,Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.0917); Loss of stability (P = 0.1252); Gain of methylation at K755 (P = 0.1317); Gain of disorder (P = 0.1637)
17:44101518:T:C,P10636,L753P,0.506,Loss of helix (P = 0.0041); Gain of loop (P = 0.0051); Loss of stability (P = 0.0319); Gain of relative solvent accessibility (P = 0.0479); Gain of glycosylation at S750 (P = 0.0485)
17:44101518:T:G,P10636,L753R,0.308,Gain of MoRF binding (P = 0.0211); Gain of methylation at L753 (P = 0.0282); Gain of solvent accessibility (P = 0.0584); Gain of phosphorylation at S752 (P = 0.0847); Gain of relative solvent accessibility (P = 0.09)
17:44101520:G:A,P10636,A754T,0.123,Gain of relative solvent accessibility (P = 0.0215); Gain of phosphorylation at A754 (P = 0.0389); Gain of solvent accessibility (P = 0.0456); Loss of stability (P = 0.0772); Loss of ubiquitination at K755 (P = 0.1815)
17:44101520:G:C,P10636,A754P,0.3,Loss of helix (P = 0.0072); Gain of relative solvent accessibility (P = 0.0082); Gain of loop (P = 0.0121); Gain of solvent accessibility (P = 0.0256); Loss of stability (P = 0.063)
17:44101520:G:T,P10636,A754S,0.165,Gain of relative solvent accessibility (P = 0.0215); Gain of phosphorylation at A754 (P = 0.0395); Gain of solvent accessibility (P = 0.0611); Gain of glycosylation at A754 (P = 0.0871); Gain of disorder (P = 0.1769)
17:44101521:C:A,P10636,A754D,0.165,Gain of relative solvent accessibility (P = 0.0215); Gain of solvent accessibility (P = 0.0306); Loss of ubiquitination at K755 (P = 0.1264); Gain of phosphorylation at S752 (P = 0.1396); Gain of glycosylation at S750 (P = 0.1489)
17:44101521:C:G,P10636,A754G,0.12,Gain of relative solvent accessibility (P = 0.0215); Loss of stability (P = 0.039); Loss of helix (P = 0.0626); Gain of loop (P = 0.069); Gain of solvent accessibility (P = 0.1422)
17:44101521:C:T,P10636,A754V,0.131,Gain of methylation at K755 (P = 0.0346); Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0917); Loss of disorder (P = 0.1155); Loss of phosphorylation at S752 (P = 0.1797)
17:44101523:A:C,P10636,K755Q,0.124,Loss of ubiquitination at K755 (P = 0.0071); Loss of methylation at K755 (P = 0.1242); Loss of phosphorylation at S752 (P = 0.1816); Gain of helix (P = 0.2294); Gain of disorder (P = 0.2977)
17:44101523:A:G,P10636,K755E,0.171,Loss of ubiquitination at K755 (P = 0.0071); Gain of glycosylation at S750 (P = 0.1165); Loss of methylation at K755 (P = 0.1242); Gain of phosphorylation at S752 (P = 0.1689); Gain of helix (P = 0.2294)
17:44101524:A:C,P10636,K755T,0.185,Loss of ubiquitination at K755 (P = 0.0071); Gain of glycosylation at K755 (P = 0.0452); Loss of methylation at K755 (P = 0.1242); Gain of relative solvent accessibility (P = 0.1571); Loss of phosphorylation at S752 (P = 0.1685)
17:44101524:A:G,P10636,K755R,0.141,Loss of ubiquitination at K755 (P = 0.0071); Gain of phosphorylation at S752 (P = 0.1213); Gain of helix (P = 0.2294); Gain of solvent accessibility (P = 0.2346); Loss of methylation at K755 (P = 0.2953)
17:44101524:A:T,P10636,K755M,0.186,Loss of ubiquitination at K755 (P = 0.0071); Loss of methylation at K755 (P = 0.1242); Loss of phosphorylation at S752 (P = 0.1932); Gain of helix (P = 0.2294); Loss of glycosylation at S750 (P = 0.2742)
17:44101525:G:C,P10636,K755N,0.141,Loss of ubiquitination at K755 (P = 0.0071); Loss of methylation at K755 (P = 0.1242); Loss of phosphorylation at S752 (P = 0.1334); Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at S752 (P = 0.3331)
17:44101525:G:T,P10636,K755N,0.141,Loss of ubiquitination at K755 (P = 0.0071); Loss of methylation at K755 (P = 0.1242); Loss of phosphorylation at S752 (P = 0.1334); Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at S752 (P = 0.3331)
17:44101526:C:A,P10636,Q756K,0.213,Gain of ubiquitination at Q756 (P = 0.0238); Gain of glycosylation at Q756 (P = 0.0673); Gain of phosphorylation at S752 (P = 0.1311); Gain of MoRF binding (P = 0.1945); Gain of helix (P = 0.2294)
17:44101526:C:G,P10636,Q756E,0.164,Gain of phosphorylation at S752 (P = 0.1165); Gain of helix (P = 0.2294); Gain of ubiquitination at K755 (P = 0.2599); Loss of methylation at K755 (P = 0.2991); Gain of glycosylation at S752 (P = 0.3324)
17:44101527:A:C,P10636,Q756P,0.191,Loss of helix (P = 0.028); Gain of loop (P = 0.0312); Loss of stability (P = 0.1061); Gain of glycosylation at S752 (P = 0.1339); Gain of phosphorylation at S752 (P = 0.1425)
17:44101527:A:G,P10636,Q756R,0.211,Gain of MoRF binding (P = 0.0378); Loss of ubiquitination at K755 (P = 0.0398); Gain of phosphorylation at S752 (P = 0.1231); Gain of solvent accessibility (P = 0.199); Gain of methylation at Q756 (P = 0.2132)
17:44101527:A:T,P10636,Q756L,0.226,Loss of solvent accessibility (P = 0.1077); Loss of disorder (P = 0.1123); Gain of phosphorylation at S752 (P = 0.207); Loss of ubiquitination at K755 (P = 0.212); Loss of methylation at K755 (P = 0.2136)
17:44101528:G:C,P10636,Q756H,0.165,Gain of catalytic residue at L758 (P = 0.0505); Loss of solvent accessibility (P = 0.1362); Loss of ubiquitination at K755 (P = 0.1815); Loss of phosphorylation at S752 (P = 0.2505); Loss of disorder (P = 0.2555)
17:44101528:G:T,P10636,Q756H,0.165,Gain of catalytic residue at L758 (P = 0.0505); Loss of solvent accessibility (P = 0.1362); Loss of ubiquitination at K755 (P = 0.1815); Loss of phosphorylation at S752 (P = 0.2505); Loss of disorder (P = 0.2555)
17:44101529:G:A,P10636,G757S,0.231,Gain of phosphorylation at G757 (P = 0.0354); Gain of solvent accessibility (P = 0.1683); Loss of helix (P = 0.2022); Loss of ubiquitination at K755 (P = 0.212); Gain of glycosylation at G757 (P = 0.2184)
17:44101529:G:C,P10636,G757R,0.267,Gain of solvent accessibility (P = 0.0037); Loss of ubiquitination at K755 (P = 0.0328); Gain of MoRF binding (P = 0.0729); Gain of stability (P = 0.1091); Gain of phosphorylation at S752 (P = 0.137)
17:44101529:G:T,P10636,G757C,0.305,Loss of ubiquitination at K755 (P = 0.0631); Gain of catalytic residue at L758 (P = 0.0721); Gain of stability (P = 0.1212); Gain of solvent accessibility (P = 0.1456); Loss of phosphorylation at S752 (P = 0.1583)
17:44101530:G:A,P10636,G757D,0.316,Loss of ubiquitination at K755 (P = 0.0563); Loss of helix (P = 0.0626); Gain of solvent accessibility (P = 0.0638); Gain of phosphorylation at S752 (P = 0.1384); Gain of glycosylation at S752 (P = 0.2439)
17:44101530:G:C,P10636,G757A,0.204,Loss of ubiquitination at K755 (P = 0.1022); Gain of stability (P = 0.1447); Gain of phosphorylation at S752 (P = 0.1838); Gain of glycosylation at S752 (P = 0.2021); Gain of helix (P = 0.2684)
17:44101530:G:T,P10636,G757V,0.299,Gain of stability (P = 0.0114); Gain of solvent accessibility (P = 0.1133); Loss of ubiquitination at K755 (P = 0.1264); Gain of methylation at K755 (P = 0.1661); Loss of phosphorylation at S752 (P = 0.2319)
17:44101532:T:A,P10636,L758M,0.225,Gain of methylation at K755 (P = 0.1763); Gain of ubiquitination at K755 (P = 0.2524); Gain of solvent accessibility (P = 0.3089); Gain of MoRF binding (P = 0.3994); Loss of helix (P = 0.4763)
17:44101532:T:G,P10636,L758V,0.319,Loss of ubiquitination at K755 (P = 0.0631); Gain of methylation at K755 (P = 0.1063); Gain of catalytic residue at L758 (P = 0.2781); Gain of loop (P = 0.4248); Gain of MoRF binding (P = 0.4408)
17:44101533:T:C,P10636,L758S,0.239,Gain of phosphorylation at L758 (P = 0.0269); Loss of stability (P = 0.0373); Gain of ubiquitination at K755 (P = 0.1733); Loss of helix (P = 0.2022); Gain of methylation at K755 (P = 0.2538)
17:44101533:T:G,P10636,L758W,0.334,Loss of ubiquitination at K755 (P = 0.0483); Gain of MoRF binding (P = 0.0674); Gain of methylation at K755 (P = 0.0682); Gain of solvent accessibility (P = 0.1014); Loss of disorder (P = 0.1168)
17:44101534:G:C,P10636,L758F,0.282,Gain of methylation at K755 (P = 0.1013); Loss of ubiquitination at K755 (P = 0.1264); Gain of catalytic residue at L758 (P = 0.1382); Gain of solvent accessibility (P = 0.2384); Loss of disorder (P = 0.3209)
17:44101534:G:T,P10636,L758F,0.282,Gain of methylation at K755 (P = 0.1013); Loss of ubiquitination at K755 (P = 0.1264); Gain of catalytic residue at L758 (P = 0.1382); Gain of solvent accessibility (P = 0.2384); Loss of disorder (P = 0.3209)
